PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Connelly, JC; deLeau, ES; Okely, EA; Leach, DRF				Connelly, JC; deLeau, ES; Okely, EA; Leach, DRF			Overexpression, purification, and characterization of the SbcCD protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SMC FAMILY; GENE; RECOMBINATION; PALINDROMES; BINDING; REPAIR; RAD50	The sbcC and sbcD genes mediate palindrome inviability in Escherichia coli, The sbcCD operon has been cloned into the plasmid pTrc99A under the control of the strong trc promoter and introduced into a strain carrying a chromosomal deletion of sbcCD. The SbcC and SbcD polypeptides were overexpressed to 6% of total cell protein, and both polypeptides copurified in a four-step purification procedure. Purified SbcCD is a processive double-strand exonuclease that has an absolute requirement for Mn2+ and uses ATP as a preferred energy source, Gel filtration chromatography and sedimentation equilibrium analyses were used to show that the SbcC and SbcD polypeptides dissociate at some stage after purification and that this dissociation is reversed by the addition of Mn2+. We demonstrate that SbcD has the potential to form a secondary structural motif found in a number of protein phosphatases and suggest that it is a metalloprotein that contains the catalytic center of the SbcCD exonuclease.	UNIV EDINBURGH,INST CELL & MOL BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Leach, David R/H-7159-2012	Leach, David R/0000-0003-4964-6913				ALANI E, 1989, GENETICS, V122, P47; ALLERS T, 1995, J MOL BIOL, V252, P70, DOI 10.1006/jmbi.1994.0476; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHALKER AF, 1988, GENE, V71, P201, DOI 10.1016/0378-1119(88)90092-3; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; EICHLER DC, 1977, J BIOL CHEM, V252, P499; GIBSON FP, 1992, J BACTERIOL, V174, P1222, DOI 10.1128/jb.174.4.1222-1228.1992; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GORDENIN DA, 1993, MOL CELL BIOL, V13, P5315, DOI 10.1128/MCB.13.9.5315; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HENDERSON ST, 1993, GENETICS, V133, P57; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; JOHZUKA K, 1995, GENETICS, V139, P1521; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KULKARNI SK, 1989, GENETICS, V123, P249; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEACH DRF, 1992, GENETICA, V87, P95, DOI 10.1007/BF00120998; LEACH DRF, 1994, BIOESSAYS, V16, pS93; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; NAG DK, 1991, GENETICS, V129, P669; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; PAPANICOLAOU C, 1989, J MOL BIOL, V207, P335, DOI 10.1016/0022-2836(89)90258-1; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; RUSKIN B, 1993, GENETICS, V133, P43; Sambrook J., 2002, MOL CLONING LAB MANU; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19819	19826		10.1074/jbc.272.32.19819	http://dx.doi.org/10.1074/jbc.272.32.19819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242643	hybrid			2022-12-27	WOS:A1997XQ05900030
J	Branchini, BR; Magyar, RA; Marcantonio, KM; Newberry, KJ; Stroh, JG; Hinz, LK; Murtiashaw, MH				Branchini, BR; Magyar, RA; Marcantonio, KM; Newberry, KJ; Stroh, JG; Hinz, LK; Murtiashaw, MH			Identification of a firefly luciferase active site peptide using a benzophenone-based photooxidation reagent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN; BIOLUMINESCENCE; LIGHT; ATP	Firefly luciferase catalyzes the highly efficient emission of yellow-green light from substrate luciferin by a series of reactions that require MgATP and molecular oxygen, We prepared 2-(4-benzoylphenyl)thiazole-4-carboxylic acid (BPTC), a novel benzophenone-based substrate analog, intending to use it in photoaffinity labeling studies to probe the luciferase active site, Instead, we found that while BPTC was a potent photoinactivating reagent for firefly luciferase, it was not a photoaffinity labeling agent. Using proteolysis, reverse phase high-performance liquid chromatography, tandem high performance liquid chromatography-electrospray ionization mass spectrometry, and Edman sequencing, we identified a single luciferase peptide, 244HHGF247, the degradation of which was directly correlated to luciferase photoinactivation. Results of enzyme kinetics and related studies were consistent with this peptide being at or near the luciferin binding site, Further, peptide model studies and additional investigations on the nature of the photoinactivation process strongly suggested that BPTC catalyzed the formation of singlet oxygen at the active site of the enzyme. We describe here an uncommon example of active site-directed photooxidation of an enzyme by singlet oxygen.	PFIZER INC,DIV CENT RES,GROTON,CT 06340	Pfizer	Branchini, BR (corresponding author), CONNECTICUT COLL,DEPT CHEM,270 MOHEGAN AVE,NEW LONDON,CT 06320, USA.							AULTZ DE, 1977, J MED CHEM, V20, P1499, DOI 10.1021/jm00221a028; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Branchini BR, 1997, ARCH BIOCHEM BIOPHYS, V340, P52, DOI 10.1006/abbi.1997.9894; BRANCHINI BR, 1989, PHOTOCHEM PHOTOBIOL, V49, P689, DOI 10.1111/j.1751-1097.1989.tb08442.x; CAMPBELL AK, 1993, FLUORESCENT LUMINESC, P58; CHATTOPADHYAY SK, 1985, J PHOTOCHEM, V30, P81, DOI 10.1016/0047-2670(85)87007-6; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DELUCA M, 1984, BIOCHEM BIOPH RES CO, V123, P764, DOI 10.1016/0006-291X(84)90295-X; Dementieva EI, 1996, BIOCHEMISTRY-MOSCOW+, V61, P115; DENBURG JL, 1969, ARCH BIOCHEM BIOPHYS, V134, P381, DOI 10.1016/0003-9861(69)90297-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIXON M, 1979, ENZYMES, P332; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; GREEN AA, 1956, BIOCHIM BIOPHYS ACTA, V20, P170, DOI 10.1016/0006-3002(56)90275-X; HSATINGS JW, 1995, CELL PHYSL SOURCE BO, P665; KAJIYAMA N, 1991, PROTEIN ENG, V4, P691, DOI 10.1093/protein/4.6.691; KRICKA LJ, 1988, ANAL BIOCHEM, V175, P14, DOI 10.1016/0003-2697(88)90354-5; LEMBERT N, 1995, BIOCHEM J, V305, P929, DOI 10.1042/bj3050929; Lloyd J.E., 1978, P241; Mamaev SV, 1996, J AM CHEM SOC, V118, P7243, DOI 10.1021/ja961053c; MATHESON IBC, 1979, PHOTOCHEM PHOTOBIOL, V29, P879, DOI 10.1111/j.1751-1097.1979.tb07786.x; MEANS GE, 1971, CHEM MODIFICATION PR, P165; OFallon JV, 1996, ANAL BIOCHEM, V239, P193, DOI 10.1006/abio.1996.0314; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; Ohmiya Y, 1996, FEBS LETT, V384, P83; PARHAM WE, 1976, J ORG CHEM, V41, P1187, DOI 10.1021/jo00869a023; RYANG HS, 1979, J AM CHEM SOC, V101, P6683, DOI 10.1021/ja00516a033; SELIGER HH, 1960, ARCH BIOCHEM BIOPHYS, V88, P136, DOI 10.1016/0003-9861(60)90208-3; SMITH SB, 1980, J BIOL CHEM, V255, P2690; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; THOMPSON A, 1986, BIOCHEM BIOPH RES CO, V140, P888, DOI 10.1016/0006-291X(86)90718-7; VELLOM DC, 1990, THESIS U CALIFORNIA; WAGNER PJ, 1981, J AM CHEM SOC, V103, P7329, DOI 10.1021/ja00414a048; WHITE E H, 1971, Bioorganic Chemistry, V1, P92, DOI 10.1016/0045-2068(71)90009-5; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x	36	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19359	19364		10.1074/jbc.272.31.19359	http://dx.doi.org/10.1074/jbc.272.31.19359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235934	hybrid			2022-12-27	WOS:A1997XP06300040
J	Carroll, SS; Cole, JL; Viscount, T; Geib, J; Gehman, J; Kuo, LC				Carroll, SS; Cole, JL; Viscount, T; Geib, J; Gehman, J; Kuo, LC			Activation of RNase L by 2',5'-oligoadenylates - Kinetic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; CONSTITUTIVE EXPRESSION; 2-5A-DEPENDENT RNASE; PROTEIN-SYNTHESIS; INHIBITOR; ENZYME	Ribonuclease L (RNase L), the 2',5'-oligoadenylate-dependent ribonuclease, is one of the cellular antiviral systems with enhanced activity in the presence of interferon, A reaction scheme has been developed to model the sequence of steps necessary for the activation of RNase L (Cole, J. L,, Carroll, S, S,, Blue, E, S,, Viscount, T,, and Kuo, L, C, (1997) J, Biol. Chem. 272, 19187-19192), The model comprises three sequential binding steps: the binding of activator to enzyme monomer, the subsequent dimerization of the activated monomer to form the active enzyme dimer, followed by the binding of substrate prior to catalysis, The model is used to evaluate the activation of RNase L by several synthetic analogs of the native activator, The 5'-phosphate of the activator has been determined to be an important structural determinant for the efficient activation of RNase L, and its loss caused a loss of activator affinity of 2-3 orders of magnitude. The length of activator is not an important determinant of activator potency for the activator analogs examined, The specific activity of the enzyme under conditions of saturation of activator binding and complete dimerization of the activated monomers varies only by about a factor of 3 for the activators examined, indicating that once dimerized in the presence of any of these activators, the enzyme exhibits a similar catalytic activity.			Carroll, SS (corresponding author), MERCK RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Cole, James/G-2586-2011	Gehman, John D/0000-0002-2599-6292				Carroll SS, 1996, J BIOL CHEM, V271, P4988; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Cole JL, 1996, J BIOL CHEM, V271, P3979; Cole JL, 1997, J BIOL CHEM, V272, P19187, DOI 10.1074/jbc.272.31.19187; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1980, VIROLOGY, V101, P81, DOI 10.1016/0042-6822(80)90485-7; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7136, DOI 10.1021/bi00396a040; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; Wong I, 1995, METHOD ENZYMOL, V259, P95; Wyman J., 1990, BINDING LINKAGE FUNC, P203	17	23	23	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19193	19198		10.1074/jbc.272.31.19193	http://dx.doi.org/10.1074/jbc.272.31.19193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235910	hybrid			2022-12-27	WOS:A1997XP06300016
J	Kuge, O; Saito, K; Nishijima, M				Kuge, O; Saito, K; Nishijima, M			Cloning of a Chinese hamster ovary (CHO) cDNA encoding phosphatidylserine synthase (PSS) II, overexpression of which suppresses the phosphatidylserine biosynthetic defect of a PSS I-lacking mutant of CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; PHOSPHATIDYLETHANOLAMINE; MEMBRANE; MITOCHONDRIA; RETENTION; MOTIF; DNA	Phosphatidylserine (PtdSer) in mammalian cells is synthesized through the exchange of free L-serine for the polar head group (base) of preexisting phospholipid, We previously showed the presence of two different enzymes catalyzing the serine base exchange in Chinese hamster ovary (CHO) cells and isolated the cDNA of one of the enzymes, PtdSer synthase (PSS) I, which also catalyzes the exchange of the base moiety of phospholipid(s) for ethanolamine and choline, In this study, we cloned a CHO cDNA, designated as pssB, which encodes a protein exhibiting 32% amino acid sequence identity with CHO PSS I. Introduction of the pssB cDNA into CHO-K1 cells resulted in striking increases in both the serine and ethanolamine base exchange activities, In contrast to the PSS I cDNA, the pssB cDNA was incapable of increasing the choline base exchange activity, The expression of the pssB gene in Sf9 insect cells also results in striking increases in both serine and ethanolamine base exchange activities. The pssB cDNA was found to transform a PtdSer-auxotrophic PSS I-lacking mutant of CHO-K1 cells to PtdSer prototrophy, The PtdSer content of the resultant transformant grown without exogenous PtdSer for 2 days was 4-fold that of the mutant and similar to that of CHO-K1 cells, indicating that the pssB cDNA complemented the PtdSer biosynthetic defect of the PSS I-lacking mutant, These results suggested that the pssB cDNA encoded the second PtdSer synthase PSS II, which catalyzed the serine and ethanol amine base exchange, but not the choline base exchange.			Kuge, O (corresponding author), NATL INST HLTH,DEPT BIOCHEM & CELL BIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.			Kuge, Osamu/0000-0003-4962-3519				GERLACH E, 1963, BIOCHEM Z, V337, P477; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1991, J BIOL CHEM, V266, P24184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669	21	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19133	19139		10.1074/jbc.272.31.19133	http://dx.doi.org/10.1074/jbc.272.31.19133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235902	hybrid			2022-12-27	WOS:A1997XP06300008
J	Lass, A; Agarwal, S; Sohal, RS				Lass, A; Agarwal, S; Sohal, RS			Mitochondrial ubiquinone homologues, superoxide radical generation, and longevity in different mammalian species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DROSOPHILA-MELANOGASTER; HEART-MITOCHONDRIA; OXIDATIVE DAMAGE; CHAIN-LENGTH; OVEREXPRESSION; DISMUTASE; REDUCTASE; CATALASE; VESICLES	Rates of mitochondrial superoxide anion radical (O-2(radical anion)) generation are known to be inversely correlated with the maximum life span potential of different mammalian species, The objective of this study was to understand the possible mechanism(s) underlying such variations in the rate of O-2(radical anion) generation, The hypothesis that the relative amounts of the ubiquinones or coenzyme Q (CoQ) homologues, CoQ(9) and CoQ(10), are related with the rate of O-2(radical anion) generation was tested. A comparison of nine different mammalian species, namely mouse, rat, guinea pig, rabbit, pig, goat, sheep, cow, and horse, which vary from 3.5 to 46 years in their maximum longevity, indicated that the rate of O-2(radical anion) generation in cardiac submitochondrial particles (SMPs) was directly related to the relative amount of CoQ(9) and inversely related to the amount of CoQ(10) extractable from their cardiac mito chondria. To directly test the relationship between CoQ homologues and the rate of O-2(radical anion) generation, rat heart SMPs, naturally containing mainly CoQ(9) and cow heart SMPs, with high natural CoQ(10), content, were chosen for depletion/reconstitution experiments. Repeated extractions of rat heart SMPs with pentane exponentially depleted both CoQ homologues while the corresponding rates of O-2(radical anion) generation and oxygen consumption were lowered linearly, Reconstitution of both rat and cow heart SMPs with different amounts of CoQ(9) or CoQ(10) caused an initial. increase in the rates of O-2(radical anion) generation, followed by a plateau at high concentrations, Within the physiological range of CoQ concentrations, there were no differences in the rates of O-2(radical anion) generation between SMPs reconstituted with CoQ(9) or CoQ(10). Only at concentrations that were considerably higher than the physiological level, the SMPs reconstituted with CoQ(9) exhibited higher rates of O-2(radical anion) generation than those obtained with CoQ(10). These in vitro findings do not support the hypothesis that differences in the distribution of CoQ homologues are responsible for the variations in the rates of mitochondrial O-2(radical anion) generation in different mammalian species.	SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA	Southern Methodist University			Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151	NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG013563] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG7657, R01 AG013563, R01 AG13563, R01 AG013563-13] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN PL, 1972, BIOL DATA BOOK, V1, P229; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARCOS JC, 1968, EXP MOL PATHOL, V8, P49, DOI 10.1016/0014-4800(68)90005-1; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COMFORT A, 1979, BIOL SENESCENCE, P60; EDLUND C, 1994, J NEUROCHEM, V63, P634; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FATO R, 1985, FEBS LETT, V179, P238, DOI 10.1016/0014-5793(85)80526-3; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HATEFI Y, 1963, ADV ENZYMOL REL S BI, V25, P275; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KATAYAMA K, 1980, BIOCHEM BIOPH RES CO, V95, P971, DOI 10.1016/0006-291X(80)91568-5; KATSIKAS H, 1982, BIOCHIM BIOPHYS ACTA, V689, P363, DOI 10.1016/0005-2736(82)90270-X; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LENAZ G, 1985, BBA-BIOENERGETICS, P83; MAGUIRE JJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P47, DOI 10.1016/0003-9861(92)90049-3; MATSURA T, 1992, BIOCHIM BIOPHYS ACTA, V1123, P309, DOI 10.1016/0005-2760(92)90012-K; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RAMASARMA T, 1985, COENZYME Q BIOCH BIO, P67; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; Sohal RS, 1995, LIFE SCI R, V56, P109; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1992, FREE RADICALS AGING, P64; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; TURRENS JF, 1990, FREE RADICALS LIPOPR, P203; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016	35	95	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19199	19204		10.1074/jbc.272.31.19199	http://dx.doi.org/10.1074/jbc.272.31.19199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235911	hybrid, Green Accepted			2022-12-27	WOS:A1997XP06300017
J	Sijts, AJAM; Pilip, I; Pamer, EG				Sijts, AJAM; Pilip, I; Pamer, EG			The Listeria monocytogenes-secreted p60 protein is an N-end rule substrate in the cytosol of infected cells - Implications for major histocompatibility complex class I antigen processing of bacterial proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; PROTEOLYTIC PATHWAY; PROTEASOME; UBIQUITIN; DEGRADATION; MOLECULES; PEPTIDES; INHIBITORS; EXPRESSION; SEQUENCES	Cytosolic antigen degradation is an initial step in the generation of major histocompatibility complex (MHC) class I-associated cytolytic T lymphocyte epitopes, Intracellular Listeria monocytogenes secretes p60, a murein hydrolase, into the host cell cytosol, where it is degraded by proteasomes, Roughly 3% of degraded p60 gives rise to p60 217-225, a nonamer peptide that is bound by H-2K(d) MHC class I molecules. Herein, we introduce targeted deletions throughout the p60 gene to identify potential proteolytic signals within p60. Degradation of mutant forms of p60 was investigated in macrophages infected with recombinant L. monocytogenes, We found that deletions within the amino-terminal two-thirds of p60 enhanced cytosolic degradation, In contrast, truncation of the C terminus resulted in modest stabilization of p60 in the host cell cytosol, Because a protein's N-terminal amino acid can determine its rate of degradation, we mutagenized this residue in p60 into known stabilizing and destabilizing residues, Valine substitution dramatically stabilized cytosolic p60 molecules, while substitution with aspartic acid resulted in rapid degradation, The number of p60 217-225 epitopes isolated from infected cells directly correlated with the rates of p60 degradation, Our data, therefore, indicate that the N-terminal amino acid and multiple internal regions of p60 influence its stability in the cytosol of infected cells, Antigen degradation and epitope generation are linked, and different degradation signals can channel bacterial proteins into the MHC class I antigen processing pathway.	YALE UNIV,SCH MED,INFECT DIS SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Yale University; Yale University				Sijts, Alice/0000-0003-3815-4788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039031, R01AI039031, R29AI033143] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39031, AI33143] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Androlewicz MJ, 1996, IMMUNITY, V5, P1, DOI 10.1016/S1074-7613(00)80304-0; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CRESSWELL P, 1994, ANTIGEN PROCESSING P, P33; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; EGGERS M, 1995, J EXP MED, V182, P1865, DOI 10.1084/jem.182.6.1865; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBEL W, 1988, INFECTION, V16, pS149, DOI 10.1007/BF01639739; GOETTRUP M, 1996, NATURE, V381, P166; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Goth S, 1996, J IMMUNOL, V157, P1894; GRANT EP, 1995, J IMMUNOL, V155, P3750; HARDING CV, 1995, J IMMUNOL, V155, P1767; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KOHLER S, 1990, INFECT IMMUN, V58, P1943; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; PALZKILL T, 1994, J BACTERIOL, V176, P563, DOI 10.1128/jb.176.3.563-568.1994; PAMER EG, 1993, CURR OPIN IMMUNOL, V5, P492, DOI 10.1016/0952-7915(93)90028-Q; PAMER EG, 1994, J IMMUNOL, V152, P686; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sijts AJAM, 1996, J IMMUNOL, V156, P1497; Sijts AJAM, 1996, J IMMUNOL, V156, P685; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; Yewdell JW, 1996, J IMMUNOL, V157, P1823	44	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19261	19268		10.1074/jbc.272.31.19261	http://dx.doi.org/10.1074/jbc.272.31.19261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235920	hybrid			2022-12-27	WOS:A1997XP06300026
J	Javitch, JA; Fu, DY; Liapakis, G; Chen, JY				Javitch, JA; Fu, DY; Liapakis, G; Chen, JY			Constitutive activation of the beta(2) adrenergic receptor alters the orientation of its sixth membrane-spanning segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; TRANSMEMBRANE HELICES; PROLINE RESIDUES; BINDING; CHANNEL; RHODOPSIN; CYSTEINES; DOMAIN	The binding site of the beta(2) adrenergic receptor, like that of other homologous G-protein-coupled receptors, is contained within a water-accessible crevice formed among its seven membrane spanning segments. Methanethiosulfonate ethylammonium (MTSEA), a charged, hydrophilic, lipophobic, sulfhydryl-specific reagent, had no effect on the binding of agonist or antagonist to wild type beta(2) receptor expressed in HEK 293 cells. This suggested that no endogenous cysteines are accessible in the binding site crevice. In contrast, in a constitutively active beta(2) receptor, MTSEA significantly inhibited antagonist binding, and isoproterenol slowed the rate of reaction of MTSEA. This implies that at least one endogenous cysteine becomes accessible in the binding site crevice of the constitutively active beta(2) receptor, Cys-285, in the sixth membrane-spanning segment, is responsible for the inhibitory effect of MTSEA on ligand binding to the constitutively active mutant. The acquired accessibility of Cys-285 in the constitutively active mutant may result from a rotation and/or tilting of the sixth membrane-spanning segment associated with activation of the receptor. This rearrangement could bring Cys-285 to the margin of the binding site crevice where it becomes accessible to MTSEA.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032	Columbia University; Columbia University; New York State Psychiatry Institute	Javitch, JA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR MOL RECOGNIT,P&S 11-401,630 W 168TH ST,NEW YORK,NY 10032, USA.			Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH54137, MH01030] Funding Source: Medline; NINDS NIH HHS [NS07258] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; Javitch JA, 1996, MOL PHARMACOL, V49, P692; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P1035; KARLE IL, 1991, P NATL ACAD SCI USA, V88, P5307, DOI 10.1073/pnas.88.12.5307; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; OPRIAN DD, 1992, J BIOENERG BIOMEMBR, V24, P211, DOI 10.1007/BF00762679; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021	27	184	186	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18546	18549		10.1074/jbc.272.30.18546	http://dx.doi.org/10.1074/jbc.272.30.18546			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228019	hybrid			2022-12-27	WOS:A1997XM34200010
J	Olive, M; Krylov, D; Echlin, DR; Gardner, K; Taparowsky, E; Vinson, C				Olive, M; Krylov, D; Echlin, DR; Gardner, K; Taparowsky, E; Vinson, C			A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; C-JUN; DIMERIZATION SPECIFICITY; INDUCED TRANSFORMATION; COILED COILS; GENE FAMILY; T-CELLS; FOS; TRANSCRIPTION; GROWTH	We describe a dominant negative (DN) to activation protein-1 (AP1) that inhibits DNA binding in an equimolar competition, AP1 is a heterodimer of the oncogenes Fos and Jun, members of the bZIP family of transcription factors. The DN, termed A-Fos, consists of a newly designed acidic amphipathic protein sequence appended onto the N-terminus of the Fos leucine zipper, replacing the normal basic region critical for DNA binding. The acidic extension and the Jun basic region form a heterodimeric coiled coil structure that stabilizes the complex over 3000-fold and prevents the basic region of Jun from binding to DNA. Gel shift assays indicate that A Fos can inactivate the DNA binding of a Fos:Jun heterodimer in an equimolar competition. Transient transfection assays indicate that A-Pos inhibits Jun-dependent transactivation. Both the acidic extension and the Fos leucine zipper are critical for this inhibition. Expression of A-Fos in mouse fibroblasts inhibits focus formation more than colony formation, reflecting the ability of A-Fos to interfere with the AP1 biological functions in mammalian cells. This reagent is more potent than a deletion of either the Fos or Jun transactivation domain, which has been used previously as a dominant negative to AP1 activity.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARDNER K, 1994, J BIOL CHEM, V269, P32963; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WICK M, 1992, ONCOGENE, V7, P859; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	236	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18586	18594		10.1074/jbc.272.30.18586	http://dx.doi.org/10.1074/jbc.272.30.18586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228025	hybrid			2022-12-27	WOS:A1997XM34200016
J	Sekine, T; Watanabe, N; Hosoyamada, M; Kanai, Y; Endou, H				Sekine, T; Watanabe, N; Hosoyamada, M; Kanai, Y; Endou, H			Expression cloning and characterization of a novel multispecific organic anion transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PROTEIN; SECRETION; TUBULE	Numerous drugs and endogenous compounds are efficiently excreted from the renal proximal tubule via carrier-mediated pathways. Transepithelial excretion of organic anions occurs via their accumulative transport from the blood into the proximal tubule cells across the basolateral membrane and subsequent secretion into the urine through the apical membrane. Here we report on the isolation of a novel complementary DNA from rat kidney that encodes a 551-amino acid residue protein (OAT1) with 12 putative membrane-spanning domains. When expressed in Xenopus laevis oocytes, OAT1 mediated sodium-independent para-aminohippurate (PAH) uptake (K-m = 14.3 +/- 2.9 mu M). The uptake rate of PAH was increased by the outwardly directed dicarboxylate gradient, consisting with the idea that OAT1 is an organic anion/dicarboxylate exchanger, OAT1 displayed remarkably wide substrate selectivity, covering endogenous substrates such as cyclic nucleotides, a prostaglandin and uric acid, and a variety of drugs with different structures (e.g. antibiotics, a nonsteroidal antiinflammatory drug, diuretics, an antineoplastic drug, and a uricosuric drug). The Northern blot analysis and in situ hybridization revealed that OAT1 is exclusively expressed in the particular segment of the proximal tubule in the kidney. These data suggest that OAT1 is a multispecific organic anion transporter at the basolateral membrane of the proximal tubule. Isolation of OAT1 will facilitate elucidation of the molecular basis of drug kinetics and the development of new drugs lacking unwanted side effects.	KYORIN UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,MITAKA,TOKYO 181,JAPAN	Kyorin University								Adkison KDK, 1996, J PHARMACOL EXP THER, V276, P1189; BOELSTERLI UA, 1995, AM J PHYSIOL-GASTR L, V268, pG797, DOI 10.1152/ajpgi.1995.268.5.G797; Bossuyt X, 1996, J PHARMACOL EXP THER, V276, P891; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Horz JA, 1996, BBA-LIPID LIPID MET, V1300, P114, DOI 10.1016/0005-2760(95)00239-1; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; Moller J. V., 1983, PHARMACOL REV, V34, P315; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SIMONSON GD, 1994, J CELL SCI, V107, P1065; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; WALKER RJ, 1992, KIDNEY PHYSL PATHOPH, P3571; WEINMAN SA, 1994, HEPATOLOGY, V20, P1642, DOI 10.1002/hep.1840200641; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	25	524	552	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18526	18529		10.1074/jbc.272.30.18526	http://dx.doi.org/10.1074/jbc.272.30.18526			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228014	hybrid			2022-12-27	WOS:A1997XM34200005
J	Shepherd, PR; Nave, BT; Rincon, J; Nolte, LA; Bevan, AP; Siddle, K; Zierath, JR; WallbergHenriksson, H				Shepherd, PR; Nave, BT; Rincon, J; Nolte, LA; Bevan, AP; Siddle, K; Zierath, JR; WallbergHenriksson, H			Differential regulation of phosphoinositide 3-kinase adapter subunit variants by insulin in human skeletal muscle.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; P85 SUBUNIT; INHIBITOR WORTMANNIN; SIGNALING PATHWAYS; GLYCOGEN-SYNTHESIS; FAT-CELLS; TRANSLOCATION; STIMULATION	The role of phosphoinositide 3-kinase (PI 3-kinase) in insulin signaling was evaluated in human skeletal muscle. Insulin stimulated both antiphosphotyrosine-precipitable PI 3-kinase activity and 3-O-methylglucose transport in isolated skeletal muscle (both approximate to 2-3-fold). Insulin stimulation of 3-O-methylglucose transport was inhibited by the PI 3-kinase inhibitor LY294002 (IC50 = 2.5 mu M). The PI 3-kinase adapter subunits were purified from muscle lysates using phosphopeptide beads based on the Tyr-751 region of the platelet-derived growth factor receptor. Immunoblotting of the material adsorbed onto the phosphopeptide beads revealed the presence of p85 alpha, p85 beta, p55(PIK)/p55 gamma, and p50 adapter subunit isoforms. In addition, p85 alpha-NSH2 antibodies recognized four adapter subunit variants of 54, 53, 48, and 46 kDa, the latter corresponding to the p50 splice variant. Serial immunoprecipitations demonstrated that these four proteins were associated with a large proportion of the total PI 3-kinase activity immunoprecipitated by p85 alpha-NSH2 domain antibodies. Antibodies to p85 beta, p55(PIK)/p55 gamma, and the p50 adapter subunit also immunoprecipitated PI 3-kinase activity from human muscle lysates. A large proportion of the total cellular pool of the 53-kDa variant, p50, and p55(PIK) was present in antiphosphotyrosine immunoprecipitates from unstimulated muscle, whereas these immunoprecipitates contained only a very small proportion of the cellular pool of p85 alpha, p85 beta, and the 48-kDa variant, Insulin greatly increased the levels of the 48-kDa variant in antiphosphotyrosine immunoprecipitates and caused smaller -fold increases in the levels of p85 alpha, p85 beta, and the 53-kDa variant. The levels of p50 and p55(PIK) were not significantly changed. These properties indicate mechanisms by which specificity is achieved in the PI 3-kinase signaling system.	UNIV CAMBRIDGE, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND; KAROLINSKA HOSP, DEPT CLIN PHYSIOL, S-10401 STOCKHOLM, SWEDEN	University of Cambridge; Karolinska Institutet; Karolinska University Hospital	Shepherd, PR (corresponding author), UCL, DEPT BIOCHEM, GOWER ST, LONDON WC1E 6BT, ENGLAND.			Bevan, Paul/0000-0002-0656-9164; Zierath, Juleen/0000-0001-6891-7497				Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELMENDORF JS, 1995, BIOCHEM BIOPH RES CO, V208, P1147, DOI 10.1006/bbrc.1995.1453; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONS S, 1995, MOL CELL BIOL, V15, P4453; REIF K, 1993, J BIOL CHEM, V268, P10780; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WHITE MF, 1994, J BIOL CHEM, V269, P1; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZIERATH JR, 1992, FEBS LETT, V307, P379, DOI 10.1016/0014-5793(92)80717-U; ZIERATH JR, 1994, DIABETOLOGIA, V37, P270, DOI 10.1007/BF00398054	49	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19000	19007		10.1074/jbc.272.30.19000	http://dx.doi.org/10.1074/jbc.272.30.19000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228082	hybrid			2022-12-27	WOS:A1997XM34200073
J	Zou, AH; Elgort, MG; Allegretto, EA				Zou, AH; Elgort, MG; Allegretto, EA			Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D-3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamn D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; OSTEOCALCIN GENE; ACID RECEPTORS; ALL-TRANS; 24-HYDROXYLASE GENE; NUCLEAR RECEPTOR; LEUKEMIA-CELLS; BETA-GENE; 9-CIS; EXPRESSION	We have previously shown that RNA levels of kidney 25-hydroxyvitamin D-3-24-hydroxylase (24(OH)ase), a key metabolic enzyme for 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), is up-regulated by retinoids in mice within hours, Deletion analysis of similar to 5500 base pairs of the human 24(OH)ase promoter showed that the sequence between -316 and -142 contained the information necessary and sufficient for retinoid-induced activation of the promoter, This region contains two previously defined vitamin D-responsive elements (VDREs) at -294 to -274 and -174 to -151, Mutation of either VDRE diminished responsiveness of the -316 to -22 promoter sequence to retinoids or 1,25(OH)(2)D-3, while mutation of both VDREs essentially abolished the activity of the ligands via the promoter, Heterologous promoter vectors driven by the VDREs were responsive to a retinoid X receptor (RXR)-selective ligand (LG100268), a retinoic acid receptor (RAR)-selective ligand (TTNPB), or 1,25(OH)(2)D-3, while combinations of LG100268 with either TTNPB or 1,25(OH)(2)D-3 resulted in additive increases in activity, Band shift analyses showed that vitamin D receptor, RAR, or RXR alone did not bind to the VDREs; however, the combination of either vitamin D receptor or RAR with RXR led to retardation of each of the labeled probes, Treatment of nontransfected CV-1 cells with retinoids or 1,25(OH)(2)D-3 resulted in induction of 24(OH)ase RNA, and ligand combinations led to increased RNA levels, These data imply that either dr both of the heterodimer partners can be occupied with ligand to induce this enzyme, with dual receptor occupation leading to increased activation.	LIGAND PHARMACEUT INC, DEPT RETINOID RES, SAN DIEGO, CA 92121 USA	Ligand Pharmaceuticals								ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BROWN G, 1994, LEUKEMIA, V8, P806; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hofmann Clementine, 1994, P387; JAMES SY, 1995, J MOL ENDOCRINOL, V14, P391, DOI 10.1677/jme.0.0140391; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OLIVA A, 1993, BIOCHEM BIOPH RES CO, V191, P908, DOI 10.1006/bbrc.1993.1303; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PIKE JW, 1994, J BONE MINER RES, V9, pS144; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAIMI M, 1991, LEUKEMIA RES, V15, P1145, DOI 10.1016/0145-2126(91)90183-T; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VERSTUYF A, 1995, J STEROID BIOCHEM, V53, P431, DOI 10.1016/0960-0760(95)00089-I; WALLINGTON LA, 1995, LEUKEMIA, V9, P1185; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	44	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19027	19034		10.1074/jbc.272.30.19027	http://dx.doi.org/10.1074/jbc.272.30.19027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228086	Green Submitted, hybrid			2022-12-27	WOS:A1997XM34200077
J	Ma, S; Wozniak, DJ; Ohman, DE				Ma, S; Wozniak, DJ; Ohman, DE			Identification of the histidine protein kinase KinB in Pseudomonas aeruginosa and its phosphorylation of the alginate regulator AlgB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; 2-COMPONENT REGULATORS; GENETIC-ANALYSIS; CYSTIC-FIBROSIS; EXPRESSION; CONSTRUCTION; COMPONENTS; BINDING; INVITRO	The exopolysaccharide alginate is an important virulence factor in chronic lung infections caused by the bacterium Pseudomonas aeruginosa. Two positive activators for alginate synthesis, algB and algR, are members of a superfamily of response regulators of the two-component regulatory system. AlgB belongs to the NtrC subfamily of response regulators and is required for high-level production of alginate. In this study, an open reading frame encoding a polypeptide of 66 kh)a, designated kinB, was identified immediately downstream of algB. The sequence of KinB is homologous to the histidine protein kinase members of two-component regulatory systems. Western blot analysis of a P. aeruginosa strain carrying a kinB-lacZ protein fusion and studies of KinB-phoA fusions indicate that KinB localizes to the inner membrane and has a NH2-terminal periplasmic domain, A KinB derivative containing the COOH terminus of KinB was generated and purified. In the presence of [gamma-P-32]ATP, the purified COOH-terminal KinB protein was observed to undergo progressive autophosphorylation in vitro. Moreover, the phosphoryl label of KinB could be rapidly transferred to purified AlgB, Substitutions of the residues conserved among histidine protein kinases abolished KinB autophosphorylation, These results provide evidence that KinB encodes the AlgB cognate histidine protein kinase.	UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; VET ADM MED CTR,MEMPHIS,TN 38163; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MICROBIOL & IMMUNOL,WINSTON SALEM,NC 27157	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019146, R56AI019146] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35177, AI19146] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIBA H, 1989, J BIOL CHEM, V264, P8563; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALTIMORE RS, 1982, J INFECT DIS, V141, P238; Baynham PJ, 1996, MOL MICROBIOL, V22, P97, DOI 10.1111/j.1365-2958.1996.tb02659.x; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CHITNIS CE, 1993, MOL MICROBIOL, V8, P583, DOI 10.1111/j.1365-2958.1993.tb01602.x; DEAN CR, 1993, MOL MICROBIOL, V8, P1095, DOI 10.1111/j.1365-2958.1993.tb01654.x; DERETIC V, 1992, MOL MICROBIOL, V6, P2761, DOI 10.1111/j.1365-2958.1992.tb01455.x; DERETIC V, 1989, J BACTERIOL, V171, P1278, DOI 10.1128/jb.171.3.1278-1283.1989; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; FLYNN JL, 1988, J BACTERIOL, V170, P3228, DOI 10.1128/jb.170.7.3228-3236.1988; GOLDBERG JB, 1987, J BACTERIOL, V169, P1593, DOI 10.1128/jb.169.4.1593-1602.1987; GOLDBERG JB, 1984, J BACTERIOL, V158, P1115, DOI 10.1128/JB.158.3.1115-1121.1984; GOVAN JRW, 1986, MICROBIOL SCI, V3, P302; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HOBBS M, 1993, MOL MICROBIOL, V7, P669, DOI 10.1111/j.1365-2958.1993.tb01158.x; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MARCUS H, 1985, INFECT IMMUN, V47, P723, DOI 10.1128/IAI.47.3.723-729.1985; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; Ohman DE, 1996, MOLECULAR BIOLOGY OF PSEUDOMONADS, P472; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SEKI T, 1988, J BACTERIOL, V170, P5935, DOI 10.1128/jb.170.12.5935-5938.1988; SELVARAJ G, 1984, GENE, V32, P235, DOI 10.1016/0378-1119(84)90051-9; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P250; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1985, 2 COMPONENT SIGNAL T, P25; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; WALKER MS, 1993, J BIOL CHEM, V268, P8391; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; Whitchurch CB, 1996, P NATL ACAD SCI USA, V93, P9839, DOI 10.1073/pnas.93.18.9839; WOZNIAK DJ, 1991, J BACTERIOL, V173, P1406, DOI 10.1128/jb.173.4.1406-1413.1991; WOZNIAK DJ, 1994, J BACTERIOL, V176, P6007, DOI 10.1128/jb.176.19.6007-6014.1994; Yu H, 1997, J BACTERIOL, V179, P187, DOI 10.1128/jb.179.1.187-193.1997	52	34	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17952	17960		10.1074/jbc.272.29.17952	http://dx.doi.org/10.1074/jbc.272.29.17952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218420	hybrid			2022-12-27	WOS:A1997XL73500010
J	Paire, A; BernierValentin, F; SelmiRuby, S; Rousset, B				Paire, A; BernierValentin, F; SelmiRuby, S; Rousset, B			Characterization of the rat thyroid iodide transporter using anti-peptide antibodies - Relationship between its expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING HORMONE; CELLS; CULTURE	Anti-peptide antibodies directed against the C-terminal portion (amino acids 603-618) of the rat thyroid iodide transporter (rTIT) have been produced to characterize the molecular forms of rTIT in the rat thyroid and in the functional rat thyroid cell line, FRTL-5. rTIT is located on the basolateral membrane of rat thyroid follicular cells and randomly distributed on the plasma membrane of FRTL-5 cells that do not exhibit cell polarity, The major rTIT component corresponds to an 80-90kDa glycosylated protein, After treatment of cell membrane fractions with N-glycosidase F or incubation of FRTL-5 cells with tunicamycin, rTIT has an apparent molecular mass of about 55 kDa, FRTL-5 cells cultured in the presence of TSH exhibit a high rTIT content and a high iodide uptake activity (IUA), Upon either removal of TSH or addition of cycloheximide, IUA declines more rapidly than rTIT. The half-life of rTIT was about 4 days, Re-exposure of 7-day TSH-deprived FRTL-5 cells to TSH causes a rapid synthesis of the glycosylated rTIT but a delayed re-induction of IUA, Tunicamycin totally prevents the TSH-dependent re-expression and activity of rTIT, Our data bring basic information on the location, structure, and turnover of rTIT and suggest that its activity is subjected to diverse control mechanisms including regulatory proteins.	FAC MED LYON, RTH LAENNEC, INSERM, U369, F-69372 LYON 08, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			selmi-ruby, Samia/L-3509-2016; RUBY, Samia/T-1131-2019	RUBY, Samia/0000-0001-9491-9285				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; EKHOLM R, 1990, INT REV CYTOL, V120, P243; Endo T, 1996, BIOCHEM BIOPH RES CO, V224, P92, DOI 10.1006/bbrc.1996.0989; Endo T, 1996, BIOCHEM BIOPH RES CO, V228, P199, DOI 10.1006/bbrc.1996.1639; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KNOPP J, 1970, J BIOL CHEM, V245, P4403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCOCCI C, 1984, ENDOCRINOLOGY, V115, P2123, DOI 10.1210/endo-115-6-2123; Rajas F, 1996, J BIOL CHEM, V271, P29882, DOI 10.1074/jbc.271.47.29882; Weber K., 1975, PROTEINS, VI, P179; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WOLFF J, 1964, PHYSIOL REV, V44, P45, DOI 10.1152/physrev.1964.44.1.45	16	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18245	18249		10.1074/jbc.272.29.18245	http://dx.doi.org/10.1074/jbc.272.29.18245			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218462	hybrid			2022-12-27	WOS:A1997XL73500052
J	Qian, XB; Balestra, ME; Innerarity, TL				Qian, XB; Balestra, ME; Innerarity, TL			Two distinct TATA-less promoters direct tissue-specific expression of the rat apo-B editing catalytic polypeptide 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; APOLIPOPROTEIN-B; RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; BINDING PROTEIN; LIVER; COMPLEMENTATION; LOCALIZATION; MODULATION; SECRETION	The species and tissue specificity of apolipoprotein (ape) B mRNA editing is determined by the expression of apoB editing catalytic polypeptide 1 (APOBEC-1), the cytidine deaminase that catalyzes apoB mRNA editing. To understand the molecular mechanisms that regulate the transcription of APOBEC-1, we characterized Fat APOBEC-1 cDNA and genomic DNA. cDNA cloning and RNase protection analysis showed two alternative promoters for the tissue-specific expression of APBBEC-1. in the liver and intestine, P-liv and P-int. Both promoters lack a TATA box, and P-int belongs to the MED-1 class of promoters, which initiate transcription at multiple sites. We also identified two allelic forms of the APOBEC-1 gene from the characterization of two rat APOBEC-1 P1 genomic clones, RE4 and RE5. The RE4 allele is 18 Kilobases long and contains six exons and five introns, whereas the RE5 allele contains an additional similar to 8 Kilobases of intron sequences and an extra exon encoding a 5'-untranslated region; however, the APOBEC-1. transcripts from the two alleles appear to have similar, If not identical, functions, Transgenic mouse studies showed that P-liv was preferentially used in the liver, kidney, brain, and adipose tissues, whereas P-int was preferentially used in the small intestine, stomach, and lung. Our results suggest that the tissue-specific expression of APOBEC-1 is governed by multiple regulatory elements exerting control over at single coding sequence, The presence car absence of these regulatory elements may determine the tissue-specific expression of APOBEC-1 in other mammalian species.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco	Qian, XB (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM CL, 1990, J BIOL CHEM, V265, P19263; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GIANNONI F, 1995, J LIPID RES, V36, P1664; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; INUI Y, 1994, J LIPID RES, V35, P1477; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483	33	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18060	18070		10.1074/jbc.272.29.18060	http://dx.doi.org/10.1074/jbc.272.29.18060			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218436	hybrid			2022-12-27	WOS:A1997XL73500026
J	Read, RD; Lionberger, JM; Smithgall, TE				Read, RD; Lionberger, JM; Smithgall, TE			Oligomerization of the Fes tyrosine kinase - Evidence for a coiled-coil domain in the unique N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID DIFFERENTIATION; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; LEUKEMIA-CELLS; GROWTH-FACTORS; PROTEIN; BCR; EXPRESSION; ABL; RECEPTOR	The c-fes proto-oncogene encodes a non-receptor tyrosine kinase (Fes) that has been implicated in cytokine receptor signal transduction and myeloid differentiation. Previous work from our laboratory has shown that Fes autophosphorylates via an intermolecular mechanism more commonly associated with growth factor receptor tyrosine kinases. Analysis of the Fes amino acid sequence with the COILS algorithm indicates that the N-terminal region of the protein has a very high probability of forming coiled-coil structures often associated with oligomeric proteins. These findings suggest that oligomerization may be a prerequisite for trans-auto-phosphorylation and activation of Fes. To establish whether the active form of Fes is oligomeric, we performed gel-filtration experiments with recombinant Fes and found that it eluted as a single symmetrical peak of approximately 500 kDa. No evidence of the monomeric, 93-kDa form of the protein was observed. Deletion of the unique N-terminal domain (amino acids 1-450, including the coiled-coil homology region) completely abolished the formation of oligomers. Furthermore, co-precipitation assays demonstrated that an immobilized glutathione S-transferase fusion protein containing the Fes N-terminal region bound to full-length Fes but not to a mutant lacking the N-terminal region. Similarly, a recombinant Fes N-terminal domain protein was readily cross-linked in vitro, whereas the SH2 and kinase domains were refractory to cross-linking. Incubation of wild-type Fes with a kinase-inactive Fes mutant or with the isolated N-terminal region suppressed Fes autophosphorylation in vitro, suggesting that oligomerization may be essential for autophosphorylation of full-length Fes. The presence of an oligomerization function iu the Fes family of tyrosine kinases suggests a novel mechanism for non-receptor protein-tyrosine kinase regulation.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [P30 CA36727, CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CARE A, 1994, ONCOGENE, V9, P739; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FANG F, 1993, BIOCHEMISTRY-US, V32, P6995, DOI 10.1021/bi00078a026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1989, ONCOGENE, V4, P759; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1992, CANCER SURV, V15, P37; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YU G, 1989, J BIOL CHEM, V264, P10276; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	40	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18498	18503		10.1074/jbc.272.29.18498	http://dx.doi.org/10.1074/jbc.272.29.18498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218495	hybrid			2022-12-27	WOS:A1997XL73500085
J	Ma, ZM; Landt, M; Bohrer, A; Ramanadham, S; Kipnis, DM; Turk, J				Ma, ZM; Landt, M; Bohrer, A; Ramanadham, S; Kipnis, DM; Turk, J			Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; BETA-CELLS; INSULIN-SECRETION; MESSENGER-RNA; OXIDATIVE-METABOLISM; RAT PANCREAS; LANGERHANS; GENE; RELEASE; EXPRESSION	Culture of rat pancreatic islets with interleukin-l (IL-1) results in up-regulation of the inducible isoform of nitric oxide synthase and overproduction of nitric oxide (NO), This is associated with reversible inhibition of both glucose-induced insulin secretion and islet glucose oxidation, and these effects are prevented by the inducible nitric oxide synthase inhibitor N-G-monomethylarginine. IL-1 also induces accumulation of nonesterified arachidonic acid in islets by an NO dependent mechanism, and one potential explanation for that effect would involve an IL-l-induced enhancement of islet glycolytic flux. We have therefore examined effects of IL-1 on islet glycolytic utilization of glucose and find that culture of islets with IL-1 in medium containing 5.5 mM glucose results in suppression of islet glucose utilization subsequently measured at glucose concentrations between 6 and 18 mM. The IL-1-induced suppression of islet glucose utilization is associated with a decline in islet glucokinase mRNA content, as determined by competitive reverse transcriptase polymerase chain reaction, and in glucokinase protein synthesis, as determined by immuoprecipitation experiments, and all of these effects are prevented by N-G-monomethylarginine. These findings suggest that IL-1 can down-regulate islet glucokinase, which is the primary component of the islet glucose-sensor apparatus, by an NO-dependent mechanism, Because reductions in islet glucokinase levels are known to cause a form of type II diabetes mellitus, these observations raise the possibility that factors which increase islet NO levels might contribute to development of glucose intolerance.	WASHINGTON UNIV, SCH MED,DEPT MED,MASS SPECTROMETRY RESOURCE, DIV ENDOCRINOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV DIABET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV METAB, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BEDOYA FJ, 1986, DIABETES, V35, P61, DOI 10.2337/diabetes.35.1.61; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; BEGGS M, 1990, FEBS LETT, V267, P217, DOI 10.1016/0014-5793(90)80928-C; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; DAVIS L, 1994, BASIC METHODS MOL BI, P669; Davis LG, 1994, BASIC METHODS MOL BI; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; EIZIRIK DL, 1988, ACTA ENDOCRINOL-COP, V119, P321, DOI 10.1530/acta.0.1190321; EIZIRIK DL, 1988, ENDOCRINOLOGY, V123, P1001, DOI 10.1210/endo-123-2-1001; EIZIRIK DL, 1989, ENDOCRINOLOGY, V125, P752, DOI 10.1210/endo-125-2-752; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HAKAN LA, 1979, BIOCHEM J, V182, P797; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KORANYI LI, 1991, DIABETES, V40, P401, DOI 10.2337/diabetes.40.3.401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MALAISSE WJ, 1976, ACTA DIABETOL LAT, V13, P202, DOI 10.1007/BF02581118; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1988, DIABETES, V37, P1311, DOI 10.2337/diabetes.37.10.1311; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MONCADA S, 1991, PHARMACOL REV, V43, P109; PACE CS, 1975, DIABETES, V24, P476, DOI 10.2337/diabetes.24.5.476; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; RABINOVITCH A, 1993, DIABETES REV, V1, P215; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SANDLER S, 1987, ENDOCRINOLOGY, V121, P1424, DOI 10.1210/endo-121-4-1424; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; SHIMA K, 1987, HORM METAB RES, V19, P395, DOI 10.1055/s-2007-1011835; SHIMIZU T, 1988, DIABETES, V37, P1524, DOI 10.2337/diabetes.37.11.1524; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN F, 1993, J CLIN INVEST, V92, P1174, DOI 10.1172/JCI116687; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WEIR GC, 1993, NEW ENGL J MED, V328, P729, DOI 10.1056/NEJM199303113281012; WELSH N, 1991, DIABETES, V40, P290, DOI 10.2337/diabetes.40.2.290; YIN L, 1992, DIABETES, V41, P792; ZAWALICH WS, 1979, DIABETOLOGIA, V16, P115, DOI 10.1007/BF01225460; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	75	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17827	17835		10.1074/jbc.272.28.17827	http://dx.doi.org/10.1074/jbc.272.28.17827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211938	hybrid			2022-12-27	WOS:A1997XK16500081
J	Malaney, S; Trumpower, BL; Deber, CM; Robinson, BH				Malaney, S; Trumpower, BL; Deber, CM; Robinson, BH			The N terminus of the Qcr7 protein of the cytochrome bc(1) complex is not essential for import into mitochondria in Saccharomyces cerevisiae but is essential for assembly of the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C REDUCTASE COMPLEX; ELECTRON-TRANSFER; 14-KDA SUBUNIT; POLYPEPTIDE SUBUNITS; RESPIRATORY-CHAIN; UBIQUINOL; YEAST; GENE; OXIDOREDUCTASE; SEQUENCE	Subunit 7 of the yeast cytochrome be, complex is encoded by the nuclear QCR7 gene and is essential for respiration, This protein does not contain a cleavable N-terminal mitochondrial targeting sequence, and it is not understood how the Qcr7 protein is imported into mitochondria and assembled into the compiler, To test the role of the N terminus of the Qcr7 protein in mitochondrial import, assembly of the complex, and proton translocation, we inactivated the endogenous QCR7 gene and expressed mutated qcr7 genes capable of synthesizing proteins truncated by 7, 10, 14, and 20 residues (Qcr7p-Delta 7, Qcr7p-Delta 10, Qcr7p-Delta 14, and Qcr7p-Delta 20, respectively) from the N terminus. In addition, we studied two mutants containing Qcr7 proteins with point mutations in addition to a Delta 7 truncation, Qcr7p-Delta 7(D13V) and Qcr7p-Delta 7(R10K). All the mutant proteins with the exception of Qcr7p-Delta 10 were present in the mitochondria at 30 degrees C, although most at lower steady-state levels than the Qcr7p from the strain overexpressing wild type QCR7, The absence of the Qcr7p-Delta 10 may be the result of an unstable protein or a decrease in the efficiency of mitochondrial import due to its compromised amphipathic a-helix and the presence of a negative charge exposed at the N terminus, Cytochrome c reductase activities and the amounts of ATP synthesized were comparable with the wild type in the strain expressing Qcr7p-Delta 7. The strain expressing Qcr7p-Delta 7(R10K) had an identical phenotype to the one containing the Qcr7p-Delta 7, whereas strains expressing the Qcr7p-Delta 10, Qcr7p-Delta 14, Qcr7p-Delta 20, and Qcr7p-Delta 7(D13V) were all respiration-deficient, Examination of the steady-state levels of complex III subunits showed that core protein 2, cytochrome c(1), the iron-sulfur protein, and the Il-kDa subunit are reduced in respiration-deficient mutant strains, Results from deletion analyses indicate that the N-terminal 20 residues (after Met-1) of the Qcr7 protein are not essential for import into mitochondria and that the N-terminal seven residues (after Met-1) are not involved in proton translocation. The results of this work show, however, that the N terminus of the Qcr7 protein is essential for the biosynthesis of ubiquinol-cytochrome c reductase.	HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,RES INST,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,RES INST,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Dartmouth College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BRANDT U, 1994, J BIOL CHEM, V269, P12947; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; DEHAAN M, 1984, EUR J BIOCHEM, V138, P169; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Fourney R.M., 1988, FOCUS, V10, P5; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GRAHAM LA, 1992, FEBS LETT, V313, P251, DOI 10.1016/0014-5793(92)81203-X; Guthrie C, 1991, GUIDE YEAST GENETICS; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HEMRIKA W, 1994, EUR J BIOCHEM, V220, P569, DOI 10.1111/j.1432-1033.1994.tb18657.x; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JAPA S, 1989, J BIOL CHEM, V264, P13994; LINK TA, 1987, CYTOCHROME SYSTEMS M, P289; LORUSSO M, 1989, EUR J BIOCHEM, V179, P535, DOI 10.1111/j.1432-1033.1989.tb14580.x; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; ROBINSON BH, 1986, J CLIN INVEST, V77, P1422, DOI 10.1172/JCI112453; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; WALLACE DC, 1982, MICROBIOL REV, V46, P208, DOI 10.1128/MMBR.46.2.208-240.1982; YANG MJ, 1994, J BIOL CHEM, V269, P1270; YANG XH, 1986, METHOD ENZYMOL, V126, P316	27	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17495	17501		10.1074/jbc.272.28.17495	http://dx.doi.org/10.1074/jbc.272.28.17495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211895	hybrid			2022-12-27	WOS:A1997XK16500038
J	Haynes, RL; Zheng, TL; Nicchitta, CV				Haynes, RL; Zheng, TL; Nicchitta, CV			Structure and folding of nascent polypeptide chains during protein translocation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBILIZED ROUGH MICROSOMES; SECRETORY PROTEINS; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; DISULFIDE BONDS; MESSENGER-RNA; ER-MEMBRANE; BIP; COMPLEX	To investigate the role of protein folding and chaperone-nascent chain interactions in translocation across the endoplasmic reticulum membrane, the translocation of wild type and mutant forms of preprolactin were studied in vivo and in vitro, The preprolactin mutant studied contains an 18-amino acid substitution at the amino terminus of the mature protein, eliminating a disulfide-bonded loop domain. In COS-7 cells, mutant prolactin accumulated in the endoplasmic reticulum as stable protein-protein and disulfide-bonded aggregates, whereas wild type prolactin was efficiently secreted. In vitro, wild type and mutant preprolactin translocated with equal efficiency although both translation products were recovered as heterogeneous aggregates. Studies with translocation intermediates indicated that aggregation occurred co-translationally. To evaluate the contribution of lumenal chaperones to translocation and folding, in vitro studies were performed with native and reconstituted, chaperone-deficient membranes, The absence of lumenal chaperones was associated with a decrease in translocation efficiency and pronounced aggregation of the translation products. These studies suggest that chaperone-nascent chain interactions significantly enhance translocation and indicate that in the absence of such interactions, aggregation can serve as the predominant in vitro protein folding end point. The ramifications of these observations on investigations into the mechanism of translocation are discussed.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Haynes, Robin L/M-4401-2016	Haynes, Robin L/0000-0003-4909-9585	NIDDK NIH HHS [DK47897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DONEEN BA, 1979, BIOCHEMISTRY-US, V18, P4851, DOI 10.1021/bi00589a013; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Horst M, 1996, PROTEIN SCI, V5, P759; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; Nicchitta CV, 1996, SEMIN CELL DEV BIOL, V7, P497, DOI 10.1006/scdb.1996.0062; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REDICK SD, 1995, J CELL SCI, V108, P1761; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797	62	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17126	17133		10.1074/jbc.272.27.17126	http://dx.doi.org/10.1074/jbc.272.27.17126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202031	hybrid			2022-12-27	WOS:A1997XH44600063
J	Kolman, MF; Egelhoff, TT				Kolman, MF; Egelhoff, TT			Dictyostelium myosin heavy chain kinase A subdomains - Coiled-coil and WD repeat roles in oligomerization and substrate targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; PURIFICATION; PROTEINS; REPLACEMENT; DISCOIDEUM; SUBUNIT; FAMILY; GENE	Myosin heavy chain kinase A (MHCK A) participates in the regulation of cytoskeletal myosin assembly in Dictyostelium, driving filament disassembly via phosphorylation of sites in the myosin tail. MHCK A contains an amino-terminal coiled-coil domain, a novel central catalytic domain, and a carboxyl-terminal domain containing a 7-fold WD repeat motif, We have overexpressed MHCK A truncation constructs to clarify the roles of each of these domains, Recombinant full-length MHCK A, MHCK A lacking the predicted coiled-coil domain, and MHCK A lacking the WD repeat domain were expressed at high levels in Dictyostelium cells lacking endogenous MHCK A, Biochemical analysis of the purified proteins demonstrates that the putative coiled-coil domain is responsible for the oligomerization of the MHCK A holoenzyme. Removal of the WD repeat domain had no effect on catalytic activity toward a synthetic peptide, hut did result in a 95% loss of protein kinase activity when native myosin filaments were used as the substrate. Cellular analysis confirms that the same severe loss of activity against myosin occurs in vivo when the WD repeat domain is eliminated. These results suggest that the WD repeat domain of MHCK A serves to target this enzyme to its physiological substrate.			Kolman, MF (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA.				NHLBI NIH HHS [HL07653] Funding Source: Medline; NIGMS NIH HHS [GM50009] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; COTE GP, 1987, J BIOL CHEM, V262, P1065; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; JAY PY, 1995, J CELL SCI, V108, P387; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MEDLEY QG, 1992, BIOCHIM BIOPHYS ACTA, V1175, P7, DOI 10.1016/0167-4889(92)90003-T; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Thanos CD, 1996, PROTEIN SCI, V5, P782; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818	32	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16904	16910		10.1074/jbc.272.27.16904	http://dx.doi.org/10.1074/jbc.272.27.16904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201999	hybrid			2022-12-27	WOS:A1997XH44600031
J	Morel, P; Cherny, D; Ehrlich, SD; Cassuto, E				Morel, P; Cherny, D; Ehrlich, SD; Cassuto, E			Recombination-dependent repair of DNA double-strand breaks with purified proteins from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED BRANCH MIGRATION; HELICASE-II UVRD; RECA PROTEIN; GENETIC-RECOMBINATION; ILLEGITIMATE RECOMBINATION; DUPLEX DNA; EXCHANGE; BINDING	We have developed an in vitro system in which repair of DNA double-strand breaks is performed by purified proteins of Escherichia coli, A segment was deleted from a circular duplex DNA molecule by restriction at two sites, 3' single-stranded overhangs were introduced at both ends of the remaining linear fragment, In a first step, RecA protein catalyzed the formation of a D-loop between one single-stranded tail and a homologous undeleted supercolied DNA molecule, In a second step, E. coli DNA polymerase II or III used the 3' end in the D-loop as a primer to copy the missing sequences of the linear substrate on one strand of the supercolied template, Under proper conditions, the integrity of the deleted substrate was restored, as shown by analysis of the products by electrophoresis, restriction, and transformation, In this reaction, DNA synthesis is strictly dependent on recombination, and repair is achieved without formation of a Holliday junction.	INRA, F-78352 JOUY EN JOSAS, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE; RUSSIAN ACAD SCI, INST MOL GENET, ELECTRON MICROSCOPY LAB, MOSCOW 123182, RUSSIA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Russian Academy of Sciences			Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; morel, patrice/0000-0003-1690-8032				BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CASSUTO E, 1986, NUCLEIC ACIDS RES, V14, P1149, DOI 10.1093/nar/14.3.1149; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CUNNINGHAM RP, 1979, NATURE, V281, P191, DOI 10.1038/281191a0; Delain E, 1995, VISUALIZATION NUCL A, P35; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUHN B, 1982, EUR J BIOCHEM, V125, P63, DOI 10.1111/j.1432-1033.1982.tb06651.x; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; LIN FL, 1984, MOL CELL BIOL, V10, P103; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; MORTIMER RK, 1958, RADIAT RES, V9, P3312; Mosig Gisela, 1994, P54; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; POLLARD EC, 1981, MOL GEN GENET, V184, P421, DOI 10.1007/BF00352516; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Sambrook J., 2002, MOL CLONING LAB MANU; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; Skaliter R, 1996, J BIOL CHEM, V271, P2478, DOI 10.1074/jbc.271.5.2478; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P168; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451	39	5	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17091	17096		10.1074/jbc.272.27.17091	http://dx.doi.org/10.1074/jbc.272.27.17091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202026	Green Published, hybrid			2022-12-27	WOS:A1997XH44600058
J	Heyduk, E; Heyduk, T; Claus, P; Wisniewski, JR				Heyduk, E; Heyduk, T; Claus, P; Wisniewski, JR			Conformational changes of DNA induced by binding of Chironomus high mobility group protein 1a (cHMG1a) - Regions flanking an HMG1 box domain do not influence the bend angle of the DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; NUCLEOPROTEIN STRUCTURES; RECEPTOR PROTEIN; SRY; COMPLEX; MURINE; LEF-1	High mobility group (HMG) proteins are thought to facilitate assembly of higher order chromatin structure through modulation of DNA conformation. In this work we investigate the bending of a 30-base pair DNA fragment induced by Chironomus HMG1 (cHMG1a), and HMGI (cHMGI) proteins. The DNA bending was measured in solution by monitoring the end-to-end distance between fluorescence probes attached to opposite ends of the DNA fragment. The distance was measured by fluorescence energy transfer using a novel europium chelate as a fluorescence donor. These measurements revealed that the end-to-end distance in the 30-base pair DNA was decreased from similar to 100 Angstrom in free DNA to similar to 50.5 Angstrom in cHMG1a.DNA complex. The most probable DNA bending angle consistent with these distance measurements is about 150 degrees. The deletion of the charged regulatory domains located close to the C terminus of the HMG1 box domain of cHMG1a protein had no effect on the induced bend angle. The ability to induce a large DNA bend distinguishes the cHMG1 from the cHMGI protein. Only small perturbation of the DNA conformation was observed upon binding of the cHMGI protein. A strong DNA bending activity of cHMG1a and its relative abundance in the cell suggests that this protein plays a very important role in modulation of chromatin structure.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104; UNIV GOTTINGEN,INST ZOOL ENTWICKLUNGSBIOL 3,D-37073 GOTTINGEN,GERMANY	Saint Louis University; University of Gottingen			Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CLAUS P, 1994, J BIOL CHEM, V269, P33042; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x	40	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19763	19770		10.1074/jbc.272.32.19763	http://dx.doi.org/10.1074/jbc.272.32.19763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242635	hybrid			2022-12-27	WOS:A1997XQ05900022
J	Gantt, SM; Clavijo, P; Bai, XM; Esko, JD; Sinnis, P				Gantt, SM; Clavijo, P; Bai, XM; Esko, JD; Sinnis, P			Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE N-SULFOTRANSFERASE; PLATELET GLYCOPROTEIN-IIIB; HEPARAN-SULFATE; I REPEATS; PLASMODIUM-FALCIPARUM; SURFACE-ANTIGEN; SEQUENCE; PEPTIDES; SPOROZOITE; PROPERDIN	The malaria circumsporozoite protein (CS), thrombospondin (TSP) and several other proteins including the terminal complement proteins and the neural adhesion molecules F-spondin and Unc-5, share a cell adhesive sequence, In CS this sequence is designated as region II-plus (EWSPCSVTCGNGIQVRIK) and in TSP it is found in the type I repeats. Previous studies aimed at fine mapping the amino acid residues required for cell adhesion have yielded discrepant results. Here we show in three different cell lines that the downstream basic residues are required for cell adhesion whereas the CS-VTCG sequence is not, Using mutant Chinese hamster ovary cells selected for deficiencies in proteoglycan synthesis, we show that in wild type cells, heparan sulfate proteoglycans are the binding sites for this motif, This finding is supported by additional experiments with two other cell lines demonstrating that treatment with heparitinase but not chondroitinase abolishes cell adhesion to peptides representing this motif, Using Chinese hamster ovary cell mutants deficient in heparan sulfate proteoglycans but possessing chondroitin sulfate proteoglycans, we show that cell surface chondroitin sulfate proteoglycans can also mediate binding to this motif although higher concentrations of peptides are required for adhesion, Chondroitinase, but not heparitinase, treatment of these cells destroys cell surface-binding sites. Taken together, these results indicate that cell adhesion to this motif involves an interaction between the downstream positively-charged residues and the negatively charged glycosaminoglycan chains of heparan sulfate, or in some cases chondroitin sulfate, proteoglycans on the cell surface.	NYU, MED CTR, DEPT MED & MOL PARASITOL, NEW YORK, NY 10016 USA; UNIV CALIF SAN DIEGO, CTR CANC, DIV CELLULAR & MOL MED, GLYCOBIOL PROGRAM, SAN DIEGO, CA 92103 USA	New York University; University of California System; University of California San Diego				Gantt, Soren/0000-0001-5743-3606	NIAID NIH HHS [P01 AI35703, K11 AI001175-05] Funding Source: Medline; NIDDK NIH HHS [5T35-DK-07421] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001175, P01AI035703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; CATIMEL B, 1992, BIOCHEM J, V284, P231, DOI 10.1042/bj2840231; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI WX, 1993, J BIOL CHEM, V268, P16179; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	52	51	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19205	19213		10.1074/jbc.272.31.19205	http://dx.doi.org/10.1074/jbc.272.31.19205			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235912	Green Accepted, hybrid			2022-12-27	WOS:A1997XP06300018
J	Jiang, BH; Zheng, JZ; Leung, SW; Roe, R; Semenza, GL				Jiang, BH; Zheng, JZ; Leung, SW; Roe, R; Semenza, GL			Transactivation and inhibitory domains of hypoxia-inducible factor 1 alpha. Modulation of transcriptional activity by oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; ENDOTHELIAL GROWTH-FACTOR; LACTATE-DEHYDROGENASE-A; FUNCTIONAL DOMAINS; ENHANCER ELEMENT; DNA-BINDING; FACTOR-I; V-MYB; C-MYB; ACTIVATION	Hypoxia-inducible factor 1 (HIF-1) binds to cis-acting hypoxia-response elements within the erythropoietin, vascular endothelial growth factor, and other genes to activate transcription in hypoxic cells, HIF-1 is a basic helix-loop-helix transcription factor composed of HIF-1 alpha and HIF-1 beta subunits, Here, we demonstrate that HIF-1 alpha contains two transactivation domains located between amino acids 531 and 826, When expressed as GAL4 fusion proteins, the transcriptional activity of these domains increased in response to hypoxia, Fusion protein levels were unaffected by changes in cellular O-2 tension, Two minimal transactivation domains were localized to amino acid residues 531-575 and 786-826, The transcriptional activation domains were separated by amino acid sequences that inhibited transactivation. Deletion analysis demonstrated that the gradual removal of inhibitory domain sequences (amino acids 576-785) was associated with progressively increased transcriptional activity of the fusion proteins, especially in cells cultured at 20% O-2. Transcriptional activity of GAL4/HIF-1 alpha fusion proteins was increased in cells exposed to 1% O-2, cobalt chloride, or desferrioxamine, each of which also increased levels of endogenous HIF-1 alpha protein but did not affect fusion protein levels, These results indicate that increased transcriptional activity mediated by HIF-1 in hypoxic cells results from both increased HIF-1 alpha protein levels and increased activity of HIF-1 alpha transactivation domains.	JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University				Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55338] Funding Source: Medline; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1991, J BIOL CHEM, V266, P15563; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Newton EM, 1996, MOL CELL BIOL, V16, P839; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; RATCLIFFE PJ, 1993, KIDNEY INT, V44, P887, DOI 10.1038/ki.1993.327; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SELDEN RF, 1987, CURRENT PROTOCOLS MO; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	43	497	528	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19253	19260		10.1074/jbc.272.31.19253	http://dx.doi.org/10.1074/jbc.272.31.19253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235919	hybrid			2022-12-27	WOS:A1997XP06300025
J	Tinti, C; Yang, CY; Seo, H; Conti, B; Kim, C; Joh, TH; Kim, KS				Tinti, C; Yang, CY; Seo, H; Conti, B; Kim, C; Joh, TH; Kim, KS			Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELL-LINE; DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; TRANSGENIC MICE; MESSENGER-RNA; BINDING PROTEIN; NERVOUS-SYSTEM; E-BOX; EXPRESSION; PROMOTER	Expression of tyrosine hydroxylase (TH) is limited to catecholamine-producing neurons and neuroendocrine cells in a cell type-specific manner and is inducible by the cAMP-regulated signaling pathway, Previous results indicated that the cAMP response element (CRE) residing at -45 to -38 base pairs upstream of the transcription initiation site is essential for both basal and cAMP-inducible promoter activity of the 2.4-kilobase or shorter upstream sequence of the TH gene (Kim, K. S., Lee, M. K., Carroll, J., and Joh, T. H. (1993) J. Biol. Chem. 268, 15689-15695; Lazaroff, M., Patankar, S., Yoon, S, O., and Chikaraishi, D. M. (1995) J. Biol. Chem, 270, 21579-21589). Here, we further report that the CRE is critical for the promoter activity of the 5.6- or 9.0-kilobase upstream sequences of the rat TH gene, which had been shown to direct the cell specific TH expression in vivo, To define the structure/function relationship of the CRE in transcriptional activation of the TH gene, we performed saturated mutational analyses of 12 nucleotides encompassing the CRE, Mutation of any nucleotide within the octamer motif results in a significant decrease of both basal and cAMP-inducible transcriptional activity of the TH reporter gene construct, Among the four nucleotides adjacent to the CRE (two 5' and two 3') only the G residue at the immediate 3' position is important for full transcriptional activity, DNase I footprint analysis indicates a positive correlation between in vivo promoter activity and in vitro interaction between the CRE motif and its cognate protein factor(s), Reconstruction experiments using a TH promoter in which the native CRE was rendered inactive show that the CRE can transactivate transcription in either orientation through a window of approximately 200 base pairs upstream of the transcription initiation site, suggesting that CRE supports transcriptional activation of the TH gene in a distance-dependent manner, Finally, when the distance between the CRE and TATA box was changed by inserting an additional 5 or 10 bases, it was observed that both insertional mutations increased activity by approximately 3-fold, The cAMP inducibility was as intact as the wild type construct. Together, these results are consistent with a model in which transcriptional activation of the TH gene by the CRE requires that it be located within a certain proximity of the CAP site but does not depend on a stringent stereospecific alignment in relationship to the TATA element.	UNIV TENNESSEE,COLL MED,DEPT ANAT & NEUROBIOL,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,DEPT NEUROL,MEMPHIS,TN 38163; CORNELL UNIV,COLL MED,MOL NEUROBIOL LAB,WM BURKE MED RES INST,NEW YORK,NY 10605	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Cornell University				Conti, Bruno/0000-0002-9185-5201	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH024285, R01MH024285, R01MH048866, R29MH048866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48866, MH24285] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARRIER A, 1993, J NEUROCHEM, V61, P2215, DOI 10.1111/j.1471-4159.1993.tb07462.x; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CICCARONE V, 1989, CANCER RES, V49, P219; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUQUET M, 1993, J NEUROCHEM, V60, P274, DOI 10.1111/j.1471-4159.1993.tb05848.x; FRANK DA, 1995, CELL, V79, P5; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1993, J BIOL CHEM, V268, P15689; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Seo HM, 1996, J NEUROSCI, V16, P4102; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SURI C, 1993, J NEUROSCI, V13, P1280; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TANK AW, 1986, MOL PHARMACOL, V30, P497; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	53	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19158	19164		10.1074/jbc.272.31.19158	http://dx.doi.org/10.1074/jbc.272.31.19158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235905	hybrid			2022-12-27	WOS:A1997XP06300011
J	Coleman, KG; Wautlet, BS; Morrissey, D; Mulheron, J; Sedman, SA; Brinkley, P; Price, S; Webster, KR				Coleman, KG; Wautlet, BS; Morrissey, D; Mulheron, J; Sedman, SA; Brinkley, P; Price, S; Webster, KR			Identification of CDK4 sequences involved in cyclin D1 and p16 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ALANINE-SCANNING MUTAGENESIS; CELL-CYCLE; PROTEIN-KINASE; G1 PHASE; PHOSPHORYLATION; ACTIVATION; G(1); CDC2; PROGRESSION	Activation of CDK4 is regulated, in part, by its association with a D-type cyclin. Conversely, CDK4 activity is inhibited when it is bound to the cyclin-dependent kinase inhibitor, p16(INK4A). TO investigate the molecular basis of the interactions between CDK4 and cyclin D1 or p16(INK4A) we performed site-directed mutagenesis of CDK4. The interaction was examined using in vitro translated wild type and mutant CDK4 proteins and bacterially expressed cyclin D1 and pig fusion proteins. As mutational analysis of CDC2 suggests that its cyclin binding domain is primarily located near its amino terminus, the majority of the mutations constructed in CDK4 were located near its amino terminus. In addition, CDK4 residues homologous to CDCS sites involved in Suc1 binding were also mutated. Our analysis indicates that cyclin D1 and pie binding sites are overlapping and located primarily near the amino terminus. All CDK4 mutations that resulted in decreased pig binding capability also diminished cyclin D1 binding. In contrast, amino-terminal sequences were identified, including the PSTAIRE region, that are important for cyclin D1 binding but are not involved in p16 binding.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT BIOMOL DRUG DISCOVERY ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOUBIN F, 1995, ONCOGENE, V10, P2281; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	37	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18869	18874		10.1074/jbc.272.30.18869	http://dx.doi.org/10.1074/jbc.272.30.18869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228064	hybrid			2022-12-27	WOS:A1997XM34200055
J	Fajas, L; Auboeuf, D; Raspe, E; Schoonjans, K; Lefebvre, AM; Saladin, R; Najib, J; Laville, M; Fruchart, JC; Deeb, S; VidalPuig, A; Flier, J; Briggs, MR; Staels, B; Vidal, H; Auwerx, J				Fajas, L; Auboeuf, D; Raspe, E; Schoonjans, K; Lefebvre, AM; Saladin, R; Najib, J; Laville, M; Fruchart, JC; Deeb, S; VidalPuig, A; Flier, J; Briggs, MR; Staels, B; Vidal, H; Auwerx, J			The organization, promoter analysis, and expression of the human PPAR gamma gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ADIPOSE-CELL-DIFFERENTIATION; PEROXISOME PROLIFERATOR; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; FATTY-ACIDS; ENHANCER; INCREASE	PPAR gamma is a member of the PPAR subfamily of nuclear receptors. In this work, the structure of the human PPAR gamma cDNA and gene was determined, and its promoters and tissue-specific expression were functionally characterized. Similar to the mouse, two PPAR isoforms, PPAR gamma 1 and PPAR gamma 2, were detected in man. The relative expression of human PPAR gamma was studied by a newly developed and sensitive reverse transcriptase-competitive polymerase chain reaction method, which allowed us to distinguish between PPAR gamma 1 and gamma 2 mRNA. In all tissues analyzed, PPAR gamma 2 was much less abundant than PPAR gamma 1. Adipose tissue and large intestine have the highest levels of PPAR gamma mRNA; kidney, liver, and small intestine have intermediate levels; whereas PPAR gamma is barely detectable in muscle. This high level expression of PPAR gamma in colon warrants further study in view of the well established role of fatty acid and arachidonic acid derivatives in colonic disease. Similarly as mouse PPAR gamma s, the human PPAR gamma s are activated by thiazolidinediones and prostaglandin J and bind with high affinity to a PPRE. The human PPAR gamma gene has nine exons and extends over more than 100 kilobases of genomic DNA. Alternate transcription start sites and alternate splicing generate the PPAR gamma 1 and PPAR gamma 2 mRNAs, which differ at their 6'-ends. PPAR gamma 1 is encoded by eight exons, and PPAR gamma 2 is encoded by seven exons. The 5'-untranslated sequence of PPAR gamma 1 is comprised of exons A1 and A2, whereas that of PPAR gamma 2 plus the additional PPAR gamma 2-specific N-terminal amino acids are encoded by exon B, located between exons A2 and A1. The remaining six exons, termed 1 to 6, are common to the PPAR gamma 1 and gamma 2. Knowledge of the gene structure will allow screening for PPAR gamma mutations in humans with metabolic disorders, whereas knowledge of its expression pattern and factors regulating its expression could be of major importance in understanding its biology.	INST PASTEUR,DEPT ATHEROSCLEROSE,INSERM,U325,F-59019 LILLE,FRANCE; UNIV LYON 1,FAC MED RENE LAENNEC,INSERM,U449,F-69373 LYON,FRANCE; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121; UNIV WASHINGTON,DEPT MED & GENET,SEATTLE,WA 98195; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ligand Pharmaceuticals; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Coll, Lluis Fajas/C-8567-2014; Auboeuf, Didier/M-4610-2014; Staels, Bart/N-9497-2016; Vidal, Hubert/M-6674-2017; Flier, jeffrey/AAG-6223-2019	Staels, Bart/0000-0002-3784-1503; Vidal, Hubert/0000-0002-9467-0317; Lefebvre, Anne-Marie/0000-0001-5644-0441; Auboeuf, Didier/0000-0002-3757-0002; Fajas, Lluis/0000-0002-1283-9503; Vidal-Puig, Antonio/0000-0003-4220-9577; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265				AMRI EZ, 1991, J LIPID RES, V32, P1449; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Aubert J, 1996, FEBS LETT, V397, P117, DOI 10.1016/S0014-5793(96)01152-0; Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/BF00210629; Auwerx J, 1996, ATHEROSCLEROSIS, V124, pS29, DOI 10.1016/0021-9150(96)05854-6; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GHARBICHIHI J, 1993, BIOCHIM BIOPHYS ACTA, V1177, P8, DOI 10.1016/0167-4889(93)90150-N; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; Greene M. E., 1995, Gene Expression, V4, P281; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NEGREL R, 1989, BIOCHEM J, V257, P399, DOI 10.1042/bj2570399; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sambrook J., 2002, MOL CLONING LAB MANU; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vidal H, 1996, J CLIN INVEST, V98, P251, DOI 10.1172/JCI118786; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU Z, 1996, GENE DEV, V16, P4128; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	57	1011	1045	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18779	18789		10.1074/jbc.272.30.18779	http://dx.doi.org/10.1074/jbc.272.30.18779			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228052	hybrid			2022-12-27	WOS:A1997XM34200043
J	Nisimoto, Y; Freeman, JLR; Motalebi, SA; Hirshberg, M; Lambeth, JD				Nisimoto, Y; Freeman, JLR; Motalebi, SA; Hirshberg, M; Lambeth, JD			Rac binding to p67(phox) - Structural basis for interactions of the Rac1 effector region and insert region with components of the respiratory burst oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; PLASMA-MEMBRANE; POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE PRODUCTION; RECOMBINANT P47-PHOX; GUANINE-NUCLEOTIDES; ANIONIC AMPHIPHILE; EXCHANGE PROTEINS	Activation of the respiratory burst oxidase involves the assembly of the membrane associated flavocyto chrome b(558) with the cytosolic components p47(phox), p67(phox), and the small GTPase Rac. Herein, the interaction between Rac and p67(phox) is explored using functional and physical methods. Mutually facilitated binding (EC50) of Rac1 and p67(phox) within the NADPH oxidase complex was demonstrated using steady state kinetic methods measuring NADPH-dependent superoxide generation. Direct binding of Rac1 and Rac2 to p67(phox) was shown using a fluorescent analog of GTP (methylanthraniloyl guanosine-5'-[beta,gamma-imido]triphosphate) bound to Rac as a reporter group. An increase in the methylanthraniloyl fluorescence was seen with added p67(phox) but not p47(phox), and the emission maximum shifted from 445 to 440 nm. Rac1 and Rac2 bound to p67(phox) with a 1:1 stoichiometry and with k(d) values of 120 and 60 nM, respectively. Mutational studies (Freeman, J., Kreck, M., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435; Freeman, J. L., Abo, A, and Lambeth, J. D. (1996) J. Biol. Chem. 271, 19794-19801) previously identified two regions in Rac1 that are important for activity: the ''effector region'' (residues 26-45) and the ''insert region'' (residues 124-135). Proteins mutated in the effector region (Rac1(N26H), Rac1(133N), and Rac1(D38N)) showed a marked increase in both the K-d and the EC50, indicating that mutations in this region affect activity by inhibiting Rac binding to p67(phox). Insert region mutations (Rac1(K132E) and L134R), while showing markedly elevated EC50 values, bound with normal affinity to p67(phox). The structure of Rac1 determined by x-ray crystallography reveals that the effector region and the insert region are located in defined sectors on the surface of Rac1. A model is discussed in which the Rac1 effector region binds to p67(phox), the C terminus binds to the membrane, and the insert region interacts with a different protein component, possibly cytochrome b(558).	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; AICHI MED UNIV,DEPT BIOCHEM,NAGAKUTE,AICHI 48011,JAPAN; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Emory University; Aichi Medical University; MRC National Institute for Medical Research					NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ANDO S, 1992, J BIOL CHEM, V267, P25709; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ESCRIOU V, 1994, J BIOL CHEM, V269, P14007; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; NAKAMURA M, 1988, BLOOD, V72, P1550; NISHIMOTO Y, 1995, J BIOL CHEM, V270, P16428; NOMANBHOY TK, 1996, J BIOL CHEM, V271, P10003; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, BLOOD, V61, P1105; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; XU XM, 1994, J BIOL CHEM, V269, P23569	64	112	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18834	18841		10.1074/jbc.272.30.18834	http://dx.doi.org/10.1074/jbc.272.30.18834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228059	hybrid			2022-12-27	WOS:A1997XM34200050
J	Gabai, VL; Meriin, AB; Mosser, DD; Caron, AW; Rits, S; Shifrin, VI; Sherman, MY				Gabai, VL; Meriin, AB; Mosser, DD; Caron, AW; Rits, S; Shifrin, VI; Sherman, MY			Hsp70 prevents activation of stress kinases - A novel pathway of cellular thermotolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-CELLS; PHOSPHORYLATION; NECROSIS; CASCADE; OVEREXPRESSION; ACCUMULATION; DENATURATION; FIBROBLASTS; AGGREGATION	Harmful conditions including heat shock, oxidative stress, UV, and so forth cause programmed cell death, whose triggering requires activation of the Jun N-terminal kinase, JNK, High levels of Hsp72, a heat-inducible member of Hsp70 family, protect cells against a variety of stresses by a mechanism that is unclear at present. Here we report that elevated levels of Hsp72. inhibit a signal transduction pathway leading to programmed cell death by preventing stress-induced activation of JNK. Stress-induced activation of another stress-kinase, p38 (HOG1), is also blocked when the level of Hsp72 is increased, Similarly, addition of a purified recombinant Hsp72 to a crude cell lysate reduced p38 kinase activation, while depletion of the whole family of Hsp70 proteins with a monoclonal antibody enhanced such activation, In addition, we have found that accumulation of abnormal proteins in cells upon incubation with amino acid analogs causes activation of JNK and p38 kinases, which can be prevented by overproduction of Hsp72, Taken together, these data suggest that, in regulation of JNK and p38 kinases, Hsp70 serves as a ''sensor'' of the build-up of abnormal proteins after heat shock and other stresses, The inhibitory effect of an increased level of Hsp70 on JNK appears to be a major contributor to acquired thermotolerance in mammalian cells.	BOSTON BIOMED RES INST,BOSTON,MA 02114; MED RADIOL RES CTR,OBNINSK 249020,RUSSIA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA; DANA FARBER CANC INST,BOSTON,MA 02115	Boston Biomedical Research Institute; National Research Council Canada; Harvard University; Dana-Farber Cancer Institute			Gabai, Vladimir L/I-1650-2013; Mosser, Dick D/A-7391-2008	Gabai, Vladimir L/0000-0003-4505-4718; Mosser, Richard/0000-0002-9183-2288; Meriin, Anatoli/0000-0003-0087-814X	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDERSON RL, 1989, MOL CELL BIOL, V9, P3509, DOI 10.1128/MCB.9.8.3509; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J IMMUNOL, V151, P4286; KABAKOV AE, 1995, EXP CELL RES, V217, P15, DOI 10.1006/excr.1995.1058; KAMPINGA HH, 1993, J CELL SCI, V104, P11; KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	35	448	498	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18033	18037		10.1074/jbc.272.29.18033	http://dx.doi.org/10.1074/jbc.272.29.18033			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218432	hybrid			2022-12-27	WOS:A1997XL73500022
J	Lanigan, TM; Russo, AF				Lanigan, TM; Russo, AF			Binding of upstream stimulatory factor and a cell-specific activator to the calcitonin calcitonin gene-related peptide enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTION FACTOR USF; MAJOR LATE PROMOTER; GAMMA-FIBRINOGEN PROMOTER; PROTEIN PRECURSOR GENE; RETINOIC ACID; DNA-BINDING; CYCLIC-AMP; ELEMENT; EXPRESSION	The calcitonin/calcitonin gene-related peptide (CT/CGRP) gene is selectively transcribed in thyroid C cells and neurons. We have previously shown that the rat CT/CGRP cell-specific enhancer is synergistically regulated by a helix-loop-helix (HLH) protein and the OB2 octamer-binding protein. in this report, we show that the HLH-OB2 enhancer is required for full promoter activity, even in the context of other HLH elements. Since this enhancer appears to be a major controlling element, we have characterized the HLH and OB2 DNA binding proteins. We have identified the major HLH complex as a heterodimer of the ubiquitous upstream stimulatory factor (USF)-1 and USF-2 proteins. USF bound the enhancer with a reasonably high affinity (K-D 1.6 nM), comparable to other genes. Characterization of a series of mutations revealed that a portion of the HLH motif is also recognized by OB2 and confirmed that HLH activity requires OB2. We have shown that OB2 is a single DNA binding protein based on UV cross-linking studies. The 68-kDa protein-DNA complex was detected only in C cell lines, including a human C cell line that has robust HLH-OB2 enhancer activity, These results suggest that the calcitonin/CGRP gene is controlled by the combinatorial activity of a ubiquitous USF HLH heterodimer and an associated cell-specific activator.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, PROGRAM MOL BIOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa				Russo, Andrew/0000-0002-8156-5649	NICHD NIH HHS [R01 HD25969] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAETSCHER M, 1991, ONCOGENE, V6, P1133; BALL DW, 1992, NUCLEIC ACIDS RES, V20, P117, DOI 10.1093/nar/20.1.117; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Blaugrund E, 1996, DEVELOPMENT, V122, P309; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; Clark Michael S., 1995, Methods (Orlando), V7, P253, DOI 10.1006/meth.1995.1030; CLARK MS, 1995, J NEUROSCI, V15, P6167; COPP DH, 1992, ENDOCRINOLOGY, V131, P1007, DOI 10.1210/en.131.3.1007; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DEBUSTROS A, 1986, J BIOL CHEM, V261, P8036; EDVINSSON L, 1994, CEPHALALGIA, V14, P320, DOI 10.1046/j.1468-2982.1994.1405320.x; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HALLE JP, 1995, J BIOL CHEM, V270, P21307, DOI 10.1074/jbc.270.36.21307; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv-8-4-377; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MONIA YT, 1995, MOL ENDOCRINOL, V9, P784; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PELEG S, 1990, MOL ENDOCRINOL, V4, P1750, DOI 10.1210/mend-4-11-1750; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PREIBISZ JJ, 1993, AM J HYPERTENS, V6, P434, DOI 10.1093/ajh/6.5.434; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; RUSSO AF, 1996, GENETIC MECH MULTIPL, V2, P137; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; VIERRA CA, 1994, MOL ENDOCRINOL, V8, P197, DOI 10.1210/me.8.2.197; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WATSON A, 1995, J BIOL CHEM, V270, P9655, DOI 10.1074/jbc.270.16.9655; YOON SO, 1994, J BIOL CHEM, V269, P18453	47	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18316	18324		10.1074/jbc.272.29.18316	http://dx.doi.org/10.1074/jbc.272.29.18316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218472	hybrid			2022-12-27	WOS:A1997XL73500062
J	Oda, M; Farukawa, K; Ogata, K; Sarai, A; Ishii, S; Nishimura, Y; Nakamura, H				Oda, M; Farukawa, K; Ogata, K; Sarai, A; Ishii, S; Nishimura, Y; Nakamura, H			Investigation sf the pyrimidine preference by the c-Myb DNA-binding domain at the initial base of the consensus sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-TURN-HELIX; REPRESSOR-OPERATOR INTERACTION; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; RECOGNITION HELICES; ONCOGENE PRODUCT; PROTO-ONCOGENE; CRO REPRESSOR; ZINC FINGERS; COMPLEX	The principal determinant of the pyrimidine preference by the c-Myb DNA-binding domain at the initial base of the consensus sequence was investigated by mutation of both the protein and the DNA base pairs, with analysis by a filter binding assay. Amino acid residue 187 was revealed to interact with the pyrimidine base position, as estimated from our previous complex structure. Unexpectedly, since the pyrimidine preference is retained even in the Gly(187) mutant, the principal origin of the base specificity should no occur via the direct-readout mechanism, but by an indirect-readout mechanism, namely in the intrinsic ''bendability'' of the pyrimidine-purine step of the DNA duplex. A significant but rather small positive base pair roll is detectable in the conformation of DNA in complex with the C-Myb DNA-binding domain. Following the conventional chemical rules of the direct-readout mechanism, amino acid mutagenesis at position 187 yielded several new base preferences for the protein.	BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN; KANAGAWA ACAD SCI & TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL STRUCT,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Kanagawa Academy Science & Technology; Yokohama City University; RIKEN; Yokohama City University			Nakamura, Haruki/O-4028-2014; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Oda, Masayuki/0000-0002-8568-4223; Nishimura, Yoshifumi/0000-0002-5148-3458				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; CALLADINE CR, 1984, J MOL BIOL, V178, P773, DOI 10.1016/0022-2836(84)90251-1; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; REBER EJ, 1994, SCIENCE, V263, P671; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RODGERS DW, 1993, STRUCTURE, V1, P227, DOI 10.1016/0969-2126(93)90012-6; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI M, 1994, P NATL ACAD SCI USA, V91, P12357, DOI 10.1073/pnas.91.26.12357; SUZUKI M, 1995, PROTEIN ENG, V8, P329, DOI 10.1093/protein/8.4.329; SUZUKI M, 1993, EMBO J, V12, P3221, DOI 10.1002/j.1460-2075.1993.tb05991.x; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17966	17971		10.1074/jbc.272.29.17966	http://dx.doi.org/10.1074/jbc.272.29.17966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218422	hybrid			2022-12-27	WOS:A1997XL73500012
J	Bruhat, A; Jousse, C; Wang, XZ; Ron, D; Ferrara, M; Fafournoux, P				Bruhat, A; Jousse, C; Wang, XZ; Ron, D; Ferrara, M; Fafournoux, P			Amino acid limitation induces expression of CHOP, a CCAAT/enhancer binding protein-related gene, at both transcriptional and post-transcriptional levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; MESSENGER-RNA; ASPARAGINE SYNTHETASE; (C/EBP)-RELATED GENE; METABOLIC-REGULATION; ENERGY-METABOLISM; DNA DAMAGE; GADD153; PROMOTER; C/EBP	In mammals, plasma concentrations of amino acids are affected by nutritional or pathological conditions, Here we examined the role of amino acid limitation in regulating the expression of CHOP, a CCAAT/enhancer binding protein (C/EBP)-related gene, CHOP protein is capable of interacting with other C/EBPs to modify their DNA binding activities and may function as a negative regulator of these transcription factors, Our data show that leucine limitation in human cell lines leads to induction of CHOP mRNA and protein in a dose-dependent manner, CHOP mRNA induction is rapidly reversed by leucine replenishment, Elevated mRNA levels result from both an increase in the rate of CHOP transcription and an increase in the CHOP mRNA stability, Using a transient expression assay, we show that a promoter fragment, when linked to a reporter gene, is sufficient to mediate the regulation of CROP expression by leucine starvation in HeLa cells. In addition, we found that decreasing amino acid concentration by itself can induce CHOP expression independently of a cellular stress due to protein synthesis inhibition, Moreover, CHOP expression is induced at leucine concentrations in the range of those observed in blood of protein-restricted animals suggesting that amino acids can participate, in concert with hormones, in the regulation of gene expression.	INRA,UNITE NUTR CELLULAIRE & MOL,F-63122 ST GENES CHAMPANE,FRANCE; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	INRAE; New York University				Ron, David/0000-0002-3014-5636				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Battey, 1986, BASIC METHODS MOL BI; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; CYNOBER L, 1989, JPEN-PARENTER ENTER, V13, P196, DOI 10.1177/0148607189013002196; FAFOURNOUX P, 1990, AM J PHYSIOL, V259, pE614, DOI 10.1152/ajpendo.1990.259.5.E614; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAINE RO, 1994, J BIOL CHEM, V269, P9693; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; LUETHY JD, 1992, CANCER RES, V52, P5; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; NAIR KS, 1987, AM J CLIN NUTR, V46, P557, DOI 10.1093/ajcn/46.4.557; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; TRIENZENBERG SJ, 1992, CURRENT PROTOCOLS MO; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	50	161	195	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17588	17593		10.1074/jbc.272.28.17588	http://dx.doi.org/10.1074/jbc.272.28.17588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211906	hybrid, Green Published			2022-12-27	WOS:A1997XK16500049
J	Krump, E; Nikitas, K; Grinstein, S				Krump, E; Nikitas, K; Grinstein, S			Induction of tyrosine phosphorylation and Na+/H+ exchanger activation during shrinkage of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; CELL-VOLUME; SIGNAL-TRANSDUCTION; BINDING PROTEINS; MAMMALIAN-CELLS; ISOFORM-1 NHE1; OKADAIC ACID; H+ EXCHANGE; ANTIPORTER	The ubiquitous isoform of the Na+/H+ exchanger (NHE1) is essential for the regulation of cellular volume, The underlying molecular mechanism, which is poorly understood, was studied in human polymorphonuclear leukocytes (PMN). Suspension of PMN in hypertonic media induced rapid cellular shrinkage and activation of NHE1, which is measurable as a cytosolic alkalinization. Concomitantly, hypertonic stress also induced extensive tyrosine phosphorylation of several proteins, Pretreatment of PMN with genistein, a tyrosine kinase inhibitor, prevented not only the tyrosine phosphorylation in response to a hypertonic shock but also the activation of NHE1, The signal elicited by hyperosmolarity that induces activation of tyrosine kinases and NHE1 was investigated, Methods were devised to change medium osmolarity without altering cell volume and vice versa, Increasing medium and intracellular osmolarity in normovolemic cells failed to activate tyrosine kinases or NHE1, However, shrinkage of cells under iso-osmotic conditions stimulated both tyrosine phosphorylation and NHE1 activity, These findings imply that cells detect alterations in cell size but not changes in osmolarity or ionic strength, The identity of the proteins that were tyrosine-phosphorylated in response to cell shrinkage was also investigated, Unexpectedly, the mitogen activated protein kinases SAPK, p38, erk1, and erk2 were not detectably phosphorylated or activated, In contrast, the tyrosine kinases p59(fgr) and p56/59(hck) were phosphorylated and activated upon hypertonic challenge. We propose that cells respond to alterations in cell size, but not to changes in osmolarity, with increased tyrosine phosphorylation, which in turn leads to the activation of NHE1. The resulting changes in ion content and cytosolic pH contribute to the restoration of cell volume in shrunken cells.	HOSP SICK CHILDREN,DIV CELL BIOL,RES INST,TORONTO,ON M5G 1X8,CANADA; HOWARD HUGHES MED INST,COCONUT GROVE,FL 33133; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Howard Hughes Medical Institute; University of Toronto								Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CASS A, 1973, NATURE-NEW BIOL, V244, P47, DOI 10.1038/newbio244047a0; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1988, AM J PHYSIOL, V254, pC272, DOI 10.1152/ajpcell.1988.254.2.C272; GRINSTEIN S, 1986, J CELL PHYSIOL, V128, P33, DOI 10.1002/jcp.1041280107; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; NACCACHE PH, 1990, BLOOD, V76, P2098; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NOBES CD, 1995, J CELL SCI, V108, P225; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SARDET C, 1991, J BIOL CHEM, V266, P19166; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; TORRES M, 1993, J IMMUNOL, V150, P1563; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WORTHEN GS, 1994, AM J RESP CELL MOL, V10, P1; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	49	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17303	17311		10.1074/jbc.272.28.17303	http://dx.doi.org/10.1074/jbc.272.28.17303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211867	hybrid			2022-12-27	WOS:A1997XK16500010
J	Laccotripe, M; Makrides, SC; Jonas, A; Zannis, VI				Laccotripe, M; Makrides, SC; Jonas, A; Zannis, VI			The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL-PROPERTIES; PLASMA; PROTEIN; ACTIVATION; VARIANTS; DOMAIN; DNA; PHOSPHATIDYLCHOLINES; SUBSTITUTIONS	We performed a series of mutations in the human apolipoprotein A-I (apoA-I) gene designed to alter specific amino acid residues and domains implicated in lecithin: cholesterol acyltransferase (LCAT) activation or lipid binding. We used the mutant apoA-I forms to establish nine stable cell lines, and developed strategies for the large scale production and purification of the mutated apoA-I proteins from conditioned media. HDL and dimyristoyl phosphatidylcholine binding assays using the variant apoA-I forms have shown that replacement of specific carboxyl-terminal hydrophobic residues Leu(222), Phe(225), and Phe(229) with lysines, as well as replacement of Leu(211), Leu(214), Leu(218), and Leu(219) with valines, diminished the ability of apoA-I to bind to HDL and to lyse dimyristoyl phosphatidylcholine liposomes. The findings indicate that Leu(222), and Phe(225), Phe(229) located in the putative random coil region, and Leu(211), Leu(214), Leu(218), and Leu(219) located in the putative helix 8, are important for lipid binding. In contrast, substitutions of alanines for specific charged residues in putative helices 7, 8, or 9 as well as various point mutations in other regions of apoA-I, did not affect the ability of the variant apoA-I forms to bind to HDL or to lyse dimyristoyl phosphatidylcholine liposomes. Cross-linking experiments confirmed that the carboxyl-terminal domain of apoA-I participates in the self-association of the protein, as demonstrated by the inability of the carboxyl-terminal deletion mutants Delta 185-243 and Delta 209-243 to form higher order aggregates in solution. Lecithin:cholesterol acyltransferase analysis, using reconstituted HDL particles prepared by the sodium cholate dialysis method, has shown that mutants (Pro(165) --> Ala,Gln(173) --> Glu) (Leu(311) --> Val,Leu(214) --> Val,Leu(318) --> Val,Leu(319) --> Val), Leu(222) --> Lys,Phe(255) --> Lys,Phe(290) --> Lys) and Delta 209-243 reduced LCAT activation (38-68%). Mutant (Glu(191) --> Ala,His(195) --> Ala,Lys(196) --> Ala) enhanced LCAT activation (131%), and mutant (Ala(162) --> Leu,Leu(189) --> Trp) exhibited normal LCAT activation as compared with the wild type proapoA-I and plasma apoA-I forms. The apparent catalytic efficiency (V-max(app)/K-m(app)) of the apoA-I mutants ranged from 17.8 to 107.2% of the control and was the result of variations in both the K-m and the V-max in the different mutants. These findings indicate that putative helices 6 and 7, and the carboxyl-terminal helices 8 and 9 contribute to the optimum activation of lecithin:cholesterol acyltransferase. In addition to their use in the present study, the variant apoA-I forms generated will serve as valuable reagents for the identification of the domains and residues of apoA-I involved in binding the scavenger receptor BI, and facilitating cholesterol efflux from cells as well as aid in the structural analysis of apoA-I.	BOSTON UNIV,MED CTR,DEPT MED,CTR ADV BIOMED RES,SECT MOL GENET,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	Boston University; Boston University; University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL48739, HL16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059, R01HL048739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albers J J, 1986, Methods Enzymol, V129, P763; ALLAN CM, 1993, BIOCHEM J, V290, P449, DOI 10.1042/bj2900449; BAKRIA A, 1991, ATHEROSCLEROSIS, V87, P135; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARKER WC, 1977, COMP BIOCHEM PHYS B, V57, P309, DOI 10.1016/0305-0491(77)90060-8; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; Cleland W W, 1979, Methods Enzymol, V63, P103; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; DEEB SS, 1991, J BIOL CHEM, V266, P13654; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FRANCESCHINI G, 1990, BIOCHIM BIOPHYS ACTA, V1043, P1, DOI 10.1016/0005-2760(90)90102-4; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; GHISELLI G, 1985, J BIOL CHEM, V260, P5662; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JONAS A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P202, DOI 10.1016/0005-2760(93)90098-T; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI WH, 1988, J LIPID RES, V29, P245; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENG QH, 1993, J BIOL CHEM, V268, P16966; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PALIAKASIS CD, 1992, PROTEIN ENG, V5, P739, DOI 10.1093/protein/5.8.739; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; SCHMITZ G, 1990, EUR HEART J, V11, P197, DOI 10.1093/eurheartj/11.suppl_E.197; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; Steinmetz A, 1984, Agents Actions Suppl, V16, P217; UTERMANN G, 1984, EUR J BIOCHEM, V144, P325, DOI 10.1111/j.1432-1033.1984.tb08467.x; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; WALD JH, 1990, J BIOL CHEM, V265, P20037; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZANNIS VI, 1982, J BIOL CHEM, V257, P536; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZANNIS VI, 1980, J BIOL CHEM, V255, P8612; ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823	59	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17511	17522		10.1074/jbc.272.28.17511	http://dx.doi.org/10.1074/jbc.272.28.17511			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211897	hybrid			2022-12-27	WOS:A1997XK16500040
J	McCoy, KD; Ahmed, N; Tan, AS; Berridge, MV				McCoy, KD; Ahmed, N; Tan, AS; Berridge, MV			The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MOUSE 3T3-L1 CELLS; RAT ADIPOSE-CELLS; INTRINSIC ACTIVITY; HEXOSE-TRANSPORT; GLUT-4 PHOSPHORYLATION; SUGAR-TRANSPORT; INSULIN ACTION; CLONE-9 CELLS; PHORBOL ESTER	Most mammalian cells rely on an external supply of glucose for survival, proliferation, and function, Glucose enters cells through specific transporter molecules at the plasma membrane by a facilitative process that does not expend energy, Regulation of glucose transport into cells is thought to occur largely through transporter expression at the cell surface, but the extent to which the intrinsic properties of glucose transporters are regulated is at present controversial, Using a bone marrow-derived cell line that responds to the hemopoietic growth factor, interleukin-3 (IL-3), we investigated IL-3 regulation of glucose transport, IL-3 significantly increased 2-deoxyglucose (2-DOG) uptake within 1 h (26 +/- 8.0%, n = 11) with a maximum 73% increase after 6 h, Withdrawal of IL-3 resulted in decreased uptake within 1 h rand this continued to decline to 43% of initial uptake by 16 h, To determine whether these changes in 2-DOG uptake were associated with corresponding changes in glucose transporter expression, subtype-specific antisera against. Glut-1 and Glut-3 were used, Little change in membrane expression of these transporters was observed prior to 16 h, Fractionation of cell membranes on Nycodenz gradients showed that the majority of each transporter subtype was associated with the plasma membrane (63-93%) and that transporter distribution did not change markedly in response to addition or withdrawal of IL-3, These results demonstrate that IL-3 regulates glucose uptake by modulating the: intrinsic transporting ability of glucose transporters, Decreased transporter affinity for 2-DOG and 3-8-methylglucose was observed following IL-3 withdrawal, Similar affinity changes were observed with 2-DOG following exposure of IL-3-stimulated cells to the protein kinase inhibitors, genistein and staurosporine, In contrast, the tyrosine phosphatase inhibitor, vanadate, acted hire IL-3 to increase transporter affinity for glucose, Together these results demonstrate that IL-3 acts to maintain the intrinsic transport properties of glucose transporters without markedly affecting their expression or translocation.	MALAGHAN INST MED RES, WELLINGTON SCH MED, WELLINGTON 6002, NEW ZEALAND	Malaghan Institute; University of Otago; Victoria University Wellington			Berridge, Michael V/I-3969-2013; McCoy, Kathy/ABD-5814-2021	Berridge, Michael/0000-0003-2619-7473				ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BEGUM N, 1993, J BIOL CHEM, V268, P3352; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BILAN PJ, 1992, BIOCHEM BIOPH RES CO, V186, P1129, DOI 10.1016/0006-291X(92)90864-H; BILAN PJ, 1992, FEBS LETT, V298, P285, DOI 10.1016/0014-5793(92)80078-U; BIRD TA, 1990, J BIOL CHEM, V265, P13578; CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DIAMOND DL, 1993, J BIOL CHEM, V268, P6437; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUILLETDENIAU I, 1994, J CELL SCI, V107, P487; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JOOST HG, 1986, J BIOL CHEM, V261, P33; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKAGI H, 1994, INVEST OPHTH VIS SCI, V35, P170; THOMAS HM, 1993, BIOCHEM J, V290, P707, DOI 10.1042/bj2900707; TOYODA N, 1987, J BIOL CHEM, V262, P2737; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	40	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17276	17282		10.1074/jbc.272.28.17276	http://dx.doi.org/10.1074/jbc.272.28.17276			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211864	hybrid			2022-12-27	WOS:A1997XK16500007
J	Widlak, P; Gaynor, RB; Garrard, WT				Widlak, P; Gaynor, RB; Garrard, WT			In vitro chromatin assembly of the HIV-1 promoter - ATP-dependent polar repositioning of nucleosomes by Sp1 and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; I-HYPERSENSITIVE SITES; TRANSCRIPTIONAL ACTIVATION; REMODELING FACTOR; GENE-EXPRESSION; DNA-REPLICATION; BINDING; DISRUPTION; ENHANCER; INVITRO	Nuclease hypersensitive sites exist in vivo in the chromatin of the integrated human immunodeficiency virus (HIV)-1 proviral genome, in the 5'-long terminal repeat (LTR) within the promoter/enhancer region near Spl and NF kappa B binding sites, Previous studies from the Kadonaga and Jones laboratories have shown that Spl and NF kappa B can establish hypersensitive sites in a truncated form of this LTR when added before in vitro chromatin assembly with Drosophiba extracts, thus facilitating subsequent transcriptional activation of a linked reporter gene upon the association of additional factors (Pazin, M. J,, Sheridan, P, L,, Cannon, Ii., Cao, Z,, Keck, J, G,, Kadanaga, J, T., and Jones, Ii, A, (1996) Genes & Dev. 10, 37-49), Here we assess the role of a full-length LTR and 1 kilobase pair of downstream flanking HIV sequences in chromatin remodeling when these transcription factors are added after chromatin assembly. Using Xenopus laevis oocyte extracts to assemble chromatin in vitro, we have confirmed that Spl and NF kappa B can indeed induce sites hypersensitive to DNase I, micrococcal nuclease, or restriction enzymes on either side of factor binding sites in chromatin but not naked DNA, We extend these earlier studies by demonstrating that the process is ATP-dependent when the factors are added after chromatin assembly and that histone H1, API, TBP, or Tat had no effect on hypersensitive site formation, Furthermore, we have found that nucleosomes upstream of NF kappa B sites are rotationally positioned prior to factor binding and that their translational frame is registered after binding-NF kappa B, On the other hand, binding of Spl positions adjacent downstream nucleosome(s), We term this polar repositioning because each factor aligns nucleosomes only on one side of its binding sites, Mutational analysis and oligonucleotide competition each demonstrated that this remodeling required Spl and NF kappa B binding sites.	UNIV TEXAS, SW MED CTR, DEPT MOL BIOL & ONCOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NIAID NIH HHS [AI25288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; ELKHARROUBI A, 1994, J BIOL CHEM, V269, P19916; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARCIAMARTINEZ LF, 1995, J MOL BIOL, V254, P350; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; Hoover T, 1996, NUCLEIC ACIDS RES, V24, P1895, DOI 10.1093/nar/24.10.1895; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1988, NUCLEIC ACIDS RES, V16, P6677, DOI 10.1093/nar/16.14.6677; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LUSE D, 1995, CHROMATIN STRUCTURE, P105; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Nagano M, 1997, BIOCHEM BIOPH RES CO, V231, P561, DOI 10.1006/bbrc.1997.6120; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Potter KN, 1996, J IMMUNOL, V157, P2982; RAZVI F, 1983, GENE, V23, P175, DOI 10.1016/0378-1119(83)90049-5; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STEGER DJ, 1996, EMBO J, V18, P875; Strouboulis J, 1996, J CELL SCI, V109, P1991; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VANHOLDE KE, 1988, CHROMATIN, P1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696	50	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17654	17661		10.1074/jbc.272.28.17654	http://dx.doi.org/10.1074/jbc.272.28.17654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211915	hybrid			2022-12-27	WOS:A1997XK16500058
J	Artigues, A; Iriarte, A; MartinezCarrion, M				Artigues, A; Iriarte, A; MartinezCarrion, M			Refolding intermediates of acid-unfolded mitochondrial aspartate aminotransferase bind to hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE TRANSLATION SYSTEM; MOLTEN GLOBULE STATE; HEAT-SHOCK; ESCHERICHIA-COLI; STRUCTURAL FEATURES; HOMOLOGOUS PROTEINS; PRECURSOR PROTEIN; FOLDING PATHWAY; IMPORT; LYSOZYME	The cytosolic (cAAT) and mitochondrial (mAAT) isozymes of eukaryotic aspartate aminotransferase share a high degree of sequence identity and almost identical three-dimensional structure, The rat liver proteins can be refolded and reassembled into active dimers after unfolding at low pH. However, refolding of the mitochondrial form after unfolding at pH 2.0 is arrested in the presence of hsp70, whereas this chaperone does not affect the refolding of the cytosolic isozyme unfolded under similar conditions. To elucidate the nature of the differential interaction between hsp70 and the two transaminase forms, eve have characterized their refolding from their acid-unfolded states, The recovery of activity of the cytosolic enzyme is monophasic and can be adequately described by a single first-order reaction, By contrast, two sequential first-order rate-limiting stops can be detected for the refolding and reactivation of the mitochondrial protein, The overall refolding pathway of mAAT includes a very fast collapse to an intermediate with 80% of the secondary structure of the active dimer, This is followed by a slow isomerization to form assembly-competent monomers that rapidly associate to form an inactive dimer and a final structural rearrangement of the dimer to the native conformation. Analysis of the interaction of hsp70 with intermediates along the folding pathway of mAAT shows that the polypeptide loses its ability to bind to the chaperone after it has proceeded through the first isomerization/fast dimerization steps, Thus it appears that only the first collapsed intermediate states in the folding of mAAT bind hsp70. By contrast a faster refolding of cAAT from this, collapsed state could explain, at least in part,the inability of hsp70 to bind this isozyme.	UNIV MISSOURI, SCH BIOL SCI, DIV MOL BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOETTCHER B, 1975, BIOCHEMISTRY-US, V14, P4528, DOI 10.1021/bi00691a030; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CHIEN JY, 1948, J AM CHEM SOC, V70, P2256, DOI 10.1021/ja01186a078; COURNIL I, 1975, J BIOL CHEM, V250, P8564; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Endo T, 1996, J BIOL CHEM, V271, P4161; FELISS N, 1970, BIOCHEM BIOPH RES CO, V40, P932, DOI 10.1016/0006-291X(70)90993-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; JAENICKE R, 1988, PROTEIN STRUCTURE PR, P191; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MARTINEZCARRION M, 1970, BIOCHEMISTRY-US, V9, P2574, DOI 10.1021/bi00815a004; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; PUIG A, 1994, J BIOL CHEM, V269, P25889; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TERADA K, 1995, MOL CELL BIOL, V15, P3708; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WU T, 1994, THESIS U MISSOURI KA; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	65	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16852	16861		10.1074/jbc.272.27.16852	http://dx.doi.org/10.1074/jbc.272.27.16852			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201992	hybrid			2022-12-27	WOS:A1997XH44600024
J	Desseyn, JL; Aubert, JP; VanSeuningen, I; Porchet, N; Laine, A				Desseyn, JL; Aubert, JP; VanSeuningen, I; Porchet, N; Laine, A			Genomic organization of the 3' region of the human mucin gene MUC5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; IN-SITU HYBRIDIZATION; VON-WILLEBRAND-FACTOR; HUMAN GASTRIC MUCIN; INTESTINAL MUCIN; GALLBLADDER MUCIN; MOLECULAR-CLONING; CHOLESTEROL GALLSTONES; EXPRESSION CLONING; AMINO-ACIDS	MUC5B, mapped clustered with MUC6, MUC2, and MUC5AC to chromosome 11p15.5, is a human mucin gene of which the genomic organization is being elucidated. We have recently published the sequence and the peptide organization of its huge central exon, 10,713 base pairs (bp) in length, We present here the genomic organization of its 3' region, which encompasses 10,690 bp. The genomic sequence has been completely determined, The 3' region of MUC5B is composed of 18 exons ranging in size from 32 to 781 bp, contrasting thus with the very large central exon, The sizes of the 18 introns range from 114 to 1118 bp, Some repetitive sequences were identified in four introns, The peptide deduced from the sequence of the 18 exons consists of an 808-amino acid peptide. This carboxyl-terminal region exhibits extensive sequence similarity to MUGS, MUC5AC, and von Willebrand factor, particularly the number and the positions of the cysteine residues, suggesting that this domain may be derived from a common ancestral gene, The presence in these components of a cystine knot also found in growth factors such as transforming growth factor-beta is of particular interest, Moreover, one part of this peptide is identical to the 196-amino acid sequence deduced from the cDNA clone pSM2-1, which codes for a part of the high molecular weight mucin MG1 isolated from human sublingual gland, Considering the expression pattern of MUC5B and the origin of MG1, we can thus conclude that MUC5B encodes MG1.	INSERM U377, F-59045 LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, HOP HURIEZ, LAB BIOCHIM & BIOL MOL, F-59037 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille			VAN SEUNINGEN, Isabelle/N-6176-2016; Desseyn, Jean-Luc/M-5070-2018	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Desseyn, Jean-Luc/0000-0001-6876-8049				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BAKER ME, 1988, BIOCHEM J, V256, P1059, DOI 10.1042/bj2561059; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; BORK P, 1992, CURR OPIN STRUC BIOL, V4, P383; Buisine MP, 1996, GASTROENTEROLOGY, V110, P84, DOI 10.1053/gast.1996.v110.pm8536891; CAMPION JP, 1995, HEPATOLOGY, V21, P223, DOI 10.1002/hep.1840210135; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CONG NV, 1990, HUM GENET, V86, P167; CREPIN M, 1990, BIORHEOLOGY, V27, P471; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; Hoffmann W, 1995, BIOCHEM SOC T, V23, P805, DOI 10.1042/bst0230805; HOFFMANN W, 1993, COMP BIOCHEM PHYS B, V105, P465, DOI 10.1016/0305-0491(93)90075-G; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; KAWAGISHI S, 1990, ARCH ORAL BIOL, V35, P265, DOI 10.1016/0003-9969(90)90041-8; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLINKSPOOR JH, 1993, EUR J GASTROEN HEPAT, V5, P226, DOI 10.1097/00042737-199304000-00007; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LAN MS, 1990, J BIOL CHEM, V265, P15294; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LOOMIS RE, 1987, ARCH BIOCHEM BIOPHYS, V258, P452, DOI 10.1016/0003-9861(87)90366-3; LYNCH DC, 1983, P NATL ACAD SCI-BIOL, V80, P2738, DOI 10.1073/pnas.80.9.2738; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, BIOCHEM BIOPH RES CO, V220, P186, DOI 10.1006/bbrc.1996.0378; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH BF, 1985, J CLIN INVEST, V76, P439, DOI 10.1172/JCI111991; SMITH BF, 1984, J BIOL CHEM, V259, P2170; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VERMA M, 1994, CANCER BIOCHEM BIOPH, V14, P151; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320	67	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16873	16883		10.1074/jbc.272.27.16873	http://dx.doi.org/10.1074/jbc.272.27.16873			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201995	hybrid			2022-12-27	WOS:A1997XH44600027
J	Upchurch, GR; Welch, GN; Fabian, AJ; Freedman, JE; Johnson, JL; Keaney, JF; Loscalzo, J				Upchurch, GR; Welch, GN; Fabian, AJ; Freedman, JE; Johnson, JL; Keaney, JF; Loscalzo, J			Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL INJURY; POSSIBLE RISK FACTOR; SMOOTH-MUSCLE CELLS; MYOCARDIAL-INFARCTION; HOMOCYSTEINE; DISEASE; SELENIUM; ATHEROSCLEROSIS; HOMOCYSTINURIA; PLASMA	Hyperhomocyst(e)inemia is believed to injure endothelial cells in vivo through a number of mechanisms, including the generation of hydrogen peroxide (H2O2), Earlier in vitro studies demonstrated that homocyst(e)ine (Hcy) decreases the biological activity of endothelium-derived relaxing factor and that this decrease can be reversed by preventing the generation of hydrogen peroxide, Here we show that Hcy treatment of bovine aortic endothelial cells leads to a dose-dependent decrease in NOx (p = 0.001 by one-way analysis of variance) independent of endothelial nitric-oxide synthase activity or protein levels and nos3 transcription, suggesting that Hcy affects the bioavailability of NO, not its production, We hypothesized that, in addition to increasing the generation of H2O2, Hcy decreases the cell's ability to detoxify H2O2 by impairing intracellular antioxidant enzymes, specifically the intracellular isoform of glutathione peroxidase (GPx), To test this hypothesis, confluent bovine aortic endothelial cells were treated with a range of concentrations of Hcy, and intracellular GPx activity was determined, Compared with control cells, cells treated with Hcy showed a significant reduction in GPx activity (up to 81% at 250 mu M Hcy), In parallel with the decrease in GPx activity, steady-state GPx mRNA levels were also significantly decreased compared with control levels after exposure to Hcy, which appeared not to be a consequence of message destabilization, These data suggest; a novel mechanism by which Hcy, in addition to increasing the generation of hydrogen peroxide, may selectively impair the endothelial cells ability to detoxify H2O2, thus rendering NO more susceptible to oxidative inactivation.	BOSTON UNIV,SCH MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115	Boston University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Loscalzo, Joseph/ABD-8980-2021	Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL47416, HL48743, P50 HL55993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055993, P01HL048743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON A, 1995, CLIN CHEM, V41, P361; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; AVISSAR N, 1989, BLOOD, V73, P318; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1989, THESIS U LUND LUND; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUCZYNSKI A, 1993, ATHEROSCLEROSIS, V100, P223, DOI 10.1016/0021-9150(93)90208-C; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; FUKUO K, 1995, J CLIN INVEST, V95, P669, DOI 10.1172/JCI117712; GABRIELSEN BO, 1980, J NUTR, V110, P1096, DOI 10.1093/jn/110.6.1096; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HAUDENSCHILD CC, 1976, EXP CELL RES, V98, P175, DOI 10.1016/0014-4827(76)90477-8; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1988, OXYRADICALS MOL BIOL; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; LENTZ SR, 1991, J CLIN INVEST, V88, P1936; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MUDD SH, 1972, BIOCHEM BIOPH RES CO, V46, P905; MUDD SH, METABOLIC BASIS INHE, P1279; NISHINAGA M, 1994, JPN J CLIN PATHOL, V42, P340; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; SALONEN JT, 1982, LANCET, V2, P175; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SMOLIN LA, 1983, J NUTR, V113, P2022, DOI 10.1093/jn/113.10.2022; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WALCH GN, 1996, METHOD ENZYMOL, V268, P293; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9	42	577	618	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17012	17017		10.1074/jbc.272.27.17012	http://dx.doi.org/10.1074/jbc.272.27.17012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202015	hybrid, Green Published			2022-12-27	WOS:A1997XH44600047
J	Armbruster, DW; Daniels, CJ				Armbruster, DW; Daniels, CJ			Splicing of intron-containing tRNATrp by the archaeon Haloferax volcanii occurs independent of mature tRNA structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA INTRON; ARCHAEBACTERIUM-DESULFUROCOCCUS-MOBILIS; HALOBACTERIUM-VOLCANII; EXTREME THERMOPHILE; SUBSTRATE RECOGNITION; STABLE RNA; ENDONUCLEASE; GENES; TRANSCRIPTION; PURIFICATION	We have investigated the requirements for mature tRNA structure in the in vivo splicing of the Haloferax volcanii, intron-containing tRNATrp RNA. A partial tRNATrp gene, which contained only the anticodon stem-loop region of the mature tRNA, Tvas fused to a carrier yeast tRNA gene far expression ins H, volcanii. Transcripts from this hybrid gene were found to be processed by endonuclease and ligase at the tRNATrp exon-intron boundaries, These results verify that the substrate recognition properties of the halobacterial endonuclease observed in vitro reflect the properties of this enzyme in vivo, namely that mature tRNA structure is not essential for recognition by the endonuclease. The independence of these reactions on mature tRNA provides further support for a relationship between archaeal tRNA and rRNA intron-processing systems and highlight a difference in the substrate recognition properties between the archaeal and eucaryal processing systems. The significance of these differences is discussed in light of the observation that the tRNA endonucleases of these organisms are related.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048665] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48665-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHARLEBOIS RL, 1987, P NATL ACAD SCI USA, V84, P8530, DOI 10.1073/pnas.84.23.8530; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DALGAARD JZ, 1994, J BIOL CHEM, V269, P28885; DANIELS CJ, 1985, J BIOL CHEM, V260, P3132; DATTA PK, 1989, CAN J MICROBIOL, V35, P189, DOI 10.1139/m89-029; GARRETT RA, 1991, TRENDS BIOCHEM SCI, V16, P22, DOI 10.1016/0968-0004(91)90011-J; GARRETT RA, 1994, SYST APPL MICROBIOL, V16, P680; HOLMES ML, 1991, J BACTERIOL, V173, P3807, DOI 10.1128/JB.173.12.3807-3813.1991; KAINE BP, 1987, J MOL EVOL, V25, P248, DOI 10.1007/BF02100018; KAINE BP, 1983, P NATL ACAD SCI-BIOL, V80, P3309, DOI 10.1073/pnas.80.11.3309; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KJEMS J, 1989, CAN J MICROBIOL, V35, P210, DOI 10.1139/m89-033; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P439, DOI 10.1073/pnas.88.2.439; KJEMS J, 1989, J BIOL CHEM, V264, P17834; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; LYKKEANDERSEN J, 1994, NUCLEIC ACIDS RES, V22, P4583, DOI 10.1093/nar/22.22.4583; LYKKEANDERSEN J, 1994, J MOL BIOL, V243, P846, DOI 10.1006/jmbi.1994.1687; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; NIEUWLANDT DT, 1990, J BACTERIOL, V172, P7104, DOI 10.1128/jb.172.12.7104-7110.1990; NIEUWLANDT DT, 1993, MOL MICROBIOL, V8, P93, DOI 10.1111/j.1365-2958.1993.tb01206.x; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PALMER JR, 1994, J BACTERIOL, V176, P3820, DOI 10.1128/JB.176.12.3820-3823.1994; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; THOMPSON LD, 1990, THESIS OHIO STAT U; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Westaway Shawn K., 1995, P79; WICH G, 1987, EMBO J, V6, P523, DOI 10.1002/j.1460-2075.1987.tb04784.x	37	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19758	19762		10.1074/jbc.272.32.19758	http://dx.doi.org/10.1074/jbc.272.32.19758			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242634	hybrid			2022-12-27	WOS:A1997XQ05900021
J	Kolkman, MAB; vanderZeijst, BAM; Nuijten, PJM				Kolkman, MAB; vanderZeijst, BAM; Nuijten, PJM			Functional analysis of glycosyltransferases encoded by the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae serotype 14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; RHIZOBIUM-MELILOTI; TRANSPOSON TN916; ESCHERICHIA-COLI; GENES; TRANSFORMATION; IDENTIFICATION; SUCCINOGLYCAN; ORGANIZATION; INFLUENZAE	Bacteria belonging to the species Streptococcus pneumoniae vary in their capsule. Presently, 90 capsular serotypes are known, all possessing their own specific polysaccharide structure. Little is known about the biosynthesis of these capsular polysaccharides. The cps locus of S. pneumoniae serotype 14 was cloned. So far, 7 open reading frames have been sequenced, cps14B to cps14H. The gene products are similar to proteins involved in bacterial polysaccharide biosynthesis, both of Gram-negative and -positive micro-organisms. Gene-specific mutants were created for cps14D to cps14H by insertional mutagenesis. All mutants no longer agglutinated with a monoclonal antibody against type 14 capsule polysaccharides. The biosynthetic function of cps14E and cps14G was determined by analysis of the intermediates in the synthesis of the oligosaccharide subunit, formed in membrane preparations of the wild-type and mutant strains and in membrane preparations of Escherichia coli expressing the pneumococcal glycosyltransferases. The enzyme encoded by cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier, the first step in the biosynthesis of the type 14 repeating unit. The gene product of cps14G encodes a beta-1,4-galactosyltransferase, the enzyme responsible for the second step in the subunit synthesis, the transfer of galactose to lipid-linked glucose.	UNIV UTRECHT, DEPT BACTERIOL, INST INFECT DIS & IMMUNOL, SCH VET MED, NL-3508 TD UTRECHT, NETHERLANDS	Utrecht University			Van der Zeijst, Bernard B.A./A-3847-2013; Van der Zeijst, Bernard/AAH-1415-2020	Van der Zeijst, Bernard B.A./0000-0001-9316-2161; Van der Zeijst, Bernard/0000-0001-9316-2161				ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BECKER A, 1995, MOL MICROBIOL, V16, P191, DOI 10.1111/j.1365-2958.1995.tb02292.x; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BOULNOIS GJ, 1989, MOL MICROBIOL, V3, P1819, DOI 10.1111/j.1365-2958.1989.tb00168.x; BRUYN GAW, 1991, EUR J CLIN MICROBIOL, V10, P897, DOI 10.1007/BF02005442; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; COLLINS LV, 1991, J BACTERIOL, V173, P2521, DOI 10.1128/jb.173.8.2521-2529.1991; CROSS AS, 1990, CURR TOP MICROBIOL, V150, P87; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DISTLER J, 1964, P NATL ACAD SCI USA, V51, P897, DOI 10.1073/pnas.51.5.897; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUANG JZ, 1995, MOL MICROBIOL, V16, P977, DOI 10.1111/j.1365-2958.1995.tb02323.x; HUNDLE BS, 1992, P NATL ACAD SCI USA, V89, P9321, DOI 10.1073/pnas.89.19.9321; JENNINGS HJ, 1990, CURR TOP MICROBIOL, V150, P97; KENNEDY EP, 1976, J BIOL CHEM, V251, P4208; Kolkman MAB, 1996, J BACTERIOL, V178, P3736, DOI 10.1128/jb.178.13.3736-3741.1996; KROLL JS, 1990, J BACTERIOL, V172, P1374, DOI 10.1128/jb.172.3.1374-1379.1990; KROLL JS, 1989, J BACTERIOL, V171, P3343, DOI 10.1128/jb.171.6.3343-3347.1989; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; MORONA R, 1994, J BACTERIOL, V176, P733, DOI 10.1128/jb.176.3.733-747.1994; MORRISON DA, 1983, J BACTERIOL, V156, P281, DOI 10.1128/JB.156.1.281-290.1983; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; VANDAM JEG, 1990, ANTON LEEUW INT J G, V58, P1; Wang L, 1996, J BACTERIOL, V178, P2598, DOI 10.1128/jb.178.9.2598-2604.1996; WATSON DA, 1990, INFECT IMMUN, V58, P3135, DOI 10.1128/IAI.58.9.3135-3138.1990; Yamazaki M, 1996, J BACTERIOL, V178, P2676, DOI 10.1128/jb.178.9.2676-2687.1996; YOTHER J, 1986, J BACTERIOL, V168, P1463, DOI 10.1128/jb.168.3.1463-1465.1986	41	65	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19502	19508		10.1074/jbc.272.31.19502	http://dx.doi.org/10.1074/jbc.272.31.19502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235953	hybrid			2022-12-27	WOS:A1997XP06300059
J	Nunez, MT; NunezMillacura, C; Beltran, M; Tapia, V; AlvarezHernandez, X				Nunez, MT; NunezMillacura, C; Beltran, M; Tapia, V; AlvarezHernandez, X			Apotransferrin and holotransferrin undergo different endocytic cycles in intestinal epithelia (Caco-2) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN; IRON; TRANSPORT; PATHWAY; BINDING	Previous studies have demonstrated that diferric transferrin and apotransferrin compete for the binding to basolateral transferrin receptors and that transferrin-mediated iron uptake by Caco-2 cells is inhibited by apotransferrin to a larger extent than that predicted solely by receptor competition, This inhibition can have important implications in determining the net exchange of iron between intestinal cells and the basolateral milieu. Accordingly, we further characterized the endocytic cycles of apotransferrin and diferric transferrin in Caco-2 cells. We found that after internalization both apotransferrin and diferric transferrin recycled to the cell exterior, but that apotransferrin had a protracted endocytic cycle. Confocal microscopy studies revealed a different cellular distribution of apotransferrin and diferric transferrin; both were found in a compartment close to the basal membrane, but apotransferrin reached as well regions closer to the apical membrane. Moreover, the intracellular distribution of transferrin receptors was influenced by the iron load of transferrin; cells incubated with apotransferrin presented a more apical distribution of transferrin receptors than cells incubated with diferric transferrin. These results indicate for the first time that the endocytic cycle of transferrin receptors in intestinal epithelial cells is determined by the iron content of transferrin. They explain also the marked inhibitory effect of apotransferrin on transferrin-mediated iron uptake by Caco-2 cells, since incubation of cells with apotransferrin resulted in the actual sequestration of the receptor in the cell interior.	LOUISIANA STATE UNIV, MED CTR, DEPT MED, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Nunez, MT (corresponding author), UNIV CHILE, FAC CIENCIAS, DEPT BIOL, CASILLA 653, SANTIAGO, CHILE.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570				ALVAREZHERNANDEZ X, 1994, BBA-BIOMEMBRANES, V1192, P215, DOI 10.1016/0005-2736(94)90121-X; ALVAREZHERNANDEZ X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P205, DOI 10.1016/0005-2736(91)90165-5; BALI PK, 1990, ARCH BIOCHEM BIOPHYS, V281, P251, DOI 10.1016/0003-9861(90)90440-A; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; FLANAGAN PR, 1990, ACTA PEDIAT SCAND S, V361, P21; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCFARLANE AS, 1963, J CLIN INVEST, V42, P346, DOI 10.1172/JCI104721; Nunez MT, 1996, J NUTR, V126, P2151, DOI 10.1093/jn/126.9.2151; Tapia V, 1996, AM J PHYSIOL-GASTR L, V271, pG443, DOI 10.1152/ajpgi.1996.271.3.G443; WILLIAMS J, 1980, BIOCHEM J, V185, P483, DOI 10.1042/bj1850483; Wrigglesworth J.M, 1980, IRON BIOCH MED, P29; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	16	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19425	19428		10.1074/jbc.272.31.19425	http://dx.doi.org/10.1074/jbc.272.31.19425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235943	hybrid			2022-12-27	WOS:A1997XP06300049
J	Reimer, DL; Kong, S; Bally, MB				Reimer, DL; Kong, S; Bally, MB			Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYAMINE-COATED DNA; GENE-TRANSFER; MAMMALIAN-CELLS; EFFICIENT; LIPOFECTION; COMPLEX; REAGENT; SERIES	Lipid-based DNA transfer formulations are typically selected on the basis of in vitro transfection studies where the activity of specific formulations is defined by transgene expression. It is unclear, however, whether expression is directly related to the efficiency of DNA transfer, In an attempt to correlate DNA transfer with transgene expression, we used a simple assay consisting of measuring DNA (H-3-plasmid encoding for beta-galactosidase) binding to murine (B16/BL6) and human (KZ) melanoma cells in vitro at 4 and 37 degrees C. The difference in cell association at these temperatures was assumed to be a consequence of DNA uptake, an assumption that was confirmed by protease removal of cell surface-associated DNA, DNA associated with B16/BL6 melanoma cells (up to 30 ng or 12% of the added DNA) following incubation with dioleoyldimethylammonium chloride/dioleoylphosphatidylethanolamine (DOPE) liposome-DNA aggregates was comparable to that achieved with 1,2-dioleoyloxypropyl-3-trimethylammonium bromide/DOPE or dimethyldioctadecylammonium bromide/ DOPE liposomes; however, transgene expression was 2- and 5-fold less for the latter two formulations, respectively, Similarly, equivalent amounts of DNA delivery were achieved with B16/BL6 and KZ melanoma cells, yet the level of transgene expression in the KZ cells was undetectable. It was demonstrated that the lack of transgene expression was not a consequence of cell-specific differences in DNA degradation.			Reimer, DL (corresponding author), BRITISH COLUMBIA CANC AGCY,DIV MED ONCOL,600 W 10TH AVE,VANCOUVER,BC V5Z 4E6,CANADA.		Bally, Marta/G-8744-2011					BARTHEL F, 1993, DNA CELL BIOL, V12, P553, DOI 10.1089/dna.1993.12.553; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P647; BERTLING WM, 1991, BIOTECHNOL APPL BIOC, V13, P390; CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GRUNER SM, 1987, LIPOSOMES BIOPHYSICS, P1; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFLAND H, 1995, BIOCHEM BIOPH RES CO, V207, P492, DOI 10.1006/bbrc.1995.1215; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SABBIONI S, 1995, ARCH VIROL, V140, P335, DOI 10.1007/BF01309866; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERPHOF GL, 1987, BIOCH SOC T S, V15, P625; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Wasan EK, 1996, J PHARM SCI-US, V85, P427, DOI 10.1021/js9504752; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	31	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19480	19487		10.1074/jbc.272.31.19480	http://dx.doi.org/10.1074/jbc.272.31.19480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235950	hybrid			2022-12-27	WOS:A1997XP06300056
J	Ubeda, M; Habener, JF				Ubeda, M; Habener, JF			The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC ELEMENT; SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; DEATH GENE CED-3; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; ANGIOTENSINOGEN GENE; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; EXPRESSION	We report the identification of the large subunit of the DNA replication factor, DSEB/RF-C140, as a new substrate for caspase-3 (CPP32/YAMA), or a very closely related protease activated during Fas-induced apoptosis in Jurkat T cells, DSEB/RF-C140 is a multifunctional DNA-binding protein with sequence homology to poly-(ADP-ribose) polymerase (PARP), This similarity includes a consensus DEVD/G cleavage site for caspase-3. Cleavage of DSEB/RF-C140 is predicted to occurs between Asp(706) and Gly(707), generating 87-kDa and 53-kDa fragments. An antiserum raised against the amino-terminal domain of DSEB/RF-C140 detects a new 87-kDa protein in Jurkat T cells in which apoptosis is activated by a monoclonal antibody to Fas, This cleavage occurs shortly after PARR cleavage, In vitro translated DSEB/RF-C140 is specifically cleaved into the predicted fragments when incubated with a cytoplasmic extract from Fas antibody-treated cells, Proteolytic cleavage was prevented by substituting Asp(706) by an alanine in the DEVD706/G caspase-3 cleavage site, The cleavage of DSEB/RF-C140 is prevented by iodoacetamide and the specific caspase-3 inhibitor, tetrapeptide aldehyde Ac-DEVD-CHO, but not by the specific ICE (interleukin-1-converting enzyme) inhibitors: CrmA and Ac-YVAD-CHO, indicating that the protease responsible for the cleavage of DSEB/RF-C140 during Fas induced apoptosis in Jurkat cells is caspase-3, or a closely related protease, This conclusion is reinforced by the fact that recombinant caspase-3 but not caspase-1 reproduced the ''in vivo'' cleavage, Inasmuch as the cleavage of DSEB/ RF-C140 separates its DNA binding from its association domain, required for replication complex formation, we propose that such a cleavage will impair DNA replication, Recent in vitro mutagenesis support this proposal (Uhlmann, F., Cai, J., Gibbs, E., O'Donnel, M., and Hurwitz, J. (1997) J. Biol. Chem. 272, 10058-10064).	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,MOL ENDOCRINOL LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Ubeda, Mariano/ABB-2691-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030457] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK30457] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FORTEDAR R, 1996, EMBO J, V15, P4423; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE SH, 1991, J BIOL CHEM, V266, P594; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; MCGEHEE RE, 1993, MOL ENDOCRINOL, V7, P551, DOI 10.1210/me.7.4.551; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stanger BZ, 1996, MOL MED, V2, P7, DOI 10.1007/BF03402198; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1996, CELL, V85, P817	49	32	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19562	19568		10.1074/jbc.272.31.19562	http://dx.doi.org/10.1074/jbc.272.31.19562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235961	hybrid			2022-12-27	WOS:A1997XP06300067
J	Hammad, SM; Ranganathan, S; Loukinova, E; Twal, WO; Argraves, WS				Hammad, SM; Ranganathan, S; Loukinova, E; Twal, WO; Argraves, WS			Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2 megalin - A mechanism to prevent pathological accumulation of amyloid beta-peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATES ENDOCYTOSIS; ORGAN DISTRIBUTION; PRECURSOR PROTEIN; GLYCOPROTEIN-330; EXPRESSION; IDENTIFICATION; PURIFICATION	Apolipoprotein J (apoJ) has been shown to be the predominant amyloid beta-peptide (A beta)-binding protein in cerebrospinal fluid. We have previously demonstrated that the endocytic receptor low density lipoprotein receptor-related protein-2/megalin (LRP-2), which is expressed by choroid plexus epithelium and ependymal cells lining the brain ventricles and neural tube, binds and mediates cellular uptake of apoJ (Kounnas, M. Z., Loukinova, E. B., Stefansson, S., Harmony, J. A., Brewer, B., Strickland, D. K., and Argraves, W. S. (1995) J. Biol. Chem. 270, 13070-13075). In the present study, we evaluated the ability of apoJ to mediate binding of A beta(1-40)-apoJ complex to LRP-2 in vitro. Immunoblot analysis showed that incubation of apoJ with A beta(1-40) resulted in the formation of A beta(1-40)-apoJ complex and the inhibition of the formation of A beta(1-40) aggregates. Using an enzyme-linked immunosorbent assay, an estimated dissociation constant (K-d) of 4.8 nM was derived for the interaction between A beta(1-40) and apoJ. Enzyme-linked immunosorbent assay was also used to study the interaction of the A beta(1-40)-apoJ complex with LRP-2. The results showed that A beta alone did not bind directly to LRP-2; however, when A beta(1-40) was combined with apoJ to form a complex, binding to LRP-2 took place. The binding interaction could be blocked by inclusion of the receptor-associated protein, an antagonist of apoJ binding to LRP-2. When LRP-2-expressing cells were given I-125-A beta(1-40), cellular uptake of the radiolabeled peptide was promoted by co-incubation with apoJ. When the cells were provided purified I-125-A beta(1-40)-apoJ complex, the complex was internalized and degraded, and both processes were inhibited with polyclonal LRP-2 antibodies. Furthermore, chloroquine treatment inhibited the cellular degradation of the complex. The data indicate that apoJ facilitates A beta(1-40) binding to LRP-2 and that the receptor mediates cellular clearance of A beta(1-40)-apoJ complex leading to lysosomal degradation of A beta(1-40). The findings support the possibility that LRP-2 can act in vivo to mediate clearance of the complex from biological fluids such as cerebrospinal fluid and thereby play a role in the regulation of A beta accumulation.	MED UNIV S CAROLINA,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29425	Medical University of South Carolina				Hammad, Samar/0000-0002-1313-2542	NIDDK NIH HHS [DK45598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BU GJ, 1994, J BIOL CHEM, V269, P18521; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; ODA T, 1994, BIOCHEM BIOPH RES CO, V204, P1131, DOI 10.1006/bbrc.1994.2580; PIKE CJ, 1993, J NEUROSCI, V13, P1676; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEFANSSON S, 1995, J CELL SCI, V108, P2361; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TSUZUKI K, 1994, BRAIN RES, V659, P213, DOI 10.1016/0006-8993(94)90881-8; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	36	173	180	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18644	18649		10.1074/jbc.272.30.18644	http://dx.doi.org/10.1074/jbc.272.30.18644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228033	hybrid			2022-12-27	WOS:A1997XM34200024
J	Harry, A; Chen, YB; Magnusson, R; Iyengar, R; Weng, GZ				Harry, A; Chen, YB; Magnusson, R; Iyengar, R; Weng, GZ			Differential regulation of adenylyl cyclases by G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATION; TRANSLATION; EXPRESSION; CELLS	Regulation of adenylyl cyclases 1, 2, and 6 by G alpha(s) was studied, All three mammalian adenylyl cyclases were expressed in insect (Sf9 or Hi-5) cells by baculovirus infection. Membranes containing the different adenylyl cyclases were stimulated by varying concentrations of mutant (Q227L) activated G alpha(s) expressed in reticulocyte lysates, G alpha(s) stimulation of AC1 involved a single site and had an apparent K-act of 0.9 nM. G alpha(s) stimulation of AC2 was best explained by a non-interactive two site model with a ''high affinity'' site at 0.9 nM and a ''low affinity'' site at 15 nM, Occupancy of the high affinity site appears to be sufficient for G beta gamma stimulation of AC2. G alpha(s) stimulation of AC6 was also best explained by a two-site model with a high affinity site at 0.6-0.8 nM and a low affinity site at 8-22 nM; however, in contrast to AC2, only a model that assumed interactions between the two sites best fit the AC6 data, With 100 mu M forskolin, G alpha(s) stimulation of all three adenylyl cyclases showed very similar profiles, G alpha(s) stimulation in the presence of forskolin involved a single site with apparent K-act of 0.1-0.4 nM. These observations indicate a conserved mechanism by which forskolin regulates G alpha(s) coupling to the different adenylyl cyclases, However, there are fundamental differences in the mechanism of G alpha(s) stimulation of the different adenylyl cyclases with AC2 and AC6 having multiple interconvertible sites, These mechanistic differences may provide an explanation for the varied responses by different cells and tissues to hormones that elevate cAMP levels.			Harry, A (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015599, R01GM054508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NIGMS NIH HHS [GM15599, GM54508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER JL, 1984, ADV CYCLIC NUCL PROT, V17, P101; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; PFEUFFER E, 1989, J BIOL CHEM, V264, P18803; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SANFORD J, 1991, J BIOL CHEM, V266, P9570; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	15	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19017	19021		10.1074/jbc.272.30.19017	http://dx.doi.org/10.1074/jbc.272.30.19017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228084	hybrid			2022-12-27	WOS:A1997XM34200075
J	NikolovaKarakashian, M; Morgan, ET; Alexander, C; Liotta, DC; Merrill, AH				NikolovaKarakashian, M; Morgan, ET; Alexander, C; Liotta, DC; Merrill, AH			Bimodal regulation of ceramidase by interleukin-1 beta - Implications for the regulation of cytochrome P450 2C11 (CYP2C11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; CONSTITUTIVE EXPRESSION; CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; LIVER MICROSOMES; FREE SPHINGOSINE; PROTEIN-KINASES; FATTY-ACID	Interleukin 1 beta (IL-1 beta) induces the hydrolysis of sphingomyelin (SM) to ceramide (Cer) in primary cultures of rat hepatocytes, and Cer has been proposed to play a role in the down-regulation of cytochrome P450 2C11 (CYP2C11) and induction of alpha(1)-acid glycoprotein (AGP) by this cytokine (Chen, J., Nikolova-Karakashian, M., Merrill, A. H. & Morgan, E. T. (1995) J. Biol. Chem. 270, 25235-25238). Nonetheless, some of the features of the down regulation of CYPSC11 do not fit a simple model of Cer as a second messenger as follows: N-acetylsphinganine (C2-DHCer) is as potent as RT-acetylsphingosine (C2-Cer) in suppression of CYP2C11; the IL-1 beta concentration dependence for SM turnover is different from that for the increase in Cer; and the increase in Cer mass is not equivalent to the amount of SM hydrolyzed nor the time course of SM hydrolysis. In this article, we report that these discrepancies are due to activation of ceramidase by the low concentrations of IL-1 beta (similar to 2.5 ng/ml) that maximally down-regulate CYP2C11 expression, whereas higher IL-1 beta concentrations (that induce AGP) do not activate ceramidase and allow Cer accumulation, This bimodal concentration dependence is demonstrated both by in vitro ceramidase assays and in intact hepatocytes using a fluorescence Cer analog, 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-Cer (NBD-Cer), and following release of the NBD-fatty acid, IL-1 beta increases both acid and neutral ceramidase activities, which appear to be regulated by tyrosine phosphorylation because pretreatment of hepatocytes with sodium vanadate increases (and 25 mu M genistein reduces) the basal and IL-1 beta-stimulated ceramidase activities, Since these findings suggested that sphingosine (and, possibly, subsequent metabolites) is the primary mediator of the down regulation of CYP2C11 by IL-1 beta, the effects of exogenous sphingosine and Ca-Cer on expression of this gene were compared, Sphingosine was more potent than C2-Cer in down-regulation of CYP2C11 when added alone or with fumonisin B-1 to block acylation of the exogenous sphingosine. Furthermore, the suppression of CYP2C11 by C2-Cer (and C2-DHCer) is probably mediated by free sphingoid bases, rather than the short chain Cer directly, because both are hydrolyzed by hepatocytes and increase cellular levels of sphingosine and sphinganine. From these observations we conclude that sphingosine, possibly via sphingosine 1-phosphate, is a mediator of the regulation of CYP2C11 by IL-1 beta in rat hepatocytes and that ceramidase activation provides a ''switch'' that determines which sphingolipids are elevated by this cytokine to produce multiple intracellular responses.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ROLLINS RES CTR,ATLANTA,GA 30322; EMORY UNIV,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	Emory University; Emory University; Emory University				Morgan, Edward/0000-0003-4273-2261; Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM 46897, GM 46368] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368, R01GM046897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BABIA T, 1993, INT J CANCER, V54, P839, DOI 10.1002/ijc.2910540519; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHEN JQ, 1995, MOL PHARMACOL, V47, P940; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Ching KZ, 1996, DRUG METAB DISPOS, V24, P542; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DBAIBO GS, 1995, BIOCHEM J, V310, P453, DOI 10.1042/bj3100453; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; KOHIRA T, 1993, J BIOCHEM-TOKYO, V114, P658, DOI 10.1093/oxfordjournals.jbchem.a124233; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; MARTIN OC, 1986, ANAL BIOCHEM, V159, P101, DOI 10.1016/0003-2697(86)90313-1; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCCORMACK M, 1987, BIOCHEM J, V244, P717, DOI 10.1042/bj2440717; MERRILL AH, 1988, ANAL BIOCHEM, V171, P337; MERRILL AH, 1996, HANDB LIP R, V8, P205; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Oral H, 1997, J BIOL CHEM, V272, P4836, DOI 10.1074/jbc.272.8.4836; PATCHINSKY T, 1982, P NATL ACAD SCI USA, V79, P973; PUSHKAREVA MY, 1993, BIOCHEM J, V294, P699, DOI 10.1042/bj2940699; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smith ER, 1997, J BIOL CHEM, V272, P5640, DOI 10.1074/jbc.272.9.5640; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SPINAS GA, 1988, ACTA ENDOCRINOL-COP, V119, P307, DOI 10.1530/acta.0.1190307; STRUM JC, 1994, J BIOL CHEM, V269, P15493; SU Y, 1994, J BIOL CHEM, V269, P16512; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	50	137	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18718	18724		10.1074/jbc.272.30.18718	http://dx.doi.org/10.1074/jbc.272.30.18718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228043	hybrid			2022-12-27	WOS:A1997XM34200034
J	Saftig, P; Hartmann, D; LullmannRauch, R; Wolff, J; Evers, M; Koster, A; Hetman, M; vonFigura, K; Peters, C				Saftig, P; Hartmann, D; LullmannRauch, R; Wolff, J; Evers, M; Koster, A; Hetman, M; vonFigura, K; Peters, C			Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TAIL; TARTRATE-RESISTANT; CELLS; GENE; SIGNAL; INTERNALIZATION; LOCALIZATION; ANTAGONISTS; PROTEINS; BINDING	Lysosomal acid phosphatase (LAP) is a tartrate-sensitive enzyme with ubiquitous expression. Neither the physiological substrates nor the functional significance is known. Mice with a deficiency of LAP generated by targeted disruption of the LAP gene are fertile and develop normally. Microscopic examination of various peripheral organs revealed progredient lysosomal storage in podocytes and tubular epithelial cells of the kidney, with regionally different ultrastructural appearance of the stored material. Within the central nervous system, lysosomal storage was detected to a regionally different extent in microglia, ependymal cells, and astroglia concomitant with the development of a progressive astrogliosis and microglial activation. Whereas behavioral and neuromotor analyses were unable to distinguish between control and deficient mice, similar to 7% of the deficient animals developed generalized seizures. From the age of 6 months onward, conspicuous alterations of bone structure became apparent, resulting in a kyphoscoliotic malformation of the lower thoracic vertebral column. We conclude from these findings that LAP has a unique function in only a subset of cells, where its deficiency causes the storage of a heterogeneously appearing material in lysosomes. The causal relationship of the enzyme defect to the clinical manifestations remains to be determined.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ANAT,D-24118 KIEL,GERMANY; UNIV GOTTINGEN,ZENTRUM ANAT,D-37075 GOTTINGEN,GERMANY	University of Kiel; University of Gottingen	Saftig, P (corresponding author), UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,BIOCHEM ABT 2,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY.		Saftig, Paul/A-7966-2010					ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SA, 1989, J BONE MINER RES, V4, P399; DANYSZ W, 1994, PHARMACOL BIOCHEM BE, V48, P111, DOI 10.1016/0091-3057(94)90506-1; de Duve C., 1969, LYSOSOME RETROSPECT, P3; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; DREXLER HG, 1994, LEUKEMIA, V8, P359; GEIER C, 1992, J HISTOCHEM CYTOCHEM, V40, P1275, DOI 10.1177/40.9.1506664; GEIER C, 1991, BIOL CHEM H-S, V372, P301, DOI 10.1515/bchm3.1991.372.1.301; GIESELMANN V, 1995, BBA-MOL BASIS DIS, V1270, P103, DOI 10.1016/0925-4439(94)00075-2; GIESELMANN V, 1984, H-S Z PHYSIOL CHEM, V365, P651, DOI 10.1515/bchm2.1984.365.1.651; Giulian Dana, 1995, P671; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Heinemann Uwe, 1995, P936; HILLE A, 1992, EUR J CELL BIOL, V59, P106; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISBRANDT D, 1994, AM J HUM GENET, V54, P454; KERSTENS HMJ, 1995, J HISTOCHEM CYTOCHEM, V43, P347, DOI 10.1177/43.4.7897179; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MARLEY RJ, 1987, LIFE SCI, V40, P2215, DOI 10.1016/0024-3205(87)90056-7; MCKUSICK VA, 1983, METABOLIC BASIS INHE, P2465; NADLER HL, 1970, NEW ENGL J MED, V282, P302, DOI 10.1056/NEJM197002052820604; NADLER HL, 1973, LYSOSOMES STORAGE DI, P475; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; PETERS C, 1989, BIOL CHEM H-S, V370, P177, DOI 10.1515/bchm3.1989.370.1.177; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAAB AK, 1995, HUM MOL GENET, V4, P529; REHKOP DM, 1975, H-S Z PHYSIOL CHEM, V356, P1775, DOI 10.1515/bchm2.1975.356.2.1775; RESNICK D, 1988, DIAGNOSIS BONE JOINT, V4, P2022; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WAHEED A, 1985, BIOCHEM GENET, V23, P309, DOI 10.1007/BF00504327; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; YU O, 1986, BRAIN RES, V399, P374, DOI 10.1016/0006-8993(86)91531-3	45	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18628	18635		10.1074/jbc.272.30.18628	http://dx.doi.org/10.1074/jbc.272.30.18628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228031	hybrid			2022-12-27	WOS:A1997XM34200022
J	Schneider, P; Bodmer, JL; Holler, N; Mattmann, C; Scuderi, P; Terskikh, A; Peitsch, MC; Tschopp, J				Schneider, P; Bodmer, JL; Holler, N; Mattmann, C; Scuderi, P; Terskikh, A; Peitsch, MC; Tschopp, J			Characterization of Fas (Apo-1, CD95)-Fas ligand interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR-BINDING; FACTOR-ALPHA; CD40 LIGAND; LYMPHOPROLIFERATIVE SYNDROME; CYTOTOXIC ACTIVITY; INDUCED APOPTOSIS; T-LYMPHOCYTES; CD95 LIGAND; CELL-DEATH	The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Pas Ligand (FasL). When human soluble FasL (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each FasL monomer were found to be essential for efficient secretion. Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods. Point mutations of amino acid residues predicted to affect the receptor-ligand interaction were introduced at three sites. The F275L mutant, mimicking the loss of function murine gld mutation, exhibited a high propensity for aggregation and was unable to bind to Fas. Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward Fas-positive cells with a concomitant decrease in the binding affinity for the recombinant Fas-immunoglobulin Fc fusion proteins. Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of FasL interacts with a cluster of three basic amino acid side chains of Fas. Interestingly, mutant Y218F could induce apoptosis in murine, but not human cells.	GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline	Schneider, P (corresponding author), UNIV LAUSANNE,INST BIOCHEM,BIL MED RES CTR,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Terskikh, Alexey/U-8407-2019; Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Schneider, Pascal/0000-0003-0677-9409				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BANNER DW, 1993, CELL, V73, P481; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BENJAMIN D, 1992, LYMPHOKINE CYTOK RES, V11, P45; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GOH CR, 1991, PROTEIN ENG, V4, P785; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JUMPER MD, 1995, J IMMUNOL, V155, P2369; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KINGSTON RE, 1995, CURRENT PROTOCOLS MO; KOYAMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P188, DOI 10.1016/0167-4781(92)90010-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LUETHY R, 1992, Nature (London), V356, P83; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Mariani SM, 1996, J IMMUNOL METHODS, V193, P63, DOI 10.1016/0022-1759(96)00051-8; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PEITSCH MC, 1995, MOL IMMUNOL, V32, P761, DOI 10.1016/0161-5890(95)00016-8; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sato K, 1996, BRIT J HAEMATOL, V94, P379, DOI 10.1046/j.1365-2141.1996.d01-1799.x; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsutsui H, 1996, J IMMUNOL, V157, P3967; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; Via CS, 1996, J IMMUNOL, V157, P5387; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	64	152	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18827	18833		10.1074/jbc.272.30.18827	http://dx.doi.org/10.1074/jbc.272.30.18827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228058	hybrid, Green Published			2022-12-27	WOS:A1997XM34200049
J	Besra, GS; Morehouse, CB; Rittner, CM; Waechter, CJ; Brennan, PJ				Besra, GS; Morehouse, CB; Rittner, CM; Waechter, CJ; Brennan, PJ			Biosynthesis of mycobacterial lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; GLYCOPROTEIN-BIOSYNTHESIS; STRUCTURAL DEFINITION; MANNOSYL DONOR; BOVIS BCG; TUBERCULOSIS; SMEGMATIS; OLIGOSACCHARIDE; MACROPHAGES; ETHAMBUTOL	The mycobacterial lipoglycans, lipomannan (LM) and lipoarabinomannan (LAM), are potent immunomodulators in tuberculosis and leprosy. Little is known of their biosynthesis, other than being based on phosphatidylinositol (PI), and they probably originate in the phosphatidylinositol mannosides (PIMs; PIMans). A novel form of cell-free incubation involving in vitro and in situ labeling with GDP-[(14)]Man of the polyprenyl-P-mannoses (C35C50-P-Man) and the simpler PIMs of mycobacterial membranes, reisolation of the [C-14]Man-labeled membranes, and in situ chase demonstrated the synthesis of a novel ru(1 --> 6)-linked linear form of LM at the expense of the C-33/C-50-P-Man. There was little or no synthesis under these conditions of PIMan(5) with its terminal. alpha(1 --> 6)Man unit or the mature LM or LAM with copious alpha(1 --> 2)Man branching. Synthesis of the linear LM, but not of the simpler PIMan(2), was susceptible to amphomycin, a lipopeptide antibiotic that specifically inhibits polyprenyl-P-requiring translocases. A mixture of P[H-3]I and P[H-3]IMan(2) was incorporated into the linear LM, supporting other evidence that, like the PIMs, LM and LAM, it is a lipid-linked mannooligosaccharide and a new member of the mycobacterial glycosylphosphatidylinositol lipoglycan/glycolipid class. Hence, the simpler PIMs originate in PI and GDP-Man, but further growth of the linear backbone emanates from C-35-/C-50-P-Man and is amphomycin-sensitive. The origin of the alpha(1 --> 1)Man branches of mature PIMan(5), LM, and LAM is not known at this time but is probably GDP-IMan.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536	Colorado State University; University of Kentucky				Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, R37AI018357, U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMANY AM, 1975, J BIOL CHEM, V250, P2842; AZUMA I, 1968, J BACTERIOL, V95, P263, DOI 10.1128/JB.95.2.263-271.1968; BALLOU CE, 1963, J BIOL CHEM, V238, P69; BALLOU CE, 1972, METHOD ENZYMOL, V28, P493; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Besra Gurdyal S., 1994, P285; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; DELL A, 1994, METHOD ENZYMOL, V230, P108; DITTMER JC, 1964, J LIPID RES, V5, P126; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HILL DL, 1966, J BIOL CHEM, V241, P895; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; KANG MS, 1978, J BIOL CHEM, V253, P8860; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LEE YC, 1964, J BIOL CHEM, V239, P1316; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; MAITRA SK, 1976, BIOCHEM BIOPH RES CO, V73, P1101, DOI 10.1016/0006-291X(76)90236-9; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; PANGBORN MC, 1966, J LIPID RES, V7, P627; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; RATLEDGE C, 1976, ADV MICROB PHYSIOL, V13, P115, DOI 10.1016/S0065-2911(08)60039-9; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROBBINS PW, 1977, J BIOL CHEM, V252, P1780; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SCHULTZ JC, 1975, BIOCHIM BIOPHYS ACTA, V381, P175, DOI 10.1016/0304-4165(75)90199-3; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SLAKOTOS AN, 1965, J AM OIL CHEM SOC, V42, P913; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1971, FEBS LETT, V18, P67, DOI 10.1016/0014-5793(71)80408-8; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V136, P217; TANAKA H, 1977, BIOCHIM BIOPHYS ACTA, V496, P633; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21621	50	144	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18460	18466		10.1074/jbc.272.29.18460	http://dx.doi.org/10.1074/jbc.272.29.18460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218490	hybrid			2022-12-27	WOS:A1997XL73500080
J	Collins, SP; Uhler, MD				Collins, SP; Uhler, MD			Characterization of PKI gamma, a novel isoform of the protein kinase inhibitor of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; REGULATORY SUBUNIT; ADENOSINE-DEAMINASE; MOUSE-BRAIN; RAT TESTIS; 2 ISOFORMS; RI-BETA; EXPRESSION	Attempts to understand the physiological roles of the protein kinase inhibitor (PKI) proteins have been hampered by a lack of knowledge concerning the molecular heterogeneity of the PKI family. The PKI gamma cDNA sequence determined here predicted an open reading frame of 75 amino acids, showing 35% identity to PKI alpha and 30% identity to PKI beta 1. Residues important for the high affinity of PKI alpha and PKI beta 1 as well as nuclear export of the catalytic (C) subunit of cAMP-dependent protein kinase were found to be conserved in PKI gamma. Northern blot analysis showed that a 1.3-kilobase PKI gamma message is widely expressed, with highest levels in heart, skeletal muscle, and testis. RNase protection analysis revealed that in most tissues examined PKI gamma is expressed at levels equal to or higher than the other known PKI isoforms and that in several mouse-derived cell lines, PKI gamma is the predominant PKI message. Partial purification of PKI activities from mouse heart by DEAE ion exchange chromatography resolved two major inhibitory peaks, and isoform-specific polyclonal antibodies raised against recombinant PKI alpha and PKI gamma identified these inhibitory activities to be PKI alpha and PKI gamma. A comparison of inhibitory potencies of PKI alpha and PKI gamma expressed in Escherichia coli revealed that PKI gamma was a potent competitive inhibitor of C alpha phosphotransferase activity in vitro (K-i = 0.44 nM) but is 6-fold less potent than PKI alpha (K-i = 0.073 nM). Like PKI alpha, PKI gamma was capable of blocking the nuclear accumulation of Flag-tagged C subunit in transiently transfected mammalian cells. Finally, the murine PKI gamma gene was found to overlap the murine adenosine deaminase gene on mouse chromosome 2. These results demonstrate that PKI gamma is a novel, functional PKI isoform that accounts for the previously observed discrepancy between PKI activity and PKI mRNA levels in several mammalian tissues.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38788] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT CM, 1991, BIOCHEM GENET, V29, P537, DOI 10.1007/BF02426869; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALUBAIDI MR, 1990, GENOMICS, V7, P476, DOI 10.1016/0888-7543(90)90189-2; ASHBY CD, 1972, J BIOL CHEM, V247, P6637; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; BAUDE EJ, 1994, J BIOL CHEM, V269, P18128; BEALE EG, 1977, J BIOL CHEM, V252, P6322; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROWN NA, 1990, J BIOL CHEM, V265, P13181; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCPHERSON JM, 1979, BIOCHEMISTRY-US, V18, P4835, DOI 10.1021/bi00589a011; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; POSNER JB, 1964, BIOCHEMISTRY-US, V3, P1040, DOI 10.1021/bi00896a005; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; Scarpetta MA, 1996, MAMM GENOME, V7, P921, DOI 10.1007/s003359900273; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SEASHOLTZ AF, 1995, P NATL ACAD SCI USA, V92, P1734, DOI 10.1073/pnas.92.5.1734; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; UHLER MD, 1986, J BIOL CHEM, V261, P5360; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D A, 1973, Recent Prog Horm Res, V29, P329; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WEBER H, 1977, J CYCLIC NUCL PROT, V3, P415; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1980, ARCH BIOCHEM BIOPHYS, V203, P734, DOI 10.1016/0003-9861(80)90233-7	58	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18169	18178		10.1074/jbc.272.29.18169	http://dx.doi.org/10.1074/jbc.272.29.18169			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218452	hybrid			2022-12-27	WOS:A1997XL73500042
J	Gurnett, CA; Felix, R; Campbell, KP				Gurnett, CA; Felix, R; Campbell, KP			Extracellular interaction of the voltage-dependent Ca2+ channel alpha(2)delta and alpha(1) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; NA,K-ATPASE BETA-SUBUNIT; SKELETAL-MUSCLE; DIHYDROPYRIDINE-BINDING; STRUCTURAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; HIGH-AFFINITY; DOMAIN; IDENTIFICATION; RECEPTOR	The role of the extracellular domain of the voltage-dependent Ca2+ channel alpha(2) delta subunit in assembly with the alpha(1C) subunit was investigated. Transiently transfected tsA201 cells processed the alpha(2) delta subunit properly as disulfide linkages and cleavage sites between the alpha(2) and delta subunits were shown to be similar to native channel protein. Coimmunoprecipitation experiments demonstrated that in the absense of delta subunits, alpha(2) subunits do not assemble with alpha(1) subunits. Furthermore, the transmembrane and cytoplasmic sequences in delta can be exchanged with those of an unrelated protein without any effect on the association between the alpha(2) delta and alpha(1) proteins. Extracellular domains of the alpha(2) delta subunits are also shown to be responsible for increasing the binding affinity of [H-3]PN200-11- (isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-([H-3]methoxycarbonyl)-pyridine-3-carboxylate) for the alpha(1C) subunit. Investigation of the corresponding interaction site on the alpha(1) subunit revealed that although tryptic peptides containing repeat III of native alpha(1S) subunit remain in association with the alpha(2) delta subunit during wheat germ agglutinin chromatography, repeat III by itself is not sufficient for assembly with the alpha(2) delta subunit likely interacts with more than one extracellular loop of the alpha(1) subunit.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Felix, Ricardo/A-6989-2008	Felix, Ricardo/0000-0002-5383-7176; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889				Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; COOPER CL, 1987, J BIOL CHEM, V262, P509; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GURNETT CA, 1995, J BIOL CHEM, V270, P9035, DOI 10.1074/jbc.270.16.9035; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; JAY SD, 1991, J BIOL CHEM, V266, P3287; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Makita N, 1996, CIRC RES, V78, P244, DOI 10.1161/01.RES.78.2.244; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHEN V, 1995, NEURON, V14, P625; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TOKUMARU H, 1995, J NEUROCHEM, V65, P831; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	31	82	87	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18508	18512		10.1074/jbc.272.29.18508	http://dx.doi.org/10.1074/jbc.272.29.18508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218497	hybrid			2022-12-27	WOS:A1997XL73500087
J	Taguchi, H; Amada, K; Murai, N; Yamakoshi, M; Yoshida, M				Taguchi, H; Amada, K; Murai, N; Yamakoshi, M; Yoshida, M			ATP-, K+-dependent heptamer exchange reaction produces hybrids between GroEL and chaperonin from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THERMOANAEROBACTER-BROCKII; BACTERIUM; PURIFICATION; HYDROLYSIS; PROTEINS; RING; HB8	Chaperonin from Thermus thermophilus (Tcpn60(14).Tcpn10(7)) splits at the plane between two Tcpn60(7) rings into two parts in a solution containing ATP and K+ (Ishii, N., Taguchi, H., Sasabe, H., and Yoshida, M. (1995) FEBS Lett. 362, 121-125). When Escherichia coli GroEL(14) was additionally included in the solution described above, hybrid chaperonins GroEL(7).Tcpn60(7) and GroEL(7).Tcpn60(7).Tcpn10(7) were formed rapidly (<20 s) at 37 degrees C. The hybrid was also formed from Tcpn60(14) and GroEL(14) but not from a mutant GroEL(14) lacking ATPase activity. The hybrid formation was saturated at similar to 300 mu M ATP and similar to 300 mM K+. These results imply that GroEL(14) also splits and undergoes a heptamer exchange reaction with Thermus chaperonin under nearly physiological conditions, Similar to parent chaperonins, the isolated hybrid chaperonins exhibited ATPase activity that was susceptible to inhibition by Tcpn10(7) or GroES(7) and mediated folding of other proteins, Once formed, the hybrid chaperonins were stable, and the parent chaperonins were not regenerated from the isolated hybrids under the same conditions in which the hybrids had been formed, Only under conditions in which GroEL in the hybrids was selectively destroyed, such as incubation at 70 degrees C, Thermus chaperonin, but not GroEL(14), was regenerated from the hybrid. Therefore, the split reaction may not be an obligatory event repeated in each turnover of the chaperonin functional cycles but an event that occurs only when chaperonin is first exposed to ATP/K+.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			MURAI, NORIYUKI/V-5747-2018; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	MURAI, NORIYUKI/0000-0002-1552-5104; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; ELLIS RJ, 1996, CHAPERONINS; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; ISHII N, 1992, FEBS LETT, V299, P69; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TAGUCHI H, 1997, IN PRESS METHODS ENZ; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; YAMAKOSHI M, 1997, IN PRESS STRUCTURE F; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029	30	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18155	18160		10.1074/jbc.272.29.18155	http://dx.doi.org/10.1074/jbc.272.29.18155			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218450	hybrid			2022-12-27	WOS:A1997XL73500040
J	vanGinkel, PR; Hsiao, KM; Schjerven, H; Farnham, PJ				vanGinkel, PR; Hsiao, KM; Schjerven, H; Farnham, PJ			E2F-mediated growth regulation requires transcription factor cooperation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING PROTEINS; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; GENE-EXPRESSION; IN-VIVO; RETINOBLASTOMA PROTEIN; DNA-BINDING; E2F FAMILY; PROMOTER; MOUSE	Previous studies have indicated that the presence of an E2F site is not sufficient for G(1)/S phase transcriptional regulation, For example, the E2F sites in the E2F1 promoter are necessary, but not sufficient, to mediate differential promoter activity in G(0) and S phase, We have now utilized the E2F1 minimal promoter to test several hypotheses that could account for these observations, To test the hypothesis that G(1)/S phase regulation is achieved via E2F-mediated repression of a strong promoter, a variety of transactivation domains were brought to the E2F1 minimal promoter, Although many of these factors caused increased promoter activity, growth regulation was not observed, suggesting that a general repression model is incorrect. However, constructs having CCAAT or YY1 sites or certain GC boxes cloned upstream of the E2F1 minimal promoter displayed E2F site-dependent regulation, Further analysis of the promoter activity suggested that E2F requires cooperation with another factor to activate transcription in S phase, However, we found that the requirement for E2F to cooperate with additional factors to achieve growth regulation could be relieved by bringing the E2F1 activation domain to the promoter via a Gal4 DNA binding domain, Our results suggest a model that explains why some, but not all, promoters that contain E2F sites display growth regulation.	UNIV WISCONSIN,MCARDLE LAB CANC RES,SCH MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Schjerven, Hilde/I-1437-2013	Schjerven, Hilde/0000-0001-9287-3375; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [R29CA045240, P30CA007175, R01CA045240, T32CA009681] Funding Source: NIH RePORTER; NCI NIH HHS [CA09681, CA07175, CA45240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Blau J, 1996, MOL CELL BIOL, V16, P2044; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTINELLI R, 1994, MOL CELL BIOL, V14, P8322, DOI 10.1128/MCB.14.12.8322; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; PANG JH, 1993, J BIOL CHEM, V268, P2909; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLANSKY J, 1995, THESIS U WISCONSIN M; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLANSKY JE, 1996, TRANSCRIPTIONAL CONT, V208, P1; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU CL, 1995, MOL CELL BIOL, V15, P2536	40	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18367	18374		10.1074/jbc.272.29.18367	http://dx.doi.org/10.1074/jbc.272.29.18367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218478	hybrid			2022-12-27	WOS:A1997XL73500068
J	Gruhler, A; Arnold, I; Seytter, T; Guiard, B; Schwarz, E; Neupert, W; Stuart, RA				Gruhler, A; Arnold, I; Seytter, T; Guiard, B; Schwarz, E; Neupert, W; Stuart, RA			N-terminal hydrophobic sorting signals of preproteins confer mitochondrial hsp70 independence for import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; INNER MEMBRANE; MATRIX ATP; INTERMEMBRANE SPACE; MOLECULAR CHAPERONES; CYTOCHROME B(2); SUBUNIT VA; TRANSLOCATION; REQUIREMENT; PRECURSOR	The requirement of mitochondrial hsp70 (mt-hsp70) for the import of a series af preproteins containing hydrophobic sorting signals into isolated yeast mitochondria was investigated. Here we demonstrate that the presence of such a sorting signal in proximity to the N-terminal matrix-targeting sequence of 21 preprotein can secure a translocating polypeptide chain in the fashion channel in a manner that does nea; require mt-hsp70 activity. Trapping the translocating chain in this fashion leads to efficient processing by the mitochondrial processing peptidase and to complete translocation across the outer mitochondrial membrane into the inner membrane space. These mt-hsp70-independent effects appear to be exerted at the level of the inner membrane through an interaction of the hydrophobic core of the sorting signal with component(s) of the translocase of the inner membrane. Hydrophobic sorting signals of inner membrane proteins inserted into the membrane from the matrix, as well as those of intermembrane space proteins, are capable of causing this mt-hsp70-independent stabilization, demonstrating that this phenomenon is not unique to those preproteins normally sorted to the intermembrane space.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich								BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CYR DM, 1993, J BIOL CHEM, V268, P23751; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1995, CURR BIOL, V5, P132; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x	37	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17410	17415		10.1074/jbc.272.28.17410	http://dx.doi.org/10.1074/jbc.272.28.17410			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211883	hybrid			2022-12-27	WOS:A1997XK16500026
J	Spurway, TD; Morland, C; Cooper, A; Sumner, I; Hazlewood, GP; ODonnell, AG; Pickersgill, RW; Gilbert, HJ				Spurway, TD; Morland, C; Cooper, A; Sumner, I; Hazlewood, GP; ODonnell, AG; Pickersgill, RW; Gilbert, HJ			Calcium protects a mesophilic xylanase from proteinase inactivation and thermal unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; ACTIVE-SITE; CELLULOMONAS-FIMI; CRYSTAL-STRUCTURE; BINDING SITES; SEQUENCE; FAMILY; ARCHITECTURE; CELLULASES; GLYCANASES	Crystal structure analysis of Pseudomonas fluorescens subsp, cellulosa xylanase A (XYLA) indicated that the enzyme contained a single calcium binding site that did not exhibit structural features typical of the EF-hand motif, Isothermal titration calorimetry revealed that XYLA binds calcium with a K-a of 4.9 x 10(4) M-1 and a stoichiometry consistent with one calcium binding site per molecule of enzyme. Occupancy of the calcium binding domain with its ligand protected XYLA from proteinase and thermal inactivation and increased the melting temperature of the enzyme from 60.8 to 66.5 degrees C, However, the addition of calcium or EDTA did not influence the catalytic activity of the xylanase, Replacement of the calcium binding domain, which is located within loop 7 of XYLA, with the corresponding short loop from Cex (a Cellulomonas fimi xylanase/exoglucanase), did not significantly alter the biochemical properties of the enzyme, These data suggest that the primary function of the calcium binding domain is to increase the stability of the enzyme against thermal unfolding and proteolytic attack, To understand further the nature of the calcium binding domain of XYLA, four variants of the xylanase, D256A, N261A, D262A, and XYLA''', in which Asp-256, Asn-261, and Asp-262 had all been changed to alanine, were constructed, These mutated enzymes did not show any significant binding to Ca2+, indicating that Asp-256, Asn-261, and Asp-262 play a pivotal role in the affinity of XYLA for the divalent cation, In the presence or absence of calcium, XYLA''' exhibited thermal stability similar to that of the native enzyme bound to Ca2+ ions, although the variant was sensitive to proteinase inactivation, The role of the calcium binding domain in vivo and the possible mechanism by which the domain evolved are discussed.	UNIV NEWCASTLE UPON TYNE, DEPT BIOL & NUTR SCI, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT AGR & ENVIRONM SCI, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND; UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; INST FOOD RES, DEPT FOOD MACROMOL SCI, READING RG6 2EF, BERKS, ENGLAND; BABRAHAM INST, DEPT CELLULAR PHYSIOL, CAMBRIDGE CB2 4AT, ENGLAND	Newcastle University - UK; Newcastle University - UK; University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; O'Donnell, Tony/0000-0003-2001-4533				BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; CHAUVAUX S, 1995, J BIOL CHEM, V270, P9757, DOI 10.1074/jbc.270.17.9757; Cooper A, 1994, Methods Mol Biol, V22, P125; Cooper A, 1994, Methods Mol Biol, V22, P137; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; GILBERT HJ, 1993, J GEN MICROBIOL, V139, P187, DOI 10.1099/00221287-139-2-187; HALL J, 1993, BIO-TECHNOL, V11, P376, DOI 10.1038/nbt0393-376; HALL J, 1989, MOL MICROBIOL, V3, P1211, DOI 10.1111/j.1365-2958.1989.tb00271.x; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HENRISSAT B, 1996, BIOCHEM J, V316, P395; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MILLWARDSADLER SJ, 1995, BIOCHEM J, V312, P39, DOI 10.1042/bj3120039; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; RUSSELL EW, 1988, SOIL CONDITIONS PLAN, P151; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TULL D, 1991, J BIOL CHEM, V266, P15621; WELFLE K, 1995, EUR J BIOCHEM, V229, P726, DOI 10.1111/j.1432-1033.1995.tb20520.x; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; [No title captured]	31	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17523	17530		10.1074/jbc.272.28.17523	http://dx.doi.org/10.1074/jbc.272.28.17523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211898	hybrid			2022-12-27	WOS:A1997XK16500041
J	Duff, SMG; Wittenberg, JB; Hill, RD				Duff, SMG; Wittenberg, JB; Hill, RD			Expression purification, and properties of recombinant barley (Hordeum sp.) hemoglobin - Optical spectra and reactions with gaseous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCARIS HEMOGLOBIN; CARBON-MONOXIDE; OXYGEN; LEGHEMOGLOBIN; MYOGLOBIN; PLANTS; AUTOOXIDATION; REACTIVITY; KINETICS; GLOBIN	A cDNA encoding barley hemoglobin (Hb) has been cloned into pUC 19 and expressed in Escherichia coli, The resulting fusion protein has five extra amino acids at the N terminus compared with the native protein, resulting in a protein of 168 amino acids (18.5 kDa), The recombinant Hb is expressed constitutively, Extracts made from the bacteria containing the. recombinant fusion construct contain a protein with a subunit molecular mass of approximately 18.5 kDa comprising approximately 5% total soluble protein. Recombinant Rb was purified to homogeneity according to SDS-polyacrylamide gel electrophoresis by sequential polyethylene glycol precipitation and fast protein liquid chromatography, Its native molecular mass as assessed by fast protein liquid chromatography-size exclusion was 40 kDa suggesting that it is a dimer. Ligand binding experiments demonstrate that 1) barley Hb has a very slow oxygen dissociation rate constant (0.0272 s(-1)) relative to other Hbs, and 2) the heme of ferrous and ferric forms of the barley Hb is low spin sis-coordinate, The subunit structure, optical spectrum, and oxygen dissociation rate of native barley hemoglobin are indistinguishable from those obtained for the recombinant protein. The implications of these kinetic data on the in vivo function of barley Hb are discussed.	UNIV MANITOBA,DEPT PLANT SCI,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba	Duff, SMG (corresponding author), ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461, USA.							Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; APPLEBY CA, 1973, P NATL ACAD SCI USA, V70, P564, DOI 10.1073/pnas.70.2.564; APPLEBY CA, 1992, SCI PROG, V76, P365; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; APPLEBY CA, 1976, J BIOL CHEM, V251, P6090; APPLEBY CA, 1973, J BIOL CHEM, V248, P3183; BOFFI A, 1994, J BIOL CHEM, V269, P20437; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BOGUSZ D, 1990, PLANT CELL, V2, P633, DOI 10.1105/tpc.2.7.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN GG, 1984, J MOL EVOL, V21, P19, DOI 10.1007/BF02100624; CARVER TE, 1992, J BIOL CHEM, V267, P14443; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; KEILIN J, 1966, HEMES HEMOPROTEINS, P173; KENNEDY D, 1960, J GEN PHYSIOL, V44, P277, DOI 10.1085/jgp.44.2.277; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb D. C., 1997, Biophysical Journal, V72, pA425; PEISACH J, 1968, J BIOL CHEM, V243, P1871; Sambrook J., 2002, MOL CLONING LAB MANU; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Wittenberg JB, 1996, PLANT SOIL, V178, P161, DOI 10.1007/BF00011579; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	32	151	159	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16746	16752		10.1074/jbc.272.27.16746	http://dx.doi.org/10.1074/jbc.272.27.16746			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201978	hybrid			2022-12-27	WOS:A1997XH44600010
J	KasusJacobi, A; Perdereau, D; TartareDeckert, S; VanObberghen, E; Girard, J; Burnol, AF				KasusJacobi, A; Perdereau, D; TartareDeckert, S; VanObberghen, E; Girard, J; Burnol, AF			Evidence for a direct interaction between insulin receptor substrate-1 and Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; BINDING-SITES; I-RECEPTOR; DOMAIN; PROTEINS; RAS; ASSOCIATION; ACTIVATION	Insulin receptor substrate-1 (IRS-I) and She are two proteins implicated ill intracellular signal transduction. They are activated by an increasing number of extracellular signals, mediated by receptor tyrosine kinases, cytokine receptors, and G protein-coupled receptors, In this study we demonstrate that She interacts directly with IRS-1, using the yeast two-hybrid system and an in. vitro interaction assay. Deletion analysis of the proteins to map the domains implicated in this interaction shows that the phosphotyrosine binding domain of She binds to the region of IRS-1 comprising amino acids 583-661. An irt vitro association assay, performed with or without activation of tyrosine kinases, gives evidence that tyrosine phosphorylation of IRS-1 and She drastically improves the interaction. Site-directed mutagenesis on IRS-I 583-693 shows that the asparagine, hut not the tyrosine residue of the N(625)GDY(628)motif domain, is implicated in the IRS-1-Shc-phosphotyrosine binding interaction. Mutation of another tyrosine residue, Tyr(608) also induced a 40% decrease in the interaction. This study, describing a phosphotyrosine-dependent interaction between IRS-1 and She, suggests that this association might be important in signal transduction.	CNRS,CTR RECH ENDOCRINOL MOL & DEV,UPR 1511,F-92190 MEUDON,FRANCE; INSERM,U145,F-06107 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			TARTARE-DECKERT, Sophie/P-6057-2015; KASUS-JACOBI, Anne/V-7799-2019; Burnol, Anne-Francoise/P-2181-2017	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; KASUS-JACOBI, Anne/0000-0003-3844-0450; 				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CASE RD, 1994, J BIOL CHEM, V269, P10467; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARPER JW, 1993, CELL, V75, P805; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Keegan K, 1996, ONCOGENE, V12, P1537; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MILLER JH, 1972, EXPT MOL GENETICS, P153; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Myers MG, 1996, MOL CELL BIOL, V16, P4147; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Raffel GD, 1996, J BIOL CHEM, V271, P4640; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17166	17170		10.1074/jbc.272.27.17166	http://dx.doi.org/10.1074/jbc.272.27.17166			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202037	hybrid			2022-12-27	WOS:A1997XH44600069
J	Nowak, G; PesticDragovich, L; Hozak, P; Philimonenko, A; Simerly, C; Schatten, G; deLanerolle, P				Nowak, G; PesticDragovich, L; Hozak, P; Philimonenko, A; Simerly, C; Schatten, G; deLanerolle, P			Evidence for the presence of myosin I in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-LIKE POLYPEPTIDE; ACTIN-BINDING-PROTEIN; INTERPHASE NUCLEI; ACANTHAMOEBA MYOSIN; MUSCLE MYOSIN; SMOOTH-MUSCLE; LOCALIZATION; IDENTIFICATION; CELLS; FAMILY	We produced and affinity-purified polyclonal antibodies to adrenal myosin I, These antibodies recognize adrenal myosin I by Western blot analysis (116 kDa) and inhibit the actin-activated ATPase activity of purified adrenal myosin I. They also recognize a 120-kDa protein in extracts prepared from many different cell lines, Fluorescence microscopy demonstrated the presence of immunoreactive material in the perinuclear region, the leading edges, and the nuclei of 3T3 cells. Fluorescence microscopy also demonstrated nuclear staining in mouse oocytes at the germinal vesicle stage and in the pronuclei during fertilization, Confocal and immuno-electron microscopy confirmed the intranuclear localization, Electron microscopy also demonstrated staining of structures in nucleoli that are thought to be associated with rDNA transcription, Western blot analyses revealed the presence of the 120-kDa protein in extracts prepared from nuclei that are apparently free of cytosolic contamination, The same nuclear protein binds I-125-calmodulin and is photoaffinity labeled with [alpha-P-32]ATP. The 120-kDa protein was partially purified from twice washed nuclei using ammonium sulfate fractionation and gel filtration chromatography. Column fractions containing 120-kDa protein as revealed by Western blot analysis also contain K+-EDTA ATPase activity. The 120-kDa protein was also shown to bind actin in the absence, but not the presence, of ATP, Since K+-EDTA ATPase activity, actin, and ATP binding are defining features of the members of the myosin superfamily of proteins, we propose that the 120-kDa protein is a previously undescribed myosin I isoform that is an intranuclear actin-based molecular motor.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612; ACAD SCI CZECH REPUBL,INST EXPT MED,DEPT CELL ULTRASTRUCT & MOL BIOL,PRAGUE 14220 4,CZECH REPUBLIC; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT OBSTET & GYNECOL,MADISON,WI 53706	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			simerly, Calvin/AAC-9564-2021; Hozak, Pavel/AAB-5359-2021; Schatten, Gerald/B-3253-2009; Hozak, Pavel/J-4182-2014	Hozak, Pavel/0000-0003-1901-1394; Schatten, Gerald/0000-0001-5206-7782; Hozak, Pavel/0000-0003-1901-1394	NHLBI NIH HHS [HI 32887, HL 02411] Funding Source: Medline; NICHD NIH HHS [HD 12912] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; AMANKWAH KS, 1994, EXP CELL RES, V210, P315, DOI 10.1006/excr.1994.1044; ANKENBAUER T, 1989, NATURE, V342, P822, DOI 10.1038/342822a0; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BERRIOS M, 1991, P NATL ACAD SCI USA, V88, P219, DOI 10.1073/pnas.88.1.219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECKLER J, 1994, CELL MOTIL CYTOSKEL, V29, P312, DOI 10.1002/cm.970290404; BREMER JW, 1981, BIOCHEMISTRY-US, V20, P2013, DOI 10.1021/bi00510a042; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEAN WL, 1989, DEVELOPMENT, V106, P325; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DUNDR M, 1993, EXP CELL RES, V208, P275, DOI 10.1006/excr.1993.1247; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HOZAK P, 1994, J CELL SCI, V107, P639; KOSLOVSKY JS, 1993, FEBS LETT, V320, P121, DOI 10.1016/0014-5793(93)80075-6; LI DQ, 1992, J NEUROCHEM, V59, P1344, DOI 10.1111/j.1471-4159.1992.tb08446.x; MARUTA H, 1981, J BIOL CHEM, V256, P499; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MILANKOV K, 1993, EXP CELL RES, V209, P189, DOI 10.1006/excr.1993.1301; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIMM DL, 1989, J CELL BIOL, V109, P585, DOI 10.1083/jcb.109.2.585; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SANGER JW, 1975, P NATL ACAD SCI USA, V72, P2451, DOI 10.1073/pnas.72.6.2451; SAUMAN I, 1994, EUR J CELL BIOL, V64, P348; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4727, DOI 10.1073/pnas.82.14.4727; SHCEER U, 1984, CELL, V39, P111; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SIMERLY C, 1993, METHOD ENZYMOL, V225, P516; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163	48	103	105	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17176	17181		10.1074/jbc.272.27.17176	http://dx.doi.org/10.1074/jbc.272.27.17176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202039	hybrid			2022-12-27	WOS:A1997XH44600071
J	Pike, RN; Potempa, J; Skinner, R; Fitton, HL; McGraw, WT; Travis, J; Owen, M; Jin, L; Carrell, RW				Pike, RN; Potempa, J; Skinner, R; Fitton, HL; McGraw, WT; Travis, J; Owen, M; Jin, L; Carrell, RW			Heparia-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ANTI-THROMBIN; ELASTASE; GLASGOW; VARIANT; ALPHA-1-ANTITRYPSIN; CLEAVAGE; PROTEINS; TRYPSIN; SITE	Antithrombin, the principal plasma inhibitor of coagulation proteinases, circulates in a form with low inhibitory activity due to partial insertion of its reactive site loop into the A-beta-sheet of the molecule. Recent crystallographic structures reveal the structural changes that occur when antithrombin is activated by the heparin pentasaccharide, with the exception of the final changes, which take place at the reactive center itself. Here we show that the side chain of the P-1 Arg of alpha-antithrombin is only accessible to modification by the enzyme peptidylarginine deiminase on addition of the heparin pentasaccharide, thereby inactivating the inhibitor, whereas the natural P-1 His variant, antithrombin Glasgow, is unaffected, indicating that only the P-1 Arg becomes accessible. Furthermore, the deimination of P-1 Arg converts antithrombin to a form with 4-fold higher affinity for the heparin pentasaccharide, similar to the affinity found for the P-1 His variant, due to a lowered dissociation rate constant for the antithrombin-pentasaccharide complex. The results support the proposal that antithrombin circulates in a constrained conformation, which when released, in this study by perturbation of the bonding of P-1 Arg to the body of the molecule, allows the reactive site loop to take up the active inhibitory conformation with exposure of the P-1 Arg.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; JAGIELLONIAN UNIV, INST MOL BIOL, DEPT MICROBIOL & IMMUNOL, PL-31120 KRAKOW, POLAND; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30205 USA; CHRISTCHURCH HOSP, DEPT CLIN BIOCHEM, CHRISTCHURCH, NEW ZEALAND	University of Cambridge; Jagiellonian University; Boston University; University System of Georgia; University of Georgia; Christchurch Hospital New Zealand					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26148] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Carrell R, 1997, THROMB HAEMOSTASIS, V78, P516; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, BRIT J HAEMATOL, V66, P523, DOI 10.1111/j.1365-2141.1987.tb01338.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; OWEN MC, 1988, FEBS LETT, V231, P317, DOI 10.1016/0014-5793(88)80841-X; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378	25	46	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19652	19655		10.1074/jbc.272.32.19652	http://dx.doi.org/10.1074/jbc.272.32.19652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242619	hybrid			2022-12-27	WOS:A1997XQ05900006
J	Platt, FM; Reinkensmeier, G; Dwek, RA; Butters, TD				Platt, FM; Reinkensmeier, G; Dwek, RA; Butters, TD			Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE METABOLISM; GLUCOCEREBROSIDE SYNTHETASE; GLUCOSYLCERAMIDE SYNTHESIS; GLYCOLIPID BIOSYNTHESIS; TAY-SACHS; TOPOLOGY; INHIBITOR; SURFACE; CERAMIDE; DISEASE	The imino sugar N-butyldeoxynojirimycin is an inhibitor of the ceramide-specific glucosyltransferase that catalyzes the first step in glycosphingolipid biosynthesis, It results in extensive glycosphingolipid depletion in cells treated in vitro, without causing toxicity. However, we currently do not know the degree to which glycosphingolipids can be depleted in vivo in a mammalian species, We have therefore administered N-butyldeoxynojirimycin long term to young mice and have found that glycosphingolipid levels are reduced (50-70%) in all tissues examined, without resulting in any overt pathology, When the lymphoid tissues from these mice were examined, they were found to be 50% acellular relative to non-lymphoid tissues. These data implicate a role for glycosphingolipids in the biology of the immune system or indicate an additional as yet unknown activity of N-butyldeoxynojirimycin Extensive glycosphingolipid depletion resulting from N-butyldeoxynojirimycin administration is therefore well tolerated in adult mice, and this compound may be in an invaluable tool for probing glycosphingolipid functions in vivo. In addition, this drug may be effective in clinical situations where glycosphingolipid depletion would be desirable, such as the in the treatment of the human glycosphingolipidoses.			Platt, FM (corresponding author), UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Platt, Frances/G-1004-2010	Platt, Frances/0000-0001-7614-0403				BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; FENDERSON BA, 1992, EXP CELL RES, V198, P362, DOI 10.1016/0014-4827(92)90392-L; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hidari KIPJ, 1996, J BIOL CHEM, V271, P14636, DOI 10.1074/jbc.271.24.14636; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; INOKUCHI JI, 1987, J LIPID RES, V28, P565; ISHIKAWA S, 1996, P NATL ACAD SCI USA, V93, P4638; JACOB GS, 1992, NATURAL PRODUCTS AS ANTIVIRAL AGENTS, P137; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; PLATT FM, 1992, CELL IMMUNOL, V143, P449, DOI 10.1016/0008-8749(92)90039-R; PLATT FM, 1995, TRENDS GLYCOSCI GLYC, V7, P495, DOI 10.4052/tigg.7.495; PLATT FM, 1994, J BIOL CHEM, V269, P27108; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; SANDHOFF K, 1993, ADV LIPID RES, V26, P119; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	32	123	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19365	19372		10.1074/jbc.272.31.19365	http://dx.doi.org/10.1074/jbc.272.31.19365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235935	hybrid			2022-12-27	WOS:A1997XP06300041
J	deMedeiros, SRB; Krey, G; Hihi, AK; Wahli, W				deMedeiros, SRB; Krey, G; Hihi, AK; Wahli, W			Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RNA-POLYMERASE-II; GENE-EXPRESSION; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; CTF/NF-I; SUPERFAMILY; COMPLEX; DOMAINS; FAMILY	Two distinct, TATA box-containing promoters regulate the transcriptional activity of the Xenopus vitellogenin Al gene. These two promoters are of different strength and are separated by 1.8 kilobase pairs of untranslated sequence. Estrogen receptor (ER) and its ligand, 17 beta-estradiol, induce the activity of both promoters. The estrogen response elements (EREs) are located a proximal to the downstream i promoter while no ERE-like sequences have been identified in the vicinity of the upstream io promoter. We show here, that transcriptional activity of the upstream io promoter is Sp1-dependent. Moreover, we demonstrate that estrogen inducibility of the io promoter results from functional interactions between the io bound Sp1 and the ER bound at the proximity of i. Functional interactions between Sp1 and ER do not require the presence of a TATA box for transcriptional activation, as is demonstrated using the acyl-CoA oxidase promoter. The relative positions that ER and Sp1 occupy with respect to the initiation site determines whether these two transcription activators can synergize for transcription initiation.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Batistuzzo de Medeiros, Silvia/H-2117-2015; Wahli, Walter/B-1398-2009; DE MEDEIROS, SILVIA REGINA BATISTUZZO/ABC-2811-2020; Wahli, Walter/I-3194-2019	Batistuzzo de Medeiros, Silvia/0000-0003-2431-0479; Wahli, Walter/0000-0002-5966-9089; DE MEDEIROS, SILVIA REGINA BATISTUZZO/0000-0003-2431-0479; 				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BONFANTI M, 1991, NUCLEIC ACIDS RES, V19, P5739, DOI 10.1093/nar/19.20.5739; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLARET FX, 1994, J BIOL CHEM, V269, P14047; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; CORTHESY B, 1989, DNA PROTEIN ENG TECH, V2, P68; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER M, 1990, J BIOL CHEM, V265, P22243; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; KUWAHARA J, 1993, BIOCHEMISTRY-US, V32, P5994, DOI 10.1021/bi00074a010; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T., 1982, MOL CLONING; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Maxam A M, 1980, Methods Enzymol, V65, P499; OSUMI T, 1987, J BIOL CHEM, V262, P8138; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TREMEA F, 1989, MOL ENDOCRINOL, V3, P1596, DOI 10.1210/mend-3-10-1596; WAHLI W, 1981, SCIENCE, V212, P298, DOI 10.1126/science.7209528; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	47	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18250	18260		10.1074/jbc.272.29.18250	http://dx.doi.org/10.1074/jbc.272.29.18250			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218463	hybrid			2022-12-27	WOS:A1997XL73500053
J	Edwards, AS; Newton, AC				Edwards, AS; Newton, AC			Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMISSIVE ACTIVATION; HIGH-AFFINITY; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE; DIACYLGLYCEROL; INACTIVATION; MEMBRANES; SITE	Mature protein kinase C is phosphorylated at a conserved carboxyl-terminal motif that contains a Ser (or Thr) bracketed by two hydrophobic residues; in protein kinase C beta II, this residue is Ser-660 (Keranen, L. M., Dutil, E. M., and Newton, A. C. (1995) Curr. Biol. 5, 1394-1403), This contribution examines how negative charge at this position regulates the function of protein kinase C. Specifically, Ser-660 in protein kinase C beta II was mutated to Ala or Glu and the enzyme's stability, membrane interaction, Ca2+ regulation, and kinetic parameters were compared with those of wild-type protein phosphorylated at residue 660, Negative charge at this position had no significant effect on the enzyme's diacylglycerol-stimulated membrane interaction nor the conformational change accompanying membrane binding. In contrast, phosphate caused a 10-fold increase in the enzyme's affinity for Ca2+ and a comparable increase in its affinity for phosphatidylserine, two interactions that are mediated by the C2 domain, Negative charge also increased the protein's thermal stability and decreased its K-m, for ATP and peptide substrate. These data indicate that phosphorylation at the extreme carboxyl terminus of protein kinase C structures the active site so that it binds ATP and substrate with higher affinity and structures determinants in the regulatory region enabling higher affinity binding of Ca2+. The motif surrounding Ser-660 in protein kinase C beta II is found in a number of other kinases, suggesting interactions promoted by phosphorylation of the carboxyl terminus may provide a general mechanism for stabilizing kinase structure.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CONRAD R, 1994, J BIOL CHEM, V269, P32051; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREBS EG, 1959, J BIOL CHEM, V234, P2867; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; YONEMOTO W, 1997, IN PRESS PROTEIN ENG; ZHANG J, 1994, J BIOL CHEM, V269, P19578	35	128	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18382	18390		10.1074/jbc.272.29.18382	http://dx.doi.org/10.1074/jbc.272.29.18382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218480	hybrid			2022-12-27	WOS:A1997XL73500070
J	Thornberry, NA; Ranon, TA; Pieterson, EP; Rasper, DM; Timkey, T; GarciaCalvo, M; Houtzager, VM; Nordstrom, PA; Roy, S; Vaillancourt, JP; Chapman, KT; Nicholson, DW				Thornberry, NA; Ranon, TA; Pieterson, EP; Rasper, DM; Timkey, T; GarciaCalvo, M; Houtzager, VM; Nordstrom, PA; Roy, S; Vaillancourt, JP; Chapman, KT; Nicholson, DW			A combinatorial approach defines specificities of members of the caspase family and granzyme B - Functional, relationships established for key mediators of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYSTEINE PROTEASE; SERINE PROTEASES; MICE DEFICIENT; PURIFICATION; IDENTIFICATION; INHIBITION; IL-1-BETA; PRECURSOR	There is compelling evidence that members of the caspase (interleukin-1 beta converting enzyme/CED-3) family of cysteine proteases and the cytotoxic lymphocyte-derived serine protease granzyme B play essential roles in mammalian apoptosis. Here we use a novel method employing a positional scanning substrate combinatorial library to rigorously define their individual specificities. The results divide these proteases into three distinct groups and suggest that several have redundant functions. The specificity of caspases 2, 3, and 7 and Caenorhabditis elegans CED-3 (DEXD) suggests that all of these enzymes function to incapacitate essential homeostatic pathways during the effector phase of apo ptosis. In contrast, the optimal sequence for caspases 6, 8, and 9 and granzyme B ((I/L/V)EXD) resembles activation sites in effector caspase proenzymes, consistent with a role for these enzymes as upstream components in a proteolytic cascade that amplifies the death signal.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOL DESIGN & DIVERS,RAHWAY,NJ 07065; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOL BIOL,DORVAL,PQ H9R 4P8,CANADA	Merck & Company; Merck & Company	Thornberry, NA (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT ENZYMOL,R80W-250,POB 2000,RAHWAY,NJ 07065, USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	1778	1841	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17907	17911		10.1074/jbc.272.29.17907	http://dx.doi.org/10.1074/jbc.272.29.17907			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218414	hybrid			2022-12-27	WOS:A1997XL73500004
J	Kelly, CR; Dickinson, CD; Ruf, W				Kelly, CR; Dickinson, CD; Ruf, W			Ca2+ binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN TISSUE FACTOR; FACTOR-X; CALCIUM-BINDING; PROTEASE DOMAIN; GLA DOMAIN; SITE; SUBSTRATE; RESIDUES; AFFINITY	Epidermal growth factor-like (EGF) domain Ca2+ binding sites in the homologous coagulation factors VII, IX, and X stabilize the structural orientation of the gamma-carboxyglutamic acid-rich (Cia) domain relative to EGF-1. Site directed mutagenesis was employed here to analyze the functional importance of Ca2+ binding to EGF-1 in factor VIIa (VIIa), which initiates coagulation in complex with its cofactor, tissue factor (TF). Ala replacements for Asp(63) Or Gln(49) resulted in reduced TF affinity concordant with the number of eliminated Ca2+-coordinating oxygen atoms in the respective side chains, Ca2+ binding to EGF-1 had no major direct effect on contacts with TF residue Gln(110) or on interactions of VIIa residues Arg(79) and Phe(40), suggesting that the stabilized Gla-EGF-1 orientation affects overall docking, Gly, Ala, and Glu replacements at Asp(46), which is a Ca2+-coordinating residue at the Gla aromatic stack carboxyl terminus, are consistent with the notion that an increased flexibility of the Gla domain relative to EGF-1 contributes significantly to loss of function, Certain mutants in the EGF-1 Ca2+ site had reduced proteolytic function, suggesting the importance of the high affinity Ca2+ binding site for macromolecular substrate interaction.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dittmar S, 1997, BIOCHEM J, V321, P787, DOI 10.1042/bj3210787; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; Monroe D M, 1990, Blood Coagul Fibrinolysis, V1, P633; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P15719; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016	33	35	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17467	17472		10.1074/jbc.272.28.17467	http://dx.doi.org/10.1074/jbc.272.28.17467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211891	hybrid			2022-12-27	WOS:A1997XK16500034
J	Roos, RS; Loetscher, M; Legler, DF; ClarkLewis, I; Baggiolini, M; Moser, B				Roos, RS; Loetscher, M; Legler, DF; ClarkLewis, I; Baggiolini, M; Moser, B			Identification of CCR8, the receptor for the human CC chemokine I-309	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHEMOKINE; BIOLOGIC ACTIVITIES; INTERLEUKIN-8; EXPRESSION; LEUKOCYTE; CLONING; TCA3; LYMPHOCYTES; NEUTROPHILS; PROTEINS	The nucleotide sequence for a putative chemokine receptor, termed TER1, ChemR1, or CKR-L1, was recently obtained by a polymerase chain reaction-based cloning technique. It encodes a protein of 355 amino acids that shows 32-45% sequence identity with human chemokine receptors. The gene was localized on human chromosome 3p21-24, the site for the genes for the five known CC chemokine receptors, suggesting that the natural ligand may be a CC chemokine, We have stably expressed this receptor in murine pre-B cells 300-19 and have tested their responsiveness to 20 human chemokines and some other potential agonists, The CC chemokine I-309 was the only agonist that selectively induced intracellular Ca2+ mobilization and chemotaxis in receptor-transfected 300-19 cells, Stromal cell-derived factor 1, which binds to murine CXCR4 expressed in parental as well as transfected 300-19 cells, served as positive control in the functional screening, The interaction of I-309 with TER1 was of high affinity as shown by I-125-I-309 binding (K-d of 1.2 nM) and transient [Ca2+](i) changes at subnanomolar concentrations of agonist, Migration responses in receptor-transfected 300-19 cells was typically bimodal with maximal activity at 10 nM of I-309, These data demonstrate that TER1 (ChemR1 or CKR-L1) is the receptor for I-309, and we propose to call this receptor CCR8 in agreement with the current nomenclature for chemokine receptors. The expression of CCR8 in blood leukocytes and lymphocytes was analyzed by Northern blot. No transcripts were found in RNA from freshly isolated blood neutrophils, monocytes, cultured macrophages, and phytohemagglutinin-stimulated T lymphocytes, and a faint hybridization signal corresponding to the RNA species of 4 kb was obtained only with RNA from interleukin-2-treated T lymphocytes, CCR8 is unusual for its selectivity for a single chemokine, previously shown only for CXCR1 and CXCR4, which bind interleukin-8 and stromal cell-derived factor 1, respectively, Identification of the receptor for I-309 represents a significant progress in determining the function of I-309 in inflammation and disease.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN 9,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	University of Bern; University of British Columbia				Moser, Bernhard/0000-0002-4354-4572; Legler, Daniel F./0000-0001-8610-4764				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BURD PR, 1987, J IMMUNOL, V139, P3126; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; DEVI S, 1995, J IMMUNOL, V154, P5376; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; LANING J, 1994, J IMMUNOL, V153, P4625; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Loetscher P, 1996, J IMMUNOL, V156, P322; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Luo Y, 1996, J IMMUNOL, V156, P742; Luo Y, 1996, J IMMUNOL, V157, P2143; LUO Y, 1994, J IMMUNOL, V153, P4616; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAPOLITANO M, 1996, J IMMUNOL, V157, P259; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; VanSnick J, 1996, J IMMUNOL, V157, P2570; Vicari AP, 1996, IMMUNOL TODAY, V17, P71, DOI 10.1016/0167-5699(96)80582-2; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595	34	152	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17251	17254		10.1074/jbc.272.28.17251	http://dx.doi.org/10.1074/jbc.272.28.17251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211859	hybrid			2022-12-27	WOS:A1997XK16500002
J	YamaguchiIwai, Y; Serpe, M; Haile, D; Yang, WM; Kosman, DJ; Klausner, RD; Dancis, A				YamaguchiIwai, Y; Serpe, M; Haile, D; Yang, WM; Kosman, DJ; Klausner, RD; Dancis, A			Homeostatic regulation of copper uptake in yeast via direct binding of MAC1 protein to upstream regulatory sequences of FRE1 and CTR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR CHARACTERIZATION; TRANSPORT PROTEIN; FERRIC REDUCTASE; METABOLISM; RESISTANCE; ACE1	Copper deprivation of Saccharomyces cerevisiae induces transcription of the FRE1 and CTR1 genes, FRE1 encodes a surface reductase capable of reducing and mobilizing copper chelates outside the cell, and CTR1 encodes a protein mediating copper uptake at the plasma membrane, In this paper, the protein encoded by MAC1 is identified as the factor mediating this homeostatic control. A novel dominant allele of MAC1, MAC1(up2), is mutated in a Cys-rich domain that may function in copper sensing (a G to A change of nucleotide 812 resulting in a Cys-271 to Tyr substitution), This mutant is functionally similar to the MAC1(up1) allele in which His-279 in the same domain has been replaced by Gin. Both mutations confer constitutive copper-independent expression of FRE1 and CTR1. A sequence including the palindrome TTTGCTCA,, TGAGCAAA, appearing within the 5'-flanking region of the CTR1 promoter, is necessary and sufficient for the copper- and MAC1-dependent CTR1 transcriptional regulation. An identical sequence appears as a direct repeat in the FRE1 promoter, The data indicate that the signal resulting from copper deprivation is transduced via the Cys-rich motif of MAC1 encompassing residues 264-279, MAC1 then binds directly and specifically to the CTR1 and FRE1 promoter elements, inducing transcription of those target genes, This model defines the homeostatic mechanism by which yeast regulates the cell acquisition of copper in response to copper scarcity or excess.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Serpe, Michael/T-4176-2019	Serpe, Michael/0000-0002-0161-1087; Serpe, Mihaela/0000-0002-9205-8589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; DAMERON CT, 1993, BIOCHEMISTRY-US, V32, P7294, DOI 10.1021/bi00079a028; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HALLIWELL B, 1988, FREE RADICAL BIO MED, P31; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KNIGHT SA, 1996, GENE DEV, V10, P1947; Koch KA, 1996, MOL CELL BIOL, V16, P724; KOSMAN DJ, 1991, METAL IONS FUNGI, P1; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Lesuisse Emmanuel, 1994, V11, P149; LINDER MC, 1991, BIOCH COPPER, P1; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; POUNTNEY DJ, 1995, BIOCHEM SOC T, V23, pS140, DOI 10.1042/bst023140s; Rose MD., 1990, METHODS YEAST GENETI; ROSEN DR, 1993, NATURE, V362, P20; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZHOU B, 1996, AM J HUM GENET S, V59	41	137	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17711	17718		10.1074/jbc.272.28.17711	http://dx.doi.org/10.1074/jbc.272.28.17711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211922	hybrid			2022-12-27	WOS:A1997XK16500065
J	Ohshima, K; Wells, RD				Ohshima, K; Wells, RD			Hairpin formation during DNA synthesis primer realignment in vitro in triplet repeat sequences from human hereditary disease genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; MISMATCH REPAIR; STRANDED-DNA; BASE-PAIRS; IN-VITRO; REPLICATION; SPECIFICITY; INSTABILITY; INVITRO	Genetic expansion of DNA triplet repeat sequences (TRS) found in neurogenetic disorders may be due to abnormal DNA replication. We have previously observed strong DNA synthesis pausings at specific loci within the long tracts (>similar to 70 repeats) of CTG.CAG and CGG.CCG as well as GTC.GAC by primer extensions in vitro using DNA polymerases (the Klenow fragment of Escherichia call DNA polymerase I, the modified T7 DNA polymerase (Sequenase), and human DNA polymerase beta). Herein, we have isolated and analyzed the products of stalled synthesis found at similar to 30-40 triplets from the beginning of the TRS, DNA sequence analyses revealed that. the stalled products contained short tracts of homogeneous TRS (6-12 repeats) in the middle of the sequence corresponding to the flanking region of the primer-template sequence, The sequence at the 3'-side terminated at the end of the primer, indicating that the primer molecule had served as a template. In addition, chemical probe and polyacrylamide gel electrophoretic analyses revealed that the stalled products existed in hairpin structures. WE postulate that these products of the DNA polymerases are caused by the existence of an unusual DP JA conformation(s) within the TRS, during the in vitro DNA synthesis, enhancing the DNA slippages and the hairpin formations in the TRS due to primer realignment. The consequence of these steps is DNA synthesis to the end of the primer and termination. Primer realignment including hairpin formation may play an important intermediate role in the replication of TRS in vivo to elicit genetic expansions.	TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,CTR GENOME RES,HOUSTON,TX 77030; TEXAS A&M UNIV,TEXAS MED CTR,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System					NIGMS NIH HHS [GM 52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P11019; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P775, DOI 10.1093/nar/24.4.775; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Mytelka DS, 1996, NUCLEIC ACIDS RES, V24, P2774, DOI 10.1093/nar/24.14.2774; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; SHIBATA D, 1994, NAT GENET, V6, P213; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SKELLY JV, 1993, P NATL ACAD SCI USA, V90, P804, DOI 10.1073/pnas.90.3.804; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706	59	78	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16798	16806		10.1074/jbc.272.27.16798	http://dx.doi.org/10.1074/jbc.272.27.16798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201985	hybrid			2022-12-27	WOS:A1997XH44600017
J	Wolberg, AS; Stafford, DW; Erie, DA				Wolberg, AS; Stafford, DW; Erie, DA			Human factor IX binds to specific sites on the collagenous domain of collagen IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; AMINO-ACID-SEQUENCE; ENDOTHELIAL-CELLS; CRO REPRESSOR; OPERATOR DNA; PEPTIDE; RECOGNITION; PROTEIN; HEPARIN; CHAIN	The primary region of factor IX that mediates binding to bovine aortic endothelial cells resides in residues 3-11 of the N-terminal region known as the Gla domain, Recently, it was proposed that the observed binding to endothelial cells is actually a measure of the interaction between factor IX and collagen IV (Cheung, W. F., van den Born, J., Kuhn, K., Kjellen, L., Hudson, B. G., and Stafford, D. W. (1996) Proc, Natl, Acad, Sci, U. S. A. 93, 11068-11073), To confirm that factor M binds to collagen IV and to examine the specificity of this interaction, we used scanning force microscopy to examine factor M binding to collagen IV, We imaged collagen IV in the presence and the absence of factor IX and observed specific interactions between factor IX and collagen IV, Our results demonstrate that factor IX binds to collagen IV at specific sites in the collagenous domain similar to 98 and similar to 50 nm from the C-terminal pepsin-cleaved end.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054136] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL06350] Funding Source: Medline; NIGMS NIH HHS [R29 GM54136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Bustamante C, 1996, ANNU REV BIOPH BIOM, V25, P395; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FRAZIER D, 1989, BLOOD, V74, P971; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GLANVILLE RW, 1979, EUR J BIOCHEM, V95, P383, DOI 10.1111/j.1432-1033.1979.tb12976.x; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; SCHWARZ U, 1986, EUR J BIOCHEM, V157, P49, DOI 10.1111/j.1432-1033.1986.tb09636.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SIXMA JJ, 1995, THROMB HAEMOSTASIS, V74, P454; SOININEN R, 1987, FEBS LETT, V225, P188; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x	38	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16717	16720		10.1074/jbc.272.27.16717	http://dx.doi.org/10.1074/jbc.272.27.16717			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201971	hybrid, Green Published			2022-12-27	WOS:A1997XH44600003
J	Churchich, JE				Churchich, JE			Conformational changes at the nucleotide binding of GroEL induced by binding of protein substrates - Luminescence studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; CHAPERONINS; CYCLE; GENES	2'-Deoxy-3'-anthraniloyl adenosine-5-triphosphate (ANT-dATP) coordinated to Tb3+ was used as an environmentally sensitive probe of the nucleotide-binding site of GroEL. Tb3+ ANT-dATP recognizes the nucleotide-binding site of GroEL and inhibits ATPase activity. Sensitized luminescence, arising from resonance energy transfer from the anthraniloyl moiety to Tb3+, is substantially enhanced in the presence of GroEL. Binding of denatured mitochondrial malate dehydrogenase to the apical domain of GroEL causes a red shift in the fluorescence emitted by anthraniloyl and, further enhancement in the phosphorescence emitted by Tb3+ upon excitation at 320 nm. It is suggested that binding of the protein substrate initiates domain movement, which is extended to the nucleotide-binding site. The luminescence results are discussed in reference to the structure of GroEL derived from x-ray crystallographic studies.			Churchich, JE (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.							AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHURCHICH JE, 1995, EUR J BIOCHEM, V231, P736, DOI 10.1111/j.1432-1033.1995.0736d.x; DEHARROCKS W, 1981, ACCOUNTS CHEM RES, V14, P384; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; Gibbons DL, 1996, J BIOL CHEM, V271, P31989, DOI 10.1074/jbc.271.50.31989; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; GREGORY EM, 1971, J BIOL CHEM, V246, P5491; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HUTCHINSON JP, 1994, BIOCHEM J, V302, P405, DOI 10.1042/bj3020405; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; Krauss O, 1996, EUR J BIOCHEM, V241, P538, DOI 10.1111/j.1432-1033.1996.00538.x; LI W, 1997, IN PRESS EUR J BIOCH; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; Mendoza JA, 1996, J BIOL CHEM, V271, P16344, DOI 10.1074/jbc.271.27.16344; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; VITANEN PV, 1992, PROTEIN SCI, V1, P363; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062	24	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19645	19648		10.1074/jbc.272.32.19645	http://dx.doi.org/10.1074/jbc.272.32.19645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242617	hybrid			2022-12-27	WOS:A1997XQ05900004
J	Izu, H; Izumi, Y; Kurome, Y; Sano, M; Kondo, A; Kato, I; Ito, M				Izu, H; Izumi, Y; Kurome, Y; Sano, M; Kondo, A; Kato, I; Ito, M			Molecular cloning expression, and sequence analysis of the endoglycoceramidase II gene from Rhodococcus species strain M-777	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOSPHINGOLIPIDS; PERFORMANCE LIQUID-CHROMATOGRAPHY; NUCLEOTIDE-SEQUENCE; CERAMIDE-GLYCANASE; CLOSTRIDIUM-THERMOCELLUM; CELLULASE GENE; ENDOGLUCANASE; HYDROLYSIS; PROTEIN; OLIGOSACCHARIDES	Endoglycoceramidase (EGCase (EC 3.2.1.123)) is a hydrolase that hydrolyzes the linkage between the oligosaccharide and ceramide of various glycosphingolipids. This paper describes the molecular cloning and expression of EGCase II, one of the isoforms of EGCases. The gene encoding EGCase HP was obtained by screening of a genomic DNA library from Rhodococcus sp. strain M-777 constructed in pUC19 with oligonucleotide probes deduced from a partial amino acid sequence of the enzyme protein, Recombinant Escherichia coli cells in which the EGCase II gene was expressed produced 14 units of the enzyme per liter of culture medium but did not produce sphingomyelinase. Recombinant EGCase II was a functioning enzyme with substrate specificity identical to that of the wild-type enzyme. Sequence analysis showed the presence of an open reading frame of 1470 base pairs encoding 490 amino acids. The N-terminal region of the deduced amine, acid sequence had the general pattern of signal peptides of secreted prokaryotic proteins, Interestingly, the consensus sequence in the active site region of the endo-1,4-beta-glucanase family A was found in the amino acid sequence of EGCase II.	KYUSHU UNIV,FAC AGR,MARINE BIOCHEM LAB,HIGASHI KU,FUKUOKA 81281,JAPAN	Kyushu University	Izu, H (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,SETA 3-4-1,OTSU,SHIGA 52021,JAPAN.		Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818				ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ASHIDA H, 1992, EUR J BIOCHEM, V205, P72; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BAIRD SD, 1990, J BACTERIOL, V172, P1576, DOI 10.1128/jb.172.3.1576-1586.1990; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; CUNNINGHAM C, 1991, MOL GEN GENET, V228, P320, DOI 10.1007/BF00282484; GOUGH CL, 1990, GENE, V89, P53, DOI 10.1016/0378-1119(90)90205-6; GREPINET O, 1986, NUCLEIC ACIDS RES, V14, P1791, DOI 10.1093/nar/14.4.1791; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HALL J, 1988, GENE, V69, P29, DOI 10.1016/0378-1119(88)90375-7; HANSSON GC, 1989, BIOCHEMISTRY-US, V28, P6672, DOI 10.1021/bi00442a021; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HIGASHI H, 1990, ANAL BIOCHEM, V186, P355, DOI 10.1016/0003-2697(90)90094-P; HIGASHI H, 1990, TRENDS GLYCOSCI GLYC, V2, P514; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; ITO M, 1993, EUR J BIOCHEM, V218, P645, DOI 10.1111/j.1432-1033.1993.tb18418.x; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; Ito M., 1990, TRENDS GLYCOSCI GLYC, V2, P399; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAIRE M, 1993, J BACTERIOL, V175, P3353, DOI 10.1128/jb.175.11.3353-3360.1993; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V202, P398, DOI 10.1006/bbrc.1994.1941; OHARA K, 1991, J CHROMATOGR, V586, P35, DOI 10.1016/0021-9673(91)80022-9; POOLE DM, 1990, MOL GEN GENET, V223, P217, DOI 10.1007/BF00265057; PY B, 1991, PROTEIN ENG, V4, P325, DOI 10.1093/protein/4.3.325; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J., 2002, MOL CLONING LAB MANU; SAUL DJ, 1989, NUCLEIC ACIDS RES, V17, P439, DOI 10.1093/nar/17.1.439; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WESTERVELT C, 1989, GLYCOCONJUGATE J, V6, P405; YAMADA H, 1991, ANAL BIOCHEM, V198, P1, DOI 10.1016/0003-2697(91)90496-G; ZHOU B, 1989, J BIOL CHEM, V264, P12272; ZHOU LQ, 1994, BIOCHEM J, V297, P359, DOI 10.1042/bj2970359	41	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19846	19850		10.1074/jbc.272.32.19846	http://dx.doi.org/10.1074/jbc.272.32.19846			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242646	hybrid			2022-12-27	WOS:A1997XQ05900033
J	Briant, L; Signoret, N; Gaubin, M; RobertHebmann, V; Zhang, X; Murali, R; Greene, MI; PiatierTonneau, D; Devaux, C				Briant, L; Signoret, N; Gaubin, M; RobertHebmann, V; Zhang, X; Murali, R; Greene, MI; PiatierTonneau, D; Devaux, C			Transduction of activation signal that follows HIV-1 binding to CD4 and CD4 dimerization involves the immunoglobulin CDR3-like region in domain 1 of CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; LONG TERMINAL REPEAT; ENVELOPE GLYCOPROTEIN; T-CELLS; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; TYPE-1; INFECTION; MOLECULE	The role of CD4 during the human immunodeficiency virus type 1 (HIV-1) life cycle in T cells is not restricted to binding functions, HIV-1 binding to CD4 also triggers signals that lead to nuclear translocation of NF-kappa B and are important to the productive infection process, In addition to its cytoplasmic tail, in the ectodomain, the immunoglobulin (Ig) CDR3-like region of CD4 domain 1 seemed to play a role in this cascade of signals, We demonstrate in this work that the structural integrity of the CDR3-like loop is required for signal transduction. Substitutions of negatively charged residues by positively charged residues within the CDR3-like loop either inhibited NF-kappa B translocation after HIV-1 and gp120-anti-gp120 immune complexes binding to E91K,E92K mutants or induced its constitutive activation for E87K,D88K mutants, Moreover, A2.01-3B cells expressing the E91K,E92K mutant exhibited a lower HIV-1(Lai) replication, These cells, however, expressed p56(lck), demonstrated NF-kappa B translocation upon PMA stimulation, bound HIV-1(Lai) envelope glycoprotein with high affinity, and contained HIV-1 DNA 24 h after exposure to virus. E91K, E92K, and E87K,D88K mutant CD4 molecules were unable to bind a CD4 synthetic aromatically modified exocyclic, CDR3.AME-(82-89), that mimics the CDR3-like loop structure and binds to native cell surface CD4, This result together with molecular modeling studies indicates that the CDR3.AME-(82-89) analog binds to the CDR3-like loop of CD4 and strongly suggests that this region represents a site for CD4 dimerization, The negative charges on the CDR3-like loop thus appear critical for CD4-mediated signal transduction most likely related to CD4 dimer formation.	INST BIOL, LAB IMMUNOL INFECT RETROVIRALES, CNRS, ERS 155, F-34060 MONTPELLIER, FRANCE; CTR IMMUNOL MARSEILLE LUMINY, F-13288 MARSEILLE, FRANCE; CNRS, UPR 420, F-94801 VILLEJUIF, FRANCE; UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); University of Pennsylvania			Murali, Ramachandran/D-1132-2009; Briant, Laurence/AAB-9281-2021	Briant, Laurence/0000-0002-1995-3501; Murali, Ramachandran/0000-0002-8384-2793; Signoret, Nathalie Yvonne Micheline/0000-0003-4977-4149				ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BAHRAOUI E, 1988, AIDS, V2, P165; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; BENKIRANE M, 1995, J VIROL, V69, P6898, DOI 10.1128/JVI.69.11.6898-6903.1995; BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; BENKIRANE M, 1995, J VIROL, V69, P6904, DOI 10.1128/JVI.69.11.6904-6910.1995; BENKIRANE M, 1994, J VIROL, V68, P6332, DOI 10.1128/JVI.68.10.6332-6339.1994; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Briant L, 1996, J IMMUNOL, V156, P3994; Briant L, 1996, J VIROL, V70, P5213, DOI 10.1128/JVI.70.8.5213-5220.1996; CHIRMULE N, 1995, J BIOL CHEM, V270, P19364, DOI 10.1074/jbc.270.33.19364; CHIRMULE N, 1994, BIOCHEM BIOPH RES CO, V203, P498, DOI 10.1006/bbrc.1994.2210; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; CORBEAU P, 1993, J IMMUNOL, V150, P290; ENGLUND G, 1991, VIROLOGY, V181, P150, DOI 10.1016/0042-6822(91)90479-U; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; GOLDING H, 1993, J VIROL, V67, P6469, DOI 10.1128/JVI.67.11.6469-6475.1993; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; Lemasson I, 1996, J IMMUNOL, V156, P859; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; MALVOISIN E, 1994, J GEN VIROL, V75, P839, DOI 10.1099/0022-1317-75-4-839; MERZOUKI A, 1995, CELL MOL BIOL, V41, P445; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHKI K, 1990, AIDS, V4, P1160, DOI 10.1097/00002030-199011000-00020; POULIN L, 1991, J VIROL, V65, P4893, DOI 10.1128/JVI.65.9.4893-4901.1991; REPKE H, 1992, J IMMUNOL, V149, P1809; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; Signoret N, 1996, AIDS RES HUM RETROV, V12, P1001, DOI 10.1089/aid.1996.12.1001; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; SZABO G, 1992, J IMMUNOL, V149, P3596; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	48	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19441	19450		10.1074/jbc.272.31.19441	http://dx.doi.org/10.1074/jbc.272.31.19441			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235945	hybrid			2022-12-27	WOS:A1997XP06300051
J	Nichols, JC; Matthews, KS				Nichols, JC; Matthews, KS			Combinatorial mutations of lac repressor - Stability of monomer-monomer interface is increased by apolar substitution at position 84	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; AMINO-ACID SEQUENCE; LACTOSE REPRESSOR; ESCHERICHIA-COLI; OPERATOR DNA; BOUNDARY ANALYSIS; BINDING; PROTEIN; INDUCER; TETRAMER	To examine the monomer-monomer subunit interface in the lac repressor, a mutation that generates dimeric protein (deletion of C-terminal amino acids to disrupt the dimer-dimer interface) has been combined with amino acid substitutions that alter the monomer-monomer interface (substitution at Lys(84) or Tyr(282)). Dimeric proteins with significantly increased stability to urea denaturation were formed by the introduction of the apolar amino acids Ala or Leu in lieu of Lys(84) in concert with the deletion of 11 C-terminal amino acids. K84A/-11 deletion protein retained wild-type affinity for operator DNA, while K84L/-11 deletion protein displayed operator affinity similar to its parent tetramer, To assess further the influence of monomer-monomer interface stability on assembly and DNA binding, triple mutants were generated with Y282D, an alteration that disrupts assembly completely in the wild-type background, The triple mutants were dimeric, but they exhibited diminished dimer stability to urea denaturation and decreased operator affinity compared with the double mutations. These results demonstrate directly the stabilizing influence of apolar substitution at position 84 on the monomer monomer interface.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NIGMS NIH HHS [GM22441, 5T32GM08362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441, T32GM008362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1978, NATURE, V274, P767, DOI 10.1038/274767a0; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BUTLER AP, 1977, BIOCHEMISTRY-US, V16, P4757, DOI 10.1021/bi00641a001; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1992, GENE, V111, P145, DOI 10.1016/0378-1119(92)90618-Y; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P8728, DOI 10.1021/bi00195a014; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GREENE RF, 1974, J BIOL CHEM, V249, P5388; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LI L, 1995, J BIOL CHEM, V270, P10640, DOI 10.1074/jbc.270.18.10640; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1978, OPERON; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OHSHIMA Y, 1972, BIOCHEM BIOPH RES CO, V47, P1444, DOI 10.1016/0006-291X(72)90234-3; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PLATT T, 1973, J BIOL CHEM, V248, P110; Ralston G., 1993, INTRO ANAL ULTRACENT; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	58	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18550	18557		10.1074/jbc.272.30.18550	http://dx.doi.org/10.1074/jbc.272.30.18550			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228020	hybrid			2022-12-27	WOS:A1997XM34200011
J	Paton, VG; Shackelford, JE; Krisans, SK				Paton, VG; Shackelford, JE; Krisans, SK			Cloning and subcellular localization of hamster and rat Isopentenyl diphosphate dimethylallyl diphosphate isomerase - A PTS1 motif targets the enzyme to peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PEROXISOMES; MEVALONATE KINASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ACETOACETYL-COA; ACETYL-COA; DISORDERS; STEP	To date, isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IPP isomerase; EC 5.3.3.2) is presumed to have a cytosolic localization, However, we have recently shown that in permeabilized cells lacking cytosolic components, mevalonate can be converted to cholesterol, implying that all of the enzymes required for the conversion of mevalonate to farnesyl diphosphate are found in the peroxisome. To provide unequivocal evidence for the subcellular localization of IPP isomerase, in this study, we have cloned the rat and hamster homologues of IPP isomerase and identified the signal that targets this enzyme to peroxisomes. In addition, we also demonstrate that IPP isomerase is regulated at the mRNA level.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32852] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; Biardi L, 1996, J BIOL CHEM, V271, P1784, DOI 10.1074/jbc.271.3.1784; BIARDI L, 1994, J BIOL CHEM, V269, P1197; CHAMBLISS LL, 1996, J BIOL CHEM, V271, P17330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Hahn FM, 1996, ARCH BIOCHEM BIOPHYS, V332, P30, DOI 10.1006/abbi.1996.0312; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; KRISANS SK, 1988, J CELL BIOL, V107, P122; MUEHLBACHER M, 1985, J AM CHEM SOC, V107, P8307, DOI 10.1021/ja00312a107; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POPJAK G, 1970, NATURAL SUBSTANCES F, P17; Purdue PE, 1996, ANN NY ACAD SCI, V804, P775, DOI 10.1111/j.1749-6632.1996.tb18699.x; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Sambrook J., 2002, MOL CLONING LAB MANU; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SPURGEON SL, 1981, BIOSYNTHESIS ISOPREN, V1, P2; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOTH JM, 1996, J BIOL CHEM, V271, P7895; XUAN J, 1994, GENOMICS, V20, P128	27	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18945	18950		10.1074/jbc.272.30.18945	http://dx.doi.org/10.1074/jbc.272.30.18945			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228075	hybrid			2022-12-27	WOS:A1997XM34200066
J	Johansson, JS				Johansson, JS			Binding of the volatile anesthetic chloroform to albumin demonstrated using tryptophan fluorescence quenching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE-FREQUENCY PHASE; HUMAN SERUM-ALBUMIN; QUANTITATIVE-DETERMINATION; MODULATION DATA; PROTEINS; HALOTHANE; STABILITY; TITRATION; CHEMISTRY; KINETICS	The site(s) of action of the volatile general anesthetics remain(s) controversial, but evidence in favor of specific protein targets is accumulating. The techniques to measure directly volatile anesthetic binding to proteins are still under development. Further experience with the intrinsic protein fluorescence quenching approach to monitor anesthetic-protein complexation is reported using chloroform. Chloroform quenches the steady state tryptophan fluorescence of bovine serum albumin (ESA) in a concentration-dependent, saturable manner with a K-d = 2.7 +/- 0.2 mM. Tryptophan fluorescence lifetime analysis reveals that the majority of the quenching is due to a static mechanism, indicative of anesthetic binding. The ability of chloroform to quench BSA tryptophan fluorescence was decreased markedly in the presence of 50% 2,2,2-trifluoroethanol, which causes loss of tertiary structural contacts in BSA, indicating that protein conformation is crucial for anesthetic binding. Circular dichroism spectroscopy revealed no measurable effect of chloroform on the secondary structure of BSA. The results suggest that chloroform binds to subdomains IB and IIA in ESA, each of which contains a single tryptophan. Earlier work has shown that these sites are also occupied by halothane. The present study therefore provides experimental support for the theory that structurally distinct general anesthetics may occupy the same domains on protein targets.	UNIV PENN, DEPT ANESTHESIA, PHILADELPHIA, PA 19104 USA; UNIV PENN, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM055876] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01-GM55876] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM MH, 1987, CHROMATOGRAPHIA, V23, P243, DOI 10.1007/BF02311772; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Chen Y, 1996, J AM CHEM SOC, V118, P9271, DOI 10.1021/ja961307u; COWAN DO, 1970, J AM CHEM SOC, V92, P6281, DOI 10.1021/ja00724a029; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; EBERSON L, 1982, ACTA CHEM SCAND B, V36, P533, DOI 10.3891/acta.chem.scand.36b-0533; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EGER EI, 1969, ANESTHESIOLOGY, V30, P129; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Gibney BR, 1997, BIOCHEMISTRY-US, V36, P2798, DOI 10.1021/bi9618225; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; HARRIS RA, 1995, FASEB J, V9, P1454, DOI 10.1096/fasebj.9.14.7589987; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Johansson JS, 1996, J PHARMACOL EXP THER, V279, P56; Johansson JS, 1996, BBA-GEN SUBJECTS, V1290, P63, DOI 10.1016/0304-4165(95)00187-5; Johansson JS, 1997, BIOPHYS J, V72, pTH406; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KARON BS, 1995, BIOPHYS J, V68, P936, DOI 10.1016/S0006-3495(95)80269-9; KAUFMAN RD, 1977, ANESTHESIOLOGY, V46, P49, DOI 10.1097/00000542-197701000-00010; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAKOWICZ JR, 1980, BIOPHYS J, V32, P591, DOI 10.1016/S0006-3495(80)84992-7; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; Laskowski RA, 1996, PROTEIN SCI, V5, P2438; LEE AG, 1991, PROG LIPID RES, V30, P323, DOI 10.1016/0163-7827(91)90002-M; MCDONAGH AF, 1992, EXPERIENTIA, V48, P246, DOI 10.1007/BF01930465; MILES JL, 1962, J BIOL CHEM, V237, P1319; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; RAINES DE, 1995, ANESTHESIOLOGY, V82, P276, DOI 10.1097/00000542-199501000-00033; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; STEINER RF, 1969, J PHYS CHEM-US, V73, P4130, DOI 10.1021/j100846a015; STEINHARDT J, 1971, BIOCHEMISTRY-US, V10, P4005, DOI 10.1021/bi00798a001; TAHERI S, 1991, ANESTH ANALG, V72, P627; WASYLEWSKI Z, 1988, EUR J BIOCHEM, V172, P719, DOI 10.1111/j.1432-1033.1988.tb13948.x; Xu Y, 1996, BIOPHYS J, V70, P532, DOI 10.1016/S0006-3495(96)79599-1; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	45	114	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17961	17965		10.1074/jbc.272.29.17961	http://dx.doi.org/10.1074/jbc.272.29.17961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218421	hybrid			2022-12-27	WOS:A1997XL73500011
J	Stafforini, DM; McIntyre, TM; Zimmermann, GA; Prescott, SM				Stafforini, DM; McIntyre, TM; Zimmermann, GA; Prescott, SM			Platelet-activating factor acetylhydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SERUM PAF ACETYLHYDROLASE; LOW-DENSITY-LIPOPROTEIN; HUMAN-PLASMA; CELLS; PURIFICATION; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; DIFFERENTIATION; MESSENGER; INCREASES; ENZYMES		UNIV UTAH,PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HUNTSMAN CANC INST,SALT LAKE CITY,UT 84112; UNIV UTAH,CARDIOVASC RES & TRAINING INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL35828, HL50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BLANK ML, 1981, J BIOL CHEM, V256, P175; Blencowe C, 1995, J BIOL CHEM, V270, P31151, DOI 10.1074/jbc.270.52.31151; CAPLAN M, 1990, PROSTAGLANDINS, V39, P705, DOI 10.1016/0090-6980(90)90030-Y; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; FARR RS, 1983, FED PROC, V42, P3120; GRAHAM RM, 1989, CLIN SCI, V82, P535; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HATTORI M, 1995, J BIOL CHEM, V270, P22308; HATTORI M, 1996, J BIOL CHEM, V271, P33032; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; Karasawa K, 1996, J BIOCHEM-TOKYO, V120, P838; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MIYAURA S, 1991, LIPIDS, V26, P1015, DOI 10.1007/BF02536494; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PALMANTIER R, 1989, BIOCHEM BIOPH RES CO, V162, P475, DOI 10.1016/0006-291X(89)92022-6; PATEL KD, 1992, J BIOL CHEM, V267, P15168; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINER O, 1995, J NEUROSCI, V15, P3730; SATOH K, 1992, STROKE, V23, P1090, DOI 10.1161/01.STR.23.8.1090; SATOH K, 1991, CLIN CHIM ACTA, V202, P95, DOI 10.1016/0009-8981(91)90260-J; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1989, PROSTAGLANDINS, V37, P673; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; SUZUKI Y, 1988, EUR J BIOCHEM, V172, P117, DOI 10.1111/j.1432-1033.1988.tb13862.x; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; VENABLE ME, 1993, J LIPID RES, V34, P691; WAKU K, 1968, J LIPID RES, V9, P12; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, P149	55	220	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17895	17898		10.1074/jbc.272.29.17895	http://dx.doi.org/10.1074/jbc.272.29.17895			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218411	hybrid			2022-12-27	WOS:A1997XL73500001
J	AbuSoud, HM; Gachhui, R; Raushel, FM; Stuehr, DJ				AbuSoud, HM; Gachhui, R; Raushel, FM; Stuehr, DJ			The ferrous-dioxy complex of neuronal nitric oxide synthase - Divergent effects of L-arginine and tetrahydrobiopterin on its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; MACROPHAGE NO SYNTHASE; ELECTRON-TRANSFER; HEME COORDINATION; OXYGENATED FORM; LOW-TEMPERATURE; CALMODULIN; ENZYME; MECHANISM; BINDING	Nitric oxide synthases (NOS) are hemeproteins that catalyze oxidation of L-arginine to nitric oxide (NO) and citrulline. The NOS heme iron is expected to participate in oxygen activation during catalysis, but its interac tions with O-2 are not characterized. We utilized the heme-containing oxygenase domain of neuronal NOS (nNOSoxy) and stopped-flow methods to study forma tion and autooxidative decomposition of the nNOSoxy oxygenated complex at 10 degrees C. Mixing ferrous nNOSoxy with air-saturated buffer generated a transient species with absorption maxima at 427 and similar to 560 nm. This species decayed within 1 s to form ferric nNOSoxy. Its formation was first order with respect to O-2, monophasic, and gave rate constants for k(on) = 9 x 10(5) M-1 s(-1) and k(off) = 108 s(-1) for an L-arginine- and tetrahydrobiopterin (H4B)-saturated nNOSoxy. Omission of L-arginine and/or H4B did not greatly effect O-2 binding and dissociation rates. Decomposition of the oxygenated intermediate was independent of O-2 concentration and was either biphasic or monophasic depending on sample conditions, L-Arginine stabilized the oxygenated intermediate (decay rate = 0.14 s(-1)), while H4B accelerated its decay by a factor of 70 irrespective of L-arginine. The spectral and kinetic properties of the intermediate identify it as the (FeO2)-O-II complex of nNOSoxy. Destabilization of a metallo-oxy species by H4B is unprecedented and may be important regarding the role of this cofactor in NO synthesis.	TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station	AbuSoud, HM (corresponding author), CLEVELAND CLIN,RES INST,DEPT IMMUNOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TYSON CA, 1972, J BIOL CHEM, V247, P5777; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	49	156	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17349	17353		10.1074/jbc.272.28.17349	http://dx.doi.org/10.1074/jbc.272.28.17349			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211873	hybrid			2022-12-27	WOS:A1997XK16500016
J	Asano, S; Matsuda, S; Tega, Y; Shimizu, K; Sakamoto, S; Takeguchi, N				Asano, S; Matsuda, S; Tega, Y; Shimizu, K; Sakamoto, S; Takeguchi, N			Mutational analysis of putative SCH 28080 binding sites of the gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; AMINO-ACID-SEQUENCE; DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; DISTAL COLON; CDNA CLONING; K+-ATPASE; NA+,K+-ATPASE	A compound, SCH 28080 (2-methyl-8-(phenylmethoxy) imidazo[1,2-a]pyridine-3-acetonitrile) reversibly inhibits gastric and renal ouabain-insensitive H+,K+-ATPase, but not colonic ouabain-sensitive H+,H+-ATPase, By using the functional expression system and site-directed mutagenesis, we analyzed the putative binding sites of SCH 28080 in gastric H+,K+-ATPase alpha-subunit, It was previously reported that the binding site of SCH 28080, which is a K+-site inhibitor specific for gastric H+,K+-ATPase, was in the first extracellular loop between the first and second transmembrane segments of the alpha-subunit; Phe-126 and Asp-138 were putative binding sites, However, we found that all the mutants in the first extracellular loop including Phe-126 and Asp-ISS retained H+,K+-ATPase activity and sensitivity to SCH 28080, Therefore, amino acid residues in the first extracellular loop are not directly involved in the SCH 28080 binding nor indispensable for the H+,K+-ATPase activity. Here rye propose a candidate residue that is important for the binding with SCH 28080, Glu-822 in the sixth transmembrane segment. Mutations of Glu-822 to Asp and Ala (mutants termed E822D and E822A, respectively) decreased the ATPase activity to about 45% and 35% of the wild-type enzyme, respectively, while the mutations to Gin and Leu abolished the activity, Mutant E822A showed a significantly lower affinity for K+ than the wild-type enzyme, indicating that Glu-822 is involved in determining the affinity for K+, The sensitivity of mutant E822D to SCH 28080 was 8 times lower than that of the wild-type enzyme, The counterpart of Glu-822 in gastric H+,K+-ATPase is Asp in Na+,K+-ATPase and other colonic ouabain-sensitive H+,K+-ATPase, which are insensitive to SCN 28080, These results suggest that Glu-822 is one of important sites that bind with SCH 28080.	TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,TOYAMA 93001,JAPAN	University of Toyama	Asano, S (corresponding author), TOYAMA MED & PHARMACEUT UNIV,MOL GENET RES CTR,2630 SUGITANI,TOYAMA 93001,JAPAN.			Asano, Shinji/0000-0003-1443-8970				ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; ASANO S, 1988, J BIOCHEM-TOKYO, V103, P672, DOI 10.1093/oxfordjournals.jbchem.a122327; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORMACK B, 1991, CURRENT PROTOCOLS MO; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FORTE JG, 1975, GASTROENTEROLOGY, V69, P175; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; MORII M, 1989, GASTROENTEROLOGY, V96, P1453, DOI 10.1016/0016-5085(89)90512-X; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; Morii M, 1996, J BIOL CHEM, V271, P4068; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCOTT CK, 1985, EUR J PHARMACOL, V112, P268, DOI 10.1016/0014-2999(85)90508-4; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	45	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17668	17674		10.1074/jbc.272.28.17668	http://dx.doi.org/10.1074/jbc.272.28.17668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211917	hybrid			2022-12-27	WOS:A1997XK16500060
J	deWeerd, WFC; LeebLundberg, LMF				deWeerd, WFC; LeebLundberg, LMF			Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled G alpha subunits G alpha(q) and G alpha(i) in caveolae in DDT1 MF-2 smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; ROUS-SARCOMA VIRUS; SIGNAL-TRANSDUCTION; PROTEIN-COMPONENT; ANCHORED PROTEINS; PLASMA-MEMBRANE; KININ RECEPTORS; GROWTH-FACTOR; EXPRESSION; TYROSINE	In this report, we show that the vasoactive peptide agonist bradykinin (BK) when bound to B2 BK receptors on DDT1 MF-2 smooth muscle. cells promotes the recruitment and sequestration of the occupied receptors and the receptor-coupled G-protein alpha subunits G alpha(q) and G alpha(i) in caveolae, Association of ligand receptor complexes and G alpha subunits with caveolae was indicated by their co-enrichment on density gradients with caveolin, a marker protein for caveolae. Caveolin and G alpha subunits were monitored by immunoblotting, whereas receptors were monitored as ligand receptor complexes formed by labeling receptors with the agonist BK or the antagonist NPC17731 prior to cell disruption and caveolae enrichment, These complexes were detected with radioligand and by immunoblotting with BR antibodies. A direct interaction of G alpha subunits with caveolin was also indicated by their co-immunoprecipitation, Immunoelectron microscopy revealed that the enriched caveolin, Ga subunits, and BK receptor complexes were present in structures of 0.1-0.2 mu m. At 4 degrees C, BH and NPC17731 receptor complexes were detected in caveolae, and both complexes were sensitive to acid washing prior to cell disruption and caveolae enrichment. Elevation of the temperature to 37 degrees C increased the amount of BK receptor complexes in caveolae with a maximal response at 10 min (continuous labeling or 20 min (single-round labelling), and the complexes became acid-resistant, These conditions also increased the amount of G alpha(q), and G alpha(i) in caveolae with a maximal response at 5-10 min, In contrast, the NPC17731 receptor complexes remained acid-sensitive and dissociated at this temperature, and antagonists did not increase the amount of Get subunits in caveolae, These results show that some agonists that act through G-protein-coupled receptors promote the association of their receptors and receptor-coupled Get subunits with caveolae.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Anderson RM, 1991, INFECT DIS HUMANS DY, P13; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LI S, 1995, J BIOL CHEM, V27, P15693; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PAGE E, 1994, CIRC RES, V75, P949, DOI 10.1161/01.RES.75.5.949; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; WALLACE H, 1969, ANAL BIOCHEM, V32, P334, DOI 10.1016/0003-2697(69)90094-3; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	59	235	236	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17858	17866		10.1074/jbc.272.28.17858	http://dx.doi.org/10.1074/jbc.272.28.17858			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211942	hybrid			2022-12-27	WOS:A1997XK16500085
J	Lisitsky, I; Kotler, A; Schuster, G				Lisitsky, I; Kotler, A; Schuster, G			The mechanism of preferential degradation of polyadenylated RNA in the chloroplast - The exoribonuclease 100RNP/polynucleotide phosphorylase displays high binding affinity for poly(A) sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' INVERTED REPEATS; MESSENGER-RNA; ESCHERICHIA-COLI; GENE-EXPRESSION; SPINACH CHLOROPLAST; NUCLEOTIDE-SEQUENCE; PROTEIN; RIBONUCLEOPROTEIN; POLYADENYLYLATION; IDENTIFICATION	Polyadenylation of mRNA in the chloroplast has recently been shown to target the RNA molecule for rapid exonucleolytic degradation. A model has been suggested in which the degradation of chloroplast mRNA is initiated by endonucleolytic cleavage(s) followed by the addition of poly(A)-rich sequences and rapid exonucleolytic degradation. When in vitro transcribed RNAs were incubated with chloroplast protein extract, competition between polyadenylated and non-polyadenylated RNAs for degradation resulted in the rapid degradation of the polyadenylated molecules and stabilization of their nonpolyadenylated counterparts, To elucidate the molecular mechanism governing this effect, we determined whether the chloroplast exoribonuclease 100RNP/polynucleotide phosphorylase (PNPase) preferably degrades polyadenylated RNA, When separately incubated with each molecule, isolated 100RNP/PNPase degraded polyadenylated and non-polyadenylated RNAs at the same rate, However, when both molecules were mixed together, the polyadenylated RNA was degraded, whereas the non-polyadenylated RNA was stabilized, In RNA binding experiments, 100RNP/PNPase bound the poly(A) sequence with much higher affinity than other RNA molecules, thereby defining the poly(ii)-rich RNA as a preferential substrate for the enzyme, 100RNP/PNPase may therefore be involved in a mechanism in which post-transcriptional addition of poly(A)-rich sequence targets the chloroplast RNA for rapid exonucleolytic degradation.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Schuster, Gadi/AAE-2010-2019					Baker EJ, 1993, CONTROL MESSENGER RN, P367; Belasco J, 1993, CONTROL MESSENGER RN, P3; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BURKARD G, 1974, P NATL ACAD SCI USA, V71, P389, DOI 10.1073/pnas.71.2.389; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; Drager RG, 1996, RNA, V2, P652; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; GRUISSEM W, 1985, EMBO J, V4, P1637, DOI 10.1002/j.1460-2075.1985.tb03831.x; Gruissem W., 1993, CONTROL MRNA STABILI, P329; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HaugelNielsen J, 1996, EMBO J, V15, P3144, DOI 10.1002/j.1460-2075.1996.tb00677.x; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; JAJACKSON RJ, 1990, CELL, V62, P15; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Li QS, 1996, J BIOL CHEM, V271, P19831, DOI 10.1074/jbc.271.33.19831; LISITSKY I, 1995, NUCLEIC ACIDS RES, V23, P2506, DOI 10.1093/nar/23.13.2506; LISITSKY I, 1994, NUCLEIC ACIDS RES, V22, P4719, DOI 10.1093/nar/22.22.4719; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; LISITSKY I, 1995, ANAL BIOCHEM, V224, P603, DOI 10.1006/abio.1995.1094; LISITSKY I, 1995, PLANT PHYSIOL, V107, P933, DOI 10.1104/pp.107.3.933; LITTAUER UZ, 1982, ENZYMES, V15, P517; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PY P, 1996, NATURE, V381, P169; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; SACHS A, 1993, J BIOL CHEM, V268, P22955; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STERN DB, 1989, PLANT MOL BIOL, V13, P615, DOI 10.1007/BF00016017; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P7699, DOI 10.1073/pnas.79.24.7699	39	60	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17648	17653		10.1074/jbc.272.28.17648	http://dx.doi.org/10.1074/jbc.272.28.17648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211914	hybrid			2022-12-27	WOS:A1997XK16500057
J	Malgaretti, N; Pozzoli, O; Bosetti, A; Corradi, A; Ciarmatori, S; Panigada, M; Bianchi, ME; Martinez, S; Consalez, GG				Malgaretti, N; Pozzoli, O; Bosetti, A; Corradi, A; Ciarmatori, S; Panigada, M; Bianchi, ME; Martinez, S; Consalez, GG			Mmot1, a new helix-loop-helix transcription factor gene displaying a sharp expression boundary in the embryonic mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; SEQUENCE; NEURONS; MICE; PCR; FOREBRAIN; HOMEOBOX; DELETION; PROTEIN; CLONING	Several genetic factors have been proven to contribute to the specification of the metencephalic-mesencephalic territory, a process that sets the developmental foundation for prospective morphogenesis of the cerebellum and mesencephalon, However, evidence stemming from genetic and developmental studies performed in man and various model organisms suggests the contribution of many additional factors in determining the fine subdivision and differentiation of these central nervous system regions, In man, the cerebellar ataxias/aplasias represent a large and heterogeneous family of genetic disorders. Here, we describe the identification by differential screening and the characterization of Mmot1, a new gene encoding a DNA-binding protein strikingly similar to the helix-leap-helix factor Ebf/Olf1, Throughout midgestation embryogenesis, Mmot1 is expressed at high levels in the metencephalon, mesencephalon, and sensory neurons of the nasal cavity. In vitro DNA binding data suggest some functional equivalence of Mmot1 and Ebf/Olf1, possibly accounting for the reported lack of olfactory or neural defects in Ebf(-/-) knockout mutants, The isolation of Mmot1 and of an additional homolog in the mouse genome defines a novel, phylogenetically conserved mammalian family of transcription factor genes of potential relevance in studies of neural development and its aberrations.	DIBIT,HSR,I-20132 MILAN,ITALY; UNIV MILAN,SCH BIOL,DEPT GENET & MICROBIOL,I-20132 MILAN,ITALY; UNIV MURCIA,SCH MED,INST MORPHOL SCI,E-30071 MURCIA,SPAIN	University of Milan; University of Murcia			Corradi, Anna/AAC-5209-2022; Bianchi, Marco Emilio/K-3417-2018; Consalez, Giacomo/AAA-2146-2019	Bianchi, Marco Emilio/0000-0002-5329-6445; Consalez, Giacomo/0000-0003-4594-6273	Telethon [E.0501] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Consalez GG, 1996, TRENDS GENET, V12, P455; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crozatier M, 1996, CURR BIOL, V6, P707, DOI 10.1016/S0960-9822(09)00452-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HURST J, 1987, CYTOGENET CELL GENET, V45, P30, DOI 10.1159/000132421; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MCCLELLAND M, 1994, PCR METH APPL, V4, pS66; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; Moore DD, 1995, GLOB MOB SURV; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SAMBROOK J, 1989, MOL LAB MANUAL; SOMERVILLE MJ, 1988, GENOME, V30, P499, DOI 10.1139/g88-083; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WELSH J, 1995, MUTAT RES-DNAGING G, V338, P215, DOI 10.1016/0921-8734(95)00026-3; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WILKINSON DG, 1992, IN SITU HYDBRIDIZATI; WURST W, 1994, DEVELOPMENT, V120, P2065	42	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17632	17639		10.1074/jbc.272.28.17632	http://dx.doi.org/10.1074/jbc.272.28.17632			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211912	hybrid			2022-12-27	WOS:A1997XK16500055
J	Roman, BB; Wieringa, B; Koretsky, AP				Roman, BB; Wieringa, B; Koretsky, AP			Functional equivalence of creatine kinase isoforms in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MICE DEFICIENT; RAT MUSCLE; LOCALIZATION; COMPARTMENTATION; ISOENZYMES; ENERGY; PHOSPHOCREATINE; PHOSPHOKINASE; METABOLISM	Creatine kinase (CK) is a highly conserved enzyme abundant in skeletal muscle that has a key role in high energy phosphate metabolism, The localization of the muscle isoenzyme of CK (MM-CK) to the M line and the sarcoplasmic reticulum of myofibrils has been suggested to be important for proper force development in skeletal muscle, The importance of this subcellular compartmentation has not been directly tested in vivo. To test the role of myofibrilar localization of CR, the consequences of a complete CR isoform switch from MM-CII to the brain (BE-CIT) isoform, which does not localize to the M Line, was studied in transgenic mouse skeletal muscle, in RIM-CK knockout mice there are large contractile defects, When MM-CK was replaced by BE-CK, the aberrant contractile phenotypes seen in MIM-CH knockout mice were returned to normal despite the lack of myofibrillar localization, These results indicate that CK compartmentation to the myofibril of skeletal muscle is not essential for contractile function and that there is functional equivalence of creatine kinase isoforms in supporting cellular energy metabolism.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,PITTSBURGH NMR CTR BIOMED RES,PITTSBURGH,PA 15213; UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,NL-6500 AB NIJMEGEN,NETHERLANDS	Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Radboud University Nijmegen			Koretsky, Alan P/C-7940-2015; Wieringa, Berend/A-5346-2011	Koretsky, Alan P/0000-0002-8085-4756; Wieringa, Berend/0000-0001-9192-8020	NHLBI NIH HHS [R01-HL40354, 5 K04 HL-02847, F32-HL08985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002847, R01HL040354, F32HL008985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACERENZA L, 1993, J THEOR BIOL, V165, P63, DOI 10.1006/jtbi.1993.1177; BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BEEKMANS S, 1993, J MOL RECOGNIT, V6, P195; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BIERMANS W, 1989, BIOCHIM BIOPHYS ACTA, V974, P74, DOI 10.1016/S0005-2728(89)80167-7; BROSNAN MJ, 1993, AM J PHYSIOL, V264, pC151, DOI 10.1152/ajpcell.1993.264.1.C151; CANDE WZ, 1983, NATURE, V304, P557, DOI 10.1038/304557a0; CUNEO P, 1992, BIOCHEM J, V281, P507, DOI 10.1042/bj2810507; DANG CV, 1982, FEBS LETT, V142, P1, DOI 10.1016/0014-5793(82)80206-8; DEHAAN A, 1995, EXP PHYSIOL, V80, P491, DOI 10.1113/expphysiol.1995.sp003863; FITCH CD, 1975, AM J PHYSIOL, V228, P1123, DOI 10.1152/ajplegacy.1975.228.4.1123; GELLERICH F, 1982, BIOCHEM BIOPH RES CO, V105, P1473, DOI 10.1016/0006-291X(82)90954-8; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1140, P327, DOI 10.1016/0005-2728(93)90073-O; KORGE P, 1993, EUR J BIOCHEM, V213, P973, DOI 10.1111/j.1432-1033.1993.tb17842.x; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; LYNCH RM, 1987, AM J PHYSIOL, V252, pC328, DOI 10.1152/ajpcell.1987.252.3.C328; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MEYER RA, 1986, AM J PHYSIOL, V250, pC264, DOI 10.1152/ajpcell.1986.250.2.C264; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Roman BB, 1996, AM J PHYSIOL-CELL PH, V270, pC1236, DOI 10.1152/ajpcell.1996.270.4.C1236; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SILVER RB, 1983, J BIOL CHEM, V258, P3287; SRERE PA, 1995, ADV MOL CEL, V11, P125; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; STEEGHS K, 1995, BBA-BIOENERGETICS, V1230, P130, DOI 10.1016/0005-2728(95)00044-J; SUMEGI B, 1991, BIOCHEM SOC T, V4, P1002; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; VANDORSTEN FA, 1996, THESIS U UTRECHT NET; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; Wallimann T, 1985, Cell Muscle Motil, V6, P239; Watchko JF, 1997, J APPL PHYSIOL, V82, P1416, DOI 10.1152/jappl.1997.82.5.1416; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WILSON IA, 1995, BIOCHEM J, V308, P599, DOI 10.1042/bj3080599; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	47	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17790	17794		10.1074/jbc.272.28.17790	http://dx.doi.org/10.1074/jbc.272.28.17790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211932	hybrid, Green Submitted, Green Published			2022-12-27	WOS:A1997XK16500075
J	Gunther, MR; Hsi, LC; Curtis, JF; Gierse, JK; Marnett, LJ; Eling, TE; Mason, RP				Gunther, MR; Hsi, LC; Curtis, JF; Gierse, JK; Marnett, LJ; Eling, TE; Mason, RP			Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; ACUTE LUNG INJURY; RIBONUCLEOTIDE REDUCTASE; ENDOPEROXIDE SYNTHASE-2; PEROXYNITRITE; KINETICS; ENZYME; QUANTITATION; EXPRESSION; INHIBITION	The determination of protein nitrotyrosine content has become a frequently used technique for the detection of oxidative tissue damage, Protein nitration has been suggested to be a final product of the production of highly reactive nitrogen oxide intermediates (e.g. peroxynitrite) formed in reactions between nitric oxide (NO.) and oxygen-derived species such as superoxide. The enzyme prostaglandin H synthase-2 (PHS-2) forms one or more tyrosyl radicals duping its enzymatic catalysis of prostaglandin formation, In the presence of She NO.-generator diethylamine nonoate, the electron spin resonance spectrum of the PHS-a-derived tyrosyl radical is replaced by the spectrum of another free radical containing a nitrogen atom. The magnitude of the nitrogen hyperfine coupling constant in the latter species unambiguously identifies it as an iminoxyl radical, which is likely formed by the oxidation of nitrosotyrosine, a stable product of the addition of NO. to tyrosyl radical. Addition of superoxide dismutase did not alter the spectra, indicating that peroxynitrite was not involved. Western blot analysis of PHS-2 after exposure to the NO.-generator revealed nitrotyrosine formation. The results provide a mechanism for nitric oxide-dependent tyrosine nitration that does not require formation of more highly reactive nitrogen oxide intermediates such as peroxynitrite or nitrogen dioxide.	NIEHS,NIH,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; GD SEARLE & CO,ST LOUIS,MO 63167; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University	Gunther, MR (corresponding author), NIEHS,LAB PHARMACOL & CHEM,NIH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				ABE K, 1995, NEUROSCI LETT, V199, P152, DOI 10.1016/0304-3940(95)12039-7; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BEAKE BD, 1994, J CHEM SOC PERK T 2, P957, DOI 10.1039/p29940000957; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROKENSHIRE JL, 1972, J AM CHEM SOC, V94, P7040, DOI 10.1021/ja00775a030; Buttery LDK, 1996, LAB INVEST, V75, P77; CASTRO A, 1987, B SOC CHIM FR, P83; EISERICH JP, 1994, FEBS LETT, V353, P53, DOI 10.1016/0014-5793(94)01011-0; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FISCHER V, 1986, CHEM-BIOL INTERACT, V57, P129, DOI 10.1016/0009-2797(86)90033-5; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Good PF, 1996, AM J PATHOL, V149, P21; GREEN RG, 1975, J CHEM SOC PERK T 2, P1380, DOI 10.1039/p29750001380; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LOW W, 1957, PHYS REV, V105, P801, DOI 10.1103/PhysRev.105.801; Mannick EE, 1996, CANCER RES, V56, P3238; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; OURY TD, 1995, FREE RADICAL RES, V23, P537, DOI 10.3109/10715769509065275; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; Schulz JB, 1995, J NEUROSCI, V15, P8419; STREIDER S, 1992, J BIOL CHEM, V267, P13870; THOMAS JR, 1964, J AM CHEM SOC, V86, P1446, DOI 10.1021/ja01061a043; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2	46	153	155	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17086	17090		10.1074/jbc.272.27.17086	http://dx.doi.org/10.1074/jbc.272.27.17086			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202025	hybrid			2022-12-27	WOS:A1997XH44600057
J	Fukushima, Y; Asano, T; Takata, K; Funaki, M; Ogihara, T; Anai, M; Tsukuda, K; Saitoh, T; Katagiri, H; Aihara, M; Matsuhashi, N; Oka, Y; Yazaki, Y; Sugano, K				Fukushima, Y; Asano, T; Takata, K; Funaki, M; Ogihara, T; Anai, M; Tsukuda, K; Saitoh, T; Katagiri, H; Aihara, M; Matsuhashi, N; Oka, Y; Yazaki, Y; Sugano, K			Role of the C terminus in histamine H2 receptor signaling, desensitization, and agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; CYTOPLASMIC TAIL; CANINE HISTAMINE-H2-RECEPTOR; PHOSPHORYLATION SITES; MOLECULAR-CLONING; H-2 RECEPTORS; TRUNCATION; ENDOCYTOSIS; EXPRESSION; CYCLASE	To evaluate the role of the histamine H2 receptor C terminus in signaling, desensitization, and agonist-induced internalization, canine H2 receptors with truncated C termini were generated. Wild-type (WT) and truncated receptors were tagged at their N termini with a hemagglutinin (HA) epitope and expressed in COS7 cells, Most of the C-terminal intracellular tail could be truncated (51 of 70 residues, termed T-308 mutant) without loss of functions: cAMP production, tiotidine binding, and plasma membrane targeting, In fact, the T-308 mutant produced more cAMP than the WT when cell-surface expression per cell was equivalent. Pretreat ment of cells with 10(-5) M histamine desensitized cAMP productions via WT and T-308 receptors 60 similar extents. Incubation of cells expressing WT receptors with 10(-5) M histamine reduced cell-surface anti-HA antibody binding by approximately 30% (by 30 min, t(1/2) similar to 15 min), but did not affect the B-max of tiotidine in membrane fractions, which represents total receptor amounts, suggesting that WT receptors were internalized from the cell surface, In contrast, no internalization was observed with T-308 receptors following histamine treatment. A mutant with a deletion of the 30 C-terminal amino acids, termed T-329, was functional but was as potent as the WT in terms of cAMP production. Apart from being desensitized by histamine, the internalization of the receptor was indistinguishable from that of the WT. Internalization was observed in the T-320 but not in T-313 mutant, narrowing the region involved in internalization to that between Glu(314) and Asn(320) (ETSLRSN). Of these seven residues, either Thr(315), Ser(316), or both, were replaced with Ala. Thr(315) and Ser(316) are conserved among species. The mutation at Thr(315) (but not that at Ser(316)) abolished internalization. Taken together, these results demonstrate that Thr(315) is involved in agonist-induced internalization. Furthermore, the finding that T-308 receptors were desensitized in the absence of internalization suggests that internalization and desensitization are meditated by independent mechanisms.	UNIV TOKYO,FAC MED,DEPT BIOCHEM 2,TOKYO 113,JAPAN; UNIV TOKYO,HLTH SERV CTR,TOKYO 113,JAPAN; GUNMA UNIV,INST MOL & CELLULAR REGULAT,LAB MOL & CELLULAR MORPHOL,MAEBASHI,GUMMA 371,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	University of Tokyo; University of Tokyo; Gunma University; Yamaguchi University	Fukushima, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.			Matsuhashi, Nobuyuki/0000-0002-0139-430X				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ARIMA N, 1993, AM J PHYSIOL, V265, pG987, DOI 10.1152/ajpgi.1993.265.5.G987; ASANO T, 1992, J BIOL CHEM, V267, P19636; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; FUKUSHIMA Y, 1995, BIOCHEM J, V310, P553, DOI 10.1042/bj3100553; FUKUSHIMA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1149, DOI 10.1006/bbrc.1993.1170; Fukushima Y, 1996, BIOCHEM J, V320, P27, DOI 10.1042/bj3200027; GAJTKOWSKI GA, 1983, NATURE, V304, P65, DOI 10.1038/304065a0; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1992, J BIOL CHEM, V267, P20840; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; Hermans E, 1996, MOL PHARMACOL, V49, P365; HOMMA M, 1977, BIOCH MED, V18, P257; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; LATTION AL, 1994, J BIOL CHEM, V269, P22887; PROST A, 1984, FEBS LETT, V177, P227, DOI 10.1016/0014-5793(84)81288-0; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; SMIT MJ, 1994, EUR J PHARM-MOLEC PH, V288, P17, DOI 10.1016/0922-4106(94)90005-1; SOLL AH, 1979, AM J PHYSIOL, V237, pE444, DOI 10.1152/ajpendo.1979.237.5.E444; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19464	19470		10.1074/jbc.272.31.19464	http://dx.doi.org/10.1074/jbc.272.31.19464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235948	hybrid			2022-12-27	WOS:A1997XP06300054
J	Schonbeck, U; Mach, F; Bonnefoy, JY; Loppnow, H; Flad, HD; Libby, P				Schonbeck, U; Mach, F; Bonnefoy, JY; Loppnow, H; Flad, HD; Libby, P			Ligation of CD40 activates interleukin 1 beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; T-CELLS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASE; CONVERTING-ENZYME; GENE-EXPRESSION; HUMAN IL-1-BETA; LIGAND; APOPTOSIS; IDENTIFICATION	Inflammation contributes to a variety of arterial diseases including atherosclerosis. Interleukin 1 beta (IL-1 beta) in its activated mature 17-kDa form may mediate aspects of vascular inflammation. As shown previously, human vascular wall cells, such as smooth muscle cells (SMC), express the IL-1 beta precursor upon stimulation and the IL-1 beta-converting enzyme (ICE) constitutively but do not produce mature IL-1 beta or express ICE activity. How SMC, the most numerous cell type in arteries, may release active IL-1 beta has therefore remained a perplexing problem, We report here that stimulation of human vascular SMC and endothelial cells (EC) through CD40 ligand, a mediator recently localized in human atheroma, induced elaboration of the IL-1 beta precursor as well as activation of cell-associated ICE, In addition to the constitutively expressed 45- and 30-kDa immunoreactive ICE proteins, vascular cells incubated with recombinant human CD40 ligand (rCD40L) (but not IL-1 or TNF) showed an increase of a 20-kDa immunoreactive ICE protein by Western blot analysis, Furthermore, SMC and EC stimulated through rCD40L processed recombinant human IL-1 beta precursor (pIL-1 beta), generating a cleavage product of approximately 17 kDa. Appearance of both the 20-kDa immunoreactive ICE protein and pIL-1 beta processing activity required at least 6 h of stimulation with 0.3 or 1.0 mu g/ml rCD40L, respectively, and was inhibited by pre-incubation of the ligand with an anti-CD40L antibody, Stimulation of vascular SMC and EC through rCD40L resulted in the release of biologically active IL-1 beta, indicating processing of the native IL-1 beta precursor induced by the ligand. These findings establish a novel mechanism of IL-1 beta activation in human vascular cells and, moreover, indicate a new pathway of ICE-activation, which could participate in inflammatory aspects of atherogenesis and other disease states.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CARDIOVASC DIV,BOSTON,MA 02115; GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND; RES CTR BORSTEL,DEPT IMMUNOL & CELL BIOL,D-23845 BORSTEL,GERMANY; UNIV HALLE WITTENBERG,D-06097 HALLE,GERMANY	Harvard University; Brigham & Women's Hospital; Harvard Medical School; GlaxoSmithKline; Forschungszentrum Borstel; Martin Luther University Halle Wittenberg			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLARK BD, 1987, NUCLEIC ACIDS RES, V15, P868, DOI 10.1093/nar/15.2.868-a; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GENG YJ, 1995, AM J PATHOL, V147, P251; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERZBECK H, 1989, SCAND J IMMUNOL, V30, P549, DOI 10.1111/j.1365-3083.1989.tb02462.x; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AD, 1995, J IMMUNOL, V154, P2321; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIBBY P, 1986, J CLIN INVEST, V78, P1432, DOI 10.1172/JCI112732; LIBBY P, 1986, AM J PATHOL, V124, P179; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; LOPPNOW H, 1989, IMMUNOBIOLOGY, V179, P283, DOI 10.1016/S0171-2985(89)80023-3; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAZZEI GJ, 1995, J BIOL CHEM, V270, P7025, DOI 10.1074/jbc.270.13.7025; MERINO R, 1995, J IMMUNOL, V155, P3830; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOYER CF, 1991, AM J PATHOL, V138, P951; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSS R, 1980, HDB PHYSL CARDIOVA 2, P66; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schonbeck U, 1997, J EXP MED, V185, P1287, DOI 10.1084/jem.185.7.1287; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SIRONI M, 1989, J IMMUNOL, V142, P549; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	58	101	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19569	19574		10.1074/jbc.272.31.19569	http://dx.doi.org/10.1074/jbc.272.31.19569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235962	hybrid			2022-12-27	WOS:A1997XP06300068
J	Hockerman, GH; Johnson, BD; Abbott, MR; Scheuer, T; Catterall, WA				Hockerman, GH; Johnson, BD; Abbott, MR; Scheuer, T; Catterall, WA			Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the alpha(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CA2+ CHANNELS; RECEPTOR; IDENTIFICATION; EXPRESSION; VERAPAMIL; MECHANISM; MEMBRANE; D600	Recent studies of the phenylalkylamine binding site in the alpha(1C) subunit of L-type Ca2+ channels have revealed three amino acid residues in transmembrane segment IVS6 that are critical for high affinity block and are unique to L-type channels, We have extended this analysis of the phenylalkylamine binding site to amino acid residues in transmembrane segment IIIS6 and the pore region. Twenty-two consecutive amino acid residues in segment IIIS6 were mutated to alanine and the conserved Glu residues in the pore region of each homologous domain were mutated to Gln. Mutant channels were expressed in tsA-201 cells along with the beta(1b) and alpha(2) delta auxiliary subunits, Assay for block of Ba2+ current by (-)-D888 at -60 mV revealed that mutation of five amino acid residues in segment IIIS6 and the pore region that are conserved between L-type and non-L-type channels (Tyr(1152), Phe(1164), Val(1165) Glu(1118) and Glu(1419)) and one L-type-specific amino acid (Ile(1153)) decreased affinity for (-)-D888 from 10-20 fold. Combination of the four mutations in segment IIIS6 increased the IC50 for block by (-)-D888 to approximately 9 mu M, similar to the affinity of non-L-type Ca2+ channels for this drug. These results indicate that there are important determinants of phenylalkylamine binding in both the S6 segments and the pore regions of domains III and IV, same of which are conserved across the different classes of voltage-gated Ca2+ channels. A model of the phenylalkylamine receptor site at the interface between domains III and IV of the alpha(1) subunit is presented.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; DECOURSEY TE, 1995, J GEN PHYSIOL, V106, P745, DOI 10.1085/jgp.106.4.745; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; EHARA T, 1978, J PHARMACOL EXP THER, V207, P49; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fleckenstein A, 1980, Eur Heart J, V1, P15; GLOSSMANN H, 1984, J CARDIOVASC PHARM S, V6, P508; GOULD RJ, 1983, COLD SPRING HARB SYM, V48, P355, DOI 10.1101/SQB.1983.048.01.039; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; PELZER D, 1982, PFLUG ARCH EUR J PHY, V394, P97, DOI 10.1007/BF00582909; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; WIT AL, 1974, CIRC RES, V35, P413, DOI 10.1161/01.RES.35.3.413; YANG J, 1993, NATURE, V366, P109	33	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18759	18765		10.1074/jbc.272.30.18759	http://dx.doi.org/10.1074/jbc.272.30.18759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228049	hybrid			2022-12-27	WOS:A1997XM34200040
J	Bisaillon, M; Bergeron, J; Lemay, G				Bisaillon, M; Bergeron, J; Lemay, G			Characterization of the nucleoside triphosphate phosphohydrolase and helicase activities of the reovirus lambda 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; PUTATIVE HELICASES; ESCHERICHIA-COLI; MESSENGER-RNA; VIRUS; AFFINITY; ATPASE; MOTIF; CORE; POLYMERASE	Previous studies have shown that the reovirus lambda 1 core protein harbors a putative nucleotide-binding motif and exhibits an affinity for nucleic acids, In addition, a nucleoside triphosphate phosphohydrolase activity present in reovirus cores has been recently assigned to hi using gene reassortment analysis. In this study, it was demonstrated that the recombinant lambda 1 protein, expressed in the yeast Pichia pastoris, is able to hydrolyze nucleoside 5'-biphosphates or deoxynucleoside 5'-triphosphates. This activity was absolutely dependent on the presence of a divalent cation, Mg2+ or Mn2+. The protein can also unwind double-stranded nucleic acid molecules in the presence of a nucleoside 5'-triphosphate or deoxynucleoside 5'-triphosphate. These results provide the first biochemical evidence that the reovirus lambda 1 protein is a nucleoside triphosphate phosphohydrolase/helicase and strongly support the idea that lambda 1 participates in transcription of the viral genome.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; Bayliss CD, 1996, J VIROL, V70, P794, DOI 10.1128/JVI.70.2.794-800.1996; BORSA J, 1970, J VIROL, V6, P295, DOI 10.1128/JVI.6.3.295-302.1970; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CASHDOLLAR LW, 1994, RES VIROLOGY, V145, P277, DOI 10.1016/S0923-2516(07)80032-X; CLERTANT P, 1984, J BIOL CHEM, V259, P5196; COOMBS KM, 1994, J VIROL, V68, P177, DOI 10.1128/JVI.68.1.177-186.1994; Coombs KM, 1996, J VIROL, V70, P4237, DOI 10.1128/JVI.70.7.4237-4245.1996; DRAYNA D, 1982, J VIROL, V41, P110, DOI 10.1128/JVI.41.1.110-118.1982; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FAUST M, 1975, NUCLEIC ACIDS RES, V2, P1329, DOI 10.1093/nar/2.8.1329; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; KAPULER AM, 1970, BIOCHEMISTRY-US, V9, P4453, DOI 10.1021/bi00824a029; KAPULER AM, 1970, NATURE, V225, P1209, DOI 10.1038/2251209a0; LEMAY G, 1994, J GEN VIROL, V75, P3261, DOI 10.1099/0022-1317-75-11-3261; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Nibert Max L., 1996, P691; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAMURA JK, 1993, VIROLOGY, V193, P1, DOI 10.1006/viro.1993.1097; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016	44	63	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18298	18303		10.1074/jbc.272.29.18298	http://dx.doi.org/10.1074/jbc.272.29.18298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218469	hybrid			2022-12-27	WOS:A1997XL73500059
J	Qin, SF; Minami, Y; Kurosaki, T; Yamamura, H				Qin, SF; Minami, Y; Kurosaki, T; Yamamura, H			Distinctive functions of Syk and Lyn in mediating osmotic stress- and ultraviolet C irradiation-induced apoptosis in chicken B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ABL TYROSINE KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAMMALIAN-CELLS; BCR-ABL; HA-RAS; ACTIVATION; JUN; PHOSPHORYLATION	By taking advantage of the established chicken B cell line, DT40 cells, which do not express tyrosine kinase Syk or Lyn, functional soles or Syk and kyn in apoptotic response elicited by cellular stress were investigated, DT40 cells underwent apoptosis after hyperosmostic stress, In Syk-deficient DT40 cells, this apoptotic process was significantly enhanced, Ectopic expression of wild type, but not kinase-inactive, porcine Syk in Syk-deficient cells rescued cells from osmotic stress-induced apoptosis, demonstrating that the presence of functionally active? Syk is necessary to protect cells from osmotic stress-induced apoptosis. In comparison these was no effect on osmotic stress-induced apoptosis in Lyn-deficency DT40 cells, Interestingly, while Syk, was not involved in ultraviolet C (UVC)-induced apoptosis, a a deficiency of Lyn rendered cells resistant to UVC irradiation, These observations defined Syk and Lyn as important mediators of apoptosis in DT40 cells in response to osmotic stress and UVC irradiation, respectively, Furthermore, osmotic stress, but not UVC irradiation, could activate c-Jun N-terminal kinase (JNK) in DT40 cells. A deficiency in either Syk or Lyn did not affect the osmotic stress-induced activation of JNK. Wet therefore, concluded that Syk and Lyn regulate the apoptotic responses to osmotic stress and UVC irradiation independently of the JNK pathway in DT40 cells.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN; FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN; KANSAI MED UNIV,DEPT BIOCHEM,MORIGUCHI,OSAKA 570,JAPAN	Kobe University; University of Fukui; Kansai Medical University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Qin, Suofu/0000-0002-3323-8846				BEDI A, 1994, BLOOD, V83, P2038; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	38	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17994	17999		10.1074/jbc.272.29.17994	http://dx.doi.org/10.1074/jbc.272.29.17994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218426	hybrid			2022-12-27	WOS:A1997XL73500016
J	Balestrieri, ML; Servillo, L; Lee, TC				Balestrieri, ML; Servillo, L; Lee, TC			The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPLEEN MICROSOMES; ALKYL ETHER ANALOG; FACTOR PAF; 1-ALKYL-2-LYSO-SN-GLYCERO-3-PHOSPHOCHOLINE-ACETYL-COA ACETYLTRANSFERASE; FACTOR 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; INDEPENDENT TRANSACYLASE; FACTOR ACETYLHYDROLASE; HUMAN NEUTROPHILS; PROTEIN-KINASE; HL-60 CELLS	Acyl analogs of platelet-activating factor (PAF) (1-acyl-2-acetyl-sn-glycero-3-phosphocholine, acylacetyl-GPC) are the predominant products synthesized during thrombin or ionophore A23187-mediated activation of endothelial cells, However, the biosynthetic pathway responsible for the production of acylacetyl-GPC is not well understood, In the present investigation, we have demonstrated that the acyl analogs of PAF are also the major products from calf pulmonary artery endothelial cells in response to a time-dependent stimulation of ATP (10(-3) M), bradykinin (10(-8) M), or ionophore A23187 (2 mu M) In addition, we have found that the CoA-independent PAF:acyllyso-GPC transacetylase recently identified by us is concurrently and transiently induced with maximal 4-fold enhancement at 5 min and returned to near basal level by 10 min treatment of endothelial cells with ATP. Acid phosphatase reduces the increased PAF:acyllyso-GPC transacetylase activity from the homogenates of ATP-activated endothelial cells, Reduced PAF:acyllyso-GPC transacetylase activity can be restored by incubating the acid phosphatase-treated homogenates with ATP (5 mM) and Mg2+ (10 mM), Furthermore, okadaic acid, a protein phosphatase I and 2A inhibitor, incubated with endothelial cells in a dose-dependent manner (1-100 nM) for 10-min potentiates and sustained the stimulation of PAF:acyllyso-GPC transacetylase activity by ATP. On the other hand, genistein, tyrphostin-25 (inhibitors of tyrosine-specific protein kinase), and calphostin C (an inhibitor of protein kinase C) block the activation of PAF:acyllyso-GPC transacetylase by ATP, These results are consistent with the notion that ATP regulates the transacetylase activity by reversible activation and inactivation via the phosphorylation and dephosphorylation cycle, ATP also augments the activities of alkyllyso-GPC/acyllyso-GPC:acetyl-CoA acetyltransferase, However, the activation of the acetyltransferases precedes that of the transacetylase with peak activation occurring at 1-2 min of the ATP treatment, In addition, sodium vanadate, also an inhibitor of protein phosphatase, stimulates the increase in the incorporation of [H-3]acetate into acyl[H-3]acetyl-GPC of the ATP-treated endothelial cells, Collectively, our data show that both acetyltransferases and transacetylase participate in and contribute to the biosynthesis of acyl analogs of PAF in a coordinate fashion in endothelial cells.	OAK RIDGE ASSOCIATED UNIV, ENVIRONM & HLTH SCI DIV, OAK RIDGE, TN 37831 USA; UNIV NAPLES, DEPT BIOCHEM & BIOPHYS F CEDRANGOLO, I-80138 NAPLES, ITALY	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Naples Federico II				Balestrieri, Maria Luisa/0000-0001-6001-1789	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52492] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLANK ML, 1990, J CHROMATOGR, V508, P382, DOI 10.1016/S0021-9673(00)91281-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CLAY KL, 1991, BIOCHIM BIOPHYS ACTA, V1094, P43, DOI 10.1016/0167-4889(91)90024-R; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLUMBO M, 1993, J ALLERGY CLIN IMMUN, V92, P325, DOI 10.1016/0091-6749(93)90176-G; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GOMEZCAMBRONERO J, 1987, BIOCHEM J, V245, P893, DOI 10.1042/bj2450893; HOLLAND MR, 1992, J BIOL CHEM, V267, P22883; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1994, J LIPID MEDIAT CELL, V9, P267; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LEE TC, 1992, METHOD ENZYMOL, V209, P396; LEE TC, 1992, J BIOL CHEM, V267, P19992; LEE TC, 1987, PLATELET ACTIVATING, P115; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZIERE C, 1994, BBA-LIPID LIPID MET, V1210, P233, DOI 10.1016/0005-2760(94)90126-0; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; NAKAGAWA Y, 1992, BIOCHIM BIOPHYS ACTA, V1126, P277, DOI 10.1016/0005-2760(92)90241-M; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1983, BIOCHIM BIOPHYS ACTA, V751, P298, DOI 10.1016/0005-2760(83)90287-4; NINIO E, 1987, J IMMUNOL, V139, P154; PINCKARD RN, 1992, J IMMUNOL, V148, P3528; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, THROMB HAEMOSTASIS, V64, P99; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; STURK A, 1989, BIOCHIM BIOPHYS ACTA, V993, P148, DOI 10.1016/0304-4165(89)90157-8; TORDAI A, 1994, J IMMUNOL, V152, P566; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; TRIGGIANI M, 1992, BIOCHEM J, V286, P497, DOI 10.1042/bj2860497; TRIGGIANI M, 1991, J BIOL CHEM, V266, P6928; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VANDENBOSCH H, 1991, LIPIDS, V26, P967, DOI 10.1007/BF02536486; VENABLE ME, 1993, J LIPID RES, V34, P691; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WYKLE RL, 1980, J BIOL CHEM, V255, P256	58	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17431	17437		10.1074/jbc.272.28.17431	http://dx.doi.org/10.1074/jbc.272.28.17431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211886	hybrid			2022-12-27	WOS:A1997XK16500029
J	Li, SL; Valente, AJ; Zhao, SJ; Clark, RA				Li, SL; Valente, AJ; Zhao, SJ; Clark, RA			PU.1 is essential for p47(phox) promoter activity in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; COLONY-STIMULATING FACTOR-1; CCAAT DISPLACEMENT PROTEIN; TRANSCRIPTION FACTOR PU.1; TUMOR-NECROSIS-FACTOR; RNA-POLYMERASE-II; NADPH OXIDASE; CD11B PROMOTER; GENE PROMOTER	Expression of the phagocyte cytosolic protein p47(phox), a component of NADPH oxidase, is restricted mainly to myeloid cells. To study the cis elements and trans acting factors responsible for its gene expression, we have cloned and characterized the p47(phox) promoter, A predominant transcriptional start site was identified 21 nucleotides upstream of the translation initiation codon, To identify the gene promoter sequences, transient transfections of HL-60 human myeloid cells were performed with a series of 5'-deletion p47(phox)-luciferase reporter constructs that extended as far upstream as -3050 bp relative to the transcriptional start site, The -224 and -86 constructs had the strongest p47(phax) promoter activity, whereas the -46 construct showed a major reduction in activity and the -36 construct a complete loss of activity. DNase I footprint analysis identified a protected region from -57 to -53. This region containing a consensus PU.1 site bound specifically both PU,I present in nuclear extracts from myeloid cells and PU.1 synthesized in vitro. Mutations of this site eliminated PU.1 binding and abolished the ability of the p47(phox) promoter to direct expression of the reporter gene, The p47(phox) promoter was active in all myeloid cell Lines tested (HL-60, THP-1, U937, PLB-985), but not in non-myeloid cells (HeLa, HEK293). Finally, PU.1 transactivated the p47(phox)-luciferase constructs in HeLa cells, We conclude that, similar to certain other myeloid specific genes, p47(phox) promoter activity in myeloid cells requires PU.1.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; S TEXAS VET HLTH CARE SYST,AUDIE L MURPHY DIV,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52665] Funding Source: Medline; NIAID NIH HHS [R37 AI020866, R01 AI020866, AI20866] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; AUSTIN GE, 1995, LEUKEMIA, V9, P848; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; CASIMIR CM, 1991, P NATL ACAD SCI USA, V88, P2753, DOI 10.1073/pnas.88.7.2753; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; Gorlach A., 1995, Blood, V86, p260A; GREEN SP, 1994, J LEUKOCYTE BIOL, V55, P530, DOI 10.1002/jlb.55.4.530; GUPTA JW, 1992, CANCER RES, V52, P2530; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kuga S, 1996, EXP HEMATOL, V24, P151; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LEVY R, 1991, J IMMUNOL, V147, P3066; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OBERMEIER H, 1995, BBA-MOL CELL RES, V1269, P25, DOI 10.1016/0167-4889(95)00095-A; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; REDEKE HH, 1991, J BIOL CHEM, V266, P21025; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; Roos D, 1996, BLOOD, V87, P1663; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1992, BLOOD, V79, P2598; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; STEINBECK MJ, 1994, J CELL BIOL, V126, P767; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WANG YB, 1994, J BIOL CHEM, V269, P9137; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhao WG, 1996, LEUKEMIA, V10, P1089; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	70	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17802	17809		10.1074/jbc.272.28.17802	http://dx.doi.org/10.1074/jbc.272.28.17802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211934	hybrid			2022-12-27	WOS:A1997XK16500077
J	Wang, BL; Golemis, EA; Kruh, GD				Wang, BL; Golemis, EA; Kruh, GD			ArgBP2, a multiple Src homology 3 domain-containing, Arg/Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; TYROSINE KINASE; C-ABL; SIGNAL-TRANSDUCTION; GENE-PRODUCT; MYOSIN-I; CYCLE; CRK; MUSCLE; ACTIVATION	Arg and c-Abl represent the mammalian members of the Abelson family of protein-tyrosine kinases. A novel Arg/Abl-binding protein, ArgBP2, is as isolated using a segment of the Arg COOH-terminal domain as bait in the yeast two-hybrid system. ArgBP2 contains three COOH-terminal Src homology 3 domains, a serine/threonine-rich domain, and several potential Abl phosphorylation sites. ArgBP2 associates with and is a substrate of Arg and v-Abl, and is phosphorylated on tyrosine in v-Abl-transformed cells, ArgBP2 is widely expressed in human tissues and extremely abundant in heart. In epithelial cells ArgBP2 is located in stress fibers and the nucleus, similar to the reported localization of c-Abl. In cardiac muscle cells ArgBP2 is located in the Z-disks of sarcomeres, These observations suggest that ArgBP2 functions as an adapter protein to assemble signaling complexes in stress fibers, and that ArgBP2 is a potential link between Abl family kinases and the actin cytoskeleton. In addition, the localization of ArgBP2 to Z-disks suggests that ArgBP2 may influence the contractile or elastic properties of cardiac sarcomeres and that the Z-disk is a target of signal transduction cascades.	FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA; FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania				Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [CA63366, CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA057273, R01CA057273, R01CA063366, R29CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOLL DE, 1991, J BIOL CHEM, V266, P8501; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hobert O, 1996, ONCOGENE, V12, P1577; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOTELIANSKY VE, 1986, EUR J BIOCHEM, V156, P619, DOI 10.1111/j.1432-1033.1986.tb09622.x; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; Law SF, 1996, MOL CELL BIOL, V16, P3327; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MITTAL B, 1987, CELL MOTIL CYTOSKEL, V8, P345, DOI 10.1002/cm.970080407; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; MORRIS JF, 1991, ONCOGENE, V6, P2339; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PEREGO R, 1991, ONCOGENE, V6, P1899; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; SANGER JM, 1986, J CELL SCI, P17; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VAGNEDESCROIX M, 1991, EUR J BIOCHEM, V201, P53, DOI 10.1111/j.1432-1033.1991.tb16254.x; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V12, P1921; Wang BL, 1996, ONCOGENE, V13, P1379; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17542	17550		10.1074/jbc.272.28.17542	http://dx.doi.org/10.1074/jbc.272.28.17542			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211900	hybrid			2022-12-27	WOS:A1997XK16500043
J	Guo, XQ; Becker, PL				Guo, XQ; Becker, PL			Cyclic ADP-ribose-gated Ca2+ release in sea urchin eggs requires an elevated [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; IONIC-STRENGTH; FERTILIZATION; EGTA; TEMPERATURE; PHOTOLYSIS; AFFINITY; TISSUES	Cyclic ADP-ribose (cADPr) has been shown to release intracellular Ca2+ from sea urchin eggs and a variety of vertebrate cell types, although its mechanism of action remains elusive, We employed the caged version of cADPr to study the [Ca2+] transient kinetics in intact sea urchin eggs for insights into how cADPr gates Ca2+ release. Ca2+ release triggered by photolytic production of cADPr was initially slow, with an effective delay of several hundred milliseconds before the onset of a rapid. Ca2+ release phase, in contrast, Ca2+ release induced by photolysis of caged inositol 1,4,5-trisphosphate was immediate in onset and roughly an order of magnitude faster. The delay before cADPr-induced Ca2+ release was eliminated when the [Ca2+] was step-elevated coincident with the photoliberation of cADPr and greatly prolonged in the presence of exogenous Ca2+ buffers. Thus, the slow onset of Ca2+ release does not reflect an intrinsically slow rate by which cADPr gates release channels, Rather, a [Ca2+] rise from resting levels is needed to achieve more than minimal cADPr activity, Fun release of Ca2+ by cADPr in intact sea urchin eggs requires a positive Ca2+ feedback.	EMORY UNIV,SCH MED,DEPT PHYSIOL,ATLANTA,GA 30322	Emory University								AARHUS R, 1995, J BIOL CHEM, V270, P7745, DOI 10.1074/jbc.270.13.7745; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUCK WR, 1994, DEV BIOL, V163, P1, DOI 10.1006/dbio.1994.1118; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, J BIOL CHEM, V272, P7669, DOI 10.1074/jbc.272.12.7669; Guo XQ, 1996, CIRC RES, V79, P147, DOI 10.1161/01.RES.79.1.147; HARRISON SM, 1989, AM J PHYSIOL, V256, pC1250, DOI 10.1152/ajpcell.1989.256.6.C1250; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1995, J BIOL CHEM, V270, P90060; MCCRAY JA, 1992, BIOCHEMISTRY-US, V31, P8856, DOI 10.1021/bi00152a023; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MOHRI T, 1991, CELL STRUCT FUNCT, V16, P157, DOI 10.1247/csf.16.157; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SHEN SS, 1979, NATURE, V282, P87, DOI 10.1038/282087a0; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; UKHANOV KY, 1995, J GEN PHYSIOL, V105, P95, DOI 10.1085/jgp.105.1.95; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Willmott N, 1996, J BIOL CHEM, V271, P3699	35	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16984	16989		10.1074/jbc.272.27.16984	http://dx.doi.org/10.1074/jbc.272.27.16984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202011	hybrid			2022-12-27	WOS:A1997XH44600043
J	Ho, GY; Broze, GJ; Schwartz, AL				Ho, GY; Broze, GJ; Schwartz, AL			Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; CARBOXY-TERMINUS; HEPATOMA-CELLS; IN-VIVO; LIPOPROTEIN; METABOLISM; BINDING; INTERNALIZATION	Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of blood coagulation factor Xa. (fXa) and factor VIIa. We have recently shown that fXa binding stimulates the uptake and degradation of cell surface-bound I-125-TFPI (He, G., Toomey, J. pg., Broze, G. J., Jr., and Schmartz, A. L. (1996) J. Biol. Chem. 271, 9497-9502). in the present study ave examined the role of cell surface glycosaminoglycans (GAGs) in this process, Removal of cell surface GAG chains by treatment of Cells with heparinase or heparitinase but not chondroitinase markedly reduced fXa-stimulated I-125-TFPI uptake and degradation, Inhibition of GAG sulfation by growth of cells in chlorate-containing medium similarly decreased fXa-stimulated I-125-TFPI degradation. These results suggest that heparan sulfate proteoglycans (HSPGs) are required fur the uptake and degradation of I-125-TFPI.fXa complexes. Chemical cross-linking/immunoprecipitation analyses revealed that I-125-TFPI was directly associated with HSPGs on the cell surface and that fXa binding increased the amount of I-125-TFPI bound, Of the several cell lines evaluated, bend endothelial cells demonstrated the greatest fXa stimulation of I-125-TFPI uptake and degradation, Cross-linking/immunoprecipitation analyses on bend cells also revealed that HSPGs were specifically associated with TFPI and fXa. These data suggest that HSPGs may directly act as the uptake and degradation receptor for TFPI.fXa complexes.	WASHINGTON UNIV,SCH MED,DEPT BIOL MOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital	Ho, GY (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,BOX 8116,ST LOUIS,MO 63110, USA.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BU G, 1994, CELL BIOL LAB HDB, P199; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1993, J BIOL CHEM, V268, P13002; COLBURN P, 1982, BIOCHEM BIOPH RES CO, V104, P220, DOI 10.1016/0006-291X(82)91962-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JI ZS, 1994, J BIOL CHEM, V269, P2764; KAZAMA Y, 1993, BLOOD, V81, P676; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NOVOTNY WF, 1991, BLOOD, V78, P394; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; SANSET PM, 1988, THROMB RES, V50, P803; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILLNOW TE, 1994, J CELL SCI, V107, P719; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270	39	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16838	16844		10.1074/jbc.272.27.16838	http://dx.doi.org/10.1074/jbc.272.27.16838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201990	hybrid			2022-12-27	WOS:A1997XH44600022
J	Kasahara, M; Shimoda, E; Maeda, M				Kasahara, M; Shimoda, E; Maeda, M			Amino acid residues responsible for galactose recognition in yeast Gal2 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; SUBSTRATE RECOGNITION; CYTOCHALASIN-B; LOCALIZATION; EXPRESSION; PROTEINS; CLONING	A novel, systematic approach was used to identify amino acid residues responsible for substrate recognition in the transmembrane 10 region of the Gal2 galactose transporter of Saccharomyces cerevisiae, A mixture of approximately 25,000 distinct plasmids that encode all the combinations of 12 amino acids in transmembrane 10 that are different in Gal2 and the homologous glucose transporter Hxt2 was synthesized. Selection of galactose transport-positive clones on galactose limited agar plates yielded 19 clones, all of which contained the Tyr(446) residue found in Gal2. 14 of the 19 clones contained Trp(455) found in Gal2, whereas the other 5 contained Cys(455), a residue not found in either Gal2 or Hxt2. When Tyr(446) Of Gal2 was replaced with any of the other 19 amino acids, no galactose transport activity was observed in the resulting transporters, indicating that Tyr(446) plays an essential role in the transport of this sugar. Replacement of 2 amino acids of Hxt2 with the corresponding Tyr(446) and Trp(455) Of Gal2 allowed the modified Hxt2 to transport galactose, The K-m of galactose transport for the modified transporter was 8- fold higher than that of Gal2. These results and other evidence unequivocally show that Tyr(446) is essential and Trp(455) is important for the discrimination of galactose versus glucose.			Kasahara, M (corresponding author), TEIKYO UNIV,SCH MED,BIOPHYS LAB,HACHIOJI,TOKYO 19203,JAPAN.							Arbuckle MI, 1996, BIOCHEMISTRY-US, V35, P16519, DOI 10.1021/bi962210n; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GIROS B, 1994, J BIOL CHEM, V269, P15985; HILL DE, 1989, CURRENT PROTOCOLS MO, V1; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; KABACK HR, 1992, INT REV CYTOL, V137A, P97; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P12; MATEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SHERMAN F, 1986, METHODS YEAST GENETI, P164; SHURMANN A, 1993, BIOCHEM J, V290, P497; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; STADLER R, 1995, PLANT PHYSIOL, V107, P33, DOI 10.1104/pp.107.1.33; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; Will A, 1996, FEBS LETT, V381, P127, DOI 10.1016/0014-5793(96)00097-X	24	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16721	16724		10.1074/jbc.272.27.16721	http://dx.doi.org/10.1074/jbc.272.27.16721			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201972	hybrid			2022-12-27	WOS:A1997XH44600004
J	Wan, Y; Bence, K; Hata, A; Kurosaki, T; Veillette, A; Huang, XY				Wan, Y; Bence, K; Hata, A; Kurosaki, T; Veillette, A; Huang, XY			Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RAS-DEPENDENT ACTIVATION; FOCAL ADHESION KINASE; B-CELL DEVELOPMENT; MAP KINASE; GROWTH-FACTOR; PERTUSSIS TOXIN; ANGIOTENSIN-II; LYSOPHOSPHATIDIC ACID; COUPLED RECEPTORS	The signal transduction pathway from heterotrimeric G proteins to the mitogen-activated protein kinase (MAPK) cascade is best understood in the yeast mating pheromone response, in which a serine/threonine protein kinase (STE20) serves as the critical linking component, Little is known in metazoans on how G proteins and the MAPK cascade are coupled, Here we provide genetic and biochemical evidence that a tyrosine kinase cascade bridges G proteins and the MAPK pathway in vertebrate cells, Targeted deletion of tyrosine kinase Csk in avian B lymphoma cells blocks the stimulation of MAPK by G(q), but not G(i)-, coupled receptors, In cells deficient in Bruton's tyrosine kinase (Btk), G(i)-coupled receptors failed to activate MAPK, while G(q)-coupled receptor-mediated stimulation is unaffected. Taken together with our previous data on tyrosine kinases Lyn and Syk, the G(q)-coupled pathway requires tyrosine kinases Csk, Lyn, and Syk, while the G(i)-coupled pathway requires tyrosine kinases Btk and Syk to feed into the MAPK cascade in these cells, The central role of Syk is further strengthened by data showing that Syk can bind to purified Lyn, Csk, or Btk.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; KANSAI MED UNIV,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA	Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Kansai Medical University; McGill University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Bence, Kendra/0000-0002-5879-4726				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	77	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17209	17215		10.1074/jbc.272.27.17209	http://dx.doi.org/10.1074/jbc.272.27.17209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202044	hybrid			2022-12-27	WOS:A1997XH44600076
J	Ricort, JM; Tanti, JF; VanObberghen, E; LaMarchandBrustel, Y				Ricort, JM; Tanti, JF; VanObberghen, E; LaMarchandBrustel, Y			Cross-talk between the platelet-derived growth factor and the insulin signaling pathways in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE PHOSPHORYLATES; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; SUBSTRATE IRS-1; PROTEIN; SUBUNIT; TRANSDUCTION; PI3-KINASE; BINDING; P85	Phosphatidylinositol (PI) 3-kinase is activated by various growth factors such as PDGF (platelet-derived growth factor) and insulin. The aim of the present study was to determine whether PDGF could modulate insulin activation of PI 3-kinase in 3T3-L1 adipocytes, When cells were preincubated for 5-15 min with PDGF, PI 3-kinase activity associated to insulin receptor substrate 1 (IRS 1) in response to insulin was decreased, due to reduced association of the PI 3-kinase p85 subunit with PRS 1, In addition, following this PDGF pretreatment, the tyrosine phosphorylation of IRS 1 in response to insulin and its electrophoretic mobility were diminished. The change in the mobility of PRS I could be attributed to PDGF-induced serine/threonine phosphorylation of the protein which was partly inhibited by PI 3-kinase inhibitors. By contrast, epidermal growth factor, which does not stimulate PI 3-kinase, had no effect on the association of PI 3-kinase with IRS 1 in response to insulin, This series of results indicates that the PDGF-induced serine/threonine phosphorylation of IRS 1 could be due to activation of PI 3-kinase pathway, Furthermore, this phosphorylation of IRS 1 is associated with a decrease in its tyrosine phosphorylation by insulin and in its association with the p85 subunit of PI 3-kinase. This study suggests that a cross-talk exists between the different pathways stimulated by PDGF and insulin in intact cells.	FAC MED NICE,INSERM,U145,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur				Tanti, Jean-Francois/0000-0003-1782-1318				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LEVYTOLEDANO R, 1995, J BIOL CHEM, V270, P30018; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	34	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19814	19818		10.1074/jbc.272.32.19814	http://dx.doi.org/10.1074/jbc.272.32.19814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242642	hybrid			2022-12-27	WOS:A1997XQ05900029
J	Yun, CH; Song, M; Kim, H				Yun, CH; Song, M; Kim, H			Conformational change of cytochrome P450 1A2 induced by phospholipids and detergents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; BETA-NAPHTHOFLAVONE; CIRCULAR-DICHROISM; P-450 REDUCTASE; ENZYME SYSTEM; RAPID METHOD; PURIFICATION; FORMS; STIMULATION; EXPRESSION	Recently, it was reported that the activity of rabbit P450 1A2 is markedly increased at elevated salt concentration (Yun, C-H., Song, M., Ahn, T., and Kim, H. (1996) J. Biol, Chem, 271, 31312-31316), The activity increase of P450 1A2 coincides with the raised alpha-helix content and decreased beta-sheet content, The presence of phospholipid magnified this effect. Here, possible structural change of rabbit P450 1A2 accompanying the phospholipid-induced increase in its enzyme activity was investigated by circular dichroism, fluorescence spectroscopy, and absorption spectroscopy, Studies with the reconstituted system supported by cumene hydroperoxide or NADPH showed that the P450 1A2 activities were found to be dependent on the head group and hydrocarbon chain length of phospholipid, Phosphatidylcholines having short hydrocarbon chains with a carbon number of 8-12 were very efficient for reconstitution of the P450-catalyzed reactions supported by both cumene hydroperoxide and NADPH, It was found that the phospholipid increased the alpha-helix content and lowered the beta-sheet content of P450, Intrinsic fluorescence intensity is also increased in the presence of phospholipid. The low spin iron configuration of P450 1A2 shifted toward the high spin configuration by most of the phospholipids in the endoplasmic reticulum, Some synthetic phospholipids having short hydrocarbon chains with a carbon number of 10-12 caused a shift in the spin equilibrium of P450 1A2 toward low spin, The effect of detergents on the activity and conformation of P450 1A2 was also studied, It was found that the addition of detergents to P450 1A2 solution increased the enzyme activity of P450 1A2. Detergents also increased the alpha-helix content and lowered the beta-sheet content of P450 1A2, Intrinsic fluorescence emissions also increased with the presence of detergents, Octyl glucoside and deoxycholate caused a shift toward high spin, On the other hand, cholate caused a shift toward low spin, It was found that the activity increase of rabbit P450 1A2 coincides with the conformational change including raised alpha-helix content. It is proposed that the interaction with the phospholipid molecules surrounding P450 1A2 in the endoplasmic reticulum is important for a functional conformation of P450 1A2 in a monooxygenase system including NADPH-P450 reductase.	KOREA ADV INST SCI & TECHNOL,DEPT SCI BIOL,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)	Yun, CH (corresponding author), PAI CHAI UNIV,DEPT BIOCHEM,SEO KU,439-6 DOMA DONG,TAEJON 302735,SOUTH KOREA.			Yun, Chul-Ho/0000-0003-2685-2968				ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; CHIANG YL, 1979, ARCH BIOCHEM BIOPHYS, V195, P178, DOI 10.1016/0003-9861(79)90339-4; COLEMAN R, 1973, BIOCHIM BIOPHYS ACTA, V300, P1, DOI 10.1016/0304-4157(73)90010-5; COON MJ, 1971, CHEM-BIOL INTERACT, V3, P248, DOI 10.1016/0009-2797(71)90046-9; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; ESTABROOK RW, 1971, METABOLISM, V20, P187, DOI 10.1016/0026-0495(71)90091-6; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1979, BIOCHEMISTRY-US, V18, P5442, DOI 10.1021/bi00591a029; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; INGELMANSUNDBERG M, 1980, BIOCHIM BIOPHYS ACTA, V599, P417, DOI 10.1016/0005-2736(80)90188-1; INGELMANSUNDBERG M, 1977, FEBS LETT, V78, P72, DOI 10.1016/0014-5793(77)80275-5; INGELMANSUNDBERG M, 1981, BIOCHEMISTRY-US, V20, P4100, DOI 10.1021/bi00517a024; INGELMANSUNDBERG M, 1980, BIOCHEMISTRY-US, V19, P4004, DOI 10.1021/bi00558a018; Jansson I, 1996, ARCH BIOCHEM BIOPHYS, V325, P265, DOI 10.1006/abbi.1996.0033; LU AYH, 1974, BIOCHEM BIOPH RES CO, V60, P266, DOI 10.1016/0006-291X(74)90200-9; LU AYH, 1968, J BIOL CHEM, V243, P1331; MIWA GT, 1984, ARCH BIOCHEM BIOPHYS, V234, P161, DOI 10.1016/0003-9861(84)90337-0; MIWA GT, 1981, ARCH BIOCHEM BIOPHYS, V211, P454, DOI 10.1016/0003-9861(81)90477-X; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER G, 1992, J BIOL CHEM, V267, P665; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; STIER A, 1973, BIOCHIM BIOPHYS ACTA, V311, P400, DOI 10.1016/0005-2736(73)90320-9; STROBEL HW, 1970, J BIOL CHEM, V245, P4851; TANIGUCHI H, 1984, ARCH BIOCHEM BIOPHYS, V232, P585, DOI 10.1016/0003-9861(84)90577-0; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; VESSEY DA, 1972, J BIOL CHEM, V247, P3023; Viner RL, 1995, BIOCHEM BIOPH RES CO, V217, P886, DOI 10.1006/bbrc.1995.2854; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WHITE RE, 1982, J BIOL CHEM, V257, P3073; WU ES, 1984, BIOCHEMISTRY-US, V23, P28, DOI 10.1021/bi00296a005; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yun CH, 1996, J BIOL CHEM, V271, P31312, DOI 10.1074/jbc.271.49.31312	43	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19725	19730		10.1074/jbc.272.32.19725	http://dx.doi.org/10.1074/jbc.272.32.19725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242629	hybrid			2022-12-27	WOS:A1997XQ05900016
J	Hwang, HY; Ullman, B				Hwang, HY; Ullman, B			Genetic analysis of purine metabolism in Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; MITOTIC RECOMBINATION; ADENINE PHOSPHORIBOSYLTRANSFERASE; STABLE TRANSFECTION; MOLECULAR-CLONING; TOXOPLASMA-GONDII; ADENOSINE KINASE; NULL MUTANTS; CELL HYBRIDS; EXPRESSION	To dissect the contributions of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and adenosine kinase (AK) to purine salvage in Leishmania donovani, null mutants genetically deficient in HGPRT and/or APRT were generated by targeted gene replacement in wild type cells and preexisting mutant strains lacking either APRT or AK activity, These knockouts were obtained either by double targeted gene replacement or by single gene replacement followed by negative selection for loss-of-heterozygosity. Genotypes were confirmed by Southern blotting and the resultant phenotypes evaluated by enzymatic assay, resistance to cytotoxic drugs, ability to incorporate radiolabeled purine bases, and growth on various purine sources. All mutant strains could propagate in defined growth medium containing any single purine source and could metabolize exogenous [H-3]hypoxanthine to the nucleotide level. The surprising ability of mutant L. donovani lacking HGPRT, APRT, and/or AK to incorporate and grow in hypoxanthine could be attributed to the ability of the parasite xanthine phosphoribosyltransferase enzyme to salvage hypoxanthine. These genetic studies indicate that HGPRT, APRT, and AK, individually or in any combination, are not essential for the survival and growth of the promastigote stage of L. donovani and intimate an important, if not crucial, role for xanthine phosphoribosyltransferase in purine salvage.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University				Hwang, Ho-Yon/0000-0003-0204-8932	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; CAMPBELL CE, 1981, MOL CELL BIOL, V1, P336, DOI 10.1128/MCB.1.4.336; CASKEY CT, 1979, CELL, V16, P1, DOI 10.1016/0092-8674(79)90182-X; CHAN TS, 1978, SOMAT CELL GENET, V4, P1, DOI 10.1007/BF01546489; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GALLERANO RH, 1990, AM J TROP MED HYG, V43, P159, DOI 10.4269/ajtmh.1990.43.159; GEARY TG, 1986, CHEMOTHERAPY PARASIT, P87; GUIEROS FJ, 1996, MOL CELL BIOL, V16, P5655; HANSON S, 1992, J BIOL CHEM, V267, P2350; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIDDER GW, 1979, P NATL ACAD SCI USA, V76, P3670, DOI 10.1073/pnas.76.8.3670; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; KOVACS JA, 1986, CHEMOTHERAPY PARASIT, P139; KUSANO T, 1971, P NATL ACAD SCI USA, V68, P82, DOI 10.1073/pnas.68.1.82; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAFON SW, 1982, BIOCHEM PHARMACOL, V31, P231, DOI 10.1016/0006-2952(82)90216-7; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LOOKER DL, 1983, MOL BIOCHEM PARASIT, V9, P15, DOI 10.1016/0166-6851(83)90053-1; MARR JJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P360, DOI 10.1016/0304-4165(78)90104-6; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; NELSON FK, 1989, MOL CELL BIOL, V9, P1284, DOI 10.1128/MCB.9.3.1284; PALELLA TD, 1989, METABOLIC BASIS INHE, P965; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; SOUZA AE, 1994, MOL BIOCHEM PARASIT, V63, P213, DOI 10.1016/0166-6851(94)90057-4; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; ULLMAN B, 1984, PHARM RES-DORDR, P194, DOI 10.1023/A:1016365128531; WASMUTH JJ, 1984, CELL, V36, P697, DOI 10.1016/0092-8674(84)90350-7; WILSON K, 1991, J BIOL CHEM, V266, P1665	49	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19488	19496		10.1074/jbc.272.31.19488	http://dx.doi.org/10.1074/jbc.272.31.19488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235951	hybrid			2022-12-27	WOS:A1997XP06300057
J	Schuit, F; DeVos, A; Farfari, S; Moens, K; Pipeleers, D; Brun, T; Prentki, M				Schuit, F; DeVos, A; Farfari, S; Moens, K; Pipeleers, D; Brun, T; Prentki, M			Metabolic fate of glucose in purified islet cells - Glucose-regulated anaplerosis in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; INSULIN RELEASE; B-CELLS; PYRUVATE-DEHYDROGENASE; GENE-EXPRESSION; MALONYL-COA; A-CELLS; CARBOXYLASE; SECRETION; GLUCOKINASE	Previous studies in rat islets have suggested that anaplerosis plays an important role in the regulation of pancreatic beta cell function and growth. However, the relative contribution of islet beta cells versus non-beta cells to glucose-regulated anaplerosis is not known. Further more, the fate of glucose carbon entering the Krebs cycle of islet cells remains to be determined. The present study has examined the anaplerosis of glucose carbon in purified rat beta cells using specific C-14-labeled glucose tracers. Between 5 and 20 mM glucose, the oxidative production of CO2 from [3,4-C-14]glucose represented close to 100% of the total glucose utilization by the cells. Anaplerosis, quantified as the difference between (CO2)-C-14 production from [3,4-C-14]glucose and [6-C-14]glucose, was strongly influenced by glucose, particularly between 5 and 10 mM. The dose dependence of glucose-induced insulin secretion correlated with the accumulation of citrate and malate in beta(INS-1) cells, All glucose carbon that was not oxidized to CO2 was recovered from the cells after extraction in trichloroacetic acid. This indirectly indicates that lactate output is minimal in beta cells. From the effect of cycloheximide upon the incorporation of C-14-glucose into the acid-precipitable fraction, it could be calculated that 25% of glucose carbon entering the Krebs cycle via anaplerosis is channeled into protein synthesis. In contrast, non-beta cells (approximately 80% glucagon producing alpha cells) exhibited rates of glucose oxidation that were 1/3 to 1/6 those of the total glucose utilization and no detectable anaplerosis from glucose carbon, This difference between the two cell types was associated with a 7-fold higher expression of the anaplerotic enzyme pyruvate carboxylase in beta cells, as well as a 4-fold lower ratio of lactate dehydrogenase to FAD-linked glycerol phosphate dehydrogenase in beta cells versus alpha cells. Finally, glucose caused a dose-dependent suppression of the activity of the pentose phosphate pathway in beta cells. In conclusion, rat beta cells metabolize glucose essentially via aerobic glycolysis, whereas glycolysis in alpha cells is largely anaerobic. The results support the view that anaplerosis is an essential pathway implicated in beta cell activation by glucose.	UNIV MONTREAL, DEPT NUTR, MOL NUTR UNIT, MONTREAL, PQ H2L 4M1, CANADA; INST CANC RES, CTR RECH LC SIMARD, MONTREAL, PQ H2L 4M1, CANADA	Universite de Montreal; Universite de Montreal	Schuit, F (corresponding author), FREE UNIV BRUSSELS, FAC MED, DIABET RES CTR, LAARBEEKLAAN 103, B-1090 BRUSSELS, BELGIUM.		; Glaser, Benjamin/F-8411-2017	BRUN, Thierry/0000-0002-1659-4283; De Vos, Anick/0000-0001-5311-1589; Glaser, Benjamin/0000-0003-4711-5000; Pipeleers, Daniel/0000-0002-6440-2485				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; DEVOS A, 1991, BIOCHEM INT, V24, P117; DIONNE KE, 1993, DIABETES, V42, P12, DOI 10.2337/diabetes.42.1.12; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HEDESKOV CJ, 1975, BIOCHEM J, V152, P571, DOI 10.1042/bj1520571; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; HELLMAN B, 1971, BIOCHIM BIOPHYS ACTA, V241, P147, DOI 10.1016/0005-2736(71)90312-9; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; KATZ J, 1963, J BIOL CHEM, V238, P517; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MALAISSE WJ, 1993, J CLIN INVEST, V91, P432, DOI 10.1172/JCI116219; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1987, BIOCHEM J, V246, P89, DOI 10.1042/bj2460089; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; YIN L, 1992, DIABETES, V41, P792; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	50	347	353	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18572	18579		10.1074/jbc.272.30.18572	http://dx.doi.org/10.1074/jbc.272.30.18572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228023	Green Published, hybrid			2022-12-27	WOS:A1997XM34200014
J	Huet, J; Conesa, C; Carles, C; Sentenac, A				Huet, J; Conesa, C; Carles, C; Sentenac, A			A cryptic DNA binding domain at the COOH terminus of TFIIIB70 affects formation, stability, and function of preinitiation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; FACTOR-TFIIB; INITIATION-FACTOR; 2 COMPONENTS; FACTOR RAP30; GENE; TBP; IDENTIFICATION; SUFFICIENT	TFIIIC-dependent assembly of yeast TFIIIB on class III genes unmasks a high avidity of TFIIIB for DNA. TFIIIB contains TATA-binding protein (TBP), TFIIIB90/B '', and TFIIIB70/Brf1, which is homologous to TFIIB. Using limited proteolysis, we have found that the COOH terminus of TFIIIB70 (residues 510-596) forms a protease-resistant domain that binds DNA tightly as seen by Southwestern, DNase I footprinting, and gel shift assays. Consistent with a role for this DNA binding activity, preinitiation complexes were formed less efficiently with truncated TFIIIB70 lacking the COOH-terminal domain and displayed an increased sensitivity to heparin, B' (TFIIIB70 + TBP).TFIIIC.DNA complexes were also particularly unstable, In addition, TFIIIB.TFIIIC.DNA complexes containing truncated TFIIIB70 were im paired in promoting transcription initiation.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BAKER RE, 1982, EMBO J, V1, P291, DOI 10.1002/j.1460-2075.1982.tb01162.x; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GABRIELSEN OS, 1987, NUCLEIC ACIDS RES, V15, P5699, DOI 10.1093/nar/15.14.5699; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IBORRA F, 1979, J BIOL CHEM, V254, P920; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	61	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18341	18349		10.1074/jbc.272.29.18341	http://dx.doi.org/10.1074/jbc.272.29.18341			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218475	hybrid			2022-12-27	WOS:A1997XL73500065
J	Krupnick, JG; Gurevich, VV; Benovic, JL				Krupnick, JG; Gurevich, VV; Benovic, JL			Mechanism of quenching of phototransduction - Binding competition between arrestin and transducin for phosphorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; RHODOPSIN KINASE; VISUAL ARRESTIN; PHOSPHODIESTERASE ACTIVATION; BETA-2-ADRENERGIC RECEPTOR; PHOTOEXCITED RHODOPSIN; CHOLINERGIC RECEPTORS; BOVINE RHODOPSIN; WILD-TYPE	Quenching of phototransduction in retinal rod cells involves phosphorylation of photoactivated rhodopsin by the enzyme rhodopsin kinase followed by binding of the protein arrestin, Although it has been proposed that the mechanism of arrestin quenching of visual transduction is via steric exclusion of transducin binding to phosphorylated light-activated rhodopsin (P-Rh*), direct evidence for this mechanism is lacking, In this study, we investigated both the role of rhodopsin phosphorylation in modulating its interaction with arrestin and transducin and the proposed binding competition between arrestin and transducin for P-Rh*. While the beta-adrenergic receptor kinase promotes significant arrestin binding to rhodopsin at a phosphorylation stoichiometry of greater than or equal to 2 mol/mol, rhodopsin kinase promotes arrestin binding at a stoichiometry of similar to 0.9 mol/mol, Moreover, while beta-adrenergic receptor kinase phosphorylation of rhodopsin only modestly decreases transducin binding and activation, rhodopsin kinase phosphorylation of rhodopsin significantly decreases transducin binding and activation, Finally, arrestin competes effectively with transducin for binding to P-Rh* (50% inhibition at similar to 1:1 molar ratio of arrestin:transducin) but has no effect on transducin binding to nonphosphorylated light activated rhodopsin (Rh*), paralleling the functional inhibition by arrestin on P-Rh*-stimulated transducin activation (50% inhibition at similar to 1.7:1 molar ratio of arrestin:transducin). These results demonstrate that a major role of rhodopsin phosphorylation is to promote high-affinity arrestin binding and decrease transducin binding thus allowing arrestin to effectively compete with transducin for binding to photoactivated rhodopsin.	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	Jefferson University	Krupnick, JG (corresponding author), THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MOL PHARMACOL & BIOCHEM,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NIDDK NIH HHS [T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM44944, GM47419] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, NATURE, V322, P869; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; DODD LR, 1996, INVEST OPTHALM VIS S, V37, P55; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7227; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2328; KIM CM, 1993, RECEPTOR, V3, P39; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PUIG J, 1995, FEBS LETT, V362, P1854; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	39	144	146	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18125	18131		10.1074/jbc.272.29.18125	http://dx.doi.org/10.1074/jbc.272.29.18125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218446	hybrid			2022-12-27	WOS:A1997XL73500036
J	Sudakin, V; Shteinberg, M; Ganoth, D; Hershko, J; Hershko, A				Sudakin, V; Shteinberg, M; Ganoth, D; Hershko, J; Hershko, A			Binding of activated cyclosome to p13(suc1) - Use for affinity purification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; M-PHASE; MITOSIS; COMPLEX; YEAST; DESTRUCTION; PROTEOLYSIS	Previous studies have indicated that a similar to 1,500-kDa complex, designated the cyclosome or anaphase-promoting complex, has a regulated cyclin-ubiquitin ligase activity that targets cyclin B for degradation at the end of mitosis. The cyclosome is inactive in the interphase of the embryonic cell cycle and is converted to the active form in late mitosis in a phosphorylation-dependent process initiated by protein kinase Cdc2-cyclin B. We show here that the active, phosphorylated form of the cyclosome from clam oocytes binds to p13(suc1), a protein known to associate with Cdc2, The following evidence indicates that the binding of the cyclosome to p13(suc1) is not mediated via the Cdc2-cyclin B complex: (a) activated cyclosome binds to p13(suc1)-Sepharose following its separation from Cdc2-cyclin B by gel filtration chromatography; (b) cyclosome from interphase extracts, activated by a kinase in which cyclin B has been replaced by an N-terminally truncated derivative fused to glutathione S-transferase, binds well to p13(suc1) Sepharose but not to glutathione-agarose. An alternative possibility, that the phosphorylated cyclosome binds directly to a phosphate-binding site of p13(suc1), is supported by the observation that the cyclosome is efficiently eluted from p13(suc1)-Sepharose by phosphate-containing compounds. This information was utilized to develop a procedure for the affinity purification of the cyclosome. A factor abundant in the fraction not adsorbed to p13(suc1)-Sepharose stimulates the activity of purified cyclosome. It is suggested that binding of Suc1 may have a role in the regulation of cyclosome activity.	FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, RAPPORT INST RES MED SCI, IL-31096 HAIFA, ISRAEL	Fox Chase Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology								Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; EDINCOTT JA, 1995, EMBO J, V14, P1004; EDINCOTT JA, 1995, STRUCTURE, V3, P321; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; ODONNELL KL, 1991, J CELL SCI, V99, P711; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18051	18059		10.1074/jbc.272.29.18051	http://dx.doi.org/10.1074/jbc.272.29.18051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218435	hybrid			2022-12-27	WOS:A1997XL73500025
J	Branstrom, R; Corkey, BE; Berggren, PO; Larsson, O				Branstrom, R; Corkey, BE; Berggren, PO; Larsson, O			Evidence for a unique long chain acyl-CoA ester binding site on the ATP-regulated potassium channel in mouse pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; SULFONYLUREA RECEPTOR; ISLETS; RELEASE; ADENINE; TRYPSIN; KATP; ADP	The mechanism by which long chain acyl-CoA (LC-CoA) esters affect the ATP-regulated potassium channel (K-ATP channel) was studied in inside-out patches isolated from mouse pancreatic beta cells, Addition of LC-CoA esters dramatically increased K-ATP, channel activity. The stimulatory effect of the esters could be explained by the induction of a prolonged open state of the channel and did not involve alterations in single channel unitary conductance. Under central conditions, absence of adenine nucleotides, the distribution of K-ATP channel open time could be described by a single exponential, with a time constant of about 25 ms, Exposing the same patch to LC-CoA esters resulted in the appearance of an additional component with a time constant of >150 ms, indicating a conformational change of the channel protein, LC-CoA esters were also able to potently activate channel activity at different ratios of ATP/ADP. Simultaneous additions of MgADP and LC-CoA esters resulted in a supra-additive effect on channel mean open time, characterized by openings of very long duration. Following modification of the K-ATP channel by a short exposure of the patch rep the protease trypsin, the stimulatory effect of ADP oil channel activity was lost while activation by LC-CoA testers still persisted, This indicates that LC-CoA esters and MgADP do not bind to the same site, We conclude that LC-CoA esters may play an important role in the physiological regulation of the K-ATP channel in the pancreatic beta cell by binding to a unique site and thereby inducing repolarization of the beta cell-membrane potential.	KAROLINSKA INST,DEPT MOL MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118	Karolinska Institutet; Boston University			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Berggren, Per-Olof/0000-0001-8991-413X; Branstrom, Robert/0000-0001-6245-7223	NIDDK NIH HHS [DK35914, DK50662] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK050662, R56DK035914, R01DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Benyon RJ, 1989, PROTEOLYTIC ENZYMES; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DEAN PM, 1968, NATURE, V219, P389, DOI 10.1038/219389a0; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HESCHELER J, 1988, J PHYSIOL-LONDON, V404, P259, DOI 10.1113/jphysiol.1988.sp017289; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; OHTA M, 1991, BIOCHEM PHARMACOL, V42, P593; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; TRUBE G, 1989, SECRETION ITS CONTRO, P83	29	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17390	17394		10.1074/jbc.272.28.17390	http://dx.doi.org/10.1074/jbc.272.28.17390			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211879	hybrid			2022-12-27	WOS:A1997XK16500022
J	Jacoby, T; Flanagan, H; Faykin, A; Seto, AG; Mattison, C; Ota, I				Jacoby, T; Flanagan, H; Faykin, A; Seto, AG; Mattison, C; Ota, I			Two protein-tyrosine phosphatases inactivate the osmotic stress response pathway in yeast by targeting the mitogen-activated protein kinase, Hog1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; GENE; GROWTH; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; CASCADE; VECTORS	Protein phosphatases inactivate mitogen-activated protein kinase (MAPK) signaling pathways by dephosphorylating components of the MAPK cascade. Two genes encoding protein-tyrosine phosphatases, PTP2, and a new phosphatase, PTP3, have been isolated in a genetic selection for negative regulators of an osmotic stress response pathway called HOG, for high osmolarity glycerol, in budding yeast. PTP2 and PTP3 were isolated as multicopy suppressors of a severe growth defect due to hyperactivation of the HOG: pathway. Phosphatase activity is required for suppression since mutation of the catalytic Cys residue in Ptp2 and Ptp3, destroys suppressor function and biochemical activity. The substrate of these phosphatases is likely to be the MAPK, Hog1. Catalytically inactive Ptp2 and Ptp3 coprecipitate with Hog1 from yeast extracts. In addition, strains lacking PTP2 and PTP3 do not dephosphorylate Hog1-phosphotyrosine as well as wild type. The latter suggests that PTP2 and PTP3 play a role in adaptation. Consistent with this role, osmotic stress induces expression of PTP2 and PTP3 transcripts in a Hog1-dependent manner. Thus Ptp2 and Ptp3 likely act in a negative feedback loop to inactivate Hog1.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM07135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Ausubel FM, 1988, MOL REPROD DEV; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Degols G, 1996, MOL CELL BIOL, V16, P2870; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1992, J BIOL CHEM, V267, P10024; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3632; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHERMAN F, 1986, METHODS YEAST GENETI, P177; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	52	126	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17749	17755		10.1074/jbc.272.28.17749	http://dx.doi.org/10.1074/jbc.272.28.17749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211927	hybrid			2022-12-27	WOS:A1997XK16500070
J	Shrimpton, CN; Glucksman, MJ; Lew, RA; Tullai, JW; Margulies, EH; Roberts, JL; Smith, AI				Shrimpton, CN; Glucksman, MJ; Lew, RA; Tullai, JW; Margulies, EH; Roberts, JL; Smith, AI			Thiol activation of endopeptidase EC 3.4.24.15 - A novel mechanism for the regulation of catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; PROTEIN DISULFIDE-ISOMERASE; DNA-BINDING ACTIVITY; PZ-PEPTIDASE; SOLUBLE METALLOENDOPEPTIDASE; THIMET OLIGOPEPTIDASE; RAT TESTES; DEPENDENT METALLOENDOPEPTIDASE; NATURAL PEPTIDES; REDOX CHANGES	Endopeptidase EC 3.4.24.15 (EP24,15) is a thermolysin-like metalloendopeptidase involved in the regulated metabolism of a number of neuropeptides. Unlike other thermolysin-like peptidases EP24.15 displays a unique thiol activation, a mechanism that is not clearly understood, In this study we show that both recombinant and tissue-derived EP24,15 are activated up to 8-fold by low concentrations (0.1 mM) of dithiothreitol, Additionally, under non-reducing conditions, recombinant and native EP24,15 forms multimers that can be returned to the monomeric form by reduction, We have also shown that competitive inhibitor binding occurs only to the monomeric form, which indicates that catalytic site access is restricted in the multimeric forms, Through systematic site-directed mutagenesis we have identified that cysteine residues 246, 253, and possibly 248 are involved in the formation of these multimers, Furthermore, both a double mutant (C246S/C253S) and a triple mutant (C246S/C248S/C253S) are fully active in the absence of reducing agents, as measured by both inhibitor binding and hydrolysis, The formation and disruption of disulfide bonds involving these cysteine residues may be a mechanism by which EP24,15 activity is regulated through changes in intra- and extracellular redox potential.	BAKER MED RES INST,PEPTIDE BIOL LAB,PRAHRAN,VIC 3181,AUSTRALIA; CUNY MT SINAI SCH MED,DR ARTHUR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Baker Heart and Diabetes Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Lew, Rebecca A/C-5454-2008	Smith, Ian/0000-0002-4143-2892	NIDDK NIH HHS [DK45493, T32-DK07645] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007645, R29DK045493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHU TG, 1984, BIOCHEMISTRY-US, V23, P3598, DOI 10.1021/bi00311a005; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GLUCKSMAN MJ, 1995, METHODS NEUROSCI, V43, P296; GOMORI G, 1955, METHOD ENZYMOL, V1, P138, DOI 10.1016/0076-6879(55)01020-3; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MORALES TI, 1977, J BIOL CHEM, V252, P4855; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PAPASTOITSIS G, 1994, BIOCHEMISTRY-US, V33, P192, DOI 10.1021/bi00167a025; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIEROTTI A, 1994, BIOCHEMISTRY-US, V33, P622, DOI 10.1021/bi00168a600; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TISLJAR U, 1990, BIOCHEM J, V267, P531, DOI 10.1042/bj2670531; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TISLJAR U, 1990, ANAL BIOCHEM, V186, P112, DOI 10.1016/0003-2697(90)90582-T; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	31	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17395	17399		10.1074/jbc.272.28.17395	http://dx.doi.org/10.1074/jbc.272.28.17395			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211880	hybrid			2022-12-27	WOS:A1997XK16500023
J	Choi, CY; Choi, BH; Park, GT; Rho, HM				Choi, CY; Choi, BH; Park, GT; Rho, HM			Activating transcription factor 2 (ATF2) down-regulates hepatitis B virus X promoter activity by the competition for the activating protein I binding site and the formation of the ATF2-Jun heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ENHANCER ELEMENT; GENE PRODUCT; TAX PROTEIN; EF-C; CELLS; REPLICATION; INTERACT; REGION; TRANSACTIVATION	The hepatitis B viral X promoter is known to be positively autoregulated by its own HBx protein, which also interacts with many cellular regulatory proteins, We investigated the effect of activating transcription factor 2, (ATF2) on the activity of the PL promoter. Cotransfection of the ATF2 expression vector with a X promoter-chloramphenicol acetyltransferase plasmid repressed the X promoter activity in HepG2 cells, HBx activated activating protein 1 (AP-1)-mediated transcription through the hepatitis B virus E element by 35-fold, while its activation activity was inhibited in the presence of ATF2, suggesting that ATF2 inhibited the autoactivation of X promoter by HBx and basal transcription mediated by AP-1. Since the binding sites of AP-1 and ATF2 in the hepatitis B virus E element overlap, the repression of X promoter activity by ATF2 is everted by the competition for the AP-1 binding site and the formation of the ATF2-Jun heterodimer as in the casa of the consensus AP-1 element. However, the small X promoter had a ATF2 binding site and was activated by ATF2. These results suggest that the syntheses of X proteins are differentially regulated by ATF2.	SEOUL NATL UNIV,DEPT MOL BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHEN M, 1994, VIROLOGY, V205, P127, DOI 10.1006/viro.1994.1627; Choi CY, 1996, EUR J BIOCHEM, V239, P579, DOI 10.1111/j.1432-1033.1996.0579u.x; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUSTIN K, 1993, VIROLOGY, V193, P653, DOI 10.1006/viro.1993.1173; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; KIM SK, 1994, J GEN VIROL, V75, P917, DOI 10.1099/0022-1317-75-4-917; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; Park GT, 1996, J GEN VIROL, V77, P2775, DOI 10.1099/0022-1317-77-11-2775; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; RIGGS P, 1992, SHORT PROTOCOLS MOL; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHEK N, 1991, MOL BIOL HEPATITIS B, P181; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SHIN HJ, 1995, J BIOL CHEM, V270, P11047, DOI 10.1074/jbc.270.19.11047; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990; ZHANG P, 1993, J VIROL, V67, P1472, DOI 10.1128/JVI.67.3.1472-1481.1993; ZHENG YW, 1994, J BIOL CHEM, V269, P22593	50	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16934	16939		10.1074/jbc.272.27.16934	http://dx.doi.org/10.1074/jbc.272.27.16934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202004	hybrid			2022-12-27	WOS:A1997XH44600036
J	Giannakakou, P; Sackett, DL; Kang, YK; Zhan, ZR; Buters, JTM; Fojo, T; Poruchynsky, MS				Giannakakou, P; Sackett, DL; Kang, YK; Zhan, ZR; Buters, JTM; Fojo, T; Poruchynsky, MS			Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; BINDING-SITE; EXCHANGEABLE GTP; MAMMALIAN-CELLS; BREAST-CANCER; ALPHA-TUBULIN; AMINO-ACIDS; TAXOL; MICROTUBULE; MECHANISM	Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovarian carcinoma cells. Single-step paclitaxel selection with verapamil yielded two clones that are resistant to paclitaxel and collaterally sensitive to vinblastine. The resistant sublines are not paclitaxel-dependent, and resistant remained stable after 3 years of drug-free culture. All cell lines accumulate [H-3]paclitaxel equally, and no MDR-1 mRNA was detected by polymerase chain reaction following reverse transcription. Total tubulin content is similar, but the polymerized fraction increased in parental but not in resistant cells following the paclitaxel addition. Purified tubulin from parental cells demonstrated paclitaxel-driven increased polymerization, in contrast to resistant cell tubulin, which did not polymerize under identical conditions. In contrast, epothilone B, an agent to which the resistant cells retained sensitivity, increased assembly. Comparable expression of beta-tubulin isotypes was found in parental and resistant cells, with predominant expression of the M40 and beta 2 isotypes. Sequence analysis demonstrated acquired mutations in the M40 isotype at nucleotide 810 (T --> G; Phe(270) --> Val) in 1A9PTX10 cells and nucleotide 1092 (G --> A; Ala(364) --> Thr) in 1A9PTX22 cells. These results identify residues beta 270 and beta 364 as important modulators of paclitaxel's interaction with tubulin.	NCI,MED BRANCH,DIV CLIN SCI,NIH,BETHESDA,MD 20892; KOREA CANC CTR HOSP,DIV HEMATOL ONCOL,SEOUL 139240,SOUTH KOREA; NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Buters, Jeroen T/G-5070-2011; BUTERS, JEROEN/AAF-6949-2020	Buters, Jeroen/0000-0003-3581-5472				BAI R, 1990, J BIOL CHEM, V265, P17141; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BOLLAG DM, 1995, CANCER RES, V55, P2325; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; CABRAL FR, 1986, ANN NY ACAD SCI, V466, P745, DOI 10.1111/j.1749-6632.1986.tb38456.x; CHAUDHARY AG, 1994, J AM CHEM SOC, V116, P4097, DOI 10.1021/ja00088a063; CHEN YN, 1990, J BIOL CHEM, V265, P10073; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Dumontet C, 1996, CANCER RES, V56, P1091; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; HAMEL E, 1992, PHARMACOL THERAPEUT, V55, P31, DOI 10.1016/0163-7258(92)90028-X; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55; Hyams J. S, 1993, MICROTUBULES; Jaffrezou JP, 1995, ONCOL RES, V7, P517; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PRATT WB, 1994, ANTI-CANCER DRUG, P50; Rai SS, 1996, J BIOL CHEM, V271, P14707, DOI 10.1074/jbc.271.25.14707; Ranganathan S, 1996, CANCER RES, V56, P2584; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SACKETT DL, 1995, BIOCHEMISTRY-US, V34, P7010, DOI 10.1021/bi00021a012; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; Sackett DL, 1997, CANCER CHEMOTH PHARM, V40, P228, DOI 10.1007/s002800050651; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SACKETT DL, 1995, ANAL BIOCHEM, V228, P343, DOI 10.1006/abio.1995.1361; SACKETT DL, 1995, PROTEIN-STRUCT FUNCT, P255; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SCHIBLER MJ, 1989, FASEB J, V3, P163, DOI 10.1096/fasebj.3.2.2563346; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0	53	626	661	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17118	17125		10.1074/jbc.272.27.17118	http://dx.doi.org/10.1074/jbc.272.27.17118			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202030	Green Published, hybrid			2022-12-27	WOS:A1997XH44600062
J	Koonce, MP				Koonce, MP			Identification of a microtubule-binding domain in a cytoplasmic dynein heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR ANALYSIS; ATP-BINDING; DICTYOSTELIUM; SEQUENCE; PROTEINS; TUBULIN; SITES; YEAST; MOTIF	As a molecular motor, dynein must coordinate ATP hydrolysis with conformational changes that lead to processive interactions with a microtubule and generate force. To understand how these processes occur, we have begun to map functional domains of a dynein heavy chain from Dictyostelium. The carboxyl-terminal 10-kilobase region of the heavy chain encodes a 380-kDa polypeptide that approximates the globular head domain. Attempts to further truncate this region fail to produce polypeptides that either bind microtubules or UV-vanadate cleave, indicating that the entire 10-kilobase fragment is necessary to produce a properly folded functional dynein head. We have further identified a region just downstream from the fourth P-loop that appears to constitute at least part of the microtubule-binding domain (amino acids 3182-3818). When deleted, the resulted head domain polypeptide no longer binds microtubules; when the excised region is expressed in vitro, it cosediments with added tubulin polymer. This microtubule-binding domain falls within an area of the molecule predicted to form extended alpha-helices. At least four discrete sites appear to coordinate activities required to bind the tubulin polymer, indicating that the interaction of dynein with microtubules is complex.	SUNY ALBANY, DEPT BIOMED SCI, ALBANY, NY 12201 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Koonce, MP (corresponding author), WADSWORTH CTR, DIV MOL MED, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA.				NIGMS NIH HHS [GM51532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051532, R29GM051532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asai David J., 1993, Trends in Cell Biology, V3, P398, DOI 10.1016/0962-8924(93)90090-N; DOLL T, 1993, J CELL SCI, V106, P633; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GEE MA, 1996, MOL BIOL CELL S, V7, P566; Gepner J, 1996, GENETICS, V142, P865; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; Goldsmith M, 1995, BIOCHEM CELL BIOL, V73, P665, DOI 10.1139/o95-074; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KNECHT DA, 1990, DEV GENET, V11, P403, DOI 10.1002/dvg.1020110513; KOONCE MP, 1994, J EUKARYOT MICROBIOL, V41, P645, DOI 10.1111/j.1550-7408.1994.tb01528.x; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; Mocz G, 1996, BIOCHEMISTRY-US, V35, P9204, DOI 10.1021/bi960662u; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLIWA M, 1986, CYTOSKELETON; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; Warner F.D., 1989, CELL MOVEMENT, V1; WEINGARTEN MD, 1974, BIOCHEMISTRY-US, V13, P5529, DOI 10.1021/bi00724a012; WILKERSON CG, 1994, J CELL SCI, V107, P497; WILLIAMS RC, 1979, BIOCHEMISTRY-US, V18, P2499, DOI 10.1021/bi00579a010; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	40	89	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19714	19718		10.1074/jbc.272.32.19714	http://dx.doi.org/10.1074/jbc.272.32.19714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242627	hybrid			2022-12-27	WOS:A1997XQ05900014
J	Odegaard, TJ; Kaltashov, IA; Cotter, RJ; Steeghs, L; vanderLey, P; Khan, S; Maskell, DJ; Raetz, CRH				Odegaard, TJ; Kaltashov, IA; Cotter, RJ; Steeghs, L; vanderLey, P; Khan, S; Maskell, DJ; Raetz, CRH			Shortened hydroxyacyl chains on lipid A of Escherichia coli cells expressing a foreign UDP-N-acetylglucosmaine O-acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; EUKARYOTIC SIGNAL-TRANSDUCTION; GRAM-NEGATIVE ENDOTOXIN; SALMONELLA-TYPHIMURIUM; LIPOPOLYSACCHARIDE LPS; NEISSERIA-GONORRHOEAE; BACTERIAL-ENDOTOXINS; A PRECURSORS; 1ST STEP; BIOSYNTHESIS	The first reaction of lipid A biosynthesis in Gram-negative bacteria is catalyzed by UDP-N-acetylglucosamine (UDP-GlcNAc) O-acyltransferase, the product of the lpxA gene. The reaction involves the transfer of an acyl chain from hydroxyacyl-acyl carrier protein (ACP) to the glucosamine 3-OH position of UDP-GlcNAc. The lipid A isolated from Escherichia coli contains (R)-3-hydroxymyristate at the 3 and 3' positions. Accordingly, LpxA of E. coli is highly selective for (R)-3-hydroxymyristoyl-ACP over ACP thioesters of longer or shorter acyl chains. We now demonstrate that the lpxA gene from Neisseria meningitidis encodes a similar acyltransferase that selectively utilizes 3-hydroxylauroyl-ACP. Strains of E. coli harboring the temperature-sensitive lpxA2 mutation make very little lipid A and lose viability rapidly at 42 degrees C. We have created an E. coli strain in which the chromosomal lpxA2 mutation is complemented by the N. meningitidis lpxA gene introduced on a plasmid. This strain, RO138/pTO6, grows similarly to wild type cells at 42 degrees C and produces wild type levels of lipid A. However, the lipid A isolated from RO138/pTO6 contains mostly hydroxylaurate and hydroxydecanoate in the 3 and 3' positions. The strain RO138/pTO6 is more susceptible than wild type to certain antibiotics at 42 degrees C. This is the first report of an E. coli strain growing with shortened hydroxyacyl chains on its lipid A. The lpxA gene product appears to be a critical determinant of the length of the ester-linked hydroxyacyl chains found on lipid A in living cells.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,MIDDLE ATLANTIC MASS SPECTROMETRY LAB,BALTIMORE,MD 21205; NATL INST PUBL HLTH & ENVIRONM,LAB VACCINE DEV & IMMUNE MECHANISMS,NL-3720 BA BILTHOVEN,NETHERLANDS; UNIV CAMBRIDGE,DEPT CLIN VET MED,CTR VET SCI,CAMBRIDGE CB3 0ES,ENGLAND	Duke University; Johns Hopkins University; Netherlands National Institute for Public Health & the Environment; University of Cambridge					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM033967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-33967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1997, IN PRESS J BIOL CHEM; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J. H., 1972, EXPT MOL GENETICS, P433; MOHAN S, 1994, J BIOL CHEM, V269, P32896; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; QURESHI N, 1988, J BIOL CHEM, V263, P5502; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; QURESHI N, 1982, J BIOL CHEM, V257, P1808; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P545, DOI 10.1128/JB.108.1.545-552.1971; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; STEAD A, 1975, J GEN MICROBIOL, V88, P123, DOI 10.1099/00221287-88-1-123; Steeghs L, 1997, GENE, V190, P263, DOI 10.1016/S0378-1119(97)00005-X; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VANALPHEN L, 1979, EUR J BIOCHEM, V101, P571; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; Wang Y, 1996, J MASS SPECTROM, V31, P138; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991	58	55	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19688	19696		10.1074/jbc.272.32.19688	http://dx.doi.org/10.1074/jbc.272.32.19688			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242624	hybrid			2022-12-27	WOS:A1997XQ05900011
J	English, JD; Sweatt, JD				English, JD; Sweatt, JD			A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MAINTENANCE; INDUCTION; CA1; INHIBITORS; BRAIN	The mitogen-activated protein kinase (MAPK) cascade has been intensely studied as a primary biochemical pathway through which a variety of extracellular stimuli initiate and regulate processes of cellular transformation. That MAPKs are abundantly expressed in postmitotic neurons, however, suggests different yet currently unknown functions for this cascade in the mature nervous system. Here we report that the MAPK cascade is required for hippocampal long term potentiation (LTP), a robust and widely studied form of synaptic plasticity, We observed that PD 098059, a selective inhibitor of the MAPK cascade, blocked MAPK activation in response to direct stimulation of the NMDA receptor as well as to LTP-inducing stimuli, Furthermore, inhibition of the MAPK cascade markedly attenuated the induction of LTP. PD 098059, however, had no effect on the expression of established LTP, and the MAPK cascade was not persistently activated during LTP expression. Our observations provide the first demonstration of a role for the MAPK cascade in the activity-dependent modification of synaptic connections between neurons in the adult mammalian nervous system.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine				Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57014] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	26	723	739	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19103	19106		10.1074/jbc.272.31.19103	http://dx.doi.org/10.1074/jbc.272.31.19103			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235897	hybrid			2022-12-27	WOS:A1997XP06300003
J	Feaver, WJ; Henry, NL; Wang, ZG; Wu, XH; Svejstrup, JQ; Bushnell, DA; Friedberg, EC; Kornberg, RD				Feaver, WJ; Henry, NL; Wang, ZG; Wu, XH; Svejstrup, JQ; Bushnell, DA; Friedberg, EC; Kornberg, RD			Genes for Tfb2, Tfb3, and Tfb4 subunits of yeast transcription/repair factor IIH - Homology to human cyclin-dependent kinase activating kinase and IIH subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; FACTOR-B; CRYSTAL-STRUCTURE; EXCISION-REPAIR; PROTEIN-KINASE; RING FINGER; CTD KINASE; TFIIH	Genes for the Tfb2, Tfb3, and Tfb4 subunits of yeast RNA polymerase transcription factor IIH (TFIIH) are described, All three genes are essential for cell viability, and antibodies against Tfb3 specifically inhibit transcription in vitro. A C-terminal deletion of Tfb2 caused a defect in nucleotide excision repair, as shown by UV sensitivity of the mutant strain and loss of nucleotide excision repair activity in cell extracts (restored by the addition of purified TFIIH). An interaction between Tfb3 and the Kin28 subunit of TFIIH was detected by the two-hybrid approach, consistent with a role for Tfb3 in linking kinase and core domains of the factor, The deduced amino acid sequence of Tfb2 is similar to that of the 52-kDa subunit of human TFIIH, while Tfb3 is identified as a RING finger protein homologous to the 36-kDa subunit of murine CAK (cyclin-dependent kinase activating kinase) and to the 32-kDa subunit of human TFIIH, Tfb4 is homologous to p34 of human TFIIH and is identified as the weakly associated 37-kDa subunit of the yeast factor. These and other findings reveal a one-to-one correspondence and high degree of sequence similarity between the entire set of yeast and human TFIIH polypeptides.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; UNIV TEXAS, SW MED CTR, DEPT PATHOL, LAB MOL PATHOL, DALLAS, TX 75235 USA; UNIV KENTUCKY, DEPT TOXICOL, LEXINGTON, KY 40536 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kentucky				Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FRIEDBERG EC, 1995, DNA REPAIR; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WANG Z, 1996, MUTAT RES, V364, P51; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023	46	64	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19319	19327		10.1074/jbc.272.31.19319	http://dx.doi.org/10.1074/jbc.272.31.19319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235928	hybrid			2022-12-27	WOS:A1997XP06300034
J	Heckman, C; Mochon, E; Arcinas, M; Boxer, LM				Heckman, C; Mochon, E; Arcinas, M; Boxer, LM			The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; WILMS-TUMOR SUPPRESSOR; C-MYC; MALIGNANT-LYMPHOMA; GENE; EXPRESSION; BINDING; CELLS; LOCUS; TRANSLOCATION	The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis. An in vivo footprint over a potential WT1 binding site in the bcl-2 5'-flanking sequence was identified on the normal silent allele. Electrophoretic mobility shift assays with the bcl-2 WT1 site demonstrated a single specific complex. UV cross-linking and Western analysis revealed that this gel shift complex contained WT1 protein. Deletion or mutation of the WT1 site resulted in an increase in activity of the bcl-2 promoter in DHL-4 cells. Cotransfection with a 3:1 ratio of a WT1 expression vector to the bcl-2 promoter construct led to a 3.0-fold repression of the bcl-2 promoter. Cotransfection with a WT1 expression vector and the bcl-2 promoter with the mutated WT1 site resulted in only 1.2-fold repression. We conclude that the WT1 site functions as a negative regulatory site for the normal silent bcl-2 allele in t(14;18) lymphomas, The WT1 site is not occupied on the translocated bcl-2 allele.	STANFORD UNIV,SCH MED,DIV HEMATOL,DEPT MED,STANFORD,CA 94305; VET ADM MED CTR,CTR MOL BIOL MED,STANFORD,CA 94305	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764, 5T32 CA09302-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764, T32CA009302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HEWITT SM, 1995, CANCER RES, V55, P5386; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZELENETZ AD, 1991, BLOOD, V78, P1552	32	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19609	19614		10.1074/jbc.272.31.19609	http://dx.doi.org/10.1074/jbc.272.31.19609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235968	hybrid			2022-12-27	WOS:A1997XP06300074
J	Li, ZY; Hiasa, H; Kumar, U; DiGate, RJ				Li, ZY; Hiasa, H; Kumar, U; DiGate, RJ			The traE gene of plasmid RP4 encodes a homologue of Escherichia coli DNA topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; REPLICATION IN-VITRO; BACILLUS-SUBTILIS; TRANSFER REGION; GYRASE GENES; SITE; BINDING; CLONING; SYSTEM; RK2	The polypeptide encoded by the plasmid RP4 traE gene shows extensive protein sequence similarity to Escherichia coli topB, the gene encoding DNA topoisomerase III (Topo III), The traE gene product has been cloned into a bacteriophage T7-based transient expression system, and the polypeptide has been expressed and purified, The TraE protein exhibits topoisomerase activity similar to that of Topo III, Relaxation is stimulated by high temperature and low concentrations of Mg2+. In addition, similar to E. coli Topo III, the TraE protein is a potent decatenase and can substitute for Topo III activity in vivo. The biochemical properties of the TraE protein in vitro suggest that the protein may be involved in the resolution of plasmid DNA replication intermediates either during vegetative replication or in conjugative DNA transfer, Putative homologues of Topo III have been found to be encoded by other broad host range, conjugative plasmids isolated from both Gram-negative and Gram-positive organisms, suggesting that Topo III-like polypeptides may have an essential role in the propagation of many promiscuous plasmids.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, DEPT MOL BIOL & BIOPHYS, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH PHARM, DEPT PHARMACEUT SCI, BALTIMORE, MD 21201 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048445, R01GM048445] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48445] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTH PT, 1978, J BACTERIOL, V133, P43, DOI 10.1128/JB.133.1.43-52.1978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTL S, 1994, GENE, V142, P155, DOI 10.1016/0378-1119(94)90372-7; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Caron Paul R., 1994, V29B, P271; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; Clewell DB, 1993, BACTERIAL CONJUGATIO, P75; Clewell DB, 1993, BACTERIAL CONJUGATIO, P349; DEAN F, 1984, THESIS U CHICAGO; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V79, P1935; FIRTH N, 1993, GENE, V136, P13, DOI 10.1016/0378-1119(93)90442-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOUET A, 1994, MOL MICROBIOL, V11, P471, DOI 10.1111/j.1365-2958.1994.tb00328.x; GERLITZ M, 1990, J BACTERIOL, V172, P6194, DOI 10.1128/jb.172.11.6194-6203.1990; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hopwood D.A., 1993, BACTERIAL CONJUGATIO, P293, DOI DOI 10.1007/978-1-4757-9357-4_11; IVEY DM, 1992, NUCLEIC ACIDS RES, V20, P4928, DOI 10.1093/nar/20.18.4928; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Macrina FL, 1993, BACTERIAL CONJUGATIO, P313, DOI [DOI 10.1007/978-1-4757-9357-4_12, 10.1007/978-1-4757-9357-4_12]; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MORTON TM, 1993, J BACTERIOL, V175, P4436, DOI 10.1128/JB.175.14.4436-4447.1993; PALOMBO EA, 1989, PLASMID, V22, P59, DOI 10.1016/0147-619X(89)90036-X; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWINFIELD TJ, 1991, PLASMID, V26, P209, DOI 10.1016/0147-619X(91)90044-W; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700	52	28	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19582	19587		10.1074/jbc.272.31.19582	http://dx.doi.org/10.1074/jbc.272.31.19582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235964	hybrid			2022-12-27	WOS:A1997XP06300070
J	Loo, RW; CondeFrieboes, K; Reynolds, LJ; Dennis, EA				Loo, RW; CondeFrieboes, K; Reynolds, LJ; Dennis, EA			Activation, inhibition, and regiospecificity of the lysophospholipase activity of the 85-kDa group IV cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; PURIFICATION; PROTEIN; P388D1; U937; ACYL	The 85-kDa Group IV calcium-dependent cytosolic phospholipase A(2) (cPLA(2)) catalyzes the hydrolysis of palmitoylglycero-3-phosphocholine to palmitic acid and glycero-3-phosphocholine. Palmitoylglycero-3-phosphocholine exists as a 9:1 equilibrium mixture of the sn-1 and sn-2 isomers, with the fatty acid predominately at the sn-1 position, We have monitored this reaction by P-31 NMR to determine which palmitoylglycero-3-phosphocholine isomer is processed by cPLA(2). When both lysophospholipid isomers are present in a 1:1 mixture under conditions in which acyl migration is minimized, cPLA(2) rapidly consumes both isomers, However, 1-palmitoylglycero-3-phosphocholine is consumed seven times faster than the 2-palmitoylglycero-3-phosphocholine isomer, We have previously reported that this lysophospholipase reaction is accelerated in the presence of glycerol, We now find that this apparent increase in activity is accounted for, in part, by glycerol acting as an alternative acceptor for the cleaved fatty acid, as is the case for this enzyme's phospholipase A(2) (PLA(2)) activity, In contrast, dioleoylglycerol, which accelerates the PLA(2) activity, does not act as an acceptor in either the lysophospholipase or the PLA(2) reaction, but can affect enzyme activities by altering substrate presentation, We also show that a known inhibitor of the PLA(2) activity of cPLA(2) is able to inhibit its lysophospholipase activity with a similar IC50 60 its PLA(2) activity, However the effect of inhibitors is dependent on the manner in which they are presented to the enzyme.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140; Conde-Frieboes, Kilian/0000-0001-5303-4448	NIGMS NIH HHS [GM20501, GM51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN HC, 1949, J AM CHEM SOC, V71, P1845, DOI 10.1021/ja01173a093; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; PLUCKTHUN A, 1981, J PHYS CHEM-US, V85, P678; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	26	34	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19214	19219		10.1074/jbc.272.31.19214	http://dx.doi.org/10.1074/jbc.272.31.19214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235913	Green Published, hybrid			2022-12-27	WOS:A1997XP06300019
J	Babichuk, CK; Bleackley, RC				Babichuk, CK; Bleackley, RC			Mutational analysis of the murine granzyme B gene promoter in primary T cells and a T cell clone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; CORE-BINDING-FACTOR; C-JUN; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; REGULATORY ELEMENTS; BETA-SUBUNITS; ACTIVATION; EXPRESSION	The granzyme B gene is induced in cytotoxic T lymphocytes in response to antigenic stimulation. Previous studies have identified several distinct regions in the granzyme B promoter which may be important in either the induction or the T cell specificity of the gene. These regions contain the canonical transcription factor binding sites AP1, cyclic AMP-responsive element (CRE), Ikaros, and core-binding factor (CBF/PEBP2). Each protein binding site was disrupted by site-directed mutagenesis to investigate its role in granzyme B promoter function. Mutations were introduced alone, or in various combinations, within the context of a 243-base pair promoter fragment known to confer high levels of reporter gene expression. Transfection assays revealed that all of the single binding site mutant promoters were capable of sustaining moderate to high levels of transcriptional activity in primary activated T lymphocytes, whereas certain mutants were more impeded in a T cell clone. A quadruple mutant promoter, with only the CRE binding site intact, showed background expression levels. This drop in expression was found to be mostly due to mutations in AP1 and the 3' CBF binding sites. Their close proximity and requirement in promoter function suggest an important role for protein-protein interaction between these two factors.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; Babichuk CK, 1996, J BIOL CHEM, V271, P16485, DOI 10.1074/jbc.271.28.16485; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BLEACKLEY RC, 1982, J IMMUNOL, V128, P758; CHIEN YH, 1993, IMMUNOL TODAY, V14, P597, DOI 10.1016/0167-5699(93)90199-U; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; FREGEAU CJ, 1991, NUCLEIC ACIDS RES, V19, P5583; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; HANSON RD, 1993, BLOOD, V9, P2749; HAVELE C, 1986, J IMMUNOL, V137, P1448; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; LU J, 1995, MOL CELL BIOL, V15, P1651; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1666; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMYTH MJ, 1990, J EXP MED, V171, P1269, DOI 10.1084/jem.171.4.1269; Taylor DS, 1996, J BIOL CHEM, V271, P14020, DOI 10.1074/jbc.271.24.14020; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	38	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18564	18571		10.1074/jbc.272.30.18564	http://dx.doi.org/10.1074/jbc.272.30.18564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228022	hybrid			2022-12-27	WOS:A1997XM34200013
J	Glerum, DM; Muroff, I; Jin, C; Tzagoloff, A				Glerum, DM; Muroff, I; Jin, C; Tzagoloff, A			COX15 codes for a mitochondrial protein essential for the assembly of yeast cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE NUCLEAR GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MEMBRANE SYSTEM; MESSENGER-RNA; PET GENES; MUTANTS; TRANSFORMATION; EXPRESSION; CLONING	The respiratory defect of Saccharomyces cerevisiae mutants assigned to complementation group G4 of a pet strain collection stems from their failure to synthesize cytochrome oxidase. The mutations do not affect expression of either the mitochondrially or nuclearly encoded subunits of the enzyme, The cytochrome oxidase deficiency also does not appear to be related to mitochondrial copper metabolism or heme a biosynthesis, These data suggest that the mutants are likely to be impaired in assembly of the enzyme, A gene designated COX15 has been cloned by transformation of mutants from complementation group G4. This gene is identical to reading frame YER141w on chromosome 5, To facilitate further studies, Cox15p has been expressed as a biotinylated protein, Biotinylated Cox15p fully restores cytochrome oxidase in cox15 mutants, indicating that the carboxyl-terminal sequence with biotin does not affect its function. Cox15p is a constituent of the mitochondrial inner membrane and, because of its resistance to proteolysis, probably is largely embedded in the phospholipid bilayer of the membrane, The present studies further emphasize the complexity of cytochrome oxidase assembly and report a new constituent of mitochondria involved in this process. The existence of COX15 homologs in Schizosaccharomyces pombe and Caenorhabditis elegans suggests that it may be widely distributed in eucaryotic organisms.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022	Muroff, Ivor/0000-0003-3721-5278	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURKL G, 1976, GENETICS BIOGENESIS, P39; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DUJON B, 1981, MOL BIOL YEAST SACCH, P506; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; POUTRE CG, 1987, GENETICS, V115, P637; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1963, GENETICS, V48, P375; SONE N, 1991, J BIOCHEM-TOKYO, V110, P1016, DOI 10.1093/oxfordjournals.jbchem.a123671; ten Berge A M, 1974, Mol Gen Genet, V131, P113; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VINGRON M, 1991, J MOL BIOL, V218, P33, DOI 10.1016/0022-2836(91)90871-3	47	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19088	19094		10.1074/jbc.272.30.19088	http://dx.doi.org/10.1074/jbc.272.30.19088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228094	hybrid			2022-12-27	WOS:A1997XM34200085
J	Kaplan, MD; Olschowka, JA; OBanion, MK				Kaplan, MD; Olschowka, JA; OBanion, MK			Cyclooxygenase-1 behaves as a delayed response gene in PC12 cells differentiated by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; MESSENGER-RNA; NEURONAL DIFFERENTIATION; PHORBOL ESTER; INDUCTION; EXPRESSION; TRANSCRIPTION; GLUCOCORTICOIDS; SYNTHASE-2; CLONING	Treatment of PC12 cells with nerve growth factor (NGF) results in a differentiation program characterized by expression of immediate early and delayed response genes. In this program, morphological changes such as neurite extension are accompanied by phenotypic changes in enzyme expression, including an in creased capacity for prostaglandin synthesis. Cyclooxygenase (COX), the enzyme responsible for prostanoid production, exists as two isoforms: constitutive COX-1 and inducible COX-2. We report that COX-1 behaves as a delayed response gene in PC12 cells exposed to NGF. Six hours following NGF treatment, COX-1 mRNA levels were elevated in PC12 cells, reaching nearly B-fold above basal levels at 12 h. This increase was blocked by cycloheximide and was accompanied by concomitant increases in COX-1 protein and enzyme activity, COX-1 protein remained elevated for at least 10 days and localized to the cytoplasm and neurites of NGF-differentiated PC12 cells. Moreover, basic fibroblast growth factor, but not epidermal growth factor, caused similar increases in COX-1, which is consistent with expression characteristics of other delayed response genes in PC12 cells. This is the first example of neurotrophic factor regulation of cyclooxygenase and may have important implications for determination of the differentiated phenotype in PC12 cells.	UNIV ROCHESTER, SCH MED & DENT, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT NEUROL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				O'Banion, M. Kerry/0000-0003-1246-3363	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K16DE000159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG009016] Funding Source: NIH RePORTER; NIA NIH HHS [LEAD AG09016] Funding Source: Medline; NIDCR NIH HHS [K16 DE00159] Funding Source: Medline; NINDS NIH HHS [R29 NS33553] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DEGEORGE JJ, 1988, J NEUROSCI RES, V21, P323, DOI 10.1002/jnr.490210225; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HERSCHMAN HR, 1995, ADV PROSTAG THROMB L, V23, P23; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; VANE JR, 1995, ADV PROSTAG THROMB L, V23, P41; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	30	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18534	18537		10.1074/jbc.272.30.18534	http://dx.doi.org/10.1074/jbc.272.30.18534			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228016	hybrid			2022-12-27	WOS:A1997XM34200007
J	Ni, L; Sheikh, S; Weiner, H				Ni, L; Sheikh, S; Weiner, H			Involvement of glutamate 399 and lysine 192 in the mechanism of human liver mitochondrial aldehyde dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; PURIFICATION; RAT; EXPRESSION; MG-2+	Mutation to the conserved Glu(399) Or Lys(192) caused the rate-limiting step of human liver mitochondrial aldehyde dehydrogenase (ALDH2) to change from deacylation to hydride transfer (Sheikh, S., Ni, L., Hurley, T, D,, and Weiner, H. (1997) J. Biol. Chem. 272, 18817-18822), Here we further investigated the role of these two NAD(+)-ribose-binding residues. The E399Q/K/H/D and K192Q mutants had lower dehydrogenase activity when compared with the native enzyme, No pre-steady state burst of NADH formation was found with the E399Q/K and R192Q enzymes when propionaldehyde was used as the substrate; furthermore, each mutant oxidized chloroacetaldehyde slower than propionaldehyde, and a primary isotope effect was observed for each mutant when [H-2]acetaldehyde was used as a substrate, However, no isotope effect was observed for each mutant when alpha-[H-2]benzaldehyde was the substrate, A pre-steady state burst of NADH formation was observed for the E399Q/H and R192Q mutants with benzaldehyde, and p-nitrobenzaldehyde was oxidized faster than benzaldehyde. Hence, when aromatic aldehydes were used as substrates, the rate-limiting step remained deacylation for all these mutants, The rate-limiting step remained deacylation for the E399H/D mutants when either aliphatic or aromatic aldehydes were used as substrates, The K192Q mutant displayed a change in substrate specificity, with aromatic aldehydes becoming better substrates than aliphatic aldehydes.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FELDMAN RI, 1972, J BIOL CHEM, V247, P260; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sheikh S, 1997, J BIOL CHEM, V272, P18817, DOI 10.1074/jbc.272.30.18817; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P2720, DOI 10.1021/bi00513a003; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; VALLARI RC, 1984, J BIOL CHEM, V259, P4927; VALLARI RC, 1984, J BIOL CHEM, V259, P4922; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	18	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18823	18826		10.1074/jbc.272.30.18823	http://dx.doi.org/10.1074/jbc.272.30.18823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228057	hybrid			2022-12-27	WOS:A1997XM34200048
J	Rumsey, SC; Kwon, O; Xu, GW; Burant, CF; Simpson, I; Levine, M				Rumsey, SC; Kwon, O; Xu, GW; Burant, CF; Simpson, I; Levine, M			Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; VITAMIN-C; HUMAN-NEUTROPHILS; XENOPUS OOCYTES; FRUCTOSE TRANSPORTER; TISSUE DISTRIBUTION; HUMAN-ERYTHROCYTES; GENE LOCALIZATION; DIABETES-MELLITUS; SKELETAL-MUSCLE	Dehydroascorbic acid (DHA) is rapidly taken up by cells and reduced to ascorbic acid (AA). Using the Xenopus laevis oocyte expression system we examined transport of DHA and AA via glucose transporter isoforms GLUT1-5 and SGLT1, The apparent K-m of DHA transport via GLUT1 and GLUT3 was 1.1 +/- 0.2 and 1.7 +/- 0.3 mM, respectively, High performance liquid chromatography analysis confirmed 100% reduction of DHA to AA within oocytes, GLUT4 transport of DHA was only 2-4-fold above control and transport kinetics could not be calculated, GLUT2, GLUT5, and SGLT1 did not transport DHA and none of the isoforms transported AA. Radiolabeled sugar transport confirmed transporter function and identity of all cDNA clones was confirmed by restriction fragment mapping. GLUT1 and GLUT3 cDNA were further verified by polymerase chain reaction, DHA transport activity in both GLUT1 and GLUT3 was inhibited by 2-deoxyglucose, D-glucose, and S-O-methylglucose among other hexoses while fructose and L-glucose showed no inhibition, Inhibition by the endofacial inhibitor, cytochalasin B, was non-competitive and inhibition by the exofacial inhibitor, 4,6-O-ethylidene-alpha-glucose, was competitive. Expressed mutant constructs of GLUT1 and GLUT3 did not transport DHA. DHA and a-deoxyglucose uptake by Chinese hamster ovary cells overexpressing either GLUT1 or GLUT3 was increased 2-8 fold over control cells. These studies suggest GLUT1 and GLUT3 isoforms are the specific glucose transporter isoforms which mediate DHA transport and subsequent accumulation of AA.	NIDDK,NIH,MOL & CLIN NUTR SECT,BETHESDA,MD 20892; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Chicago			Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003				ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BANERJEE A, 1982, ANN CLIN BIOCHEM, V19, P65, DOI 10.1177/000456328201900201; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BERGSTEN P, 1995, ARCH BIOCHEM BIOPHYS, V317, P208, DOI 10.1006/abbi.1995.1155; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; BIANCHI J, 1986, AM J PHYSIOL, V250, pG461, DOI 10.1152/ajpgi.1986.250.4.G461; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHATTERJEE IB, 1979, ANAL BIOCHEM, V98, P368, DOI 10.1016/0003-2697(79)90155-6; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; COX BD, 1975, BIOCHEM MED METAB B, V12, P183, DOI 10.1016/0006-2944(75)90110-6; CRAIK JD, 1995, THROMB RES, V79, P461, DOI 10.1016/0049-3848(95)00136-F; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DHARIWAL KR, 1990, ANAL BIOCHEM, V189, P18, DOI 10.1016/0003-2697(90)90037-A; DIXON SJ, 1992, J BONE MINER RES, V7, P675; DYER DL, 1994, AM J PHYSIOL, V267, pC301, DOI 10.1152/ajpcell.1994.267.1.C301; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HABER RS, 1993, ENDOCRINOLOGY, V132, P2538, DOI 10.1210/en.132.6.2538; HEATH H, 1966, EXP EYE RES, V5, P156, DOI 10.1016/S0014-4835(66)80002-7; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; HORNIG D, 1971, CLIN CHIM ACTA, V33, P187, DOI 10.1016/0009-8981(71)90267-1; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; INUKAI K, 1995, ENDOCRINOLOGY, V136, P4850, DOI 10.1210/en.136.11.4850; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KELLER K, 1990, BIOMED BIOCHIM ACTA, V49, P1201; KERN HL, 1987, CURR EYE RES, V6, P885, DOI 10.3109/02713688709034857; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; NEWILL A, 1984, ANN CLIN BIOCHEM, V21, P488, DOI 10.1177/000456328402100608; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; SHEPHERD PR, 1992, BIOCHEM BIOPH RES CO, V188, P149, DOI 10.1016/0006-291X(92)92362-2; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SINCLAIR AJ, 1991, DIABETOLOGIA, V34, P171, DOI 10.1007/BF00418271; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; STEVENSON NR, 1974, GASTROENTEROLOGY, V67, P952; THORN NA, 1991, ACTA PHYSIOL SCAND, V141, P97, DOI 10.1111/j.1748-1716.1991.tb09049.x; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WANG JF, 1986, P NATL ACAD SCI USA, V83, P3277, DOI 10.1073/pnas.83.10.3277; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WRIGHT JR, 1981, J APPL PHYSIOL, V51, P1477, DOI 10.1152/jappl.1981.51.6.1477; YAMAMOTO I, 1990, J PHARMACOBIO-DYNAM, V13, P688, DOI 10.1248/bpb1978.13.688; ZHOU J, 1993, J CLIN INVEST, V91, P845, DOI 10.1172/JCI116305	67	373	388	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18982	18989		10.1074/jbc.272.30.18982	http://dx.doi.org/10.1074/jbc.272.30.18982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228080	hybrid			2022-12-27	WOS:A1997XM34200071
J	Che, WY; Asahi, M; Takahashi, M; Kaneto, H; Okado, A; Higashiyama, S; Taniguchi, N				Che, WY; Asahi, M; Takahashi, M; Kaneto, H; Okado, A; Higashiyama, S; Taniguchi, N			Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells - The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; DIPHTHERIA-TOXIN RECEPTOR; FACTOR MESSENGER-RNA; GLYOXALASE SYSTEM; MAILLARD REACTION; FACTOR EXPRESSION; N-ACETYLCYSTEINE; ANGIOTENSIN-II; PROTEIN-KINASE; FREE-RADICALS	Methylglyoxal (MG) and 3-deoxyglucosone (3-DG), reactive dicarbonyl metabolites in the glyoxalase system and glycation reaction, respectively, selectively induced heparin-binding epidermal growth factor (HB-EGF)-like growth factor mRNA in a dose- and time-dependent manner in rat aortic smooth muscle cells (RASMC). A nuclear run-on assay revealed that the dicarbonyl may regulate expression of HB-EGF at the transcription level. The dicarbonyl also increased the secretion of HB-EGF from RASMC. However, platelet-derived growth factor, another known growth factor of smooth muscle cells (SMC), was not induced by both dicarbonyls. The dicarbonyl augmented intracellular peroxides prior to the induction of HB-EGF mRNA as judged by flow cytometric analysis using 2',7'-dichlorofluorescin diacetate. N-acetyl-L-cysteine and aminoguanidine suppressed both dicarbonyl-increased HB-EGF mRNA and intracellular peroxide levels in RASMC. DL-Buthionine-(S,R)-sulfoximine increased the levels of 3-DG-induced HB-FGF mRNA. Furthermore, hydrogen peroxide alone also induced HB-EGF mRNA in RASMC. These results indicate that MG and 3-DG induce HB-EGF by increasing the intracellular peroxide levels. In addition, the pretreatment with 12-O-tetra-decanoylphorbol-13-acetate failed to alter dicarbonyl-induced HB-EGF mRNA expression in RASMC, suggesting that the signal transducing mechanism is not mediated by protein kinase C. Since HB-EGF is known as a potent mitogen for smooth muscle cells and is abundant in atherosclerotic plaques, the induction of HB-EGF by MG and 3-DG, as well as the concomitant increment of intracellular peroxides, may trigger atherogenesis during diabetes.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University			Taniguchi, Naoyuki/I-4182-2014; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Takahashi, Motoko/0000-0002-2112-6142				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BASS DA, 1983, J IMMUNOL, V130, P1910; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD D, 1988, ONCOGENE, V3, P27; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FUKUDA K, 1995, ARTERIOSCL THROM VAS, V15, P1680, DOI 10.1161/01.ATV.15.10.1680; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KALAPOS MP, 1993, ARCH TOXICOL, V67, P369, DOI 10.1007/BF01973710; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KHADEM HE, 1971, CARBOHYD RES, V17, P183; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LIBBY P, 1991, LAB INVEST, V64, P5; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MEISTER A, 1986, J AM COLL NUTR, V5, P137; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NIWA T, 1993, BIOCHEM BIOPH RES CO, V196, P837, DOI 10.1006/bbrc.1993.2325; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; Phillips Susan A., 1993, Biochemical Society Transactions, V21, p163S; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Selwood Trevor, 1993, Biochemical Society Transactions, V21, p170S; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI M, 1993, GENE, V127, P249, DOI 10.1016/0378-1119(93)90728-L; Taniguchi N, 1996, DIABETES, V45, pS81, DOI 10.2337/diab.45.3.S81; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; VALENTE AJ, 1988, J CELL PHYSIOL, V136, P479, DOI 10.1002/jcp.1041360312; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YAMADA H, 1994, J BIOL CHEM, V269, P20275; YIM HS, 1995, J BIOL CHEM, V270, P28228	57	99	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18453	18459		10.1074/jbc.272.29.18453	http://dx.doi.org/10.1074/jbc.272.29.18453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218489	hybrid			2022-12-27	WOS:A1997XL73500079
J	Clark, AF; Sharp, MGF; Morley, SD; Fleming, S; Peters, J; Mullins, JJ				Clark, AF; Sharp, MGF; Morley, SD; Fleming, S; Peters, J; Mullins, JJ			Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAY; PITUITARY ATT-20 CELLS; ANGIOTENSIN-II; DEFICIENT MICE; BLOOD-PRESSURE; MOUSE; GENE; EXPRESSION; GLAND; HYPOTENSION	The secretion of renin from granules stored in renal juxtaglomerular cells plays a key role in blood pressure homeostasis. The synthesis and release of renin and the extent of granulation is regulated by several mechanisms including signaling from the macula densa, neuronal input, and blood pressure. Through the use of a gene-targeting vector containing homology arms generated using the polymerase chain reaction, we have inactivated the Ren-1(d) gene, one of two mouse genes encoding renin, and report that lack of renin-1(d) results in altered morphology of the macula densa of the kidney distal tubule and complete absence of juxtaglomerular cell granulation. Furthermore, Ren-1(d-/-) mice exhibit sexually dimorphic hypotension. The altered growth morphology of the macula densa in Ren-1(d)-null mice should provide a tool for the investigation of the JG cell-macula densa signaling. Furthermore, the current data indicate that expression of the Ren-1(d) gene is a prerequisite for the formation of storage granules, even though the related protein renin-2 is present in these mice, suggesting that renin-1(d) and renin-2 are secreted by distinct pathways in vivo.	UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV HEIDELBERG,DEPT PHARMACOL,D-69120 HEIDELBERG,GERMANY	University of Edinburgh; University of Edinburgh; Ruprecht Karls University Heidelberg			Morley, Steve/AAY-9985-2020	Morley, Steven/0000-0002-7355-3349				ABEL KJ, 1990, GENETICS, V124, P937; BING J, 1980, J HISTOCHEM CYTOCHEM, V28, P874, DOI 10.1177/28.8.7003007; Briggs JP, 1996, KIDNEY INT, V49, P1724, DOI 10.1038/ki.1996.255; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DICKINSON DP, 1984, GENETICS, V108, P651; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; HERMANN K, 1988, CLIN CHEM, V34, P1046; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KING JA, 1993, AM J PHYSIOL, V265, pC305, DOI 10.1152/ajpcell.1993.265.2.C305; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; MILLER CCJ, 1992, P NATL ACAD SCI USA, V89, P5020, DOI 10.1073/pnas.89.11.5020; MILLER CCJ, 1989, NUCLEIC ACIDS RES, V17, P3117, DOI 10.1093/nar/17.8.3117; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; PETERS J, 1993, J CLIN INVEST, V91, P742, DOI 10.1172/JCI116292; PRATT RE, 1987, P NATL ACAD SCI USA, V84, P7837, DOI 10.1073/pnas.84.22.7837; PRATT RE, 1988, J BIOL CHEM, V263, P3137; PRATT RE, 1988, ENDOCRINOLOGY, V123, P1721, DOI 10.1210/endo-123-4-1721; SCHELLING P, 1980, NEUROENDOCRINOLOGY, V31, P297, DOI 10.1159/000123092; SHARP MGF, 1996, HYPERTENSION, V26, P1126; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Taugner R, 1989, JUXTAGLOMERULAR APPA; VILLARD E, 1994, J BIOL CHEM, V269, P30307	34	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18185	18190		10.1074/jbc.272.29.18185	http://dx.doi.org/10.1074/jbc.272.29.18185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218454	hybrid			2022-12-27	WOS:A1997XL73500044
J	Flanagan, SA; MecklingGill, KA				Flanagan, SA; MecklingGill, KA			Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; INTESTINAL EPITHELIAL-CELLS; CHORIOCARCINOMA BEWO CELLS; PROTEIN-KINASE-C; NUCLEOSIDE-TRANSPORT; URIDINE-TRANSPORT; HL-60 LEUKEMIA; MAMMALIAN-CELLS; MONOCYTIC DIFFERENTIATION; HUMAN-ERYTHROCYTES	NB4 cells are the only bona fide in vitro model of human acute promyelocytic leukemia. We have examined cytidine and guanosine transport in this cell fine and characterized a novel guanosine-specific transporter. Cytidine transport occurred predominately by equilibrative nitrobenzylthioinosine (NBMPR)-sensitive (es) transport, In the presence of Na+, guanosine at various concentrations accumulated at lease 6-fold above equilibrium. Th initial rate of guanosine transport in Na+ buffer decreased by 75% with the addition of 1 mu M NBMPR and the IC50 for NBMPR inhibition was 0.7 +/- 0.1 mM. Replacement of Na+ with choline also resulted in a 75% decrease in total guanosine transport, Tbe potent inhibition of guanosine transport by NBMPR and the loss of transport in choline suggested that a Na+-dependent NBMPR-sensitive transporter was responsible for the majority of guanosine uptake, This concentrative, sensitive transporter is Na+ dependent with a stoichiometric coupling ratio of 1:1. This novel transporter, referred to as csg, is guanosine-specific with total guanosine transport inhibited by only 50% in the presence of 1 mM competing nucleosides, HL-60, acute myelocytic leukemia cells, do not exhibit csg activity while L1210, murine acute lymphocytic leukemia cells, exhibit csg transport, The presence of the csg transporter suggests an important role for guanosine in particular forms of leukemia and may provide a new target for cytotoxic therapy.	UNIV GUELPH, DEPT HUMAN BIOL & NUTR SCI, GUELPH, ON N1G 2W1, CANADA	University of Guelph								BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BHATIA M, 1994, LEUKEMIA, V8, P1744; BOUMAH CE, 1992, BIOCHEM J, V288, P987, DOI 10.1042/bj2880987; BURRES NS, 1986, J CELL PHYSIOL, V128, P375, DOI 10.1002/jcp.1041280305; CARVER JD, 1995, J NUTR BIOCHEM, V6, P58, DOI 10.1016/0955-2863(94)00019-I; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHEN SF, 1986, CANCER RES, V46, P3449; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; DALTON WT, 1988, BLOOD, V71, P242; FIDEU MD, 1993, CELL MOL NEUROBIOL, V13, P493, DOI 10.1007/BF00711458; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; GOH LB, 1993, BIOCHEM J, V294, P693, DOI 10.1042/bj2940693; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; JACKSON RC, 1980, CANCER RES, V40, P1286; JAKOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; JARVIS SM, 1989, BIOCHEM SOC T, V17, P448, DOI 10.1042/bst0170448; JONES KW, 1994, BRAIN RES, V660, P104, DOI 10.1016/0006-8993(94)90844-3; LANOTTE M, 1991, BLOOD, V77, P1080; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; LEE CW, 1988, BIOCHIM BIOPHYS ACTA, V942, P139, DOI 10.1016/0005-2736(88)90283-0; MECKLINGGILL KA, 1992, BIOCHEM J, V282, P147, DOI 10.1042/bj2820147; MECKLINGGILL KA, 1993, J CELL PHYSIOL, V155, P530, DOI 10.1002/jcp.1041550311; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; Segel I.H., 1975, ENZYME KINETICS; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SOKOLOSKI JA, 1991, BIOCHEM J, V280, P515, DOI 10.1042/bj2800515; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TRICOT GJ, 1987, CANCER RES, V47, P4988; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; VOET D, 1990, BIOCHEMISTRY-US, P740; WEBER G, 1988, ADV ENZYME REGUL, V27, P405, DOI 10.1016/0065-2571(88)90029-5; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WOFFENDIN C, 1987, BIOCHIM BIOPHYS ACTA, V903, P18, DOI 10.1016/0005-2736(87)90151-9; WRIGHT DG, 1987, BLOOD, V69, P334; WU XC, 1992, J BIOL CHEM, V267, P8813; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	53	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18026	18032		10.1074/jbc.272.29.18026	http://dx.doi.org/10.1074/jbc.272.29.18026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218431	hybrid			2022-12-27	WOS:A1997XL73500021
J	Fraaije, MW; vanBerkel, WJH				Fraaije, MW; vanBerkel, WJH			Catalytic mechanism of the oxidative demethylation of 4-(methoxymethyl)phenol by vanillyl-alcohol oxidase - Evidence for formation of a p-quinone methide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE OXIDASE; PENICILLIUM-SIMPLICISSIMUM; SUBSTRATE; CRESOL	The catalytic mechanism for the oxidative demethylation of 4-(methoxymethyl)phenol by the covalent flavoprotein vanillyl-alcohol oxidase was studied, Using (H2O)-O-18, it was found that the carbonylic oxygen atom from the product 4-hydroxybenzaldehyde originates from a water molecule. Oxidation of vanillyl alcohol did not result in any incorporation of O-18. Enzyme-monitored turnover experiments revealed that for both substrates a process involving flavin reduction is rate determining, During anaerobic reduction of vanillyl-alcohol oxidase by 4-(methoxymethyl)phenol, a relatively stable spectral intermediate is formed, Deconvolution of its spectral characteristics showed a typical ps-independent absorption maximum at 364 nm (epsilon(364 nm) = 46 mM(-1) cm(-1)). A similar transient species was observed upon anaerobic reduction by vanillyl alcohol. The rate of flavin reduction and synchronous intermediate formation by 4-(methoxymethyl)phenol is 3.3 s(-1) and is fast enough to account for turnover (3.1 s(-1)). The anaerobic decay of the intermediate was too slow (0.01 s(-1)) to be of catalytical relevance, The reduced binary complex is rapidly reoxidized (1.5 x 10(5) M-1 s(-1)) and is accompanied with formation and release of product. Oxidation of free-reduced enzyme is an even faster process (3.1 x 10(5) M-1 s(-1)). The kinetic data for the oxidative demethylation of 4-(methoxymethyl)phenol are in accordance with a ternary complex mechanism in which the reduction rate is rate-limiting. It is proposed that, upon reduction, a binary complex is produced composed of the p-quinone methide of 4-(methoxymethyl)phenol and reduced enzyme.	AGR UNIV WAGENINGEN,DEPT BIOCHEM,NL-6703 HA WAGENINGEN,NETHERLANDS	Wageningen University & Research			van Berkel, Willem J.H./O-2431-2014; Fraaije, Marco/E-8421-2014	van Berkel, Willem J.H./0000-0002-6551-2782; Fraaije, Marco/0000-0001-6346-5014				DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DIAO L, 1995, J AM CHEM SOC, V117, P5369, DOI 10.1021/ja00124a024; FILAR LJ, 1960, TETRAHEDRON LETT, V25, P9; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; FRAAIJE MW, 1997, FLAVINS FLAVOPROTEIN, V12; GEISSLER J, 1986, EUR J BIOCHEM, V160, P93, DOI 10.1111/j.1432-1033.1986.tb09944.x; GHISLA S, 1979, J BIOL CHEM, V254, P662; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; LEARY G, 1972, J CHEM SOC PERK T 2, P640, DOI 10.1039/p29720000640; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; MENON V, 1995, BIOORG CHEM, V23, P42, DOI 10.1006/bioo.1995.1004; Palmer G, 1968, BIOL OXIDATIONS, P263; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; TAN AK, 1993, BIOCHEMISTRY-US, V32, P2137, DOI 10.1021/bi00060a003; THOMPSON D, 1989, J BIOL CHEM, V264, P1016; THOMPSON DC, 1995, BIOCHEM BIOPH RES CO, V209, P6, DOI 10.1006/bbrc.1995.1462; THOMPSON DC, 1995, CHEM RES TOXICOL, V8, P55, DOI 10.1021/tx00043a007; VANBERKEL WJH, 1997, Patent No. 0710289	27	72	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18111	18116		10.1074/jbc.272.29.18111	http://dx.doi.org/10.1074/jbc.272.29.18111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218444	hybrid, Green Published			2022-12-27	WOS:A1997XL73500034
J	Larrain, J; CizmeciSmith, G; Troncoso, V; Stahl, RC; Carey, DJ; Brandan, E				Larrain, J; CizmeciSmith, G; Troncoso, V; Stahl, RC; Carey, DJ; Brandan, E			Syndecan-1 expression is down-regulated during myoblast terminal differentiation - Modulation by growth factors and retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; HEPARAN-SULFATE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FACTOR-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; MESENCHYMAL INTERACTIONS; MUSCLE DEVELOPMENT; SODIUM-BUTYRATE; BASAL LAMINA	Syndecan-1 is an integral membrane proteoglycan involved in the interaction of cells with extracellular matrix proteins and growth factors. It is transiently expressed in several condensing mesenchymal tissues after epithelial induction. In this study we evaluated the expression of syndecan-1 during skeletal muscle differentiation. The expression of syndecan-1 as determined by Northern blot analyses and immunofluorescence microscopy is down-regulated during differentiation. The transcriptional activity of a syndecan-1 promoter construct is also down-regulated in differentiating muscle cells. The decrease in syndecan-1 gene expression is not dependent on the presence of E-boxes, binding sites for the MyoD family of transcription factors in the promoter region, or myogenin expression. Deletion of the region containing the E-boxes or treatment of differentiating cells with sodium butyrate, an inhibitor of myogenin expression, had no effect on syndecan-1 expression. Basic fibroblast growth factor and transforming growth factor type beta, which are inhibitors of myogenesis, had little effect on syndecan-1 expression. When added together, however, they induced syndecan-1 expression. Retinoic acid, an inducer of myogenesis, inhibited syndecan-1 expression and abolished the effect of the growth factors. These results indicate that syndecan-1 expression is down-regulated during myogenesis and that growth factors and retinoic acid modulate syndecan-1 expression by a mechanism that is independent of myogenin.	PONTIFICIA UNIV CATOLICA CHILE, FAC CIENCIAS BIOL, DEPT BIOL CELULAR & MOL, SANTIAGO, CHILE; WEIS CTR RES, DANVILLE, PA 17822 USA	Pontificia Universidad Catolica de Chile			Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059	FIC NIH HHS [TW 00093] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; Brandan E, 1996, EUR J CELL BIOL, V71, P170; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; CAMPOS A, 1993, EUR J BIOCHEM, V216, P587, DOI 10.1111/j.1432-1033.1993.tb18178.x; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FISZMAN MY, 1980, EXP CELL RES, V126, P31, DOI 10.1016/0014-4827(80)90467-X; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LARRAIN J, 1997, IN PRESS EXP CELL RE; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LUNDOLPH DC, 1995, FASEB J, V9, P1595; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; MOORE JW, 1991, DEVELOPMENT, V111, P741; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAIRIO S, 1992, DEV BIOL, V152, P221; VAIRIO S, 1991, DEV BIOL, V147, P322; VANSWEARINGEN J, 1995, DEV BIOL, V170, P321, DOI 10.1006/dbio.1995.1218; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	60	69	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18418	18424		10.1074/jbc.272.29.18418	http://dx.doi.org/10.1074/jbc.272.29.18418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218485	hybrid			2022-12-27	WOS:A1997XL73500075
J	McCarthy, TL; Ji, CH; Shu, H; Casinghino, S; Crothers, K; Rotwein, P; Centrella, M				McCarthy, TL; Ji, CH; Shu, H; Casinghino, S; Crothers, K; Rotwein, P; Centrella, M			17 beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; ESTROGEN-RECEPTOR GENE; PARATHYROID-HORMONE; OVARIECTOMIZED RATS; BONE LOSS; CANCELLOUS BONE; ENRICHED CULTURES; INTERLEUKIN-6 PRODUCTION; TRANSCRIPTIONAL CONTROL; HYPOPHYSECTOMIZED RATS	Insulin-like growth factor-I (IGF-I) is a key factor in bone remodeling. In osteoblasts, IGF-I synthesis is enhanced by parathyroid hormone and prostaglandin E-2 (PGE(2)) through cAMP-activated protein kinase. In rats, estrogen loss after ovariectomy leads to a rise in serum IGF-I and an increase in bone remodeling, both of which are reversed by estrogen treatment, To examine estrogen-dependent regulation of IGF-P expression at the molecular level, primary fetal rat osteoblasts were co-transfected with the estrogen receptor (hER, to ensure active ER expression), and luciferase reporter plasmids controlled by promoter I of the rat IGF-I gene (HGF-P PP), used exclusively in these cells, Bs reported, 1 mu M PGE(2) increased IGF-I P1 activity by 5-fold. 17 beta-Estradiol alone had no effect, but dose-dependently suppressed the stimulatory effect of PGE(2) by up to 90% (ED50 similar to-0.1 nM). This occurred within 3 In, persisted for at least 16 h, required ER, and appeared specific, since 17 alpha-estradiol was 100-300-fold less effective, By contrast, 17 beta-Estradiol stimulated estrogen response element (ERE)dependent reporter expression by up to 10-fold, 17 beta-Estradiol also suppressed an HGF-I PP. construct retaining only minimal promoter sequence required for cAMP-dependent gene activation, but did not affect the 60-fold increase in cAMP induced by PGE(2). There is no consensus ERE in rat HGF-H P1, suggesting novel downstream interactions in the cAMP pathway that normally enhances IGF-I expression ist skeletal cells, To explore this, nuclear extract from osteoblasts expressing hER were examined by electrophoretic mobility shift assay using the atypical cAMP response element in IGF-I P1. Estrogen alone did not cause DNA-protein binding, while PGE(2) induced a characteristic gel shift complex. eo-treatment with both hormones caused a gel shift greatly diminished in intensity, consistent with their combined effects on IGF-H promoter activity. Nonetheless, hER did not bind IGF-I cAMP response element or any adjacent sequences,These results provide new molecular evidence that estrogen may temper the biological effects of hormones acting through cAMP to regulate skeletal IGF-I expression and activity,.	OREGON HLTH SCI UNIV,DIV MOL MED,PORTLAND,OR 97201	Oregon Health & Science University	McCarthy, TL (corresponding author), YALE UNIV,SECT PLAST SURG,SCH MED,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.		Rotwein, Peter/R-5783-2019	Crothers, Kristina/0000-0001-9702-0371; Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449, R01DK047421] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37449, DK47421] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BAGI C, 1995, BONE, V16, P559, DOI 10.1016/8756-3282(95)00078-R; BAGI CM, 1994, J BONE MINER RES, V9, P1301; Baron Roland E., 1996, P3; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Borski RJ, 1996, ENDOCRINOLOGY, V137, P3253, DOI 10.1210/en.137.8.3253; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CANTATORE FP, 1995, CLIN RHEUMATOL, V14, P157, DOI 10.1007/BF02214935; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; DEMPSTER DW, 1995, BONE, V16, P157, DOI 10.1016/S8756-3282(94)00024-7; Diamond T, 1996, OSTEOPOROSIS INT, V6, P329, DOI 10.1007/BF01623394; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; HSUEH AJW, 1989, ENDOCRINOLOGY, P1929; JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756-3282(90)90078-D; JEE WSS, 1992, BONE, V13, P153, DOI 10.1016/8756-3282(92)90005-H; Kaji H, 1996, ENDOCRINOLOGY, V137, P2217, DOI 10.1210/en.137.6.2217; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KALU DN, 1994, BONE MINER, V25, P135, DOI 10.1016/S0169-6009(08)80255-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, V313, P36; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; OLDHAM SB, 1992, OSTEOPOROSIS INT, V2, P174, DOI 10.1007/BF01623923; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAY A, 1994, J BIOL CHEM, V269, P12940; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563; SALIH MA, 1993, BONE MINER, V23, P285, DOI 10.1016/S0169-6009(08)80104-3; SATO F, 1993, CALCIFIED TISSUE INT, V53, P111, DOI 10.1007/BF01321888; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SHEN V, 1992, CALCIFIED TISSUE INT, V50, P214, DOI 10.1007/BF00296285; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SKOTTNER A, 1987, J ENDOCRINOL, V112, P123, DOI 10.1677/joe.0.1120123; SLOOTWEG MC, 1992, J ENDOCRINOL, V132, P433, DOI 10.1677/joe.0.1320433; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEPAN JJ, 1987, BONE, V8, P279; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TURNER RT, 1992, ENDOCRINOLOGY, V131, P883, DOI 10.1210/en.131.2.883; TURNER RT, 1993, J BONE MINER RES, V8, P359; TURNER RT, 1991, MODERN CONCEPTS INSU, P143; TURNER RT, 1994, ENDOCR REV, V15, P129; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823; Zofkova I, 1996, BONE, V19, P227	68	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18132	18139		10.1074/jbc.272.29.18132	http://dx.doi.org/10.1074/jbc.272.29.18132			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218447	hybrid			2022-12-27	WOS:A1997XL73500037
J	Notarnicola, SM; Mulcahy, HL; Lee, J; Richardson, CC				Notarnicola, SM; Mulcahy, HL; Lee, J; Richardson, CC			The acidic carboxyl terminus of the bacteriophage T7 gene 4 helicase/primase interacts with T7 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; LAGGING STRAND SYNTHESIS; NUCLEOTIDE-BINDING SITE; DEOXYRIBONUCLEIC-ACID; REPLICATION INVITRO; TEMPLATE RECOGNITION; T7-DNA POLYMERASE; RNA PRIMER; PROTEIN; PRIMASE	The gene 4 proteins of bacteriophage T7 provide both primase and helicase activities at the replication fork. Efficient DNA replication requires that the functions of the gene 4 protein be coordinated with the movement of the T7 DNA polymerase. We show that a carboxyl-terminal domain of the gene 4 protein is required for interaction with T7 DNA polymerase during leading strand DNA synthesis. The carboxyl terminus of the gene 4 protein is highly acidic: of the 17 carboxyl-terminal amino acids 7 are negatively charged. Deletion of the coding region for these 17 residues results in a gene 4 protein that cannot support the growth of T7 phage. The purified mutant gene 4 protein has wild-type levels of both helicase and primase activities; however, DNA synthesis catalyzed by T7 DNA polymerase on a duplex DNA substrate is stimulated by this mutant protein to only about 5% of the level of synthesis obtained with wildtype protein. The mutant gene 4 protein can form hexamers and bind single-stranded DNA, but as determined by native PAGE analysis, the protein cannot form a stable complex with the DNA polymerase. The mutant gene 4 protein can prime DNA synthesis normally, indicating that for lagging strand synthesis a different set of helicase/primase-DNA polymerase interactions are involved. These findings have implications for the mechanisms coupling leading and lagging strand DNA synthesis at the T7 replication fork.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; SUFFOLK UNIV,DEPT BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Suffolk University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM S, 1996, CELL, V84, P343; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599; Yang XM, 1996, J BIOL CHEM, V271, P24207, DOI 10.1074/jbc.271.39.24207	50	81	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18425	18433		10.1074/jbc.272.29.18425	http://dx.doi.org/10.1074/jbc.272.29.18425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218486	Green Published, hybrid			2022-12-27	WOS:A1997XL73500076
J	Sullivan, PM; Mezdour, H; Aratani, Y; Knouff, C; Najib, J; Reddick, RL; Quarfordt, SH; Maeda, N				Sullivan, PM; Mezdour, H; Aratani, Y; Knouff, C; Najib, J; Reddick, RL; Quarfordt, SH; Maeda, N			Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-ARGININE INTERCHANGE; RECEPTOR-BINDING ACTIVITY; TRANSGENIC MICE; LIPOPROTEIN RECEPTOR; PLASMA-LIPOPROTEINS; E POLYMORPHISM; C-I; HYPERLIPOPROTEINEMIA; EXPRESSION; IDENTIFICATION	Apolipoprotein (apo) E, a constituent of several lipoproteins, is a ligand for the low density lipoprotein receptor, and this interaction is important for maintaining cholesterol and triglyceride homeostasis. We have use a gene replacement strategy to generate mice that express the human apoE3 isoform in place of the mouse protein. The levels of apoE mRNA in various tissues are virtually the same in the human apoE3 homozygous (3/3) mice and their littermates having the wild type mouse allele (+/+). Total cholesterol and triglyceride levels in fasted plasma from the 3/3 mice were not different from those in the +/+ mice, when maintained on a normal (low fat) chow diet. We found, however, notable differences in the distribution of plasma lipoproteins and apo-lipoprotein E between the two groups: beta-migrating lipoproteins and plasma apoB100 levels are decreased in the 3/3 mice, and the apoE distribution is shifted from high density lipoproteins to larger lipoprotein particles. In addition, the fractional catabolic rate of exogenously administered remnant particles without apoE was 6-fold slower in the 3/3 mice compared with the +/+ mice. When the 3/3 and +/+ animals were fed a high fat/high cholesterol diet, the 3/3 animals responded with a dramatic increase (5-fold) in total cholesterol compared with the +/+ mice (1.5-fold), and after 12 weeks on this same diet the 3/3 animals developed significantly (at least 13-fold) larger atherosclerotic plaques in the aortic sinus area than the +/+ animals. Thus the structural differences between human APOE3 and mouse ApoE proteins are sufficient to cause an increased susceptibility to dietary-induced hypercholesterolemia and atherosclerosis in the 3/3 mice.	UNIV N CAROLINA, DEPT PATHOL & LAB MED, CHAPEL HILL, NC 27599 USA; INST PASTEUR, LILLE, FRANCE; DURHAM VA HOSP, DEPT MED, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA	University of North Carolina; University of North Carolina Chapel Hill; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Duke University					NHLBI NIH HHS [HL42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1982, J BIOL CHEM, V257, P9788; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOERWINKLE E, 1987, AM J MED GENET, V27, P567, DOI 10.1002/ajmg.1320270310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; FAZIO S, 1994, J LIPID RES, V35, P408; GREEN EK, 1991, CLIN CHEM, V37, P1263; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IMAIZUMI K, 1978, J LIPID RES, V19, P712; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LANDIS BA, 1987, AM J PHYSIOL, V252, pG805, DOI 10.1152/ajpgi.1987.252.6.G805; LEROY A, 1988, J IMMUNOASSAY, V9, P309, DOI 10.1080/01971528808053219; MAHLEY R W, 1978, P181; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J BIOL CHEM, V252, P3980; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PAIK YK, 1988, J BIOL CHEM, V263, P13340; QUARFORDT SH, 1995, J LIPID RES, V36, P1227; RALL SC, 1982, J BIOL CHEM, V257, P4171; ROBINSON SF, 1978, BIOCHIM BIOPHYS ACTA, V541, P492, DOI 10.1016/0304-4165(78)90158-7; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH JD, 1990, J BIOL CHEM, V265, P14709; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UTERMANN G, 1982, RES CLIN LAB, V12, P23; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YANG YW, 1991, J MOL EVOL, V32, P469, DOI 10.1007/BF02102649; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	47	382	394	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17972	17980		10.1074/jbc.272.29.17972	http://dx.doi.org/10.1074/jbc.272.29.17972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218423	Green Published, hybrid			2022-12-27	WOS:A1997XL73500013
J	Eguchi, H; Ikuta, T; Tachibana, T; Yoneda, Y; Kawajiri, K				Eguchi, H; Ikuta, T; Tachibana, T; Yoneda, Y; Kawajiri, K			A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator hypoxia-inducible factor 1 beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED TRANSCRIPTION FACTOR; PROTEIN IMPORT; AH-RECEPTOR; FUNCTIONAL DOMAINS; CYTOSOLIC FACTORS; DIOXIN RECEPTOR; DNA-BINDING; IDENTIFICATION; TRANSPORT; SEQUENCE	Aryl hydrocarbon receptor nuclear translocator (ARNT) is a component of the transcription factors, aryl hydrocarbon receptor (AhR) and hypoxia-inducible factor 1, which transactivate their target genes, such as CYP1A1 and erythropoietin, in response to xenobiotic aromatic hydrocarbons and to low O-2 concentration, respectively, Since ARNT was isolated as a factor required for the nuclear translocation of AhR from the cytoplasm in response to xenobiotics, the subcellular localization of ARNT has been of great interest, In this investigation, we analyzed the subcellular distribution of ARNT using transient expression of a fusion gene with P-galactosidase and microinjection of recombinant proteins containing various fragments of ARNT in the linker region of glutathione S-transferase/green fluorescent protein, We found a clear nuclear localization of ARNT in the absence of exogenous li,bands to AhR, and identified the nuclear localization signal (NLS) of amino acid residues 39-61, The characterized NLS consists of 23 amino acids, and can be classified as a novel variant of the bipartite type on the basis of having tyro separate regions responsible for efficient nuclear translocation activity, but considerable deviation of the sequence from the consensus of the classical bipartite type. NLSs. Like the well characterized NLS of the SV40 T-antigen, this variant bipartite type of ARNT NLS was also mediated by the two components of nuclear pore targeting complex, PTAC58 and PTAC97, to target to the nuclear rim in an in vitro nuclear transport assay.	SAITAMA CANC CTR, RES INST, DEPT BIOCHEM, INA, SAITAMA 362, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN	Osaka University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUJIIKURIYAMA Y, 1994, EXP CLIN IMMUNOGENET, V11, P65; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri K., 1996, CYTOCHROMES P450 MET, P77; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	51	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17640	17647		10.1074/jbc.272.28.17640	http://dx.doi.org/10.1074/jbc.272.28.17640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211913	hybrid			2022-12-27	WOS:A1997XK16500056
J	Acker, J; deGraaff, M; Cheynel, I; Khazak, V; Kedinger, C; Vigneron, M				Acker, J; deGraaff, M; Cheynel, I; Khazak, V; Kedinger, C; Vigneron, M			Interactions between the human RNA polymerase II subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; STRESS SURVIVAL; YEAST; TRANSCRIPTION; MOLECULES; SEQUENCE; ENCODES; PORTION; COMMON	As an initial approach to characterizing the molecular structure of the human RNA polymerase II (hRPB), we systematically investigated the protein-protein contacts that the subunits of this enzyme may establish with each other, To this end, we applied a glutathione S-transferase-pulldown assay to extracts from Sf9 insect cells, which were coinfected with all possible combinations of recombinant baculoviruses expressing hRPB subunits, either as untagged polypeptides or as glutathione S-transferase fusion proteins, This is the first comprehensive study of interactions between eukaryotic RNA polymerase subunits; among the 116 combinations of hRPB subunits tested, 56 showed significant to strong interactions, whereas 60 were negative, Within the intricate network of interactions, subunits hRPB3 and hRPB5 play a central role in polymerase organization, These subunits, which are able to homodimerize and to interact, may constitute the nucleation center for polymerase assembly, by providing a large interface to most of the other subunits.	ULP,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Acker, Joël/F-5138-2010	Acker, Joël/0000-0002-0855-875X				ACKER J, 1994, DNA SEQUENCE, V4, P329, DOI 10.3109/10425179409020860; ACKER J, 1993, NUCLEIC ACIDS RES, V21, P5345, DOI 10.1093/nar/21.23.5345; ACKER J, 1992, J MOL BIOL, V226, P1295, DOI 10.1016/0022-2836(92)91071-V; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; ARCHAMBAULT J, 1990, MOL CELL BIOL, V10, P6123, DOI 10.1128/MCB.10.12.6123; BOCCO JL, 1993, ONCOGENE, V8, P2977; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEONG J, 1994, EMBO J, V14, P143; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fanciulli M, 1996, FEBS LETT, V384, P48, DOI 10.1016/0014-5793(96)00277-3; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; MCKUNE K, 1994, MOL CELL BIOL, V14, P4155, DOI 10.1128/MCB.14.6.4155; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PATI UK, 1990, J BIOL CHEM, V265, P8400; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; PATI UK, 1989, J BIOL CHEM, V264, P13114; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Treich Isabelle, 1992, Gene Expression, V2, P31; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	44	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16815	16821		10.1074/jbc.272.27.16815	http://dx.doi.org/10.1074/jbc.272.27.16815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201987	hybrid			2022-12-27	WOS:A1997XH44600019
J	Boumans, H; vanGaalen, MCM; Grivell, LA; Berden, JA				Boumans, H; vanGaalen, MCM; Grivell, LA; Berden, JA			Differential inhibition of the yeast bc(1) complex by phenanthrolines and ferroin - Implications for structure and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; PROTONMOTIVE Q-CYCLE; PHOTOSYNTHETIC REACTION CENTER; 17-KDA SUBUNIT-VI; SACCHAROMYCES-CEREVISIAE; UBIQUINONE OXIDOREDUCTASE; RHODOPSEUDOMONAS-VIRIDIS; BC1 COMPLEX; MITOCHONDRIA; PROTEIN	o-Phenanthroline and m-phenanthroline both inhibit the electron transfer activity of lauryl maltoside-solubilized yeast be, complex progressively with time, Presteady state kinetics indicate that these compounds bind to the complex on the intermembrane space side, thereby blocking reduction of cytochrome b via the ubiquinol oxidation site, o-Phenanthroline is additionally capable of chelating an iron atom derived from the Rieske Fe-S cluster, thereby distorting the structure of the Rieske protein, EPR analysis shows that the secondary effect of o-phenanthroline occurs after initial inactivation and that m-phenanthroline, which lacks chelating activity, does not affect the Rieske Fe-S cluster, Spectral analysis shows that the b and c(1) cytochromes are still dithionite-reducible after inactivation by o-phenanthroline, indicating that they remain intact, Inactivation by o-phenanthroline can be prevented by the addition of Fe2+, Surprisingly, ferroin, the o-phenanthroline-ferrous sulfate complex, also inhibits the bc(1) complex activity, In contrast to o-phenanthroline, this effect is instantaneous, The two types of inhibition are clearly distinguishable by pre-steady-state reduction kinetics, Interestingly, ferroin can only inhibit electron transfer activity by about 50%, This behavior is discussed in relation to the dimeric structure of the bc(1) complex, and we conclude that ferroin binds to only one of the two protomers, The rate of inactivation by o-phenanthroline is dependent on the incubation temperature and can be quantitated in terms of the half-life for a certain temperature, the time at which the be, activity is reduced to 50%. In contrast to the solubilized form, the bc(1) complex in intact mitochondria is insensitive to o-phenanthroline, suggesting that the inactivation rate by o-phenanthroline is dependent on accessibility of the complex to the agent. Reaction with o-phenanthroline is thus a useful technique for study of structural stability of the bc(1) complex under different conditions and should provide a sensitive tool for determination of the relative stability of mutant enzymes.	UNIV AMSTERDAM, EC SLATER INST BIOCHEM RES, NL-1018 TV AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, BIOCTR, DEPT MOL CELL BIOL, MOL BIOL SECT, NL-1018 TV AMSTERDAM, NETHERLANDS	University of Amsterdam; University of Amsterdam								ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BOWYER JR, 1981, FEBS LETT, V126, P93, DOI 10.1016/0014-5793(81)81041-1; BRANDT U, 1994, J BIOL CHEM, V269, P12947; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; FINEL M, 1994, FEBS LETT, V339, P142, DOI 10.1016/0014-5793(94)80402-8; GIESSLER A, 1994, EUR J BIOCHEM, V222, P147, DOI 10.1111/j.1432-1033.1994.tb18852.x; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; LANCASTER CRD, 1997, IN PRESS REACTION CT; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; Link TA, 1996, BBA-BIOENERGETICS, V1275, P54, DOI 10.1016/0005-2728(96)00050-3; LJUNGDAHL PO, 1986, METHOD ENZYMOL, V126, P181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRES CAM, 1991, BIOCHIM BIOPHYS ACTA, V1057, P51, DOI 10.1016/S0005-2728(05)80083-0; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; NAKAI T, 1994, J BIOCHEM-TOKYO, V116, P752, DOI 10.1093/oxfordjournals.jbchem.a124592; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NIEBOER P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P90, DOI 10.1016/0167-4838(92)90472-P; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; PFISTER K, 1981, P NATL ACAD SCI-BIOL, V78, P981, DOI 10.1073/pnas.78.2.981; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SINNING I, 1992, TRENDS BIOCHEM SCI, V17, P150, DOI 10.1016/0968-0004(92)90324-3; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; van Gelder B F, 1978, Methods Enzymol, V53, P125; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YASUHARA T, 1994, J BIOCHEM-TOKYO, V115, P1166, DOI 10.1093/oxfordjournals.jbchem.a124474; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16753	16760		10.1074/jbc.272.27.16753	http://dx.doi.org/10.1074/jbc.272.27.16753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201979	hybrid, Green Published			2022-12-27	WOS:A1997XH44600011
J	Lange, Y; Ye, J; Chin, J				Lange, Y; Ye, J; Chin, J			The fate of cholesterol exiting lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN FIBROBLASTS; PLASMA-MEMBRANE; INTRACELLULAR-TRANSPORT; CELLS; PROGESTERONE; HOMEOSTASIS; SUPPRESSION; INHIBITION; METABOLISM	Cholesterol released from ingested low density lipoproteins in lysosomes moves both to the plasma membrane and to the endoplasmic reticulum (ER) where it is re-esterified, Whether cholesterol can move directly from lysosomes to ER or first must traverse the plasma membrane has not been established, To examine this question, the endocytic pathway of rat hepatoma cells was loaded at 18 degrees C with low density lipoproteins (LDL) labeled with [H-3]cholesteryl linoleate, and the label then was chased at 37 degrees C, The hydrolysis of the accumulated ester proceeded linearly for several hours, Almost all of the released [H-3]cholesterol moved to the plasma membrane rapidly and without a discernable lag, In contrast, the re-esterification in the ER of the released [H-3]cholesterol showed a characteristic lag of 0.5-1 h, These data are inconsistent with direct cholesterol transfer from lysosomes to ER; rather, they suggest movement through the plasma membrane. Furthermore, we found that progesterone, imipramine and 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one (U18666A) strongly inhibited the re-esterification of lysosomal cholesterol in the ER, However, contrary to previous reports, they did not block transfer of [H-3]cholesterol from lysosomes to the cell surface, Therefore, the site of action of these agents was not at the lysosomes. We suggest instead that their known ability to block cholesterol movement from the plasma membrane to the ER accounts for the inhibition of lysosomal cholesterol esterification. These findings are consistent with the hypothesis that cholesterol released from lysosomes passes through the plasma membrane or, its way to the ER rather than proceeding there directly, As a result, ingested cholesterol is subject to the same homeostatic regulation as the bulk of cell cholesterol, which is located in the plasma membrane.	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University	Lange, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PATHOL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA.		Lange, Yvonne/A-7794-2009		NHLBI NIH HHS [HL 28448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; FIELDING CJ, 1985, BIOCH LIPIDS MEMBRAN, P404; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SUCKLING KE, 1985, J LIPID RES, V26, P647; Underwood KW, 1996, J LIPID RES, V37, P1556	24	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17018	17022		10.1074/jbc.272.27.17018	http://dx.doi.org/10.1074/jbc.272.27.17018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202016	hybrid			2022-12-27	WOS:A1997XH44600048
J	Ottilie, S; Diaz, JL; Chang, J; Wilson, G; Tuffo, KM; Weeks, S; McConnell, M; Wang, Y; Oltersdorf, T; Fritz, LC				Ottilie, S; Diaz, JL; Chang, J; Wilson, G; Tuffo, KM; Weeks, S; McConnell, M; Wang, Y; Oltersdorf, T; Fritz, LC			Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DEFICIENT MICE; HOMOLOG BAK; PROTEIN; APOPTOSIS; FAMILY; SURVIVAL; GENE; HETERODIMERIZATION; DISTINCT	Interactions among proteins in the Bcl-2 family regulate the onset of programmed cell death. Previous work has shown that the death-inhibiting family members Bcl-2 and Bcl-x(L) form heterodimers with the death-promoting homologue Bax and that certain site-directed mutants of Bcl-2 and Bcl-x(L) lose both biological activity and the ability to bind Bax. To better understand the structural basis of heterodimer formation, we have used a yeast two-hybrid assay to screen for mutants of Bax that regain the ability to bind to these inactive Bcl-2(G145A) and Bcl-x(L)(G138A) mutants. This screen identified a series of C-terminally truncated Fax molecules that contain complete BH3 (Bcl-2 homology domain 3) domains but that have lost BH1 and BH2 sequences. These results indicate that while the Bcl-2 and Bcl-x(L) mutants fail to bind full-length Bax, they still retain a binding site for the critical BH3 domain. This suggests that conformational constraints in full-length Pax regulate its ability to bind to other Bcl-2 family members. Furthermore, we demonstrate that the normally inert Bcl-2(G145A) mutant effectively blocks apoptosis induced by a C-terminally truncated Fax molecule, but does not block apoptosis induced by wild-type Bax. This demonstrates that cell protection can be effected by directly binding pro-apoptotic members of the Bcl-2 family.			Ottilie, S (corresponding author), IDUN PHARMACEUT INC, 11085 N TORREY PINES RD, SUITE 300, LA JOLLA, CA 92037 USA.							BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DIAZ JL, 1997, J BIOL CHEM, V272, P11650; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gibson L, 1996, ONCOGENE, V13, P665; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Han J, 1996, MOL CELL BIOL, V16, P5857; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG H, 1995, BIOCHEM BIOPH RES CO, V208, P920	37	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16955	16961		10.1074/jbc.272.27.16955	http://dx.doi.org/10.1074/jbc.272.27.16955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202007	hybrid			2022-12-27	WOS:A1997XH44600039
J	Tortosa, P; Aymerich, S; Lindner, C; Saier, MH; Reizer, J; LeCoq, D				Tortosa, P; Aymerich, S; Lindner, C; Saier, MH; Reizer, J; LeCoq, D			Multiple phosphorylation of SacY, a Bacillus subtilis transcriptional antiterminator negatively controlled by the phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; ESCHERICHIA-COLI; GENE-EXPRESSION; BGL OPERON; PROTEIN; PHOSPHOENOLPYRUVATE; LEVANSUCRASE; MODULATION; INDUCTION; BACTERIA	The Bacillus subtilis SacY transcriptional antiterminator is a regulator involved in sucrose-promoted induction of the sacB gene, SacY activity is negatively controlled by enzyme I and HPr, the general energy coupling proteins of the phosphoenolpyruvate:sugar phosphotransferase system (PTS), and by SacX, a membranal protein homologous to SacP, the B. subtilis sucrose-specific PTS-permease. Previous studies suggested that the negative control exerted by the PTS oil bacterial antiterminators of the SacY family involves phosphoenolpyruvate-dependent phosphorylation by the sugar-specific PTS-permeases. However, data reported herein show direct phosphorylation of SacY by HPr(His similar to P) with no requirement for SacX, Experiments were carried out to determine the phosphorylatable residues in SacY, In silico analyses of SacY and its homologues revealed the modular structure of these proteins as well as four conserved histidines within two homologous domains (here designated P1 and P2), present in 14 distinct mRNA- and DNA-binding bacterial transcriptional regulators, Single or multiple substitutions of these histidyl residues were introduced in SacY by site-directed mutagenesis, and their effects on phosphorylation and antitermination activity were examined. In vitro phosphorylation experiments showed that SacY was phosphorylated on three of the conserved histidines. Nevertheless, in vivo studies using cells bearing a sacB'-lacZ reporter fusion, as well as SacY mutants lacking the phosphorylatable histidyls, revealed that only His-99 is directly involved in regulation of SacY antitermination activity.	INRA, CNRS ERS 567, LAB GENET MICROORGANISMES, F-78850 THIVERVAL GRIGNON, FRANCE; INST BIOL & CHIM PROT, CNRS UPR 412, F-69367 LYON 07, FRANCE; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego				Tortosa, Pablo/0000-0002-7928-7264; Le Coq, Dominique/0000-0001-5756-2280	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055434] Funding Source: NIH RePORTER; NIAID NIH HHS [5RO1 AI21702] Funding Source: Medline; NIGMS NIH HHS [9K01 GM55434] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERT CA, 1985, BIOCHEMISTRY-US, V24, P959, DOI 10.1021/bi00325a023; AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; AYMERICH S, 1987, MOL GEN GENET, V208, P114, DOI 10.1007/BF00330431; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GONZYTREBOUL G, 1987, J BACTERIOL, V169, P2287, DOI 10.1128/jb.169.5.2287-2290.1987; KRUGER S, 1995, J BACTERIOL, V177, P5590; Kruger S, 1996, J BACTERIOL, V178, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; MADADEVAN S, 1987, CELL, V50, P485; MANIVAL X, 1997, IN PRESS EMBO J; Miller J.H., 1972, EXPT MOL GENETICS; PIGGOT PJ, 1987, J BACTERIOL, V169, P1260, DOI 10.1128/jb.169.3.1260-1266.1987; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reizer Aiala, 1994, V25, P319; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; SHIMOTSU H, 1986, J BACTERIOL, V168, P380, DOI 10.1128/jb.168.1.380-388.1986; STEINMETZ M, 1986, ANN INST PASTEUR MIC, V137A, P3, DOI 10.1016/S0769-2609(86)80001-1; STEINMETZ M, 1994, GENE, V142, P79, DOI 10.1016/0378-1119(94)90358-1; STULKE J, 1995, J BACTERIOL, V177, P6928; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	40	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17230	17237		10.1074/jbc.272.27.17230	http://dx.doi.org/10.1074/jbc.272.27.17230			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202047	Green Published, hybrid			2022-12-27	WOS:A1997XH44600079
J	Nakajima, K; Murakami, M; Yanoshita, R; Samejima, Y; Karasawa, K; Setaka, M; Nojima, S; Kudo, I				Nakajima, K; Murakami, M; Yanoshita, R; Samejima, Y; Karasawa, K; Setaka, M; Nojima, S; Kudo, I			Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; CYTOSOLIC PHOSPHOLIPASE A(2); D-2 GENERATION; HL-60 CELLS; IGE; PURIFICATION; DEGRADATION; CHILDREN; PATHWAY; SUBUNIT	IgE-dependent and -independent activation of mouse bone marrow-derived mast cells (BMMC) elicited rapid and transient production of platelet-activating factor (PAF), which reached a maximal level by 2-5 min and was then degraded rapidly, returning to base-line levels by 10-20 min. Inactivation of PAF was preceded by the release of PAF acetylhydrolase (PAF-AH) activity, which reached a plateau by 3-5 min and paralleled the release of beta-hexosaminidase, a marker of mast cell exocytosis. Immunochemical and molecular biological studies revealed that the PAF-AH released from activated mast cells was identical to the plasma-type isoform. In support of the autocrine action of exocytosed PAF-AH, adding exogenous recombinant plasma-type PAF-AH markedly reduced PAF accumulation in activated BMMC. Furthermore, culture of BMMC with a combination of c-kit ligand, interleukin-1 beta and interleukin-10 for > 24 h led to an increase in plasma-type PAF-AH expression, accompanied by a reduction in stimulus-initiated PAF production. Collectively, these results suggest that plasma-type PAF-AH released from activated mast cells sequesters proinflammatory PAF produced by these cells, thereby revealing an intriguing anti-inflammatory aspect of mast cells.	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN; HOSHI UNIV,INST MED CHEM,SHINAGAWA KU,TOKYO 142,JAPAN; TEIKYO UNIV,FAC PHARMACEUT SCI,SAGAMIKO,KANAGAWA 19901,JAPAN	Showa University; Hoshi University; Teikyo University								Ashraf M, 1996, BIOCHEM J, V320, P965, DOI 10.1042/bj3200965; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HSIEH KH, 1993, J ALLERGY CLIN IMMUN, V91, P650, DOI 10.1016/0091-6749(93)90271-G; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Karasawa K, 1996, J BIOCHEM-TOKYO, V120, P838; LuKuo JM, 1996, J BIOL CHEM, V271, P22169, DOI 10.1074/jbc.271.36.22169; MARTIN TW, 1979, NATURE, V279, P250, DOI 10.1038/279250a0; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; Ogasawara T, 1997, J IMMUNOL, V158, P393; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUGA K, 1990, J BIOL CHEM, V265, P12363; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; YASUDA K, 1992, ENDOCRINOLOGY, V130, P708, DOI 10.1210/en.130.2.708	41	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19708	19713		10.1074/jbc.272.32.19708	http://dx.doi.org/10.1074/jbc.272.32.19708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242626	hybrid			2022-12-27	WOS:A1997XQ05900013
J	Liu, QJ; Huang, SS; Huang, JS				Liu, QJ; Huang, SS; Huang, JS			Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; AUTOCRINE TRANSFORMATION; KINASE; EXPRESSION; IDENTIFICATION; RESPONSIVENESS; SPECIFICITY; COMPLEXES; MECHANISM	The type V transforming growth factor beta (TGF-beta) is a 400-kDa nonproteoglycan membrane protein that co-expresses with the type I, type II, and type III TGF-beta receptors in most cell types, The type V TGF-beta receptor exhibits a Ser/Thr-specific protein kinase activity with distinct substrate specificity (Liu, Q., Huang, S. S., and Huang, J. (1994) J. Biol. Chem. 269, 9221-9226). In mink lung epithelial cells, the type V TGF-beta receptor was found to form heterocomplexes with the type I TGF-beta receptor by immunoprecipitation with antiserum to the type V TGF-beta receptor after I-125-TGF-beta affinity labeling or Trans(35)S-label metabolic labeling of the cells, The kinase activity of the type V TGF-beta receptor was stimulated after treatment of mink lung epithelial cells with TGF-beta. TGF-beta stimulation resulted in the growth inhibition of wild-type mink lung epithelial cells and to a lesser extent of the type I and type II TGF-beta receptor-defective mutants, although higher concentrations of TGF-beta were required for the growth inhibition of these mutants, TGF-beta was unable to induce growth inhibition in human colorectal carcinoma cells lacking the type V TGF-beta receptor but expressing the type I and type II TGF-beta receptors, These results suggest that the type V TGF-beta receptor can mediate the TGF-beta-induced growth inhibitory response in the absence of the type I or type II TGF-beta receptor, These results also support the hypothesis that loss of the type V TGF-beta receptor may contribute to the malignancy of certain carcinoma cells.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HUANG SS, 1988, J BIOL CHEM, V263, P12608; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU QJ, 1994, J BIOL CHEM, V269, P9221; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OGRADY P, 1992, J BIOL CHEM, V267, P21035; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P410; SHAH M, 1995, J CELL SCI, V108, P985; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18891	18895		10.1074/jbc.272.30.18891	http://dx.doi.org/10.1074/jbc.272.30.18891			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228067	hybrid			2022-12-27	WOS:A1997XM34200058
J	Martini, JF; Pezet, A; Guezennec, CY; Edery, M; PostelVinay, MC; Kelly, PA				Martini, JF; Pezet, A; Guezennec, CY; Edery, M; PostelVinay, MC; Kelly, PA			Monkey growth hormone (GH) receptor gene expression - Evidence for two mechanisms for the generation of the GH binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE JAK2; MESSENGER-RNA; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; PROLACTIN RECEPTOR; HUMAN-PLASMA; FACTOR-I; PHOSPHORYLATION; IDENTIFICATION	The growth hormone receptor (GHR) cDNA was cloned from the liver of Rhesus macaque using polymerase chain reaction. As deduced from the nucleotide sequence, the mature GHR is a protein of 620 amino acids which presents 94.1% identity with the human receptor. The monkey GHR (mkGHR) expressed in 293 cells presented the expected specificity for a primate GHR and was able to transduce a transcriptional effect of GH. Human GH was able to activate tyrosine phosphorylation of both the tyrosine kinase JAK2 and the receptor in 293 cells co-transfected with mkGHR and JAK2 cDNAs. The GH binding protein (GHBP), the soluble short form of the GHR, was also present in monkey serum. Expression of the GHR cDNA in eucaryotic cells indicated that the GHBP can be produced by proteolytic cleavage of the membrane receptor. Northern blot analysis of GHR gene expression in different tissues allowed us to identify three different transcripts of 5.0 and 2.8 kilobase pairs and a smaller one of 1.7 kilobase pairs which could encode a GHBP. Rapid amplification of cDNA extremities (3'-RACE-polymerase chain reaction) was used to identify a cDNA encoding a protein in which the transmembrane and cytoplasmic domains of the receptor are substituted by a short sequence of 9 amino acids. This transcript was present in various tissues and could encode a GHBP as well, suggesting for the first time that two different mechanisms can coexist for the generation of the GHBP: proteolytic cleavage of the membrane receptor and a specific mRNA produced by alternative splicing.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, F-75730 PARIS 15, FRANCE; CERMA, DEPT PHYSIOL SYST, F-91228 BRETIGNY SUR ORGE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DELEHAYEZERVAS MC, 1994, J CLIN ENDOCR METAB, V78, P1473; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; GOLOS TG, 1993, ENDOCRINOLOGY, V133, P1744, DOI 10.1210/en.133.4.1744; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HERINGTON AC, 1986, J CLIN INVEST, V77, P1817, DOI 10.1172/JCI112507; HOCQUETTE JF, 1989, ENDOCRINOLOGY, V125, P2167, DOI 10.1210/endo-125-4-2167; HOCQUETTE JF, 1990, ENDOCRINOLOGY, V127, P1665, DOI 10.1210/endo-127-4-1665; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI CH, 1986, ARCH BIOCHEM BIOPHYS, V245, P287, DOI 10.1016/0003-9861(86)90216-X; LI CH, 1956, SCIENCE, V124, P1293, DOI 10.1126/science.124.3235.1293; MANN DR, 1992, J CLIN ENDOCR METAB, V74, P1263, DOI 10.1210/jc.74.6.1263; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MERCADO M, 1994, J CLIN ENDOCR METAB, V78, P731, DOI 10.1210/jc.78.3.731; MERTANI HC, 1995, ENDOCRINE, V3, P135, DOI 10.1007/BF02990065; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGANO M, 1995, AM J PHYSIOL-GASTR L, V268, pG431, DOI 10.1152/ajpgi.1995.268.3.G431; POSNER BI, 1974, ENDOCRINOLOGY, V95, P521, DOI 10.1210/endo-95-2-521; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; RUI H, 1994, J BIOL CHEM, V269, P5364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; TAR A, 1990, J CLIN ENDOCR METAB, V71, P1202, DOI 10.1210/jcem-71-5-1202; TIONG TS, 1989, BIOCHEM BIOPH RES CO, V158, P141, DOI 10.1016/S0006-291X(89)80189-5; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; URBANEK M, 1992, MOL ENDOCRINOL, V6, P279, DOI 10.1210/me.6.2.279; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; YOON JB, 1987, J BIOL CHEM, V262, P4284	54	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18951	18958		10.1074/jbc.272.30.18951	http://dx.doi.org/10.1074/jbc.272.30.18951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228076	hybrid			2022-12-27	WOS:A1997XM34200067
J	Nair, D; Misra, RP; Sallis, JD; Cheung, HS				Nair, D; Misra, RP; Sallis, JD; Cheung, HS			Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; HYDROXYAPATITE; GROWTH; PHOSPHORYLATION; TRANSCRIPTION; INDUCTION; PROSTAGLANDIN-E2; PROTOONCOGENES; CHONDROCYTES; COLLAGENASE	Calcium deposition diseases caused by calcium pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP) crystals are a significant source of morbidity in the elderly, We have shown previously that both types of crystals can induce mitogenesis, as well as metalloproteinase synthesis and secretion by fibroblasts and chondrocyte, These responses may promote degradation of articular tissues, We have also shown previously that both CPPD and BCP crystals activate expression of the c-fos and c-jun proto oncogenes. Phosphocitrate (PC) can specifically block mitogenesis and proto-oncogene expression induced by either BCP or CPPD crystals in 3T3 cells and human fibroblasts, suggesting that PC may be an effective therapy for calcium deposition diseases, To understand how PC inhibits BCP and CPPD-mediated cellular effects, we have investigated the mechanism by which BCP and CPPD transduce signals to the nucleus, Here we demonstrate that BCP and CPPD crystals activate a protein kinase signal transduction pathway involving p42 and p44 mitogen activated protein (MAP) kinases (ERK 2 and ERK 1). BCP and CPPD also cause phosphorylation of a nuclear transcription factor, cyclic AMP response element-binding protein (CREB), on serine 133, a residue essential for CREB's ability to transactivate. Treatment of cells with PC at concentrations of 10(-3) to 10(-5) M blocked both the activation of p42/p44 MAP kinases, and CREB serine 133 phosphorylation, in a dose-dependent fashion, At 10(-3) M, a PC analogue, n-sulfo-2-aminotricarballylate and citrate also modulate this signal transduction pathway, Inhibition by PC is specific for BCP- and CPPD-mediated signaling, since all three compounds had no effect on serum-induced p42/P44 or interleukin-1 beta induced p38 MAP kinase activities. Treatment of cells with an inhibitor of MEK1, an upstream activator of MAPKs, significantly inhibited crystal-induced cell proliferation, suggesting that the MAPK pathway is a significant mediator of crystal-induced signals.	UNIV MIAMI,SCH MED,DEPT MED ARTHRIT,MIAMI,FL 33135; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,MIAMI,FL 33135; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; UNIV TASMANIA,DEPT BIOCHEM,HOBART,TAS 7001,AUSTRALIA	University of Miami; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin; University of Tasmania					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38421] Funding Source: Medline; NIGMS NIH HHS [R55GM/OD51856] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETT JAS, 1967, J AM CHEM SOC, V89, P5535, DOI 10.1021/ja00998a003; BROWN MR, 1985, UROLITHIASIS RELATED, P891; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; CHEUNG HS, 1989, CANCER RES, V49, P134; CHEUNG HS, 1988, RHEUM DIS CLIN N AM, V14, P365; CHEUNG HS, 1986, J CELL PHYSIOL, V128, P143, DOI 10.1002/jcp.1041280202; Cheung HS, 1996, J BIOL CHEM, V271, P28082, DOI 10.1074/jbc.271.45.28082; CHEUNG HS, 1983, P SOC EXP BIOL MED, V173, P181; CHEUNG HS, 1993, BASIC CLIN ASPECTS I, P209; CURRAN T, 1988, COLD SPRING HARB SYM, V53, P769, DOI 10.1101/SQB.1988.053.01.087; DAYER JM, 1987, ARTHRITIS RHEUM, V30, P1372, DOI 10.1002/art.1780301208; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALVERSON PB, 1992, ARTHRITIS ALLIED CON, P1737; HOWARD JE, 1976, JOHNS HOPKINS MED J, V139, P239; JOHNSSON M, 1991, CALCIFIED TISSUE INT, V49, P134, DOI 10.1007/BF02565136; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KRUG HE, 1993, ARTHRITIS RHEUM, V36, P1603, DOI 10.1002/art.1780361116; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; MCCARTY DJ, 1979, ARTHRITIS RHEUM, V22, P718, DOI 10.1002/art.1780220705; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MITCHELL PG, 1989, J BIOL CHEM, V264, P14071; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PANKOWSKI AH, 1994, TETRAHEDRON LETT, V35, P227; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHENBERG RJ, 1987, ARTHRITIS RHEUM, V30, P266, DOI 10.1002/art.1780300304; ROTHENBERG RJ, 1988, AM J PHYSIOL-CELL PH, V23, pC554; RYAN LM, 1992, ARTHRITIS ALLIED CON, P1711; SALLIS JD, 1995, SCANNING MICROSCOPY, V9, P127; SHANKAR R, 1985, ATHEROSCLEROSIS, V50, P191; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TEW WP, 1981, P NATL ACAD SCI-BIOL, V78, P5528, DOI 10.1073/pnas.78.9.5528; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WIERZBICKI A, 1995, CALCIFIED TISSUE INT, V56, P297, DOI 10.1007/BF00318050; WILLIAMS G, 1982, CALCIFIED TISSUE INT, V34, P169, DOI 10.1007/BF02411229; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	36	62	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18920	18925		10.1074/jbc.272.30.18920	http://dx.doi.org/10.1074/jbc.272.30.18920			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228071	hybrid			2022-12-27	WOS:A1997XM34200062
J	Schlador, ML; Nathanson, NM				Schlador, ML; Nathanson, NM			Synergistic regulation of m2 muscarinic acetylcholine receptor desensitization and sequestration by G protein-coupled receptor kinase-2 and beta-arrestin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT-PHOSPHORYLATION; MEDIATED GENE-TRANSCRIPTION; EMBRYONIC CHICK HEART; GTP-BINDING-PROTEIN; CHOLINERGIC RECEPTORS; WILD-TYPE; ADENYLYL-CYCLASE; RAT-BRAIN; EXPRESSION; CLONING	The m2 muscarinic acetylcholine receptor (m2 mAChR) belongs to the superfamily of G protein coupled receptors and is regulated by many processes that attenuate signaling following prolonged stimulation by agonist, We used a heterologous expression system to examine the ability of G protein-coupled receptor kinase-2 (GRK2) and beta-arrestin-1 to regulate the phosphorylation state and to promote desensitization and sequestration of the m2 mAChR. Treatment of JEG-3 cells transiently expressing the m2 mAChR with a muscarinic agonist induced an similar to 4- or 8-fold increase in receptor phosphorylation in the absence or presence of cotransfected GRK2, respectively, compared with untreated cells transfected with receptor alone. Using the expression of a cAMP-regulated reporter gene to measure receptor function, we found that transiently transfected m2 mAChRs underwent functional desensitization following exposure to agonist, Transfected GRK2 enhanced agonist-induced functional desensitization in a manner that was synergistically enhanced by cotransfection of beta-arrestin-1, which had no effect on m2 mAChR function when coexpressed in the absence of GRK2. Finally, GRK2 and beta-arrestin-1 synergistically enhanced both the rate and extent of agonist-induced m2 mAChR sequestration. These results are the first to demonstrate that agonist-induced desensitization and sequestration of the m2 mAChR in the intact cell can be enhanced by the presence of GRK2, and beta-arrestin-1 and show that these molecules have multiple actions on the m2 mAChR.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL44948] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HUNTER DD, 1986, J NEUROSCI, V6, P3739; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MCKINNON LA, 1995, J BIOL CHEM, V270, P20636, DOI 10.1074/jbc.270.35.20636; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4871; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MIGEON JC, 1994, J BIOL CHEM, V269, P29146; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Sambrook J., 2002, MOL CLONING LAB MANU; Tiberi M, 1996, J BIOL CHEM, V271, P3771; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VILARO MT, 1992, NEUROSCIENCE, V47, P367, DOI 10.1016/0306-4522(92)90253-X; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	54	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18882	18890		10.1074/jbc.272.30.18882	http://dx.doi.org/10.1074/jbc.272.30.18882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228066	hybrid			2022-12-27	WOS:A1997XM34200057
J	White, JA; BeckettJones, B; Guo, YD; Dilworth, FJ; Bonasoro, J; Jones, G; Petkovich, M				White, JA; BeckettJones, B; Guo, YD; Dilworth, FJ; Bonasoro, J; Jones, G; Petkovich, M			cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; CELLS; RESISTANCE; RECEPTORS; PROTEIN; HAMSTER; CANCER	Retinoids, including all-trans retinoic acid (RA) and its stereoisomer 9-cis-RA play important roles in regulating gene expression, through interactions with nuclear receptors, during embryonic development and in the maintenance of adult epithelial tissues (Chambon, P. (1995) Rec. Prog. Horm. Res. 50, 317-32; Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850; Petkovich, M. (1992) Annu. Rev. Nutr. 12, 443-471). Evidence suggests that 4-hydroxylation of RA inside the target cell limits its biological activity and initiates a degradative process of RA leading to its eventual elimination. However, 18-hydroxylation and glucuronidation may also be important steps in this process. In this paper, we describe the cloning and characterization of the first mammalian retinoic acid-inducible retinoic acid-metabolizing cytochrome P450 (hP450RAI), which belongs to a novel class of cytochromes (CYP26). We demonstrate that hP450RAI is responsible for generation of several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-RA. We also show that hP450RAI mRNA expression is highly induced by RA in certain human tumor cell lines and further show that RA-inducible RA metabolism may correlate with P450RAI expression. We conclude that this enzyme plays a key role in RA metabolism, functioning in a feedback loop where RA levels are controlled in an autoregulatory manner.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada				Dilworth, F. Jeffrey/0000-0002-6265-8102				Blaner William S., 1994, P229; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRENTANO ST, 1992, ENDOCRINOLOGY, V131, P3010, DOI 10.1210/en.131.6.3010; CAMPLING BG, 1995, CANCER, V75, P2442, DOI 10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUBLER ML, 1990, METHOD ENZYMOL, V189, P525; Han IS, 1996, J CLIN ENDOCR METAB, V81, P2069, DOI 10.1210/jc.81.6.2069; JONES BB, 1995, MOL CELL BIOL, V15, P5226; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANOTTE M, 1991, BLOOD, V77, P1080; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MOASSER MM, 1994, ONCOGENE, V9, P833; MUINDEL JR, 1994, LEUKEMIA BALTIMORE, P1807; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; ROBERTS AB, 1979, J BIOL CHEM, V254, P6303; SEBAG M, 1992, J BIOL CHEM, V267, P12162; Taimi M, 1997, BIOCHEM BIOPH RES CO, V232, P432, DOI 10.1006/bbrc.1997.6309; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WOUTERS W, 1992, CANCER RES, V52, P2841; Zheng WL, 1996, ENDOCRINOLOGY, V137, P5028, DOI 10.1210/en.137.11.5028	27	328	348	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18538	18541		10.1074/jbc.272.30.18538	http://dx.doi.org/10.1074/jbc.272.30.18538			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228017	hybrid			2022-12-27	WOS:A1997XM34200008
J	Watson, F; Gasmi, L; Edwards, SW				Watson, F; Gasmi, L; Edwards, SW			Stimulation of intracellular Ca2+ levels in human neutrophils by soluble immune complexes - Functional activation of Fc gamma RIIIb during priming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID; TYROSINE PHOSPHORYLATION; RHEUMATOID-ARTHRITIS; RESPIRATORY BURST; MEDIATED PHAGOCYTOSIS; SIGNAL TRANSDUCTION; RECEPTOR EXPRESSION; OXIDASE ACTIVITY; NADPH OXIDASE; MECHANISMS	Soluble immune complexes bind to unprimed neutrophils and generate intracellular Ca2+ transients but fail to activate the NADPH oxidase. Following priming of the neutrophils with either tumor necrosis factor alpha of granulocyte-macrophage colony-stimulating factor, stimulation of the cells with the soluble immune complexes leads to an enhanced Ca2+ signal and significant secretion of reaction oxidants. The enhanced Ca2+ signal observed in primed neutrophils results from the influx of Ca2+ from the external environment and is partly sensitive to tyrosine kinase inhibitors. This is in contrast to the Ca2+ signal observed in unprimed neutrophils, which arises from the mobilization of intracellular stores. When the surface expression of Fc gamma RIIIb on primed neutrophils was decreased wither through incubation with Pronase of phosphoinositide-specific phospholipase C, the extra enhanced Ca2+ mobilization seen in primed cells was significantly lowered, while the initial rise in intracellular Ca2+ was unaffected. Depletion of Fc gamma RIIIb had no significant effect on the Ca2+ transients in unprimed neutrophils. Cross-linking Fc gamma RII, but not Fc gamma RIIIb, induced increase in intracellular Ca2+ in unprimed neutrophils, while cross-linking either of these receptors increased Ca2+ levels in primed neutrophils. The Fc gamma RII-dependent intracellular Ca2+ rise in primed cells was unaffected by incubation in Ca2+-free medium, whereas the Fc gamma RIIIb-dependent transient was significantly decreased when Ca2+ influx was prevented in Ca2+-free medium supplemented with EGTA. Cross-linking wither Fc gamma RII or Fc gamma RIIIb in primed or unprimed cells failed to stimulate substantial levels of inositol 1,4,5-trisphosphate production. These results indicate that following stimulation of primed neutrophils with soluble immune complexes the enhanced Ca2+ mobilization observed is the result of a functional activation of the glycosylphosphatidylinositol-linked Fc gamma RIIIb.	UNIV LIVERPOOL,SCH BIOL SCI,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool				Edwards, Steven/0000-0002-7074-0552				ABRAHAM JS, 1993, NATURAL IMMUNE SYSTE; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BRUNKHORST BA, 1992, J BIOL CHEM, V267, P20659; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DEHAAS M, 1995, BLOOD, V86, P2403, DOI 10.1182/blood.V86.6.2403.bloodjournal8662403; Dularay B, 1988, Autoimmunity, V1, P159, DOI 10.3109/08916938808997161; DUSI S, 1994, BIOCHEM BIOPH RES CO, V201, P30, DOI 10.1006/bbrc.1994.1665; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Edwards Steven W., 1996, Methods (Orlando), V9, P563, DOI 10.1006/meth.1996.0064; EDWARDS SW, 1990, BIOSCIENCE REP, V10, P393, DOI 10.1007/BF01117239; EDWARDS SW, 1995, TRENDS BIOCHEM SCI, V20, P362, DOI 10.1016/S0968-0004(00)89077-5; EDWARDS SW, 1987, J CLIN LAB IMMUNOL, V22, P35; EDWARDS SW, 1990, FREE RADICAL RES COM, V256, P333; EMERY P, 1991, ANN RHEUM DIS, V47, P34; FEARON DT, 1983, J IMMUNOL, V130, P370; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HENSON PM, 1972, AM J PATHOL, V68, P593; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KUIJPERS TW, 1991, BLOOD, V78, P1105; MACKENZIE SJ, 1995, BIOCHEM J, V306, P519, DOI 10.1042/bj3060519; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MERRY P, 1989, ANN RHEUM DIS, V48, P864, DOI 10.1136/ard.48.10.864; NAZIRUDDIN B, 1992, J IMMUNOL, V149, P3702; NURCOMBE HL, 1991, ANN RHEUM DIS, V50, P147, DOI 10.1136/ard.50.3.147; NURCOMBE HL, 1991, ANN RHEUM DIS, V50, P237, DOI 10.1136/ard.50.4.237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RICHARD S, 1994, BIOCHEM BIOPH RES CO, V199, P653, DOI 10.1006/bbrc.1994.1278; ROBINSON J, 1992, BIOCHEM J, V286, P345, DOI 10.1042/bj2860345; ROBINSON JJ, 1992, EUR J CLIN INVEST, V22, P314, DOI 10.1111/j.1365-2362.1992.tb01468.x; ROBINSON JJ, 1993, ANN RHEUM DIS, V52, P347, DOI 10.1136/ard.52.5.347; ROBINSON JJ, 1994, FEMS IMMUNOL MED MIC, V8, P247; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSALES C, 1992, J BIOL CHEM, V267, P5265; SALMON JE, 1991, J IMMUNOL, V146, P997; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; VEYS PA, 1991, BLOOD, V78, P852, DOI 10.1182/blood.V78.3.852.bloodjournal783852; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; WALKER BAM, 1991, J IMMUNOL, V146, P735; WATSON F, 1991, J BIOL CHEM, V266, P7432; WATSON F, 1992, BIOSCIENCE REP, V12, P123, DOI 10.1007/BF02351217; WATSON F, 1993, ANN RHEUM DIS, V52, P353; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17944	17951		10.1074/jbc.272.29.17944	http://dx.doi.org/10.1074/jbc.272.29.17944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218419	hybrid			2022-12-27	WOS:A1997XL73500009
J	Matsuguchi, T; Zhao, YM; Lilly, MB; Kraft, AS				Matsuguchi, T; Zhao, YM; Lilly, MB; Kraft, AS			The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TRANSCRIPTIONAL ACTIVATION; EXPRESSION CLONING; BONE-MARROW; CELL-GROWTH; C-JUN; PROTEINS; INTERLEUKIN-3	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates differentiation, survival, and proliferation of colony-forming unit-granulocyte-macrophage progenitor cells. The biologic actions of GM-CSF are mediated by binding to a specific receptor consisting of two chains designated as alpha and beta subunits. We have demonstrated that the murine FDC-P1-derived cell line WT-19 transfected with the human GM-CSF receptor alpha and beta subunits (GM-CSFR alpha and beta) can be induced to differentiate by the addition of human GM-CSF (hGM-CSF). By expressing a series of GM-CSFR alpha cytoplasmic domain that regulate cell differentiation, proliferation, and survival. We found that the membrane proximal proline-rich domain and adjacent 16 residues are essential for both hGM-CSF-dependent cell proliferation and differentiation. In contrast, the C-terminal region of the GM-CSFR alpha cytoplasmic domain was not necessary for cell differentiation mediated by hGM-CSF, but the removal of this region severely impaired the ability of hGM-CSF to support cell survival. While the activation of JAK2, Shc, Erk, and STAT5 proteins correlated with hGM-CSF-mediated cell growth, cellular differentiation occurred in the absence of activation of these signal transduction pathways.	UNIV COLORADO,HLTH SCI CTR,DIV MED ONCOL,DENVER,CO 80262; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV WASHINGTON,DIV MED ONCOL,SEATTLE,WA 98108; VET ADM MED CTR,SEATTLE,WA 98108	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Kentucky; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1026; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EMERSON SG, 1989, BLOOD, V74, P49; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HO MK, 1983, J BIOL CHEM, V258, P636; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Till KJ, 1996, BLOOD, V88, P479, DOI 10.1182/blood.V88.2.479.bloodjournal882479; TOMONAGA M, 1986, BLOOD, V67, P31; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEISS M, 1993, BLOOD, V82, P3298; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOKOTA T, 1993, LEUKEMIA, V7, pS102; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	51	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17450	17459		10.1074/jbc.272.28.17450	http://dx.doi.org/10.1074/jbc.272.28.17450			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211889	hybrid			2022-12-27	WOS:A1997XK16500032
J	Arribas, J; LopezCasillas, F; Massague, J				Arribas, J; LopezCasillas, F; Massague, J			Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; T-LYMPHOCYTES; TNF RECEPTOR; TGF-ALPHA; MEMBRANE; CLEAVAGE; INHIBITOR; BETAGLYCAN; PROTEOGLYCAN	Although regulated ectodomain shedding is a well known process that affects a large group of transmembrane molecules, it is not clear how the shedding system selects its substrates. Here we investigate the structural requirements for the regulated shedding of two substrates of the general shedding system, the transforming growth factor-alpha precursor, pro-TGF-alpha and the beta-amyloid precursor protein, beta-APP. The ability of different regions of pro-TGF-alpha or beta-APP to confer susceptibility to the shedding system was tested using as a reporter a transmembrane molecule that is not a substrate of this shedding system. For this purpose we chose the TGF-beta accessory receptor, betaglycan, since genetic and biochemical evidence showed that betaglycan is not a substrate of the shedding system, We determined that replacement of the 14 extracellular amino acids adjacent to the transmembrane region of betaglycan with the corresponding regions of TGF-alpha or beta-APP rendered betaglycan susceptible to ectodomain shedding, These domain swap constructs were cleaved ill response to protein kinase C stimulation, and cleavage. was prevented by the metalloprotease inhibitor TAPI, both effects being characteristic of the general shedding system, Domain swap constructs containing the transmembrane and/or the cytoplasmic domains of pro-TGF-alpha did not undergo regulated ectodomain cleavage. We conclude that despite a lack of sequence similarity, the extracellular regions of pro-TGF-alpha and beta-APP immediately preceding their transmembrane domains are key determinants of ectodomain shedding.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NATL AUTONOMOUS UNIV MEXICO,INST FISIOL CELULAR,MEXICO CITY 04510,DF,MEXICO	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Universidad Nacional Autonoma de Mexico			Arribas, Joaquin/M-4482-2014; Arribas, Jose/A-1595-2015	Arribas, Joaquin/0000-0002-0504-0664; Massague, Joan/0000-0001-9324-8408; Arribas, Jose/0000-0002-7410-9450				ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CROWE PD, 1993, J IMMUNOL, V151, P6882; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; XU H, 1996, J BIOL CHEM, V270, P23243	29	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17160	17165		10.1074/jbc.272.27.17160	http://dx.doi.org/10.1074/jbc.272.27.17160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202036	hybrid			2022-12-27	WOS:A1997XH44600068
J	Kim, JK; Palaniappan, C; Wu, WM; Fay, PJ; Bambara, RA				Kim, JK; Palaniappan, C; Wu, WM; Fay, PJ; Bambara, RA			Evidence for a unique mechanism of strand transfer from the transactivation response region of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NUCLEOCAPSID PROTEIN; RNA ANNEALING ACTIVITIES; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; TAT GENE-PRODUCT; REVERSE-TRANSCRIPTASE; INTERNAL REGIONS; RETROVIRAL RECOMBINATION; TEMPLATES	We previously found that strand transfer by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is promoted at sites where RT pauses during synthesis, In this report, strand transfer is measured within the 5' transactivation response region (TAR) of HIV-1 RNA, We hypothesized that the stable hairpin structure of TAR would induce RT pausing, promoting RNase II-directed cleavage of the template and subsequent transfer at that site, We further predicted that HIV-1 nucleocapsid protein (NC), known to melt secondary structures, would decrease transfer, We show that TAR created a strong pause site for RT, but NC significantly promoted strand transfer, The effect of NC is specific, since other single strand binding proteins failed to stimulate transfer, In another unexpected outcome, preferred positions of internal transfer were not at the pause site but were in the upper stem and loop of TAR, Thus, we propose a new mechanism for transfer within TAR described by an interactive hairpin model, in which association between the donor and the acceptor templates within the TAR stem promotes transfer, The model is consistent with the observed stimulation of strand transfer by NC, The model is applicable to internal and replicative end transfer.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOWELL RM, 1991, AIDS RES HUM RETROV, V7, P869, DOI 10.1089/aid.1991.7.869; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KHAN R, 1992, J BIOL CHEM, V267, P6689; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; KORNBERG A, 1992, DNA REPLICATION, P323; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	36	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16769	16777		10.1074/jbc.272.27.16769	http://dx.doi.org/10.1074/jbc.272.27.16769			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201981	hybrid			2022-12-27	WOS:A1997XH44600013
J	Mark, MD; Storm, DR				Mark, MD; Storm, DR			Coupling of epidermal growth factor (EGF) with the antiproliferative activity of cAMP induces neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; G1 CYCLIN EXPRESSION; PROTEIN-KINASE; AMP; INHIBITION; ENCODES; PROLIFERATION; TRIGGERS; YEAST; GENE	Nerve growth factor (NGF) functions as a progression factor with both mitogenic and antimitogenic activities. When PC12 cells are treated with NGF, they advance to the G(1) stage of the cell cycle before they differentiate, The correlation between cessation of proliferation and differentiation suggests that the antimitotic activity of NGF may be obligatory for differentiation Although epidermal growth factor- (EGF) and NGF-treated PC12 cells share several common properties, including activation of the mitogen-activated protein (MAP) kinase pathway and induction of immediate early genes, EGF is mitogenic for PC12 cells and does not normally stimulate differentiation However, combinations of EGF and low levels of cAMP stimulate differentiation even though neither agent alone does (Mark, M. D., Liu, Y., Wong, S. T., Hinds, T. R., and Storm, D.R. (1995) J. Cell Biol. 130, 701-710), Since EGF is mitogenic for PC12 cells and differentiation may not occur until proliferation is inhibited, differentiation caused by cAMP and EGF may be due to the antiproliferative activity of cAMP, To test this hypothesis, we examined the effect of EGF or combinations of EGF and cAMP on PC12 cell proliferation. EGF alone stimulated proliferation of PC12 cells and increased the levels of several cell cycle progression factors including cdk2, cdk4, and cyclin B1, Cyclic AMP inhibited the EGF-stimulated increases in cell cycle progression factors as well as proliferation, Other antiproliferative agents including rapamycin, mimosine, and nitric oxide agonists also synergized with EGF to stimulate differentiation, These data indicate that the coupling of antiproliferative signals with EGF modifies the biological properties of EGF and converts it to a differentiating growth factor.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Mark, Melanie/ABF-9102-2020	Mark, Melanie/0000-0002-2788-6003	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20498] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchkovich K, 1994, MOL BIOL CELL, V5, P1226; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COHEN STANLEY, 1965, DEVELOP BIOL, V12, P394, DOI 10.1016/0012-1606(65)90005-9; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2421; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SEWING A, 1993, J CELL SCI, V104, P545; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, ONCOGENE, V8, P174; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VALVERDE AM, 1995, EXP CELL RES, V218, P305, DOI 10.1006/excr.1995.1159; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VITTET D, 1995, J CELL PHYSIOL, V163, P645, DOI 10.1002/jcp.1041630327; YAN GZ, 1995, J NEUROSCI, V15, P6200	39	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17238	17244		10.1074/jbc.272.27.17238	http://dx.doi.org/10.1074/jbc.272.27.17238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202048	hybrid			2022-12-27	WOS:A1997XH44600080
J	Wu, MY; Hsu, TL; Lin, WW; Campbell, RD; Hsieh, SL				Wu, MY; Hsu, TL; Lin, WW; Campbell, RD; Hsieh, SL			Serine/threonine kinase activity associated with the cytoplasmic domain of the lymphotoxin-beta receptor in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR TNF RECEPTOR; PROTEIN-KINASE; HETEROMERIC COMPLEX; 33-KDA GLYCOPROTEIN; SIGNAL-TRANSDUCTION; SURFACE; MICE; FAMILY; IDENTIFICATION	The lymphotoxin-beta receptor (LT-beta R) has been shown to be the receptor for the membrane-bound lymphotoxin heterotrimers LT alpha 1/beta 2 and LT alpha 2/beta 1. The extracellular domain of LT-beta R shows extensive similarity with members of the turner necrosis factor receptor family, while its cytoplasmic domain is distinct and lacks any inherent enzymatic activity. This suggests that the interaction of LT-beta R with other molecules might be important for signal transduction, Here we demonstrate the asso ciation of a fusion protein, comprising glutathione S-transferase and the cytoplasmic domain of LT-beta R (GST-LT-beta R(GD)), with several proteins in the size range 29-80 kDa from HepG2 cell lysates, We present evidence that two of these proteins are serine/threonine kinases, which associate with amino acids 324-377 of the cytoplasmic domain of LT-beta R and phosphorylate this receptor. The characteristics of these novel kinases indicate that they are distinct from the previously described tumor necrosis factor receptor-associated kinases, This suggests the presence of novel signal transduction pathway(s) for LT-beta R.	NATL YANG MING UNIV,DEPT MICROBIOL & IMMUNOL,SCH MED,TAIPEI 11221,TAIWAN; NATL YANG MING UNIV,SCH MED,IMMUNOL RES CTR,TAIPEI 11221,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PHARMACOL,TAIPEI 100,TAIWAN; UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; University of Oxford			Hsu, Tsui-Ling/AAE-8821-2019; Hsieh, Shie-Liang Edmond/ABA-9184-2021; Hsu, Tsui-Ling/H-6704-2015	Hsu, Tsui-Ling/0000-0002-2912-3261; Lin, Wan Wan/0000-0002-3207-734X				ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DE TP, 1994, SCIENCE, V264, P703; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; GUO H, 1993, J BIOL CHEM, V268, P11193; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SONG HY, 1994, J BIOL CHEM, V269, P22492; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	38	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17154	17159		10.1074/jbc.272.27.17154	http://dx.doi.org/10.1074/jbc.272.27.17154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202035	hybrid			2022-12-27	WOS:A1997XH44600067
J	Bayle, D; Weeks, D; Sachs, G				Bayle, D; Weeks, D; Sachs, G			Identification of membrane insertion sequences of the rabbit gastric cholecystokinin-A receptor by in vitro translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CHARGED RESIDUES; SPANNING PROTEINS; TOPOLOGY; ORIENTATION; TOPOGRAPHY; RHODOPSIN; HELICES; RULE	To determine which amino acid sequences account for transmembrane folding of G7 receptors, the membrane domain of the rabbit cholecystokinin-A (CCK-A) G-protein-coupled receptor has been investigated by in vitro transcription/translation of two types of fusion vectors containing sequences that include putative transmembrane segments. First, the seven putative transmembrane domains of the CCK-A receptor were inserted individually into pGEM vectors beginning with the cDNA encoding the first 101 (HK-M0) or 139 (HK-M1) amino acids of the alpha subunit of the gastric H,K-ATPase. These were separated by the cDNA for the inserted transmembrane domains from the cDNA encoding the last 177 amino acids of the beta subunit of the H,K-ATPase containing five N-linked glycosylation consensus sequences (Bamberg, K., and Sachs, G. (1994) J. Biol. Chem. 269, 16909-16919). Transcription/translation of these fusion vectors in rabbit reticulocyte lysate +/- dog pancreatic microsomes followed by SDS-polyacrylamide gel electrophoresis defined the presence of signal anchor sequences in HK-M0 by glycosylation and stop transfer sequences in HK-M1 by inhibition of glycosylation. Six out of the seven putative transmembrane domains had membrane insertion signals, but no membrane insertion activity was found for the H3 segment in these vectors. To test the effect of specific upstream and downstream sequences on membrane insertion, vectors were also made starting with the cDNA encoding the N terminus of the CCK-A receptor separated from the last 177 amino acids of the H,K-ATPase beta subunit by cDNA encoding CCK-A receptor sequences of different lengths. In addition to transcription/translation, endoglycosidase H treatment was used to verify glycosylation when multiple bands were found in the presence of microsomes. The four positive charges in the loop between H1 and H2 were required for the correct orientation of the first transmembrane domain. The H3 segment acted as a stop transfer sequence only when the whole N terminus and H3 were followed by the positive charges in the cytoplasmic loop between H3 and H4. The activity of H6 as a signal anchor sequence depended on preceding positive charges. These translation data using two types of fusion vectors establish a seven-transmembrane folding model using only in vitro translation for the CCK-A receptor beginning with two signal anchor sequences and then alternating stop transfer and signal anchor insertions. Positive charges between H1 and H2, H3 and H4, and H5 and H6 function as cytoplasmic anchors in the membrane folding of this receptor.	WADSWORTH VA HOSP,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles					NIDDK NIH HHS [DK41301, DK40615, DK17294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK040615, R01DK017294, P30DK041301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P6780; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRNBAUMER M, 1996, MOL BIOL MEMBRANE TR, P321; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CRCNET P, 1993, PROTEIN ENG, V6, P59; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REUBEN M, 1994, BBA-GENE STRUCT EXPR, V1219, P321, DOI 10.1016/0167-4781(94)90055-8; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SEAL AJ, 1994, NEUROPHARMACOLOGY, V33, P1065, DOI 10.1016/0028-3908(94)90144-9; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WANG HY, 1989, J BIOL CHEM, V264, P14424; WEISS ER, 1987, J BIOL CHEM, V262, P4319; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19697	19707		10.1074/jbc.272.32.19697	http://dx.doi.org/10.1074/jbc.272.32.19697			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242625	hybrid			2022-12-27	WOS:A1997XQ05900012
J	Brodeur, SR; Cheng, GH; Baltimore, D; ThorleyLawson, DA				Brodeur, SR; Cheng, GH; Baltimore, D; ThorleyLawson, DA			Localization of the major NF-kappa B-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NECROSIS-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; CELL ACTIVATION; EXPRESSION; TRANSFORMATION; GENE; CD40; INDUCTION	The TRAF3 molecule interacts with the cytoplasmic carboxyl terminus (COOH terminus) of the Epstein Barr virus-encoded oncogene LMP-1, NF-kappa B activation is a downstream signaling event of tumor necrosis factor receptor-associated factor (TRAF) molecules in other signaling systems (CD40 for example) and is an event caused by LMP-1 expression. One region capable of TRAF3 interaction in LMP-1 is the membrane-proximal 45 amino acids (188-242) of the COOH terminus, We show that this region contains the only site for binding of TRAF3 in the 200-amino acid COOH terminus of LMP-I, The site also binds TRAF2 and TRAF5, brit not TRAF6. TRAF3 binds to critical residues localized between amino acids 196 and 212 (HHDDSLPHPQQAT-DDSG), including the PXQX(T/S) motif, that share limited identity to the CD40 receptor TRAF binding site (TAAPVQETL), Mutation of critical residues in the TRAF3 binding site of LMP-1 that prevents binding of TRAF2, TRAF3, and TRAF5 does not affect NF-kappa B-activating potential, Deletion mapping localized the major NF-kappa B activating region of LMP-1 to critical residues in the distal 4 amino acids of the COOH terminus (385-386). Therefore, TRAF3 binding and NF-KB activation occur through two separate motifs at opposite ends of the LMP-1 COOH-terminal sequence.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Tufts University; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA031893, R37CA031893, R01CA065883] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31893, CA 65883] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Baker SJ, 1996, ONCOGENE, V12, P1; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CORMACK B, 1991, CURRENT PROTOCOLS S, V15; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, VIROLOGY, V2, P2343; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MILLER WE, 1995, J VIROL, V69, P4890; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Moorthy R, 1992, Curr Top Microbiol Immunol, V182, P359; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NICHOLSON LJ, 1997, IN PRESS ONCOGENE; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PENG M, 1992, ONCOGENE, V7, P1775; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; ZHANG Q, 1994, EUR J IMMUNOL, V24, P1467, DOI 10.1002/eji.1830240635	49	100	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19777	19784		10.1074/jbc.272.32.19777	http://dx.doi.org/10.1074/jbc.272.32.19777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242637	hybrid, Green Accepted			2022-12-27	WOS:A1997XQ05900024
J	Enjo, F; Nosaka, K; Ogata, M; Iwashima, A; Nishimura, H				Enjo, F; Nosaka, K; Ogata, M; Iwashima, A; Nishimura, H			Isolation and characterization of a thiamin transport gene, THI10, from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE REGULATORY GENE; ACID-PHOSPHATASE; HYDROXYETHYLTHIAZOLE KINASE; BINDING ACTIVITY; YEAST; PROTEIN; MEMBRANE; PYROPHOSPHORYLASE; BIOSYNTHESIS; METABOLISM	We isolated a thiamin transporter gene, THI10, from a genomic library of Saccharomyces cerevisiae by the complementation of a yeast mutant defective in thiamin transport activity, The THI10 gene contained an open reading frame of 1,794 base pairs encoding a 598-amino acid polypeptide with a calculated molecular weight of 66,903, The nucleotide sequence of THI10 is completely identical to that of an anonymous DNA (open reading frame L8083.2) mapped to chromosome XII; two other genes (open reading frames YOR071c and YOR192c) in chromosome XV are extremely similar to THI10, Moreover, the THI10 gene product showed significant sequence homology with yeast allantoin and uracil transporters, Hydropathy profile suggested that THI10 product is highly hydrophobic and contains many transmembrane regions. Gene disruption of the THI10 locus completely abolished the thiamin transport activity and thiamin binding activity in yeast plasma membrane fraction, Both the transport and thiamin binding activities were restored in the disrupted cells when the THI10 open reading frame was expressed by yeast GAL1 promoter, suggesting that the THI10 gene encodes for the thiamin transport carrier protein, Northern blot analysis demonstrated that THI10 gene expression is regulated at the mRNA level by intracellular thiamin pyrophosphate and that it requires a positive regulatory factor encoded by THI3 gene.	KYOTO PREFECTURAL INST HYG & ENVIRONM SCI,FUSHIMI KU,KYOTO 612,JAPAN		Enjo, F (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT BIOCHEM,KAMIGYO KU,KYOTO 602,JAPAN.							Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; COOPER TG, 1987, J BACTERIOL, V169, P4660, DOI 10.1128/jb.169.10.4660-4667.1987; IWASHIMA A, 1976, J BACTERIOL, V128, P855, DOI 10.1128/JB.128.3.855-857.1976; IWASHIMA A, 1979, BIOCHIM BIOPHYS ACTA, V557, P460, DOI 10.1016/0005-2736(79)90343-2; IWASHIMA A, 1986, J GEN MICROBIOL, V132, P1541; IWASHIMA A, 1990, BIOCHIM BIOPHYS ACTA, V1022, P211, DOI 10.1016/0005-2736(90)90116-6; IWASHIMA A, 1973, BIOCHIM BIOPHYS ACTA, V330, P222, DOI 10.1016/0005-2736(73)90227-7; IWASHIMA A, 1992, FEBS LETT, V311, P60, DOI 10.1016/0014-5793(92)81367-U; IWASHIMA A, 1981, EXPERIENTIA, V37, P473, DOI 10.1007/BF01986142; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KAWASAKI Y, 1993, J BACTERIOL, V175, P5153, DOI 10.1128/JB.175.16.5153-5158.1993; KAWASAKI Y, 1990, J BACTERIOL, V172, P6145, DOI 10.1128/jb.172.10.6145-6147.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NISHIMURA H, 1986, EXPERIENTIA, V42, P607, DOI 10.1007/BF01955555; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; NISHIMURA H, 1991, J BACTERIOL, V173, P2716, DOI 10.1128/jb.173.8.2716-2719.1991; NISHIMURA H, 1992, FEBS LETT, V297, P155, DOI 10.1016/0014-5793(92)80349-L; NOSAKA K, 1990, BIOCHIM BIOPHYS ACTA, V1037, P147, DOI 10.1016/0167-4838(90)90160-H; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1994, J BIOL CHEM, V269, P30510; NOSAKA K, 1992, FEBS LETT, V305, P244, DOI 10.1016/0014-5793(92)80678-A; NOSAKA K, 1989, FEMS MICROBIOL LETT, V60, P55, DOI 10.1016/0378-1097(89)90077-3; Rose MD., 1990, METHODS YEAST GENETI; Ruml T, 1996, YEAST, V12, P1279, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1279::AID-YEA23>3.0.CO;2-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	38	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19165	19170		10.1074/jbc.272.31.19165	http://dx.doi.org/10.1074/jbc.272.31.19165			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235906	hybrid			2022-12-27	WOS:A1997XP06300012
J	ErsdalBadju, E; Lu, AQ; Zuo, YC; Picard, V; Bock, SC				ErsdalBadju, E; Lu, AQ; Zuo, YC; Picard, V; Bock, SC			Identification of the antithrombin III heparin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTI-THROMBIN-III; CRYSTAL-STRUCTURE; BOVINE ANTITHROMBIN; MOLECULAR-MODEL; HIGH-AFFINITY; BETA-SHEET; GLYCOSYLATION; SERPINS; PENTASACCHARIDE	The heparin binding site of the anticoagulant protein antithrombin III (ATIII) has been defined at high resolution by alanine scanning mutagenesis of 17 basic residues previously thought to interact with the cofactor based on chemical modification experiments, analysis of naturally occurring dysfunctional antithrombins, and proximity to helix D. The baculovirus expression system employed for this study produces antithrombin which is highly similar to plasma ATIII in its inhibition of thrombin and factor Xa and which resembles the naturally occurring beta-ATIII isoform in its interactions with high affinity heparin and pentasaccharide (Ersdal-Badju, E., Lu, A., Peng, X., Picard, V., Zendehrouh, P., Turk, B., Bjork, I., Olson, S. T., and Beck, S. C. (1995) Biochem. J. 310, 323-330). Relative heparin affinities of basic-to-Ala substitution mutants were determined by NaCl gradient elution from heparin columns. The data show that only a subset of the previously implicated basic residues are critical for binding to heparin. The key heparin binding residues, Lys-ll, Arg-13, Arg-24, Arg-47, Lys-125, Arg-129, and Arg-145, line a 50-Angstrom long channel on the surface of ATIII. Comparisons of binding residue positions in the structure of P14-inserted ATIII and models of native antithrombin, derived from the structures of native ovalbumin and native antichymotrypsin, suggest that heparin may activate antithrombin by breaking salt bridges that stabilize its native conformation. Specifically, heparin release of intramolecular helix D-sheet B salt bridges may facilitate s123AhDEF movement and generation of an activated species that is conformationally primed for reactive loop uptake by central beta-sheet A and for inhibitory complex formation. In addition to providing a structural explanation for the conformational change observed upon heparin binding to antithrombin III, differences in the affinities of native, heparin-bound, complexed, and cleaved ATIII molecules for heparin can be explained based on the identified binding site and suggest why heparin functions catalytically and is released from antithrombin upon inhibitory complex formation.	TEMPLE UNIV,SCH MED,DEPT IMMUNOL MICROBIOL,PHILADELPHIA,PA 19140; SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NHLBI NIH HHS [R01-HL30712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, BIOCHEM J, V286, P793; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P5211; BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BRENNAN SO, 1988, FEBS LETT, V237, P118, DOI 10.1016/0014-5793(88)80183-2; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; FRANZEN LE, 1980, J BIOL CHEM, V255, P5090; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; MIZUOCHI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P458, DOI 10.1016/0003-9861(80)90199-X; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; Permyakov E. A., 1993, LUMINESCENT SPECTROS, P57; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; RAGAZZI M, 1987, CARBOHYD RES, V165, pC1, DOI 10.1016/0008-6215(87)80093-9; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P9541; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURK B, 1997, IN PRESS BIOCHEMISTR; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; WATTON J, 1995, THROMB HAEMOSTASIS, V73, pA936; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	58	82	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19393	19400		10.1074/jbc.272.31.19393	http://dx.doi.org/10.1074/jbc.272.31.19393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235938	hybrid			2022-12-27	WOS:A1997XP06300044
J	Urban, P; Mignotte, C; Kazmaier, M; Delorme, F; Pompon, D				Urban, P; Mignotte, C; Kazmaier, M; Delorme, F; Pompon, D			Cloning, yeast expression, and characterization of the coupling of two distantly related Arabidopsis thaliana NADPH-Cytochrome P450 reductases with P450 CYP73A5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; GENE FAMILY; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; SACCHAROMYCES-CEREVISIAE; PLANT CYTOCHROME-P-450; P-450 REDUCTASE; CINNAMATE 4-HYDROXYLASE; CATHARANTHUS-ROSEUS; MOLECULAR-CLONING; 54-KDA SUBUNIT	Two NADPH-cytochrome P450 reductase-encoding cDNAs were isolated from an Arabidopsis cDNA library by metabolic interference in a Saccharomyces cerevisiae mutant disrupted for its endogenous cpr1 gene, ATR1 encodes a protein of 692 amino acids, while ATR2 encodes either a 712-residue protein (ATR2-1), or a 702-residue protein (ATR2-2) depending on the choice of the initiation codon, Comparative analysis of ATR1 and ATR2-1 indicates 64% amino acid sequence identity and the absence of conservation in the third base of conserved amino acid codons. The two Arabidopsis reductases are encoded by distinct genes whose divergence is expected an early event in angiosperms evolution, A poly(Ser/Thr) stretch reminiscent of a plant chloroplastic targeting signal is present at the ATR2-1 N-terminal end but absent in ATR1, The cDNA open reading frames were expressed in yeast, The recombinant polypeptides were found present in the yeast endoplasmic reticulum membrane and exhibited a high specific NADPH-cytochrome c reductase activity, To gain more insight into the respective functions of the two reductases, the Arabidopsis cDNA encoding cinnamate 4-hydroxylase (CYP73A5) was cloned and co-expressed with ATR1 or ATR2 in yeast, Biochemical characterization of the Arabidopsis ATR1/CYP73A5 and ATR2-1/CYP73A5 systems demonstrates that the two distantly related Arabidopsis reductases similarly support the first oxidative step of the phenylpropanoid general pathway.	CNRS, CTR GENET MOL, UPR 9061, F-91198 GIF SUR YVETTE, FRANCE; CTR ORSAN RECH BIOTECHNOL, F-91953 LES ULIS, FRANCE; CEA, SERV RADIOPHYSIOL VEGETALE, F-13108 ST PAUL LES DURANCE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA				Urban, Philippe/0000-0003-0557-839X				AKADA S, 1995, PLANT MOL BIOL, V29, P189, DOI 10.1007/BF00043645; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BENVENISTE I, 1991, BIOCHEM BIOPH RES CO, V177, P105, DOI 10.1016/0006-291X(91)91954-B; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DURBIN ML, 1995, P NATL ACAD SCI USA, V92, P3338, DOI 10.1073/pnas.92.8.3338; DURST F, 1993, HDB EXPT PHARM, V10, P293; FAHRENDORF T, 1993, ARCH BIOCHEM BIOPHYS, V305, P509, DOI 10.1006/abbi.1993.1454; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FUJITA M, 1985, PLANT CELL PHYSIOL, V26, P397, DOI 10.1093/oxfordjournals.pcp.a076923; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; HALLAHAN DL, 1993, BIOCHEM SOC T, V21, P1068, DOI 10.1042/bst0211068; HANSIKOVA H, 1994, GEN PHYSIOL BIOPHYS, V13, P149; HEDDEN P, 1978, ANNU REV PLANT PHYS, V29, P149, DOI 10.1146/annurev.pp.29.060178.001053; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERZOG M, 1995, PLANT MOL BIOL, V27, P743, DOI 10.1007/BF00020227; HOTZE M, 1995, FEBS LETT, V374, P345, DOI 10.1016/0014-5793(95)01141-Z; Huang SR, 1996, PLANT PHYSIOL, V111, P115, DOI 10.1104/pp.111.1.115; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KINKEMA M, 1994, PLANT MOL BIOL, V26, P1139, DOI 10.1007/BF00040695; LESOT A, 1995, PLANT PHYSIOL BIOCH, V33, P751; LINDSTROM JT, 1993, PLANT MOL BIOL, V23, P1265, DOI 10.1007/BF00042359; MEIJER AH, 1993, PLANT J, V4, P47, DOI 10.1046/j.1365-313X.1993.04010047.x; MENTING JGT, 1994, PLANT PHYSIOL, V106, P643, DOI 10.1104/pp.106.2.643; MIGNOTTE C, 1993, Patent No. 92082454; MIGNOTTE C, 1992, Patent No. 13969; MINET M, 1992, PLANT J, V2, P417; MOORE TC, 1976, PHYTOCHEMISTRY, V15, P1241, DOI 10.1016/0031-9422(76)85085-6; MURPHY GJP, 1975, PHYTOCHEMISTRY, V14, P429, DOI 10.1016/0031-9422(75)85104-1; OMURA T, 1964, J BIOL CHEM, V239, P2370; PLEWA MJ, 1993, ANNU REV GENET, V27, P93; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; POMPON D, Patent No. 58796; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PURUGGANAN MD, 1995, GENETICS, V140, P345; SANDERMANN H, 1994, PHARMACOGENETICS, V4, P225, DOI 10.1097/00008571-199410000-00001; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SHET MS, 1993, P NATL ACAD SCI USA, V90, P2890, DOI 10.1073/pnas.90.7.2890; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/1360-1385(96)10040-6; SIMMONS DL, 1985, J BIOL CHEM, V260, P515; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; TAGUE BW, 1995, PLANT MOL BIOL, V28, P267, DOI 10.1007/BF00020246; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YOSHIDA Y, 1991, BIOCHEM SOC T, V19, P778, DOI 10.1042/bst0190778; ZHU DH, 1993, P NATL ACAD SCI USA, V90, P9310, DOI 10.1073/pnas.90.20.9310	62	268	294	4	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19176	19186		10.1074/jbc.272.31.19176	http://dx.doi.org/10.1074/jbc.272.31.19176			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235908	hybrid			2022-12-27	WOS:A1997XP06300014
J	Chazenbalk, GD; Jaume, JC; McLachlan, SM; Rapoport, B				Chazenbalk, GD; Jaume, JC; McLachlan, SM; Rapoport, B			Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TSH RECEPTOR; LUTROPIN CHORIOGONADOTROPIN RECEPTOR; RECOMBINANT EXTRACELLULAR DOMAIN; THYROID-STIMULATING ANTIBODY; HAMSTER OVARY CELLS; MONOCLONAL-ANTIBODIES; RADIORECEPTOR ASSAY; MOLECULAR-CLONING; HORMONE RECEPTOR; BINDING-ACTIVITY	Previous attempts to generate autoantibody-reactive, secreted thyrotropin receptor (TSHR) ectodomain in mammalian cells have failed because of retention within the cell of material with immature carbohydrate. We have overcome this difficulty by performing progressive carboxyl-terminal truncations of the human TSHR ectodomain (418 amino acid residues including signal peptide). Three ectodomain variants (TSHR-261, TSHR-289, and TSHR-309) were truncated at residues 261, 289, and 309, respectively. Unlike the full ectodomain, ectodomain variants were secreted with an efficiency inversely proportional to their size, Secreted ectodomain variants contained similar to 20 kDa of complex carbohydrate. TSHR-261 was chosen for further study because it was secreted very efficiently and neutralized autoantibodies in Graves' patients' sera, This ectodomain variant was partially purified using sequential lectin and nickel-chelate chromatography, permitting the first direct visualization and quantitation of the mammalian TSHR. Most important, very small (nanogram) quantities of this material neutralized 70-100% of TSHR autoantibody activity in all 18 Graves' sera studied. In summary, carboxyl-terminal truncation of the human TSHR ectodomain generates a secreted protein with complex carbohydrate that neutralizes autoantibodies in Graves' patients' sera. Antigenically active TSHR will be valuable for future studies on the diagnosis, pathogenesis, and immunotherapy of Graves' disease.	VET ADM MED CTR,THYROID MOL BIOL UNIT 111T,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Jaume, Juan/0000-0002-2723-331X	NIDDK NIH HHS [DK19289, DK 48216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289, R01DK048216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; COSTAGLIOLA S, 1994, J MOL ENDOCRINOL, V13, P11, DOI 10.1677/jme.0.0130011; DIRMIKIS S, 1973, J ENDOCRINOL, V58, P577, DOI 10.1677/joe.0.0580577; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1391, DOI 10.1016/S0006-291X(05)81560-8; FILETTI S, 1991, J CLIN ENDOCR METAB, V72, P1096, DOI 10.1210/jcem-72-5-1096; FOTI D, 1991, J CLIN ENDOCR METAB, V73, P710, DOI 10.1210/jcem-73-4-710; GRAVES PN, 1995, ENDOCRINOLOGY, V136, P521, DOI 10.1210/en.136.2.521; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; HARFST E, 1992, MOL CELL ENDOCRINOL, V83, P117, DOI 10.1016/0303-7207(92)90152-V; HARFST E, 1992, J MOL ENDOCRINOL, V9, P227, DOI 10.1677/jme.0.0090227; HARFST E, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90273-6; HUANG GC, 1992, J MOL ENDOCRINOL, V8, P137, DOI 10.1677/jme.0.0080137; HUANG GC, 1993, J MOL ENDOCRINOL, V10, P127, DOI 10.1677/jme.0.0100127; Jaume JC, 1997, J CLIN ENDOCR METAB, V82, P500, DOI 10.1210/jc.82.2.500; JOHNSTONE AP, 1994, MOL CELL ENDOCRINOL, V105, pR1, DOI 10.1016/0303-7207(94)90175-9; Kakinuma A, 1996, ENDOCRINOLOGY, V137, P2664, DOI 10.1210/en.137.7.2664; KAKINUMA A, 1997, IN PRESS J CLIN ENDO; KAUFMAN KD, 1991, MOL CELL ENDOCRINOL, V78, P107; KOO YB, 1994, ENDOCRINOLOGY, V134, P19, DOI 10.1210/en.134.1.19; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRESS BC, 1986, ENDOCRINOLOGY, V118, P974, DOI 10.1210/endo-118-3-974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LUDGATE M, 1990, MOL CELL ENDOCRINOL, V73, pR13, DOI 10.1016/0303-7207(90)90050-I; MATSUBA T, 1995, J BIOCHEM-TOKYO, V118, P265, DOI 10.1093/oxfordjournals.jbchem.a124901; MCLACHLAN SM, 1993, J INTERN MED, V234, P347, DOI 10.1111/j.1365-2796.1993.tb00756.x; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; Morgenthaler NG, 1996, J CLIN ENDOCR METAB, V81, P700, DOI 10.1210/jc.81.2.700; MORRIS JC, 1994, AUTOIMMUNITY, V17, P287, DOI 10.3109/08916939409010669; MURAKAMI M, 1995, EUR J ENDOCRINOL, V133, P80, DOI 10.1530/eje.0.1330080; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGY EV, 1992, BIOCHEM BIOPH RES CO, V188, P28, DOI 10.1016/0006-291X(92)92345-X; Nicholson LB, 1996, J MOL ENDOCRINOL, V16, P159, DOI 10.1677/jme.0.0160159; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Rapoport B, 1996, J CLIN ENDOCR METAB, V81, P2525, DOI 10.1210/jc.81.7.2525; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; Seetharamaiah GS, 1997, J IMMUNOL, V158, P2798; SEETHARAMAIAH GS, 1995, ENDOCRINOLOGY, V136, P2817, DOI 10.1210/en.136.7.2817; SEETHARAMAIAH GS, 1993, AUTOIMMUNITY, V14, P315, DOI 10.3109/08916939309079234; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHEWRING G, 1982, CLIN ENDOCRINOL, V17, P409, DOI 10.1111/j.1365-2265.1982.tb01607.x; SHI Y, 1983, THYROID, V3, P129; Shimojo N, 1996, P NATL ACAD SCI USA, V93, P11074, DOI 10.1073/pnas.93.20.11074; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; SMITH BR, 1970, J ENDOCRINOL, V46, P45, DOI 10.1677/joe.0.0460045; TAHARA K, 1991, BIOCHEM BIOPH RES CO, V179, P70, DOI 10.1016/0006-291X(91)91335-A; TAKAI O, 1991, BIOCHEM BIOPH RES CO, V179, P319, DOI 10.1016/0006-291X(91)91372-J; TAKESHITA A, 1992, BIOCHEM BIOPH RES CO, V188, P1214, DOI 10.1016/0006-291X(92)91360-3; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; VLASE H, 1995, J CLIN ENDOCR METAB, V80, P46, DOI 10.1210/jc.80.1.46; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	60	96	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18959	18965		10.1074/jbc.272.30.18959	http://dx.doi.org/10.1074/jbc.272.30.18959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228077	hybrid			2022-12-27	WOS:A1997XM34200068
J	Schlesinger, PH; Blair, HC; Teitelbaum, SL; Edwards, JC				Schlesinger, PH; Blair, HC; Teitelbaum, SL; Edwards, JC			Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; INTRACELLULAR PH TRANSIENTS; PROTON PUMP; CARBONIC-ANHYDRASE; MEMBRANE-VESICLES; MARROW CULTURES; RECONSTITUTION; SUBUNIT; LOCALIZATION; PURIFICATION	Bone resorption by osteoclasts requires massive transcellular acid transport, which is accomplished by the parallel action of a V-type proton pump and a chloride channel in the osteoclast ruffled border. We have studied the molecular basis for the appearance of acid transport as avian bone marrow mononuclear cells acquire a bone resorptive phenotype in vitro. We demonstrate a critical role for regulated expression of a ruffled border chloride channel as the cells become competent to resorb bone. Molecular characterization of the chloride channel shows that it is related to the renal microsomal chloride channel, p64. In planar bilayers, the ruffled border channel is a stilbene sulfonate-inhibitable, outwardly rectifying chloride channel. A mechanism by which outward rectification of the single channel chloride current could allow efficient regulation of acidification by the channel is discussed.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; VET ADM MED CTR, LAB SERV, BIRMINGHAM, AL 35294 USA	Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schlesinger, PH (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Schlesinger, Paul H/C-6049-2012	Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42370] Funding Source: Medline; NIDDK NIH HHS [R29DK46212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ARKETT SA, 1992, ANN NY ACAD SCI, V671, P464, DOI 10.1111/j.1749-6632.1992.tb43831.x; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BEKKER PJ, 1990, J BONE MINER RES, V5, P569, DOI 10.1002/jbmr.5650050606; Blair Harry C., 1992, P259; BLAIR HC, 1993, CLIN ORTHOP RELAT R, P7; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHAMBERS TJ, 1984, J CELL SCI, V70, P61; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; DEWEER P, 1978, RESP PHYSIOL, V33, P41, DOI 10.1016/0034-5687(78)90082-8; DIFFENBACH LW, 1995, RESP PHYSL, V33, P41; GAY CV, 1974, SCIENCE, V183, P432, DOI 10.1126/science.183.4123.432; Harlow E., 1988, ANTIBODIES LAB MANUA; HATTERSLEY G, 1989, ENDOCRINOLOGY, V124, P1689, DOI 10.1210/endo-124-4-1689; Kahn A J, 1982, Prog Clin Biol Res, V110 Pt B, P239; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MARUSHACK MM, 1992, AM J PHYSIOL, V263, pF171, DOI 10.1152/ajprenal.1992.263.1.F171; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MATTSSON JP, 1993, BIOCHIM BIOPHYS ACTA, V1146, P106, DOI 10.1016/0005-2736(93)90344-Y; MATTSSON JP, 1992, ACTA PHYSIOL SCAND, V146, P253; NEUMAN WF, 1958, CHEM DYNAMICS BONE M, P23; PRALLET B, 1992, J BONE MINER RES, V7, P405; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAMBROOK J, 1989, MOL CLONING LAB MANU, P58; SCHLESINGER PH, 1994, MINER ELECTROL METAB, V20, P31; Sims Stephen M., 1992, P223; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAES G, 1988, CLIN ORTHOP RELAT R, P239; ZAIDI M, 1993, BIOL REV, V68, P197, DOI 10.1111/j.1469-185X.1993.tb00996.x	40	144	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18636	18643		10.1074/jbc.272.30.18636	http://dx.doi.org/10.1074/jbc.272.30.18636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228032	hybrid			2022-12-27	WOS:A1997XM34200023
J	Mecham, RP; Broekelmann, TJ; Fliszar, CJ; Shapiro, SD; Welgus, HG; Senior, RM				Mecham, RP; Broekelmann, TJ; Fliszar, CJ; Shapiro, SD; Welgus, HG; Senior, RM			Elastin degradation by matrix metalloproteinases - Cleavage site specificity and mechanisms of elastolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE SPECIFICITIES; MACROPHAGE ELASTASE; TISSUE INHIBITOR; IV COLLAGENASES; MATRILYSIN; GELATINASES; STROMELYSIN; PUMP; IDENTIFICATION; ACTIVATION	Insoluble elastin was used as a substrate to characterize the peptide bond specificities of human (HME) and mouse macrophage elastase (MME) and to compare these enzymes with other mammalian metalloproteinases and serine elastases, New amino termini detected by protein sequence analysis in insoluble elastin following proteolytic digestion reveal the P'(1) residues in the carboxyl-terminal direction from the scissile bond, The relative proportion of each amino acid in this position reflects the proteolytic preference of the elastolytic enzyme, The predominant amino acids detected by protein sequence analysis following cleavage of insoluble elastin with HME, MME, and 92-kDa gelatinase were Leu, Ile, Ala, Gly, and Val, HME and RIME were similar ill their substrate specificity and showed a stronger preference for Leu/Ile than did the 92-kDa enzyme, Fibroblast collagenase showed no activity toward elastin, The amino acid residues detected in insoluble elastin following hydrolysis with porcine pancreatic elastase and human neutrophil elastase were predominantly Gly and Ala, with lesser amounts of Val, Phe, Ile, and Leu, There were interesting specificity differences between the two enzymes, however, For both the serine and matrix metalloproteinases, catalysis of peptide bond cleavage in insoluble elastin was characterized by temperature effects and water requirements typical of common enzyme catalysed reactions, even those involving soluble substrates. In contrast to what has been observed for collagen, the energy requirements for elastolysis were not extraordinary, consistent with cleavage sites in elastin being readily accessible to enzymatic attack.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Mecham, RP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,BOX 8228,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053325, R01HL047328, R37HL053325, R01HL041926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47328, HL41926, HL53325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BANDA MJ, 1981, METHODS STUDYING MON, P603; Bieth JG, 1986, REGULATION MATRIX AC, P217; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; INDIK Z, 1990, GENES EXTRACELLULAR, P221; KETTNER C, 1981, BIOCHEM J, V195, P369, DOI 10.1042/bj1950369; LANSING AI, 1952, ANAT RECORD, V114, P555, DOI 10.1002/ar.1091140404; MEANS GE, 1971, CHEM MODIFICATION PR, P119; MORIHARA K, 1967, ARCH BIOCHEM BIOPHYS, V120, P68, DOI 10.1016/0003-9861(67)90599-1; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; RUCKER RB, 1984, ENV HLTH PERSPECT, V53, P179; SAULNIER J, 1992, EUR J CLIN CHEM CLIN, V30, P285; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, P160; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; WELGUS HG, 1981, J BIOL CHEM, V256, P9516; WELGUS HG, 1985, J BIOL CHEM, V260, P1052	31	175	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18071	18076		10.1074/jbc.272.29.18071	http://dx.doi.org/10.1074/jbc.272.29.18071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218437	hybrid			2022-12-27	WOS:A1997XL73500027
J	Sippel, CJ; Dawson, PA; Shen, TX; Perlmutter, DH				Sippel, CJ; Dawson, PA; Shen, TX; Perlmutter, DH			Reconstitution of bile acid transport in a heterologous cell by cotransfection of transporters for bile acid uptake and efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE CANALICULAR MEMBRANE; ECTO-ATPASE PROTEIN; INFLUENZA-VIRUS; RAT; EXPRESSION; TAUROCHOLATE; MECHANISMS; ADHESION; BICARBONATE; ISOFORMS	The rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105 (CBATP) is a 110-kDa transmembrane phosphoglycoprotein that is thought to have bile acid efflux, ecto-ATPase, and cell adhesion properties, Its extracellular amino-terminal domain is highly homologous to carcinoembryonic antigen (CEA), a glycophosphatidyl inositol anchored membrane protein with cell adhesion properties and a marker for adenocarcinoma, In the current study, we examined the possibility of more clearly defining the role of CBATP in bile acid efflux by cotransfecting a heterologous cell, the COS cell, with cDNAs for a bile acid importer, the ileal bile acid transporter (IBAT), as well as for CBATP, The results show that when IBAT mediates uptake of [H-3]taurocholate to a level 20-fold higher than that achieved previously by nonspecific pinocytosis, CBATP mediates time-, temperature- and concentration-dependent efflux, Efflux of [H-3]taurocholate mediated by CBATP in the cotransfected COS cells is saturable and has curvilinear kinetic characteristics (V-max = 400 pmol/mg protein/min, K-m = 70 mu M). It is inhibited by 4,4'-diisothiocysanostilbene-2,2-disulfonic acid and dependent on ATP but not dependent; on membrane potential, Although CEA could not mediate bile acid efflux ill COS cells cotransfected with IBAT and CEA, efflux of [H-3]taurocholate was detected in COS cells cotransfected with HEAT and a chimeric molecule having the carboxyl-terminal tail and membrane spanning domain of CBATP and the amino-terminal extracellular tail of CEA. Taken together, these data provide further evidence that CBATP confers bile acid efflux properties on heterologous cells and that its cytoplasmic tail and membrane spanning segment are integral to this property. The data also establish a model system for more clearly defining the molecular determinants of bile acid transport mediated by this molecule.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,WINSTON SALEM,NC 27157	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047084, R29DK047987] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HDO7409] Funding Source: Medline; NIDDK NIH HHS [R29 DK047987, DK47084] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT T, 1988, Genomics, V3, P59, DOI 10.1016/0888-7543(88)90160-7; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; BLITZER BL, 1982, GASTROENTEROLOGY, V82, P346; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DUMONT M, 1980, GASTROENTEROLOGY, V79, P82; FORKER EL, 1977, ANNU REV PHYSIOL, V39, P323, DOI 10.1146/annurev.ph.39.030177.001543; GAITMAN ZC, 1995, PHYSIOL REV, V75, P261; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDISON WGM, 1978, AM J PHYSIOL, V235, pE158, DOI 10.1152/ajpendo.1978.235.2.E158; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KAST C, 1994, J BIOL CHEM, V269, P5179; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; SCHARSCHMIDT BF, 1983, GASTROENTEROLOGY, V85, P1199; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SKEHEL JJ, 1992, NATURE, V358, P110, DOI 10.1038/358110b0; STEVE A, 1991, NEURON, V7, P403; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WONG MH, 1994, J BIOL CHEM, V269, P1340; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18290	18297		10.1074/jbc.272.29.18290	http://dx.doi.org/10.1074/jbc.272.29.18290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218468	hybrid			2022-12-27	WOS:A1997XL73500058
J	Stevens, VL; Tang, JH				Stevens, VL; Tang, JH			Fumonisin B-1-induced sphingolipid depletion inhibits vitamin uptake via the glycosylphosphatidylinositol-anchored folate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-MONILIFORME; BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; INTRACELLULAR-TRANSPORT; EPITHELIAL-CELLS; MEMBRANE; CAVEOLAE; INTERNALIZATION; MICRODOMAINS; CANCER	The folate receptor, like many glycosylphosphatidylinositol-anchored proteins, is found associated with membrane domains that art? insoluble in Triton X-100 at low temperature and that are enriched in cholesterol and sphingolipids. Depletion of cellular cholesterol has been shown to inhibit vitamin uptake by this receptor (Chang, W.-J., Rothberg, K, G., Kamen, B. A,, and Anderson, BP. G. W. (1993) J, Cell Biol, IIS, 63-69), suggesting that these domains regulate this process. In this study, the importance of sphingolipids for folate receptor function was investigated in Caco-2 cells using fumonisin B-1, a mycotoxin that inhibits the biosynthesis of these lipids, The folate receptor-mediated transport of 5-methyltetrahydrofolate was almost completely blocked in cells in which sphingolipids had been reduced by similar to 40%. This inhibition was dependent on the concentration and duration of the treatment with the mycotoxin and was mediated by the sphingolipid decrease, Neither receptor-mediated nor facilitative transport was inhibited by fumonisin B-1 treatment, indicting that the effect of sphingolipid depletion was specific for folate receptor-mediated vitamin uptake, A concurrent loss in the total amount of folate binding capacity in the cells was seen as sphingolipids were depleted, suggesting a causal relationship between folate receptor number and vitamin uptake. These findings suggest that dietary exposure to fumonisin B-1 could adversely affect folate uptake and potentially compromise cellular processes dependent on this vitamin, Furthermore, because folate deficiency causes neural tube defects, some birth defects unexplained by other known risk factors may be caused by exposure to fumonisin B-1.	EMORY UNIV,SCH MED,DIV CANC BIOL,DEPT RADIAT ONCOL,ATLANTA,GA 30335; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30335	Emory University; Emory University								ALBRECHT LJ, 1994, TEX MED, V90, P16; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUTTERWORTH CE, 1993, J AM COLL NUTR, V12, P438, DOI 10.1080/07315724.1993.10718334; Canfield MA, 1996, AM J EPIDEMIOL, V143, P1; Canfield MA, 1996, AM J EPIDEMIOL, V143, P12; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; DANSKY LV, 1992, NEUROLOGY, V42, P32; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FLOSS JL, 1994, MYCOPATHOLOGIA, V128, P33, DOI 10.1007/BF01104276; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; GARCIA M, 1993, J CELL SCI, V104, P1281; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROSS SM, 1994, MYCOPATHOLOGIA, V128, P111, DOI 10.1007/BF01103018; GROSS SM, 1994, MYCOPATHOLOGIA, V8, P2357; GROSS SM, 1994, FASEB J, V8, P2357; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIBBARD BM, 1993, BRIT J OBSTET GYNAEC, V100, P307, DOI 10.1111/j.1471-0528.1993.tb12970.x; HORVATH A, 1994, EMBO J, V13, P36877; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schroeder J. J., 1995, MOL APPROACHES FOOD, P429; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; *TEX DEP HLTH, 1992, INV CLUST NEUR TUB D, P4; WANG E, 1991, J BIOL CHEM, V266, P14486; YANG CS, 1980, CANCER RES, V40, P2633; YU J, 1973, J SUPRAMOL STRUCT, V3, P233	50	152	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18020	18025		10.1074/jbc.272.29.18020	http://dx.doi.org/10.1074/jbc.272.29.18020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218430	hybrid			2022-12-27	WOS:A1997XL73500020
J	Zhou, QS; Zhao, J; Stout, JG; Luhm, RA; Wiedmer, T; Sims, PJ				Zhou, QS; Zhao, J; Stout, JG; Luhm, RA; Wiedmer, T; Sims, PJ			Molecular cloning of human plasma membrane phospholipid scramblase - A protein mediating transbilayer movement of plasma membrane phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOAGULANT ACTIVITY; HUMAN ERYTHROCYTES; PHOSPHATIDYLSERINE; EXPOSURE; CELL; REDISTRIBUTION; ASYMMETRY; PLATELETS; SURFACE	The rapid movement of phospholipids (PL) between plasma membrane leaflets in response to increased intracellular Ca2+ is thought to play a key role in expression of platelet procoagulant activity and in clearance of injured or apoptotic cells. We recently reported isolation of a similar to 37-kDa protein in erythrocyte membrane that mediates Ca2+-dependent movement of PL between membrane leaflets, similar to that observed upon elevation of Ca2+ in the cytosol (Basse, F., Stout, J. G., Sims, P. J., and Wiedmer, T. (1996) J. Biol. Chem. 271, 17205-17210). Based on internal peptide sequence obtained from this protein, a 1,445-base pair cDNA was cloned from a K-562 cDNA Library, The deduced ''PL scramblase'' protein is a proline-rich, type II plasma membrane protein with a single transmembrane segment near the C terminus. Antibody against the deduced C-terminal peptide was found to precipitate the similar to 37-kDa red blood cell protein and absorb PL scramblase activity, confirming the identity of the cloned cDNA to erythrocyte PL scramblase, Ca2+-dependent PL scramblase activity was also demonstrated in recombinant protein expressed from plasmid containing the cDNA. Quantitative immunoblotting revealed an approximately 10-fold higher abundance of PL scramblase in platelet (similar to 10(4) molecules/cell) than in erythrocyte (similar to 10(3) molecules/cell), consistent with apparent increased PL scramblase activity of the platelet plasma membrane, PL scramblase mRNA was found in a variety of hematologic and nonhematologic cells and tissues, suggesting that this protein functions in all cells.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53201	Versiti Blood Center of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSE F, 1996, J BIOL CHEM, V271, P17025; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; CHANG CP, 1993, J BIOL CHEM, V268, P7171; Comfurius P, 1996, BIOCHEMISTRY-US, V35, P7631, DOI 10.1021/bi9606859; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; MARTIN DW, 1995, J BIOL CHEM, V270, P10468, DOI 10.1074/jbc.270.18.10468; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Sulpice JC, 1996, BIOCHEMISTRY-US, V35, P13345, DOI 10.1021/bi960624a; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; WANG RH, 1993, J CLIN INVEST, V92, P1326, DOI 10.1172/JCI116706; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	19	346	359	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18240	18244		10.1074/jbc.272.29.18240	http://dx.doi.org/10.1074/jbc.272.29.18240			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218461	hybrid			2022-12-27	WOS:A1997XL73500051
J	Cheng, J; Weber, JD; Baldassare, JJ; Raben, DM				Cheng, J; Weber, JD; Baldassare, JJ; Raben, DM			Ablation of G(o) alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; BETA-GAMMA-SUBUNITS; MITOGENIC SIGNAL-TRANSDUCTION; CHOLINE KINASE-ACTIVITY; G-PROTEIN ONCOGENES; CULTURED FIBROBLASTS; ADENYLYL CYCLASE; PITUITARY-TUMORS; ENDOCRINE TUMORS; DNA-SYNTHESIS	Modulation of the components involved in mitogenic signaling cascades is critical to the regulation of cell growth. GTP-binding proteins and the stimulation of phosphatidylcholine (PC) hydrolysis have been shown to play major roles in these cascades, One of the enzymes involved in PC hydrolysis, a PC-specific phospholipase C (PC-PLC) has received relatively little attention, In this paper we examined the role of a particular heterotrimeric GTP-binding protein, G(o), in the regulation of cell growth and PC-PLC-mediated hydrolysis of PC in IIC9 fibroblasts. The G(o) alpha-subunit was ablated in IIC9 cells by stable expression of antisense RNA, These stably transfected cells acquired a transformed phenotype as indicated by: (a) the formation of multiple foci in monolayer cultures, (b) the acquisition of anchorage-independent growth in soft agar; and (c) an increased level of thymidine incorporation in the absence of added mitogens. These data implicate G(o) alpha as a novel tumor suppressor, Interestingly, PC-PLC activity was constitutively active in the G(o) alpha-ablated cells as evidenced by the chronically elevated levels of diacylglycerol and phosphorylcholine in the absence of growth factors, In contrast, basal activities of PG-phospholipase D, phospholipase A(2), or phosphoinositol-PLC were not affected, These data demonstrate, for the first time, a role for G(o) in regulating cell growth and provide definitive evidence for the existence of a PC-PLC in eukaryotic cells, The data further indicate that a subunit of G(o), is involved is regulating this enzyme.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; ST LOUIS UNIV, SCH MED, DEPT CELL SCI, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT PHARMACOL SCI, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT PHYSIOL SCI, ST LOUIS, MO 63104 USA	Johns Hopkins University; Saint Louis University; Saint Louis University; Saint Louis University				Weber, Jason/0000-0002-1069-6983	NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1988, CANCER RES, V48, P2756; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BLANK JL, 1992, J BIOL CHEM, V267, P23069; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLLU R, 1988, ENDOCRINOLOGY, V122, P1176, DOI 10.1210/endo-122-3-1176; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOUGLASS EC, 1990, CYTOGENET CELL GENET, V53, P87, DOI 10.1159/000132901; EXTON JH, 1993, ADV SEC MESS PHOSPH, V28, P65; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HUFF V, 1992, CANCER RES, V52, P6117; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; KATO K, 1987, CANCER RES, V47, P5800; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LAVIADA ID, 1995, FEBS LETT, V364, P301, DOI 10.1016/0014-5793(95)00414-5; LEE SB, 1993, J BIOL CHEM, V268, P25952; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MANDAHL N, 1994, J CANCER RES CLIN, V120, P707, DOI 10.1007/BF01194267; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MURTHY KS, 1995, MOL PHARMACOL, V48, P293; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; Podo F, 1996, ANTICANCER RES, V16, P1399; PREISS J, 1986, J BIOL CHEM, V261, P8597; RABEN DM, 1990, J CELL BIOCHEM, V44, P117, DOI 10.1002/jcb.240440206; RABEN DM, 1987, J CELL PHYSIOL, V130, P466, DOI 10.1002/jcp.1041300322; RANDELL E, 1992, BIOCHIM BIOPHYS ACTA, V1124, P273, DOI 10.1016/0005-2760(92)90139-M; RANGAN LA, 1991, CELL REGUL, V2, P311, DOI 10.1091/mbc.2.4.311; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; SANDS WA, 1994, BIOCHEM BIOPH RES CO, V199, P461, DOI 10.1006/bbrc.1994.1251; SEUWEN K, 1992, ADV CANCER RES, V58, P75, DOI 10.1016/S0065-230X(08)60291-2; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TIAN WN, 1993, LIFE SCI, V52, P1899, DOI 10.1016/0024-3205(93)90630-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHARA H, 1995, J CUTAN PATHOL, V22, P146, DOI 10.1111/j.1600-0560.1995.tb01397.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKELAM MJO, 1993, BIOCHEM SOC T, V21, P873; WATERFIELD MD, 1989, BRIT MED BULL, V45, P570, DOI 10.1093/oxfordjournals.bmb.a072343; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	66	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17312	17319		10.1074/jbc.272.28.17312	http://dx.doi.org/10.1074/jbc.272.28.17312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211868	hybrid			2022-12-27	WOS:A1997XK16500011
J	McNew, JA; Sogaard, M; Lampen, NM; Machida, S; Ye, RR; Lacomis, L; Tempst, P; Rothman, JE; Sollner, TH				McNew, JA; Sogaard, M; Lampen, NM; Machida, S; Ye, RR; Lacomis, L; Tempst, P; Rothman, JE; Sollner, TH			Ykt6p, a prenylated SNARE essential for endoplasmic reticulum golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY PATHWAY; FUSION PROTEIN; TRITON X-114; IN-VITRO; YEAST; COMPLEX	Vesicular transport between secretory compartments requires specific recognition molecules called SNAREs, Here we report the identification of three putative SNAREs, p14 (Sft1p), p28 (Qos1p), and a detailed characterization of p26 (Ykt6p). All three were originally isolated as interacting partners of the cis Golgi target membrane-associated SNARE Sed5p, when Sec18p (yeast NSF) was inactivated, YKT6 is an essential gene that codes for a novel vesicle-associated SNARE functioning at the endoplasmic reticulum-Golgi transport step in the yeast secretory pathway, Depletion of Ykt6p results in the accumulation of the pi precursor (endoplasmic reticulum form) of the vacuolar enzyme carboxypeptidase Y and morphological abnormalities consistent with a defect in secretion, Membrane localization of Ykt6p is essential fur protein function and is normally mediated by isoprenylation, However, replacement of the isoprenylation motif with a bona fide transmembrane anchor results in a functional protein confirming that membrane localization, but not isoprenylation pel se, is required for function, Ykt6p and its homologues are highly conserved from yeast to human as demonstrated by the functional complementation of the lass of Ykt6p by its human counterpart, This is the first example of a human SNARE protein functionally replacing a yeast SNARE, This observation implies that the specific details of the vesicle targeting code, like the genetic code, are conserved in evolution.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			McNew, James/ABD-8081-2020; McNew, James/AAV-4911-2020	McNew, James/0000-0001-8459-3664	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017722] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM17722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P1095; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MITCHELL DA, 1995, METHOD ENZYMOL, V250, P68; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567	58	174	185	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17776	17783		10.1074/jbc.272.28.17776	http://dx.doi.org/10.1074/jbc.272.28.17776			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211930	hybrid			2022-12-27	WOS:A1997XK16500073
J	Mould, AP; Askari, JA; Aota, S; Yamada, KM; Irie, A; Takada, Y; Mardon, HJ; Humphries, MJ				Mould, AP; Askari, JA; Aota, S; Yamada, KM; Irie, A; Takada, Y; Mardon, HJ; Humphries, MJ			Defining the topology of integrin alpha 5 beta 1-fibronectin interactions using inhibitory anti-alpha 5 and anti-beta 1 monoclonal antibodies - Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha 5 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; ADHESIVE FUNCTION; LIGAND-BINDING; SITE; IDENTIFICATION; RECEPTOR; REGION; FRAGMENTS; MIGRATION	The high affinity interaction of integrin alpha 5 beta 1 with the central cell binding domain (CCBD) of fibronectin requires both the Arg-Gly-Asp (RGD) sequence (in the 10th type III repeat) and a second site (in the adjacent 9th type III repeat) which synergizes with RGD, We have attempted to map the fibronectin binding interface on alpha 5 beta 1 using monoclonal antibodies (mAbs) that inhibit ligand recognition, The binding of two anti-alpha 5 mAbs (P1D6 and JBS5) to alpha 5 beta 1 was strongly inhibited by a tryptic CCBD fragment of fibronectin (containing both synergy sequence and RGD) but not by GRGDS peptide. Using recombinant wild type and mutated fragments of the CCBD, we show that the synergy region of the 9th type III repeat is involved in blocking the binding of P1D6 and JBS5 to alpha 5 beta 1. In contrast, binding of the anti-beta 1 mAb P4C10 to alpha 5 beta 1 was inhibited to a similar extent by GRGDS peptide, the tryptic CCBD fragment, or recombinant proteins lacking the synergy region, indicating that the RGD sequence is involved in blocking P4C10 binding, P1D6 inhibited the interaction of a wild type CCBD fragment with alpha 5 beta 1 but had no effect on the binding of a mutant fragment that lacked the synergy region, The epitopes of P1D6 and JBS5 mapped to the NH2-terminal repeats of the alpha 5 subunit, Our results indicate that the synergy region is recognized primarily by the alpha 5 subunit (in particular by its NH2-terminal repeats) but that the beta 1 subunit plays the major role in binding of the RGD sequence. These findings provide new insights into the mechanisms, specificity, and topology of integrin-ligand interactions.	NIDR, CRANIOFACIAL DEV BIOL & REGENERAT BRANCH, NIH, BETHESDA, MD 20892 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Scripps Research Institute; University of Oxford	Mould, AP (corresponding author), UNIV MANCHESTER, SCH BIOL SCI, WELLCOME TRUST CTR CELL MATRIX RES, 2-205 STOPFORD BLDG, OXFORD RD, MANCHESTER M13 9PT, LANCS, ENGLAND.			takada, yoshikazu/0000-0001-5481-9589; Yamada, Kenneth/0000-0003-1512-6805; Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MAHLER HR, 1966, BIOL CHEM, P250; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1996, J CELL SCI, V109, P2613; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; OBARA M, 1995, EXP CELL RES, V216, P273, DOI 10.1006/excr.1995.1033; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	37	139	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17283	17292		10.1074/jbc.272.28.17283	http://dx.doi.org/10.1074/jbc.272.28.17283			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211865	hybrid			2022-12-27	WOS:A1997XK16500008
J	Oh, CS; Toke, DA; Mandala, S; Martin, CE				Oh, CS; Toke, DA; Mandala, S; Martin, CE			ELO2 and ELO3, homologues of the Saccharomyces cerevisiae ELO1 gene, function in fatty acid elongation and are required for sphingolipid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; NEUROSPORA-CRASSA; PLASMA-MEMBRANE; ACYLTRANSFERASE; PHOSPHOLIPIDS; PHOSPHATE; INHIBITOR; CLONING	ELO2 and ELO3 were identified from the Saccharomyces cerevisiae genome data base as homologues of ELO1, a gene involved in the elongation of the fatty acid 14:0 to 16:0, Mutations in these genes have previously been shown to produce pleiotropic effects involving a number of membrane functions, The simultaneous disruption of ELO2 and ELO3 has also been shown to produce synthetic lethality, indicating that they have related and/or overlapping functions, Gas chromatography and gas chromatography/mass spectroscopy analyses reveal that mull mutations of ELO2 and ELO3 produce defects in the formation of very long chain fatty acids, Analysis of the null mutants indicates that these genes encode components of the membrane-bound fatty acid elongation systems that produce the 26-carbon very long chain fatty acids that are precursors for ceramide and sphingolipids, Elo2p appears to be involved in the elongation of fatty acids up to 24 carbons, it appears to have the highest affinity for substrates with chain lengths less than 22 carbons. Elo3p apparently has a broader substrate specificity and is essential for the conversion of 24-carbon acids to as carbon species. Disruption of either gene reduces cellular sphingolipid levels and results in the accumulation of the long chain base, phytosphingosine. Null mutations In ELO3 result in accumulation of labeled precursors into inositol phosphoceramide, with little labeling in the more complex mannosylated sphingolipids, whereas disruption of ELO2 results in reduced levels of all sphingolipids.	RUTGERS STATE UNIV,BUR BIOL RES,NELSON BIOL LABS,PISCATAWAY,NJ 08855; MERCK RES LABS,RAHWAY,NJ 07065	Rutgers State University New Brunswick; Merck & Company					NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON LR, 1983, BIOCHIM BIOPHYS ACTA, V735, P252, DOI 10.1016/0005-2736(83)90300-0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; GARCIAARRANZ M, 1994, J BIOL CHEM, V269, P18076; HANSON BA, 1980, J LIPID RES, V21, P309; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; LESTER RL, 1993, ADV LIPID RES, V26, P253; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; Sherman F., 1982, METHODS YEAST GENETI; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	22	380	407	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17376	17384		10.1074/jbc.272.28.17376	http://dx.doi.org/10.1074/jbc.272.28.17376			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211877	hybrid			2022-12-27	WOS:A1997XK16500020
J	Hemmer, W; McGlone, M; Tsigelny, I; Taylor, SS				Hemmer, W; McGlone, M; Tsigelny, I; Taylor, SS			Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; REGULATORY SUBUNIT; PEPTIDE INHIBITOR; KINETIC MECHANISM; ESCHERICHIA-COLI; GAMMA-SUBUNIT; PHOSPHORYLATION; FAMILY; MUTAGENESIS	A glycine-rich loop in the ATP-binding site is one of the most highly conserved sequence motifs in protein kinases, Each conserved glycine (Gly-50, Gly-52, and Gly-SS) in the catalytic (C) subunit of cAMP-dependent protein kinase (cAPK) was replaced with Ser and/or Ala. Active mutant proteins were expressed in Escherichia coli, purified to apparent homogeneity, separated into phosphoisoforms, and characterized, Replacing Gly-55 had minimal effects on steady-state kinetic parameters, whereas replacement of either Gly-50 or Gly-52 had major effects on both K-m and k(cat) values consistent. with the prediction of the importance of the tip of the glycine-rich loop for catalysis, Substitution of Gly-50 caused a 5-8-fold reduction in K-m(ATP), an 8-12-fold increase in K-m(peptide), and a 3-5-fold drop in k(cat). The K-m(ATP) and K-m(peptide) values of C(G52S) were increased 8- and 18-fold, respectively, and the k(cat) was decreased 6-fold. In contrast to catalytic efficiency, the ATPase: rates of C(G50S) and C(G52S) were increased by more than an order of magnitude, The thermostability of each mutant was slightly increased, Unphosphorylated C(G52S) was characterized as well as several isoforms phosphorylated at a single site, Ser-338. All of these phosphorylation-defective mutants displayed a substantial decrease in bath enzymatic activity and thermal stability that correlated with the missing phosphate at Thr-197. These results are correlated with the crystal structure, models of the respective mutant proteins, and conservation of the Glys within the protein kinase family.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; SWISS FED OFF PUBL HLTH,DIV FOOD SCI,SECT MICROBIOL & HYG,CH-3003 BERN,SWITZERLAND	University of California System; University of California San Diego								ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ADAMS JA, 1993, PROTEIN SCI, V2, P2177, DOI 10.1002/pro.5560021217; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BUBIS J, 1988, J BIOL CHEM, V263, P9668; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; COOKE M P, 1989, New Biologist, V1, P66; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEMMER W, 1996, ANAL BIOCHEM, V245, P115; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; LEW J, 1997, IN PRESS BIOCHEMISTR; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	115	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16946	16954		10.1074/jbc.272.27.16946	http://dx.doi.org/10.1074/jbc.272.27.16946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202006	hybrid			2022-12-27	WOS:A1997XH44600038
J	Tozser, J; Bagossi, P; Weber, IT; Louis, JM; Copeland, TD; Oroszlan, S				Tozser, J; Bagossi, P; Weber, IT; Louis, JM; Copeland, TD; Oroszlan, S			Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTRATE-BINDING-SITE; CLEAVAGE SITES; RETROVIRAL PROTEINASES; MOLECULAR-DYNAMICS; PROTEASE; TYPE-1; REQUIREMENTS; GAG	Two major types of cleavage sites with different sequence preferences have been proposed for the human immunodeficiency virus type 1 (HIV-1) proteinase, To understand the nature of these sequence preferences better, single and multiple amino acid substitutions were introduced into a type 1 cleavage site peptide, thus changing it to a naturally occurring type 2 cleavage site sequence, Our results indicated that the previous classification of the retroviral cleavage sites may not be generally valid and that the preference for a residue at a particular position in the substrate depends strongly on the neighboring residues, including both those at the same side and at the opposite side of the peptide backbone of the substrate, Based on these results, pseudosymmetric (palindromic) substrates were designed, The retroviral proteinases are symmetrical dimers of two identical subunits; however, the residues of naturally occurring cleavage sites do not show symmetrical arrangements, and no obvious symmetrical substrate preference has been observed for the specificity of HIV proteinase, To examine the role of the asymmetry created by the peptide bonds on the specificity of the respective primed and nonprimed halves of the binding site, amino acid substitutions were introduced into a palindromic sequence, In general, the results suggested that the asymmetry does not result in substantial differences in specificity of the S-3 and S-3' subsites, whereas its effect is more pronounced for the S-2 and S-2' subsites, Although it was possible to design several good palindromic substrates, asymmetrical arrangements may be preferred by the HIV proteinase.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; NIDDK, CELLULAR & DEV BIOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, MOL VIROL & CARCINOGENESIS LAB, ADV BIOSCI LABS, FREDERICK, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tozser, J (corresponding author), DEBRECEN UNIV MED, SCH MED, DEPT BIOCHEM, H-4012 DEBRECEN, HUNGARY.		Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Louis, John M/0000-0002-0052-1899; Tozser, Jozsef/0000-0001-5076-8729	NATIONAL CANCER INSTITUTE [R01CA058166] Funding Source: NIH RePORTER; NCI NIH HHS [CA58166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagossi P, 1996, PROTEIN ENG, V9, P997, DOI 10.1093/protein/9.11.997; BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; Chou KC, 1996, PROTEINS, V24, P51, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;51::AID-PROT4&gt;3.0.CO;2-R; COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334; DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FAN NS, 1995, J BIOL CHEM, V270, P13573; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; GAEDIGKNITSCHKO K, 1995, FEBS LETT, V357, P275, DOI 10.1016/0014-5793(94)01370-G; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; Mellors JW, 1996, NAT MED, V2, P274, DOI 10.1038/nm0396-274; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PETTIT SC, 1991, J BIOL CHEM, V266, P14539; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; POZSGAY M, 1981, EUR J BIOCHEM, V115, P497; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOMASSELLI AG, 1993, PROTEIN SCI, V2, P2167, DOI 10.1002/pro.5560021216; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; TOZSER J, 1986, ACTA BIOCHIM BIOPHYS, V21, P335; Weber IT, 1996, PROTEIN ENG, V9, P679, DOI 10.1093/protein/9.8.679; Winslow D L, 1995, AIDS, V9 Suppl A, pS183; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	36	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16807	16814		10.1074/jbc.272.27.16807	http://dx.doi.org/10.1074/jbc.272.27.16807			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201986	hybrid			2022-12-27	WOS:A1997XH44600018
J	Anand, G; Yin, XY; Shahidi, AK; Grove, L; Prochownik, EV				Anand, G; Yin, XY; Shahidi, AK; Grove, L; Prochownik, EV			Novel regulation of the helix-loop-helix protein Id1 by S5a, a subunit of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING PROTEINS; MUSCLE DIFFERENTIATION PROGRAM; B-CELL DEVELOPMENT; C-MYC; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; NEGATIVE REGULATOR; LEUCINE-ZIPPER; GENE FAMILY; G(1) PROGRESSION	Id proteins negatively regulate the dimerization, DNA binding, and biological properties of basic helix-loop-helix proteins. In a search for novel factors that interact with Id1, we identified a component of the 26 S proteasome, S5a, that has previously been implicated only in the recognition of ubiquitinated polypeptides destined for proteolysis. S5a interacts strongly with Id1, less strongly with the basic helix loop-helix proteins MyoD and E12, and not at all with other Id proteins. S5a restores DNA binding by MyoD-Id1 and E12-Id1 heterodimers, enhances DNA binding by MyoD and E12 homodimers, and reverses Id1-mediated repression of the muscle creatine kinase promoter during myogenic differentiation. Mutagenesis experiments showed that amino acids flanking the helix-loop-helix domain plus three residues in the first helix of Id1 impart S5a recognition. This requires only the NH2-terminal half of S5a. S5a thus appears to promote the positive regulation of myogenic genes through ubiquitin-independent mechanisms involving inhibition of Id1 and the enhancement of DNA binding by MyoD and E12. This latter property may permit the selection of novel promoter binding sites during myogenesis.	CHILDRENS HOSP PITTSBURGH, HEMATOL ONCOL SECT, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DONAGHUE M, 1988, GENE DEV, V2, P1779; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FARMER K, 1992, J BIOL CHEM, V267, P5631; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FERELL K, 1996, FEBS LETT, V381, P143; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARA E, 1994, J BIOL CHEM, V269, P2139; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2622; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGATA T, 1991, BIOCHEM BIOPH RES CO, V180, P1194, DOI 10.1016/S0006-291X(05)81322-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REICHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSE MR, 1990, UCLA SYM BI, V123, P19; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J., 2002, MOL CLONING LAB MANU; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAM SW, 1994, ONCOGENE, V9, P2663; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VANDOREN M, 1991, DEVELOPMENT, V113, P245; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	113	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19140	19151		10.1074/jbc.272.31.19140	http://dx.doi.org/10.1074/jbc.272.31.19140			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235903	hybrid			2022-12-27	WOS:A1997XP06300009
J	Glasgow, WC; Hui, RT; Everhart, AL; Jayawickreme, SP; AngermanStewart, J; Han, BB; Eling, TE				Glasgow, WC; Hui, RT; Everhart, AL; Jayawickreme, SP; AngermanStewart, J; Han, BB; Eling, TE			The linoleic acid metabolite, (13S)-hydroxyperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation - Differential response in Syrian hamster embryo tumor suppressor phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ARACHIDONIC-ACID; DNA-SYNTHESIS; MAP KINASE; MITOGENIC RESPONSE; EGF RECEPTOR; CELLS; CANCER; MODULATION; EXPRESSION	In Syrian hamster embryo (SHE) fibroblasts, epidermal growth factor receptor (EGFR) tyrosine kinase activity regulates the metabolism of endogenous linoleic acid to (13S)-hydroperoxyoctadecadienoic acid (13S)-HPODE), (13S)-HPODE stimulates EGF-dependent mitogenesis in a SHE cell phenotype, which expresses tumor suppressor genes (supB(+)), but was not effective in a variant that does not express these suppressor genes (supB(-)). In the present study, we have investigated the potential effects of this lipid metabolite on the EGFR signaling pathways in these two SHE cell lines, Treatment of quiescent SHE cells with EGF produced a rapid, transient increase in the tyrosine phosphorylation of EGFR, Dependence on EGF concentration for EGFR tyrosine phosphorylation was similar in both SHE cell lines, but a more prolonged phosphorylation was detected in the supB(-) variant. Incubation of supB(+) cells with (13S)-HPODE and EGF increased EGFR autophosphorylation and tyrosine phosphorylation on several signaling proteins with Src homology-a domains including GTPase-activating protein, The lipid metabolite did not significantly alter EGF-dependent tyrosine phosphorylation in the supB(-) variant, Tyrosine phosphorylation of mitogen-activated protein (MAP) kinase was also measured, The addition of (13S)-HPODE increased the extent and duration of MAP kinase tyrosine phosphorylation in supB(+) cells but not in the supB(-) variant, MAP kinase activity in supB(+) cells, as measured in immunoprecipitates from cells after the addition of EGF, was increased by the presence of (13S)-HPODE. The addition of (1SS)-HPODE did not directly alter EGFR kinase activity or the internalization of the EGFR, However, the addition of (13S)-HPODE to supB(+) cells extended the tyrosine phosphorylation of the EGFR in response to EGF, The dephosphorylation of the EGFR was measured directly, and a slower rate was observed in the supB(-) compared with the supB(+) cells, Incubation of the supB(+) cells with (1SS)-HPODE attenuated the dephosphorylation of the EGFR. Thus, (13S)-HPODE stimulates EGF-dependent mitogenesis and up-regulation of EGF-dependent tyrosine phosphorylation by inhibiting the dephosphorylation of the EGFR. This study shows that a metabolite of an essential dietary fatty acid, linoleic acid, can modulate tyrosine phosphorylation and activity of key signal transduction proteins in a growth factor mitogenic pathway.	NIEHS,EICOSANOID BIOCHEM SECT,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; MERCER UNIV,SCH MED,DIV BASIC MED SCI,MACON,GA 31207	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Mercer University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANGERMANSTEWART JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P378, DOI 10.1006/abbi.1995.1243; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COWLEN MS, 1993, BIOCHIM BIOPHYS ACTA, V1174, P234, DOI 10.1016/0167-4781(93)90192-G; COWLEN MS, 1992, CANCER RES, V52, P6912; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUNK CD, 1993, BIOCHIM BIOPHYS ACTA, V754, P135; GLASGOW WC, 1990, MOL PHARMACOL, V38, P503; GLASGOW WC, 1994, ARCH BIOCHEM BIOPHYS, V311, P286, DOI 10.1006/abbi.1994.1239; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HERNANDEZSOTOMAYOR SMT, 1993, P NATL ACAD SCI USA, V90, P7691, DOI 10.1073/pnas.90.16.7691; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; LASGOW WC, 1996, MOL PHARMACOL, V49, P1042; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; RAO GN, 1994, J BIOL CHEM, V269, P32586; ROSE DP, 1989, BIOCHEM BIOPH RES CO, V164, P277, DOI 10.1016/0006-291X(89)91714-2; ROSE DP, 1993, CANCER RES, V53, P4686; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SORKIN A, 1992, J BIOL CHEM, V267, P8672; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THUN MJ, 1993, CANCER RES, V53, P1322; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251	39	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19269	19276		10.1074/jbc.272.31.19269	http://dx.doi.org/10.1074/jbc.272.31.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235921	hybrid			2022-12-27	WOS:A1997XP06300027
J	Kostenis, E; Degtyarev, MY; Conklin, BR; Wess, J				Kostenis, E; Degtyarev, MY; Conklin, BR; Wess, J			The N-terminal extension of G alpha(q) is critical for constraining the selectivity of receptor coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; BETA-GAMMA; MUSCARINIC RECEPTOR; PHOSPHOLIPASE-C; PALMITOYLATION; CLONING; IDENTIFICATION; SPECIFICITY; EXPRESSION; MEMBRANE	Characteristically, an individual member of the superfamily of G protein coupled receptors can interact only with a limited number of the many structurally closely related G protein heterotrimers that are expressed within a cell. Interestingly, the N termini of two G protein a subunits, G alpha(q) and G alpha(11), differ from those of other or subunits in that they display a unique, highly conserved six-amino acid extension, To test the hypothesis that this sequence element is critical for proper receptor recognition, we prepared a G alpha(q) deletion mutant (-6q) lacking these first six amino acids. The -6q construct (or wild type G alpha(q) as a control) was coexpressed (in COS-7 cells) with several different G(i/o)- or G(s)-coupled receptors, and ligand-induced increases in inositol phosphate production were determined as a measure of G protein activation. Whereas these receptors did not efficiently interact with wild type G alpha(q), most of them gained the ability to productively couple to -6q. Additional experiments indicated that the observed functional promiscuity of -6q is not due to overexpression (as compared with wild type G alpha q) or to a lack of palmitoylation. We conclude that the N-terminal extension characteristic for G alpha(q/11) proteins is critical. for constraining the receptor coupling selectivity of these subunits, indicative of a novel mechanism by which the fidelity of receptor-G protein interactions can be regulated.	NIDDK,NIH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT PHARMACOL,SAN FRANCISCO,CA 94141	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes			Conklin, Bruce/E-4738-2019					ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chen BW, 1996, BBA-BIOMEMBRANES, V1281, P125, DOI 10.1016/0005-2736(96)00039-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZHU J, 1995, LIFE SCI, V56, P201	42	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19107	19110		10.1074/jbc.272.31.19107	http://dx.doi.org/10.1074/jbc.272.31.19107			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235898	hybrid			2022-12-27	WOS:A1997XP06300004
J	Souttou, B; Ahmad, S; Riegel, AT; Wellstein, A				Souttou, B; Ahmad, S; Riegel, AT; Wellstein, A			Signal transduction pathways involved in the mitogenic activity of pleiotrophin - Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; AFFIN REGULATORY PEPTIDE; NIH 3T3; HEPARIN; CELLS; RECOMBINANT; EXPRESSION; CLONING; ACID; AKT	Pleiotrophin (PTN) is a developmentally regulated protein which exhibits neurite-outgrowth, mitogenic, and angiogenic properties. It has also been shown to be involved in tumor growth and metastasis, Here we used primary BEL (bovine epithelial lens) cells to investigate the signal transduction pathways involved in the mitogenic activity of recombinant PTN. PTN was purified from conditioned media of SW-13 cells transfected with the human PTN cDNA. We show that inhibitors of tyrosine kinase, mitogen-activated protein kinase, or phosphoinositide (PI) 3-kinase inhibit DNA synthesis stimulated by PTN. Analysis of tyrosine-phosphorylated proteins following PTN stimulation showed phosphorylation of two novel 190- and 215-kDa proteins in addition to SHC, ERK1, and ERK2. A mobility shift of phosphorylated ERK1 and ERK2 was detected with a panERK antibody confirming the phosphorylation of the two ERKs. Furthermore, in vitro immunocomplex kinase assay with Akt1, a natural substrate of PI 3-kinase, showed an activation of the kinase following PTN stimulation and a reversal by the PI 3-kinase inhibitor wortmannin, We conclude that the mitogenic activity of PTN is dependent on tyrosine kinase activation and utilizes the mitogen-activated protein kinase and the PI 3-kinase pathways to transduce a mitogenic signal.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University				Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V216, P574, DOI 10.1006/bbrc.1995.2661; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1993, BIOCHEM BIOPH RES CO, V195, P1089, DOI 10.1006/bbrc.1993.2156; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAULO E, 1992, J BIOL CHEM, V267, P11408; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63	30	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19588	19593		10.1074/jbc.272.31.19588	http://dx.doi.org/10.1074/jbc.272.31.19588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235965	hybrid			2022-12-27	WOS:A1997XP06300071
J	Shintani, T; Nomura, K; Ichishima, E				Shintani, T; Nomura, K; Ichishima, E			Engineering of porcine pepsin - Alteration of S-1 substrate specificity of pepsin to those of fungal aspartic proteinases by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY ANALYSES; HUMAN CATHEPSIN-D; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; INHIBITOR COMPLEXES; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; PEPTIDE-INHIBITOR; 1.8-A RESOLUTION; RENIN INHIBITORS	The S-1 substrate specificity of porcine pepsin has been altered to resemble that of fungal aspartic proteinase with preference for a basic amino acid residue in P-1 by site directed mutagenesis. On the basis of primary and tertiary structures of aspartic proteinases, the active site-flap mutants of porcine pepsin were constructed, which involved the replacement of Thr-77 by Asp (T77D), the insertion of Ser between Gly-78 and Ser-79 (G78(S)S79), and the double mutation (T77D/G78(S)S79). The specificities of the mutants were determined using p-nitrophenylalanine-based substrates containing a Phe or Lys residue at the P-1 position. The double mutant cleaved the Lys-Phe(4-NO2) bonds, while wild-type enzyme digested other bonds. In addition, the pH dependence of hydrolysis of Lys-containing substrates by the double mutant indicates that the interactions between Asp-77 of the mutant and P-1 Lys contribute to the transition state stabilization. The double mutant was also able to activate bovine trypsinogen to trypsin by the selective cleavage of the Lys(6)-Ile(7) bond of trypsinogen. Results of this study suggest that the structure of the active site flap contributes to the S-1 substrate specificity for basic amino acid residues in aspartic proteinases.	TOHOKU UNIV,FAC AGR,DEPT APPL BIOL CHEM,LAB MOL ENZYMOL,AOBA KU,SENDAI,MIYAGI 981,JAPAN	Tohoku University			SHINTANI, Takahiro/ABE-1267-2020	Shintani, Takahiro/0000-0001-6630-5892				ABITA JP, 1969, EUR J BIOCHEM, V8, P314, DOI 10.1111/j.1432-1033.1969.tb00530.x; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BLUNDELL TL, 1987, BIOCHEMISTRY-US, V26, P5585, DOI 10.1021/bi00392a001; COOPER J, 1992, BIOCHEMISTRY-US, V31, P8142, DOI 10.1021/bi00150a005; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; COOPER JB, 1989, BIOCHEMISTRY-US, V28, P8596, DOI 10.1021/bi00447a049; DEALWIS CG, 1994, J MOL BIOL, V236, P342, DOI 10.1006/jmbi.1994.1139; DHANARAJ V, 1992, NATURE, V357, P466, DOI 10.1038/357466a0; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P293; FRUTON JS, 1987, HYDROLYTIC ENZYMES, P1; FUJINAGA M, 1995, PROTEIN SCI, V4, P960; GABELOTEAU C, 1960, BIOCHIM BIOPHYS ACTA, V42, P230, DOI 10.1016/0006-3002(60)90786-1; Green BN, 1996, BIOCHEM J, V313, P241, DOI 10.1042/bj3130241; HOFMANN T, 1982, BIOCHEM J, V203, P603, DOI 10.1042/bj2030603; ICHISHIMA E., 1970, METHOD ENZYMOL, V19, P397; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; JAMES MNG, 1985, ASPARTIC PROTEINASES, P163; KAGEYAMA T, 1983, J BIOCHEM, V93, P743, DOI 10.1093/jb/93.3.743; KAY J, 1985, BIOCHEM SOC T, V13, P1027, DOI 10.1042/bst0131027; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; LOWTHER WT, 1995, PROTEIN SCI, V4, P689; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILNERWHITE EJ, 1986, BIOCHEM J, V240, P289, DOI 10.1042/bj2400289; MORIHARA K, 1973, ARCH BIOCHEM BIOPHYS, V157, P561, DOI 10.1016/0003-9861(73)90675-9; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; POHL J, 1988, BIOCHEMISTRY-US, V27, P4827, DOI 10.1021/bi00413a037; RAO C, 1985, ASPARTIC PROTEINASES, P91; SCARBOROUGH PE, 1994, PROTEIN ENG, V7, P495, DOI 10.1093/protein/7.4.495; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shintani T, 1996, J BIOCHEM-TOKYO, V120, P974; SHINTANI T, 1994, BBA-PROTEIN STRUCT M, V1204, P257, DOI 10.1016/0167-4838(94)90016-7; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SODEK J, 1970, METHOD ENZYMOL, V19, P372; STROP P, 1990, BIOCHEMISTRY-US, V29, P9863, DOI 10.1021/bi00494a016; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; SUZUKI J, 1989, PROTEIN ENG, V2, P563, DOI 10.1093/protein/2.7.563; TANAKA N, 1977, BIOCHIM BIOPHYS ACTA, V485, P406, DOI 10.1016/0005-2744(77)90176-0; TANG J, 1973, P NATL ACAD SCI USA, V70, P3437, DOI 10.1073/pnas.70.12.3437; TSUKAGOSHI N, 1988, GENE, V65, P285; VALVERDE V, 1995, J BIOL CHEM, V270, P15821, DOI 10.1074/jbc.270.26.15821; VEERAPANDIAN B, 1990, J MOL BIOL, V216, P1017, DOI 10.1016/S0022-2836(99)80017-5; YANG JT, 1986, METHOD ENZYMOL, V130, P208; [No title captured]	47	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18855	18861		10.1074/jbc.272.30.18855	http://dx.doi.org/10.1074/jbc.272.30.18855			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228062	hybrid			2022-12-27	WOS:A1997XM34200053
J	Dhar, M; Mascareno, EM; Siddiqui, MAQ				Dhar, M; Mascareno, EM; Siddiqui, MAQ			Two distinct factor-binding DNA elements in cardiac myosin light chain 2 gene are essential for repression of its expression in skeletal muscle - Isolation of a cDNA clone for repressor protein Nished	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC TRANSCRIPTION; NEGATIVE REGULATORY ELEMENT; C-FOS PROMOTER; EVEN-SKIPPED PROTEIN; SILENCER ELEMENTS; OSTEOCALCIN GENE; VIMENTIN GENE; MESSENGER-RNA; ACTIN GENE; SEQUENCE	The expression of the cardiac myosin light chain 2 (MLCS) gene is repressed in skeletal muscle as a result of the negative regulation of its transcription. Two regulatory elements, the cardiac specific sequence (CSS) located upstream (-360 base pairs) and a downstream negative modulatory sequence (NMS), which function in concert with each other, are required for repression of the MLC2 promoter activity in skeletal muscle. Individually, CSS and NMS have no effect. Transient transfection analysis with recombinant plasmids indicated that CSS- and NMS-mediated repression of transcription is position- and orientation-dependent and is transferable to heterologous promoters. A minimal conserved motif, GAAG/CTTC, present in both CSS and NMS, is responsible for repression as the mutation in the core CTTC sequence alone was sufficient to abrogate its repressor activity. The DNA binding assay by gel mobility shift analysis revealed that one of the two complexes, CSSBP2, is significantly enriched in embryonic skeletal muscle relative to cardiac muscle. In extracts from adult skeletal muscle, where the cardiac MLC2 expression is suppressed, both complexes, CSSBP1 and CSSBP2, were present, whereas the cardiac muscle extracts contained CSSBP1 alone, suggesting that the protein(s) in the CSSBP2 complex accounts for the negative regulation of cardiac MLC2 in skeletal muscle. A partial cDNA clone (Nished) specific for the candidate repressor factor was isolated by expression screening of the skeletal muscle cDNA library by multimerized CSS-DNA as probe. The recombinant Nished protein binds to the CSS-DNA, but not to Delta CSS-DNA where the core CTTC sequence was mutated. The amino acid sequence of Nished showed a significant structural similarity to the sequence of transcription factor ''runt,'' a known repressor of gap and pair-rule gene expression in Drosophila.	SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, CTR CARDIOVASC & MUSCLE RES, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD HH, 1988, EUR J BIOCHEM, V178, P53, DOI 10.1111/j.1432-1033.1988.tb14428.x; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COVITZAN PA, 1993, GENE DEV, V7, P1398; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DYAN WS, 1989, CELL, V58, P1; EMERSON C, 1986, UCLA S MOL CELLULAR, V29; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GOSWAMI S, 1994, MOL CELL BIOL, V14, P5130, DOI 10.1128/MCB.14.8.5130; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IP YT, 1991, CELL, V64, P439; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KONDO S, 1992, MOL CELL BIOL, V12, P4496, DOI 10.1128/MCB.12.10.4496; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LENNY N, 1995, ONCOGENE, V11, P1761; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MIN LW, 1992, J IMMUNOL, V148, P1913; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZZEN K, 1992, GENE, V119, P293; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NISHIYAMA S, 1994, GENE, V141, P261, DOI 10.1016/0378-1119(94)90582-7; OGAWA E, 1993, P NATL ACAD SCI USA, V89, P11823; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; QASBA P, 1992, MOL CELL BIOL, V12, P1107, DOI 10.1128/MCB.12.3.1107; RINCONLIMAS DE, 1995, MOL CELL BIOL, V15, P6561; SAIDAPET C, 1984, ARCH BIOCHEM BIOPHYS, V233, P565, DOI 10.1016/0003-9861(84)90480-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TADA H, 1991, VIROLOGY, V180, P327, DOI 10.1016/0042-6822(91)90037-C; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TROUCHE D, 1995, FEBS LETT, V361, P140, DOI 10.1016/0014-5793(95)00140-5; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; WERNER H, 1994, J BIOL CHEM, V269, P12577; ZARRAGA AM, 1986, J BIOL CHEM, V261, P3852; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; Zhou Ming-Dong, 1992, Gene Expression, V2, P127	63	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18490	18497		10.1074/jbc.272.29.18490	http://dx.doi.org/10.1074/jbc.272.29.18490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218494	hybrid			2022-12-27	WOS:A1997XL73500084
J	Leech, CA; Habener, JF				Leech, CA; Habener, JF			Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; MEDIATED CALCIUM ENTRY; PEPTIDE-I; SECRETING CELLS; INTRACELLULAR CALCIUM; ACINAR-CELLS; CA2+ INFLUX; G-PROTEIN; RECEPTOR; CHANNELS	Maitotoxin (MTX) activates a Ca2+-dependent non-selective cation current (ICa-NS) in insulinoma cells whose time course is identical to non selective cation currents activated by incretin hormones such as glucagon-like peptide-1 (GLP-1), which stimulate glucose-dependent insulin secretion by activating cAMP signaling pathways, We investigated the mechanism of activation of ICa-NS in insulinoma cells using specific pharmacological reagents, and these studies further support an identity between MTX- and GLP-1-activated currents, ICa-NS is inhibited by extracellular application of genistein, econazole, and SKF 96365. This inhibition by genistein suggests that tyrosine phophorylation may play a role in the activation of ICa-NS. ICa-NS is not inhibited by incubation of cells in glucose-free solution, by extracellular tetrodotoxin, nimodipine, or tetraethylammonium, or by intracellular dialysis with 4-aminopyridine, ATP, ryanodine, or heparin, ICa-NS is also not significantly inhibited by staurosporine, which does, however, partially inhibit the MTX-induced rise of intracellular Ca2+ concentration, These effects of staurosporine suggest that protein kinase C may not be involved in the activation of ICa-NS but that it may regulate intracellular Ca2+ release, Alternatively, ICa-NS may have a small component that is carried through separate divalent cation-selective channels that are inhibited by staurosporine. ICa-NS is neither activated nor inhibited by dialysis with KF, KF + AlF3 or GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)), suggesting that GTP-binding proteins do not play a major role in the activation of this current.			Leech, CA (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,LAB MOL ENDOCRINOL,BOSTON,MA 02114, USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERTHOD A, 1995, CHROMATOGR SCI SERIE, V68, P1; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; Estacion M, 1996, AM J PHYSIOL-CELL PH, V270, pC1145, DOI 10.1152/ajpcell.1996.270.4.C1145; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAHN HJ, 1988, BIOCHIM BIOPHYS ACTA, V630, P425; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; LEBRUN P, 1987, BIOCHEM BIOPH RES CO, V144, P172, DOI 10.1016/S0006-291X(87)80491-6; LEE KM, 1993, J BIOL CHEM, V268, P9945; Leech CA, 1996, ANN NY ACAD SCI, V805, P81; LEECH CA, 1995, ENDOCRINOLOGY, V136, P1530, DOI 10.1210/en.136.4.1530; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LEECH CA, 1994, METHOD CELL BIOL, V40, P135; MARUYAMA Y, 1984, J MEMBRANE BIOL, V81, P83, DOI 10.1007/BF01868812; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; MURATA M, 1992, EUR J PHARM-MOLEC PH, V227, P43, DOI 10.1016/0922-4106(92)90140-Q; PFEIFFER F, 1995, PFLUG ARCH EUR J PHY, V430, P916, DOI 10.1007/BF01837405; Poyer JF, 1996, J MEMBRANE BIOL, V153, P13; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; RIBALET B, 1994, J MEMBRANE BIOL, V142, P395; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SATIN LS, 1995, ENDOCRINOLOGY, V136, P4589, DOI 10.1210/en.136.10.4589; SILVA AM, 1994, J BIOL CHEM, V269, P17095; SOERGEL DG, 1990, J PHARMACOL EXP THER, V255, P1360; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; STURGESS NC, 1986, FEBS LETT, V208, P397, DOI 10.1016/0014-5793(86)81056-0; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Vostal JG, 1996, J BIOL CHEM, V271, P19524, DOI 10.1074/jbc.271.32.19524; WOLTERS GHJ, 1984, DIABETES, V33, P409, DOI 10.2337/diabetes.33.5.409; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; YADA T, 1994, J BIOL CHEM, V269, P1290	46	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17987	17993		10.1074/jbc.272.29.17987	http://dx.doi.org/10.1074/jbc.272.29.17987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218425	hybrid			2022-12-27	WOS:A1997XL73500015
J	Popov, M; Tam, LY; Li, J; Reithmeier, RAF				Popov, M; Tam, LY; Li, J; Reithmeier, RAF			Mapping the ends of transmembrane segments in a polytopic membrane protein - Scanning N-glycosylation mutagenesis of extracytosolic loops in the anion exchanger, Band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; STILBENE DISULFONATE BINDING; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; TRANSPORT PROTEIN; ENDOPLASMIC-RETICULUM; CYTOPLASMIC SIDE; SIGNAL SEQUENCE; P-GLYCOPROTEIN; CELL MEMBRANE	Band 3, the anion exchanger of human erythrocytes, contains up to 14 transmembrane (TM) segments and has a single endogenous site of N-glycosylation at Asn(642) in extracellular (EC) loop 4, The requirements for N-glycosylation of EC loops and the topology of this :polytopic membrane protein were determined by scanning N-glycosylation mutagenesis and cell-free translation in a reticulocyte lysate supplemented with microsomal membranes. The endogenous and novel acceptor sites located near the middle of the 35 residue EC loop 4 were efficiently N-glycosylated; however, no N-glycosylation occurred at sites located within sharply defined regions close to the adjacent TM segments, Acceptor sites located in the center of EC loop 3, which contains 25 residues, were poorly N-glycosylated, Expansion of this loop with a 4-residue insert containing an acceptor site increased N-glycosylation, Acceptor sites located in short (<10 residues) loops (putative EC loops 1, 2, 6, and 7) were not N-glycosylated; however, insertion of EC loop 4 into EC loops 1, 2, or 7, but not 6, resulted in efficient N-glycosylation, Acceptor sites in putative intracellular (IC) loop 5 exhibited a similar pattern of N-glycosylation as EC loop 4, indicating a lumenal disposition during biosynthesis, To be efficiently N-glycosylated, EC loops in polytopic membrane proteins must be larger than 25 residues in size, with acceptor sites located greater than 12 residues away from the preceding TM segment and greater than 14 residues away from the following TM segment, Application of this requirement allowed a significant refinement of the topology of Band 3 including a more accurate mapping of the ends of TM segments, The strict distance dependence for N-glycosylation of loops suggests that TM segments in polytopic membrane proteins are held quite precisely within the translocation machinery during the N-glycosylation process.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto								Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; COBB CE, 1990, BIOCHEMISTRY-US, V29, P8283, DOI 10.1021/bi00488a012; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUBNER S, 1992, BIOCHEM J, V285, P17; JENNINGS ML, 1984, BIOCHEMISTRY-US, V23, P6432, DOI 10.1021/bi00321a024; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH, P503; Kalo MS, 1996, BIOCHEMISTRY-US, V35, P999, DOI 10.1021/bi951702h; KANG D, 1992, J BIOL CHEM, V267, P19211; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OKUBO K, 1994, J BIOL CHEM, V269, P1918; OKUBO K, 1991, J BIOL CHEM, V266, P16420; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PASSOW H, 1992, BIOPHYS J, V62, P98, DOI 10.1016/S0006-3495(92)81791-5; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; REITHMEIER RAF, 1996, TRANSPORT PROCESSES, V2, P281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Simon S, 1993, CURR OPIN CELL BIOL, V5, P581, DOI 10.1016/0955-0674(93)90126-B; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; Tam LY, 1996, BIOCHEM J, V318, P645, DOI 10.1042/bj3180645; TAM LY, 1994, J BIOL CHEM, V269, P32542; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; Wang L, 1997, J BIOL CHEM, V272, P10631; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	57	160	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18325	18332		10.1074/jbc.272.29.18325	http://dx.doi.org/10.1074/jbc.272.29.18325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218473	hybrid			2022-12-27	WOS:A1997XL73500063
J	Wang, XH; Nakayama, K; Shimma, Y; Tanaka, A; Jigami, Y				Wang, XH; Nakayama, K; Shimma, Y; Tanaka, A; Jigami, Y			MNN6, a member of the KRE2/MNT1 family, is the gene for mannosylphosphate transfer in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; YEAST MANNAN STRUCTURE; PROTEIN GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; O-GLYCOSYLATION; OUTER CHAIN; MUTANTS; TRANSFORMATION; SEQUENCE; MANNOSYLTRANSFERASE	In yeast Saccharomyces cerevisiae the N-linked sugar chain is modified at different positions by the addition of mannosylphosphate, The mnn6 mutant is deficient in the mannosylphosphate transferase activity toward mannotetraose (Karson, E. M., and Ballou, C. E. (1978) J. Biol. Chem. 253, 6484-6492). We have cloned the MNN6 gene by complementation. It has encoded a 446-amino acid polypeptide with the characteristics of type II membrane protein, The deduced Mnn6p showed a significant similarity to Kre2p/Mnt1p, a Golgi alpha-1,2-mannosyltransferase involved in O-glycosylation, The null mutant of MNN6 showed a normal cell growth, less binding to Alcian blue, hypersensitivity to Calcoflour White and hygromycin B, and diminished mannosylphosphate transferase activity toward the endoplasmic reticulum core oligosaccharide accepters (Man8GlcNAc2-PA and Man5GlcNAc2-PA) in vitro, suggesting the involvement of the MNNG gene in the endoplasmic reticulum core oligosaccharide phosphorylation. However, no differences were observed in N-linked mannoprotein oligosaccharides between Delta och1 Delta mnn1 cells and Delta och1 Delta mnn1 Delta mnn6 cells, indicating the existence of redundant genes required for the core oligosaccharide phosphorylation. Based on a dramatic decrease in polymannose outer chain phosphorylation by MNN6 gene disruption and a determination of the mannosylphosphorylation site in the acceptor, it is postulated that the MNNG gene may be a structural gene encoding a mannosylphosphate transferase, which recognizes any oligosaccharides with at least one alpha-1,2-linked mannobiose unit.	NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN; ASAHI CHEM IND CO LTD, FUJI, SHIZUOKA 416, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CAWLEY T N, 1972, Journal of Bacteriology, V111, P690; COUSO R, 1986, J BIOL CHEM, V261, P6326; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; HASHIMOTO C, 1981, P NATL ACAD SCI-BIOL, V78, P2244, DOI 10.1073/pnas.78.4.2244; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JARS MU, 1995, J BIOL CHEM, V270, P24810, DOI 10.1074/jbc.270.42.24810; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KARSON EM, 1978, J BIOL CHEM, V253, P6484; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHLE L, 1995, PROTEIN GLYCOSYLATIO, P475; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; LUSSIER M, 1996, YEAST, V271, P11001; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MILL PJ, 1966, J GEN MICROBIOL, V44, P329, DOI 10.1099/00221287-44-3-329; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7685; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; RASCHKE WC, 1971, BIOCHEMISTRY-US, V10, P4130, DOI 10.1021/bi00798a018; ROSENFEL.L, 1974, J BIOL CHEM, V249, P2319; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; THIEME TR, 1971, BIOCHEMISTRY-US, V10, P4121, DOI 10.1021/bi00798a017; TRIMBLE RB, 1995, TRENDS GLYCOSCI GLYC, V7, P1, DOI 10.4052/tigg.7.1	44	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18117	18124		10.1074/jbc.272.29.18117	http://dx.doi.org/10.1074/jbc.272.29.18117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218445	hybrid			2022-12-27	WOS:A1997XL73500035
J	Avellar, MCW; Gregory, CW; Power, SGA; French, FS				Avellar, MCW; Gregory, CW; Power, SGA; French, FS			Androgen-dependent protein interactions within an intron 1 regulatory region of the 20-kDa protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RESPONSE ELEMENT; DNASEI HYPERSENSITIVE SITES; PROMOTER IN-VIVO; TRANSCRIPTION FACTORS; STEROID-HORMONES; BINDING PROTEINS; OVALBUMIN GENE; PROBASIN GENE; BENDS DNA	The 20-kDa protein gene is androgen regulated in rat ventral prostate, Intron 1 contains a 130-base pair complex response element (D2) that binds androgen (AR) and glucocorticoid receptor (GR) but transactivates only with AR in transient cotransfection assays in CV1 cells using the reporter vector D2-tkCAT. To better understand the function of this androgen-responsive unit, nuclear protein interactions with D2 were analyzed by DNase I footprinting in ventral prostate nuclei of intact or castrated rats and in vitro with ventral prostate nuclear protein extracts from intact, castrated, and testosterone-treated castrated rats, Multiple androgen-dependent protected regions and hypersensitive sites were identified in the D2 region with both methods, Mobility shift assays with P-32-labeled oligonucleotides spanning D2 revealed specific interactions with ventral prostate nuclear proteins. Four of the D2-protein complexes decreased in intensity within 24 h of castration, UV cross-linking of the androgen-dependent DNA binding proteins identified protein complexes of approximately 140 and 55 kDa. The results demonstrate androgen-dependent nuclear protein DNA interactions within the complex androgen response element D2.	UNIV N CAROLINA,LABS REPROD BIOL,SCH MED,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Avellar, Maria Christina W./E-2865-2013; Avellar, Maria Christina/E-2865-2013	Avellar, Maria Christina W./0000-0003-4392-7554; Avellar, Maria Christina/0000-0003-2810-3581	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, F32HD007992, R01HD004466, R37HD004466] Funding Source: NIH RePORTER; NICHD NIH HHS [HD04466, HD07992, P30-HD18968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; Dean DM, 1996, MOL ENDOCRINOL, V10, P1489, DOI 10.1210/me.10.12.1489; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1994, J STEROID BIOCHEM, V48, P317, DOI 10.1016/0960-0760(94)90071-X; FABER S, 1993, J BIOL CHEM, V268, P24976; FABRE S, 1994, J BIOL CHEM, V269, P5857; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRESSMANN ME, 1995, J BIOL CHEM, V270, P10968; HAECKER SAE, 1995, MOL ENDOCRINOL, V9, P1113, DOI 10.1210/me.9.9.1113; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Harris S E, 1988, Prog Clin Biol Res, V284, P53; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; HO KC, 1993, J BIOL CHEM, V268, P27226; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KASPER S, 1994, J BIOL CHEM, V269, P31763; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MARSCHKE KB, 1995, ENDOCRINE, V3, P819, DOI 10.1007/BF02935687; Maxam A M, 1980, Methods Enzymol, V65, P499; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NORDSTROM LA, 1993, J BIOL CHEM, V268, P13193; PRENDERGAST P, 1994, J STEROID BIOCHEM, V48, P1, DOI 10.1016/0960-0760(94)90245-3; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RHEE M, 1991, MOL ENDOCRINOL, V5, P564, DOI 10.1210/mend-5-4-564; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; TAN JA, 1992, J BIOL CHEM, V267, P4456; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WINDERICKX J, 1994, J STEROID BIOCHEM, V48, P165, DOI 10.1016/0960-0760(94)90141-4; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZHANG YL, 1990, MOL ENDOCRINOL, V4, P1219, DOI 10.1210/mend-4-8-1219	61	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17623	17631		10.1074/jbc.272.28.17623	http://dx.doi.org/10.1074/jbc.272.28.17623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211911	hybrid, Green Published			2022-12-27	WOS:A1997XK16500054
J	Beetham, JK; Myung, KS; McCoy, JJ; Wilson, ME; Donelson, JE				Beetham, JK; Myung, KS; McCoy, JJ; Wilson, ME; Donelson, JE			Glycoprotein 46 mRNA abundance is post-transcriptionally regulated during development of Leishmania chagasi promastigotes to an infectious form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; CUTANEOUS LEISHMANIASIS; DIFFERENTIAL EXPRESSION; EFFECTIVE IMMUNIZATION; MAJOR PROMASTIGOTES; NUCLEOTIDE-SEQUENCE; TRYPANOSOMA-BRUCEI; SURFACE PROTEASE; GP63 RNAS; DONOVANI	GP46 is an abundant glycoprotein of 46 kDa on the surface of the promastigote form of mast Leishmania species. We show that the steady stale level of GP46 mRNA increases >30-fold as Leishmania chagasi promastigotes develop in vitro from a less infections form during logarithmic growth to a highly infections form in the stationary phase of cultivation Nuclear run on experiments demonstrate that this increase in GP46 mRNA abundance is regulated post-transcriptionally. Plasmids containing the 3'-untranslated regions (UTRs) and downstream intergenic regions (IRs) of two differ ent GP46 genes fused immediately downstream of the beta-galactosidase coding region were transfected into L. chagasi, and beta-galactosidase activity and mRNA levels were examined. The presence of the 3'-UTR + IR of one GP46 gene (gp46A) resulted in a steady increase in p-galactosidase activity and mRNA level as the transfected promastigotes developed from logarithmic to stationary phase. This differential effect parallels that of the 3'-UTRs + IRs of a family of genes for an unrelated Leishmania surface glycoprotein, GP63. Thus, post-transcriptional regulation of the genes for two different surface glycoproteins of Leishmania occurs via a similar mechanism.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET AFFAIRS MED CTR,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NHLBI NIH HHS [HL07121] Funding Source: Medline; NIAID NIH HHS [AI32135] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R21AI032135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; CHAMPSI J, 1988, INFECT IMMUN, V52, P3272; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; Handman E, 1995, MOL BIOCHEM PARASIT, V74, P189, DOI 10.1016/0166-6851(95)02500-6; KAHL LP, 1987, J IMMUNOL, V138, P1587; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; MCMAHONPRATT D, 1992, MOL BIOCHEM PARASIT, V50, P151, DOI 10.1016/0166-6851(92)90252-F; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; PEARSON RD, 1980, J IMMUNOL, V125, P2195; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SACKS DL, 1987, J IMMUNOL, V139, P3088; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEIN Y, 1993, PARASITOL TODAY, V9, P255, DOI 10.1016/0169-4758(93)90070-V; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SYMONS FM, 1994, MOL BIOCHEM PARASIT, V67, P103, DOI 10.1016/0166-6851(94)90100-7; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; WILSON ME, 1993, J BIOL CHEM, V268, P15731; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	39	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17360	17366		10.1074/jbc.272.28.17360	http://dx.doi.org/10.1074/jbc.272.28.17360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211875	hybrid			2022-12-27	WOS:A1997XK16500018
J	Lander, HM; Tauras, JM; Ogiste, JS; Hori, O; Moss, RA; Schmidt, AM				Lander, HM; Tauras, JM; Ogiste, JS; Hori, O; Moss, RA; Schmidt, AM			Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; CELL-SURFACE; EXPRESSION; INDUCTION; MECHANISM; GLUCOSE; IDENTIFICATION; COMPLICATIONS	Advanced glycation end products (AGEs) exert their cellular effects on cells by interacting with specific cellular receptors, the best characterized of which is the receptor for AGE (RAGE), The transductional processes by which RAGE ligation transmits signals to the nuclei of cells is unknown and was investigated, AGE-albumin, a prototypic ligand, activated p21(ras) in rat pulmonary artery smooth muscle cells that express RAGE, whereas nonglycated albumin was without effect, MAP kinase activity was enhanced at concentrations of AGE-albumin, which activated p21(ras) and NF-kappa B, Depletion of intracellular glutathione rendered cells more sensitive to AGE-mediated activation of this signaling pathway, in contrast, signaling was blocked by preventing p21(ras) from associating with the plasma membrane or mutating Cys(118) on p21(ras) to Ser. Signaling was receptor-dependent, because it was prevented by blocking access to RAGE with either anti-RAGE IgG or by excess soluble RAGE, These data suggest that RAGE-mediated induction of cellular oxidant stress triggers a cascade of intracellular signals involving p21(ras) and MAP kinase, culminating in transcription factor activation, The molecular mechanism that triggers this pathway likely involves oxidant modification and activation of p21(ras).	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University	Lander, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,1300 YORK AVE,NEW YORK,NY 10021, USA.			Moss, Rebecca/0000-0002-0139-5396	NIAID NIH HHS [AI37637] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NIGMS NIH HHS [GM55509] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055509] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DYER DG, 1991, J BIOL CHEM, V266, P11654; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FRIEDMAN J, 1994, CIRCULATION, V90, P1567; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V92, P2155; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STEVENSON MA, 1994, CANCER RES, V54, P12; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1994, J BIOL CHEM, V269, P9889	36	637	671	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17810	17814		10.1074/jbc.272.28.17810	http://dx.doi.org/10.1074/jbc.272.28.17810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211935	hybrid			2022-12-27	WOS:A1997XK16500078
J	Sandigursky, M; Yacoub, A; Kelley, MR; Deutsch, WA; Franklin, WA				Sandigursky, M; Yacoub, A; Kelley, MR; Deutsch, WA; Franklin, WA			The Drosophila ribosomal protein S3 contains a DNA deoxyribophosphodiesterase (dRpase) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; DAMAGED DNA; FPG PROTEIN; EXCISION; REPAIR; ENDONUCLEASES; RESIDUES; GLYCOSYLASE	The Drosophila ribosomal protein S3 has been previously demonstrated to cleave DNA containing 8-oxoguanine residues and has also been found to contain an associated apurinic/apyrimidinic (AP) lyase activity that cleaves phosphodiester bonds via a beta, delta-elimination reaction. The activity of this protein on DNA substrates containing incised AP sites was examined. A glutathione S-transferase fusion protein of S3 was found to efficiently remove sugar-phosphate residues from DNA substrates containing 5'-incised AP sites as well as from DNA substrates containing 3'-incised sites. Removal of 2-deoxyribose-5-phosphate as 4-hydroxy-2-pentenal-5-phosphate from a substrate containing 5'-incised AP sites occurred via a beta-elimination reaction, as indicated by reaction of the released sugar-phosphate products with sodium thioglycolate. The reaction for the removal of 4-hydroxy-2-pentenal-5-phosphate from the substrate containing 3'-incised AP sites was dependent oil the presence of the Mg2+ cation. These findings suggest that the S3 ribosomal protein may function in several steps of the DNA base excision repair pathway in eukaryotes and may represent an important DNA repair function for the repair of oxidative and ionizing radiation-induced DNA damage.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT RADIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,BRONX,NY 10461; LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,BATON ROUGE,LA 70808; INDIANA UNIV,SCH MED,DEPT PEDIAT,WELLS CTR PEDIAT RES,SECT PEDIAT ENDOCRINOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Kelley, Mark/0000-0002-6120-9532	NATIONAL CANCER INSTITUTE [R01CA052025, R29CA052025] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007815] Funding Source: NIH RePORTER; NCI NIH HHS [CA52025] Funding Source: Medline; NCRR NIH HHS [RR09884] Funding Source: Medline; NIEHS NIH HHS [ES07815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOITEUX S, 1990, J BIOL CHEM, V265, P3916; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3616; FRIEDBERG EC, 1995, DNA REPAIR; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P1743; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; SANDIGURSKY M, 1992, RADIAT RES, V131, P332, DOI 10.2307/3578424; SANDIGURSKY M, 1996, RADIAT RES, V145, P629; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; WILSON DM, 1994, J BIOL CHEM, V269, P25359; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; Yacoub A, 1996, NUCLEIC ACIDS RES, V24, P4298, DOI 10.1093/nar/24.21.4298	21	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17480	17484		10.1074/jbc.272.28.17480	http://dx.doi.org/10.1074/jbc.272.28.17480			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211893	hybrid			2022-12-27	WOS:A1997XK16500036
J	Choi, DJ; Koch, WJ; Hunter, JJ; Rockman, HA				Choi, DJ; Koch, WJ; Hunter, JJ; Rockman, HA			Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; FAILING HUMAN HEART; INOTROPIC RESPONSE; TRANSGENIC MICE; GAMMA-SUBUNITS; G-PROTEINS; EXPRESSION; TRANSDUCTION; ACTIVATION; INHIBITOR	Pressure overload cardiac hypertrophy in the mouse was achieved following 7 days of transverse aortic constriction, This was associated with marked beta-adrenergic receptor (beta-AR) desensitization in vivo, as determined by a blunted inotropic response to dobutamine. Extracts from hypertrophied hearts had approximate to 3-fold increase in cytosolic and membrane G protein-coupled receptor kinase (GRK) activity, Incubation with specific monoclonal antibodies to inhibit different GRK subtypes showed that the increase in activity could be attributed predominately to the beta-adrenergic receptor kinase (beta ARK), Although overexpression of a beta ARK inhibitor in hearts of transgenic mice did not alter the development of cardiac hypertrophy, the beta-AR desensitization associated with pressure overload hypertrophy was prevented, To determine whether the induction of beta ARK occurred because of a generalized response to cellular hypertrophy, beta ARK activity was measured in transgenic mice homozygous for oncogenic ras overexpression in the heart. Despite marked cardiac hypertrophy, no difference in beta ARK activity was found in these mice overexpressing oncogenic ras compared with controls, Taken together, these data suggest that beta ARK is a central molecule involved in alterations of beta-AR signaling in pressure overload hypertrophy, The mechanism for the increase in beta ARK activity appears not to be related to the induction of cellular hypertrophy but to possibly be related to neurohumoral activation.	UNIV CALIF SAN DIEGO, DEPT MED, SCH MED, LA JOLLA, CA 92093 USA; DUKE UNIV, DEPT SURG, DURHAM, NC 27710 USA	University of California System; University of California San Diego; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; BOHM M, 1995, HYPERTENSION, V25, P962, DOI 10.1161/01.HYP.25.5.962; BOHM M, 1994, HYPERTENSION, V24, P653, DOI 10.1161/01.HYP.24.6.653; BOHM M, 1995, CIRCULATION, V92, P3006, DOI 10.1161/01.CIR.92.10.3006; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; FELDMAN AM, 1993, CIRCULATION, V87, P27; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; MERTENS MJF, 1992, J HYPERTENS, V10, P1361, DOI 10.1097/00004872-199211000-00008; MORAVEC CS, 1995, J MOL CELL CARDIOL, V27, P2101, DOI 10.1016/S0022-2828(95)91191-X; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1993, CIRCULATION, V87, P14; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Swertfeger DK, 1996, AM J PATHOL, V148, P1971; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Ungerer M, 1996, CIRC RES, V79, P455, DOI 10.1161/01.RES.79.3.455; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; YURENEV AP, 1992, AM J HYPERTENS, V5, pS164, DOI 10.1093/ajh/5.6.266	44	219	222	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17223	17229		10.1074/jbc.272.27.17223	http://dx.doi.org/10.1074/jbc.272.27.17223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202046	hybrid			2022-12-27	WOS:A1997XH44600078
J	Feng, L; Kim, E; Lee, WL; Miller, CJ; Kuang, B; Reisler, E; Rubenstein, PA				Feng, L; Kim, E; Lee, WL; Miller, CJ; Kuang, B; Reisler, E; Rubenstein, PA			Fluorescence probing of yeast actin subdomain 3/4 hydrophobic loop 262-274 - Actin-actin and actin-myosin interactions in actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRENE EXCIMER FLUORESCENCE; F-ACTIN; CONFORMATIONAL-CHANGES; STRUCTURAL DYNAMICS; POLYMERIZATION; TERMINUS; COMPLEX; MODEL; SUBFRAGMENT-1; TROPOMYOSIN	Residues 262-274 form a loop between subdomains 3 and 4 of actin, This loop may play an important role in actin filament formation and stabilization, To assess directly the behavior of this loop, we mutated Ser(265) Of yeast actin to cysteine (S265C) and created another mutant (S265C/C374A) by changing Cys(374) Of S265C actin to alanine, These changes allowed us to attach a pyrene maleimide stoichiometrically to either Cys(374) Or Cys(265), These mutations had no detectable effects on the protease susceptibility, intrinsic ATPase activity, and thermal stability of labeled or unlabeled G-actin. The presence of the loop cysteine, either labeled or unlabeled, did not affect the actin-activated S1 ATPase activity or the in vitro motility of the actin, Both mutant actins, either labeled or unlabeled, nucleated filament formation considerably faster than wild-type (WT) actin, although the critical concentration was not affected, Whereas the fluorescence of the C-terminal (WT) probe increased during polymerization, that of the loop (S265C/C374A) probe decreased, and the fluorescence of the doubly labeled actin (S265C) was similar to 50% less than the sum of the fluorescence of the individual fluorophores. Quenching was also observed in copolymers of labeled WT and S265C/C374A actins, An excimer peak was present in the emission spectrum of labeled S265C F-actin and in the labeled S265C/C374A-WT actin copolymers. These results show that in the filaments, the C-terminal pyrene of a substantial fraction of monomers directly interacts with the loop pyrene of neighboring monomers, bringing the two cysteine sulfurs to within 18 Angstrom of one another, Finally, when bound to labeled S265C/C374A F-actin, myosin S1, but not tropomyosin, caused an increase in fluorescence of the loop probe, Both proteins had no effect on excimer fluorescence, These results help establish the orientation of monomers in F-actin and show that the binding of S1 to actin subdomains 1 and 2 affects the environment of the loop between subdomains 3 and 4.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Rubenstein, Peter/0000-0003-1225-4414	NIAMS NIH HHS [R01 AR022031, AR-22031] Funding Source: Medline; NIGMS NIH HHS [GM-33689, GM-07185] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR022031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; FIEVEZ S, 1993, FEBS LETT, V316, P186, DOI 10.1016/0014-5793(93)81212-I; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HEGRI G, 1992, PROTEIN SCI, V1, P132; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 1996, BIOPHYS J, V71, P1914, DOI 10.1016/S0006-3495(96)79390-6; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; Lehrer S S, 1995, Subcell Biochem, V24, P115; LEHRER SS, 1972, ARCH BIOCHEM BIOPHYS, V150, P164, DOI 10.1016/0003-9861(72)90023-9; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MEYER WH, 1987, BLOOD, V70, P363; MIHASHI K, 1981, EUR J BIOCHEM, V114, P33; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MONCMAN CL, 1993, CELL MOTIL CYTOSKEL, V25, P73, DOI 10.1002/cm.970250109; NG R, 1980, P NATL ACAD SCI USA, V77, P2546; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1994, BIOPHYS J, V66, P276, DOI 10.1016/S0006-3495(94)80791-X; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	44	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16829	16837		10.1074/jbc.272.27.16829	http://dx.doi.org/10.1074/jbc.272.27.16829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201989	hybrid			2022-12-27	WOS:A1997XH44600021
J	Li, H; Zhao, LL; Funder, JW; Liu, JP				Li, H; Zhao, LL; Funder, JW; Liu, JP			Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TERMINAL TRANSFERASE; IMMORTAL CELLS; TUMOR-ANTIGEN; ENZYME; RIBONUCLEOPROTEIN; ASSOCIATION; TETRAHYMENA; YEAST; CYCLE	Most cancer cells have increased levels of telomerase activity implicated in cell immortalization. Activation of telomerase, a ribonucleoprotein complex, catalyzes the elongation of the ends of mammalian chromosomal DNA (telomeres), the length of which regulates cell proliferation. Currently, how telomerase is regulated in cancer is not yet established, The present study shows that telomerase activity is regulated by protein phosphorylation in human breast cancer cells, Incubation of cell nuclear telomerase extracts with protein phosphatase 2A (PP2A) abolished the telomerase activity; in contrast cytoplasmic telomerase activity was unaffected, and protein phosphatases 1 and 2B were ineffective, Inhibition of telomerase activity by PP2A was both concentration- and time-dependent and was prevented by the protein phosphatase inhibitor okadaic acid, In addition, nuclear telomerase inhibited by PP2A was reactivated by endogenous protein kinase(s) in the presence of ATP, but not in the presence of ATP gamma S, Furthermore, telomerase activity in cultured human breast cancer PMC42 cells was stimulated by okadaic acid, consistent with a role for PP2A in the regulation of telomerase activity in intact cells, These findings suggest that protein phosphorylation reversibly regulates the function of telomerase and that PP2A is a telomerase inhibitory factor in the nucleus of human breast cancer cells.	BAKER MED RES INST,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute			Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116				ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WHITEHEAD RH, 1984, JNCI-J NATL CANCER I, V73, P643; Xu D, 1996, LEUKEMIA, V10, P1354; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	40	170	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16729	16732		10.1074/jbc.272.27.16729	http://dx.doi.org/10.1074/jbc.272.27.16729			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201974	hybrid			2022-12-27	WOS:A1997XH44600006
J	Tamura, K; Umemura, S; Nyui, N; Yamaguchi, S; Ishigami, T; Hibi, K; Yabana, M; Kihara, M; Fukamizu, A; Murakami, K; Ishii, M				Tamura, K; Umemura, S; Nyui, N; Yamaguchi, S; Ishigami, T; Hibi, K; Yabana, M; Kihara, M; Fukamizu, A; Murakami, K; Ishii, M			A novel proximal element mediates the regulation of mouse Ren-1C promoter by retinoblastoma protein in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENIN GENE; TRANSCRIPTION FACTOR PIT-1; SUSCEPTIBILITY GENE; SP1-MEDIATED TRANSCRIPTION; JUXTAGLOMERULAR CELLS; MOLECULAR MECHANISM; ANGIOTENSIN SYSTEM; TRANSGENIC MICE; BINDING-SITE; C-MYC	The protein product of the retinoblastoma susceptibility gene, RE, is a nuclear phosphoprotein that modulates transcription of genes involved in growth control via interactions with transcription factors. Renin is a rate-limiting enzyme of the renin-angiotensin system that regulates blood pressure and water-electrolyte balance. Renin gene expression is regulated in a tissue-specific and developmentally linked manner. Similarly, the expression of RE is controlled in a differentiation-linked manner, Thus, to investigate whether RE is involved in the regulation of renin gene expression, we examined the effects of RE on transcriptional activity of the mouse renin (Ren-1C) promoter. The Ren-1C promoter contains two transcriptionally important elements; the RU-1 (-224 to -138) and RP-2 (-75 to -47) elements. RE activated the Ren-IC promoter in human embryonic kidney cells. The promoter element responsible for RE-mediated transcriptional regulation was the RP-2 element, The results of DNA-protein binding experiments showed that RE increased nuclear binding activity to the RP-2 element, and site-directed mutation which disrupted binding of nuclear factors to the RP-2 element markedly reduced RE-mediated activation of Ren-IC promoter in human embryonic kidney cells. These results indicate that the RP-2 element plays an important role in RE-mediated transcriptional regulation of Ren-IC promoter activity in human embryonic kidney cells, thereby suggesting an interesting mechanism by which RE may modulate the renin-angiotensin system.	YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,SAKURA,IBARAKI 305,JAPAN	Yokohama City University; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BURT DW, 1989, J BIOL CHEM, V264, P7357; CATANZARO DF, 1994, KIDNEY INT, V46, P1513, DOI 10.1038/ki.1994.433; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DZAU VJ, 1988, AM J PHYSIOL, V255, pF563, DOI 10.1152/ajprenal.1988.255.4.F563; FUKAMIZU A, 1991, BIOCHEM J, V278, P601, DOI 10.1042/bj2780601; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Klemm DJ, 1996, J BIOL CHEM, V271, P8082, DOI 10.1074/jbc.271.14.8082; LEE WH, 1995, ANN NY ACAD SCI, V752, P432, DOI 10.1111/j.1749-6632.1995.tb17453.x; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATIN A, 1994, ONCOGENE, V9, P1333; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAUL M, 1992, AM J PHYSIOL, V262, pE644, DOI 10.1152/ajpendo.1992.262.5.E644; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; Tamura K, 1995, Hypertens Res, V18, P7, DOI 10.1291/hypres.18.7; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; TAMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1172, P306, DOI 10.1016/0167-4781(93)90218-3; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	58	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16845	16851		10.1074/jbc.272.27.16845	http://dx.doi.org/10.1074/jbc.272.27.16845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201991	hybrid			2022-12-27	WOS:A1997XH44600023
J	Kinoshita, A; Yamada, S; Haslam, SM; Morris, HR; Dell, A; Sugahara, K				Kinoshita, A; Yamada, S; Haslam, SM; Morris, HR; Dell, A; Sugahara, K			Novel tetrasaccharides isolated from squid cartilage chondroitin sulfate E contain unusual sulfated disaccharide units GlcA(3-O-sulfate)beta 1-3GalNAc(6-O-sulfate) or GlcA(3-O-sulfate)beta 1-3GalNAc(4,6-O-disulfate)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SWARM RAT CHONDROSARCOMA; SYNANCEJA-HORRIDA VENOM; PROTEIN LINKAGE REGION; MOUSE BONE-MARROW; MAST-CELLS; HEPARAN-SULFATE; GLUCURONIC-ACID; FLUOROPHORE 2-AMINOACRIDONE; PERITONEAL-MACROPHAGES	We previously isolated novel tetrasaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K and demonstrated that the disaccharide units containing 3-O-sulfated glucuronic acid were decomposed by chondroitinase ABC digestion (Sugahara, K., Tanaka, Y., Yamada, S., Seno, N., Kitagawa, H., Haslam, S. M., Morris, H.R., and Dell, A. (1986) J. Biol. Chem. 271, 26745-26754). The findings indicated the necessity to re-evaluate the disaccharide compositions of chondroitin sulfate preparations purified from other biological sources and analyzed using the above enzyme, in this study, to evaluate squid cartilage chondroitin sulfate E a series of even-numbered oligosaccharides were isolated after exhaustive digestion with sheep testicular hyaluronidase and subsequent fractionation by gel chromatography. The tetrasaccharide fraction was subfractionated by high performance liquid chromatography on an amine-bound silica column. Systematic structural analysis of five major fractions, h, l, m, n, and q, by fast atom bombardment mass spectrometry, enzymatic digestions in conjunction with capillary electrophoresis, and 500-MHz H-1 NMR spectroscopy revealed one disulfated, three trisulfated, and one diasulfated tetrasaccharide structure: fraction h, GlcA beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S); fraction l, GlcA(3S)beta 1-3GalNAc(6S)beta 1-4GlcA beta 1-3GalNAc(4S) fraction m, GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S); fraction n, GlcA beta 1-3GalNAc(4S.6S)beta 1-4GlcA beta 1-3GaINAc(4S); and fraction q, GlcA(3S)beta 1-3GalNAc(4S,6S)beta 1-4GlcA beta 1-3GalNAc(4S), where 3S, 4S, and 6S represent 3-O-, 4-O- and 6-O-sulfate, respectively. The structures found in fractions h and m as well as the unsaturated counterpart of that found in fraction n have beem reported, whereas those in fractions l and q are novel in that they contained unusual disulfated and trisulfated disaccharide units where GlcA(3S) is directly linked to GalNAc(6S) and GalNAc(4S,6S), respectively. These novel tetrasaccharide sequences are distinct from those found in other chondroitin sulfate isoforms and may play key roles in the biological functions and activities of chondroitin sulfate E not only from squid cartilage but also from mammalian cells and tissues.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE,HYOGO 658,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND	Kobe Pharmaceutical University; Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA F, 1982, TOHOKU J EXP MED, V136, P359, DOI 10.1620/tjem.136.359; ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; ARIGA T, 1987, J BIOL CHEM, V262, P848; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GOTO F, 1994, BIOORG MED CHEM LETT, V4, P619, DOI 10.1016/S0960-894X(01)80166-9; GREGOIRE PE, 1972, BIOCHIM BIOPHYS ACTA, V279, P102, DOI 10.1016/0304-4165(72)90245-0; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HIGHSMITH S, 1975, J BIOL CHEM, V250, P7473; HOJIMA Y, 1984, BLOOD, V63, P1453; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; INOUE H, 1986, J BIOL CHEM, V261, P4460; IWATA H, 1969, J JAP ORTHOP ASSN, V43, P455; JACKSON P, 1991, ANAL BIOCHEM, V196, P238, DOI 10.1016/0003-2697(91)90460-B; KARAMANOS NK, 1992, EUR J BIOCHEM, V204, P553, DOI 10.1111/j.1432-1033.1992.tb16667.x; KARAMANOS NK, 1995, ARCH BIOCHEM BIOPHYS, V316, P100, DOI 10.1006/abbi.1995.1015; KARAMANOS NK, 1994, ANAL BIOCHEM, V221, P189, DOI 10.1006/abio.1994.1396; KARAMANOS NK, 1994, BIOCHIMIE, V76, P79, DOI 10.1016/0300-9084(94)90066-3; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KIM JJ, 1982, J BIOL CHEM, V257, P1670; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; KITAGAWA H, 1995, ANAL BIOCHEM, V232, P114, DOI 10.1006/abio.1995.9952; Kitagawa H, 1997, BIOCHEMISTRY-US, V36, P3998, DOI 10.1021/bi962740j; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; KOLSET SO, 1986, BIOCHEM BIOPH RES CO, V139, P377, DOI 10.1016/S0006-291X(86)80001-8; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; Mathews M B, 1966, Clin Orthop Relat Res, V48, P267; MATHEWS MB, 1962, NATURE, V193, P378, DOI 10.1038/193378a0; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; Meyer K., 1971, ENZYMES, V5, P307; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; POH CH, 1992, COMP BIOCHEM PHYS B, V101, P159, DOI 10.1016/0305-0491(92)90172-N; POOLE AR, 1986, BIOCHEM J, V236, P1; RAZIN E, 1982, J BIOL CHEM, V257, P7229; ROTHENBERG ME, 1987, J IMMUNOL, V138, P2616; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCULLY MF, 1986, BIOCHEM BIOPH RES CO, V137, P15, DOI 10.1016/0006-291X(86)91169-1; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V343, P423, DOI 10.1016/0304-4165(74)90107-X; SENO N, 1982, CARBOHYD RES, V103, P190; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SODA T, 1940, NIPPON KAGAKU ZASSHI, V61, P43; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; SPEIGHT G, 1981, BIOCHIM BIOPHYS ACTA, V672, P89, DOI 10.1016/0304-4165(81)90282-8; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; SUGAHARA K, 1996, 18 INT CARB S MIL JU, P40; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; TAKASU Y, 1982, BIOCHIM BIOPHYS ACTA, V716, P316, DOI 10.1016/0304-4165(82)90022-8; TSUJI M, 1980, BIOCHIM BIOPHYS ACTA, V612, P373, DOI 10.1016/0005-2744(80)90120-5; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WEISSMANN B, 1955, J BIOL CHEM, V216, P783; WILSON JG, 1984, J IMMUNOL, V132, P3058; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YURT RW, 1977, J BIOL CHEM, V252, P518	85	93	94	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19656	19665		10.1074/jbc.272.32.19656	http://dx.doi.org/10.1074/jbc.272.32.19656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242620	hybrid			2022-12-27	WOS:A1997XQ05900007
J	Ruelland, E; LemaireChamley, M; LeMarechal, P; IssakidisBourguet, E; Djukic, N; MiginiacMaslow, M				Ruelland, E; LemaireChamley, M; LeMarechal, P; IssakidisBourguet, E; Djukic, N; MiginiacMaslow, M			An internal cysteine is involved in the thioredoxin-dependent activation of sorghum leaf NADP-malate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; REGULATORY SITE; PHOTOSYNTHESIS; EXPRESSION; ENZYMES; UNIQUE; ACID	The chloroplastic NADP-malate dehydrogenase is activated by thiol/disulfide interchange with reduced thioredoxins, Previous experiments showed that four cysteines located in specific N- and carboxyl-terminal extensions were implicated in this process, leading to a model where no internal cysteine was involved in activation, In the present study, the role of the conserved four internal cysteines was investigated, Surprisingly, the mutation of cysteine 207 into alanine yielded a protein with accelerated activation time course, whereas the mutations of the three other internal cysteines into alanines yielded proteins with unchanged activation kinetics, These results suggested that cysteine 207 might be linked in a disulfide bridge with one of the four external cysteines, most probably with one of the two amino-terminal cysteines whose mutation similarly accelerates the activation rate, To investigate this possibility, mutant malate dehydrogenases (MDHs) where a single amino terminal cysteine was mutated in combination with the mutation of both carboxyl-terminal cysteines were produced and purified, The C29S/C365A/C377A mutant MDH still needed activation by reduced thioredoxin, while the C24S/C365A/C377A mutant MDH exhibited a thioredoxin-insensitive spontaneous activity, leading to the hypothesis that a Cys(24)-Cys(207) disulfide bridge might be formed during the activation process, Indeed, an NADP-MDH where the cysteines 29, 207, 365, and 377 are mutated yielded a permanently active enzyme very similar to the previously created permanently active C24S/C29S/C365A/C377A mutant. A two-step activation model involving a thioredoxin-mediated disulfide isomerization at the amino terminus is proposed.	UNIV PARIS 11,ERS 569 CNRS,INST BIOTECHNL PLANTES,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay			Ruelland, Eric/D-4863-2012	Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364; Lemaire-Chamley, Martine/0000-0002-7687-894X				Buchanan Bob B., 1994, Seminars in Cell Biology, V5, P285, DOI 10.1006/scel.1994.1035; Chang JY, 1997, J BIOL CHEM, V272, P69; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; HATCH MD, 1992, PLANT PHYSIOL, V100, P360, DOI 10.1104/pp.100.1.360; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hennecke J, 1997, J BIOL CHEM, V272, P189; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; JACKSON RM, 1992, J COMPUT AID MOL DES, V6, P1, DOI 10.1007/BF00124383; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; JOHNSON HS, 1970, BIOCHEM J, V119, P273, DOI 10.1042/bj1190273; KAMPFENKEL K, 1993, BIOCHIM BIOPHYS ACTA, V1156, P71; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; Lemaire M, 1996, FEBS LETT, V382, P137, DOI 10.1016/0014-5793(96)00153-6; MIGINIACMASLO M, 1997, IN PRESS AUSTR J PLA, V24; OCHERETINA O, 1994, FEBS LETT, V355, P254, DOI 10.1016/0014-5793(94)01214-8; OCHERETINA O, 1993, BIOCHIM BIOPHYS ACTA, V1163, P10, DOI 10.1016/0167-4838(93)90272-S; RENG W, 1993, EUR J BIOCHEM, V217, P189, DOI 10.1111/j.1432-1033.1993.tb18233.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	28	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19851	19857		10.1074/jbc.272.32.19851	http://dx.doi.org/10.1074/jbc.272.32.19851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242647	Green Published, hybrid			2022-12-27	WOS:A1997XQ05900034
J	Buckhaults, P; Chen, L; Fregien, N; Pierce, M				Buckhaults, P; Chen, L; Fregien, N; Pierce, M			Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TRANSFORMED HAMSTER CELLS; MOUSE MELANOMA-CELLS; HERBIMYCIN-A; KIDNEY CELLS; BETA-1,4-GALACTOSYLTRANSFERASE GENE; BRANCHED OLIGOSACCHARIDES; CONTACT-INHIBITION; SUGAR CHAINS; BHK CELLS	Transformation of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the GlcNAc beta(1,6)Man-branched oligosaccharides by elevating the activity and mRNA transcript levels encoding N-acetylglucosaminyltransferase V (GlcNAc-T V). Elevated activity arid mRNA levels could be inhibited by blocking cell proliferation with herbimycin A, demonstrating that Src kinase activity can regulate GlcNAc-T V expression. 5' RACE analysis was used to identify a 3-kilobase 5'-untranslated region from GlcNAc-T V mRNA and locate a transcriptional start site in a 25-kilobase pair GlcNAc-T V human genomic clone, A 6-kilobase pair fragment of the 5' region of the gene contained AP-1 and PEA3/Ets binding elements and, when co-transfected with a src expression plasmid into HepG2 cells, conferred src-stimulated transcriptional enhancement upon a luciferase reporter gene, This stimulation by src could be antagonized by co-transfection with a dominant-negative mutant of the Raf kinase, suggesting the involvement of Ets transcription factors in the regulation of GlcNAc-T V gene expression. The src-responsive element was localized by 5' deletion analysis to a 250-base pair region containing two overlapping Ets sites. src stimulation of transcription from this region was inhibited by co-transfection with a dominant-negative mutant of Ets-2, demonstrating that the effects of the src kinase on GlcNAc-T V expression are dependent on Ets.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA; UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Miami								AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCK CA, 1971, BIOCHEMISTRY-US, V10, P2176, DOI 10.1021/bi00787a034; BUCK CA, 1970, BIOCHEMISTRY-US, V9, P4567, DOI 10.1021/bi00825a016; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; FERNANDES B, 1991, CANCER RES, V51, P718; FINNE J, 1989, INT J CANCER, V43, P300, DOI 10.1002/ijc.2910430223; GLICK MC, 1979, BIOCHEMISTRY-US, V18, P2525, DOI 10.1021/bi00579a015; GLICK MC, 1973, BIOCHEMISTRY-US, V12, P85, DOI 10.1021/bi00725a016; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAHN TJ, 1992, J BIOL CHEM, V267, P23982; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KUDO T, 1995, GLYCOBIOLOGY, V5, P397, DOI 10.1093/glycob/5.4.397; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MURAKAMI Y, 1988, CANCER RES, V48, P1587; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SUZUKAKETSUCHIYA K, 1989, J ANTIBIOT, V42, P1831, DOI 10.7164/antibiotics.42.1831; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TUSZYNSKI GP, 1978, J BIOL CHEM, V253, P6092; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WARREN L, 1972, P NATL ACAD SCI USA, V69, P1838, DOI 10.1073/pnas.69.7.1838; WARREN L, 1972, NATURE, V235, P276, DOI 10.1038/235275a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YAMAMURA K, 1991, J INVEST DERMATOL, V97, P735, DOI 10.1111/1523-1747.ep12484282; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	50	115	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19575	19581		10.1074/jbc.272.31.19575	http://dx.doi.org/10.1074/jbc.272.31.19575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235963	hybrid			2022-12-27	WOS:A1997XP06300069
J	Chantry, D; Vojtek, A; Kashishian, A; Holtzman, DA; Wood, C; Gray, PW; Cooper, JA; Hoekstra, MF				Chantry, D; Vojtek, A; Kashishian, A; Holtzman, DA; Wood, C; Gray, PW; Cooper, JA; Hoekstra, MF			p110 delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; PROTEIN-KINASE; SH2 DOMAINS; CLONING; BINDING; RECEPTOR; IDENTIFICATION; INTERACTS; HOMOLOG; PRODUCT	We have identified a novel p110 isoform of phosphatidylinositol 3-kinase from human leukocytes that we have termed p110 delta, In addition, we have independently isolated p110 delta from a mouse embryo library on the basis of its ability to interact with Ha-Ras(V12) in the yeast two-hybrid system, This unique isoform contains all of the conserved structural features characteristic of the p110 family, Recombinant p110 delta phosphorylates phosphatidylinositol and coimmunoprecipitates with p85, However, in contrast to previously described p110 subunits, p110 delta is expressed in a tissue-restricted fashion; it is expressed at high levels in lymphocytes and lymphoid tissues and may therefore play a role in phosphatidylinositol 3-kinase-mediated signaling in the immune system.	ICOS CORP,BOTHELL,WA 98021; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Icos Corporation; University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1642; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VOJTEK AB, 1993, J CELL SCI, V105, P777; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLINIA S, 1992, ONCOGENE, V7, P789; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	32	206	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19236	19241		10.1074/jbc.272.31.19236	http://dx.doi.org/10.1074/jbc.272.31.19236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235916	hybrid			2022-12-27	WOS:A1997XP06300022
J	Fan, GS; Ma, XM; Kren, BT; Rice, M; Kmiec, EB; Steer, CJ				Fan, GS; Ma, XM; Kren, BT; Rice, M; Kmiec, EB; Steer, CJ			A novel link between REC2, a DNA recombinase, the retinoblastoma protein, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							USTILAGO-MAYDIS; ADENOVIRUS E1A; GENE ENCODES; LARGE-T; BINDING; E2F; RB	The REC2 recombinase is essential for recombinational repair following DNA damage as well as for successful meiosis and gene targeting in the corn smut Ustilago maydis, Here we report that overexpression of REC2 induced apoptotic cell death in human HuH-7, Hep G2, and Hep 3B hepatoma cells. Apoptosis was related to recombinase activity and was significantly increased by inhibition of retinoblastoma (Rb) expression with transforming growth factor-beta 1. REC2-induced apoptosis was associated with a significantly reduced percentage of cells in the G(1) phase of the cell cycle and a significant reduction in G(2)/M only in the Rb((-)/(-)) Hep 3B cells. Overexpression of REC2 resulted in increased abundance of the hyperphosphorylated form of Rb. However, by immunoprecipitation REC2 was associated primarily with hypophosphorylated Rb, suggesting that REC2 may be involved in modulating the phosphorylation state of Rb. The A and B pocket domains with the spacer amino acid sequence and the carboxyl-terminal region of Rb were required for maximal binding to REC2. Overexpression of Rb significantly inhibited REC2-induced apoptosis even in the presence of transforming growth factor-beta 1. Taken together, these data suggest a novel interaction of Rb with the recombinase REC2 and a role for this complex in bridging DNA recombination and apoptosis.	UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,DEPT PHARMACOL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; University of Minnesota System; University of Minnesota Twin Cities								BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Fan GS, 1996, ADV ENZYME REGUL, V36, P283, DOI 10.1016/0065-2571(95)00013-5; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Fan GS, 1996, ONCOGENE, V12, P1909; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUBIN BP, 1994, MOL CELL BIOL, V14, P6287, DOI 10.1128/MCB.14.9.6287; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wick MJ, 1996, MOL BRAIN RES, V36, P322, DOI 10.1016/0169-328X(95)00258-T; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x	25	11	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19413	19417		10.1074/jbc.272.31.19413	http://dx.doi.org/10.1074/jbc.272.31.19413			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235941	hybrid			2022-12-27	WOS:A1997XP06300047
J	Floer, M; Blobel, G; Rexach, M				Floer, M; Blobel, G; Rexach, M			Disassembly of RanGTP-karyopherin beta complex, an intermediate in nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RNA1 GENE-PRODUCT; BINDING-PROTEIN; PORE COMPLEX; CHROMOSOME CONDENSATION; TRANSPORT SUBSTRATE; MEDIATED BINDING; YEAST MUTANT; IDENTIFICATION; RAN/TC4	We previously showed that RanGTP forms a 1:1 complex with karyopherin beta that renders RanGTP inaccessible to RanGAP (Floer, M., and Blobel, G. (1996) J. Biol. Chem. 271, 5313-5316) and karyopherin beta functionally inactive (Rexach, M., and Blobel, G. (1995) Cell 83, 683-692). Recycling of both factors for another round of function requires dissociation of the RanGTP-karyopherin beta complex, Here we show using BIAcore(TM), a solution binding assay, and GTP hydrolysis and exchange assays, with yeast proteins, that karyopherin beta and RanGTP are recycled efficiently in a reaction that involves karyopherin alpha, RanBP1, RanGAP, and the C terminus of the nucleoporin Nup1. We find that karyopherin alpha first releases RanGTP from karyopherin beta in a reaction that does not require GTP hydrolysis, The released RanGTP is then sequestered by RanBP1, and the newly formed karyopherin alpha beta binds to the C terminus of Nup1. Finally, RanGTP is converted to RanGDP via nucleotide hydrolysis when RanGrAP is present, Conversion of RanGTP to RanGDP can also occur via nucleotide exchange in the presence of RanGEF, an excess of GDP, and if RanBP1 is absent. Additional nucleoporin domains that bind karyopherin alpha beta stimulate recycling of karyopherin beta and Ran in a manner similar to the C terminus of Nup1.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	70	117	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19538	19546		10.1074/jbc.272.31.19538	http://dx.doi.org/10.1074/jbc.272.31.19538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235958	hybrid			2022-12-27	WOS:A1997XP06300064
J	Gongora, C; David, G; Pintard, L; Tissot, C; Hua, TD; Dejean, A; Mechti, N				Gongora, C; David, G; Pintard, L; Tissot, C; Hua, TD; Dejean, A; Mechti, N			Molecular cloning of a new interferon-induced PML nuclear body-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DNA-BINDING PROTEIN; C-FOS GENE; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; T(1517) TRANSLOCATION; GROWTH-SUPPRESSOR; VIRUS-INFECTION	Transcriptional induction of genes is an essential part of the cellular response to interferons. We have established a cDNA library from human lymphoblastoid Daudi cells treated for 16 h with human alpha/beta-interferon (IFN) and made use of differential screening to search for as yet unidentified IFN regulated genes, In the course of this study, we have isolated a human cDNA that codes for a 20-kDa protein sharing striking homology with the product of the Xenopus laevis XPMC2 gene. This new gene is induced by both type I and II IFNs in various cell lines and will be referred to as ISG20 for interferon-stimulated gene product of 20 kDa. Confocal immunofluorescence analysis of the subcellular localization of ISG20 protein reveals that it is closely associated with PML and SP100 gene products within the large nuclear matrix associated multiprotein complexes termed the PML nuclear bodies.	INST GENET MOL MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; INST PASTEUR,INSERM,UNITE RECOMBINAISON & EXPRESS GENET,U163,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			pintard, lionel/AAD-8356-2020; PINTARD, Lionel/AAP-7361-2020; Dejean, Anne/L-5145-2018; PINTARD, Lionel/H-3756-2018	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630; , gregory/0000-0002-3371-4558; GONGORA, Celine/0000-0001-9034-4031				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Boddy MN, 1996, ONCOGENE, V13, P971; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENSEN P, 1980, COMPUT APPL BIOSCI, V6, P355; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GRIGNANI F, 1994, BLOOD, V83, P10; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LAMOND AI, 1993, MOL BIOL REP, V18, P127, DOI 10.1007/BF00986767; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LAVAU C, 1995, ONCOGENE, V11, P871; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TERRIS B, 1995, CANCER RES, V55, P1590; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901	59	114	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19457	19463		10.1074/jbc.272.31.19457	http://dx.doi.org/10.1074/jbc.272.31.19457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235947	Green Published, hybrid			2022-12-27	WOS:A1997XP06300053
J	Ungewickell, E; Ungewickell, H; Holstein, SEH				Ungewickell, E; Ungewickell, H; Holstein, SEH			Functional interaction of the auxilin J domain with the nucleotide- and substrate-binding modules of Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CLATHRIN-ASSOCIATED PROTEIN; MOLECULAR CHAPERONE HSC70; COATED VESICLES; ESCHERICHIA-COLI; ATPASE ACTIVITY; UNCOATING ATPASE; COGNATE PROTEIN; DNAK CHAPERONE; BOVINE BRAIN	The uncoating of clathrin-coated vesicles requires the DnaJ homologue auxilin for targeting Hsc70 to clathrin coats. This function involves a transient interaction of the auxilin J domain with Hsc70. We have now identified the structural elements of Hsc70 that are responsible for the uncoating activity, and we show that the hitherto accepted view, which implicates the 10-kDa carboxyl-terminal variable domain of Hsc70, is incorrect. A 60-kDa chymotryptic or analogous recombinant fragment of Hsc70, which contains the ATPase- and substrate-binding domains, is sufficient to liberate clathrin from coated vesicles, Consistent with this was the observation that Hsp70 uncoats coated vesicles with the same efficacy as Hsc70 and that DnaK possesses vestigial uncoating activity, Direct binding studies demonstrated that the auxilin J domain undergoes an ATP-dependent reaction only with fragments of Hsc70 that contain both the ATPase- and substrate-binding domains, The individual domains by themselves did not bind to the J domain nor did a recombinant protein that contained the substrate-binding domain attached to the 10-kDa variable domain.			Ungewickell, E (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CAMPBELL CH, 1983, J BIOL CHEM, V258, P2628; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Hartl F U, 1991, Semin Immunol, V3, P5; HOHFELD J, 1995, CELL, V83, P589; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; JIANG F, 1997, J BIOL CHEM, V272, P6141; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P137; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; TSAI MY, 1994, J BIOL CHEM, V269, P5958; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	45	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19594	19600		10.1074/jbc.272.31.19594	http://dx.doi.org/10.1074/jbc.272.31.19594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235966	hybrid			2022-12-27	WOS:A1997XP06300072
J	Gugneja, S; Scarpulla, RC				Gugneja, S; Scarpulla, RC			Serine phosphorylation within a concise amino-terminal domain in nuclear respiratory factor 1 enhances DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CASEIN KINASE-II; TRANSCRIPTION FACTOR; GENE; EXPRESSION; PROTEINS; SITES; NRF-1; ACTIVATION; INITIATION	Nuclear respiratory factor 1 (NRF-1) is a transcriptional activator that acts on a diverse set of nuclear genes required for mitochondrial respiratory function in mammalian cells, These genes encode respiratory proteins as well as components of the mitochondrial transcription, replication, and heme biosynthetic machinery, Here, we establish that NRF-1 is a phosphoprotein in vivo. Phosphorylation occurs on serine residues within a concise NH2-terminal domain with the major sites of phosphate incorporation at serines 39, 44, 46, 47, and 52. The in vivo phosphorylation pattern can be approximated in vitro by phosphorylating recombinant NRF-1 with purified casein kinase II, Phosphate incorporation at the sites utilized in vivo results in a marked stimulation of DNA binding activity which is not observed in mutated proteins lacking these sites, Pairwise expression of the wild-type protein with each of a series of truncated derivatives in transfected cells results in the formation of a dimer between wild-type and mutant forms demonstrating that a homodimer is the active binding species. Although NRF-1 can dimerize in the absence of DNA, phosphorylation does not enhance the formation of these dimers, These findings suggest that phosphorylation results in an intrinsic change in the NRF-1 dimer enhancing its ability to bind DNA.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOL BIOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GOMEZCUADRADO A, 1995, MOL CELL BIOL, V15, P6670; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	36	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18732	18739		10.1074/jbc.272.30.18732	http://dx.doi.org/10.1074/jbc.272.30.18732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228045	hybrid			2022-12-27	WOS:A1997XM34200036
J	Horiuchi, M; Hayashida, W; Kambe, T; Yamada, T; Dzau, VJ				Horiuchi, M; Hayashida, W; Kambe, T; Yamada, T; Dzau, VJ			Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NERVE GROWTH-FACTOR; TYROSINE-PHOSPHATASE; MAP KINASE; MEDIATES INHIBITION; NEUROTROPHIC FACTOR; EXPRESSION; RAT; SUBTYPES; 3CH134	We examined the cellular and signaling mechanism of angiotensin II (Ang II) type 2 (AT2) receptor-induced apoptosis in PC12W (rat pheochromocytoma cell line) cells that express abundant AT2 receptor but not Ang II type 1 receptor. In these cells, nerve growth factor (NGF) inhibited the internucleosomal DNA fragmentation induced by serum depletion, whereas Ang II antagonized this NGF cell survival action and induced apoptosis, We studied the mechanism of NGF and AT2 receptor interaction on apoptosis by examining their effects on the survival factor Bcl-2, AT2 receptor activation did affect intracellular Bcl-2 protein levels, Bcl-2 phosphorylation was stimulated by NGF, whereas AT2 receptor activation blocked this NGF effect. Pretreatment with antisense oligonucleotide of mitogen-activated protein (MAP) kinase phosphatase-1 enhanced the effects of NGF on MAP kinase activation and Bcl-2 phosphorylation but attenuated the inhibitory effects of AT2 receptor on MAP kinase, Bcl-2 phosphorylation, and apoptosis, Taken together, these results suggest that MAP kinase plays a critical role in inhibiting apoptosis by phosphorylating Bcl-2, The AT2 receptor inhibits MAP kinase activation, resulting in the inactivation of Bcl-2 and the induction of apoptosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NHLBI NIH HHS [HL46631, HL35610, HL35252] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046631, R01HL035610, R37HL035610, R01HL035252] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CLEARLY ML, 1992, CELL, V47, P19; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; MAY WS, 1994, J BIOL CHEM, V269, P26865; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; UDLEY DT, 1993, REGUL PEPTIDES, V44, P199; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	39	248	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19022	19026		10.1074/jbc.272.30.19022	http://dx.doi.org/10.1074/jbc.272.30.19022			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228085	hybrid			2022-12-27	WOS:A1997XM34200076
J	Noel, RJ; Antinozzi, PA; McGarry, JD; Newgard, CB				Noel, RJ; Antinozzi, PA; McGarry, JD; Newgard, CB			Engineering of glycerol-stimulated insulin secretion in islet beta cells - Differential metabolic fates of glucose and glycerol provide insight into mechanisms of stimulus-secretion coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; PANCREATIC-ISLETS; MALONYL-COA; GENE; DEHYDROGENASE; GLYCOLYSIS; INHIBITION; LANGERHANS; PHOSPHATE; CHANNELS	Insulin secretion from beta cells in the islets of Langerhans can be stimulated by a number of metabolic fuels, including glucose and glyceraldehyde, and is thought to be mediated by metabolism of the secretagogues and an attendant increase in the ATP:ADP ratio. Curiously, glycerol fails to stimulate insulin secretion, even though it has been reported that islets contain abundant glycerol kinase activity and oxidize glycerol efficiently, We have reinvestigated this point and find that rat islets and the well differentiated insulinoma cell line INS-1 contain negligible glycerol kinase activity. A recombinant adenovirus containing the bacterial glycerol kinase gene (AdCMV-GlpK) was constructed and used to express the enzyme in islets and INS-1 cells, resulting in insulin secretion in response to glycerol. In AdCMV-GlpK-treated INS-1 cells a greater proportion of glycerol is converted to lactate and a lesser proportion is oxidized compared with glucose. The two fuels are equally potent as insulin secretagogues, despite the fact that oxidation of glycerol at its maximally effective dose (2-5 mM) occurs at a rate that is similar to the rate of glucose oxidation at its basal, nonstimulatory concentration (3 mM). We also investigated the possibility that glycerol may signal via expansion of the glycerol phosphate pool to allow enhanced fatty acid esterification and formation of complex lipids. Addition of Triacsin-C, an inhibitor of long-chain acyl-CoA synthetase, to AdCMV-GlpK-treated INS-1 cells did not inhibit glycerol-stimulated insulin secretion despite the fact that it blocked glycerol incorporation into cellular lipids. We conclude from these studies that glycerol kinase expression is sufficient to activate glycerol signaling in beta cells, showing that the failure of normal islets to respond to this substrate is due to a lack of this enzyme activity. Further, our studies show that glycerol signaling is not Linked to esterification or oxidation of the substrate, but is likely mediated by its metabolism in the glycerol phosphate shuttle and/or the distal portion of the glycolytic pathway, either of which can lead to production of ATP and an increased ATP:ADP ratio.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 46492-05] Funding Source: Medline; NIGMS NIH HHS [T32 GM08014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492, R37DK046492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUKES ID, 1994, J BIOL CHEM, V269, P10979; FERBER S, 1994, J BIOL CHEM, V269, P11523; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, HORM METAB RES, V14, P678, DOI 10.1055/s-2007-1019117; McCrory W.J., 1988, VIROLOGY, V163, P614; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PETTIGREW DW, 1988, J BIOL CHEM, V263, P135; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; SENER A, 1988, INT J BIOCHEM, V20, P595, DOI 10.1016/0020-711X(88)90098-5; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; YILMAZ MT, 1987, MOL CELL ENDOCRINOL, V52, P251, DOI 10.1016/0303-7207(87)90051-7	33	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18621	18627		10.1074/jbc.272.30.18621	http://dx.doi.org/10.1074/jbc.272.30.18621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228030	hybrid			2022-12-27	WOS:A1997XM34200021
J	Perry, DK; Smyth, MJ; Stennicke, HR; Salvesen, GS; Duriez, P; Poirier, GG; Hannun, YA				Perry, DK; Smyth, MJ; Stennicke, HR; Salvesen, GS; Duriez, P; Poirier, GG; Hannun, YA			Zinc is a potent inhibitor of the apoptotic protease, caspase-3 - A novel target for zinc in the inhibition of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT ENDONUCLEASE; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; INTRACELLULAR ZINC; IDENTIFICATION; CLEAVAGE; THYMOCYTES; ACTIVATION; LEUKEMIA	The prevention of apoptosis by Zn2+ has generally been attributed to its inhibition of an endonuclease acting in the late phase of apoptosis. In this study we investigated the effect of Zn2+ on an earlier event in the apoptotic process, the proteolysis of the ''death substrate'' poly(ADP-ribose) polymerase (PARP). Pretreatment of intact Molt4 leukemia cells with micromolar concentrations of Zn2+ caused an inhibition of PARP proteolysis induced by the chemotherapeutic agent etoposide, Using a cell-free system consisting of purified bovine PARP as a substrate and an apoptotic extract or recombinant caspase-3 as the PARP protease, Zn2+ inhibited PARP proteolysis in the low micromolar range. To rule out an effect of Zn2+ on PARP, a protein with two zinc finger domains, we used recombinant caspase-3 and a chromogenic tetrapeptide substrate containing the caspase-3 cleavage site. In this system, Zn2+ inhibited caspase-3 with an IC50 of 0.1 mu M. These results identify caspase-3 as a novel target of Zn2+ inhibition in apoptosis and suggest a regulatory role for Zn2+ in modulating the upstream apoptotic machinery.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710; LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037; UNIV LAVAL,CHU LAVAL,RES CTR,ST FOY,PQ G1V 4G2,CANADA	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Sanford Burnham Prebys Medical Discovery Institute; Laval University				Duriez, Patrick/0000-0003-1814-2552; Poirier, Guy/0000-0002-4869-1424	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; FADY C, 1995, J INTERF CYTOK RES, V15, P71, DOI 10.1089/jir.1995.15.71; FAILLA ML, 1978, BIOCHIM BIOPHYS ACTA, V538, P435, DOI 10.1016/0304-4165(78)90405-1; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Jiang SN, 1997, CELL DEATH DIFFER, V4, P39, DOI 10.1038/sj.cdd.4400204; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENTNER C, 1981, SCI TABLES, P79; MARTIN SJ, 1991, CLIN EXP IMMUNOL, V83, P338; Matsushita K, 1996, BRAIN RES, V743, P362, DOI 10.1016/S0006-8993(96)01112-2; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MCCABE MJ, 1993, LAB INVEST, V69, P101; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; PATTISON SE, 1986, FASEB J, V45, P2805; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; POWERS SG, 1981, J BIOL CHEM, V256, P1160; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SMITH GK, 1992, CANCER RES, V52, P4895; SUHY DA, 1995, MET IONS BIOL SYST, P557; SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P1; THOMAS DJ, 1991, TOXICOLOGY, V68, P327, DOI 10.1016/0300-483X(91)90078-F; TREVES S, 1994, EXP CELL RES, V211, P339, DOI 10.1006/excr.1994.1096; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251	33	407	419	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18530	18533		10.1074/jbc.272.30.18530	http://dx.doi.org/10.1074/jbc.272.30.18530			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228015	hybrid			2022-12-27	WOS:A1997XM34200006
J	Scheibel, T; Neuhofen, S; Weikl, T; Mayr, C; Reinstein, J; Vogel, PD; Buchner, J				Scheibel, T; Neuhofen, S; Weikl, T; Mayr, C; Reinstein, J; Vogel, PD; Buchner, J			ATP-binding properties of human Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR INACTIVATION; SPIN-RESONANCE SPECTROSCOPY; PROGESTERONE-RECEPTOR; MOLYBDATE IONS; KINASE; EPIMERIZATION; CHAPERONES; ACTIVATION; MECHANISM	Hsp90 is one of the most abundant proteins in the cytosol of eukaryotic cells, Under physiological conditions Hsp90 has been shown to play a major role in several specific signaling pathways, including maturation of various kinases and maintenance of steroid receptors in an activable state. It is well established that the level of Hsp90 increases severalfold under stress conditions, and it has been shown that the chaperone function of Hsp90 is ATP-independent. Although yeast Hsp90 does not bind ATP, as determined by a number of methods monitoring tight binding, ATP dependent functions of Hsp90 in the presence of co-factors and elevated temperatures are still under discussion. Here, we have reinvestigated ATP-binding properties and ATPase activity of human Hsp90 under various conditions, We show that human Hsp90 does not bind ATP tightly and does not exhibit detectable ATPase activity. However, using electron spin resonance spectroscopy, weak binding of spin-labeled ATP analogues with half-maximal binding at 400 mu M ATP was detected. The functional significance of this weak interaction remains enigmatic.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV KAISERSLAUTERN,FACHBEREICH CHEM BIOCHEM,D-67663 KAISERSLAUTERN,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Regensburg; University of Kaiserslautern; Max Planck Society			Buchner, Johannes/A-2651-2010; Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423; Buchner, Johannes/0000-0003-1282-7737; Vogel, Pia/0000-0002-8135-4649				BAUER M, 1992, FEBS LETT, V313, P288, DOI 10.1016/0014-5793(92)81211-4; BILIK V, 1975, CHEM ZVESTI, V29, P690; BILIK V, 1978, CHEM ZVESTI, V32, P242; BILIK V, 1972, CHEM ZVESTI, V26, P182; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BODINE PVN, 1995, RECEPTOR, V5, P117; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOSE S, 1996, SCIENCE, V274, P171; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BURGARD S, 1994, J BIOL CHEM, V269, P17815; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LEACH KL, 1979, J BIOL CHEM, V254, P1884; Losel RM, 1997, BIOCHEMISTRY-US, V36, P1188, DOI 10.1021/bi9614601; Losel RM, 1996, SPECTROCHIM ACTA A, V52, P73, DOI 10.1016/0584-8539(95)01549-3; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; Nardai G, 1996, J BIOSCIENCE, V21, P179, DOI 10.1007/BF02703107; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neuhofen S, 1996, EUR J BIOCHEM, V240, P78, DOI 10.1111/j.1432-1033.1996.0078h.x; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; PAIGEN K, 1958, J BIOL CHEM, V233, P388; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, STEROID HORMONE RECE, P247; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGELCLAUDE P, 1987, FEBS LETT, V227, P107; WALTER U, 1981, EXPERIENTIA, V37, P1263, DOI 10.1007/BF01948349; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	61	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18608	18613		10.1074/jbc.272.30.18608	http://dx.doi.org/10.1074/jbc.272.30.18608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228028	Green Published, hybrid			2022-12-27	WOS:A1997XM34200019
J	Srinivasula, SM; Ahmad, M; Ottilie, S; Bullrich, F; Banks, S; Wang, Y; FernandesAlnemri, T; Croce, CM; Litwack, G; Tomaselli, KJ; Armstrong, RC; Alnemri, ES				Srinivasula, SM; Ahmad, M; Ottilie, S; Bullrich, F; Banks, S; Wang, Y; FernandesAlnemri, T; Croce, CM; Litwack, G; Tomaselli, KJ; Armstrong, RC; Alnemri, ES			FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; PROTEIN; INTERACTS	We identified and cloned a novel human protein that contains FADD/Mortl death effector domain homology regions, designated FLAME-1, FLAME-1, although most similar in structure to Mch4 and Mch5, does not possess caspase activity but can interact specifically with FADD, Mch4, and Mch5. Interestingly, FLAME-1 is recruited to the Fas receptor complex and can abrogate Fas/TNFR-induced apoptosis upon expression in Fast/tumor necrosis factor-sensitive MCF-7 cells, possibly by acting as a dominant-negative inhibitor. These findings identify a novel endogenous control point that regulates Fas/TNFR1-mediated apoptosis.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107; IDUN PHARMACEUT,SAN DIEGO,CA 92121	Jefferson University; Jefferson University; Jefferson University			Young, Richard A/F-6495-2012; Alnemri, Emad S/B-4526-2010	Young, Richard A/0000-0001-8855-8647; 	NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BULLRICH F, 1995, CANCER RES, V55, P1199; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENKART PA, 1996, IMMUNITY, V4, P1955; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P13706	16	292	307	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18542	18545		10.1074/jbc.272.30.18542	http://dx.doi.org/10.1074/jbc.272.30.18542			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228018	hybrid			2022-12-27	WOS:A1997XM34200009
J	Steel, DJ; Tieman, TL; Schwartz, JH; Feinmark, SJ				Steel, DJ; Tieman, TL; Schwartz, JH; Feinmark, SJ			Identification of an 8-lipoxygenase pathway in nervous tissue of Aplysia californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-CATALYZED TRANSFORMATION; ARACHIDONIC-ACID METABOLITES; LONG-TERM POTENTIATION; NORDIHYDROGUAIARETIC ACID; PRESYNAPTIC INHIBITION; PLEXAURA-HOMOMALLA; OOCYTE MATURATION; DENTATE GYRUS; K+-CHANNELS; 12-LIPOXYGENASE	Arachidonic acid is converted to (8R)-hydroperoxyeicosa-5,9,11,14-tetraenoic acid (8-HPETE) during incubations with homogenates of the central nervous system of the marine mollusc, Aplysia californica. 8-HPETE can be reduced to the corresponding hydroxy acid or be enzymatically converted to a newly identified metabolite, 8-ketoeicosa-5,9,11,14-tetraenoic acid (8-KETE). These metabolites were identified by high performance liquid chromatography, UV absorbance, and gas chromatography/mass spectrometry. Stereochemical analysis of the products demonstrate that the neuronal enzyme is an (8R)-lipoxygenase. Previously we have shown that the neurotransmitters, histamine and Phe-Met-Arg-Phe-amide, activate 12-lipoxygenase metabolism in isolated identified Aplysia neurons. We now show that acetylcholine activates the (8R)-lipoxygenase pathway within intact nerve cells. Thus, both (12S)- and (8R)-lipoxygenase co exist in intact Aplysia nervous tissue but are differentially activated by several neurotransmitters. The precise physiological role of the 8-lipoxygenase products is currently under investigation, but by analogy to the well-described 12-lipoxygenase pathway, we suggest that (8R)-HPETE and 8-KETE may serve as second messengers in Aplysia cholinoceptive neurons.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University			Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00921] Funding Source: Medline; NINDS NIH HHS [NS29832] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE M, 1995, BRAIN RES, V683, P200, DOI 10.1016/0006-8993(95)00375-Z; BABA A, 1989, J BIOL CHEM, V264, P15790; BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BUNDY GL, 1986, J BIOL CHEM, V261, P747; BUTTNER N, 1989, NATURE, V342, P553, DOI 10.1038/342553a0; CARLEN PL, 1989, BRAIN RES, V497, P171, DOI 10.1016/0006-8993(89)90984-0; CHANG WC, 1992, J BIOL CHEM, V267, P3657; DELACLOS BF, 1987, PROSTAGLANDINS, V33, P315, DOI 10.1016/0090-6980(87)90016-5; EISENSTADT M, 1973, P NATL ACAD SCI USA, V70, P3371, DOI 10.1073/pnas.70.12.3371; FEINMARK SJ, 1992, ADV EXP MED BIOL, V318, P159; FEINMARK SJ, 1983, J CLIN INVEST, V72, P1839, DOI 10.1172/JCI111144; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; HAMEDA H, 1994, AM J PHYSIOL, V266, pC243; HAMPSON AJ, 1992, BIOCHIM BIOPHYS ACTA, V1124, P143, DOI 10.1016/0005-2760(92)90090-I; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HERMAN RP, 1987, PROSTAGLANDINS, V34, P129; HILL EM, 1988, PROC R SOC SER B-BIO, V234, P455, DOI 10.1098/rspb.1988.0058; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; Liu B., 1996, Society for Neuroscience Abstracts, V22, P330; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MEIJER L, 1986, DEV BIOL, V114, P22, DOI 10.1016/0012-1606(86)90380-5; MEIJER L, 1986, J BIOL CHEM, V261, P7040; MEIJER L, 1986, PROSTAG LEUKOTR ESS, V23, P179, DOI 10.1016/0262-1746(86)90183-6; MURPHY RC, 1993, MASS SPECTROMETRY LI, P112; Nishiyama M., 1996, Society for Neuroscience Abstracts, V22, P1459; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; PIOMELLI D, 1988, J BIOL CHEM, V263, P16591; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; POURPLANCHE C, 1994, J BIOL CHEM, V269, P31585; REYNAUD D, 1994, J BIOL CHEM, V269, P23976; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P277; SHAPIRO E, 1988, COLD SPRING HARB SYM, V53, P425, DOI 10.1101/SQB.1988.053.01.050; SONG WC, 1991, ARCH BIOCHEM BIOPHYS, V290, P427, DOI 10.1016/0003-9861(91)90562-W; TAUC L, 1967, PHYSIOL REV, V47, P521, DOI 10.1152/physrev.1967.47.3.521; Tieman T., 1996, Society for Neuroscience Abstracts, V22, P621; VOLTERRA A, 1988, P NATL ACAD SCI USA, V85, P7810, DOI 10.1073/pnas.85.20.7810; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WILLIAMS JH, 1988, NEUROSCI LETT, V88, P81, DOI 10.1016/0304-3940(88)90319-9	45	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18673	18681		10.1074/jbc.272.30.18673	http://dx.doi.org/10.1074/jbc.272.30.18673			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228037	hybrid			2022-12-27	WOS:A1997XM34200028
J	Thompson, JF; Geoghegan, KF; Lloyd, DB; Lanzetti, AJ; Magyar, RA; Anderson, SM; Branchini, BR				Thompson, JF; Geoghegan, KF; Lloyd, DB; Lanzetti, AJ; Magyar, RA; Anderson, SM; Branchini, BR			Mutation of a protease-sensitive region in firefly luciferase alters light emission properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; ADENINE MOIETY; BIOLUMINESCENCE; SYNTHETASE; GENE	Luciferase (EC 1.13.12.7) from the North American firefly, Photinus pyralis, is widely used as a reporter enzyme in cell biology, One of its distinctive properties is a pronounced susceptibility to proteolytic degradation that causes luciferase to have a very short intracellular half-life, To define the structural basis for this behavior and possibly facilitate the design of more stable forms of luciferase, limited proteolysis studies were undertaken using trypsin and chymotrypsin to identify regions of the protein whose accessible and flexible character rendered them especially sensitive to cleavage. Regions of amino acid sequence 206-220 and 329-341 were found to be sensitive, and because the region around 206-220 had high homology with other luciferases, CoA ligases, and peptidyl synthetases, this region was selected for mutagenesis experiments intended to determine which of its amino acids were essential for activity, Surprisingly, many highly conserved residues including Ser(198), Ser(201), Thr(202), and Gly(203) could be mutated with little effect on the luminescent activity of P. pyralis luciferase, One mutation, however, S198T, caused several alterations in enzymatic properties including shifting the pH optimum from 8.1 to 8.7, lowering the K-m for Mg-ATP by a factor of 4 and increasing the half-time for light emission decay by a factor of up to 150. While the S198T luciferase was less active than wild type, activity could be restored by the introduction of the additional L194F and N197Y mutations. In addition to indicating the involvement of this region in ATP binding, these results provide a new form of the enzyme that affords a more versatile reporter system.	PFIZER INC,DIV CENT RES,DEPT MOL SCI,GROTON,CT 06340	Pfizer	Thompson, JF (corresponding author), CONNECTICUT COLL,DEPT CHEM,NEW LONDON,CT 06320, USA.			Thompson, John/0000-0001-8568-3311				AIRTH RL, 1958, BIOCHIM BIOPHYS ACTA, V27, P519, DOI 10.1016/0006-3002(58)90381-0; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Branchini BR, 1997, ARCH BIOCHEM BIOPHYS, V340, P52, DOI 10.1006/abbi.1997.9894; BRANCHINI BR, 1989, PHOTOCHEM PHOTOBIOL, V49, P689, DOI 10.1111/j.1751-1097.1989.tb08442.x; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Dementieva EI, 1996, BIOCHEMISTRY-MOSCOW+, V61, P115; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORD SR, 1995, BBA-PROTEIN STRUCT M, V1252, P180, DOI 10.1016/0167-4838(95)00150-S; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; ORTIZ B, 1995, J PHOTOCH PHOTOBIO B, V29, P33; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAZZAGLI M, 1992, ANAL BIOCHEM, V204, P315, DOI 10.1016/0003-2697(92)90245-3; SELIGER HH, 1960, ARCH BIOCHEM BIOPHYS, V88, P136, DOI 10.1016/0003-9861(60)90208-3; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VIVIANI VR, 1995, PHOTOCHEM PHOTOBIOL, V62, P490, DOI 10.1111/j.1751-1097.1995.tb02373.x; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x	18	55	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18766	18771		10.1074/jbc.272.30.18766	http://dx.doi.org/10.1074/jbc.272.30.18766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228050	hybrid			2022-12-27	WOS:A1997XM34200041
J	Yan, SZ; Huang, ZH; Rao, VD; Hurley, JH; Tang, WJ				Yan, SZ; Huang, ZH; Rao, VD; Hurley, JH; Tang, WJ			Three discrete regions of mammalian adenylyl cyclase form a site for G(s alpha) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN; ALPHA; FORSKOLIN; MODELS	The interaction between the alpha subunit of G protein G(s) (G(s alpha)) and the two cytoplasmic domains of adenylyl cyclase (C-1 and C-2) is a key step in the stimulation of cAMP synthesis by hormones, Mutational analysis reveals that three discrete regions in the primary sequence of adenylyl cyclase affect the EC50 values for G(s alpha) activation and thus are the affinity determinants of G(s alpha). Based on the three-dimensional structure of C-2 forskolin dimer, these three regions (C-2, alpha 2, C-2 alpha 3/beta 4, and C-1 beta 1) are close together and form a negatively charged and hydrophobic groove the width of an alpha helix that can accommodate the positively charged adenylyl cyclase binding region of G(s alpha). Two mutations in the C-2 alpha 3/beta 4 region decrease the V-max values of G(s alpha) activation without an increase in the EC50 values, Since these three regions are distal to the catalytic site, the likely mechanism for G(s alpha) activation is to modulate the structure of the active site by controlling the orientation of the C-2 alpha 2 and alpha 3/beta 4 structures.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; NIDDK, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Tang, Wei-Jen/0000-0002-8267-8995	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53459] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; HERN J, 1990, METHOD ENZYMOL, V183, P626; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1997, IN PRESS ADV 2 MESSE; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	28	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18849	18854		10.1074/jbc.272.30.18849	http://dx.doi.org/10.1074/jbc.272.30.18849			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228061	hybrid			2022-12-27	WOS:A1997XM34200052
J	Foresti, R; Clark, JE; Green, CJ; Motterlini, R				Foresti, R; Clark, JE; Green, CJ; Motterlini, R			Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells - Involvement of superoxide and peroxynitrite anions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; RELAXING FACTOR; HYDROGEN-PEROXIDE; UVA RADIATION; RAT-LIVER; GLUTATHIONE; ACCUMULATION; PROTEINS; NO; HYDROXOCOBALAMIN	Thiols are very important antioxidants that protect cells against oxidative insults. Recently, a different and new physiological role has been defined for these compounds because of their involvement in nitric oxide (NO) binding and transport in biological systems, in view of these characteristics, we examined the effect of thiols and NO on the expression of the inducible form of heme oxygenase (HO-1), a stress protein that degrades heme to carbon monoxide and biliverdin. Cultured bovine aortic endothelial cells exposed to the NO donors sodium nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP) resulted in increased heme oxygenase activity and HO-1 expression. Co-incubation with N-acetylcysteine, a precursor of glutathione synthesis, significantly attenuated heme oxygenase induction by SNP and SNAP, and a reduction in heme oxygenase activity was also observed when cells were preincubated with N-acetylcysteine for 16 h prior to exposure to NO donors. This effect appears to be associated with NO stabilization by thiols through the formation of S-nitroso-thiols. Hydroxocobalamin, a specific NO scavenger, significantly decreased endothelial heme oxygenase activity, indicating a direct involvement of NO released by NO donors to regulate the expression of this stress protein. Moreover, superoxide anion (0(-).(2)) and its reaction product with NO, peroxynitrite (ONOO-), were found to partially contribute to the observed NO-mediated activation of endothelial heme oxygenase. Thus, we suggest the existence of a dynamic equilibrium among free NO, 0(-).(2), and endogenous glutathione, which might constitute an interactive signaling mechanism modulating stress and adaptive responses in tissues.			Foresti, R (corresponding author), NORTHWICK PK INST MED RES,DEPT SURG RES,HARROW HA1 3UJ,MIDDX,ENGLAND.		Motterlini, Roberto/Q-1890-2019; Motterlini, Roberto/G-2489-2013	Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRUNE B, 1987, MOL PHARMACOL, V32, P497; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FEELISCH M, 1996, METHODS NITRIC OXIDE, P521; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HENRY PJ, 1989, BRIT J PHARMACOL, V98, P757, DOI 10.1111/j.1476-5381.1989.tb14603.x; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHAN MT, 1987, FASEB J, V46, P385; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lilley E, 1996, BRIT J PHARMACOL, V119, P432, DOI 10.1111/j.1476-5381.1996.tb16004.x; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Motterlini R, 1996, BIOCHEM BIOPH RES CO, V225, P167, DOI 10.1006/bbrc.1996.1148; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; Motterlini Roberto, 1996, P74; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RAJANAYAGAM MAS, 1993, BRIT J PHARMACOL, V108, P3, DOI 10.1111/j.1476-5381.1993.tb13429.x; RIZZARDINI M, 1994, BIOCHEM J, V304, P477, DOI 10.1042/bj3040477; ROCHELLE LG, 1995, J PHARMACOL EXP THER, V275, P48; ROCHELLE LG, 1994, TOXICOL APPL PHARM, V128, P123, DOI 10.1006/taap.1994.1189; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	50	275	282	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18411	18417		10.1074/jbc.272.29.18411	http://dx.doi.org/10.1074/jbc.272.29.18411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218484	hybrid			2022-12-27	WOS:A1997XL73500074
J	Pallud, S; Lennon, AM; Ramauge, M; Gavaret, JM; Croteau, W; Pierre, M; Courtin, F; StGermain, DL				Pallud, S; Lennon, AM; Ramauge, M; Gavaret, JM; Croteau, W; Pierre, M; Courtin, F; StGermain, DL			Expression of the type II iodothyronine deiodinase in cultured rat astrocytes is selenium-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; GLUTATHIONE-PEROXIDASE; ASTROGLIAL CELLS; 5'-DEIODINASE ACTIVITY; DIETARY SELENIUM; 12-O-TETRADECANOYLPHORBOL 13-ACETATE; SELENOCYSTEINE INSERTION; CEREBRAL-CORTEX; GENE-EXPRESSION; TARGET TISSUES	The iodothyronine deiodinases are a family of selenoproteins that metabolize thyroxine and other thyroid hormones to active and inactive metabolites in a number of tissues including brain, Using primary cultures of rat astroglial cells as a model system, we demonstrate that the mRNA for the type II iodothyronine deiodinase (DIE) selenoenzyme is rapidly and markedly induced by forskolin and 8-bromo-cAMP. The induction DII activity, however, was significantly impaired by culturing cells in selenium-deficient medium for 7 days, Under such conditions, the addition of selenium resulted in a rapid increase in cAMP-induced DII activity that was dose-dependent, with maximal effects noted within 2 h, Cycloheximide blocked this effect of selenium on restoring cAMP-induced DII activity, whereas actinomycin D did not. These data demonstrate that the DII selenoenzyme is expressed in cultured astrocytes and that the induction of DII activity by cAMP analogues appears to be mediated, at least in part, by pretranslational mechanisms, Furthermore, selensium deprivation impairs the expression of DII activity at the level of translation.	UNITE RECH GLANDE THYROIDE & REGULAT HORMONALE,U96 INSERM,F-94276 LE KREMLIN BICETR,FRANCE; DARTMOUTH COLL SCH MED,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03756	Institut National de la Sante et de la Recherche Medicale (Inserm); Dartmouth College; Dartmouth College					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZENMAN Y, 1987, BRAIN RES, V414, P301, DOI 10.1016/0006-8993(87)90010-2; BECKER KB, 1995, ENDOCRINOLOGY, V136, P4424, DOI 10.1210/en.136.10.4424; BEECH SG, 1995, ANALYST, V120, P827, DOI 10.1039/an9952000827; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERMANO G, 1995, BIOCHEM J, V311, P425, DOI 10.1042/bj3110425; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; CamposBarros A, 1996, J CLIN ENDOCR METAB, V81, P2179, DOI 10.1210/jc.81.6.2179; CAVALIERI RR, 1986, BRAIN RES, V364, P382, DOI 10.1016/0006-8993(86)90852-8; CHANOINE JP, 1993, J CLIN INVEST, V91, P2709, DOI 10.1172/JCI116510; CHANOINE JP, 1992, ENDOCRINOLOGY, V130, P479; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN MJ, 1992, J NUTR, V122, P1620, DOI 10.1093/jn/122.8.1620; COURTIN F, 1991, J NEUROCHEM, V56, P1107, DOI 10.1111/j.1471-4159.1991.tb11399.x; COURTIN F, 1988, ENDOCRINOLOGY, V123, P1577, DOI 10.1210/endo-123-3-1577; COURTIN F, 1989, ENDOCRINOLOGY, V125, P1277, DOI 10.1210/endo-125-3-1277; COURTIN F, 1986, MOL CELL ENDOCRINOL, V48, P167, DOI 10.1016/0303-7207(86)90039-0; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; DEPALO D, 1994, J BIOL CHEM, V269, P16223; ESFANDIARI A, 1994, GLIA, V11, P255, DOI 10.1002/glia.440110306; ESFANDIARI A, 1992, ENDOCRINOLOGY, V131, P1682, DOI 10.1210/en.131.4.1682; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GROSS M, 1995, BIOCHEM J, V306, P851, DOI 10.1042/bj3060851; KAPLAN MM, 1981, J CLIN INVEST, V67, P1208, DOI 10.1172/JCI110136; KAPLAN MM, 1980, J CLIN INVEST, V66, P551, DOI 10.1172/JCI109887; KARMARKAR MG, 1993, AM J CLIN NUTR S, V57; KOHRLE J, 1994, EXP CLIN ENDOCRINOL, V102, P63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI XG, 1995, J NUTR, V125, P1438; LENNON AM, 1994, J NEUROCHEM, V62, P2116; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; Ramauge M, 1996, ENDOCRINOLOGY, V137, P3021, DOI 10.1210/en.137.7.3021; Safran M, 1996, J BIOL CHEM, V271, P16363, DOI 10.1074/jbc.271.27.16363; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Salvatore D, 1996, J CLIN INVEST, V98, P962, DOI 10.1172/JCI118880; SILVA JE, 1984, J CLIN INVEST, V74, P1035, DOI 10.1172/JCI111471; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; STGERMAIN DL, 1994, TRENDS ENDOCRIN MET, V5, P36, DOI 10.1016/1043-2760(94)90119-8; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; STGERMAIN DL, 1990, J BIOL CHEM, V265, P20087; TOYODA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P301, DOI 10.1016/0167-4781(89)90020-1; VADHANAVIKIT S, 1993, J NUTR, V123, P1124; VALVERDE RC, 1997, ENDOCRINOLOGY, V138, P642; VANDOORN J, 1986, ACTA ENDOCRINOL-COP, V113, P59, DOI 10.1530/acta.0.1130059; VANDOORN J, 1984, ENDOCRINOLOGY, V115, P174, DOI 10.1210/endo-115-1-174; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080	57	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18104	18110		10.1074/jbc.272.29.18104	http://dx.doi.org/10.1074/jbc.272.29.18104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218443	hybrid			2022-12-27	WOS:A1997XL73500033
J	Mukhopadhyay, S; Shankar, S; Walden, W; Chakrabarty, AM				Mukhopadhyay, S; Shankar, S; Walden, W; Chakrabarty, AM			Complex formation of the elongation factor Tu from Pseudomonas aeruginosa with nucleoside diphosphate kinase modulates ribosomal GTP synthesis and peptide chain elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS	The elongation factor Tu (EF-Tu) from Pseudomonas aeruginosa was purified as a 45-kDa polypeptide that forms a complex with both the 12- and 16-kDa forms of nucleoside-diphosphate kinase (Ndk) and predominantly synthesizes GTP, 70 S ribosomes of P. aeruginosa predominantly synthesize GTP, which is inhibited in presence of anti-Ndk antibodies, Anti-EF-Tu antibodies change the specificity of ribosomal GTP synthesis to all nucleoside triphosphate synthesis, Ndk has been shown to be a part of 30 S ribosomes, whereas EF-Tu is found to be associated with the 50 S ribosomal subunit, These data indicate that GTP synthesis in the ribosome is modulated both by Ndk and by EF-Tu, Peptide chain elongation as measured by polymerization of Phe-tRNA on a poly(U) template in presence of GDP can be inhibited by anti Ndk antibodies and restored by the addition of GTP, Anti-EF-Tu antibodies similarly inhibit peptide chain elongation by P. aeruginosa ribosomes in the in vitro translation assay; however, this inhibition cannot be overcome by adding back GTP, Because the purified EF-Tu.16-kDa Ndk complex predominantly synthesizes GTP, it seems likely that this complex is a significant source of GTP for translational elongation in protein biosynthesis.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031546, R01AI016790, R37AI016790] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31546-04, AI-16790-16] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER C, 1995, J BIOL CHEM, V270, P14541, DOI 10.1074/jbc.270.24.14541; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; Cashel M., 1994, METH MOL G, V3, P341; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; EHRENBERG M, 1990, RIBOSOME, P373; GARRILOVA LP, 1974, METHODS ENZUYMOL, V30, P452; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLINKER JF, 1995, BIOCHEM BIOPH RES CO, V209, P575, DOI 10.1006/bbrc.1995.1539; MARCH PE, 1992, MOL MICROBIOL, V6, P1253, DOI 10.1111/j.1365-2958.1992.tb00845.x; MOORE PB, 1995, SCIENCE, V270, P1453, DOI 10.1126/science.270.5241.1453; PILLUTLA RC, 1995, J BACTERIOL, V177, P2194, DOI 10.1128/jb.177.8.2194-2196.1995; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; ZHANG YX, 1994, J BACTERIOL, V176, P1184, DOI 10.1128/JB.176.4.1184-1187.1994	19	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17815	17820		10.1074/jbc.272.28.17815	http://dx.doi.org/10.1074/jbc.272.28.17815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211936	hybrid			2022-12-27	WOS:A1997XK16500079
J	Shen, JR; Ikeuchi, M; Inoue, Y				Shen, JR; Ikeuchi, M; Inoue, Y			Analysis of the psbU gene encoding the 12-kDa extrinsic protein of photosystem II and studies on its role by deletion mutagenesis in Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-STABILIZING PROTEIN; OXYGEN-EVOLUTION; PHORMIDIUM-LAMINOSUM; 33-KDA PROTEIN; SP PCC-6803; CYANOBACTERIAL MUTANTS; CYTOCHROME C-550; PARTICLES; POLYPEPTIDE; RECONSTITUTION	The gene encoding the 1a-kDa extrinsic protein of photosystem II from Synechocystis sp, PCC 6803 was cloned based on N-terminal sequence of the mature protein, This gene, named psbU, encodes a polypeptide of 131 residues, the first 36 residues of which were absent in the mature protein and thus served as a transit peptide required for its transport into the thylakoid lumen, A psbU gene deletion mutant grew photoautotrophically in normal BG11 medium at almost the same rate as that of the wild type strain, This mutant, however, grew apparently slower than the wild type did upon depletion of Ca2+ or Cl- from the growth medium, Photosystem II oxygen evolution decreased to 81% in the mutant as compared with that in the wild type, and the thermoluminescence B- and Q-bands shifted to higher temperatures accompanied by an increase in the Q-band intensity, These results indicate that the 12-kDa protein is not essential for oxygen evolution but may play a role in optimizing the ion (Ca2+ and Cl-) environment and maintaining a functional structure of the cyanobacterial oxygen-evolving complex, In addition, a double deletion mutant lacking cytochrome c-550 and the 1a-kDa protein grew photoautotrophically with a phenotype identical to that of the single deletion mutant of cytochrome c-550, This supports our previous biochemical results that the 1a-kDa protein cannot bind to photosystem II in the absence of cytochrome c-550 (Shen, J.-R., and Inoue, Y. (1993) Biochemistry 32, 1825-1832).	RIKEN, INST PHYS & CHEM RES, PHOTOSYNTHESIS RES LAB, WAKO, SAITAMA 35101, JAPAN; UNIV TOKYO, DEPT BIOL, TOKYO 153, JAPAN	RIKEN; University of Tokyo	Shen, JR (corresponding author), RIKEN, INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN.		Shen, Jian-Ren/B-2558-2011					BOCKHOLT R, 1991, FEBS LETT, V294, P59, DOI 10.1016/0014-5793(91)81343-7; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; ENGELS DH, 1994, PHOTOSYNTH RES, V42, P227, DOI 10.1007/BF00018265; HAN KC, 1994, FEBS LETT, V355, P121, DOI 10.1016/0014-5793(94)01182-6; Inoue Y, 1996, BIOPHYSICAL TECHNIQU, P93; Kaneko T, 1996, DNA Res, V3, P109; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; ROLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V973, P220, DOI 10.1016/S0005-2728(89)80425-6; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1993, J BIOL CHEM, V268, P20408; SHEN JR, 1995, BIOCHEMISTRY-US, V34, P12661, DOI 10.1021/bi00039a023; SHEN JR, 1995, J BIOL CHEM, V270, P6901, DOI 10.1074/jbc.270.12.6901; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; STEWART AC, 1985, FEBS LETT, V193, P175, DOI 10.1016/0014-5793(85)80145-9; STEWART AC, 1985, BIOCHIM BIOPHYS ACTA, V808, P353, DOI 10.1016/0005-2728(85)90145-8; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE TP, 1989, MOL GEN GENET, V216, P334, DOI 10.1007/BF00334373; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JJ, 1990, PLANT CELL, V2, P315	30	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17821	17826		10.1074/jbc.272.28.17821	http://dx.doi.org/10.1074/jbc.272.28.17821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211937	hybrid			2022-12-27	WOS:A1997XK16500080
J	Wang, CC; Pavlov, A; Karam, JD				Wang, CC; Pavlov, A; Karam, JD			Evolution of RNA-binding specificity in T4 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDYLATE SYNTHASE; TRANSLATIONAL REPRESSOR; EXONUCLEASE ACTIVITY; BACTERIOPHAGE-T4; PROTEIN; DEHYDROGENASE; ACONITASE; SITE; IDENTIFICATION; EXPRESSION	DNA polymerase of phage T4 (T4 gp43), an essential component of the T4 DNA replicase, is a multifunctional single-chained (898-amino acid) protein that catalyzes the highly accurate synthesis of DNA in phage replication, The enzyme functions both as a DNA-binding replication protein and as a sequence-specific RNA-binding autogenous translational repressor. We have utilized a phylogenetic approach to study the relationships between the two nucleic acid-binding functions of the protein, We found that autogenous translational control of gp43 biosynthesis has been conserved in phage RB69, a distant relative of T4, although we also found that the RB69 system differs from its T4 counterpart in two regards: (a) nucleotide sequence and predicted secondary structure of the RNA target (translational operator), and (b) RNA specificity of the protein. T4 gp43 is specific to the RNA operator sequence of the T4 genome whereas RB69 gp43 can bind and repress operator RNA from both phages equally well. In studies with T4-RB69 gp43 chimeras, we mapped T4 gp43 RNA-binding specificity to a protein segment that also harbors important determinants for DNA binding and the polymerase catalytic function, Our results suggest that RNA functions as a regulator of both the dosage and activity of this DNA replication enzyme.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University			Pavlov, Andrey/HGB-3637-2022	Pavlov, Andrey/0000-0001-7891-269X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018842, R01GM054627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54627, GM18842] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ANDRAKE MD, 1991, GENETICS, V128, P203; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; DRESSMAN HK, 1997, IN PRESS P NATL ACAD; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GOULIAN M, 1968, J BIOL CHEM, V243, P627; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HSU T, 1990, J BIOL CHEM, V265, P5303; HUGHES MB, 1987, GENETICS, V115, P393; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LIN TC, 1994, J BIOL CHEM, V269, P19286; Miller Eric S., 1994, P193; MILLER ES, 1990, J BACTERIOL, V172, P5180, DOI 10.1128/jb.172.9.5180-5186.1990; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; Nossal Nancy G., 1994, P43; ODONNELL PV, 1972, J VIROL, V9, P990, DOI 10.1128/JVI.9.6.990-998.1972; PAVLOV AR, 1994, J BIOL CHEM, V269, P12968; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PREISS T, 1993, J BIOL CHEM, V268, P24523; Reha-Krantz Linda J., 1994, P307; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; RUSSELL RL, 1974, GENETICS, V78, P967; RUSSELL RL, 1974, GENETICS, V78, P989; RUSSELL RL, 1967, THESIS CALIFORNIA I; SAMBROOK JF, 1967, NATURE, V214, P452, DOI 10.1038/214452a0; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; WANG CC, 1997, THESIS TULANE U NEW; WANG J, 1997, IN PRESS CELL; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X	44	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17703	17710		10.1074/jbc.272.28.17703	http://dx.doi.org/10.1074/jbc.272.28.17703			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211921	hybrid			2022-12-27	WOS:A1997XK16500064
J	Vaccaro, AM; Tatti, M; Ciaffoni, F; Salvioli, R; Barca, A; Scerch, C				Vaccaro, AM; Tatti, M; Ciaffoni, F; Salvioli, R; Barca, A; Scerch, C			Effect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-GLUCOSIDASE; ACTIVATOR PROTEIN; GAUCHERS-DISEASE; PHOSPHATIDYLSERINE LIPOSOMES; BILAYER CURVATURE; BINDING; DEFICIENCY; GLUCOCEREBROSIDASE; FIBROBLASTS; VESICLES	The degradation of glucosylceramide in lysosomes is accomplished by glucosylceramidase with the assistance of, at least, another protein, saposin C (Sap C), which is generated from a large precursor together with three other similar proteins, saponins A, B, and D. In the present study, we have examined the effects of saposins on the enzymatic hydrolysis of glucosylceramide inserted in large and small phospholid liposomes. The glucosylceramide contained in large unilamellar vesicles (LUV) was degraded by glucosylceramidase at a rate 7-8-fold lower than glucosylceramide inserted in small unilamellar vesicles (SUV). The separate addition of either Sap A of Sap C to the LUV system partially stimulated the sphingolipid degradation while saposins B and D had no effect. In the presence of both Sap A and Sap C, the rate of sphingolipid degradation was higher than the sum of the rates with the two saposins individually, indicating synergism in their actions. The stimulatory effect of the two saposins depended on the incorporation of an acidic phospholipid such as phosphatidylserine (PS) into LUV. The characteristics of glucosylceramidase activation by Sap C were different from those of Sap A. Sap C increased the rate of hydrolysis of both the artificial water soluble substate, 4-methylumbelliferyl-beta-D-glucopyranoside, and the lipid substrate, glucosylceramide, while Sap A only stimulated degradation of the sphingolipid. Also the binding properties of Saps A and C were markedly different. At acidic pH values, Sap C bound to PS-containing LUV and promoted the association of glucosylceramidase with the membrane. In contrast, Sap A had poor affinity for the membrane even in the presence of glucosylceramide; moreover, Sap A did not potentiate the capacity of Sap C to mediate glucosylceramidase binding. In conclusion, our results show that both Sap A and Sap C are required for maximal hydrolysis of glucosylceramide inserted in PS-containing LUV, that their effects are synergistic, and that their mode of action is different. Sap C is responsible for the membrane binding of glucosylceramide, while Sap A stimulation is possibly related to its effect on the conformation of the enzyme. It can be envisaged that Sap A in conjunction with Sap C might have a physiological role in glucosylceramide degradation.			Vaccaro, AM (corresponding author), IST SUPER SANITA,DEPT METAB & PATHOL BIOCHEM,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		tatti, Massimo/N-1382-2017					BASU A, 1984, J BIOL CHEM, V259, P1714; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CURATOLO W, 1986, J BIOL CHEM, V261, P7177; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLEW RH, 1988, LAB INVEST, V58, P5; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCMASTER MC, 1977, J LABELLED COMPD RAD, V13, P353, DOI 10.1002/jlcr.2580130309; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MURRAY GJ, 1985, ANAL BIOCHEM, V147, P301, DOI 10.1016/0003-2697(85)90276-3; NIR S, 1982, BIOCHIM BIOPHYS ACTA, V688, P275, DOI 10.1016/0005-2736(82)90604-6; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OHKI S, 1984, J MEMBRANE BIOL, V77, P265, DOI 10.1007/BF01870574; PATON BC, 1989, EUR J CELL BIOL, V51, P157; QI XY, 1994, J BIOL CHEM, V269, P16746; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1988, J BIOL CHEM, V263, P19597; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; VACCARO AM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P239, DOI 10.1016/0167-4838(92)90208-U; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; VACCARO AM, 1990, BIOCHIM BIOPHYS ACTA, V1033, P73, DOI 10.1016/0304-4165(90)90196-4; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223	35	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16862	16867		10.1074/jbc.272.27.16862	http://dx.doi.org/10.1074/jbc.272.27.16862			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201993	hybrid			2022-12-27	WOS:A1997XH44600025
J	Ferrell, JE; Bhatt, RR				Ferrell, JE; Bhatt, RR			Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; XENOPUS OOCYTES; PATHWAYS; THREONINE; SITES; CELLS; AUTOPHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION	Previous work on the responses of mitogen-activated protein (MAP) kinase cascade components in a Xenopus oocyte extract system demonstrated that p42 MAP kinase (MAPK) exhibits a sharp, sigmoidal stimulus/response curve, rather than a more typical hyperbolic curve, One plausible explanation for this behavior requires the assumption that MAP kinase kinase (MAPKK) carries out its dual phosphorylation of p42 MAPK by a distributive mechanism, where MAPKK dissociates from MAPK between the first and second phosphorylations, rather than a processive mechanism, where MAPKK carries out both phosphorylations before dissociating, Here we have investigated the mechanism through which a constitutively active form of human MAPKK-1 (denoted MAPKK-1 R4F or MAPKK-1*) phosphorylates Xenopus p42 MAPK in vitro, We found that the amount of monophosphorylated MAPK formed during the phosphorylation reaction exceeded the amount of MAPKK-1* present, which would not be possible if the phosphorylation occurred exclusively by a processive mechanism, The monophosphorylated MAPK was phosphorylated predominantly on tyrosine, but a small proportion was phosphorylated on threonine, indicating that the first phosphorylation is usually, but not invariably, the tyrosine phosphorylation, We also found that the rate at which pulse labeled monophosphorylated MAPK became bisphosphorylated depended on the MAPKK-1* concentration, behavior that is predicted by the distributive model but incompatible with the processive model, These findings indicate that MAPKK-1* phosphorylates p42 MAPK by a two-collision, distributive mechanism rather than a single-collision, processive mechanism, and provide a mechanistic basis for understanding how MAP kinase can convert graded inputs into switch-like outputs.			Ferrell, JE (corresponding author), STANFORD UNIV, SCH MED, DEPT MOL PHARMACOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415, R01GM046383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SCHULZ AR, 1994, ENZYME KINETICS, P22; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P14373; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	39	251	256	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19008	19016		10.1074/jbc.272.30.19008	http://dx.doi.org/10.1074/jbc.272.30.19008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228083	hybrid			2022-12-27	WOS:A1997XM34200074
J	Gotoh, T; Niino, Y; Tokuda, M; Hatase, O; Nakamura, S; Matsuda, M; Hattori, S				Gotoh, T; Niino, Y; Tokuda, M; Hatase, O; Nakamura, S; Matsuda, M; Hattori, S			Activation of R-Ras by Ras-guanine nucleotide-releasing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; FUNCTIONAL INTERACTION; GENE-PRODUCT; PROTEIN; GROWTH; IDENTIFICATION; P21; RESIDUES; BINDING; REGIONS	Ras-GRF/CDC25(Mm), mSos, and C3G have been identified as guanine nucleotide releasing factors for Ras family proteins. We investigated in this study the guanine nucleotide-releasing activities of Ras-GRF, mSos, and C3G toward R-Ras, which shows high sequence similarity to Ras. Ras-GRF markedly stimulated the dissociation of GDP from R-Ras, and C3G also promoted the release of R-Ras-bound GDP. Under the same conditions, mSos little affected the reaction. When Ras GRF and R-Ras were coexpressed in COS7 cells, the remarkable accumulation of the active GTP bound form of R-Ras was observed. C3G also increased active R-Ras in COS7 cells, while mSos did not give any effect. These results indicated that Ras-GRF and C3G could activate R-Ras. Furthermore, the activation of R-Ras by Ras-GRF was enhanced when cells were treated with ionomycin, which is known to increase the intracellular calcium concentration. The examination of tissue distribution of R-Ras, Ras-GRF, and mSos by the reverse transcription-polymerase chain reaction revealed that Ras GRF was expressed only in brain and testis, whereas R-Ras, C3G, and mSos were expressed rather ubiquitously. These findings raise the possibility that R-Ras is activated by Ras-GRF in brain and testis, and by C3G in other tissues, respectively.	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; KAGAWA MED UNIV,FAC MED,DEPT PHYSIOL,DIV 1,MIKI,KAGAWA 76107,JAPAN; INT MED CTR JAPAN,RES INST,DEPT PATHOL,SHINJUKU KU,TOKYO 162,JAPAN	National Center for Neurology & Psychiatry - Japan; Kagawa University; National Center for Global Health & Medicine - Japan				Matsuda, Michiyuki/0000-0002-5876-9969				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COX AD, 1994, ONCOGENE, V9, P3281; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUROYA K, 1992, ONCOGENE, V7, P277; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; REY I, 1994, ONCOGENE, V9, P685; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zippel R, 1996, ONCOGENE, V12, P2697	43	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18602	18607		10.1074/jbc.272.30.18602	http://dx.doi.org/10.1074/jbc.272.30.18602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228027	hybrid			2022-12-27	WOS:A1997XM34200018
J	Shields, JM; Yang, VW				Shields, JM; Yang, VW			Two potent nuclear localization signals in the gut-enriched Kruppel-like factor define a subfamily of closely related Kruppel proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; GROWTH-FACTORS; GENE; FAMILY; ENCODES; DOMAIN; NLS	The gut-enriched Kruppel-like factor (GKLF) is a newly identified transcription factor that contains three C2H2 Kruppel-type zinc fingers. Previous immunocytochemical studies indicate that GKLF is exclusively localized to the nucleus. To identify the nuclear localization signal (NLS) within GKLF, cDNA constructs with various deletions in the coding region of GKLF were generated and analyzed by indirect immunofluorescence in transfected COS-1 cells. In addition, constructs fusing regions representing putative NLSs of GKLF to green fluorescent protein (GFP) were generated and examined by fluorescence microscopy in similarly transfected cells. The results indicate that GKLF contains two potent, independent NLSs: one within the zinc fingers and the other in a cluster of basic amino acids (called 5' basic region) immediately preceding the first zinc finger. In comparison, putative NLSs within the zinc fingers and the 5' basic region of a related Kruppel protein, zif268/Egr-1, are relatively less efficient in their ability to translocate GFP into the nucleus. A search in the protein sequence data base revealed that despite the existence of numerous Kruppel proteins, only two, the lung Kruppel-like factor (LKLF) and the erythroid Kruppel-like factor (EKLF), exhibit similar NLSs to those of GKLF. These findings indicate that GKLF, LKLF, and EKLF are members of a subfamily of closely related Kruppel proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,GI DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [DK52230, DK44484, R01 DK052230, R01 DK052230-03, P01 DK044484-100005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, P01DK044484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812	22	113	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18504	18507		10.1074/jbc.272.29.18504	http://dx.doi.org/10.1074/jbc.272.29.18504			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218496	hybrid, Green Accepted			2022-12-27	WOS:A1997XL73500086
J	Waring, P; Khan, T; Sjaarda, A				Waring, P; Khan, T; Sjaarda, A			Apoptosis induced by gliotoxin is preceded by phosphorylation of histone H3 and enhanced sensitivity of chromatin to nuclease digestion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CHROMOSOME CONDENSATION; INTRACELLULAR CALCIUM; DNA FRAGMENTATION; PROTEIN-SYNTHESIS; KINASE-ACTIVITY; INHIBITOR; CYCLE; CAMP; MACROPHAGES	The fungal toxin gliotoxin induces apoptotic I-ell death in a variety of cells. Apoptosis induced in thymocytes by gliotoxin is rapid, and DNA fragmentation is observable within 4 h treatment. Apoptosis induced by gliotoxin is calcium independent and unaffected by protein synthesis inhibitors. We have previously shown that gliotoxin results in phosphorylation of a 16.3-kDa protein within 10 min treatment of thymocytes. Here we show that this protein is histone HS and phosphorylation occurs on Ser-10. Cyclic AMP levels and activity of protein kinase A (PKA) are raised in cells treated with gliotoxin. Apoptosis is inhibited by genistein which also inhibits PKA and histone H3 phosphorylation. Apoptosis is also inhibited by a number of specific inhibitors of PKA suggesting apoptosis induced by gliotoxin is modulated by this kinase. The agents forskolin and cholera toxin do not induce rapid phosphorylation of H3 although some increase in phosphorylation of H3 does occur after 8 h with these agents. Forskolin and cholera toxin also induce apoptosis but over a longer time course than gliotoxin. In all cases levels of apoptosis correlate with degree of H3 phosphorylation. Cells: treated with gliotoxin show an early sensitivity to micrococcal nuclease and DNase I digestion indicating a functional relationship between DNA fragmentation and H3 phosphorylation.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV IMMUNOL & CELL BIOL, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHOCHUNG YS, 1979, INFLUENCE HORMONES T, V1, P55; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLOMBEL M, 1992, CANCER RES, V52, P4313; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ELLIOTT ME, 1990, LIFE SCI, V46, P1479, DOI 10.1016/0024-3205(90)90465-4; FENG JL, 1991, BIOCHEMISTRY-US, V30, P4747, DOI 10.1021/bi00233a016; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Kerr J.F.R., 1987, P93; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; Lu ZX, 1996, BIOL CHEM H-S, V377, P373; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MULLBACHER A, 1988, TRANSPLANTATION, V46, P120; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Sutton P, 1995, BIOCHEM PHARMACOL, V50, P2009, DOI 10.1016/0006-2952(95)02101-9; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; THNG JPH, 1994, J BIOL CHEM, V269, P9568; THNG JPH, 1992, MOL CELLULAR APPROAC, P381; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; WARING P, 1990, INT J IMMUNOPHARMACO, V12, P445, DOI 10.1016/0192-0561(90)90028-L; Waring P, 1996, EXP CELL RES, V227, P264, DOI 10.1006/excr.1996.0276; WARING P, 1988, J BIOL CHEM, V263, P18493; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WARING P, 1995, CELL DEATH DIFFER, V2, P201; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129	54	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17929	17936		10.1074/jbc.272.29.17929	http://dx.doi.org/10.1074/jbc.272.29.17929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218417	hybrid			2022-12-27	WOS:A1997XL73500007
J	Yip, JW; Ko, WH; Viberti, G; Huganir, RL; Donowitz, M; Tse, CM				Yip, JW; Ko, WH; Viberti, G; Huganir, RL; Donowitz, M; Tse, CM			Regulation of the epithelial brush border Na+/H+ exchanger isoform 3 stably expressed in fibroblasts by fibroblast growth factor and phorbol esters is not through changes in phosphorylation of the exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; MOLECULAR-CLONING; NHE1; ACTIVATION; PROTEINS; SITES; INHIBITION; MECHANISM; MUTATION; PH	The epithelial brush border Na+/H+ exchanger isoform 3 (NHE3) is regulated by growth factors and protein kinases. When stably expressed in PS120 fibro blasts, NHE3 is stimulated by serum and fibroblast growth factor (FGF) and inhibited by phorbol esters. To examine the role of phosphorylation of NHE3 in growth factor/protein kinase regulation, NHE3 was C-terminally tagged with an 11-amino acid epitope of the vesicular stomatitis virus glycoprotein (VSVG) and stably expressed in Na+/H+ exchanger null PS120 fibroblasts (PS120/NHE3V). NHE3V was regulated by serum, FGF, and phorbol ester in a manner identical to wild type non-VSVG-tagged NHE3. Phosphorylation of NHE3V was evaluated via immunoprecipitation with anti-VSVG antibody after in vivo labeling of PS120/NHE3V cells with [P-32]orthophosphate. NHE3V was phosphorylated under basal conditions. However, FGF and PMA, under conditions in which these agonists regulate NHE3V, altered neither the amount of phosphorylation of NHE3V as analyzed by one dimensional SDS-polyacrylamide gel electrophoresis and autoradiography nor two-dimensional phosphopeptide maps of tryptic digests of NHE3V. In contrast, while changes in NHE3V phosphorylation were not observed with serum exposure by one dimensional SDS-polyacrylamide gel electrophoresis, two-dimensional studies showed increases in two phosphopeptides. Under all these conditions, phosphoamino acid analysis showed that NHE3V was phosphorylated only on serine residues. By cell surface protein biotinylation studies under basal conditions, at least 27% of the NHE3V was expressed on the cell surface. To further analyze the phosphorylation status of the surface and intracellular forms of NHE3V under basal conditions and determine whether the amount of phosphorylation of the surface form changes upon serum, FGF, and PMA regulation, the surface form of NHE3V was separated from intracellular form by biotinylation/avidin-agarose precipitation. Under basal conditions, both intracellular and surface forms of NHE3V were phosphorylated. However, the amount of phosphorylation of the surface form of NHE3V did not change upon stimulation by serum and FGF and inhibition by PMA based on one-dimensional SDS-polyacrylamide gel electrophoresis and autoradiography. Thus, we conclude that when expressed in PS120 cells, while NHE3 is a phosphoprotein under basal conditions, its regulation by FGF and PMA is not by changes in the phosphorylation of NHE3, while regulation by serum may involve changes in its phosphorylation. Regulation of NHE3 probably involves intermediate associated regulatory proteins. The function of basal phosphorylation of NHE3 is not known.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,GI DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV LONDON,UNITED MED & DENT SCH GUYS & ST THOMAS,DIV MED,LONDON SE1 9RT,ENGLAND	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of London; King's College London					NIDDK NIH HHS [R01DK26523, P01DK44484, R29DK43778] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484, R29DK043778] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; COTTARDI CJ, 1995, AM J PHYSIOL, V268, pF285; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; JANECKI A, 1997, FASEB J, V11, pA376; JHOOGERWERF WA, 1996, AM J PHYSIOL, V270, pG29; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1991, J BIOL CHEM, V266, P19166; SARDET C, 1990, SCIENCE, V218, P1219; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2134; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	29	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18473	18480		10.1074/jbc.272.29.18473	http://dx.doi.org/10.1074/jbc.272.29.18473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218492	hybrid			2022-12-27	WOS:A1997XL73500082
J	Freedman, NJ; Ament, AS; Oppermann, M; Stoffel, RH; Exum, ST; Lefkowitz, RJ				Freedman, NJ; Ament, AS; Oppermann, M; Stoffel, RH; Exum, ST; Lefkowitz, RJ			Phosphorylation and desensitization of human endothelin A and B receptors - Evidence for G protein-coupled receptor kinase specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT-PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; RHODOPSIN; INVOLVEMENT; MECHANISMS; EXPRESSION; TERMINATION; INHIBITION; ACTIVATION	Although endothelin-l can elicit prolonged physiologic responses, accumulating evidence suggests that rapid desensitization affects the primary G protein-coupled receptors mediating these responses, the endothelin A and B receptors (ETA-R and ETB-R). The mechanisms by which this desensitization proceeds remain obscure, however. Because some intracellular domain sequences of the ETA-R and ETB-R. differ substantially, we tested the possibility that these receptor subtypes might. be differentially regulated by G protein-coupled receptor kinases (GRKs). Homologous, or receptor-specific, desensitization occurred within 4 min both in the ETA-R-expressing A10 cells and in 293 cells transfected with either the human ETA-R or ETB-R, In 293 cells, this desensitization corresponded temporally with agonist-induced phosphorylation of each receptor, assessed by receptor immunoprecipitation from P-32(i)-labeled cells. Agonist-induced receptor phosphorylation was not substantially affected by PKC inhibition but was reduced 40% (p < 0.03) by GRK inhibition, effected by a dominant negative GRK2 mutant, Inhibition of agonist-induced phosphorylation abrogated agonist-induced ETA-R desensitization. Overexpression of GRK2, -5, or -6 in 293 cells augmented agonist-induced ET-R phosphorylation similar to 2-fold (p < 0.02), but each kinase reduced receptor-promoted phosphoinositide hydrolysis differently. While GRK5 inhibited ET-R signaling by only similar to 25%, GRK2 inhibited ET-R signaling by 80% (p < 0.01), Congruent with its superior efficacy in suppressing ET-R signaling, GRK2, but not GRK5, co-immunoprecipitated with the ET-Rs in an agonist-dependent manner. ma conclude that both the ETA-R and ETB-R can be regulated indistinguishably by GRK-initiated desensitization, We propose that because of its affinity for ET-Rs demonstrated by co-immunoprecipitation, GRK2 is the most likely of the GRKs to initiate ET-R desensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Freedman, NJ (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MED CARDIOL, BOX 3821, DURHAM, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL03008, HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CARDELL LO, 1992, BRIT J PHARMACOL, V105, P376, DOI 10.1111/j.1476-5381.1992.tb14261.x; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; Colton T., 1974, STAT MED, V1; CYR CR, 1993, J BIOL CHEM, V268, P26071; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOKHAC L, 1994, MOL PHARMACOL, V46, P485; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GOLIGORSKY MS, 1994, J CELL PHYSIOL, V158, P485, DOI 10.1002/jcp.1041580313; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY PJ, 1993, BRIT J PHARMACOL, V110, P435, DOI 10.1111/j.1476-5381.1993.tb13829.x; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KITAZONO T, 1995, J PHARMACOL EXP THER, V273, P1; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; Krueger KM, 1997, J BIOL CHEM, V272, P5; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LEITE MF, 1994, AM J PHYSIOL-HEART C, V267, pH2193, DOI 10.1152/ajpheart.1994.267.6.H2193; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PARIS S, 1987, J BIOL CHEM, V262, P1970; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI G, 1995, MOL PHARMACOL, V48, P173; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SEMLER DE, 1995, J PHARMACOL EXP THER, V272, P1052; Sokolovsky M, 1995, PHARMACOL THERAPEUT, V68, P435, DOI 10.1016/0163-7258(95)02015-2; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; Tiberi M, 1996, J BIOL CHEM, V271, P3771; VANHEUGTEN HAA, 1993, J MOL CELL CARDIOL, V25, P41, DOI 10.1006/jmcc.1993.1006; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	52	174	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17734	17743		10.1074/jbc.272.28.17734	http://dx.doi.org/10.1074/jbc.272.28.17734			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211925	hybrid			2022-12-27	WOS:A1997XK16500068
J	Rhee, S; Silva, MM; Hyde, CC; Rogers, PH; Metzler, CM; Metzler, DE; Arnone, A				Rhee, S; Silva, MM; Hyde, CC; Rogers, PH; Metzler, CM; Metzler, DE; Arnone, A			Refinement and comparisons of the crystal structures of pig cytosolic aspartate aminotransferase and its complex with 2-methylaspartate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; CONFORMATIONAL-CHANGES; DOMAIN CLOSURE; CLOSED-FORM; PROTEINS; RESOLUTION; DEHYDROGENASE; CHICKEN; PRODUCE	Two high resolution crystal structures of cytosolic aspartate aminotransferase from pig heart provide additional insights into the stereochemical mechanism for ligand-induced conformational changes in this enzyme, Structures of the homodimeric native structure and its complex with the substrate analog 2-methylaspartate have been refined, respectively, with 1.74-Angstrom x-ray diffraction data to an R value of 0.170, and with 1.6-Angstrom data to an R value of 0.173, In the presence of 2-methylaspartate, one of the subunits (subunit 1) shows a ligand induced conformational change that involves a large movement of the small domain (residues 12-49 and 327-412) to produce ''closed'' conformation, No such transition is observed in the other subunit (subunit 2), because crystal lattice contacts lock it in an ''open'' conformation like that adopted by subunit 1 in the absence of substrate, By comparing the open and closed forms of cAspAT, we propose a stereochemical mechanism for the open-to-closed transition that involves the electrostatic neutralization of two active site arginine residues by the negative charges of the incoming substrate, a large change in the backbone (phi,psi) conformational angles of two key glycine residues, and the entropy-driven burial of a stretch of hydrophobic residues on the N-terminal helix, The calculated free energy for the burial of this ''hydrophobic plug'' appears to be sufficient to serve as the driving force for domain closure.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; IOWA STATE UNIV, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	University of Iowa; Iowa State University								ARNONE A, 1977, J MOL BIOL, V112, P509, DOI 10.1016/S0022-2836(77)80196-4; ARNONE A, 1985, TRANSAMINASES, P326; ARNONE A, 1984, CHEM BIOL ASPECTS B, P171; Arnone A, 1985, TRANSAMINASES, P138; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BIRCHMEIER W, 1973, J BIOL CHEM, V248, P1751; BOETTCHER B, 1976, BIOCHEMISTRY-US, V15, P5657, DOI 10.1021/bi00670a035; BORISOV VV, 1985, TRANSAMINASES, P155; Braunstein AE., 1973, ENZYMES, V3d, P379, DOI [10.1016/S1874-6047%2808%2960122-5, DOI 10.1016/S1874-6047%2808%2960122-5]; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Christen P, 1985, TRANSAMINASES; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GEHRING H, 1978, J BIOL CHEM, V253, P3158; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBER R, 1988, ANGEW CHEM INT EDIT, V27, P79, DOI 10.1002/anie.198800791; HYDE CC, 1984, PEPTIDE PROTEIN REV, V4, P47; IVANOV VI, 1969, ADV ENZYMOL RAMB, V32, P21; JAGER J, 1989, J MOL BIOL, V209, P499, DOI 10.1016/0022-2836(89)90014-4; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESK AM, 1991, PROTEIN ARCHITECTURE; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; Metzler C M, 1979, Methods Enzymol, V62, P551; Morino Y., 1994, P49; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; PAN QW, 1993, J BIOL CHEM, V268, P24758; PETSKO GA, 1984, ANNU REV BIOPHYS BIO, V13, P331; PFISTER K, 1985, J BIOL CHEM, V260, P1414; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RHEE S, 1994, THESIS U IOWA; RHEE S, 1992, AM CRYST ASS 1992 2, V20, P98; SCHLEGEL H, 1977, J BIOL CHEM, V252, P5835; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; SILVA MM, 1990, ABSTR AM CRYST ASS, V18, P69; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; TAYLOR JE, 1990, ANN NY ACAD SCI, V585, P58, DOI 10.1111/j.1749-6632.1990.tb28041.x; Yang B I, 1979, Methods Enzymol, V62, P528; YUEN PS, 1979, J APPL CRYSTALLOGR, V12, P258, DOI 10.1107/S002188987901236X; [No title captured]	57	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17293	17302		10.1074/jbc.272.28.17293	http://dx.doi.org/10.1074/jbc.272.28.17293			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211866	hybrid			2022-12-27	WOS:A1997XK16500009
J	Wang, WY; Hou, ZL; Honzatko, RB; Fromm, HJ				Wang, WY; Hou, ZL; Honzatko, RB; Fromm, HJ			Relationship of conserved residues in the IMP binding site to substrate recognition and catalysis in Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ISOTOPE EXCHANGE; SEQUENCE; PURIFICATION; PROTEINS; PURA; GENE	Gln(34), Gln(224), Leu(228), and Ser(240) are conserved residues in the vicinity of bound IMP in the crystal structure of Escherichia coli adenylosuccinate synthetase. Directed mutations were carried out, and wild-type and mutant enzymes were purified to homogeneity. Circular dichroism spectroscopy indicated no difference in secondary structure between the mutants and the wildtype enzyme in the absence of substrates. Mutants L228A and S240A exhibited modest changes in their initial rate kinetics relative to the wild-type enzyme, suggesting that neither Leu(228) nor Ser(240) play essential roles in substrate binding or catalysis. The mutants Q224M and Q224E exhibited no significant change in K-m(GTP) and K-m(ASP) and modest changes in K-m(IMP) relative to the wild-type enzyme. However, k(cat) decreased 13-fold for the Q224M mutant and 10(4)-fold for the Q224E mutant relative to the wild-type enzyme. Furthermore, the Q224E mutant showed an optimum pH at 6.2, which is 1.5 pH units lower than that of the wild-type enzyme. Tryptophan emission fluorescence spectra of Q224M, Q224E, and wild-type proteins under denaturing conditions indicate comparable stabilities. Mutant Q34E exhibits a 60-fold decrease in k(cat) compared with that of the wild-type enzyme, which is attributed to the disruption of the Gln(34) to Gln(224) hydrogen bond observed in crystal structures. Presented here is a mechanism for the synthetase, whereby Gln(224) works in concert with Asp(13) to stabilize the B-oxyanion of IMP.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; Bouyoub A, 1996, J MOL BIOL, V261, P144, DOI 10.1006/jmbi.1996.0448; Braford M.M., 1976, ANAL BIOCHEM, V72, P248, DOI [10.1016/j.cj.2017.04.003, DOI 10.1016/J.CJ.2017.04.003]; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HEIM DR, 1995, PESTIC BIOCHEM PHYS, V53, P138, DOI 10.1006/pest.1995.1061; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MANTSALA P, 1992, J BACTERIOL, V174, P1883; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; RUDOLPH FB, 1971, THESIS IOWA STATE U; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; WANG WY, 1995, J BIOL CHEM, V270, P13160, DOI 10.1074/jbc.270.22.13160; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	35	11	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16911	16916		10.1074/jbc.272.27.16911	http://dx.doi.org/10.1074/jbc.272.27.16911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202000	hybrid			2022-12-27	WOS:A1997XH44600032
J	Gallagher, PG; Tse, WT; Scarpa, AL; Lux, SE; Forget, BG				Gallagher, PG; Tse, WT; Scarpa, AL; Lux, SE; Forget, BG			Structure and organization of the human ankyrin-1 gene - Basis for complexity of pre-mRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; DOMINANT HEREDITARY SPHEROCYTOSIS; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; REGULATORY DOMAIN; ANION-EXCHANGER; MAJOR ANKYRIN; MEMBRANE-SKELETON; HEMOLYTIC-ANEMIA; PLASMA-MEMBRANE	Ankyrin-1 (ANK-1) is an erythrocyte membrane protein that is defective in many patients with hereditary spherocytosis, a common hemolytic anemia. In the red cell, ankyrin-1 provides the primary linkage between the membrane skeleton and the plasma membrane, To gain additional insight into the structure and function of this protein and to provide the necessary tools for further genetic studies of hereditary spherocytosis patients, we cloned the human ANK-1 chromosomal gene, Characterization of the ANK-1 gene genomic structure revealed that the erythroid transcript is composed of 42 exons distributed over similar to 160 kilobase pairs of DNA. Comparison of the genomic structure with the protein do mains reveals a near-absolute correlation between the tandem repeats encoding the membrane-binding domain of ankyrin with the location of the intron/exon boundaries in the corresponding part of the gene, Erythroid stage-specific, complex patterns of alternative splicing were identified in the region encoding the regulatory domain of ankyrin-1. Novel brain-specific transcripts were also identified in this region, as well as in the ''hinge'' region between the membrane-binding and spectrin-binding domains, Utilization of alternative polyadenylation signals was found to be the basis for the previously described, stage-specific 9.0- and 7.2-kilobase pair transcripts of the ANK-1 gene.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Yale University; Yale University; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gallagher, PG (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,333 CEDAR ST,POB 208064,NEW HAVEN,CT 06520, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AXTON JM, 1994, EMBO J, V13, P462, DOI 10.1002/j.1460-2075.1994.tb06281.x; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BIRKENMEIER JE, 1995, BLOOD S1, V86, pA467; BODINE DM, 1984, CELL, V37, P721, DOI 10.1016/0092-8674(84)90408-2; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; delGiudice EM, 1996, BRIT J HAEMATOL, V93, P828; DEMARTIN R, 1995, GENE, V152, P253, DOI 10.1016/0378-1119(94)00726-9; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gallagher P. G., 1996, Blood, V88, p6A; GALLAGHER PG, 1992, T ASSOC AM PHYSICIAN, V105, P268; GALLAGHER PG, 1992, BLOOD, V80, P1856; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HALL TG, 1987, J BIOL CHEM, V262, P10537; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOVER KK, 1993, GENETICS, V135, P507; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; JAROLIM P, 1995, J CLIN INVEST, V95, P941, DOI 10.1172/JCI117802; JAROLIM P, 1995, BLOOD, V85, P3278, DOI 10.1182/blood.V85.11.3278.bloodjournal85113278; JAROLIM P, 1992, BLOOD S, V80, pA144; JAROLIM P, 1990, BLOOD S, V76, pA37; Jenkins PB, 1996, J CLIN INVEST, V97, P373, DOI 10.1172/JCI118425; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; LUNA EJ, 1979, J BIOL CHEM, V254, P2526; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; Morle L., 1995, Blood, V86, p467A; MORROW JS, 1997, HDB PHYSIOL 14, P485; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; Ozcan R., 1996, Blood, V88, p5A; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1992, BLOOD, V80, P2122; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PLATT OS, 1993, J BIOL CHEM, V268, P24421; POLYMEROPOULOS MH, 1990, NUCLEIC ACIDS RES, V19, P969; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SIEGEL DL, 1980, BIOCHIM BIOPHYS ACTA, V598, P517, DOI 10.1016/0005-2736(80)90032-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TSE WT, 1991, GENOMICS, V10, P858, DOI 10.1016/0888-7543(91)90173-C; TSE WT, 1991, BLOOD, V78, P517; WANG YC, 1992, J BIOL CHEM, V267, P2728; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156; WHITE RA, 1990, P NATL ACAD SCI USA, V87, P3117, DOI 10.1073/pnas.87.8.3117; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449	85	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19220	19228		10.1074/jbc.272.31.19220	http://dx.doi.org/10.1074/jbc.272.31.19220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235914	hybrid			2022-12-27	WOS:A1997XP06300020
J	Baskaran, R; Chiang, GG; Mysliwiec, T; Kruh, GD; Wang, JYJ				Baskaran, R; Chiang, GG; Mysliwiec, T; Kruh, GD; Wang, JYJ			Tyrosine phosphorylation of RNA polymerase II carboxyl-terminal domain by the Abl-related gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; CELL-CYCLE; ACTIVATING KINASE; BINDING; TRANSCRIPTION; ENCODES; MICE; DNA; CRK	The largest subunit of RNA polymerase II contains a C-terminal repeated domain (CTD) thai is the site of phosphorylation by serine (threonine) and tyrosine kinases. Phosphorylation of the CTD is correlated with transcription elongation. A number of different kinases have previously been shown to phosphorylate the CTD; among them is a nuclear tyrosine kinase encoded by the c-abl proto-oncogene. The processive and high stoichiometric phosphorylation of RNA polymerase II by c-Abl requires the tyrosine kinase, the SH2 domain, and a CTD-interacting domain (CTD-ID) in the Abl protein. The physiological tyrosine phosphorylation of RNA polymerase II by c-Abl in DNA damage response has previously been demonstrated. Basal tyrosine phosphorylation of RNA polymerase II, however, is observed in cells derived from abl-deficient mice, indicating the existence of other CTD tyrosine kinases. hi this report, we Show that the tyrosine kinase encoded by an Abl-related gene (Arg) also phosphorylates the CTD in vitro and in transfected cells. The SH2 and kinase domain of Arg are 95% identical to that of c-Abl. However, these two proteins Share only 29% identity in the large C-terminal region, Interestingly, a CTD-ID is also found in the C-terminal region of Arg. Mapping studies and sequence analysis have led to the identification of the CTD-that is highly conserved among the divergent C-terminal regions of Abl and Arg. These results indicate that tyrosine phosphorylation of RNA polymerase II CTD could be catalyzed by either c-Abl or Arg kinase.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111	University of California System; University of California San Diego; University of California System; University of California San Diego; Fox Chase Cancer Center				Chiang, Gary/0000-0003-3004-7400	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054, CA-43054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P838; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Mysliwiec T, 1996, ONCOGENE, V12, P631; PEREGO R, 1991, ONCOGENE, V6, P1899; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	32	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18905	18909		10.1074/jbc.272.30.18905	http://dx.doi.org/10.1074/jbc.272.30.18905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228069	hybrid			2022-12-27	WOS:A1997XM34200060
J	Kapila, YL; Niu, JJ; Johnson, PW				Kapila, YL; Niu, JJ; Johnson, PW			The high affinity heparin-binding domain and the V region of fibronectin mediate invasion of human oral squamous cell carcinoma cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FN-C/H-V; SYNTHETIC PEPTIDE; SULFATE PROTEOGLYCAN; ADHESION; INTEGRIN; RECEPTOR; MOTILITY; ALPHA-4-BETA-1; IDENTIFICATION; METASTASIS	Fibronectin is an extracellular matrix molecule composed of repeating subunits that create functional domains. These domains contain multiple binding sites for heparin and for various cell-surface receptors that modulate cell function. To examine the role that the high affinity heparin-binding region and the alternatively spliced V region of fibronectin play in tumor invasion, we expressed and purified four complementary recombinant fibronectin proteins. These proteins either included or excluded the alternatively spliced V region and contained either a mutated, non-functional high affinity heparin-binding domain (Hep(-)) or an unmutated heparin-binding domain (Hep(+)), Cultured oral squamous cell carcinoma cells were assayed for invasion into a Matrigel/collagen matrix supplemented with these four purified recombinant proteins, and for spreading and motility on plastic, Increased invasion was observed in gels supplemented with the V(-)Hep(+) protein when compared with the V(-)Hep(-) protein. Inclusion of the V region in the proteins enhanced the invasion and migration associated with both Hep(+) and Hep(-) proteins, whereas cell spreading was enhanced with the Hep(+) recombinant proteins, These data demonstrate that both the high affinity heparin-binding domain and the V region of fibronectin play important roles in invasion, motility, and spreading of oral squamous cell carcinoma cells.	UNIV CALIF SAN FRANCISCO, SCH DENT, DEPT STOMATOL, DIV PERIODONTOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Kapila, Yvonne/AAG-5418-2021		NIDCR NIH HHS [D15-DE 00344-03] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HYNES RO, 1990, FIBRONECTINS, P115; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JANIAK M, 1994, EXP HEMATOL, V22, P559; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; Mohri H, 1996, EXP CELL RES, V222, P326, DOI 10.1006/excr.1996.0042; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PETERS JH, 1995, CELL ADHES COMMUN, V3, P67, DOI 10.3109/15419069509081278; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Regezi J, 1993, ORAL PATHOLOGY CLIN, P77; SAIKI I, 1993, JPN J CANCER RES, V84, P326, DOI 10.1111/j.1349-7006.1993.tb02874.x; SAIKI I, 1990, JPN J CANCER RES, V81, P1003, DOI 10.1111/j.1349-7006.1990.tb03338.x; SONCIN F, 1994, J BIOL CHEM, V269, P8999; VLODAVSKY I, 1992, ADV EXP MED BIOL, V313, P317; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAHL SM, 1994, J CLIN INVEST, V94, P655, DOI 10.1172/JCI117382; WILKE MS, 1993, J INVEST DERMATOL, V101, P43, DOI 10.1111/1523-1747.ep12358823; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YONEDA J, 1994, JPN J CANCER RES, V85, P723, DOI 10.1111/j.1349-7006.1994.tb02421.x; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18932	18938		10.1074/jbc.272.30.18932	http://dx.doi.org/10.1074/jbc.272.30.18932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228073	hybrid			2022-12-27	WOS:A1997XM34200064
J	Rapaport, D; Neupert, W; Lill, R				Rapaport, D; Neupert, W; Lill, R			Mitochondrial protein import - Tom40 plays a major role in targeting and translocation of preproteins by forming a specific binding site for the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; OUTER-MEMBRANE; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; INNER MEMBRANE; CELL VIABILITY; CROSS-LINKING; MACHINERY; INSERTION; MATRIX	During preprotein transport across the mitochondrial outer membrane, the N-terminal presequence initially binds to a surface-exposed site, termed cis site, of the protein translocation complex of this membrane (the TOM complex). The presequence then moves into the translocation pore and becomes exposed at the intermembrane space side. Membrane passage is driven by specific interaction of the presequence with the trans site, We have used chemical cross-linking to identify components in the vicinity of the translocating presequence. Preproteins bound to the surface-exposed cis site can be cross-linked via their N-terminal presequence to Tom20 and Tom22, demonstrating their direct association with this part of the preprotein, In addition, the presequence establishes an early contact to Tom40, a membrane-embedded protein of the TOM complex. Upon further entry of the preprotein into the translocation pore, the presequence loses its contact with Tom20/Tom22, but remains in firm association with Tom40, Our study suggests that Tom40 plays an important function in guiding the presequence of a preprotein across the mitochondrial outer membrane, We propose that Tom40 forms a major part of the traits presequence binding site.	UNIV MARBURG, INST ZYTOBIOL, D-35033 MARBURG, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY	Philipps University Marburg; University of Munich				Lill, Roland/0000-0002-8345-6518				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066; COURT DA, 1996, MOL CELL BIOL, V16, P4034; GAIKWAD AS, 1994, J BIOL CHEM, V269, P6437; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LILL R, 1996, ADV MOL CELL BIOL, P51; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; TRANEL PJ, 1995, EMBO J, V14, P1436; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	38	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18725	18731		10.1074/jbc.272.30.18725	http://dx.doi.org/10.1074/jbc.272.30.18725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228044	hybrid			2022-12-27	WOS:A1997XM34200035
J	Lim, HM; Lee, HJ; Jaxel, C; Nadal, M				Lim, HM; Lee, HJ; Jaxel, C; Nadal, M			Hin-mediated inversion on positively supercoiled DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; STRAND EXCHANGE; TN3 RESOLVASE; PHAGE-MU; REVERSE GYRASE; RES SITES; ENHANCER; INVITRO; GIN; PROTEIN	Hin recombinase requires negatively supercoiled DNA for an efficient inversion. We have generated positively supercoiled plasmid DNA using reverse gyrase from Sulfolobus shibatae and subjected it to he Hin-mediated inversion reaction. Both Hin and Fis showed the same DNA binding activity regardless of the superhelical handedness of the substrate plasmid. However, inversion activity on positively supercoiled DNA was less than 1% of negatively supercoiled DNA. Assays designed to probe steps in inversion, showed that on positively supercoiled DNA, Hin was able to cleave the recombination sites with the same efficiency shown on negatively supercoiled DNA but was not able to exchange the cleaved DNA. Based on the theoretical differences between positive and negative supercoiling, our data may suggest that unwinding of the double helix at recombination sites is needed after DNA cleavage for strand exchange to occur.	UNIV PARIS 11,INST GENET & MICROBIOL,LAB ENZYMOL ACIDES NUCL,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Lim, HM (corresponding author), CHUNGNAM NATL UNIV,COLL NAT RESOURCES,DEPT BIOL,TAEJON 305764,SOUTH KOREA.			NADAL, Marc/0000-0001-9637-7694; Lim, Heon/0000-0003-1711-2589				BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; DREW HR, 1985, EMBO J, V4, P1025, DOI 10.1002/j.1460-2075.1985.tb03734.x; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1988, P NATL ACAD SCI USA, V85, P752, DOI 10.1073/pnas.85.3.752; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KLIPPEL A, 1988, EMBO J, V7, P1229, DOI 10.1002/j.1460-2075.1988.tb02935.x; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LIM HM, 1992, J BIOL CHEM, V267, P11183; LIM HM, 1992, J BIOL CHEM, V267, P11176; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MERTENS G, 1984, EMBO J, V3, P2415, DOI 10.1002/j.1460-2075.1984.tb02148.x; MIZUUCHI K, 1978, J MOL BIOL, V121, P375, DOI 10.1016/0022-2836(78)90370-4; NADAL M, 1994, J BIOL CHEM, V269, P5255; NADAL M, 1986, NATURE, V321, P256, DOI 10.1038/321256a0; PLASTERK RHA, 1984, P NATL ACAD SCI-BIOL, V81, P2689, DOI 10.1073/pnas.81.9.2689; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1994, J MOL BIOL, V239, P25, DOI 10.1006/jmbi.1994.1348; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x	38	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18434	18439		10.1074/jbc.272.29.18434	http://dx.doi.org/10.1074/jbc.272.29.18434			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218487	hybrid			2022-12-27	WOS:A1997XL73500077
J	Nakahashi, Y; Nelson, E; Fagan, K; Gonzales, E; Guillou, JL; Cooper, DMF				Nakahashi, Y; Nelson, E; Fagan, K; Gonzales, E; Guillou, JL; Cooper, DMF			Construction of a full-length Ca2+-sensitive adenylyl cyclase aequorin chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RECOMBINANT AEQUORIN; CA2+ CONCENTRATION; INTACT-CELLS; NCB-20 CELLS; FREE CALCIUM; BIOLUMINESCENCE; PHOTOPROTEIN; ORGANELLES; MEMBRANES	Ca2+-sensitive adenylyl cyclases are key integrators of Ca2+ and cAMP signaling, To selectively probe dynamic changes in [Ca2+](i) at the plasma membrane where adenylyl cyclases reside, a full-length, Ca2+-inhibitable type VI adenylyl cyclase/aequorin chimera has been constructed by a two stage polymerase chain reaction method. The expressed adenylyl cyclase/aequorin chimera was appropriately localized to the plasma membrane, as judged by biochemical fractionation and functional analysis, The chimera retained full adenylyl cyclase activity and sensitivity to inhibition by physiological [Ca2+](i) elevation. The aequorin portion of the chimeric construct was also capable of measuring changes in [Ca2+] both in vitro and in vivo, When the plasma membrane-tagged aequorin and cytosolic aequorin were compared in their measurement of [Ca2+](i), they showed contrasting sensitivities depending on whether the [Ca2+](i) originated from internal stores or capacitative entry, This is the first full-length enzyme-aequorin chimera that retains the full biological properties of both aequorin and a Ca2+-sensitive adenylyl cyclase. This novel chimeric Ca2+ sensor provides the unique ability to directly report the dynamics of [Ca2+](i) that regulates this Ca2+-sensitive enzyme under a variety of physiological conditions, Since this chimera is localized to the plasma membrane, it can also be used to assess local changes in [Ca2+](i) at the plasma membrane as distinct from global changes in [Ca2+](i) within the cytosol.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM NEUROSCI, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Jean-Louis, Guillou/Y-2569-2019	Jean-Louis, Guillou/0000-0002-4497-9551	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28389] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; FAGAN KA, 1996, J BIOL CHEM, V271, P12433; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NOMURA M, 1991, FEBS LETT, V295, P63, DOI 10.1016/0014-5793(91)81385-L; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANLEY KK, 1980, BIOCHEM J, V186, P59, DOI 10.1042/bj1860059; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	28	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18093	18097		10.1074/jbc.272.29.18093	http://dx.doi.org/10.1074/jbc.272.29.18093			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218441	hybrid			2022-12-27	WOS:A1997XL73500031
J	Hall, JA; Ganesan, AK; Chen, J; Nikaido, H				Hall, JA; Ganesan, AK; Chen, J; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Functional significance in active transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTODEXTRIN TRANSPORT; CYTOPLASMIC MEMBRANE; SYSTEM; COMPONENTS; SUBSTRATE; OVERPRODUCTION; SPECTROSCOPY; RECOGNITION; SPECIFICITY; DIFFUSION	In the preceding two papers (Hall, J. A., Gehring, K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17605-17609; Hall, J. A., Thorgeirson, T. E., Liu, J., Shin, Y.-E., and Nikaido, H. (1997) J. Biol. Chem. 272, 17610-17614), we showed that ligands that bind to the Escherichia coli maltose-binding protein (MBP) without producing the closure of its two lobes are not transported into the cytoplasm. Here, we examine various combinations of ligands, MBPs, and membrane-associated transporters, by utilizing reconstituted proteoliposomes, right side out membrane vesicles, and intact cells. Closed forms of wild type MBP, complexed with maltose or maltodextrins, interacted with wild type transporter complex to stimulate the hydrolysis of ATP by MalK ATPase located on the other side of the membrane, as shown earlier for the maltose-MBP complex (Davidson, A. L., Shuman, H. A., and Nikaido, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2360-2364). In contrast, open forms of liganded MBPs, such as the complex containing wild type MBP and reduced, oxidized, or cyclic maltodextrins or the complex containing the mutant MBP MalE254 and unmodified maltodextrins, did not stimulate ATP hydrolysis, suggesting that the proper interaction between the ligand-MBP complex and the external surface of the transporter requires the former to be in the closed conformation. However, when a mutant transporter containing MalG511 was used, the already significant basal level of ATP hydrolysis was further stimulated not only by ligand MBPs in the closed form but also by those in the open form (except that containing beta-cyclodextrin), data suggesting that the mutant transporter does not always require the closed MBP complex presumably because of its exceptionally strong affinity to MBP, described earlier (Dean, D. A., Her, L.-I., Shuman, H. A., and Nikaido, H. (1992) Mel. Microbiol. 6, 2033-2040). Furthermore, this mutant transporter was able to transport reduced maltodextrin, and cells expressing the transporter were able to grow by using reduced maltodextrin, if the periplasmic concentrations of MBP were kept low so as not to inhibit the transport process.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Gustedt W. V., 1996, Biophysical Journal, V70, pA203; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; Kaback H R, 1974, Methods Enzymol, V31, P698; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MILLER JH, 1972, EXPT MOL GENETICS, P82; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; STOCK JB, 1977, J BIOL CHEM, V252, P7850; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WANDERSMAN C, 1979, J BACTERIOL, V140, P1	33	48	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17615	17622		10.1074/jbc.272.28.17615	http://dx.doi.org/10.1074/jbc.272.28.17615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211910	hybrid			2022-12-27	WOS:A1997XK16500053
J	Tischfield, JA				Tischfield, JA			A thematic series on phospholipases .5. A reassessment of the low molecular weight phospholipase A(2) gene family in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROUP-II PHOSPHOLIPASE-A(2); ARTHRITIC SYNOVIAL-FLUID; CULTURED MAST-CELLS; RAT MESANGIAL CELLS; EXTRACELLULAR PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; P388D(1) CELLS; SEPTIC SHOCK; CLONING		INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Tischfield, JA (corresponding author), INDIANA UNIV, SCH MED, DEPT MED & MOL GENET, 975 W WALNUT ST, IB-130, INDIANAPOLIS, IN 46202 USA.			Tischfield, Jay/0000-0003-3217-8287	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES05652-06] Funding Source: Medline; NIGMS NIH HHS [R01 GM 38185] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Chen J, 1997, J CELL BIOCHEM, V64, P369, DOI 10.1002/(SICI)1097-4644(19970301)64:3<369::AID-JCB3>3.0.CO;2-T; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FORSTER S, 1983, BRIT J DERMATOL, V108, P103, DOI 10.1111/j.1365-2133.1983.tb04585.x; FORSTER S, 1985, BRIT J DERMATOL, V112, P135, DOI 10.1111/j.1365-2133.1985.tb00077.x; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P201; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Johnson L K, 1990, Adv Exp Med Biol, V275, P17; KAWATA R, 1995, J IMMUNOL, V155, P818; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; Kowalski PE, 1997, GENOMICS, V39, P38, DOI 10.1006/geno.1996.4471; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MARSHALL LA, 1995, INFLAMMATION MEDIATO, P1; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NEVALAINEN TJ, 1993, INFLAMMATION, V17, P453, DOI 10.1007/BF00916585; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; REDDY SR, J BIOL CHEM, V272, P13591; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCHRODER T, 1980, SCAND J GASTROENTERO, V15, P633, DOI 10.3109/00365528009182227; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tseng A, 1996, J BIOL CHEM, V271, P23992, DOI 10.1074/jbc.271.39.23992; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1984, J LAB CLIN MED, V104, P873; VADAS P, 1988, CRIT CARE MED, V16, P1, DOI 10.1097/00003246-198801000-00001; VANDENBOSCH H, 1989, J BIOL CHEM, V364, P10008; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0	53	264	267	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17247	17250		10.1074/jbc.272.28.17247	http://dx.doi.org/10.1074/jbc.272.28.17247			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211858	hybrid			2022-12-27	WOS:A1997XK16500001
J	Eitinger, T; Wolfram, L; Degen, O; Anthon, C				Eitinger, T; Wolfram, L; Degen, O; Anthon, C			A Ni2+ binding motif is the basis of high affinity transport of the Alcaligenes eutrophus nickel permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; EXPRESSION; UREASE; MUTAGENESIS; CLONING; SYSTEM	Amino acid exchanges in the Alcaligenes eutrophus nickel permease (HoxN) were constructed by site-directed mutagenesis, and their effects on nickel ion uptake were investigated, Mutant hoxN alleles were expressed in Escherichia coli, and activity of the altered permeases was examined via a recently described physiological assay (Wolfram, L., Friedrich, B., and Eitinger, T. (1995) J. Bacteriol, 177, 1840-1843), Replacement of Cys-37, Cys-256, or Cys-318 by alanine did not severely affect nickel ion uptake, This activity of a C331A mutant was diminished by 60%, and a similar phenotype was obtained with a cysteine-less mutant harboring four Cys to Ala exchanges, Alterations in a histidine-containing sequence motif (His-62, Asp-67, His-68), which is conserved in microbial nickel transport proteins, strongly affected or completely abolished transport activity in the E. coli system, The analysis of HoxN alkaline phosphatase fusion proteins implied that His-62, Asp-67, and His-68 exchanges did not interfere with overall membrane topology or stability of the nickel permease, These mutations were reintroduced into the A, eutrophus wild-type strain, Analyses of the resulting HoxN mutants indicated that exchanges in the histidine motif led to a clearly decreased affinity of the permease for nickel ion.	FREE UNIV BERLIN,INST PFLANZENPHYSIOL & MIKROBIOL,D-14195 BERLIN,GERMANY	Free University of Berlin	Eitinger, T (corresponding author), HUMBOLDT UNIV BERLIN,INST BIOL MIKROBIOL,CHAUSSEESTR 117,D-10115 BERLIN,GERMANY.		Eitinger, Thomas/C-3926-2019	Eitinger, Thomas/0000-0003-1449-6433				Bernhard M, 1996, J BACTERIOL, V178, P4522, DOI 10.1128/jb.178.15.4522-4529.1996; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Eitinger T, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P235; EITINGER T, 1994, MOL MICROBIOL, V12, P1025, DOI 10.1111/j.1365-2958.1994.tb01090.x; EITINGER T, 1991, J BIOL CHEM, V266, P3222; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; FU CL, 1994, P NATL ACAD SCI USA, V91, P5099, DOI 10.1073/pnas.91.11.5099; HAUSINGER RP, 1993, BIOCH NICKEL, P181; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12272; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; LOHMEYER M, 1987, ARCH MICROBIOL, V149, P130, DOI 10.1007/BF00425078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1994, J BACTERIOL, V176, P432, DOI 10.1128/JB.176.2.432-442.1994; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MOBLEY HLT, 1995, MOL MICROBIOL, V16, P97, DOI 10.1111/j.1365-2958.1995.tb02395.x; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P551; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; WOLFRAM L, 1995, J BACTERIOL, V177, P1840, DOI 10.1128/jb.177.7.1840-1843.1995; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	23	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17139	17144		10.1074/jbc.272.27.17139	http://dx.doi.org/10.1074/jbc.272.27.17139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202033	hybrid			2022-12-27	WOS:A1997XH44600065
J	MatsunoYagi, A; Hatefi, Y				MatsunoYagi, A; Hatefi, Y			Ubiquinol:cytochrome c oxidoreductase - The redox reactions of the bis-heme cytochrome b in unenergized and energized submitochondrial particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; ELECTRON-TRANSFER; OXIDATIVE-PHOSPHORYLATION; BEEF-HEART; COMPLEX; MECHANISM; MITOCHONDRIA; INHIBITORS; ANTIMYCIN	The redox reactions of the bis-heme cytochrome b of the ubiquinol:cytochrome c oxidoreductase complex (complex III, bc(1) complex) were studied in bovine heart submitochondrial particles (SMP), It was shown that (i) when SMP were treated with the complex III inhibitor myxothiazol (or MOA-stilbene or stigmatellin) or with KCN and ascorbate rep reduce the high potential centers of complex III (iron-sulfur protein and cytochromes c + c(1)), NADH or succinate reduced heme b(L) slowly and incompletely, In contrast, heme b(H) was reduced by these substrates completely and much more rapidly, Only when the complex III inhibitor was antimycin, and the high potential centers were in the oxidized state, NADH or succinate was able to reduce both b(H) and b(L) rapidly and completely, (ii) When NADH or succinate was added to SMP inhibited at complex III by antimycin and energized by ATP, the bis-heme cytochrome b was reduced only partially, Prereduction of the high potential centers was not necessary for this partial b reduction, but slowed down the reduction rate, Deenergization of SMP by uncoupling (or addition of oligomycin to inhibit ATP hydrolysis) resulted in further b reduction. Addition of ATP after b was reduced by substrate resulted in partial b oxidation, and the heme remaining reduced appeared to be mainly b(L). Other experiments suggested that the redox changes of cytochrome ZI effected by energization and deenergization of SMP occurred via electronic communication with the ubiquinone pool, These results have been discussed in relation to current concepts regarding the mechanism of electron transfer by complex III.	Scripps Res Inst, DEPT MOL & EXPT MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWYER JR, 1981, FEBS LETT, V126, P93, DOI 10.1016/0014-5793(81)81041-1; BOWYER JR, 1980, FEBS LETT, V115, P171, DOI 10.1016/0014-5793(80)81160-4; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHANCE B, 1970, P NATL ACAD SCI USA, V66, P1175, DOI 10.1073/pnas.66.4.1175; CHANCE B, 1974, DYNAMICS ENERGY TRAN, P553; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; HATEFI Y, 1982, BIOCHEMISTRY-US, V24, P6614; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; RIESKE JS, 1971, ARCH BIOCHEM BIOPHYS, V145, P179, DOI 10.1016/0003-9861(71)90025-7; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WILSON DF, 1970, BIOCHEM BIOPH RES CO, V39, P59, DOI 10.1016/0006-291X(70)90757-6; Xia D., 1996, Biophysical Journal, V70, pA253	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16928	16933		10.1074/jbc.272.27.16928	http://dx.doi.org/10.1074/jbc.272.27.16928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202003	hybrid			2022-12-27	WOS:A1997XH44600035
J	Miaczynska, M; Lorenzetti, S; Bialek, U; BenitoMoreno, RM; Schweyen, RJ; Ragnini, A				Miaczynska, M; Lorenzetti, S; Bialek, U; BenitoMoreno, RM; Schweyen, RJ; Ragnini, A			The yeast Rab escort protein binds intracellular membranes in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; SACCHAROMYCES-CEREVISIAE; GERANYLGERANYL TRANSFERASE; COMPONENT-A; GENE ENCODES; CHOROIDEREMIA; HOMOLOG; ACYLATION; VESICLES; MRS6P	Tn both mammals and yeast, intracellular vesicular transport depends on the correct shuttling between membrane and cytosol of the Rab/Ypt small G proteins, Membrane association of these proteins requires prenylation by the Rab geranylgeranyl transferase that recognizes a complex formed by the Rab/Ypt protein and the Rab escort protein (REP), After prenylation the Rab/Ypt protein is delivered to the tar,aet membranes by REP, Little is known about the early steps of the Rab-REP complex formation and where this association occurs in the cell, Although prenylation is believed to take place in the cytosol, we show that the yeast Rab escort protein Mrs6 is present in both soluble and particulate fractions of cell extracts, Mrs6p is associated with the heavy microsomal fraction that contains endoplasmic reticulum-Golgi membranes but is absent iu the plasma membrane, vacuoles, mitochondria, and microsomal subfraction associated with mitochondria. The solubilization pattern of the particulate pool of Mrs6p implies that this protein is peripherally but tightly associated with membranes via hydrophobic interactions and metal ions. We also report that the C terminus of Mrs6p is important for maintaining the solubility of the protein because its deletion or replacement with the C terminus of RabGDI results in a protein that localizes only to membranes.	UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC)			Białek-Wyrzykowska, Urszula/AAT-1041-2021; LORENZETTI, STEFANO/C-6063-2015; Ragnini, Antonella/A-8089-2014	LORENZETTI, STEFANO/0000-0001-5358-8002; Ragnini, Antonella/0000-0001-7963-7554; Miaczynska, Marta/0000-0003-0031-5267				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; Bauer BE, 1996, MOL BIOL CELL, V7, P1521, DOI 10.1091/mbc.7.10.1521; BENITOMORENO RM, 1994, CURR GENET, V27, P23, DOI 10.1007/BF00326574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DAUM G, 1982, J BIOL CHEM, V257, P3028; FERRONOVICK S, 1995, GUIDEBOOK SMALL GTPA, P60; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; KOHRER K, 1993, J BIOL CHEM, V268, P559; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; Penefsky H. S., 1971, METHOD ENZYMOL, V22, P204; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RAGNINI A, 1994, CURR GENET, V26, P308, DOI 10.1007/BF00310494; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEABRA MC, 1995, GUIDEBOOK SMALL GTPA, P45; Shen F, 1996, J BIOL CHEM, V271, P3692; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	40	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16972	16977		10.1074/jbc.272.27.16972	http://dx.doi.org/10.1074/jbc.272.27.16972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202009	hybrid			2022-12-27	WOS:A1997XH44600041
J	Aggeler, R; Ogilvie, I; Capaldi, RA				Aggeler, R; Ogilvie, I; Capaldi, RA			Rotation of a gamma-epsilon subunit domain in the Escherichia coli F1F0-ATP synthase complex - The gamma-epsilon subunits are essentially randomly distributed relative to the alpha(3)beta(3)delta domain in the intact complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; F1 ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITES; CRYOELECTRON MICROSCOPY; F1-ATPASE; MECHANISM; ASYMMETRY; BINDING; BETA	A triple mutant of Escherichia coli F1F0-ATP synthase, alpha Q2C/alpha S411C/epsilon S108C, has been generated for studying movements of the gamma and epsilon subunits during functioning of the enzyme, It includes mutations that allow disulfide bond formation between the Cys at alpha 411 and both Cys-87 of gamma and Cys-108 of epsilon, two covalent cross-links that block enzyme function (Aggeler, R., and Capaldi, R. A. (1996) J. Biol. Chem. 271, 13888-13891). A cross-link is also generated between the Cys at alpha 2 and Cys-140 of the delta subunit, which has no effect on functioning (Ogilvie, I., Aggeler, R., and Capaldi, R. A. (1997) J. Biol. Chem. 272, 16652-16656), CuCl2 treatment of the mutant alpha Q2C/ alpha S411C/epsilon S108C generated five major cross-linked products. These are alpha-gamma-delta, alpha-gamma, alpha-delta-epsilon, alpha-delta, and alpha-epsilon. The ratio of alpha-gamma-delta to the alpha-gamma product was close to 1:2, i.e. in one-third of the ECF1F0 molecules the gamma subunit was attached to the alpha subunit at which the delta subunit is bound. Also, 20% of the epsilon subunit was present as a alpha-delta-epsilon product. With regard to the delta subunit, 30% was in the alpha-gamma-delta, 20% in the alpha-delta-epsilon, and 50% in the alpha-delta products when the cross-linking was done after incubation in ATP + MgCl2. The amounts of these three products were 40, 22, and 38%, respectively, in experiments where Cu2+ was added after preincubation in ATP + Mg2+ + azide. The delta subunit is fixed to, and therefore identifies, one specific alpha subunit (alpha(delta)). A distribution of the gamma and epsilon subunits, which is essentially random with respect to the alpha subunits, can only be explained by rotation of gamma-epsilon relative to the alpha(3) beta(3) domain in ECF1F0.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GRUBER G, 1997, IN PRESS FEBS LETT; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	36	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19621	19624		10.1074/jbc.272.31.19621	http://dx.doi.org/10.1074/jbc.272.31.19621			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235970	hybrid			2022-12-27	WOS:A1997XP06300076
J	Gao, TY; Puri, TS; Gerhardstein, BL; Chien, AJ; Green, RD; Hosey, MM				Gao, TY; Puri, TS; Gerhardstein, BL; Chien, AJ; Green, RD; Hosey, MM			Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; SKELETAL-MUSCLE; DIFFERENTIAL PHOSPHORYLATION; ALPHA(1) SUBUNIT; CA2+ CHANNELS; BETA-SUBUNIT; DIHYDROPYRIDINE; RECEPTORS; PURIFICATION; EXPRESSION	The properties of cardiac L-type channels have been well characterized electrophysiologically, and many such studies have demonstrated that the channels are regulated by a cAMP-dependent pathway, However, the subunit composition of native cardiac L-type calcium channels has not been completely defined, Furthermore, a very important question exists regarding the status of the C-terminal domain of the pore-forming alpha(1) subunit, as this domain has the potential to be the target of protein kinases but may be truncated as a result of posttranslational processing, In the present studies, the alpha(1C) and beta(2) subunits were identified by subunit-specific antibodies after partial purification from heart membranes, or immunoprecipitation from cardiac myocytes, Both the beta(2) and the full-length alpha(1C) subunits were found to be expressed and co-localized in intact cardiac myocytes along T-tubule membranes. Using a quantitative antibody binding analysis, we demonstrated that the majority of the alpha(1C) subunits in intact cardiac myocytes appear to be full-length, In addition, we observed that adenylyl cyclase is localized in a pattern similar to the channel subunits in cardiac myocytes, Taken together, our results provide new insights into the structural basis for understanding the regulation of L-type calcium channels by a cAMP-mediated signaling pathway.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; UNIV ILLINOIS,DEPT PHARMACOL,CHICAGO,IL 60612	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL23306] Funding Source: Medline; NIDDK NIH HHS [T32 DK07169] Funding Source: Medline; NIMH NIH HHS [MH10770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CHANG FC, 1988, J BIOL CHEM, V263, P18929; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COOPER CL, 1987, J BIOL CHEM, V262, P509; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; FORBES MS, 1980, TISSUE CELL, V12, P467, DOI 10.1016/0040-8166(80)90037-3; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; HADDAD J, 1988, AM J PHYSIOL, V255, pC19, DOI 10.1152/ajpcell.1988.255.1.C19; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOSEY MM, 1985, J PHARMACOL EXP THER, V232, P795; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOBAYASHI M, 1985, ANAL BIOCHEM, V145, P351, DOI 10.1016/0003-2697(85)90373-2; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; SIMPSON DG, 1993, J CELL BIOL, V123, P323, DOI 10.1083/jcb.123.2.323; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; WEI XY, 1994, J BIOL CHEM, V269, P1635; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; YU HJ, 1993, MOL PHARMACOL, V44, P689	31	143	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19401	19407		10.1074/jbc.272.31.19401	http://dx.doi.org/10.1074/jbc.272.31.19401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235939	hybrid			2022-12-27	WOS:A1997XP06300045
J	Cai, JS; Gibbs, E; Uhlmann, F; Phillips, B; Yao, N; ODonnell, M; Hurwitz, J				Cai, JS; Gibbs, E; Uhlmann, F; Phillips, B; Yao, N; ODonnell, M; Hurwitz, J			A complex consisting of human replication factor C p40, p37, and p36 subunits is a DNA-dependent ATPase and an intermediate in the assembly of the holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-III HOLOENZYME; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; SLIDING CLAMPS; MULTIPLE FUNCTIONS; RF-C; DELTA	Human replication factor C (hRFC) is a multi-subunit protein complex capable of supporting proliferating cell nuclear antigen (PCNA) dependent DNA synthesis by DNA polymerases delta and epsilon. The hRFC complex consists of five different subunits with apparent molecular masses of 140, 40, 38, 37, and 36 kDa. We have previously reported the expression of a three-subunit core complex, consisting of the p40, p37, and p36 subunits following coupled in vitro transcription-translation of the cDNAs encoding these proteins (Uhlmann, F., Cai, J., Flores-Rozas, H., Dean, F. B., Finkelstein, J., O'Donnell, M., and Hurwitz, J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6521-6526). Here we describe the isolation of a stable complex composed of the p40, p37, and p36 subunits of hRFC from baculovirus-infected insect cells. The purified p40.p37.p36 complex, like the five-subunit RFC, contained DNA-dependent ATPase activity that was stimulated by PCNA, preferentially bound to primed DNA templates, interacted with PCNA, and was capable of unloading PCNA from singly nicked circular DNA. In contrast to the five subunit RFC, the three-subunit core complex did not load PCNA onto DNA. The p40.p37.p36 complex inhibited the elongation of primed DNA templates catalyzed by the DNA polymerase delta holoenzyme. Incubation of the p40.p37.p36 complex with the hRFC p140 and p38 subunits formed the five-subunit hRFC complex that supported PCNA-dependent DNA synthesis by DNA polymerase delta.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Rockefeller University				Uhlmann, Frank/0000-0002-3527-6619	NIGMS NIH HHS [GM 38559, GM 54705] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054705] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689	33	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18974	18981		10.1074/jbc.272.30.18974	http://dx.doi.org/10.1074/jbc.272.30.18974			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228079	hybrid			2022-12-27	WOS:A1997XM34200070
J	Chandel, NS; Budinger, GRS; Choe, SH; Schumacker, PT				Chandel, NS; Budinger, GRS; Choe, SH; Schumacker, PT			Cellular respiration during hypoxia - Role of cytochrome oxidase as the oxygen sensor in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CELLS; OXIDATIVE-PHOSPHORYLATION; ENERGY METABOLISM; MITOCHONDRIA; DEPENDENCE; GRADIENTS; ATP; O2	We previously reported that hepatocytes exhibit a reversible suppression of respiration during prolonged hypoxia (PO2 = 20 torr for 3-5 h), Also, isolated bovine heart cytochrome c oxidase undergoes a reversible decrease in apparent V-max when incubated under similar conditions, This study sought to link the hypoxia induced changes in cytochrome oxidase to the inhibition of respiration seen in intact cells, Hepatocytes incubated at PO2 = 20 torr exhibited decreases in respiration and increases in [NAD(P)H] after 2-3 h that were reversed upon reoxygenation (PO2 = 100 torr), Respiration during hypoxia was also inhibited when N,N,N',N'-tetramethyl-p-phenylenediamine (0.5 mM) and ascorbate (5 mM) were used to reduce cytochrome c, suggesting that cytochrome oxidase was partially inhibited. Similarly, liver submitochondrial particles revealed a 44% decrease in the apparent V-max of cytochrome oxidase after hypoxic incubation, In hepatocytes loaded with tetramethylrhodamine ethyl ester (10 nM) to quantify mitochondrial membrane potential, acute hypoxia (<30 min) produced no change in fluorescence, consistent with the absence of an acute change in respiration, However, fluorescence increased during acute reoxygenation after prolonged hypoxia, suggesting an increase in potential, The control exhibited by NADH over mitochondrial respiration was not altered during hypoxia, Thus, changes in the V-max of cytochrome oxidase during prolonged hypoxia correlate with the changes in respiration and mitochondrial potential, This suggests that the oxidase functions as an oxygen sensor in the intact hepatocyte.	UNIV CHICAGO,DEPT MED,SECT PULM & CRIT CARE,CHICAGO,IL 60637	University of Chicago				Schumacker, Paul T/0000-0001-9591-2034	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R55HL032646, R01HL032646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35440, HL32646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; JONES DP, 1978, J BIOL CHEM, V253, P4874; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; JONES DP, 1992, ANNU REV NUTR, V12, P327, DOI 10.1146/annurev.nu.12.070192.001551; KADENBACH B, 1995, BBA-MOL BASIS DIS, V1271, P103, DOI 10.1016/0925-4439(95)00016-W; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SEGLEN PO, 1972, EXP CELL RES, V74, P450, DOI 10.1016/0014-4827(72)90400-4; Warburg O, 1929, BIOCHEM Z, V214, P5; WILSON DF, 1988, J BIOL CHEM, V263, P2712	20	146	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18808	18816		10.1074/jbc.272.30.18808	http://dx.doi.org/10.1074/jbc.272.30.18808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228055	hybrid			2022-12-27	WOS:A1997XM34200046
J	Hall, MC; Matson, SW				Hall, MC; Matson, SW			Mutation of a highly conserved arginine in motif IV of Escherichia coli DNA helicase II results in an ATP-binding defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; INDUCED CONFORMATIONAL-CHANGES; SINGLE-STRANDED-DNA; UVRD GENE-PRODUCT; BOX RNA HELICASE; MISMATCH CORRECTION; EXCISION-REPAIR; POLYMERASE-I; PROTEIN; RECOMBINATION	A site-directed mutation in motif IV of Escherichia coli DNA helicase II (UvrD) was generated to examine the functional significance of this region. The highly conserved arginine at position 284 was replaced with alanine to construct UvrD-R284A. The ability of the mutant allele to function in methyl-directed mismatch repair and UvrABC-mediated nucleotide excision repair was examined by genetic complementation assays. The R284A substitution abolished function in both DNA repair pathways. To identify the biochemical defects responsible for the loss of biological function, UvrD-R284A was purified to apparent homogeneity, and its biochemical properties were compared with wild-type UvrD, UvrD-R284A failed to unwind a 92-base pair duplex region and was severely compromised in unwinding a 20-base pair duplex region. The K-m of UvrD-R284A for ATP was significantly greater than 3 mM compared with 80 mu M for UvrD. A large decrease in ATP binding was confirmed using a nitrocellulose filter binding assay. These data suggested that the R284A mutation severely reduced the affinity of helicase II for ATP. The reduced unwinding activity and loss of biological function of UvrD-R284A was probably the result of decreased affinity for ATP. These results implicate motif IV of superfamily I helicases in nucleotide binding and represent the first characterization of a helicase mutation outside motifs I and II that severely impacted the K-m for ATP.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Hall, Mark C./D-1698-2011	Hall, Mark/0000-0001-6429-2506	NIGMS NIH HHS [GM-33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brosh RM, 1997, J BIOL CHEM, V272, P572; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FEINSTEIN SI, 1986, GENETICS, V113, P13; FERNANDEZ A, 1995, NUCLEIC ACIDS RES, V23, P1327, DOI 10.1093/nar/23.8.1327; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; Kornberg A., 1992, DNA REPLICATION; KUEMMERLE NB, 1980, J BACTERIOL, V142, P535, DOI 10.1128/JB.142.2.535-546.1980; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MENDONCA VM, 1993, J BACTERIOL, V175, P4641, DOI 10.1128/JB.175.15.4641-4651.1993; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; NEVERS P, 1975, MOL GEN GENET, V139, P233, DOI 10.1007/BF00268974; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SCHELLHORN HE, 1991, J BACTERIOL, V173, P6192, DOI 10.1128/jb.173.19.6192-6198.1991; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	60	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18614	18620		10.1074/jbc.272.30.18614	http://dx.doi.org/10.1074/jbc.272.30.18614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228029	hybrid			2022-12-27	WOS:A1997XM34200020
J	Iyer, R; Delcour, AH				Iyer, R; Delcour, AH			Complex inhibition of OmpF and OmpC bacterial porins by polyamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PORINS; RECTIFIER K+ CHANNEL; CYTOPLASMIC POLYAMINES; INWARD RECTIFICATION; OUTER-MEMBRANE; ION CHANNELS; PATCH-CLAMP; BLOCK; DEPENDENCE; MECHANISM	The effects of four polyamines (putrescine, cadaverine, spermidine, and spermine) on the activity of bacterial porins OmpC and OmpF were investigated by electrophysiology. Membrane vesicles made from the outer membrane of Escherichia coli strains expressing only OmpC or OmpF were reconstituted into liposomes probed by patch clamp. The channel activity was recorded in control solutions and in the presence of increasing concentrations of a specific polyamine. In all cases, concentration- and voltage-dependent inhibitory effects were observed. They include both the suppression of channel openings and the enhancement of channel closures as well as the promotion of blocked or inactivated states, OmpF and OmpC, although highly homologous, have distinct sensitivities to modulation, especially by spermine. This compound inhibits OmpF in the nanomolar range, which is in agreement with its potency on eukaryotic channels. Putrescine was the least effective (upper millimolar range) and also had inhibitory effects qualitatively distinct from those exerted by the other polyamines. The compounds appear to bind to at least two distinct binding sites, one of which resides within the pore. The potencies to this site are lower when the polyamines are applied from the extracellular side than from the periplasmic side, suggesting an asymmetric binding site.	UNIV HOUSTON,DEPT BIOL,HOUSTON,TX 77204; UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston			Iyer, Ram/AAQ-1329-2020	Iyer, Ram/0000-0002-3638-2421	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034905, R01AI034905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34905] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Delcour AH, 1997, FEMS MICROBIOL LETT, V151, P115, DOI 10.1016/S0378-1097(97)00166-3; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOMEZ M, 1995, PFLUG ARCH EUR J PHY, V430, P501, DOI 10.1007/BF00373886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JAYARAMAN V, 1997, BIOPHYS J, V72, P334; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KOSKI P, 1991, J BACTERIOL, V173, P3695, DOI 10.1128/JB.173.12.3695-3699.1991; LIU N, 1996, BIOPHYS J, V70, P352; LIU N, 1997, IN PRESS BIOPHYS BIO; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; Neely MN, 1996, J BACTERIOL, V178, P5522, DOI 10.1128/jb.178.18.5522-5528.1996; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Uehara A, 1996, BIOPHYS J, V71, P769, DOI 10.1016/S0006-3495(96)79276-7; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	35	86	88	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18595	18601		10.1074/jbc.272.30.18595	http://dx.doi.org/10.1074/jbc.272.30.18595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228026	hybrid			2022-12-27	WOS:A1997XM34200017
J	Pedersen, JI; Eggertsen, G; Hellman, U; Andersson, U; Bjorkhem, I				Pedersen, JI; Eggertsen, G; Hellman, U; Andersson, U; Bjorkhem, I			Molecular cloning and expression of cDNA encoding 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoyl-CoA oxidase from rabbit liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RAT-LIVER; TRIHYDROXYCOPROSTANOYL-COA; CHOLIC-ACID; FATTY-ACIDS; PURIFICATION; PEROXISOMES; 3-ALPHA; PROTEIN; CHAIN	The steroid side chain cleavage in bile acid formation is catalyzed by liver peroxisomal enzymes (Pedersen, J. I. and Gustafsson, J. (1980) FEES Lett. 121, 345-348; Kase, F., Bjorkhem, I., and Pedersen, J. I. (1983) J. Lipid Res. 24, 1560-1567). We here describe the cloning and sequencing of a cDNA coding the first of these enzymes, a 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoyl-CoA oxidase (THCA-CoA oxidase) from rabbit liver peroxisomes. After tryptic digestion of purified protein in a polyacrylamide gel, five peptides were isolated and sequenced. Using two oligonucleotides deduced from the amino acid sequence data, two overlapping clones were isolated from a rabbit liver cDNA library, which together made up a unique cDNA sequence of 2139 base pairs. It contained an open reading frame of 2846 base pairs encoding a protein of 681 amino acids with a molecular mass of 76,209 daltons. All five peptides could be localized within the sequence. Transfection of COS cells with the coding part of the cDNA resulted in a significant expression of THCA-CoA oxidase activity. We were not able to demonstrate 3 alpha,7 alpha dihydroxy-5 beta-cholestanoyl-CoA oxidase activity under the same conditions. The obtained sequence showed 73.6% similarity with a proposed rat THCA-CoA oxidase and 81% similarity with a recently reported human branched chain acyl-CoA oxidase, indicating that these three proteins represent the same enzyme. The similarity with rat palmitoyl-CoA oxidase was 41.8%. The C-terminal tripeptide of the protein was SNL, a previously undescribed variant of the main class of peroxisomal targeting signals. Northern blot analysis revealed that the gene is transcribed in liver and kidney, and the major mRNA fraction had a size of approximately 2.6 kilobase pairs.	HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN; UNIV UPPSALA,LUDWIG INST CANC RES,BIOMEDICUM,S-75124 UPPSALA,SWEDEN	Karolinska Institutet; Ludwig Institute for Cancer Research; Uppsala University	Pedersen, JI (corresponding author), UNIV OSLO,INST NUTR RES,POB 1046,N-0316 OSLO,NORWAY.		Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				BATTA AK, 1979, J LIPID RES, V20, P935; BATTA AK, 1979, J BIOL CHEM, V254, P1907; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Baumgart E, 1996, BIOCHEM J, V320, P115, DOI 10.1042/bj3200115; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, V12, P231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; FARRANTS AKO, 1992, THESIS U OSLO; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUSTAFSSON J, 1975, J BIOL CHEM, V250, P3889; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOFMANN AF, 1969, BIOCHIM BIOPHYS ACTA, V176, P204, DOI 10.1016/0005-2760(69)90092-7; KASE F, 1983, J LIPID RES, V24, P1560; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PEDERSEN JI, 1988, BIOCHEM INT, V17, P163; PEDERSEN JI, 1993, BIOCHIMIE, V75, P159, DOI 10.1016/0300-9084(93)90073-2; Pedersen JI, 1996, BIOCHEM BIOPH RES CO, V224, P37, DOI 10.1006/bbrc.1996.0981; PEDERSEN JI, 1980, FEBS LETT, V121, P345, DOI 10.1016/0014-5793(80)80377-2; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PRYDZ K, 1986, J LIPID RES, V27, P622; PRYDZ K, 1988, J LIPID RES, V29, P997; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SMALL GM, 1993, PEROXISOMES BIOL IMP, P1; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1994, BIOCHEM J, V304, P195, DOI 10.1042/bj3040195; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WEBSTER LT, 1970, METHOD ENZYMOL, V77, P430; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	37	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18481	18489		10.1074/jbc.272.29.18481	http://dx.doi.org/10.1074/jbc.272.29.18481			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218493	hybrid			2022-12-27	WOS:A1997XL73500083
J	Wang, JJ; Gagne, SM; Sykes, BD; Ryan, RO				Wang, JJ; Gagne, SM; Sykes, BD; Ryan, RO			Insight into lipid surface recognition and reversible conformational adaptations of an exchangeable apolipoprotein by multidimensional heteronuclear NMR techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT APOLIPOPHORIN-III; SECONDARY STRUCTURE; LARGER PROTEINS; N-15-LABELED PROTEINS; IMPROVED SENSITIVITY; H-1-NMR ASSIGNMENTS; LOCUSTA-MIGRATORIA; AMPHIPATHIC HELIX; MANDUCA-SEXTA; SPECTROSCOPY	Apolipophorin III (apoLp-III) from the insect Manduca sexta is a 166-residue (M-r 18,340) member of the exchangeable apolipoprotein Glass that functions to stabilize lipid-enriched plasma lipoproteins, Hn the present study, we present the secondary structure and global fold of recombinant apoLp-III derived from three-dimensional heteronuclear NMR spectroscopy experiments. Five discrete alpha-helical segments (21-30 residues in length) with well defined boundaries were characterized by four NMR. parameters: medium range nuclear Overhauser enhancement contacts between proton pairs, chemical shift index, coupling constants, and amide, proton exchange rates, An antiparallel arrangement of helical segments has been obtained based an the long range interhelical nuclear Overhauser enhancement contacts. The NMR solution structure reveals a globular, up and down helix bundle organization similar to that of Locusta migratoria apoLp-III (Breiter, D. R., Kanost, M. R., Benning, M, M., Wesenberg, G., Law, J. H., Wells, M. A., Rayment, I., and Holden, H. M. (1991) Biochemistry 30, 603-608). However, a short helix (comprised of 5 amino, acids) has been identified ill the region between helix 3 and helix 4, This helix is postulated to play a role in lipid surface recognition and/or initiation of binding. Our results also indicate the existence of buried polar and charged residues in the helix bundle, providing a structural basis for the relatively low stability of apoLp-III in its Lipid-free state. It is suggested that the intrinsic low stability of lipid-free apoLp-III may be important in terms of its ability to undergo a reversible, lipid binding induced, conformational change, This study underscores the striking: resemblance in molecular architecture between insect apoLp-III and the N-terminal domain of human apolipoprotein E, The potential for application of NMR techniques to studies of the exchangeable apolipoprotein, possibly in their biologically active, lipid-associated state, has broad implications in terms of our understanding of the molecular basis of their physiological functions.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,MRC,GRP PROT STRUCT & FUNCT,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRESLOW JL, 1991, ANNU REV MED, V42, P357, DOI 10.1146/annurev.me.42.020191.002041; BUCHKO GW, 1995, PEPTIDE RES, V8, P86; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HARD K, 1993, BIOCHEMISTRY-US, V32, P766, DOI 10.1021/bi00054a005; Hoffman RC, 1996, J BIOMOL NMR, V7, P273; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LYCKSELL PO, 1992, EUR J BIOCHEM, V205, P223, DOI 10.1111/j.1432-1033.1992.tb16772.x; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; OHMAN A, 1993, EUR BIOPHYS J BIOPHY, V22, P351, DOI 10.1007/BF00213558; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; ROZEK A, 1995, BIOCHEMISTRY-US, V34, P7401, DOI 10.1021/bi00022a013; RYAN RO, 1995, J LIPID RES, V36, P1066; RYAN RO, 1993, J BIOL CHEM, V268, P1525; RYAN RO, 1996, BIOCH CELL BIOL, V75, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Wang GS, 1996, BBA-LIPID LIPID MET, V1301, P174, DOI 10.1016/0005-2760(96)00037-9; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; Wang JJ, 1997, TECH PROT CHEM, V8, P427, DOI 10.1016/S1080-8914(97)80043-9; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014; ZHU G, 1992, J MAGN RESON, V100, P202, DOI 10.1016/0022-2364(92)90379-L; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	53	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17912	17920		10.1074/jbc.272.29.17912	http://dx.doi.org/10.1074/jbc.272.29.17912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218415	hybrid			2022-12-27	WOS:A1997XL73500005
J	MacFarland, KJ; Shan, Q; Inman, RB; Cox, MM				MacFarland, KJ; Shan, Q; Inman, RB; Cox, MM			RecA as a motor protein - Testing models for the role of ATP hydrolysis in DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DUPLEX DNA; NUCLEOSIDE TRIPHOSPHATE; NUCLEOPROTEIN FILAMENTS; GENETIC-RECOMBINATION; PARTIAL DENATURATION; HETEROLOGOUS INSERT; BINDING; COMPLEXES; MECHANISM	ATP hydrolysis (by RecA protein) fundamentally alters the properties of RecA protein-mediated DNA strand exchange reactions, ATP hydrolysis renders DNA strand exchange unidirectional, greatly increases the lengths of hybrid DNA created, permits the bypass of heterologous DNA insertions in one or both DNA substrates, and is absolutely required for exchange reactions involving four DNA strands, There are at least two viable models to explain how ATP hydrolysis is coupled to DNA strand exchange so as to bring about these effects, The first couples ATP hydrolysis to a redistribution of RecA monomers within a RecA filament, The second couples ATP hydrolysis to a facilitated rotation of the DNA substrates. The RecA monomer redistribution model makes the prediction that heterology bypass should not occur if the single-stranded DNA substrate is linear, The facilitated DNA rotation model predicts that RecA protein should promote the separation of paired DNA strands within a RecA filament if one of them is contiguous with a length of DNA being rotated about the filament exterior, Here, a facile bypass of heterologous insertions with linear DNA substrates is demonstrated, providing evidence against a role for RecA monomer redistribution in heterology bypass, In addition, we demonstrate that following a four-strand DNA exchange reaction, a distal segment of DNA hundreds of base pairs in length can be unwound in a nonreciprocal phase of the reaction, consistent with the direct coupling of an ATP hydrolytic motor to the proposed DNA rotation.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 14711, GM 32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM032335, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1991, J BIOL CHEM, V266, P6499; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BIANCHI M, 1985, EMBO J, V4, P3025, DOI 10.1002/j.1460-2075.1985.tb04039.x; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; Cox M.M., 1989, P43; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; Ishimori K, 1996, J MOL BIOL, V264, P696, DOI 10.1006/jmbi.1996.0670; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; Kubista M, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 1, P49; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREL P, 1994, J BIOL CHEM, V269, P19830; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1987, J BIOL CHEM, V262, P1337; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898	52	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17675	17685		10.1074/jbc.272.28.17675	http://dx.doi.org/10.1074/jbc.272.28.17675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211918	hybrid			2022-12-27	WOS:A1997XK16500061
J	Zhang, H; Fan, SJ; Prochownik, EV				Zhang, H; Fan, SJ; Prochownik, EV			Distinct roles for MAX protein isoforms in proliferation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTEIN; CELL-CYCLE PROGRESSION; DNA-BINDING; ORNITHINE DECARBOXYLASE; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; ONCOGENIC ACTIVITY; REPRESSOR SIN3; GROWTH-FACTOR	MAX is a basic helix-loop-helix-leucine zipper protein that plays a central role in the transcriptional control of Myc oncoproteins. MYC-MAX heterodimers stimulate transcription, whereas MAX homodimers, or heterodimers between MAX and members of the MAD family of basic helix-loop-helix-leuciue zipper proteins, repress transcription, Max exists in two major isomeric forms, MAX(L) and MAX(S), which differ from one another only by a 9-amino acid insertion/deletion. We show here that MAX(L) is much more effective at homodimeric DNA binding than MAX(S). In NIH3T3 cells, MAX(L) was able to repress a c-Myc-responsive reporter gene whereas MAX(S) either stimulated the reporter gene or had little effect on its expression. Hn comparison to control cell lines or those stably over-expressing MAX(S), MAX(L)-over-expressing cell lines showed reduced expression of transiently expressed or endogenous c-Myc responsive genes, grew more slowly, possessed a higher growth factor requirement, and showed accelerated apoptosis following growth factor deprivation, Differential effects on growth and apoptosis represent two previously unrecognized properties of MAX proteins. These can at least partly be explained by the differences in their DNA binding abilities and their effects on target gents expression.	CHILDRENS HOSP PITTSBURGH, HEMATOL ONCOL SECT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, INST CANC, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL33741] Funding Source: Medline; PHS HHS [538572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIN SY, 1992, ONCOGENE, V7, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	58	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17416	17424		10.1074/jbc.272.28.17416	http://dx.doi.org/10.1074/jbc.272.28.17416			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211884	hybrid			2022-12-27	WOS:A1997XK16500027
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			Identification and reconstruction of the binding site within alpha(M)beta(2) for a specific and high affinity ligand, NIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN CR3 CD11B/CD18; I-DOMAIN; LEUKOCYTE ADHESION; CRYSTAL-STRUCTURE; RECOGNITION SITE; INHIBITOR NIF; A-DOMAIN; MAC-1; CD18; GLYCOPROTEIN	Engagement of the alpha(M) beta(2) (CD11b/CD18, Mac-1) integrin on neutrophils supports adhesion and induces various cellular responses. These responses can be blocked by a specific ligand of alpha M beta(2), neutrophil inhibitory factor (MF). The molecular basis of alpha(M) beta(2)-NIF interactions was studied. The single chain alpha(M) subunit, expressed on the surface of human 293 cells, bound NIF with an affinity equivalent to that of alpha(M) beta(2) heterodimer. This observation, coupled with previous data showing that the alpha(M)I domain alone supported high affinity NIF binding, indicated that the binding site for NIF is restricted to the I domain. Guided by the crystal structure of the alpha(M)I domain, 16 segments corresponding to the entire enter hydrated surface of alpha(M)I domain were switched to their counterparts sequences in alpha(L), which does not bind NIF. Surface expression and heterodimer formation were achieved for all mutants, and correct folding was confirmed. Of the 16 switches, only 5 affected NIF binding substantially, reducing affinity by 8-300-fold. These data confined the NIF-binding site to a narrow region composed of Pro(147)-Arg(152), Pro(201)-Lys(217), and Asp(248) Arg(261) of alpha(M). Verifying this localization, when these segments were introduced inter the alpha(X)I-domain, the resulting chimeric receptor was converted into a high affinity NIF-binding protein.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BAUER C, 1995, SHOCK, V4, P187, DOI 10.1097/00024382-199509000-00006; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; HOGG N, 1989, EMBO J, V8, P3759; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26149; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V867, P872; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	26	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17558	17564		10.1074/jbc.272.28.17558	http://dx.doi.org/10.1074/jbc.272.28.17558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211902	hybrid			2022-12-27	WOS:A1997XK16500045
J	Cowley, SM; Hoare, S; Mosselman, S; Parker, MG				Cowley, SM; Hoare, S; Mosselman, S; Parker, MG			Estrogen receptors alpha and beta form heterodimers on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAINS; CRYSTAL-STRUCTURE; BINDING DOMAIN; IDENTIFICATION; EXPRESSION; CELLS; ASSAY	The estrogen receptor (ER) is expressed in two forms, ER alpha and ER beta. Here we show that ER alpha and ER beta, expressed both in vitro and in vivo, form heterodimers which bind to DNA with an affinity (K-d of approximately 2 nM) similar to that of ER alpha and greater than that of ER beta homodimers. Mutation analysis of the hormone binding domain of ER alpha suggests that the dimerization interface required to form heterodimers with ER beta is very similar but not identical to that required for homodimer formation, The heterodimer, like the homodimers, are capable of binding the steroid receptor coactivator-1 when bound to DNA and stimulating transcription of a reporter gene in transfected cells, Given the relative expression of ER alpha and ER beta in tissues and the difference in DNA binding activity between ER alpha/ER beta heterodimers and ER beta it seems Likely that the heterodimer is functionally active in a subset of target cells.	IMPERIAL CANC RES FUND,MOL ENDOCRINOL LAB,LONDON WC2A 3PX,ENGLAND; NV ORGANON,DEPT BIOTECHNOL & BIOCHEM,NL-5340 BH OSS,NETHERLANDS	Cancer Research UK; University of London; Queen Mary University London; Merck & Company				Cowley, Shaun/0000-0002-2510-1305				BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ONATE SA, 1995, SCIENCE, V270, P1354; Parker M. G., 1995, V51, P267; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	30	553	580	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19858	19862		10.1074/jbc.272.32.19858	http://dx.doi.org/10.1074/jbc.272.32.19858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242648	hybrid			2022-12-27	WOS:A1997XQ05900035
J	Mauricio, L; Lima, LMTR; dePratGay, G				Mauricio, L; Lima, LMTR; dePratGay, G			Conformational changes and stabilization induced by ligand binding in the DNA-binding domain of the E2 protein from human papillomavirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FLUORESCENCE; RECOGNITION; HELIX	We are investigating the folding of the 81-residue recombinant dimeric DNA binding domain of the E2 protein from human papillomavirus and how it is coupled to the binding of its DNA ligand, Modifications in buffer composition, such as ionic strength and phosphate, cause an similar to 5.0 kcal mol(-1) stabilization of the domain to urea unfolding, based on very similar conformational changes as measured by far UV circular dichroism, Binding of DNA produces an even greater stabilization, magnitude similar to that caused by the nonspecific polymer ligand heparin, which shifts the urea midpoint 2.5-fold. The DNA-bound complex displays substantial changes similar to those caused by ionic strength and phosphate in terms of overall secondary structure, Bis-8-anilino-1-naphthalenesulfonate provides a very sensitive conformational probe, which shows alterations in the domain caused by the above mentioned compounds, In general terms, binding of DNA involves an overall conformational readjustment in the protein but maintains the beta-barrel scaffold intact, This conformational plasticity seems to be of importance in the regulatory functions of this type of DNA-binding protein, The extremely long half-life of the E2-DNA complex, together with its very high stability, suggests that, in the absence of other factors that may affect its stability in vivo, the possibility of dissociation once formed is restricted.	UNIV FED RIO DE JANEIRO, DEPT BIOQUIM MED, ICB, BR-21941590 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro			Lima, Luis Mauricio/AAL-2098-2021	Prat Gay, Gonzalo/0000-0001-5748-6863; TR Lima, Luis Mauricio/0000-0001-6020-0504				Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Boren K, 1996, PROTEIN SCI, V5, P2479, DOI 10.1002/pro.5560051210; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; Butler W L, 1979, Methods Enzymol, V56, P501; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; Dean FB, 1996, CURR BIOL, V6, P931, DOI 10.1016/S0960-9822(02)00629-2; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOWLEY PM, 1996, PAPILLOMAVIRINAE VIR, P2045; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PLOTKIN BJ, 1984, BIOCHEMISTRY-US, V23, P5353, DOI 10.1021/bi00317a038; RESTALL CJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P305, DOI 10.1016/0167-4838(86)90029-4; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SAHA R, 1992, J BIOL CHEM, V267, P5862; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; SPALHOLZ BA, 1988, J VIROL, V62, P3143, DOI 10.1128/JVI.62.9.3143-3150.1988; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAYLOR I, 1994, DNA PROTEIN INTERACT, P327; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WEBER G, 1954, BIOCHEM J, V56, pR31; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	31	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19295	19303		10.1074/jbc.272.31.19295	http://dx.doi.org/10.1074/jbc.272.31.19295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235925	hybrid			2022-12-27	WOS:A1997XP06300031
J	Stein, B; Yang, MX; Young, DB; Janknecht, R; Hunter, T; Murray, BW; Barbosa, MS				Stein, B; Yang, MX; Young, DB; Janknecht, R; Hunter, T; Murray, BW; Barbosa, MS			p38-2, a novel mitogen-activated protein kinase with distinct properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; NF-KAPPA-B; MAP KINASE; PHOSPHORYLATION; DOMAIN; IDENTIFICATION; TRANSCRIPTION; TRANSDUCTION; PATHWAYS; CASCADE	Mitogen-activated protein (MAP) kinases are involved in many cellular processes. Here we describe the cloning and characterization of a new MAP kinase, p38-2. p38-2 belongs to the p38 subfamily of MAP kinases and shares with it the TGY phosphorylation motif. The complete p38-2 cDNA was isolated by polymerase chain reaction. It encodes a 364-amino acid protein with 73% identity to p38, Two shorter isoforms missing the phosphorylation motif were identified. Analysis of various tissues demonstrated that p38-2 is differently expressed from p38. Highest expression levels were found in heart and skeletal muscle. Like p38, p38-2 is activated by stress-inducing signals and proinflammatory cytokines. The preferred upstream kinase is MEK6. Although p38-2 and p38 phosphorylate the same substrates, the site specificity of phosphorylation can differ as shown by two-dimensional phosphopeptide analysis of Sap-1a. Additionally, kinetic studies showed that p38-2 appears to be about 180 times more active than p38 on certain substrates such as ATF2. Both kinases are inhibited by a class of pyridinyl imidazoles. p38-2 phosphorylation of ATF2 and Sap-1a but not Elk1 results in increased transcriptional activity of these factors. A sequential kinetic mechanism of p38-2 is suggested by steady state kinetic analysis. In conclusion, p38-2 may be an important component of the stress response required for the homeostasis of a cell.	SALK INST,MOL BIOL & VIROL LAB,SAN DIEGO,CA 92186	Salk Institute	Stein, B (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN DR,SAN DIEGO,CA 92121, USA.			murray, brion/0000-0003-1591-2566; Janknecht, Ralf/0000-0003-1741-1562				Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cleland W W, 1979, Methods Enzymol, V63, P103; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLE PA, 1994, J BIOL CHEM, V269, P30880; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEGAL IH, 1975, ENZYME KINETICS BEHA, P643; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sen J, 1996, J IMMUNOL, V156, P4535; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stein B, 1996, ANNU REP MED CHEM, V31, P289, DOI 10.1016/S0065-7743(08)60468-6; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; VANDERGEER, 1994, CELL BIOL LAB HDB, V3, P422; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	61	145	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19509	19517		10.1074/jbc.272.31.19509	http://dx.doi.org/10.1074/jbc.272.31.19509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235954	hybrid			2022-12-27	WOS:A1997XP06300060
J	Puertollano, R; Li, SW; Lisanti, MP; Alonso, MA				Puertollano, R; Li, SW; Lisanti, MP; Alonso, MA			Recombinant expression of the MAL proteolipid, a component of glycolipid-enriched membrane microdomains, induces the formation of vesicular structures in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; EPITHELIAL-CELLS; PLASMA-MEMBRANE; MDCK CELLS; PROTEIN; CAVEOLAE; VESICLES; DOMAINS; DIFFERENTIATION; VIP21-CAVEOLIN	The MAL proteolipid has been identified as a component of glycolipid-enriched membrane microdomains resistant to detergent solubilization in epithelial Madin-Darby canine cells, as well as in T lymphocytes and in myelin-forming cells, To study the function of the MAL proteolipid we have ectopically expressed a tagged form of MAL in both mammalian and insect cellular backgrounds, Immunofluorescence analysis in transiently transfected COS-7 cells showed the presence of MAL in large vesicular structures, and biochemical analysis identified MAL in the fraction of membranes resistant to Triton X-100 solubilization, Electron microscopic analysis showed that the expression of MAL in Sf21 cells morphologically resulted in the intracellular accumulation of large vesicles with a diameter from 200 to greater than 700 nm that were absent in uninfected or control infected cultures, Thus, ectopic expression of MAL in this heterologous expression system was sufficient to drive the formation of vesicles with a size similar to that of the vesicles detected in mammalian cells, These vesicles were clearly different from the caveolae-like vesicles induced by caveolin expression, as evidenced by co-infection experiments using a recombinant caveolin baculovirus. Taken together, these results suggest that the MAL proteolipid might play a role as a component of the machinery of vesiculation of glycolipid-enriched membranes.	UNIV AUTONOMA MADRID,CTR BIOL MOL SEVERO OCHOA,CONSEJO SUPER INVEST CIENT,E-28049 MADRID,SPAIN; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael P/C-6866-2013; Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael/B-6131-2018; li, wj/HGD-7322-2022; Alonso, Miguel A/J-3945-2016	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382; Alonso, Miguel A/0000-0002-7001-8826	NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; ALONSO MA, 1988, IMMUNOGENETICS, V27, P91, DOI 10.1007/BF00351081; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Possee RD., 1992, BACULOVIRUS EXPRESSI; RANCANO C, 1994, J BIOL CHEM, V269, P8159; RANCANO C, 1994, GENOMICS, V21, P447, DOI 10.1006/geno.1994.1294; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P6407; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	33	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18311	18315		10.1074/jbc.272.29.18311	http://dx.doi.org/10.1074/jbc.272.29.18311			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218471	hybrid			2022-12-27	WOS:A1997XL73500061
J	Feron, O; Smith, TW; Michel, T; Kelly, RA				Feron, O; Smith, TW; Michel, T; Kelly, RA			Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; GUINEA-PIG; MEMBRANE; PROTEINS; CELLS; DESENSITIZATION; INTERNALIZATION; ENDOCYTOSIS; ANTIBODIES; MECHANISMS	In cardiac myocytes, as well as specialized conduction and pacemaker cells, agonist binding to muscarinic acetylcholine receptors (mAchRs) results in the activation of several sigma; transduction cascades including the endothelial isoform of nitric-oxide synthase (eNOS) expressed in these cells, Recent evidence indicates that, as in endothelial cells, eNOS in cardiac myocytes is localized to plasmalemma caveolae, specialized lipid microdomains that contain caveolin-3, a muscle-specific isoform of the scaffolding protein caveolin. In this report, using a detergent-free method for isolation of sarcolemmal caveolae from primary cultures of adult rat ventricular myocytes, we demonstrated that the muscarinic cholinergic agonist carbachol promotes the translocation of mAchR into low density gradient fractions containing most myocyte caveolin-3 and eNOS, Following isopycnic centrifugation, the different gradient fractions were exposed to the muscarinic radioligand [H-3]quinuclidinyl benzilate (QNB), and binding was determined after membrane filtration or immunoprecipitation, In a direct radioligand binding assay, we found that [H-3]QNB binding can be detected ill caveolin-enriched fractions only when cardiac myocytes have been previously exposed to carbachol, Furthermore, most of this [3H]QNB binding can be specifically immunoprecipitated by an antibody to the m2 mAchR, indicating that the translocation of this receptor subtype is responsible for the [H-3]QNB binding detected in the low density fractions, Moreover, the [H-3]QNB binding could be quantitatively immunoprecipitated from the light membrane fractions with a caveolin-3 antibody (but not a control IgG1 antibody), confirming that the m2 mAchR is targeted to caveolae after carbachol treatment, Importantly, atropine, a muscarinic cholinergic antagonist, did not induce translocation of m2 mAchR to caveolae and prevented receptor translocation in response to the agonist carbachol. Thus, dynamic targeting of sarcolemmal m2 mAchR to caveolae following agonist binding may be essential to initiate specific downstream signaling cascades in these cells.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	NHLBI NIH HHS [HL-52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Belhassen L, 1997, J BIOL CHEM, V272, P11198; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EGLEN RM, 1988, J PHARMACOL EXP THER, V247, P911; EVA C, 1990, J PHARMACOL EXP THER, V253, P257; FERON O, 1992, BRIT J PHARMACOL, V105, P480, DOI 10.1111/j.1476-5381.1992.tb14279.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GALLO MP, 1993, J PHYSIOL-LONDON, V471, P41, DOI 10.1113/jphysiol.1993.sp019890; Goldman PS, 1996, J BIOL CHEM, V271, P4215; HAN X, 1995, J GEN PHYSIOL, V106, P45, DOI 10.1085/jgp.106.1.45; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HO AKS, 1991, CELL SIGNAL, V3, P587, DOI 10.1016/0898-6568(91)90035-S; KORTH M, 1985, PFLUG ARCH EUR J PHY, V403, P266, DOI 10.1007/BF00583598; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTHIN GR, 1988, MOL PHARMACOL, V34, P327; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MUNTZ KH, 1994, TRENDS CELL BIOL, V6, P356; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SVOBODA P, 1994, EUR J BIOCHEM, V224, P455, DOI 10.1111/j.1432-1033.1994.00455.x; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; WOODWARD MP, 1978, P NATL ACAD SCI USA, V75, P4394, DOI 10.1073/pnas.75.9.4394	42	228	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17744	17748		10.1074/jbc.272.28.17744	http://dx.doi.org/10.1074/jbc.272.28.17744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211926	hybrid			2022-12-27	WOS:A1997XK16500069
J	Liu, MY; Gui, GJ; Wei, BD; Preston, JF; Oakford, L; Yuksel, U; Giedroc, DP; Romeo, T				Liu, MY; Gui, GJ; Wei, BD; Preston, JF; Oakford, L; Yuksel, U; Giedroc, DP; Romeo, T			The RNA molecule CsrB binds to the global regulatory protein CsrA and antagonizes its activity in Escherichia coli.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTOVORA SUBSP CAROTOVORA; GLYCOGEN BIOSYNTHESIS; COMPUTER-SIMULATION; GENE-EXPRESSION; N-(3-OXOHEXANOYL)-L-HOMOSERINE LACTONE; ANTISENSE RNA; ERWINIA; IDENTIFICATION; BACTERIA; PRODUCT	The RNA-binding protein CsrA (carbon storage regulator) is a new kind of global regulator, which facilitates specific mRNA decay. A recombinant CsrA protein containing a metal-binding affinity tag (CsrA-H6) was purified to homogeneity and authenticated by N-terminal sequencing, matrix-assisted laser desorption/ionization time of flight mass spectrometry, and other studies. This protein was entirely contained within a globular complex of approximately 18 CsrA-H6 subunits and a single similar to 350-nucleotide RNA, CsrB. cDNA cloning and nucleotide sequencing revealed that the csrB gene is located downstream from syd in the 64-min region of the Escherichia coli K-12 genome and contains no open reading frames. The purified CsrA-CsrB ribonucleoprotein complex was active in regulating glg (glycogen biosynthesis) gene expression in vitro, as was the RNA-free form of the CsrA protein. Overexpression of csrB enhanced glycogen accumulation in E. coti, a stationary phase process that is repressed by CsrA. Thus, CsrB RNA is a second component of the Csr system, which binds to CsrA and antagonizes its effects on gene expression. A model for regulatory inter actions in Csr is presented, which also explains previous observations on the homologous system in Erwinia carotovora. A highly repeated nucleotide sequence located within predicted stem-loops and other single-stranded regions of CsrB, CAGGA(U/A/C)G, is a plausible CsrA-binding element.	UNIV N TEXAS, HLTH SCI CTR, DEPT IMMUNOL & MICROBIOL, FT WORTH, TX 76107 USA; UNIV N TEXAS, HLTH SCI CTR, DEPT ANAT & CELL BIOL, FT WORTH, TX 76107 USA; UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, FT WORTH, TX 76107 USA; UNIV FLORIDA, DEPT MICROBIOL & CELL SCI, GAINESVILLE, FL 32611 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; State University System of Florida; University of Florida; Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIAID NIH HHS [AI 40187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; CHATTERJEE A, 1995, APPL ENVIRON MICROB, V61, P1959, DOI 10.1128/AEM.61.5.1959-1967.1995; CUI Y, 1995, J BACTERIOL, V177, P5108, DOI 10.1128/jb.177.17.5108-5115.1995; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; FLEISCHMANN MD, 1995, SCIENCE, V269, P796; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GULTYAEV AP, 1991, NUCLEIC ACIDS RES, V19, P2489, DOI 10.1093/nar/19.9.2489; GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HEINS JN, 1966, P NUCL ACID RES; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MY, 1995, J BACTERIOL, V177, P2663, DOI 10.1128/jb.177.10.2663-2672.1995; MCMASTER K, 1977, P NATL ACAD SCI USA, V11, P4835; Miller J.H., 1972, EXPT MOL GENETICS; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; MURATA H, 1994, APPL ENVIRON MICROB, V60, P3150, DOI 10.1128/AEM.60.9.3150-3159.1994; MURYAMA N, 1996, J MOL BIOL, V256, P483; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; ROMEO T, 1993, J BACTERIOL, V175, P5740, DOI 10.1128/JB.175.17.5740-5741.1993; ROMEO T, 1989, J BACTERIOL, V171, P2773, DOI 10.1128/jb.171.5.2773-2782.1989; ROMEO T, 1993, J BACTERIOL, V175, P4744, DOI 10.1128/JB.175.15.4744-4755.1993; Romeo T, 1996, RES MICROBIOL, V147, P505, DOI 10.1016/0923-2508(96)84004-6; SABNIS NA, 1995, J BIOL CHEM, V270, P29096, DOI 10.1074/jbc.270.49.29096; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT G, 1945, J BIOL CHEM, V161, P83; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGO JM, 1987, ELECTRON MICROS, P61; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; White D, 1996, GENE, V182, P221, DOI 10.1016/S0378-1119(96)00547-1; Yang HH, 1996, J BACTERIOL, V178, P1012, DOI 10.1128/jb.178.4.1012-1017.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	317	336	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17502	17510		10.1074/jbc.272.28.17502	http://dx.doi.org/10.1074/jbc.272.28.17502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211896	hybrid			2022-12-27	WOS:A1997XK16500039
J	Schleiff, E; Shore, GC; Goping, IS				Schleiff, E; Shore, GC; Goping, IS			Interactions of the human mitochondrial protein import receptor, hTom20, with precursor proteins in vitro reveal pleiotropic specificities and different receptor domain requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; SECONDARY STRUCTURE; YEAST MITOCHONDRIA; UNCOUPLING PROTEIN; INNER MEMBRANE; SIGNAL PEPTIDE; MOM19; POLYPEPTIDE; PREDICTION; INSERTION	Tom20 is part of a multiple component, dynamic complex that functions to import specific cytosolic proteins into or through the outer membrane of the mitochondrion, To analyze the contribution of Tom20 to precursor protein recognition, the cytosolic domain of the human mitochondrial import receptor, hTom20, has been expressed as a fusion protein with glutathione S-transferase and conditions established to measure specific interactions of the receptor component with precursor proteins in vitro, Reconstitution of receptor binding from purified components revealed that a prototypic matrix-destined precursor protein, pODHFR, interacts with Tom20 by a mechanism that is dependent on an active matrix targeting signal but does not require cytosolic components or ATP, Binding was influenced by both salt concentration and detergent, The effect of salt or detergent, however, varied for different precursor proteins, In particular, detergent selectively enhanced binding of pODHFR to receptor, possibly because of induced changes in the structure of the signal sequence, Finally, mutations were introduced into hTom20 which had a dramatic effect on binding of some precursor proteins but not on others, Taken together, the results suggest that; hTom20 recognizes and physically interacts with precursor proteins bearing a diverse array of topogenic sequences and that such pleiotropic specificity for these precursor proteins may involve different domains within the receptor molecule.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			Schleiff, Enrico/C-5105-2017	Schleiff, Enrico/0000-0002-0518-3489				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V131, P289, DOI 10.1016/0006-291X(85)91801-7; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Bomer U, 1996, FEBS LETT, V382, P153, DOI 10.1016/0014-5793(96)00156-1; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; EPAND RM, 1986, J BIOL CHEM, V261, P17; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Heins L, 1996, PLANT J, V9, P829, DOI 10.1046/j.1365-313X.1996.9060829.x; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LITHGOW T, 1995, J BIOL CHEM, V270, P14267, DOI 10.1074/jbc.270.24.14267; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; MCBRIDE HM, 1995, BBA-BIOMEMBRANES, V1237, P162, DOI 10.1016/0005-2736(95)00088-K; Millar DG, 1996, J BIOL CHEM, V271, P25823, DOI 10.1074/jbc.271.42.25823; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; STULTZ CM, 1993, PROTEIN SCI, V2, P305; WHITE JV, 1994, MATH BIOSCI, V119, P35, DOI 10.1016/0025-5564(94)90004-3; YI TM, 1993, J MOL BIOL, V232, P1117, DOI 10.1006/jmbi.1993.1464; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	47	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17784	17789		10.1074/jbc.272.28.17784	http://dx.doi.org/10.1074/jbc.272.28.17784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211931	hybrid			2022-12-27	WOS:A1997XK16500074
J	Shenoy, SK; Yu, L; Yu, CA				Shenoy, SK; Yu, L; Yu, CA			The smallest membrane anchoring subunit (QPs3) of bovine heart mitochondrial succinate-ubiquinone reductase - Cloning, sequencing, topology, and Q-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; ESCHERICHIA-COLI; BEEF-HEART; FLAVOPROTEIN SUBUNIT; FUMARATE REDUCTASE; DEHYDROGENASE; PROTEIN; COMPLEX; OXIDOREDUCTASE; IDENTIFICATION	The cDNA encoding the smallest membrane-anchoring subunit (QPs3) of bovine heart mitochondrial succinate-ubiquinone reductase was cloned and sequenced, This cDNA is 1330 base pairs long with an open reading frame of 474 base pairs that encodes the 103 amino acid residues of mature QPs3 and a 55-amino acid residue presequence. The cDNA insert has an 820-base pair long 3'-untranslated region, including a poly(A) tail. The molecular mass of QPs3, deduced from the nucleotide sequence, is 10,989 Pa. QPs3 is a very hydrophobic protein; the hydropathy plot of the amino acid sequence reveals three transmembrane helices, Previous photoaffinity labeling studies of succinate-ubiquinone reductase, using 3-azido-2-methyl-5-methoxy[H-3]-6-decyl-1,4- benzoquinone ([H-3]azido-Q), identified QPs3 as one of the putative Q-binding proteins in this reductase. An azido-Q-linked peptide with a retention time of 66 min is obtained by high performance liquid chromatography of the chymotrypsin digest of carboxymethylated and succinylated [H-3]azido Q-labeled QPs3 purified from labeled succinate-ubiquinone reductase by a procedure involving phenyl-Sepharose 4B column chromatography, preparative SDS-polyacrylamide gel electrophoresis, and acetone precipitation, The amino acid sequence of this peptide is NH2-L-N-P-C-S-A-M-D-Y-COOH, corresponding to residues 29-37, The structure of QPs3 in the inner mitochondrial membrane is proposed based on the hydropathy profile of the amino acid sequence, on the predicted tendencies to form alpha-helices and beta-sheets, and on immunobinding of Fab' fragment horseradish peroxidase conjugates prepared from antibodies against two synthetic peptides, corresponding to the NH, terminus region and the loop connecting helices 2 and 3 of QPs3, in mitoplasts and submitochondrial particles, The ubiquinone-binding domain in the proposed model of QPs3 is probably located at the end of transmembrane helix 1 toward the C-side of the mitochondrial inner membrane.	OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater			Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; BIRCHMACHIN MA, 1992, J BIOL CHEM, V267, P11553; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHU TW, 1987, J BIOL CHEM, V262, P12806; *CLONTECH, 1995, CLONT, V10, P4; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; COLE ST, 1982, EUR J BIOCHEM, V122, P479; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HARMON HJ, 1982, J BIOENERG BIOMEMBR, V14, P377, DOI 10.1007/BF00743065; HARMON HJ, 1976, BIOCHIM BIOPHYS ACTA, V440, P45, DOI 10.1016/0005-2728(76)90112-2; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HE DY, 1994, J BIOL CHEM, V269, P2292; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JENNER ER, 1973, Patent No. 3737516; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LI LB, 1991, BIOCHIM BIOPHYS ACTA, V1057, P215, DOI 10.1016/S0005-2728(05)80104-5; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Saruta F, 1996, BBA-BIOENERGETICS, V1276, P1, DOI 10.1016/0005-2728(96)00070-9; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; WEBER K, 1969, J BIOL CHEM, V244, P4406; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508; ZIEGLER DM, 1992, ARCH BIOC BIOPHYS, V97, P41	43	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17867	17872		10.1074/jbc.272.28.17867	http://dx.doi.org/10.1074/jbc.272.28.17867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211943	hybrid			2022-12-27	WOS:A1997XK16500086
J	Weber, JD; Cheng, J; Raben, DM; Gardner, A; Baldassare, JJ				Weber, JD; Cheng, J; Raben, DM; Gardner, A; Baldassare, JJ			Ablation of G(o) alpha overrides G(1) restriction point control through Ras/ERK/cyclin D1-CDK activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ACTIVATED PROTEIN-KINASE; BETA-GAMMA-SUBUNITS; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HUMAN CHROMOSOME-16; MAMMALIAN-CELLS; G1 PHASE; D1; RAS	We have generated stable IIC9 cell lines, Goa1 and Goa2, that overexpress full-length antisense G(o) alpha RNA, As shown previously, expression of antisense G(o) alpha RNA ablated the a subunit of the heterotrimeric G protein, G(o), resulting in growth in the absence of mitogen, To better understand this change in IIC9 phenotype, we have characterized the signaling pathway and cell cycle events previously shown to be important in control of IIC9 G(1)/S phase progression. In this paper we clearly demonstrate that ablation of G(o) alpha results in growth, constitutively active Ras/ERK, elevated expression of cyclin D1, and constitutively active cyclin D1-CDK complexes, all in the absence of mitogen, Furthermore, these characteristics were abolished by the transient overexpression of the transducin heterotrimeric G protein alpha subunit strongly suggesting the transformation of G(o) alpha-ablated cells involves G(o) beta gamma subunits. This is the first study to implicate a heterotrimeric G protein in tumor suppression.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT CELL & MOL BIOL,ST LOUIS,MO 63104; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Saint Louis University; Saint Louis University; Johns Hopkins University				Weber, Jason/0000-0002-1069-6983	NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AnamthawatJonsson K, 1996, CANCER GENET CYTOGEN, V88, P1, DOI 10.1016/0165-4608(95)00203-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BATES S, 1994, ONCOGENE, V9, P71; BIGGS PJ, 1995, NAT GENET, V11, P441, DOI 10.1038/ng1295-441; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; Cheng J, 1997, J BIOL CHEM, V272, P17312, DOI 10.1074/jbc.272.28.17312; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Doggett N A, 1996, Cytogenet Cell Genet, V72, P271; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; DOUGLASS EC, 1990, CYTOGENET CELL GENET, V53, P87, DOI 10.1159/000132901; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAURE M, 1994, J BIOL CHEM, V269, P7851; FILMUS J, 1994, ONCOGENE, V9, P3627; GRANA X, 1995, ONCOGENE, V11, P211; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUFF V, 1992, CANCER RES, V52, P6117; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KATO J, 1993, GENE DEV, V7, P331; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI Y, 1989, ONCOGENE, V4, P795; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MANDAHL N, 1994, J CANCER RES CLIN, V120, P707, DOI 10.1007/BF01194267; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McManus AP, 1996, CANCER GENET CYTOGEN, V87, P179, DOI 10.1016/0165-4608(95)00267-7; MURTAGH JJ, 1991, MOL CELL BIOL, V11, P1146, DOI 10.1128/MCB.11.2.1146; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TSUDA H, 1995, CANCER RES, V55, P3395; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Veronese ML, 1996, CANCER RES, V56, P728; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WEBER JD, 1997, IN PRESS BIOCH J; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Winston JT, 1996, ONCOGENE, V12, P127	48	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17320	17326		10.1074/jbc.272.28.17320	http://dx.doi.org/10.1074/jbc.272.28.17320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211869	hybrid			2022-12-27	WOS:A1997XK16500012
J	Bame, KJ; Danda, J; Hassall, A; Tumova, S				Bame, KJ; Danda, J; Hassall, A; Tumova, S			A beta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro - A role for heparan sulfate proteoglycan turnover in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-SURFACE; A4 PEPTIDE; BINDING; ACCUMULATION; PROTEOLYSIS; AGGREGATION; INHIBITION; AFFINITY; RELEASE	Alzheimer's disease is characterized by senile plaques composed of polymeric fibrils of beta amyloid (A beta), a 39-42-amino acid peptide formed after proteolytic processing of the amyloid precursor protein (beta APP). Heparan sulfate proteoglycans have been shown to colocalize with A beta in Alzheimer's disease brain, and experimental evidence indicates that the interactions between the proteoglycan and the peptide are important for the promotion, deposition, and/or persistence of the senile plaques. Studies in rat brain indicated that both the core protein and the heparan sulfate glycosaminoglycan chains are required for amyloid fiber formation and deposition in vivo (Snow, A. D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, Ra., Schreier, W. A., and Morgan, D. G. (1994) Neuron 12, 219-234), suggesting that one mechanism to prevent the formation of A beta-heparan sulfate proteoglycan complexes that lead to deposition of amyloid would be to degrade the proteoglycan. Normally, heparan sulfate proteoglycans are internalized and degraded to short glycosaminoglycans by intracellular heparanases. These reactions occur in the endosomal-lysosomal pathway, which is the same intracellular location where beta APP is processed to A beta. Using partially purified heparanase activities from Chinese hamster ovary cells we examined whether A beta(1-40) affects the catabolism of Chinese hamster ovary heparan sulfate glycosaminoglycans and proteoglycans in vitro. A beta(1-40) binds to both the long heparan sulfate glycosaminoglycans attached to core proteins and the short, heparanase-derived chains in a concentration-dependent and pH-dependent manner. When A beta(1-40) is added to heparanase assays, it prevents the partially purified activities from releasing heparan sulfate chains from core proteins and degrading them to short glycosaminoglycans; however, a large molar excess of the peptide to heparan sulfate is required to see the effect. Our results suggest that normally the levels of A beta in the endosomal pathway are not sufficient to interfere with heparanase activity in vivo. However, once the level of A beta-peptides are elevated, as they are in Alzheimer's disease, they could interact with heparan sulfate proteoglycans and prevent their catabolism. This could promote the formation and deposition of amyloid, since the binding of A beta to the proteoglycan species will predominate.			Bame, KJ (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV MOL BIOL & BIOCHEM,KANSAS CITY,MO 64110, USA.		Tumova, Sarka/AAD-6353-2019	Tumova, Sarka/0000-0003-2044-4998				Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAUKER JH, 1987, J BIOL CHEM, V262, P13093; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1991, ANAL BIOCHEM, V195, P238, DOI 10.1016/0003-2697(91)90323-L; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; BURDICK D, 1992, J BIOL CHEM, V267, P546; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Tumova S, 1997, J BIOL CHEM, V272, P9078; YAMISHIRO DJ, 1987, J CELL BIOL, V105, P2723; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	42	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17005	17011		10.1074/jbc.272.27.17005	http://dx.doi.org/10.1074/jbc.272.27.17005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202014	hybrid			2022-12-27	WOS:A1997XH44600046
J	Faux, MC; Scott, JD				Faux, MC; Scott, JD			Regulation of the AKAP79-protein kinase C interaction by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; POSTSYNAPTIC DENSITIES; ANCHORING PROTEINS; CALCIUM CALMODULIN; BINDING-PROTEIN; MARCKS; PHOSPHATIDYLSERINE; PHOSPHORYLATION; LOCALIZATION; SUBSTRATE	The A kinase-anchoring protein AKAP79 coordinates the location of the cAMP-dependent protein kinase (protein kinase A), calcineurin, and protein kinase C (PKC) at the postsynaptic densities in neurons, Individual enzymes in the AKAP79 signaling complex are regulated by distinct second messenger signals; however, both PKC and calcineurin are inhibited when associated with the anchoring protein, suggesting that additional regulatory signals must be required to release active enzyme. This report focuses on the regulation of AKAP79-PKC interaction by calmodulin. AKAP79 binds calmodulin with high affinity (K-D of 28 +/- 4 nM (n = 3)) in a Ca2+-dependent. manner. Immunofluorescence staining shows that both proteins exhibit overlapping staining patterns in cultured hippocampal neurons. Calmodulin reversed the inhibition of PKC beta II by the AKAP79(31-52) peptide and reduced inhibition by the fun-length AKAP79 protein. The effect of calmodulin on inhibition of a constitutively active PKC fragment by the AKAP79(31-52) peptide was shown to be partially dependent on Ca2+, Ca2+/calmodulin reduced PKC coimmunoprecipitated with AKAP79 and resulted in a 2.6 +/- 0.5-fold (n = 6) increase in PKC activity in a preparation of postsynaptic densities. Collectively, these findings suggest that Ca2+/calmodulin competes with PKC for binding to AKAP79, releasing the inhibited kinase from its association with the anchoring protein.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NIGMS NIH HHS [GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DAVIES RD, 1994, TECH PROTEIN CHEM, V5, P2985; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FAUX MC, 1996, CELL, V70, P8; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P40; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SARKAR D, 1984, J BIOL CHEM, V259, P9840; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF M, 1986, BIOCHEM BIOPH RES CO, V140, P691, DOI 10.1016/0006-291X(86)90787-4; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	38	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17038	17044		10.1074/jbc.272.27.17038	http://dx.doi.org/10.1074/jbc.272.27.17038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202019	hybrid			2022-12-27	WOS:A1997XH44600051
J	Wang, MH; Julian, FM; Breathnach, R; Godowski, PJ; Takehara, T; Yoshikawa, W; Hagiya, M; Leonard, EJ				Wang, MH; Julian, FM; Breathnach, R; Godowski, PJ; Takehara, T; Yoshikawa, W; Hagiya, M; Leonard, EJ			Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; AMINO-ACID-SEQUENCE; TYROSINE KINASE; SCATTER FACTOR; EXTRACELLULAR DOMAIN; MOLECULAR EVOLUTION; GENE-PRODUCT; FAMILY; ACTIVATION; EXPRESSION	Macrophage stimulating protein (MSP) is a 78-kDa disulfide-linked heterodimer belonging to the plasminogen-related kringle protein family. MSP activates the RON receptor protein-tyrosine kinase, which results in cell migration, shape change, or proliferation. A structure-activity study of MSP was performed using pro-MSP, MSP, MSP alpha and beta chains, and a complex including the first two kringles and IgG Fc (MSP-NK2). Radioiodinated MSP and MSP beta chain both bound specifically to RON. The K-d of 1.4 nM for MSP beta chain is higher than the reported K-d range of 0.6-0.8 nM for MSP. Pro-MSP, MSP alpha chain, and MSP-NK2 did not bind. Only MSP stimulated RON autophosphorylation. Although the beta chain bound to RON and partially inhibited MSP-induced RON phosphorylation in kidney 293 cells, it did not induce RON phosphorylation. Pro-MSP, MSP alpha chain, or MSP-NK2 failed to activate RON, consistent with their inability to bind to the RON receptor. Functional studies showed that only MSP induced cell migration, and shape change in resident macrophages, and growth of murine keratinocytes. Our data indicate that the primary receptor binding domain is located in a region of the MSP beta chain, in contrast to structurally similar hepatocyte growth factor, in which the receptor binding site is in the alpha chain. However, full activation of RON requires binding of the complete MSP disulfide-linked alpha beta chain heterodimer.	NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; IMMUNOTECH SA,ANTIBODY DEPT,F-13276 MARSEILLE 09,FRANCE; INST BIOL,INSERM U211,F-44035 NANTES 01,FRANCE; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; TOYOBO CO LTD,OTSU,SHIGA 52002,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm); Roche Holding; Genentech; Toyobo Co., Ltd			Breathnach, Richard/K-7599-2015					Banu N, 1996, J IMMUNOL, V156, P2933; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Broxmeyer HE, 1996, ANN HEMATOL, V73, P1, DOI 10.1007/s002770050192; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PADMANABHAN K, 1994, PROTEIN SCI, V3, P898; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	34	58	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16999	17004		10.1074/jbc.272.27.16999	http://dx.doi.org/10.1074/jbc.272.27.16999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202013	hybrid			2022-12-27	WOS:A1997XH44600045
J	Mangiarotti, G; Chiaberge, S				Mangiarotti, G; Chiaberge, S			Reconstitution of functional eukaryotic ribosomes from Dictyostelium discoideum ribosomal proteins and RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; YEAST; BIOGENESIS	40 and 60 S ribosomal subunits have been reconstituted in vitro from purified ribosomal RNA and ribosomal proteins of Dictyostelium discoideum. The functionality of the reconstituted ribosomes was demonstrated in in vitro mRNA-directed protein synthesis. The reassembly proceeded well with immature precursors of ribosomal RNA but poorly if at all with mature cytoplasmic RNA species. Reassembly also required a preparation of small nuclear RNA(s), acting as morphopoietic factor(s).			Mangiarotti, G (corresponding author), UNIV TURIN, OSPED SAN LUIGI GONZAGA, DEPT CLIN & BIOL SCI, REG GONZOLE 10, I-10043 ORBASSANO, ITALY.							AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BATTSYOUNG B, 1977, J BIOL CHEM, V252, P3952; CECCARELLI A, 1978, FEBS LETT, V93, P348, DOI 10.1016/0014-5793(78)81137-5; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; England T E, 1980, Methods Enzymol, V65, P65; FRANKEL G, 1977, J MOL BIOL, V109, P539, DOI 10.1016/S0022-2836(77)80090-9; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; IWABUCHI M, 1971, BIOCHIM BIOPHYS ACTA, V228, P693, DOI 10.1016/0005-2787(71)90734-9; KLOOTWIJK J, 1989, METHOD ENZYMOL, V180, P96; LIGEROU Z, 1966, SCIENCE, V272, P268; LINDHAL T, 1973, NATURE, V221, P132; MANGIARO.G, 1968, BIOCHEMISTRY-US, V7, P456, DOI 10.1021/bi00841a058; MANGIAROTTI G, 1975, NATURE, V253, P569, DOI 10.1038/253569a0; MANGIAROTTI G, 1981, NUCLEIC ACIDS RES, V9, P947, DOI 10.1093/nar/9.4.947; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1983, NATURE, V301, P616, DOI 10.1038/301616a0; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1974, NATURE, V247, P147, DOI 10.1038/247147a0; MARUTA H, 1971, J MOL BIOL, V61, P123, DOI 10.1016/0022-2836(71)90210-5; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; PENMAN S, 1977, J MOL BIOL, V20, P115; RAMAGOPAL S, 1980, EUR J BIOCHEM, V105, P245, DOI 10.1111/j.1432-1033.1980.tb04495.x; RAUE HA, 1995, GENE EXPRESSION, V5, P71; RAUE HA, 1991, PROG NUCLEIC ACID RE, V41, P89; SANCHEZ E, 1995, EUR J BIOCHEM, V233, P809, DOI 10.1111/j.1432-1033.1995.809_3.x; Sanchez ME, 1996, BBA-PROTEIN STRUCT M, V1292, P140; SONNEMAN J, 1933, FEBS LETT, V329, P183; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P275, DOI 10.1016/0005-2787(76)90302-6; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; TURCO E, 1974, BIOCHEMISTRY-US, V13, P4752, DOI 10.1021/bi00720a011; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19682	19687		10.1074/jbc.272.32.19682	http://dx.doi.org/10.1074/jbc.272.32.19682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242623	hybrid			2022-12-27	WOS:A1997XQ05900010
J	Zhou, TQ; Rosen, BP				Zhou, TQ; Rosen, BP			Tryptophan fluorescence reports nucleotide-induced conformational changes in a domain of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; BINDING SITE; MUTAGENESIS; SUBUNITS; SEQUENCE; GENES; PUMP	The ars operon of plasmid R773 encodes an ATP-dependent extrusion pump for arsenite and antimonite in Escherichia coli, The ArsA ATPase is the catalytic subunit of the pump protein, with two nucleotide binding consensus sequences, one in the NH2-terminal half and one in the COOH-terminal half of the protein, A la-residue consensus sequence (DTAPTGHTIRLL) has been identified in ArsA homologs from eubacteria, archebacteria, fungi, plants, and animals, ArsA enzymes were constructed containing single tryptophan residues at either end of this conserved sequence, The emission spectrum of the fluorescence of the tryptophan on the COOH-terminal end (Trp-159) indicated a relatively hydrophilic environment for this residue, An increase in intrinsic tryptophan fluorescence and a blue shift of the maximum emission wavelength were observed upon addition of MgATP, indicating movement of Trp-P59 into a relatively less polar environment, No fluorescence response was observed with MgADP, with nonhydrolyzable ATP analogs, or with MgATP by catalytically inactive enyzmes, This suggests that the location Trp-159 is shifted only during hydrolysis of ATP, In contrast, the emission spectrum of Trp-141, located on the NH2-terminal side of the consensus sequence, indicated a reliatively nonpolar environment, The maximum emission wavelength red shifted upon addition of MgADP, MgATP slowly produced a response that correlated with product formation, suggesting that the environment of Trp-141 is sensitive only to MgADP binding, Thus, during ATP hydrolysis the COOH-terminal end of the conserved domain moves into a less polar Environment, whereas the NH2-terminal end moves into a more hydrophilic environment as product is formed, A hypothesis is presented in which the conserved domain of ArsA and homologs is an energy transduction domain involved in transmission of the energy of ATP hydrolysis to biological functions such as transport.	WAYNE STATE UNIV, DEPT BIOCHEM & MOL BIOL, SCH MED, DETROIT, MI 48201 USA	Wayne State University			Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; Boskovic J, 1996, YEAST, V12, P1377, DOI 10.1002/(SICI)1097-0061(199610)12:13<1377::AID-YEA35>3.0.CO;2-R; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHUNG S, 1994, PHOTOSYNTH RES, V41, P261, DOI 10.1007/BF02184167; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; Dijkstra DS, 1996, BIOCHEMISTRY-US, V35, P6628; Fiske CH, 1925, J BIOL CHEM, V66, P375; Kaneko T, 1996, DNA Res, V3, P109; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1992, J BIOL CHEM, V267, P19272; KurdiHaidar B, 1996, GENOMICS, V36, P486, DOI 10.1006/geno.1996.0494; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; MEI-HSU C, 1991, Journal of Biological Chemistry, V266, P2327; RAYNAL M, 1993, ARABIDOPSIS THALIANA; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SULTSON J, 1992, NATURE, V356, P37; THEOPHILUS BDM, 1987, NUCLEIC ACIDS RES, V15, P7443, DOI 10.1093/nar/15.18.7443; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1994, J BIOL CHEM, V269, P11261; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042	30	66	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19731	19737		10.1074/jbc.272.32.19731	http://dx.doi.org/10.1074/jbc.272.32.19731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242630	hybrid			2022-12-27	WOS:A1997XQ05900017
J	Burnham, CE; Amlal, H; Wang, ZH; Shull, GE; Soleimani, M				Burnham, CE; Amlal, H; Wang, ZH; Shull, GE; Soleimani, M			Cloning and functional expression of a human kidney Na+:HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; BASOLATERAL MEMBRANE-VESICLES; NA+-HCO3 COTRANSPORTER; CELLS; PH; BICARBONATE; TRANSPORTERS; LOCALIZATION; EXCHANGERS; MECHANISMS	Several modes of HCO3- transport occur in the kidney, including Na+-independent Cl/HCO3- exchange (mediated by the AE family of Cl-/HCO3- exchangers), sodium-dependent Cl-/HCO3-, exchange, and Na+:HCO3- cotransport. The functional similarities between the Na+ coupled HCO3- transporters and the AE isoforms (i.e. transport of HCO3- and sensitivity to inhibition by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid) suggested a strategy for cloning the other transporters based on structural similarity with the AE family, An expressed sequence tag encoding part of a protein that is related to the known anion exchangers was identified in the GenBank(TM) expressed sequence tag data base and used to design an oligonucleotide probe, This probe was used to screen a human kidney cDNA library, Several clones were identified, isolated, and sequenced, Two overlapping cDNA clones were spliced together to form a 7.6-kilobase cDNA that contained the entire coding region of a novel protein, Based on the deduced amino acid sequence, the cDNA encodes a protein with a M-r of 116,040. The protein has 29% identity with human brain AE3. Northern blot analysis reveals that the 7.6-kilobase mRNA is highly expressed in kidney and pancreas, with detectable levels in brain. Functional studies in transiently transfected HEK-293 cells demonstrate that the cloned transporter mediates Na+:HCO3- cotransport.	UNIV CINCINNATI,SCH MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,SCH MED,DEPT INTERNAL MED,CINCINNATI,OH 45267; VET AFFAIRS MED CTR,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center					NIDDK NIH HHS [DK 50594, DK 46789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK046789, R01DK050594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; Amlal H, 1997, BBA-BIOMEMBRANES, V1323, P319, DOI 10.1016/S0005-2736(96)00200-3; ARONSON PS, 1991, SEMIN NEPHROL, V11, P28; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; RUIZ OS, 1992, AM J PHYSIOL, V262, pF560, DOI 10.1152/ajprenal.1992.262.4.F560; SOLEIMANI M, 1995, J INVEST MED, V43, P419; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; TALOR Z, 1987, EUR J BIOCHEM, V164, P695, DOI 10.1111/j.1432-1033.1987.tb11182.x; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	23	161	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19111	19114		10.1074/jbc.272.31.19111	http://dx.doi.org/10.1074/jbc.272.31.19111			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235899	hybrid			2022-12-27	WOS:A1997XP06300005
J	Li, SW; Nakamura, S; Hattori, S				Li, SW; Nakamura, S; Hattori, S			Activation of R-Ras GTPase by GTPase activating proteins for Ras, Gap1(m), and p120GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; PC12 CELLS; PRODUCT; DOMAIN; GAP; IDENTIFICATION; PURIFICATION; STIMULATION	The enzymatic properties of Gap1(m) were characterized using three Ras and R-Ras proteins as substrates and were compared with those of p120GAP. Gap1(m) stimulated the GTPase of Ras better than that of R-Ras, in contrast to p120GAP which promoted the GTPase of R-Ras better than that of Ras, The EC50 values of Gap1(m) for Ha-Ras and R-Ras were 0.48 +/- 0.02 and 1.13 +/- 0.12 nM, respectively, whereas the EC50 values of p120GAP for Ha-Ras and R-Ras were 23.1 +/- 1.9 and 3.86 +/- 0.38 nM, respectively, The affinities of Gap1(m) and p120GAP to the substrates determined by competitive inhibition by using Ha-Ras.GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)) or R-Ras.GTP gamma S as a competitor agreed well with the substrate specificities of these GTPase-activating proteins, The K-m values of Gap1(m) for Ha-Ras and R-Ras were 1.53 +/- 0.27 and 3.38 +/- 0.53 mu M, respectively, which were lower than that of p120GAP for Ha-Ras (145 +/- 11 mu m) by almost 2 orders of magnitude, The high affinity of Gap1(m) to the substrates and its membrane localization suggest that Gap1(m) may act as a regulator of the basal activity of Ha-Ras and R-Bas.	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Bryant SS, 1996, J BIOL CHEM, V271, P5195; COX AD, 1994, ONCOGENE, V9, P3281; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DAVIS MM, 1993, GENE, V134, P305, DOI 10.1016/0378-1119(93)90114-I; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HATTORI S, 1992, ONCOGENE, V7, P481; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; REY I, 1994, ONCOGENE, V9, P685; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIROUZU M, 1992, ONCOGENE, V7, P475; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YAO R, 1995, ONCOGENE, V11, P1607; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	33	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19328	19332		10.1074/jbc.272.31.19328	http://dx.doi.org/10.1074/jbc.272.31.19328			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235929	hybrid			2022-12-27	WOS:A1997XP06300035
J	Newham, P; Craig, SE; Seddon, GN; Schofield, NR; Rees, A; Edwards, RM; Jones, EY; Humphries, MJ				Newham, P; Craig, SE; Seddon, GN; Schofield, NR; Rees, A; Edwards, RM; Jones, EY; Humphries, MJ			alpha 4 integrin binding interfaces on VCAM-1 and MAdCAM-1 - Integrin binding footprints identify accessory binding sites that play a role in integrin specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; AMINO-ACID-RESIDUES; PLASMA FIBRONECTIN; CRYSTAL-STRUCTURE; COUNTER-RECEPTOR; SPLICED DOMAIN; IDENTIFICATION; SEQUENCE; VLA-4; CLONING	Integrins are a family of heterodimeric adhesion receptors that mediate cellular interactions with a range of matrix components and cell surface proteins. Vascular cell adhesion molecule-l (VCAM-1) is an endothelial cell ligand for two leukocyte integrins (alpha 4 beta 1 and alpha 4 beta 7). A related CAM, mucosal addressin cell adhesion molecule-l (MAdCAM-1) is recognized by alpha 4 beta 7 but is a poor ligand for alpha 4 beta 1. Previous studies have revealed that all alpha 4 integrin-ligand interactions are dependent on a key acidic ligand motif centered on the CAM domain 1 C-D loop region. By generating VCAM-1/MAdCAM-1 chime ras and testing recombinant proteins in cell adhesion assays we have found that alpha 4 beta 1 binds to the MAdCAM-1 adhesion motif when present in VCAM-1, but not when the VCAM-1 motif was present in MAdCAM-1, suggesting that this region does not contain all of the information necessary to determine integrin binding specificity. To characterize integrin-CAM specificity further we measured alpha 4 beta 1 and alpha 4 beta 7 binding to a comprehensive set of mutant VCAM-1 constructs containing amino acid substitutions within the predicted integrin adhesion face. These data revealed the presence of key ''regulatory residues'' adjacent to integrin contact sites and an important difference in the ''footprint'' of alpha 4 beta 1 and alpha 4 beta 7 that was associated with an accessory binding site located in VCAM-1 Ig domain 2. The analogous region in MAdCAM-1 is markedly different in size and sequence and when mutated abolishes integrin binding activity.	ZENECA PHARMACEUT,MACCLESFIELD SK10 4TF,CHESHIRE,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND; UNIV OXFORD,MOL BIOPHYS LAB,OXFORD CTR MOL SCI,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford	Newham, P (corresponding author), UNIV MANCHESTER,WELLCOME TRUST CTR CELL MATRIX RES,SCH BIOL SCI,2-205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.		Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Briskin MJ, 1996, J IMMUNOL, V156, P719; BRISKIN MJ, 1993, NATURE, V363, P61; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHIU HH, 1995, J IMMUNOL, V155, P5257; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; ERLE DJ, 1994, J IMMUNOL, V153, P517; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LI R, 1993, J BIOL CHEM, V268, P17513; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NEWHAM P, 1992, BIOCHEM SOC T, V21, pS339; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Shyjan AM, 1996, J IMMUNOL, V156, P2851; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STRAUCH UG, 1994, INT IMMUNOL, V6, P263, DOI 10.1093/intimm/6.2.263; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	55	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19429	19440		10.1074/jbc.272.31.19429	http://dx.doi.org/10.1074/jbc.272.31.19429			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235944	hybrid			2022-12-27	WOS:A1997XP06300050
J	Micol, V; FernandezSilva, P; Attardi, G				Micol, V; FernandezSilva, P; Attardi, G			Functional analysis of in vivo and in organello footprinting of HeLa cell mitochondrial DNA in relationship to ATP and ethidium bromide effects on transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-STRAND TRANSCRIPTION; PROTEIN-BINDING; RIBOSOMAL-RNA; HEAVY-STRAND; INVITRO TRANSCRIPTION; IDENTIFICATION; PROMOTER; INITIATION; SITES; TERMINATION	In vivo and in organello footprinting techniques based on methylation interference have been utilized to investigate protein-DNA interactions in the transcription initiation and rDNA transcription termination regions of human mitochondrial DNA (mtDNA) in functionally active mitochondria, In particular, the changes in methylation reactivity of these regions in response to treatment of the organelles with ATP or ethidium bromide, which affects differentially the rates of mitochondrial rRNA and mRNA synthesis, have been analyzed, Two major sites of protein-DNA interactions have been identified in the main control region of mtDNA, both in vivo and in organello, which correspond to the regions of the light-strand promoter and heavy-strand rRNA-specific promoter, The in organello footprinting of the latter showed ATP- and ethidium bromide-dependent modifications that could be correlated with changes in the rate of rRNA but not of mRNA synthesis, By contrast, no ATP effects were observed on the in organello footprinting pattern of the termination region and on in vitro transcription termination, strongly suggesting that ATP control of rRNA synthesis occurs at the initiation level, Several methylation interference sites were found upstream of the whole H-strand transcription unit, pointing to possible protein-DNA interactions related to the activity of this unit, In vivo footprinting of the rDNA transcription termination region of human mtDNA has revealed a very strong protection pattern, indicating a high degree of occupancy of the termination site by mitochondrial transcription termination factor (similar to 80%).	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Silva, Patricio Fernandez/U-2256-2017; Micol, Vicente/K-6841-2014	Silva, Patricio Fernandez/0000-0001-8971-7355; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammini C V, 1996, Methods Enzymol, V264, P23, DOI 10.1016/S0076-6879(96)64005-1; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOGENHAGEN DF, 1984, CELL, V36, P1105, DOI 10.1016/0092-8674(84)90061-8; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CANTATORE P, 1987, FEBS LETT, V213, P144, DOI 10.1016/0014-5793(87)81480-1; CANTATORE P, 1995, J BIOL CHEM, V270, P25020, DOI 10.1074/jbc.270.42.25020; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHOMYN A, 1992, MOL MECHANISMS BIOEN, P483; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGA A, 1993, J BIOL CHEM, V268, P8123; Enriquez JA, 1996, EUR J BIOCHEM, V237, P601, DOI 10.1111/j.1432-1033.1996.0601p.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FABER S, 1993, J BIOL CHEM, V268, P24976; Fernandez-Silva P, 1996, Methods Enzymol, V264, P129, DOI 10.1016/S0076-6879(96)64014-2; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HIXSON JE, 1985, P NATL ACAD SCI USA, V82, P2660, DOI 10.1073/pnas.82.9.2660; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; MADSEN CS, 1993, MOL CELL BIOL, V13, P2162, DOI 10.1128/MCB.13.4.2162; Micol V, 1996, Methods Enzymol, V264, P3, DOI 10.1016/S0076-6879(96)64003-8; Micol V, 1996, Methods Enzymol, V264, P158, DOI 10.1016/S0076-6879(96)64017-8; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5; YOZA BK, 1984, J BIOL CHEM, V259, P3909	43	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18896	18904		10.1074/jbc.272.30.18896	http://dx.doi.org/10.1074/jbc.272.30.18896			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228068	hybrid, Green Accepted			2022-12-27	WOS:A1997XM34200059
J	Saenko, EL; Scandella, D				Saenko, EL; Scandella, D			The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VIII; SURFACE-PLASMON RESONANCE; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; ANTIHEMOPHILIC-FACTOR; FACTOR-X; ACTIVATION; CLEAVAGE; THROMBIN; PORCINE	A binding site for von Willebrand factor (vWf) was previously localized to the carboxyl terminus of the C2 domain of the light chain (LCh) of factor VIII (fVIII). Time acidic region of the LCh, residues 1649-1689, arise controls fVIII vWf binding by an unknown mechanism, Although anti-acidic region monoclonal antibodies prevent formation of the fVIII-vWf complex, the direct involvement of the acidic region in this binding has not been demonstrated, By limited proteolysis of LCh with Staphylococcus aureus V8 protease, we prepared 14- and 63-kDa LCh fragments, which begin with fVIII residues 1672 and 1795, respectively, Using surface plasmon resonance to measure binding interactions, we demonstrated that the 14-kDa fragment binds to vWf, but its affinity for vWf (K-d 72 nM) was 19-fold lower than that of LCh, This was not due to an altered conformation of the acidic region within the 14-kDa fragment,since its affinity for an anti-acidic region monoclonal antibody was similar to that of LCh. All LCh derivatives lacking the acidic region (thrombin-cleaved LCh, recombinant C2, and 63-kDa fragment) had also greatly reduced affinities for vWf (K-d 564-660 nM) compared with LCh (K-d 3.8 nM). In addition, the similar affinities of these derivatives for vWf indicated that apart from its acidic region, the LCh contains no vWf binding site other than the one within C2, The reduced affinities of the LCh derivatives lacking the acidic region for monoclonal antibody NMC-VIII/5 (epitope, C2 residues 2170-2327) indicated that removal of the acidic region leads to a conformational change within C2, This change is likely to affect the conformation of the vWf binding site in C2, which overlaps the epitope of NMC-VIII/5; therefore, the acidic region also appears to be required to maintain the optimal conformation of this vWf binding site, Our results demonstrate that the acidic region and the C2 domain are both directly involved in forming a high affinity binding site for vWf.	AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL055273, R01HL036099] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55273, P50-HL44336, HL36099] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FOSTER PA, 1990, THROMB HAEMOSTASIS, V63, P403; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KOPPELMAN SJ, 1994, J LAB CLIN MED, V123, P585; LAVERGNE JM, 1993, BIOCHEM BIOPH RES CO, V194, P1019, DOI 10.1006/bbrc.1993.1923; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; MCMULLEN BA, 1995, PROTEIN SCI, V4, P740; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NISHINO M, 1989, BLOOD, V74, P1591; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PIENEMAN WC, 1993, THROMB HAEMOSTASIS, V69, P473; PRECUP JW, 1991, BLOOD, V77, P1929; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SAENKO EL, 1995, J BIOL CHEM, V270, P13286; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SHIMA M, 1992, BRIT J HAEMATOL, V81, P533, DOI 10.1111/j.1365-2141.1992.tb02988.x; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VLOT AJ, 1995, BLOOD, V85, P3150, DOI 10.1182/blood.V85.11.3150.bloodjournal85113150; Vlot AJ, 1996, BLOOD, V87, P1809; WISE RJ, 1991, J BIOL CHEM, V266, P21948; YEUNG D, 1995, TRAC-TREND ANAL CHEM, V14, P49, DOI 10.1016/0165-9936(95)91472-5	46	157	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18007	18014		10.1074/jbc.272.29.18007	http://dx.doi.org/10.1074/jbc.272.29.18007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218428	hybrid			2022-12-27	WOS:A1997XL73500018
J	DeSmedt, F; Missiaen, L; Parys, JB; Vanweyenberg, V; DeSmedt, H; Erneux, C				DeSmedt, F; Missiaen, L; Parys, JB; Vanweyenberg, V; DeSmedt, H; Erneux, C			Isoprenylated human brain type I inositol 1,4,5-trisphosphate 5-phosphatase controls Ca2+ oscillations induced by ATP in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; SMOOTH-MUSCLE CELLS; RAT-BRAIN; POLYPHOSPHATE 5-PHOSPHATASE; BOVINE BRAIN; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; 3-KINASE ACTIVITY; ESCHERICHIA-COLI; KINASE-ACTIVITY	D-myo-Inositol 1,4,5-trisphosphate (InsP(3)) 5-phosphatase and 3-kinase are thought to be critical regulatory enzymes in the control of InsP(3) and Ca2+ signaling, In brain and many other cells, type I InsP(3) B-phosphatase is the major phosphatase that dephosphorylates InsP(3) and D-myo-inositol 1,3,4,5-tetrakisphosphate. The type I B-phosphatase appears to be associated with the particulate fraction of cell homogenates, Molecular cloning of the human brain enzyme identifies a C-terminal farnesylation site CVVQ. Post-translational modification of this enzyme promotes membrane interactions and changes in specific activity, We have now compared the cytosolic Ca2+ ([Ca2+](i)) responses induced by ATP, thapsigargin, and ionomycin in Chinese hamster ovary (CHO-K1) cells transfected with the intact InsP(3) B-phosphatase and with a mutant in which the C-terminal cysteine cannot be farnesylated, [Ca2+](i) was also measured in cells transfected with an InsP(3) 3-kinase construct encoding the A isoform, The Ca2+ oscillations detected in the presence of 1 mu M ATP in control cells were totally lost in 87.5% of intact (farnesylated) InsP(3) B-phosphatase-transfected cells, while such a loss occurred in only 1.1% of the mutant InsP(3) 5-phosphatase-transfected cells, All cells overexpressing the InsP(3) S-kinase also responded with an oscillatory pattern, However, in contrast to control cells, the [Ca2+](i) returned to base-line levels in between a couple of oscillations, The [Ca2+](i) responses to thapsigarin and ionomycin were identical for all cells, The four cell clones compared in this study also behaved similarly with respect to capacitative Ca2+ entry, In permeabilized cells, no differences in extent of InsP(3)-induced Ca2+ release nor in the threshold for InsP(3) action were observed among the four clones and no differences in the expression levels of the various InsP(3) receptor isoforms could be shown between the clones, Our data support the contention that the ATP-induced increase in InsP(3) concentration in transfected CHO-KI cells is essentially restricted to the site of its production near the plasma membrane, where it can be metabolized by the type I InsP(3) B-phosphatase. This enzyme directly controls the [Ca2+](i) response and the Ca2+ oscillations in intact cells.	FREE UNIV BRUSSELS, INST INTERDISCIPLINARY RES, B-1070 BRUSSELS, BELGIUM; CATHOLIC UNIV LEUVEN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven				Parys, Jan/0000-0002-3591-4967				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BALLA T, 1991, J BIOL CHEM, V266, P24719; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIDEN TJ, 1987, J BIOL CHEM, V262, P9437; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DeSmedt H, 1997, BIOCHEM J, V322, P575; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; HARRISON RAP, 1990, CELL SIGNAL, V2, P277, DOI 10.1016/0898-6568(90)90055-F; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEE SY, 1990, J BIOL CHEM, V265, P9434; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; MAILLEUX P, 1991, BRAIN RES, V539, P203, DOI 10.1016/0006-8993(91)91622-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1991, BIOCHEM J, V274, P622, DOI 10.1042/bj2740622; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NYE KE, 1992, CLIN EXP IMMUNOL, V89, P89; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rowles SJ, 1996, BIOCHEM J, V319, P913, DOI 10.1042/bj3190913; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SWILLENS S, 1990, BIOCHEM J, V271, P835, DOI 10.1042/bj2710835; TAKAZAWA K, 1988, BIOCHEM BIOPH RES CO, V153, P632, DOI 10.1016/S0006-291X(88)81142-2; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VanSande J, 1996, MOL CELL ENDOCRINOL, V119, P161, DOI 10.1016/0303-7207(96)03804-X; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1994, BIOCHEM J, V304, P679, DOI 10.1042/bj3040679; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652	72	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17367	17375		10.1074/jbc.272.28.17367	http://dx.doi.org/10.1074/jbc.272.28.17367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211876	hybrid			2022-12-27	WOS:A1997XK16500019
J	Morley, SJ; McKendrick, L				Morley, SJ; McKendrick, L			Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTAMINE KINASE; FACTOR EIF-4E; COMPLEX-FORMATION; GROWTH-FACTOR; TRANSLATION; LYMPHOCYTES; ASSOCIATION; REGULATOR; DEFINE; P220	The initiation factor (eIF) 4E is regulated by modulating both the phosphorylation and the availability of the protein to participate in the initiation process. Here we show that either serum treatment or activation of the stress-activated protein kinase (JNK/SAPK) led to enhanced phosphorylation of eIF4E in quiescent NIH 3T3 cells, Although the immunosuppressant, rapamycin, was found to stabilize the association of eIF4E with its negative regulator, 4E-BP1, this drug did not prevent the early effects of serum stimulation on the overall rate of translation, polysome formation, the phosphorylation status of eIF4E, or the recruitment of eIF4E into the eIF4F complex. However, the rapid enhancement of eIF4E phosphorylation in response to serum was largely prevented by the inhibitor of mitogen-activated protein (MAP) kinase activation, PD98059. Activation of the JNK/SAPK signaling pathway with anisomycin resulted in enhanced phosphorylation of eIF4E, which was prevented by either rapamycin or the highly specific p38 MAP kinase inhibitor, SB203580. These data. illustrate that multiple signaling pathways, including those of distinct members of the MAP kinase family, mediate the phosphorylation of eIF4E and that the association of eIF4E with 4E-BP1 does not necessarily prevent phosphorylation of eIF4E in vivo.			Morley, SJ (corresponding author), UNIV SUSSEX,SCH BIOL SCI,BIOCHEM LAB,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BU X, 1993, J BIOL CHEM, V268, P4975; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Haas David W., 1992, Second Messengers and Phosphoproteins, V14, P163; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KLEIJN M, 1996, J CELL BIOCHEM, V59, P443; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Shu JY, 1996, ONCOGENE, V13, P2421; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	47	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17887	17893		10.1074/jbc.272.28.17887	http://dx.doi.org/10.1074/jbc.272.28.17887			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211946	hybrid			2022-12-27	WOS:A1997XK16500089
J	Natochin, M; Granovsky, AE; Artemyev, NO				Natochin, M; Granovsky, AE; Artemyev, NO			Regulation of transducin GTPase activity by human retinal RGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENT MEMBRANES; CGMP PHOSPHODIESTERASE; G-PROTEIN; INHIBITORY SUBUNIT; MOLECULAR MECHANISM; VISUAL TRANSDUCTION; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; BINDING-SITE	The intrinsic GTPase activity of transducin controls inactivation of the effector enzyme, cGMP phosphodiesterase (PDE), during turnoff of the visual signal, The inhibitory gamma-subunit of PDE (P gamma), an unidentified membrane factor and a retinal specific member of ta-Le RGS family of proteins have been shown to accelerate GTP hydrolysis by transducin, ae have expressed a human homologue of murine retinal specific RGS (hRGSr) in Escherichia coli and investigated its role in the regulation of transducin GTPase activity, As other RGS proteins, hRGSr interacted preferentially with a transitional conformation of the transducin cu-subunit, G(t alpha)GDPAlF(4)(-), while its binding to G(t alpha)GTP gamma S or G(t alpha)GDP was weak, hRGSr and P gamma did not compete for the interaction with G(t alpha)GPAlF(4)(-) Affinity of the P gamma-G(t alpha)GDPAlF(4)(-) interaction was modestly enhanced by addition of hRGSr, as measured by a fluorescence assay of G(t alpha)DPAlF(4)(-) binding to P gamma labeled with 3-(bromoacetyl)-7-diethylaminocoumarin (P gamma BC), Binding of hRGSr to G(t alpha)GDPAlF(4)(-) complexed with P gamma BC resulted in a maximal similar to 40% reduction of BC fluorescence allowing estimation of the hRGSr affinity for G(t alpha)GDPAlF(4)(-) (K-d 35 nM). In a single turnover assay, hRGSr accelerated GTPase activity of transducin reconstituted with the urea-stripped rod outer segment (ROS) membranes by more than 10-fold to a rate of 0.23 s(-1), Addition of P gamma to the reconstituted system reduced the GTPase level accelerated by hRGSr (K-cat 0.085 s(-1)), The GTPase activity of transducin and the PDE inactivation rates in native ROS membranes in the presence of hRGSr were elevated 3-fold or more regardless of the membrane concentrations, In ROS suspensions containing 30 mu M rhodopsin these rates exceeded 0.7 s(-1), Our data suggest that effects of hRGSr on transducin's GTPase activity are attenuated by P gamma but. independent of a putative membrane GTPase activating protein factor, The rate of transducin GTPase activity in the presence of hRGSr is sufficient to correlate it with in vivo turnoff kinetics of the visual cascade.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa			Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CLERC A, 1992, J BIOL CHEM, V267, P6620; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	49	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17444	17449		10.1074/jbc.272.28.17444	http://dx.doi.org/10.1074/jbc.272.28.17444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211888	hybrid			2022-12-27	WOS:A1997XK16500031
J	Trzebiatowski, JR; EscalanteSemerena, JC				Trzebiatowski, JR; EscalanteSemerena, JC			Purification and characterization of CobT, the nicotinate-mononucleotide:5,6-dimethylbenzimidazole phosphoribosyltransferase enzyme from Salmonella typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENES; SPOROMUSA-OVATA; NUCLEOTIDE LOOP; COBALAMIN; VITAMIN-B12; CORRINOIDS; DIMETHYLBENZIMIDAZOLE; IDENTIFICATION; COBAMIDE; BACTERIA	We report the purification and biochemical characterization of the cobalamin biosynthetic enzyme nicotinate-mononucleotide:5,6-dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella typhimurium. cobT was overexpressed and the protein purified to approximately 97% homogeneity. NH2-terminal sequence analysis confirmed that the protein encoded by cobT was purified. Homogeneous CobT catalyzed the synthesis of N-1-(5-phospho-alpha-D-ribosyl)-5,6-dimethyl benzimidazole, The identity of high performance liquid chromatography-purified product was confirmed by fast atom bombardment mass spectrometry. CobT activity was optimal at 45 degrees C and pH 10.0. The apparent K-m for nicotinate mononucleotide was 680 mu M; the apparent K-m for 5,6-dimethylbenzimidazole was less than 10 mu M. CobT used nicotinamide mononucleotide as a ribose phosphate donor, CobT phosphoribosylated alternative base substrates including benzimidazole, 4,5-dimethyl-1,2-phenylenediamine, imidazole, histidine, adenine, and guanine in vitro. The resulting ribotides were incorporated into cobamides that were differentially utilized by methionine synthase (EC 2,1,1.13) ethanolamine ammonia-lyase (EC 4,3.1.7), and 1,2-propanediol dehydratase (EC 4.2,1.28) in vivo. The lack of base substrate specificity by CobT may explain the inability to isolate mutants blocked in the synthesis of 5,6-dimethylbenzimidazole in this bacterium.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM40313, R01 GM040313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLAG DM, 1991, PROTEIN METHODS, P162; BRADBEER C, 1982, B12, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; CHANG GW, 1975, NATURE, V254, P150, DOI 10.1038/254150a0; CHEN P, 1995, J BACTERIOL, V177, P1461, DOI 10.1128/jb.177.6.1461-1469.1995; DAVIS RW, 1980, MANUAL GENETIC ENG A, P201; DRENNAN CL, 1994, SCIENCE, V266, P1660; EBERHARD G, 1988, BIOL CHEM H-S, V369, P1091, DOI 10.1515/bchm3.1988.369.2.1091; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; FRIEDMAN.HC, 1965, J BIOL CHEM, V240, P413; FRIEDMANN HC, 1970, ANNU REV MICROBIOL, V24, P159, DOI 10.1146/annurev.mi.24.100170.001111; FYFE JA, 1969, J BIOL CHEM, V244, P1659; JETER RM, 1990, J GEN MICROBIOL, V136, P887, DOI 10.1099/00221287-136-5-887; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; JOHNSON MG, 1992, J BIOL CHEM, V267, P13302; KRAUTLER B, 1988, EUR J BIOCHEM, V176, P461, DOI 10.1111/j.1432-1033.1988.tb14303.x; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; MERVYN L, 1964, PROG IND MICROBIOL, V5, P152; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; STUPPERICH E, 1987, J BACTERIOL, V169, P3076, DOI 10.1128/jb.169.7.3076-3081.1987; STUPPERICH E, 1989, EUR J BIOCHEM, V186, P657, DOI 10.1111/j.1432-1033.1989.tb15256.x; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; STUPPERICH E, 1988, ARCH MICROBIOL, V149, P213; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TAYLOR RT, 1973, ENZYMES, V9, P121; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; VOGEL HJ, 1956, J BIOL CHEM, V218, P97	35	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17662	17667		10.1074/jbc.272.28.17662	http://dx.doi.org/10.1074/jbc.272.28.17662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211916	hybrid			2022-12-27	WOS:A1997XK16500059
J	Ginestra, A; Monea, S; Seghezzi, G; Dolo, V; Nagase, H; Mignatti, P; Vittorelli, ML				Ginestra, A; Monea, S; Seghezzi, G; Dolo, V; Nagase, H; Mignatti, P; Vittorelli, ML			Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; FIBROBLAST GROWTH-FACTOR; HUMAN AMNIOTIC MEMBRANE; MURINE MELANOMA-CELLS; HUMAN SARCOMA-CELLS; IV COLLAGENASE; MATRIX METALLOPROTEINASE; ENZYMATIC-PROPERTIES; ENDOTHELIAL-CELLS; TUMOR-CELLS	Membrane vesicles are shed by tumor cells both in vivo and in vitro, Although their functions are not well understood, it has been proposed that they may play multiple roles in tumor progression, We characterized membrane vesicles from human HT1080 fibrosarcoma cell cultures for the presence of proteinases involved in tumor invasion, By gelatin zymography and Western blotting, these Vesicles showed major bands corresponding to the zymogen and active forms of gelatinase B (MMP-9) and gelatinase A (MMP-2) and to the MMP-9.tissue inhibitor of metalloproteinase 1 complex, Both gelatinases appeared to be associated with the vesicle membrane, HT1080 cell vesicles also showed a strong, plasminogen-dependent fibrinolytic activity in I-125 fibrin assays; this activity was associated with urokinase plasminogen activator, as shown by casein zymography and Western blotting, Urokinase was bound to its high affinity receptor on the vesicle membrane, Addition of plasminogen resulted in activation of the progelatinases associated with the vesicles, indicating a role of the urokinase-plasmin system in MMP-2 and MMP-9 activation, We propose that vesicles shed by tumor cells may provide a large membrane surface for the activation of membrane-associated proteinases involved in extracellular matrix degradation and tissue invasion.	UNIV PALERMO, DEPT CELLULAR & DEV BIOL, I-90128 PALERMO, ITALY; UNIV AQUILA, DEPT EXPT MED, I-67010 LAQUILA, ITALY; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA; COBS, CTR ONCOBIOL SPERIMENTALE, I-90128 PALERMO, ITALY	University of Palermo; University of L'Aquila; University of Kansas; University of Kansas Medical Center			Dolo, Vincenza/AAB-2885-2021	Dolo, Vincenza/0000-0003-0424-6676; Mignatti, Paolo/0000-0002-8157-457X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALEXANDER P, 1974, CANCER RES, V34, P2077; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHIBA I, 1989, CANCER RES, V49, P3972; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535; DOLO V, 1995, CLIN EXP METASTAS, V13, P277, DOI 10.1007/BF00133483; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; EMONARD HP, 1992, CANCER RES, V52, P5845; GARBISA S, 1980, CANCER LETT, V9, P359, DOI 10.1016/0304-3835(80)90030-0; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LERNER MP, 1983, CANCER LETT, V20, P125, DOI 10.1016/0304-3835(83)90040-X; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1985, J BIOL CHEM, V260, P4303; MONSKY WL, 1993, CANCER RES, V53, P3159; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NAGASE H, 1996, MATRIX METALLOPROTEI, P153; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POSTE G, 1980, P NATL ACAD SCI-BIOL, V77, P399, DOI 10.1073/pnas.77.1.399; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TARIN D, 1969, BRIT J CANCER, V23, P417, DOI 10.1038/bjc.1969.54; TARIN D, 1967, INT J CANCER, V2, P195, DOI 10.1002/ijc.2910020302; Taylor D D, 1986, Dev Biol (N Y 1985), V3, P33; TAYLOR DD, 1985, J NATL CANCER I, V74, P859; TAYLOR DD, 1988, INT J CANCER, V41, P629, DOI 10.1002/ijc.2910410425; TAYLOR DD, 1983, BIOCHEM BIOPH RES CO, V113, P470, DOI 10.1016/0006-291X(83)91749-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNKELESS JC, 1973, J EXP MED, V137, P85, DOI 10.1084/jem.137.1.85; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	69	149	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17216	17222		10.1074/jbc.272.27.17216	http://dx.doi.org/10.1074/jbc.272.27.17216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202045	hybrid			2022-12-27	WOS:A1997XH44600077
J	Kondratyuk, T; Rossie, S				Kondratyuk, T; Rossie, S			Depolarization of rat brain synaptosomes increases phosphorylation of voltage-sensitive sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CAMP-DEPENDENT PHOSPHORYLATION; ALPHA-SUBUNIT; NA+ CHANNEL; CEREBROCORTICAL SYNAPTOSOMES; FUNCTIONAL MODULATION; CATALYTIC SUBUNIT; XENOPUS OOCYTES; CALCIUM ACTION; NEURONS	Depolarization of rat brain synaptosomes causes an increase in phosphorylation of serine residues 573, 610, 623, and 687 on voltage-sensitive sodium channels. Although these sites have bean shown to be phosphorylated by cAMP-dependent protein kinase in vitro and in situ, the depolarization-induced increase in their state of phosphorylation is not due to increased cAMP-dependent protein kinase activity, but requires calcium influx and protein kinase C, Since phosphorylation at this cluster of sites inhibits sodium current and would decrease neuronal excitability, this may be an important negative feedback mechanism whereby calcium influx during prolonged or repetitive depolarization can attenuate neuronal excitability and prevent further calcium accumulation. Phosphorylation of purified channels by protein kinase C decreases dephosphorylation of cAMP-dependent phosphorylation sites by purified calcineurin or protein phosphatase 2A, This suggests that one mechanism by which protein kinase C may increase phosphorylation of cAMP-dependent phosphorylation sites in sodium channels is to inhibit their dephosphorylation, This represents an important new mechanism for convergent regulation of an ion channel by two distinct signal transduction pathways.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT VET PATHOBIOL, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031221, R01NS031221] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Cantrell AR, 1996, NEURON, V16, P1019, DOI 10.1016/S0896-6273(00)80125-7; CHANDLER LJ, 1989, J NEUROCHEM, V52, P1905, DOI 10.1111/j.1471-4159.1989.tb07275.x; CHEN TC, 1995, J BIOL CHEM, V270, P7750, DOI 10.1074/jbc.270.13.7750; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; GERSHON E, 1992, J NEUROSCI, V12, P3743; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROTHERMEL JD, 1983, J BIOL CHEM, V258, P2125; SCHREIBMAYER W, 1991, FEBS LETT, V291, P341, DOI 10.1016/0014-5793(91)81316-Z; Smith RD, 1996, J NEUROSCI, V16, P1965; SUMMERS MD, 1987, TEXAS AGR EXPT STAT, V1555; SURMEIER DJ, 1993, PROG BRAIN RES, V99, P309; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WANG JKT, 1988, J NEUROSCI, V8, P281; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	48	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16978	16983		10.1074/jbc.272.27.16978	http://dx.doi.org/10.1074/jbc.272.27.16978			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202010	hybrid			2022-12-27	WOS:A1997XH44600042
J	LevakFrank, S; Weinstock, PH; Hayek, T; Verdery, R; Hofmann, W; Ramakrishnan, R; Sattler, W; Breslow, JL; Zechner, R				LevakFrank, S; Weinstock, PH; Hayek, T; Verdery, R; Hofmann, W; Ramakrishnan, R; Sattler, W; Breslow, JL; Zechner, R			Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTIONAL CATABOLIC RATE; RECEPTOR-RELATED PROTEIN; TRANSGENIC MICE; MISSENSE MUTATION; ENZYME-ACTIVITY; DEFICIENCY; TISSUE; OVEREXPRESSION; METABOLISM; SEQUENCE	To determine the contribution of muscle lipoprotein lipase (LPL) to lipoprotein metabolism, induced mutant mice were generated that express human LPL exclusively in muscle, By cross-breeding heterozygous LPL knockout mice with transgenic mice expressing human LPL only in muscle, animals were obtained that express human LPL primarily in skeletal muscle on either the null (L0-MCK) or normal (L2-MCK) LPL backgrounds, and these were compared with control littermanes (L2), Fed and fasted post-heparin plasma (PHP) LPI; activities were increased 1.4- and 2.3-fold, respectively, in L2-MCK mice and were normal in L0-MCK mice compared with controls. The specific enzyme activities of human LPL in mouse plasma was comparable to human LPL in human PHP. Skeletal muscle LPL activity was increased in both LB-MCH and L0-MCK mice in the fed (6.6-fold) and fasted (4.2-fold ill L2-MCK; and 3.4-fold in L0-MCK) states, Adipose tissue LPL mRNA and activity were not detectable ill L0-MCK mice, Growth and body mass composition were similar among all groups, In the fasted and fed state, L2-MCK mice had 31% and 53% reductions, respectively, in plasma triglycerides (TG), compatible with increased PHP LPL activity. Unexpectedly, both ill the fasted and fed state the L0-MCK mice also had reduced TG (22%), despite normal PHP LPL activities. Very law density lipoprotein (VLDL) turnover studies revealed that She decreased TG were due Eo increased particle fractional catabolic rate in both L2-MCK and L0-MCK mice. Despite reduced TG, both L2-MCK and L0-MCK mice showed reduced high density lipoprotein (HDL) cholesterol levels (16% and 19%, respectively). HDL turnover studies indicated increased HDL cholesteryl ester fractional catabolic rate in the L2-MCK and L0-MCK compared with control mice. In summary, these Studies suggest that muscle LPL is particularly potent with regard to VLDL metabolism and is sufficient to compensate for the lack of LPL in other tissues with regard to lipolyzing VLDL particles. With regard to HDL, muscle LPL expression does not result in normal levels due to enhanced breakdown either by mediating accelerated HDL clearance or by failing to establish normal HDL particles that are then cleared more quickly than normal. These studies provide new insights on the tissue-specific effects of LPL on lipoprotein metabolism.	GRAZ UNIV,INST MED BIOCHEM,A-8010 GRAZ,AUSTRIA; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; UNIV ARIZONA,ARIZONA CTR AGING,TUCSON,AZ 85721; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10021	University of Graz; Rockefeller University; University of Arizona; Columbia University			Weinstock, Peter H/AAD-2297-2021; Weinstock, Peter H/GQP-2426-2022; Breslow, Jan L/B-7544-2008	Zechner, Rudolf/0000-0001-5483-1182; Weinstock, Peter/0000-0002-4425-3232	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBAUMBOWDEN D, 1985, ARTERIOSCLEROSIS, V5, P273, DOI 10.1161/01.ATV.5.3.273; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BORENSZTAJN J, 1970, J LIPID RES, V11, P102; BOSELLO O, 1984, INT J OBESITY, V8, P213; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; BRUN LD, 1989, METABOLISM, V38, P1005, DOI 10.1016/0026-0495(89)90013-9; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; CRYER A, 1985, REPROD NUTR DEV, V25, P255, DOI 10.1051/rnd:19850216; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; GAVFELS ME, 1993, SOMAT CELL MOLEC GEN, V3, P557; Goldberg IJ, 1996, J LIPID RES, V37, P693; GREENWOOD MRC, 1985, INT J OBESITY, V9, P67; GREENWOOD MRC, 1984, INT J OBESITY, V8, P561; GRUEN R, 1979, METAB CLIN EXP, V27, P1955; HAYEK T, 1991, ARTERIOSCLER THROMB, V11, P1295, DOI 10.1161/01.ATV.11.5.1295; HUTTUNEN JK, 1976, CLIN SCI MOL MED, V50, P49; JENSEN GL, 1980, J BIOL CHEM, V255, P1141; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LITHELL H, 1977, ACTA U UPSAL, P272; LIU MS, 1994, J BIOL CHEM, V269, P11417; MAILLY F, 1995, ARTERIOSCL THROM VAS, V15, P468, DOI 10.1161/01.ATV.15.4.468; MATHEWS CME, 1957, PHYS MED BIOL, V2, P36; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; MIKKILA EA, 1978, ATHEROSCLEROSIS, V29, P497; ODONKOR JM, 1984, BIOCHEM PHARMACOL, V33, P1337, DOI 10.1016/0006-2952(84)90189-8; OHRVALL M, 1995, METABOLISM, V44, P212, DOI 10.1016/0026-0495(95)90267-8; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGERS MP, 1974, J LIPID RES, V15, P263; ROSSNER S, 1976, EUR J CLIN INVEST, V6, P299, DOI 10.1111/j.1365-2362.1976.tb00524.x; RUOTOLO G, 1992, J LIPID RES, V33, P1541; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCHOTZ MC, 1972, BIOCHIM BIOPHYS ACTA, V270, P472, DOI 10.1016/0005-2760(72)90112-9; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TASKINEN MR, 1981, CLIN CHIM ACTA, V112, P325, DOI 10.1016/0009-8981(81)90455-1; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P247; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; VERDERY RB, 1989, J LIPID RES, V30, P1085; VESSBY B, 1982, ATHEROSCLEROSIS, V44, P113, DOI 10.1016/0021-9150(82)90057-0; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; ZECHNER R, 1991, GENOMICS, V11, P62, DOI 10.1016/0888-7543(91)90102-K; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	59	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17182	17190		10.1074/jbc.272.27.17182	http://dx.doi.org/10.1074/jbc.272.27.17182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202040	hybrid			2022-12-27	WOS:A1997XH44600072
J	Masmoudi, T; Hihi, AK; Vazquez, M; Artur, Y; Desvergne, B; Wahli, W; Goudonnet, H				Masmoudi, T; Hihi, AK; Vazquez, M; Artur, Y; Desvergne, B; Wahli, W; Goudonnet, H			Transcriptional regulation by triiodothyronine of the UDP-glucuronosyltransferase family 1 gene complex in rat liver - Comparison with induction by 3-methylcholanthrene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RESPONSE ELEMENT; RETINOID X-RECEPTOR; THYROID-HORMONE; MESSENGER-RNA; AH-RECEPTOR; BINDING; EXPRESSION; ACID; IDENTIFICATION; CIPROFIBRATE	This study demonstrates that the expression of the phenol UDP-glucuronosyltransferase I gene (UGT1A1) is regulated at the transcriptional level by thyroid hormone in rat liver, Following 3,5,3'-triiodo-L-thyronine (T-3) stimulation in vivo, there is a gradual increase in the amount of UGT1A1 mRNA with maximum levels reached 24 h after treatment, In comparison, induction with the specific inducer, 3-methylcholanthrene (3-MC), results in maximal levels of UGT1A1 mRNA after 8 h of treatment, In primary hepatocyte cultures, the stimulatory effect of both T-3 and 3-MC is also observed. This induction is suppressed by the RNA synthesis inhibitor actinomycin D, indicating that neither inducer acts at the level of mRNA stabilization, Indeed, nuclear run-on assays show a 3-fold increase in UGT1A1 transcription after T-3 treatment and a 6-fold increase after 3-MC stimulation, This transcriptional induction by T-3 is prevented by cycloheximide in primary hepatocyte cultures, while 3-MC stimulation is only partially affected after prolonged treatment with the protein synthesis inhibitor, Together, these data provide evidence for a transcriptional control of UGT1A1 synthesis and indicate that T-3 and 3-MC use different activation mechanisms, Stimulation of the UGT1A1 gene by T-3 requires de novo protein synthesis, while 3-MC-dependent activation is the result of a direct action of the compound, most likely via the aromatic hydrocarbon receptor complex.	UNIV BOURGOGNE,FAC PHARM,LAB BIOCHIM PHARMACOL,F-21033 DIJON,FRANCE; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	Universite de Bourgogne; University of Lausanne			ARTUR, Yves E/A-8504-2019; Vázquez-Carrera, Manuel/H-2612-2015; Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				[Anonymous], 1980, GLUCURONIDATION DRUG; BECTSTRA JB, 1991, ENDOCRINOLOGY, V128, P741; BENDER TP, 1995, CURRENT PROTOCOLS MO, V26, P1; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CIOTTI M, 1995, J BIOL CHEM, V270, P3284, DOI 10.1074/jbc.270.7.3284; CORTHESY B, 1990, TRANSCRIPTION FACTOR, V2, P57; CURRAN PG, 1991, ENDOCR REV, V12, P135, DOI 10.1210/edrv-12-2-135; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOUDONNET H, 1990, BIOCHIM BIOPHYS ACTA, V1035, P12, DOI 10.1016/0304-4165(90)90167-U; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAMB JG, 1994, BIOCHEMISTRY-US, V33, P10513, DOI 10.1021/bi00200a037; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Masmoudi T, 1996, FEBS LETT, V379, P181, DOI 10.1016/0014-5793(95)01507-8; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PACOT C, 1993, BIOCHEM PHARMACOL, V45, P1437, DOI 10.1016/0006-2952(93)90043-V; RITTER JK, 1992, J BIOL CHEM, V267, P3257; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STROBL W, 1992, ATHEROSCLEROSIS, V97, P161, DOI 10.1016/0021-9150(92)90129-5; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; VASILIOU V, 1993, ADV EXP MED BIOL, V328, P131; VISSER TJ, 1993, ENDOCRINOLOGY, V133, P2177, DOI 10.1210/en.133.5.2177; VISSER TJ, 1991, BIOCHEM PHARMACOL, V42, P444, DOI 10.1016/0006-2952(91)90735-N; VISSER TJ, 1990, THYROID GLAND, P255; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	38	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17171	17175		10.1074/jbc.272.27.17171	http://dx.doi.org/10.1074/jbc.272.27.17171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202038	hybrid			2022-12-27	WOS:A1997XH44600070
J	Wu, T; Angus, CW; Yao, XL; Logan, C; Shelhamer, JH				Wu, T; Angus, CW; Yao, XL; Logan, C; Shelhamer, JH			p11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CYTOPLASMIC PHOSPHOLIPASE-A(2); LIGHT-CHAIN; CALPACTIN-I; MAST-CELLS; ANNEXIN-II; KINASE-C; PHOSPHORYLATION; EXPRESSION; LIPOCORTIN	Using a two hybrid system screen of a human cDNA library, we have found that pll, a unique member of the S100 family of calcium-binding proteins, interacts with the carboxyl region of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)), p11 synthesized in a cell-free system interacts with cPLA(2) in vitro, The p11-cPLA(2) complex is detectable from a human bronchial epithelial cell line (BEAS 2B), Furthermore, pll inhibits cPLA(2) activity in vitro, Selective inhibition of pll expression in the BEAS 2B cells by antisense RNA results in an increased PLA(2) activity as well as an increased release of prelabeled arachidonic acid, This study demonstrates a novel mechanism for the regulation of cPLA(2) by an S100 protein.	NIH,CRIT CARE MED DEPT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; AHN NG, 1988, J BIOL CHEM, V263, P18657; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DURHAM ACH, 1983, CELL CALCIUM, V4, P33, DOI 10.1016/0143-4160(83)90047-7; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FONTEH AN, 1993, J IMMUNOL, V150, P563; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HARDER T, 1993, J CELL SCI, V104, P1109; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JOHNSSON N, 1990, PROG CLIN BIOL RES, V349, P123; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUBE E, 1991, GENE, V102, P255, DOI 10.1016/0378-1119(91)90086-Q; LABARCA C, 1980, ANAL BIOCHEM, V102, P334; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSOMARIE F, 1992, ANNEXINS, P35; Sambrook J., 2002, MOL CLONING LAB MANU; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	63	99	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17145	17153		10.1074/jbc.272.27.17145	http://dx.doi.org/10.1074/jbc.272.27.17145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202034	hybrid			2022-12-27	WOS:A1997XH44600066
J	Bock, PE; Olson, ST; Bjork, I				Bock, PE; Olson, ST; Bjork, I			Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; HUMAN ALPHA-THROMBIN; ANION-BINDING EXOSITE; REACTIVE-BOND LOOP; ACTIVE-SITE; ANTI-THROMBIN; KINETIC CHARACTERIZATION; HUMAN THROMBOMODULIN	Exosite I of the blood clotting proteinase, thrombin, mediates interactions of the enzyme with certain inhibitors, physiological substrates and regulatory proteins, Specific binding of a fluorescein-labeled derivative of the COOH-terminal dodecapeptide of hirudin ([5F]Hir(54-65)) to exosite I was used to probe changes in the function of the regulatory site accompanying inactivation of thrombin by its physiological serpin inhibitor, antithrombin, Fluorescence-monitored equilibrium binding studies showed that [5F]Hir(54-65) and Hir(54-65) bound to human cu-thrombin with dissociation constants of 26 +/- 2 nM and 38 +/- 5 nM, respectively, while the affinity of the peptides for the stable thrombin-antithrombin complex was undetectable (greater than or equal to 200-fold weaker), Kinetic studies showed that the loss of binding sites for [5F]Hir(54-65) occurred with the same time-course as the loss of thrombin catalytic activity, Binding of [5F]Hir(54-65) and Hir(54-65) to thrombin was correlated quantitatively with partial inhibition of the rate of the thrombin-antithrombin reaction, maximally decreasing the bimolecular rate constants 1.7- and 2.1-fold, respectively, These results support a mechanism in which thrombin and the thrombin-Hir(54-65) complex can associate with antithrombin and undergo formation of the covalent thrombin-antithrombin complex at modestly different rates, with inactivation of exosite I leading to dissociation of the peptide occurring subsequent to the rate-limiting inactivation of thrombin, This mechanism may function physiologically in localizing the activity of thrombin by allowing inactivation of thrombin that is bound in exosite I-mediated complexes with regulatory proteins, such as thrombomodulin and fibrin, without prior dissociation of these complexes, Concomitant with inactivation of thrombin, the thrombin-antithrombin complex may be irreversibly released due to exosite I inactivation.	UNIV ILLINOIS,CTR MOL BIOL ORAL DIS,CHICAGO,IL 60612; SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Swedish University of Agricultural Sciences	Bock, PE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PATHOL,C3321A MED CTR N,NASHVILLE,TN 37232, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL038779, R29HL039888, R37HL039888, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779, HL02832, HL39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, J BIOL CHEM, V267, P19047; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FERGUSON WS, 1983, ARCH BIOCHEM BIOPHYS, V220, P301, DOI 10.1016/0003-9861(83)90414-9; FISH WW, 1979, FEBS LETT, V98, P103, DOI 10.1016/0014-5793(79)80162-3; FISH WW, 1979, EUR J BIOCHEM, V101, P39, DOI 10.1111/j.1432-1033.1979.tb04213.x; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KOYAMA T, 1991, EUR J BIOCHEM, V198, P563, DOI 10.1111/j.1432-1033.1991.tb16051.x; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; LOLLAR P, 1984, J BIOL CHEM, V259, P4335; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; PRIESTLE JP, 1993, PROTEIN SCI, V2, P1630, DOI 10.1002/pro.5560021009; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023; YE J, 1994, J BIOL CHEM, V269, P17965	63	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19837	19845		10.1074/jbc.272.32.19837	http://dx.doi.org/10.1074/jbc.272.32.19837			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242645	hybrid			2022-12-27	WOS:A1997XQ05900032
J	Borecky, J; Jezek, P; Siemen, D				Borecky, J; Jezek, P; Siemen, D			108-pS channel in brown fat mitochondria might be identical to the inner membrane anion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE MITOCHONDRIA; UNCOUPLING PROTEIN; HEART-MITOCHONDRIA; ION CHANNEL; K+-CHANNEL; RAT-LIVER; INHIBITION; SITES; UNIPORT; PATHWAY	Single-channel and whole-mitoplast patch-clamp recordings were employed to characterize the 108-pS (Cl-) channel in brown fat mitochondrial mitoplasts, We demonstrated the ability of this channel to conduct di- and trivalent anions, such as sulfate, phosphate, and benzenetricarboxylates, and its blockage by propranolol, 1,4-dihydropyridine-type Ca2+ antagonists, and Cibacron blue, Moreover, we have revealed its pH dependence for the first time, As a basis for the characteristic potential dependence of the whole-mitoplast current, we identified an open probability, increasing with depolarizing (positive) potentials, E-h, and being almost zero in the hyperpolarizing range, Events at negative E-h exhibit a short flickering behavior, whereas at positive E-h, they become much longer, This voltage dependence is influenced by pH in such a way that, at acidic pH, the 108-pS channel possesses a low open probability throughout the observed potential range, whereas at alkaline pH, the channel switches to long openings, even at a negative potential, All these properties lead us to conclude that the inner membrane anion channel, which has been characterized only by light scattering studies, and the 108-pS inner membrane channel, which has been characterized electrophysiologically, are one and the same process.	ACAD SCI CZECH REPUBL, INST PHYSIOL, DEPT MEMBRANE TRANSPORT BIOPHYS, CZ-14220 PRAGUE 4, CZECH REPUBLIC; CHRISTIAN ALBRECHTS UNIV KIEL, INST ZOOL, BIOLOGIEZENTRUM, D-24118 KIEL, GERMANY	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of Kiel			Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395				ANTONENKO YN, 1991, FEBS LETT, V285, P89, DOI 10.1016/0014-5793(91)80731-H; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BALLARIN C, 1995, J BIOL CHEM, V270, P19262, DOI 10.1074/jbc.270.33.19262; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BRAU ME, 1990, J PHYSIOL-LONDON, V420, P365, DOI 10.1113/jphysiol.1990.sp017918; CAMPO ML, 1992, J BIOL CHEM, V267, P8123; Cannon B, 1979, Methods Enzymol, V55, P65; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herick K, 1995, PROG CELL R, V5, P83; Huang SG, 1996, BIOCHEMISTRY-US, V35, P16806, DOI 10.1021/bi960989v; Jezek P, 1996, INT J BIOCHEM CELL B, V28, P659, DOI 10.1016/1357-2725(96)00008-8; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1989, AM J PHYSIOL, V257, pC1142, DOI 10.1152/ajpcell.1989.257.6.C1142; KINALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374; KLITSCH T, 1991, J MEMBRANE BIOL, V122, P69, DOI 10.1007/BF01872740; MORAN O, 1990, J BIOL CHEM, V265, P908; MURRAY AG, 1988, EBEC REP, V5, P206; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; POWERS MF, 1991, J BIOL CHEM, V266, P17250; SELWYN MJ, 1987, NATURE, V330, P424, DOI 10.1038/330424a0; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; Sorgato MC, 1988, INTEGRATION MITOCHON, P305; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; WARHURST IW, 1982, FEBS LETT, V149, P249, DOI 10.1016/0014-5793(82)81110-1; ZERNIG G, 1990, MOL PHARMACOL, V38, P362; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	34	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19282	19289						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235923				2022-12-27	WOS:A1997XP06300029
J	Foncea, R; Andersson, M; Ketterman, A; Blakesley, V; SapagHagar, M; Sugden, PH; LeRoith, D; Lavandero, S				Foncea, R; Andersson, M; Ketterman, A; Blakesley, V; SapagHagar, M; Sugden, PH; LeRoith, D; Lavandero, S			Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; LEFT-VENTRICULAR HYPERTROPHY; PROTEIN-COUPLED RECEPTORS; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; PARACRINE MECHANISM; PLASMA-MEMBRANE; ANGIOTENSIN-II; STIMULATE	In response to insulin-like growth factor-I (IGF-I), neonatal rat cardiac myocytes exhibit a hypertrophic response, The elucidation of the IGF-I signal transduction system in these cells remains unknown, We show here that cardiac myocytes present a single class of high affinity receptors (12,446 +/- 3,669 binding sites/cell) with a dissociation constant of 0.36 +/- 0.10 nM. Two different beta-subunits of IGF-I receptor were detected, and their autophosphorylation was followed by increases in the phosphotyrosine content of extracellular signal-regulated kinases (ERKs), insulin receptor substrate 1, phospholipase C-gamma 1, and phosphatidylinositol 3-kinase. IGF-I transiently activates c-Raf in cultured neonatal cardiac myocytes, whereas A raf is activated much less than c-Raf, Two peaks of ERK activity (ERK1 and ERK2) were resolved in cardiac myocytes treated with IGF-I by fast protein liquid chromatography, both being stimulated by IGF-I (with EC50 values for the stimulation of ERK1 and ERK2 by IGF-I of 0.10 and 0.12 nM, respectively), Maximal activation of ERK2 (12-fold) and ERK1 (8.3-fold) activities was attained after a 5-min exposure to IGF-I. Maximal activation of p90 S6 kinase by IGF-I was achieved after 10 min, and then the activity decreased slowly, Interestingly, IGF-I stimulates incorporation of [H-3]phenylalanine (1.6-fold) without any effect on [H-3]thymidine incorporation. These data suggest that IGF-I activates multiple signal transduction pathways in cardiac myocytes some of which may be relevant to the hypertrophic response of the heart.	UNIV CHILE, FAC CIENCIAS QUIM & FARMACEUT, DEPT BIOQUIM & BIOL MOL, SANTIAGO, CHILE; NATL HEART & LUNG INST, IMPERIAL COLL, SCH MED, DIV CARDIAC MED, LONDON SW3 6LY, ENGLAND; NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA	Universidad de Chile; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Lavandero, Sergio/B-6001-2013	Lavandero, Sergio/0000-0003-4258-1483; Hagar, Mohamed Esam/0000-0003-0169-7738	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMO M, 1992, BIOFACTORS, V3, P151; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; ALEXANDRIDES TK, 1993, REGUL PEPTIDES, V48, P279, DOI 10.1016/0167-0115(93)90357-E; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; CLERK A, 1994, J BIOL CHEM, V269, P32848; Delafontaine P, 1996, TRENDS CARDIOVAS MED, V6, P187, DOI 10.1016/S1050-1738(96)00058-8; DEROLE AJ, 1984, P NATL ACAD SCI USA, V81, P935; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Duerr RL, 1996, CIRCULATION, V93, P2188, DOI 10.1161/01.CIR.93.12.2188; DZAU VJ, 1992, AM J CARDIOL, V70, pC4; ENGELMANN GL, 1989, MOL CELL ENDOCRINOL, V63, P1, DOI 10.1016/0303-7207(89)90076-2; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GUTIERREZ J, 1995, J ENDOCRINOL, V146, P35, DOI 10.1677/joe.0.1460035; HANSON MC, 1993, AM J MED SCI, V306, P69, DOI 10.1097/00000441-199308000-00001; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KLEIN I, 1992, J CLIN ENDOCR METAB, V75, P339, DOI 10.1210/jc.75.2.339; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAVIADES C, 1991, ARCH MAL COEUR VAISS, V84, P1039; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MAO L, 1995, CIRCULATION, V92, P239; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Rabkin SW, 1996, AM J HYPERTENS, V9, P230, DOI 10.1016/0895-7061(95)00382-7; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; Sacca L, 1996, NAT MED, V2, P29, DOI 10.1038/nm0196-29; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugden PH, 1996, TRENDS CARDIOVAS MED, V6, P87, DOI 10.1016/1050-1738(96)00013-8; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHLANDER H, 1992, HYPERTENSION, V19, P25, DOI 10.1161/01.HYP.19.1.25; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	76	174	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19115	19124		10.1074/jbc.272.31.19115	http://dx.doi.org/10.1074/jbc.272.31.19115			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235900	hybrid			2022-12-27	WOS:A1997XP06300006
J	Fourie, AM; Hupp, TR; Lane, DP; Sang, BC; Barbosa, MS; Sambrook, JF; Gething, MJH				Fourie, AM; Hupp, TR; Lane, DP; Sang, BC; Barbosa, MS; Sambrook, JF; Gething, MJH			HSP70 binding sites in the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; WILD-TYPE P53; MOLECULAR CHAPERONE BIP; SARCOMA CELL-LINE; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; COGNATE PROTEIN; T-ANTIGEN; KINASE-C	Mutations within conserved regions of the tumor suppressor protein, p53, result in oncogenic forms of the protein with altered tertiary structures. In most cases, the mutant p53 proteins are selectively recognized and bound by members of the HSP70 family of molecular chaperones, but the binding site(s) in p53 for these chaperones have not been clearly defined, We have screened a library of overlapping biotinylated peptides, spanning the entire human p53 sequence, for binding to the HSP70 proteins, Hsc70 and DnaK, We show that most of the high affinity binding sites for these proteins map to secondary structure elements, particularly beta-strands, in the hydrophobic core of the central DNA binding domain, where the majority of oncogenic p53 mutations are found, Although peptides corresponding to the C-terminal region of p53 also contain potential binding sites, p53 proteins with C-terminal deletions are capable of binding to Hsc70, indicating that this region is not required for complex formation, We propose that mutations in the p53 protein alter the tertiary structure of the central DNA binding domain, thus exposing high affinity HSP70 binding sites that are cryptic in the wild-type molecule.	UNIV MELBOURNE,DEPT BIOCHEM & MOL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; RW JOHNSON PHARMACEUT RES INST,SAN DIEGO,CA 92121; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; PHARMINGEN,SAN DIEGO,CA 92121; SIGNAL PHARMACEUT,SAN DIEGO,CA 92121; PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA	University of Melbourne; Johnson & Johnson; Johnson & Johnson USA; University of Dundee; Peter Maccallum Cancer Center			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; EHRHART JC, 1988, ONCOGENE, V3, P595; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, PHILOS T ROY SOC B, V339, P369, DOI 10.1098/rstb.1993.0036; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIHEI T, 1993, CANCER LETT, V73, P181, DOI 10.1016/0304-3835(93)90262-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SANG BC, 1994, ONCOGENE, V9, P853; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; YANUCK M, 1993, CANCER RES, V53, P3257	72	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19471	19479		10.1074/jbc.272.31.19471	http://dx.doi.org/10.1074/jbc.272.31.19471			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235949	hybrid			2022-12-27	WOS:A1997XP06300055
J	Haddad, TC; Conover, CA				Haddad, TC; Conover, CA			Insulin and interleukin-4 induce desensitization to the mitogenic effects of insulin-like growth factor-I - Pivotal role for insulin receptor substrate-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FACTOR BINDING PROTEIN-3; PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; IRS-1; KINASE; EXPRESSION; 3-KINASE; STIMULATION	Insulin-induced desensitization to insulin-like growth factor-I (IGF-I) stimulated mitogenesis in bovine fibroblasts involves steps distal to IGF-I binding to its tyrosine kinase receptor, When quiescent cultures of bovine fibroblasts were stimulated with 10 nM IGF-I and total cell lysates immunoblotted with anti-phosphotyrosine antibody, we observed a band at similar to 97 kDa, representing the beta-subunit of the IGF-I receptor, and a predominant tyrosyl-phosphorylated species migrating as a broad band between 170 and 190 kDa. The majority of proteins in this latter band were immunoprecipitated by antibodies against insulin receptor substrate (IRS)-2 and not by antibodies against IRS-1. Pretreatment of bovine fibroblasts with 10 nM insulin for 48 h blocked subsequent IGF-I-stimulated DNA synthesis and the IGF-I-induced increase in tyrosyl-phosphorylated IRS-2. Insulin pretreatment did not alter IRS-1 or IRS-2 expression by these cells, as assessed by metabolic labeling and direct immunoblotting with IRS antibodies. The interleukin-4 (IL-4) cytokine receptor also has IRS-2 as its major substrate for tyrosine phosphorylation. Although 10 nM IL-4 was as effective as 10 nM IGF-I in stimulating IRS-2 phosphorylation, 10 nm IL-4 did not have comparable mitogenic power in these cells. Nonetheless, pretreatment of bovine fibroblasts with IL-4 inhibited IGF-I-stimulated DNA synthesis by 50-60%, concomitant with a decrease in IGF-I-induced IRS-2 phosphorylation. Insulin-induced desensitization could be prevented if a specific inhibitor of phosphatidylinositol 3-kinase (LY294002), but not an inhibitor of mitogen-activated protein kinase (PD98059), was present during the preincubation period. LY294002 also prevented the shift in IRS-2 molecular mass in response to prolonged incubation of cells with insulin. These data indicate that, in a nontransformed cell system, IRS-2 plays a key role in cellular desensitization to IGF-I-stimulated mitogenesis most likely through a feedback mechanism in the phosphatidylinositol 3-kinase pathway. Furthermore, they suggest that signaling through IRS-2 may provide an important point of integration for hormone, growth factor, and cytokine receptor systems that regulate critical cellular growth responses.	MAYO CLIN & MAYO FDN, ENDOCRINE RES UNIT, ROCHESTER, MN 55905 USA	Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; CONOVER CA, 1995, J CLIN ENDOCR METAB, V80, P987, DOI 10.1210/jc.80.3.987; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1994, DIABETES, V43, P1130, DOI 10.2337/diabetes.43.9.1130; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Inoue G, 1996, J BIOL CHEM, V271, P28206, DOI 10.1074/jbc.271.45.28206; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAM K, 1994, J BIOL CHEM, V269, P20648; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAAD MJA, 1995, ENDOCRINOLOGY, V136, P1579, DOI 10.1210/en.136.4.1579; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Takahashi Y, 1997, ENDOCRINOLOGY, V138, P741, DOI 10.1210/en.138.2.741; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WEBSTER J, 1994, MOL ENDOCRINOL, V8, P539, DOI 10.1210/me.8.5.539; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; White MF, 1996, PHILOS T ROY SOC B, V351, P181, DOI 10.1098/rstb.1996.0015; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19525	19531		10.1074/jbc.272.31.19525	http://dx.doi.org/10.1074/jbc.272.31.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235956	hybrid			2022-12-27	WOS:A1997XP06300062
J	Huang, C; Tandon, NN; Greco, NJ; Ni, YS; Wang, T; Zhan, X				Huang, C; Tandon, NN; Greco, NJ; Ni, YS; Wang, T; Zhan, X			Proteolysis of platelet cortactin by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; CA-2+-DEPENDENT PROTEASE; C-SRC; ACTIVATION; SUBSTRATE; IDENTIFICATION; CYTOSKELETON; INTEGRIN	Cortactin, a substrate of pp60(c-src) and a potent filamentous actin binding and cross-linking protein, is abundant in circulating platelets. After stimulation of platelet aggregation with collagen, cortactin undergoes a dramatic increase in tyrosine phosphorylation followed by a rapid degradation. The cleavage of platelet cortactin was detected in lysates prepared using either Triton-containing buffer or SDS-sample buffer. However, the degradation of cortactin was not observed in platelets derived from a Glanzmann's patient, who lacked functional integrin alpha(IIb)beta(3) (GPIIb-IIIa). In addition, the proteolysis of cortactin was abolished by treating platelets before but not after collagen stimulation with EGTA or calpeptin. Furthermore, recombinant cortactin was digested by mu-calpain in vitro in a dose-dependent manner, indicating that cortactin is a substrate for calpain. We also observed that the calpain-mediated digestion in vitro is dependent on the presence of a sequence containing a proline-rich region and multiple tyrosine residues that are phosphorylated by pp(60c-src). Tyrosine phosphorylation by pp60(c-src) up-regulates the activity of calpain toward cortactin. Our data suggest that the calpain-mediated proteolysis of tyrosine-phosphorylated cortactin may provide a mechanism to remodel irreversibly the cytoskeleton in response to platelet agonists.	AMER RED CROSS,HOLLAND LAB,DEPT EXPT PATHOL,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT PLATELET BIOL,ROCKVILLE,MD 20855; GLAXO & WELLCOME RES INST,DIV BIOL,RES TRIANGLE PK,NC 27709; GEORGE WASHINGTON UNIV,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20037	American Red Cross; American Red Cross; GlaxoSmithKline; George Washington University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL52753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bringuier PP, 1996, ONCOGENE, V12, P1747; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAA MC, 1992, ONCOGENE, V7, P2429; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NADA S, 1994, ONCOGENE, V9, P3571; ODA A, 1993, J BIOL CHEM, V268, P12603; OZAWA K, 1995, EXP CELL RES, V221, P197, DOI 10.1006/excr.1995.1367; RYBAK ME, 1988, BLOOD, V72, P414; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; Seiffert D, 1996, J BIOL CHEM, V271, P11170, DOI 10.1074/jbc.271.19.11170; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	33	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19248	19252		10.1074/jbc.272.31.19248	http://dx.doi.org/10.1074/jbc.272.31.19248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235918	hybrid			2022-12-27	WOS:A1997XP06300024
J	Miyamoto, A; Laufs, U; Pardo, C; Liao, JK				Miyamoto, A; Laufs, U; Pardo, C; Liao, JK			Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C; RELEASE; ACTIVATION; ENDOTHELIUM; SYNTHASE; INHIBITION; EXPRESSION; CYCLASE; CLONING	To determine whether nitric oxide (NO) can modulate bradykinin (BK) signaling pathways, we treated endothelial cells with an NO donor, S-nitrosoglutathione (GSNO), to determine its effect(s) on G-proteins (G(i) and G(q)) that are coupled to the type II kinin (BK2) receptor. Radioligand binding assays and Western analyses showed that GSNO (10-500 mu M, 0-72 h) did not alter the expression of BK2 receptor, G(i), or G(q). However, GSNO caused a 6-fold increase in basal cGMP production and decreased high affinity BK bindings sites and GTPase activity by 74 and 85%, respectively. The cGMP analogue, dibutyryl-cGMP, also inhibited BK-stimulated GTPase activity by 74% suggesting that some of the effects of NO may be mediated through activation of guanylyl cyclase. The NO synthase inhibitor, N-omega-monomethyl-L-arginine, inhibited endogenous NO synthase activity and cGMP production by 91 and 76%, respectively, but increased BK-stimulated GTPase activity by 61%. To determine which G-proteins are affected by NO, we performed GTP binding assays with [S-35]GTP gamma S followed by immunoprecipitation with specific G-protein antisera. Both GSNO and dibutyryl-cGMP increased basal G-protein GTP binding activities by 18-26%. However, GSNO decreased BK-stimulated G alpha(i2%), G alpha(i3), and G alpha(q/11) GTP binding activity by 93, 61, and 90%, respectively, whereas epinephrine-stimulated G alpha(s) GTP binding activity was unaffected. These results suggest that NO can modulate BK signaling pathways by selectively inhibiting G-proteins of the G(i) and G(q) family.	BRIGHAM & WOMENS HOSP, DEPT MED,DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07718, HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTEN KF, 1974, NEW ENGL J MED, V291, P661, DOI 10.1056/NEJM197409262911306; BARTHA K, 1989, BIOCHEM J, V263, P149, DOI 10.1042/bj2630149; Bauer J A, 1995, Adv Pharmacol, V34, P361; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; Busse R, 1996, DIABETES, V45, pS8, DOI 10.2337/diab.45.1.S8; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOLBERT TM, 1968, NEW ENGL J MED, V278, P1180; HESS DT, 1994, NEUROPHARMACOLOGY, V33, P1283, DOI 10.1016/0028-3908(94)90028-0; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1993, J IMMUNOL, V151, P7182; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIAO JK, 1994, J BIOL CHEM, V269, P12987; LOEB AL, 1988, AM J CARDIOL, V62, pG36; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RASBAND W, 1993, NIH IMAGE PROGRAM VE; REGOLI D, 1993, CAN J PHYSIOL PHARM, V71, P556, DOI 10.1139/y93-079; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147, DOI 10.1111/j.1476-5381.1994.tb17117.x; SAID SI, 1983, HYPERTENSION, V5, pI17, DOI 10.1161/01.HYP.5.2_Pt_2.I17; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	39	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19601	19608		10.1074/jbc.272.31.19601	http://dx.doi.org/10.1074/jbc.272.31.19601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235967	hybrid			2022-12-27	WOS:A1997XP06300073
J	Nishikawa, A; Gregory, W; Frenz, J; Cacia, J; Kornfeld, S				Nishikawa, A; Gregory, W; Frenz, J; Cacia, J; Kornfeld, S			The phosphorylation of bovine DNase I Asn-linked oligosaccharides is dependent on specific lysine and arginine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME PHOSPHORYLATION; PROTEIN RECOGNITION DETERMINANTS; PROCATHEPSIN-D; MANNOSE PHOSPHORYLATION; AMINO; RECOMBINANT; RECEPTORS; CELLS; LOBE	The secretory glycoprotein DNase I acquires mannose B-phosphate moieties on its Asn-linked oligosaccharides, indicating that it is a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase) (Cacia, J., Quan, C., and Frenz, J. (1995) Glycobiology 4, 99), Phosphotransferase recognizes a conformation-dependent protein determinant that is present in lysosomal hydrolases, but absent in most secretory glycoproteins. To identify the amino acid residues of DNase I that are required for interaction with phosphotransferase, wild-type and mutant forms of bovine DNase I were expressed in COS-1 cells and the extent of oligosaccharide phosphorylation determined. Phosphorylation of DNase I oligosaccharides decreased from 12.6% to 2.3% when Lys-50, Lys-124, and Arg-27 were mutated to alanines, indicating that these residues are required for the basal level of phosphorylation, Mutation of lysines at other positions did not impair phosphorylation, demonstrating the selectivity of this process, When Arg-27 was replaced with a lysine, phosphorylation increased to 54%, showing that phosphotransferase prefers lysine residues to arginines, Mutation of Asn-74 to a lysine also increased phosphorylation to 50.3%, and the double mutant (R27K/N74K) was phosphorylated 79%, equivalent to the values obtained with lysosomal hydrolases. Interestingly, Lys-27 and Lys-74 caused selective phosphorylation of the neighboring Asn-linked oligosaccharide. Finally, mutation of Lys-117 to an alanine stimulated phosphorylation, demonstrating that some residues may be negative regulators of this process, We conclude that selected lysine and arginine residues on the surface of DNase I constitute the major elements of the phosphotransferase recognition domain present on this secretory glycoprotein.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; GENENTECH INC,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Roche Holding; Genentech			Nishikawa, Atsushi/E-6766-2013	Nishikawa, Atsushi/0000-0003-4325-1160	NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CACIA J, 1995, GLYCOBIOLOGY, V4, P99; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Dittmer F, 1997, J BIOL CHEM, V272, P852, DOI 10.1074/jbc.272.2.852; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAZZARINO D, 1989, EMBO J, V3, P5015; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Mannherz H G, 1995, Curr Top Microbiol Immunol, V198, P161; PAUDEL HK, 1986, J BIOL CHEM, V261, P6012; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SCHOREY JS, 1995, J CELL SCI, V108, P2007; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WORRALL AF, 1990, J BIOL CHEM, V265, P21889	26	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19408	19412		10.1074/jbc.272.31.19408	http://dx.doi.org/10.1074/jbc.272.31.19408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235940	hybrid			2022-12-27	WOS:A1997XP06300046
J	Akasako, A; Haruki, M; Oobatake, M; Kanaya, S				Akasako, A; Haruki, M; Oobatake, M; Kanaya, S			Conformational stabilities of Escherichia coli RNase HI variants with a series of amino acid substitutions at a cavity within the hydrophobic core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RIBONUCLEASE HI; STRUCTURAL-ANALYSIS; PROTEIN CORE; T4 LYSOZYME; PACKING ARRANGEMENTS; CREATING MUTATIONS; FILLING MUTATIONS; INTERNAL CAVITIES; GLOBULAR-PROTEINS	Escherichia coli ribonuclease HI has a cavity within the hydrophobic core, Two core residues, Ala(52) and Val(74), resided at both ends of this cavity, We have constructed a series of single mutant proteins at Ala(52), and double mutant proteins, in which Ala(52) was replaced by Gly, Val, Ile, Leu, or Phe, and Val(74) was replaced by Ala or Leu, All of these mutant proteins, except for A52W, A52R, and A52G/V74A, were overproduced and purified, Measurement of the thermal denaturations of the proteins at pH 3.2 by CD suggests that the cavity is large enough to accommodate three methyl or methylene groups without creating serious strains, A correlation was observed between the protein stability and the hydrophobicity of the substituted residue, As a result, a number of the mutant proteins were more stable than the wild-type protein, The stabilities of the mutant proteins with charged or extremely bulky residues at the cavity were lower than those expected from the hydrophobicities of the substituted residues, suggesting that considerable strains are created at the mutation sites in these mutant proteins, However, examination of the far- and near-UV GD spectra and the enzymatic activities suggest that all of the mutant proteins have structures similar to that of the wild-type protein, These results suggest that the cavity in the hydrophobic core off. coli RNase HI is conformationally fairly stable, This may be the reason why the cavity-filling mutations effectively increase the thermal stability of this protein.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; Axe DD, 1996, P NATL ACAD SCI USA, V93, P5590, DOI 10.1073/pnas.93.11.5590; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; BALDWIN EP, 1993, SCIENCE, V262, P1715, DOI 10.1126/science.8259514; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CONNOLLY ML, 1986, INT J PEPT PROT RES, V28, P360; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; EIJSINK VGH, 1992, PROTEIN ENG, V5, P421, DOI 10.1093/protein/5.5.421; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Gassner NC, 1996, P NATL ACAD SCI USA, V93, P12155, DOI 10.1073/pnas.93.22.12155; Gray TM, 1996, PROTEIN SCI, V5, P742; HARUKI M, 1994, J BIOL CHEM, V269, P26904; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P7136, DOI 10.1021/bi00079a010; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6171, DOI 10.1021/bi00075a009; ISHIKAWA K, 1993, PROTEIN ENG, V6, P85, DOI 10.1093/protein/6.1.85; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; KANAYA E, 1995, J BIOL CHEM, V270, P19853, DOI 10.1074/jbc.270.34.19853; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1991, J BIOL CHEM, V266, P6038; Kanaya S, 1996, J BIOL CHEM, V271, P32729, DOI 10.1074/jbc.271.51.32729; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KIMURA S, 1992, J BIOL CHEM, V267, P22014; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1991, NATURE, V352, P448, DOI 10.1038/352448a0; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SNEDDON SF, 1992, BIOCHEMISTRY-US, V31, P2842, DOI 10.1021/bi00125a028; Sun SJ, 1995, PROTEIN ENG, V8, P1205, DOI 10.1093/protein/8.12.1205; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; VANGUNSTEREN WF, 1992, J MOL BIOL, V227, P389, DOI 10.1016/0022-2836(92)90895-Q; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WILSON KP, 1992, J BIOL CHEM, V267, P10842; Yamasaki K, 1995, BIOCHEMISTRY-US, V34, P16552, DOI 10.1021/bi00051a003; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; Zhang H, 1996, J MOL BIOL, V259, P148, DOI 10.1006/jmbi.1996.0309; Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F	60	72	74	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18686	18693		10.1074/jbc.272.30.18686	http://dx.doi.org/10.1074/jbc.272.30.18686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228039	hybrid			2022-12-27	WOS:A1997XM34200030
J	Imaizumi, K; Tsuda, M; Imai, Y; Wanaka, A; Takagi, T; Tohyama, M				Imaizumi, K; Tsuda, M; Imai, Y; Wanaka, A; Takagi, T; Tohyama, M			Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CULTURED SYMPATHETIC NEURONS; CELL-DEATH; FACTOR DEPRIVATION; PROTEIN-SYNTHESIS; FACTOR WITHDRAWAL; FACTOR DEPENDENCE; GENE-EXPRESSION; C-JUN; APOPTOSIS	To study the molecular mechanisms underlying neuronal programmed cell death (PCD), we performed differential display screening for genes, the expression of which was induced during PCD in the sympathetic neuron culture model deprived of NGF. We cloned a gene encoding a novel polypeptide (DP5) which consisted of 92 amino acids, DP5 polypeptide had no homology with any other known protein and contained no motif that would indicate its putative biochemical functions, DP5 mRNA levels peaked at 15 h after nerve growth factor withdrawal, concurrent with the time at which neurons were committed to die, The induction of DP5 gene expression was blocked when cell death was rescued by treatment with cycloheximide, KCl, or the cyclic AMP analogue CPTcAMP. Overexpression of the full-length DP5 in cultured sympathetic neurons was in itself sufficient to induce apoptosis, These results suggest that DP5 plays a role in programmed neuronal death.	OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, SUITA, OSAKA 565, JAPAN; TANABE SEIYAKU CO LTD, LEAD GENERAT RES LAB, OSAKA 532, JAPAN; FUKUSHIMA MED COLL, INST BIOMED SCI, DEPT CELL SCI, FUKUSHIMA 96012, JAPAN	Osaka University; Mitsubishi Tanabe Pharma Corporation; Fukushima Medical University	Imaizumi, K (corresponding author), OSAKA UNIV, SCH MED, TANABE, DEPT MOL NEUROBIOL, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.		Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 				ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; Shimizu S, 1996, ONCOGENE, V13, P21; STANISIC T, 1978, INVEST UROL, V16, P19; TANAKA S, 1992, BIOCHIM BIOPHYS ACTA, V1175, P114, DOI 10.1016/0167-4889(92)90017-6; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9	35	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18842	18848		10.1074/jbc.272.30.18842	http://dx.doi.org/10.1074/jbc.272.30.18842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228060	hybrid			2022-12-27	WOS:A1997XM34200051
J	Moloney, DJ; Lin, AI; Haltiwanger, RS				Moloney, DJ; Lin, AI; Haltiwanger, RS			The O-linked fucose glycosylation pathway - Evidence for protein-specific elongation of O-linked fucose in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR DOMAIN; HUMAN FACTOR-IX; PLASMINOGEN-ACTIVATOR; IDENTIFICATION; LINKAGE; PEPTIDE; GLCNAC; OLIGOSACCHARIDES; TRANSFERASE; SERINE-61	O-Linked fucose is an unusual form of glycosylation recently shown to modify the hydroxyls of serine or threonine residues at a strict consensus site within epidermal growth factor-like domains of several serum proteins, Here we demonstrate that Chinese hamster ovary cells modify numerous proteins with O-linked fucose and that the fucose is elongated on specific proteins. We have identified at least two forms of O-linked fucose elongation in Chinese hamster ovary cells: a disaccharide (Glc beta 1,3Fuc) and a larger oligosaccharide of indeterminate structure, Interestingly, it appears that the level of monosaccharide accumulates in the cells over time whereas the disaccharide does not. Analysis of the O-linked fucose containing saccharides on individual proteins revealed that some proteins are modified with the monosaccharide only, whereas others are modified with monosaccharide and disaccharide, or monosaccharide and oligosaccharide. These results suggest that elongation of the O-linked fucose monosaccharide is a protein-specific phenomena, The presence of elongated O-linked fucose moieties suggests that a novel glycosylation pathway exists in mammalian cells with O-linked fucose as the core.	SUNY STONY BROOK,INST CELL & DEV BIOL,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM 48666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BJOERN S, 1991, J BIOL CHEM, V266, P11051; CAMANI C, 1995, J BIOL CHEM, V270, P26053, DOI 10.1074/jbc.270.44.26053; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOLT GD, 1986, J BIOL CHEM, V261, P8049; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MORTON PA, 1985, BIOCHEM J, V225, P59, DOI 10.1042/bj2250059; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WANG Y, 1996, GLYCOBIOLOGY, V8, P837	34	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19046	19050		10.1074/jbc.272.30.19046	http://dx.doi.org/10.1074/jbc.272.30.19046			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228088	hybrid			2022-12-27	WOS:A1997XM34200079
J	Shanmugam, K; Featherstone, MS; Saragovi, HU				Shanmugam, K; Featherstone, MS; Saragovi, HU			Residues flanking the HOX YPWM motif contribute to cooperative interactions with PBX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENE; CRYSTAL-STRUCTURE; HOMEOTIC GENE; PRE-B; PROTEINS; EXTRADENTICLE; HOMEODOMAIN; MURINE; EXPRESSION	Hox genes encode transcription factors that are major determinants of embryonic patterning. Recently, we and others have shown that specific recognition of target sites in DNA is partly achieved through cooperative interaction with the extradenticle/pre-B-cell transformation-related gene (EXD/PBX) family of homeodomain-containing proteins. This interaction is mediated by the YPWM motif present N-terminal to the homeodomain in HOX proteins. In the present study, we use YPWM peptides to confirm the importance of this motif for mediating HOX/PBX interactions. We also used a novel monoclonal antibody directed against the YPWM to show that occlusion of this motif abrogates cooperativity with PBX. In addition, we present evidence that residues flanking the YPWM, both N-terminally and C-terminally, stabilize the HOX.PBX cooperative complex. Because these flanking residues are also conserved among paralogs, they are likely to help distinguish the specificity of HOX/PBX interactions. Our data further show that the relative importance of individual residues within and flanking the YPWM is dependent on the identity of position 6 of the cooperative binding site (TGATT (N) under bar ATGG). These results suggest that interactions between PBX and the YPWM motif are modified by a base pair predicted to contact the N-terminal arm of the HOX homeodomain.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University; McGill University			Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				BURGLIN TR, 1994, GUIDEBOOK HOMEOBOX G, P44; CATTY D, 1988, ANTIBODIES PRACTICAL, V1, P1; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1994, DEVELOPMENT, P135; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LeSauteur L, 1996, J NEUROSCI, V16, P1308; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6	44	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19081	19087		10.1074/jbc.272.30.19081	http://dx.doi.org/10.1074/jbc.272.30.19081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228093	hybrid			2022-12-27	WOS:A1997XM34200084
J	Xie, PG; Parsons, SH; Speckhard, DC; Bosron, WF; Hurley, TD				Xie, PG; Parsons, SH; Speckhard, DC; Bosron, WF; Hurley, TD			X-ray structure of human class IV sigma sigma alcohol dehydrogenase - Structural basis for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RETINOIC ACID; RESOLUTION; METABOLISM; OXIDATION; ISOZYMES	The structural determinants of substrate recognition in the human class IV, or sigma sigma, alcohol dehydrogenase (ADH) isoenzyme were examined through x-ray crystallography and site-directed mutagenesis. The crystal structure of sigma sigma ADH complexed with NAD(+) and acetate was solved to 3-Angstrom resolution. The human beta(1) beta(1) and sigma sigma ADH isoenzymes share 69% sequence identity and exhibit dramatically different kinetic properties. Differences in the amino acids at positions 57, 116, 141, 309, and 317 create a different topology within the sigma sigma substrate-binding pocket, relative to the beta(1) beta(1) isoenzyme. The nicotinamide ring of the NAD(H) molecule, in the sigma sigma structure, appears to be twisted relative to its position in the beta(1) beta(1) isoenzyme. In conjunction with movements of Thr-48 and Phe-93, this twist widens the substrate pocket in the vicinity of the catalytic zinc and may contribute to this isoenzyme's high K-m for small substrates. The presence of Met-57, Met-141, and Phe-309 narrow the middle region of the sigma sigma substrate pocket and may explain the substantially decreased K-m values with increased chain length of substrates in sigma sigma ADH. The kinetic properties of a mutant sigma sigma enzyme (sigma 309L317A) suggest that widening the middle region of the substrate pocket increases K-m by weakening the interactions between the enzyme and smaller substrates while not affecting the binding of longer alcohols, such as hexanol and retinol.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202; LORAS COLL,DEPT CHEM,DUBUQUE,IA 52001	Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NIAAA NIH HHS [K21-AA00150, R29-AA10399] Funding Source: Medline; PHS HHS [R37-07117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010399, K21AA000150] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Cleland W W, 1979, Methods Enzymol, V63, P103; Davis GJ, 1996, J BIOL CHEM, V271, P17057, DOI 10.1074/jbc.271.29.17057; EDENBERG HJ, 1989, ENZYMOLOGY MOL BIOL, V2, P181; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EHRIG T, 1990, ALCOHOL ALCOHOLISM, V25, P105, DOI 10.1093/oxfordjournals.alcalc.a044985; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HAGASHI T, 1990, RAXIS IIC DATA PROCE; HOOG JO, 1992, EUR J BIOCHEM, V205, P519, DOI 10.1111/j.1432-1033.1992.tb16808.x; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1992, BIOCHEM BIOPH RES CO, V183, P93, DOI 10.1016/0006-291X(92)91613-U; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; HURLEY TD, 1995, ENZYMOLOGY MOL BIOL, V5, P321; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAGE MI, 1973, CHEM SOC REV, V2, P295, DOI 10.1039/cs9730200295; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; PULLARKAT RK, 1991, ALCOHOL CLIN EXP RES, V15, P565, DOI 10.1111/j.1530-0277.1991.tb00561.x; Ramaswamy S, 1996, PROTEIN SCI, V5, P663; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; STONE CL, 1992, J BIOL CHEM, V268, P892; THEORELL H, 1969, ACTA CHEM SCAND, V23, P255, DOI 10.3891/acta.chem.scand.23-0255; VALLEE BL, 1983, ISOZYMES-CURR T BIOL, V8, P219; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x	38	72	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18558	18563		10.1074/jbc.272.30.18558	http://dx.doi.org/10.1074/jbc.272.30.18558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228021	hybrid			2022-12-27	WOS:A1997XM34200012
J	Jordan, A; Aslund, F; Pontis, E; Reichard, P; Holmgren, A				Jordan, A; Aslund, F; Pontis, E; Reichard, P; Holmgren, A			Characterization of Escherichia coli NrdH - A glutaredoxin-like protein with a thioredoxin-like activity profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SEQUENCE; RIBONUCLEOTIDE REDUCTASE; HYDROGEN DONOR; SECONDARY STRUCTURE; T4 THIOREDOXIN; GLUTATHIONE; DISULFIDE; PURIFICATION; ASSIGNMENTS	Ribonucleotides are converted to deoxyribonucleotides by ribonucleotide reductases. Either thioredoxin or glutaredoxin is a required electron donor for class I and II enzymes. Glutaredoxins are reduced by glutathione, thioredoxins by thioredoxin reductase. Recently, a glutaredoxin-like protein, NrdH, was isolated as the functional electron donor for a NrdEF ribonucleotide reductase, a class Ib enzyme, from Lactococcus lactis. The absence of glutathione in this bacterium raised the question of the identity of the intracellular reductant for NrdH. Homologues of NrdH are present in the genomes of Escherichia coli and Salmonella typhimurium, upstream of the genes for the poorly transcribed nrdEF, separated from it by arm open reading frame (nrdI) coding for a protein of unknown function, Overexpression of E. coli NrdH protein shows that it is a functional hydrogen donor with higher specificity for the class Ib (NrdEF) than for the class Ia (NrdAB) ribonucleotide reductase. Furthermore, this glutaredoxin-like enzyme is reduced by thioredoxin reductase and not by glutathione. We suggest that several uncharacterized glutaredoxin-like proteins present in the genomes of organisms lacking GSH, including archae, will also react with thioredoxin reductase and be related to the ancestors from which the GSH-dependent glutaredoxins have evolved by the acquisition of a GSH-binding site, We also show that NrdI, encoded by all nrdEF operons, hats a stimulatory effect on ribonucleotide reduction.	KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, MED NOBEL INST BIOCHEM, S-17177 STOCKHOLM, SWEDEN; UNIV AUTONOMA BARCELONA, FAC SCI, DEPT GENET & MICROBIOL, BARCELONA 08193, SPAIN	Karolinska Institutet; Autonomous University of Barcelona			jordan, albert/ABC-8229-2020; jordan, albert/K-4678-2014	jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693				ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; ASUND F, 1996, J BIOL CHEM, V271, P6736; BERGLUND O, 1975, J BIOL CHEM, V250, P2778; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gvakharia BO, 1996, J BIOL CHEM, V271, P15307, DOI 10.1074/jbc.271.26.15307; HALL DE, 1971, EUR J BIOCHEM, V23, P328, DOI 10.1111/j.1432-1033.1971.tb01625.x; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; JOELSON T, 1990, J BIOL CHEM, V265, P3183; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MCFARLAN SC, 1992, J BIOL CHEM, V267, P10561; MINAKUCHI K, 1994, FEBS LETT, V337, P157, DOI 10.1016/0014-5793(94)80264-5; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Scotti C, 1996, MICROBIOL-SGM, V142, P2995, DOI 10.1099/13500872-142-11-2995; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; SODANO P, 1991, J MOL BIOL, V221, P1311; Thelander L, 1978, Methods Enzymol, V51, P227; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	48	124	127	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18044	18050		10.1074/jbc.272.29.18044	http://dx.doi.org/10.1074/jbc.272.29.18044			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218434	hybrid			2022-12-27	WOS:A1997XL73500024
J	Kresse, H; Liszio, C; Schonherr, E; Fisher, LW				Kresse, H; Liszio, C; Schonherr, E; Fisher, LW			Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; CORE PROTEIN; FIBRILLAR COLLAGEN; TENDON COLLAGEN; BINDING; EXPRESSION; FIBROBLASTS; CDNA; LOCALIZATION; FIBRONECTIN	The chondroitin/dermatan sulfate proteoglycan decorin is known to interact via its core protein with fibrillar collagens, thereby influencing the kinetics of fibril formation and the final diameter of the fibrils. To define the binding site(s) for type I collagen along the core protein, which is mainly composed of leucine-rich repeat structures, decorin cDNAs were constructed and expressed in human kidney 293 cells. The constructs encoded (i) C-terminally truncated molecules, (ii) core proteins with deletions of selected leucine-rich repeats, or (iii) various point mutations, The deletion of the sixth leucine-rich repeat Met(176)-Lys(201) and the mutation E180K drastically interfered with the binding to reconstituted type I collagen fibrils, In contrast, the deletion of the seventh repeat Leu(202)-Ser(222) led at the most to a marginally impaired binding, although the secretion of this proteoglycan was abnormally low. Decorin with two other point mutations in the sixth leucine-rich repeat, Lys(187) --> Gln and Lys(200) --> Gln, respectively, bound type I collagen either normally or even better than the normal recombinant proteoylycan. These data suggest that a major collagen-binding site of decorin is located within the sixth leucine-rich repeat and that glutamate-180 within this repeat is of special importance for ionic interactions between the two matrix components.	NIDR, CRANIOFACIAL & SKELETAL DIS BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kresse, H (corresponding author), UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-48149 MUNSTER, GERMANY.							BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Bittner K, 1996, BIOCHEM J, V314, P159, DOI 10.1042/bj3140159; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HAUSSER H, 1992, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hudson DL, 1996, MOL BIOL CELL, V7, P496; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KINGSTON RE, 1996, CURRENT PROTOCOLS MO, V1; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MANN DM, 1990, J BIOL CHEM, V265, P5317; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SELDEN RF, 1996, CURRENT PROTOCOLS MO, V1; SPIRO RC, 1994, MOL BIOL CELL, V5, P303; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; ULDBJERG N, 1988, BIOCHEM J, V251, P643, DOI 10.1042/bj2510643; VANKUPPEVELT THMSM, 1987, HISTOCHEM J, V19, P520, DOI 10.1007/BF01675423; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WITSCHPREHM P, 1992, ARTHRITIS RHEUM-US, V35, P1042, DOI 10.1002/art.1780350909; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YU L, 1993, DERMATAN SULPHATE PR, P183	50	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18404	18410		10.1074/jbc.272.29.18404	http://dx.doi.org/10.1074/jbc.272.29.18404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218483	hybrid			2022-12-27	WOS:A1997XL73500073
J	Lima, WF; Mohan, V; Crooke, ST				Lima, WF; Mohan, V; Crooke, ST			The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODEOXYNUCLEOTIDES; DEGRADATION; EXPRESSION	The ability of Escherichia coli RNase H1 to hydrolyze structured substrates containing antisense oligonucleotides preannealed to a 47 mer RNA was compared with its ability to hydrolyze unstructured substrates containing antisense oligonucleotides duplexed with 13-mer RNA. These results demonstrate that when antisense oligonucleotides were bound to structured RNA, the resultant duplexes were cleaved at rates significantly slower than when the same oligonucleotides were bound to unstructured oligoribonucleotides. Structured substrates exhibited fewer cleavage sites, and each cleavage site was cleaved less rapidly than in unstructured substrates. Furthermore, the enzymatic activity of E. coli RNase H1 for the structured substrates was most affected when the cleavage sites corresponding to the enzymatically most active sites on the unstructured substrates were blocked in the structured substrates. Molecular modeling suggests that the observed ablation of RNase H activity was due to the steric hindrance of the enzyme by the structured RNA, i.e. steric interference of the phosphate groups on the substrate and/or the binding site of the enzyme. When chimeric oligonucleotides composed of a five-base deoxynucleotide sequence flanked by chemically modified nucleotides were bound to structured RNA, the resultant duplexes were even worse substrates for RNase H. These results offer further insights into the role of antisense-induced RNA structure on RNase H activity and may facilitate the design of effective antisense oligonucleotides.			Lima, WF (corresponding author), ISIS PHARMACEUT,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; Ausubel FM, 1988, MOL REPROD DEV; Bennington CPJ, 1996, P TECH AS P, P171; Cheatham TE, 1996, J MOL BIOL, V259, P434; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Cook P.D., 1993, ANTISENSE RES APPL, P149; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crooke ST, 1996, MED RES REV, V16, P319, DOI 10.1002/(SICI)1098-1128(199607)16:4<319::AID-MED2>3.0.CO;2-#; Crooke ST., 1995, THERAPEUTIC APPL OLI; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; GUINOSSO CJ, 1991, NUCLEOS NUCLEOT, V10, P259, DOI 10.1080/07328319108046455; HAUSEN P, 1970, EUR J BIOCHEM, V14, P279; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; McKay RA, 1996, NUCLEIC ACIDS RES, V24, P411, DOI 10.1093/nar/24.3.411; MIRABELLI CK, 1993, ANTISENSE RES APPL, P15; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MONIA BP, 1996, J BIOL CHEM, V271, P14583; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; PLEIJ CW, 1990, NUCLEIC ACIDS RES, V13, P1717; PUGLISI JD, 1988, NATURE, V321, P283; Saenger W., 1984, PRINCIPLES NUCL ACID, P116, DOI DOI 10.1007/978-1-4612-5190-3_6; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Sproat BS, 1993, ANTISENSE RES APPLIC, P351; TIDD DM, 1989, BRIT J CANCER, V60, P343, DOI 10.1038/bjc.1989.283; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	32	49	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18191	18199		10.1074/jbc.272.29.18191	http://dx.doi.org/10.1074/jbc.272.29.18191			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218455	hybrid			2022-12-27	WOS:A1997XL73500045
J	Lyon, M; Rushton, G; Gallagher, JT				Lyon, M; Rushton, G; Gallagher, JT			The interaction of the transforming growth factor-beta s with heparin heparan sulfate is isoform-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; MESSENGER-RNA; ADULT TISSUES; RAT-LIVER; EXPRESSION; ALPHA-2-MACROGLOBULIN; FACTOR-BETA-1; PROTEOGLYCAN	We have undertaken a comparative study of the interaction of the three mammalian transforming growth factor-beta s (TGF-beta) with heparin and heparan sulfate. TGP-beta 1 and -beta 2, but not -beta 3, bind to heparin and the highly sulfated liver heparan sulfate, These polysaccharides potentiate the biological activity of TGF-beta 1 (but, not the other isoforms), whereas a low sulfated mucosal heparan sulfate fails to de, see, Potentiation is due to antagonism of the binding and inactivation of TGF-beta 1 by alpha(2)-macroglobulin, rather than by modulation of growth factor-receptor interactions. TGF-beta 2.alpha(2)-macroglobulin complexes are more refractory to heparin/heparan sulfate, and those involving TGF-beta 3 cannot be affected, Comparison of the amino acid sequences of the TGF-beta isoforms strongly implicates the basic amino acid residue at position 26 of each monomer as being a vital binding determinant, A model is proposed in which polysaccharide binding occurs at two distinct sites on the TGF-beta dimer. interaction with heparin and liver heparan sulfate may be most effective because of the ability of the dimer to co-operatively engage two specific sulfated binding sequences, separated by a distance of approximately seven disaccharides, within the same chain.			Lyon, M (corresponding author), UNIV MANCHESTER, DEPT MED ONCOL, CHRISTIE HOSP NHS TRUST, CANC RES CAMPAIGN, WILMSLOW RD, MANCHESTER M20 4BX, LANCS, ENGLAND.			Lyon, Malcolm/0000-0001-9575-6879				ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FRANSSON LA, 1980, BIOCHIM BIOPHYS ACTA, V630, P287, DOI 10.1016/0304-4165(80)90433-X; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GATHERER D, 1990, DEVELOPMENT, V110, P445; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GRUBER BL, 1994, J IMMUNOL, V152, P5860; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HU ZQ, 1994, IMMUNOLOGY, V82, P482; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P1186, DOI 10.1210/mend-2-12-1186; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KEKOW J, 1995, INT J ONCOL, V7, P177; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; LYON M, 1994, J BIOL CHEM, V269, P11208; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1926, DOI 10.1210/mend-3-12-1926; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PENNINGTON DW, 1992, J CLIN INVEST, V90, P35, DOI 10.1172/JCI115853; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RIZZINO A, 1986, CANCER RES, V46, P2816; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roberts AB, 1990, GROWTH FACTORS, V3, P277, DOI 10.3109/08977199009003670; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; SOKER S, 1993, J BIOL CHEM, V268, P7685; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	61	225	238	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18000	18006		10.1074/jbc.272.29.18000	http://dx.doi.org/10.1074/jbc.272.29.18000			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218427	hybrid			2022-12-27	WOS:A1997XL73500017
J	vanderLeede, BM; vandenBrink, CE; Pijnappel, WWM; Sonneveld, E; vanderSaag, PT; vanderBurg, B				vanderLeede, BM; vandenBrink, CE; Pijnappel, WWM; Sonneveld, E; vanderSaag, PT; vanderBurg, B			Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; VITAMIN-A; 13-CIS-RETINOIC ACID; RECEPTOR-BETA; INTERFERON ALPHA-2A; INVIVO METABOLISM; BINDING PROTEIN; GENE-EXPRESSION; LUNG-CANCER; X RECEPTOR	Previous studies have shown that all-trans-retinoic acid (RA) inhibits in vitro proliferation of hormone-dependent human breast cancer cells but not the growth of hormone-independent cells, Here we report on RA metabolism in breast cancer cells as examined by high performance liquid chromatography analysis and found a correlation with sensitivity to growth inhibition by RA, RA-sensitive T-47D and MCF-7 cells exhibited high rate metabolism to polar metabolites, whereas RA-resistant MDA-MB 231 and MDA-MB-468 cells metabolized RA to a much lesser extent, and almost no polar metabolites could be detected. The high metabolic rate in RA-sensitive cells appears to be the result of autoinduction of RA metabolism, whereas RA-resistant cells showed no such induction of metabolism, We observed furthermore that transfection with retinoic acid receptor-alpha expression vectors in RA-resistant MDA-MB-231 cells resulted in increased RA metabolism and inhibition of cell proliferation, Metabolism of RA, however, seems not to be required to confer growth inhibition of human breast cancer cells, The biological activity of the polar metabolites formed in RA-sensitive cells was found to be equal or lower than that of RA, indicating that RA itself is the most active retinoid in these cells, Together our data suggest that RA-sensitive cells contain mechanisms to activate strongly the catabolism of RA probably to protect them from the continuous exposure to this active retinoid.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)				Pijnappel, Pim/0000-0002-7042-2482				ADAMSON PC, 1993, J NATL CANCER I, V85, P993, DOI 10.1093/jnci/85.12.993; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CORNIC M, 1994, LEUKEMIA, V8, P16; DE LUCA LM, 1991, FASEB J, V5, P2924; FONTANA JA, 1990, CANCER RES, V50, P1977; FORRESTER LM, 1990, CARCINOGENESIS, V11, P2136; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; Gaemers IC, 1996, ENDOCRINOLOGY, V137, P479, DOI 10.1210/en.137.2.479; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; Han IS, 1996, J CLIN ENDOCR METAB, V81, P2069, DOI 10.1210/jc.81.6.2069; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LEO MA, 1989, ARCH BIOCHEM BIOPHYS, V269, P305, DOI 10.1016/0003-9861(89)90112-4; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; Mangelsdorf David J., 1994, P319; MARTH C, 1984, BIOCHEM PHARMACOL, V33, P2217, DOI 10.1016/0006-2952(84)90657-9; Moon Richard C., 1994, P573; MUINDI JF, 1993, CANCER RES, V53, P1226; MUINDI JRF, 1992, CANCER RES, V52, P2138; MURRAY M, 1991, ARCH BIOCHEM BIOPHYS, V286, P618, DOI 10.1016/0003-9861(91)90089-2; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; NIKAWA T, 1995, ARCH BIOCHEM BIOPHYS, V316, P1; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; PILKINGTON T, 1992, DRUGS, V43, P597, DOI 10.2165/00003495-199243040-00010; REYNOLDS NJ, 1993, J PHARMACOL EXP THER, V266, P1636; RIGAS JR, 1993, J NATL CANCER I, V85, P1921, DOI 10.1093/jnci/85.23.1921; Rigas JR, 1996, CANCER RES, V56, P2692; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROMAN SD, 1993, CANCER RES, V53, P5940; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Takatsuka J, 1996, CANCER RES, V56, P675; TAKITANI K, 1995, J NUTR SCI VITAMINOL, V41, P493, DOI 10.3177/jnsv.41.493; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1993, MOL CARCINOGEN, V8, P112, DOI 10.1002/mc.2940080208; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; VANWAUWE J, 1994, BIOCHEM PHARMACOL, V47, P737, DOI 10.1016/0006-2952(94)90137-6; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; VECCHINI F, 1994, BIOCHEM BIOPH RES CO, V201, P1205, DOI 10.1006/bbrc.1994.1833; WESTIN S, 1993, MOL PHARMACOL, V44, P997; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WOUTERS W, 1992, CANCER RES, V52, P2841	60	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17921	17928		10.1074/jbc.272.29.17921	http://dx.doi.org/10.1074/jbc.272.29.17921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218416	hybrid			2022-12-27	WOS:A1997XL73500006
J	Falson, P; Menguy, T; Corre, F; Bouneau, L; deGracia, AG; Soulie, S; Centeno, F; Moller, JV; Champeil, P; leMaire, M				Falson, P; Menguy, T; Corre, F; Bouneau, L; deGracia, AG; Soulie, S; Centeno, F; Moller, JV; Champeil, P; leMaire, M			The cytoplasmic loop between putative transmembrane segments 6 and 7 in sarcoplasmic reticulum Ca2+-ATPase binds Ca2+ and is functionally important	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GASTRIC H+/K+-ATPASE; CALCIUM-BINDING; 3-DIMENSIONAL STRUCTURE; TRANSPORT SITES; ADENOSINE-TRIPHOSPHATASE; CA-2+-BINDING PROTEINS; GEL-ELECTROPHORESIS; CATION OCCLUSION; NA/K-ATPASE	Limited proteolysis Toy proteinase K of rabbit SERCA1 Ca2+-ATPase generates 21 number of fragments which have been identified recently, Here, we have focused on two proteolytic C-terminal fragments, p20C and p19C, starting at Gly-808 and Asp-818, respectively. The longer peptide p20C binds Ca2+, as deduced from changes in migration rate by SDS-polyacrylamide gel electrophoresis performed in the presence of Ca2+ as well as from labeling with Ca-45(2+) in overlay experiments. In contrast, the shorter peptide p19C, a proteolysis fragment identical to p20C but for 10 amino acids missing at the N-terminal side, did not bind Ca2+ when submitted to the same experiments, Two cluster mutants of Ca2+-ATPase, D813A/D818A and D813A/D815A/D818A, expressed in the yeast Saccharomyces cerevisiae, were found to have a very low Ca2+-ATPase activity. Region 808-818 is thus essential for both Ca2+ binding and enzyme activity, in agreement with similar results recently reported for the homologous gastric H+, K+-ATPase (Swarts, H, G. P., Klaassen, C, H. W., de Boer, M., Fransen, J. A, M., and De Pont, J, J, H, Pi, M., (1996) J. Biol. Chem. 271, 29764-29772). However, the accessibility of proteinase K to the peptidyl huh between Leu-807 and Oly-808 clearly shows that the transmembrane segment M6 ends before region 808-818, It is remarkable that critical residues]far enzyme activity are located in a cytoplasmic loop starting at Gly-808.	CENS, CEA, DBCM, SBPM, F-91191 GIF SUR YVETTE, FRANCE; CENS, CNRS URA 2096, F-91191 GIF SUR YVETTE, FRANCE; AARHUS UNIV, DANISH BIOMEMBRANE RES CTR, DEPT BIOPHYS, DK-8000 AARHUS C, DENMARK	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University			Centeno, Francisco/F-7287-2016	Centeno, Francisco/0000-0001-6154-5424; Falson, Pierre/0000-0002-9760-4577				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1992, FEBS LETT, V306, P101; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG E, 1994, SODIUM PUMP; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CAMPBELL KP, 1986, SARCOPLASMIC RETICUL, V1, P65; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COX JA, 1981, BIOCHEMISTRY-US, V20, P5430, DOI 10.1021/bi00522a012; COZENS B, 1984, J BIOL CHEM, V259, P6248; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; DUX L, 1985, J BIOL CHEM, V260, P1730; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; Groves JD, 1996, P NATL ACAD SCI USA, V93, P12245, DOI 10.1073/pnas.93.22.12245; HALL L, 1982, NUCLEIC ACIDS RES, V10, P3503, DOI 10.1093/nar/10.11.3503; HEBERT H, 1992, FEBS LETT, V299, P159, DOI 10.1016/0014-5793(92)80237-B; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1990, NATURE, V346, P617; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MOHRAZ M, 1987, J CELL BIOL, V105, P1, DOI 10.1083/jcb.105.1.1; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLER JV, 1994, SODIUM PUMP, P131; OR E, 1993, J BIOL CHEM, V268, P16929; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P489, DOI 10.1093/oxfordjournals.jbchem.a122495; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1	71	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17258	17262		10.1074/jbc.272.28.17258	http://dx.doi.org/10.1074/jbc.272.28.17258			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211861	hybrid			2022-12-27	WOS:A1997XK16500004
J	Sokurenko, EV; Chesnokova, V; Doyle, RJ; Hasty, DL				Sokurenko, EV; Chesnokova, V; Doyle, RJ; Hasty, DL			Diversity of the Escherichia coli type 1 fimbrial lectin - Differential binding to mannosides and uroepithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTIONS; FUNCTIONAL-HETEROGENEITY; BACTERIAL ADHERENCE; FIMH GENES; PILI; ADHESION; RECEPTORS; COLONIZATION; STRAINS; MICE	Type I fimbriae are the most common adhesive organelles of Escherichia coli. Because of their virtual ubiquity, previous epidemiological studies have not found a correlation between the presence of type I fimbriae and urinary tract infections (UTIs). Recently it has become clear that type 1 fimbriae exhibit several different phenotypes, due to allelic variation of the gene for the lectin subunit, FimH, and that these phenotypes are differentially distributed among fecal and UTI isolates, In this study, me have analyzed in more detail the ability of isogenic, recombinant strains of E. coli expressing fimH genes of the predominant fecal and UTI phenotypes to adhere to glycoproteins and to uroepithelial cells. Evidence was obtained to indicate that type 1 fimbriae differ in their ability to recognize various mannosides, utilizing at least two different mechanisms. All FimH subunits studied to date are capable of mediating adhesion via trimannosyl residues, but only certain variants are capable of mediating high levels of adhesion via monomannosyl residues. The ability of the FimH lectins to interact with monomannosyl residues strongly correlates with their ability 60 mediate E. coli adhesion to uroepithelial cells. In this way, it: would be possible for certain phenotypic variants of type I fimbriae to contribute more than others to virulence off. coli in the urinary tract.	VET AFFAIRS MED CTR, RES SERV 151, MEMPHIS, TN 38104 USA; UNIV TENNESSEE, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA; UNIV LOUISVILLE, DEPT MICROBIOL & IMMUNOL, LOUISVILLE, KY 40292 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Louisville					NIDCR NIH HHS [DE-07218] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007218] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABRAHAM SN, 1985, INFECT IMMUN, V48, P625, DOI 10.1128/IAI.48.3.625-628.1985; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BLOCH CA, 1992, MOL MICROBIOL, V6, P697, DOI 10.1111/j.1365-2958.1992.tb01518.x; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; COHEN PS, 1994, FIMBRIAE ADHESION GE, P213; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; COURTNEY HS, 1991, INFECT IMMUN, V59, P1661, DOI 10.1128/IAI.59.5.1661-1666.1991; Donnenberg Michael S., 1996, P135; DOYLE RJ, 1985, MOL BASIS ORAL MICRO, P109; DUGUID JP, 1955, J PATHOL BACTERIOL, V70, P335, DOI 10.1002/path.1700700210; FIRON N, 1987, INFECT IMMUN, V55, P472, DOI 10.1128/IAI.55.2.472-476.1987; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; HAGBERG L, 1981, INFECT IMMUN, V31, P564, DOI 10.1128/IAI.31.2.564-570.1981; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HULTGREN SJ, 1986, INFECT IMMUN, V54, P613, DOI 10.1128/IAI.54.3.613-620.1986; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1985, MOL GEN GENET, V199, P410, DOI 10.1007/BF00330751; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; MCCORMICK BA, 1989, INFECT IMMUN, V57, P3022, DOI 10.1128/IAI.57.10.3022-3029.1989; Moshier A, 1996, CURR MICROBIOL, V33, P200, DOI 10.1007/s002849900100; NEESER JR, 1986, INFECT IMMUN, V52, P428, DOI 10.1128/IAI.52.2.428-436.1986; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; OFEK I, 1982, SCAND J INFECT DIS, P61; SCHAEFFER AJ, 1987, INFECT IMMUN, V55, P373, DOI 10.1128/IAI.55.2.373-380.1987; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; SHERMAN PM, 1985, INFECT IMMUN, V49, P797, DOI 10.1128/IAI.49.3.797-804.1985; SILVERBLATT FJ, 1979, J CLIN INVEST, V64, P333, DOI 10.1172/JCI109458; SOKURENKO EV, 1994, J BACTERIOL, V176, P748, DOI 10.1128/jb.176.3.748-755.1994; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; SOKURENKO EV, 1992, INFECT IMMUN, V60, P4709, DOI 10.1128/IAI.60.11.4709-4719.1992; SOKURENKO EV, 1995, METHOD ENZYMOL, V253, P519; SVANBORG C, 1994, FIMBRIAE ADHESION GE, P239; Teraguchi S, 1996, INFECT IMMUN, V64, P1075, DOI 10.1128/IAI.64.3.1075-1077.1996; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630	42	143	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17880	17886		10.1074/jbc.272.28.17880	http://dx.doi.org/10.1074/jbc.272.28.17880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211945	hybrid			2022-12-27	WOS:A1997XK16500088
J	Greenwel, P; Inagaki, Y; Hu, W; Walsh, M; Ramirez, F				Greenwel, P; Inagaki, Y; Hu, W; Walsh, M; Ramirez, F			Sp1 is required for the early response of alpha 2(I) collagen to transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; FACTOR-BETA; TRANSGENIC MICE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SP1-MEDIATED TRANSCRIPTION; PRO-ALPHA-2(I) COLLAGEN; HUMAN-FIBROBLASTS; DNA-SEQUENCES; MESSENGER-RNA	It is currently debated whether AP1 or Sp1 is the factor that mediates transforming growth factor beta 1 (TGF-beta) stimulation of the human alpha 2(I) collagen (COL1A2) gene by binding to an upstream promoter element (TbRE). The present study was designed to resolve this controversy by correlating expression of COL1A2, AP1, and Sp1 in the same cell line and under different experimental conditions. The results strongly indicate that Sp1 is required for the immediate early response of COL1A2 to TGF-beta and AP1 is not. The Sp1 inhibitor mithramycin blocked stimulation of alpha 2(I) collagen mRNA accumulation by TGF-beta, whereas the AP1 inhibitor curcumin had no effect. Furthermore, antibodies against Jun-B and c-Jun failed to identify immunologically related in the TbRE-bound complex, irrespective of whether they were purified from untreated or TGF-beta-treated cells. AP1 did bind to the TbRE probe in vitro, but only in the absence of the upstream Sp1 recognition sequence. Based on this finding and DNA transfection results, we conclude that the AP1 sequence of the TbRE represents a cryptic site used under experimental conditions that either eliminate the more favorable Sp1 binding site or force the balance toward the less probable. Finally, a combination of cell transfections and DNA-binding assays excluded that COL1A2 transactivation involves the retinoblastoma gene product (pRb), an activator of Sp1, the pRb-related protein p107, an inhibitor of Sp1, or the Sp1-related repressor, Sp3.	CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029; NATL KANAZAWA HOSP,DEPT INTERNAL MED,KANAZAWA,ISHIKAWA 920,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR038648, R01AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOAST S, 1990, J BIOL CHEM, V265, P13351; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DEWET W, 1987, J BIOL CHEM, V262, P16032; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOCH AE, 1995, J INVEST MED, V43, P28; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHAFITZAGARDO B, 1983, NATURE, V304, P277, DOI 10.1038/304277a0; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRUTER S, 1992, J BIOL CHEM, V267, P25389; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	47	153	158	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19738	19745		10.1074/jbc.272.32.19738	http://dx.doi.org/10.1074/jbc.272.32.19738			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242631	hybrid			2022-12-27	WOS:A1997XQ05900018
J	Harris, RA; BowkerKinley, MM; Wu, PF; Jeng, JJ; Popov, KM				Harris, RA; BowkerKinley, MM; Wu, PF; Jeng, JJ; Popov, KM			Dihydrolipoamide dehydrogenase-binding protein of the human pyruvate dehydrogenase complex - DNA-derived amino acid sequence, expression, and reconstitution of the pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; TRANSACETYLASE COMPONENT; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEX; GENETIC RECONSTRUCTION; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; BOVINE KIDNEY; E2 COMPONENT	Protein X, recently renamed dihydrolipoamide dehydrogenase-binding protein (E3BP), is required for anchoring dihydrolipoamide dehydrogenase (E-3) to the dihydrolipoamide transacetylase (E-2) core of the pyruvate dehydrogenase complexes of eukaryotes. DNA and deduced protein sequences for E3BP of the human pyruvate dehydrogenase complex are reported here, With the exception of only a single lipoyl domain, the protein has a segmented multi-domain structure analogous to that of the E-2 component of the complex. The protein has 46% amino acid sequence identity in its amino-terminal region with the second lipoyl domain of E-2, 38% identity in its central region with the putative peripheral subunit-binding domain of E-2, and 50% identity in its carboxyl-terminal region with the catalytic inner care do. main of E-2. The similarity in the latter domain stands in contrast to E3BP of Saccharomyces cerevisiae, which is quite different from its homologous transacetylase in this region, The putative catalytic site histidine residue present in the inner core domains of all dihyrdrolipoamide acyltransferases is replaced by a serine residue in human E3BP; thus, catalysis of coenzyme A acetylation by this protein is unlikely, Coexpression of cDNAs for E3BP and E-2 resulted in the formation of ale E-2.E3BP subcomplex that spontaneously reconstituted the pyruvate dehydrogenase complex in the presence of native E-3 and recombinant pyruvate decarboxylase (E-1).	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIADDK NIH HHS [PHS AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051262, R29GM051262] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; DEMARCUCCI OGL, 1986, EUR J BIOCHEM, V158, P587; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GRIFFIN TA, 1990, J BIOL CHEM, V265, P13174; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; GUEST JR, 1985, J MOL BIOL, V185, P743, DOI 10.1016/0022-2836(85)90059-2; HODGSON JA, 1986, EUR J BIOCHEM, V158, P595, DOI 10.1111/j.1432-1033.1986.tb09796.x; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; JENG JJ, 1994, BIOCHEM BIOPH RES CO, V203, P225, DOI 10.1006/bbrc.1994.2171; JILKA JM, 1986, J BIOL CHEM, V261, P1858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; MENG MH, 1994, BIOCHEMISTRY-US, V33, P12879, DOI 10.1021/bi00209a020; NEAGLE J, 1989, FEBS LETT, V253, P11, DOI 10.1016/0014-5793(89)80919-6; PACKMAN LC, 1986, FEBS LETT, V206, P193, DOI 10.1016/0014-5793(86)80979-6; PETTIT FH, 1982, METHOD ENZYMOL, V89, P376; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P66, DOI 10.1111/j.1749-6632.1989.tb14987.x; RUSSELL GC, 1992, BIOCHEM J, V287, P611, DOI 10.1042/bj2870611; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SPENCER ME, 1984, EUR J BIOCHEM, V141, P361, DOI 10.1111/j.1432-1033.1984.tb08200.x; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V573, P113, DOI 10.1111/j.1749-6632.1989.tb14990.x; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	39	93	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19746	19751		10.1074/jbc.272.32.19746	http://dx.doi.org/10.1074/jbc.272.32.19746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242632	hybrid			2022-12-27	WOS:A1997XQ05900019
J	Munzer, JS; Basak, A; Zhong, M; Mamarbachi, A; Hamelin, J; Savaria, D; Lazure, C; Benjannet, S; Chretien, M; Seidah, NG				Munzer, JS; Basak, A; Zhong, M; Mamarbachi, A; Hamelin, J; Savaria, D; Lazure, C; Benjannet, S; Chretien, M; Seidah, NG			In vitro characterization of the novel proprotein convertase PC7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; KEX2-LIKE ENDOPROTEASE; PROCESSING ENZYMES; HUMAN FURIN; ENZYMATIC CHARACTERIZATION; SUBSTRATE-SPECIFICITY; CONSENSUS SEQUENCE; SUBTILISIN FAMILY; CLEAVAGE; PRECURSOR	Biochemical and enzymatic characterization of the novel proprotein convertase rat PC7 (rPC7) was carried out using vaccinia virus recombinants overexpressed in mammalian BSC40 cells. Pro-PC7 is synthesized as a glycosylated zymogen (101 kDa) and processed into mature rPC7 (89 kDa) in the endoplasmic reticulum. No endogenously produced soluble forms of this membrane-anchored protein were detected. a deletion mutant (65 kDa), truncated well beyond the expected C-terminal boundary of the P-domain, produced soluble rPC7 in the culture medium. Enzymatic activity assays of rPC7 using fluorogenic peptidyl substrates indicated that the pH optimum, Ca2+ dependence, and cleavage specificity of this enzyme are largely similar to those of furin. However, with some substrates, cleavage specificity more closely resembled that of yeast kexin, suggesting differential processing of proprotein substrates by this novel convertase. We examined the rPC7- and human furin-mediated cleavage of synthetic peptides containing the processing sites of three proteins known to colocalize in situ with rPC7. Whereas both enzymes correctly processed the pro-parathyroid hormone tridecapeptide and the pro-PC4 heptadecapeptide, neither enzyme cleaved a pro-epidermal growth factor hexadecapeptide. Thus, this study establishes that rPC7 is an enzymatically functional subtilisin/kexin-like serine proteinase with a cleavage specificity resembling that of hfurin. In addition, we have demonstrated that rPC7 can correctly process peptide precursors that contain the processing sites of at least two potential physiological substrates.	CLIN RES INST MONTREAL,BIOCHEM NEUROENDOCRINOL LAB,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DE SEVE LAB MOL NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DE SEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,LAB STRUCT & METAB NEUROPEPTIDES,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				BAIIYES EM, 1992, BIOCHEM J, V286, P223; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLUE ML, 1993, IMMUNOLOGY, V78, P80; BOUDREAULT A, 1995, J CELL BIOCH B, V19, P243; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PAQUET L, 1994, J BIOL CHEM, V269, P19279; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1997, IN PRESS ANN NY ACAD; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SEIZEN RJ, 1994, EUR J BIOCHEM, V222, P255; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zhong M, 1996, FEBS LETT, V396, P31, DOI 10.1016/0014-5793(96)01059-9	55	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19672	19681		10.1074/jbc.272.32.19672	http://dx.doi.org/10.1074/jbc.272.32.19672			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242622	hybrid			2022-12-27	WOS:A1997XQ05900009
J	Clement, B; Lomb, R; Moller, W				Clement, B; Lomb, R; Moller, W			Isolation and characterization of the protein components of the liver microsomal O-2-insensitive NADH-benzamidoxime reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-HYDROXYLATION; RABBIT LIVER; NITRIC-OXIDE; CYTOCHROME-P-450; OXIDATION; DEBRISOQUINE; METABOLITE; DEXTROMETHORPHAN; CITRULLINE; ARGININE	Drugs containing strong basic nitrogen functional groups can be N-oxygenated to genotoxic products. While the reduction of such products is of considerable toxicological significance, most in vitro studies have focused on oxygen-sensitive reductase systems. However, an oxygen-insensitive microsomal hydroxylamine reductase consisting of NADH, cytochrome b(5), its reductase, and a third unidentified protein component has been known for some time (Kadlubar, F. F., and Ziegler, D. M. (1974) Arch. Biochem. Biophys. 162, 83-92). This report describes the isolation and identification of all of the components required for the reconstitution of an oxygen-insensitive liver microsomal system capable of catalyzing the efficient reduction of primary N-hydroxylated structures such as amidines, guanidines, amidino-hydrazones, and similar functional groups. In addition to cytochrome b(5) and its reductase, the reconstituted system requires phosphatidylcholine and a P450 isoenzyme that has been purified to homogeneity from pig liver. The participation of cytochrome b(5) and NADH cytochrome b(5) reductase in cytochrome P450-dependent biotransformations has previously only been described for oxidative processes, The data presented suggest that this system may be an important catalyst in the reduction of genotoxic N-hydroxylated nitrogen components in liver, Their facile reduction by cellular NADH may be the reason why N-hydroxylated products can be missed by studies in vivo. Furthermore, the enzyme system is involved in the reduction of amidoximes and similar functional groups, which can be used as prodrug functionalities for amidines and related groups.			Clement, B (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST PHARMAZEUT,GUTENBERGSTR 76,D-24118 KIEL,GERMANY.							BICKEL MH, 1969, PHARMACOL REV, V21, P325; CLEMENT B, 1987, XENOBIOTICA, V17, P659, DOI 10.3109/00498258709043973; CLEMENT B, 1993, ARCH PHARM, V326, P807, DOI 10.1002/ardp.19933261008; CLEMENT B, 1993, MOL PHARMACOL, V43, P335; CLEMENT B, 1988, ARCH PHARM, V321, P955, DOI 10.1002/ardp.19883211228; Clement B, 1996, CHEM RES TOXICOL, V9, P682, DOI 10.1021/tx9502047; CLEMENT B, 1994, DRUG METAB DISPOS, V22, P486; CLEMENT B, 1993, BIOCHEM PHARMACOL, V46, P2249, DOI 10.1016/0006-2952(93)90616-5; CLEMENT B, 1983, XENOBIOTICA, V13, P467, DOI 10.3109/00498258309052286; CLEMENT B, 1985, CHEM BER-RECL, V118, P3481, DOI 10.1002/cber.19851180905; CLEMENT B, 1988, J CANCER RES CLIN, V114, P363, DOI 10.1007/BF02128179; CLEMENT B, 1992, ARCH PHARM, V325, P61, DOI 10.1002/ardp.19923250114; COUTTS RT, 1977, DRUG METAB REV, V6, P51, DOI 10.3109/03602537708993765; CRETTON EM, 1993, DRUG METAB DISPOS, V21, P946; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; Estabrook R W, 1978, Methods Enzymol, V52, P212; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; HAUPTMANN J, 1988, PHARMAZIE, V43, P559; INGELMANSUNDBERG M, 1984, ACTA CHEM SCAND B, V38, P845, DOI 10.3891/acta.chem.scand.38b-0845; JARURATANASIRIKUL S, 1994, J PHARM PHARMACOL, V46, P933, DOI 10.1111/j.2042-7158.1994.tb05721.x; KADLUBAR FF, 1973, ARCH BIOCHEM BIOPHYS, V156, P46, DOI 10.1016/0003-9861(73)90339-1; KADLUBAR FF, 1974, ARCH BIOCHEM BIOPHYS, V162, P83, DOI 10.1016/0003-9861(74)90107-6; KLING L, 1985, BIOCHEM PHARMACOL, V34, P85, DOI 10.1016/0006-2952(85)90104-2; Kruger P., 1885, BER DTSCH CHEM GES, V18, P1055; KUPFER A, 1984, LANCET, V2, P517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU YH, 1974, BIOCHEM BIOPH RES CO, V60, P266; Mihara K, 1978, Methods Enzymol, V52, P102; OMURA T, 1964, J BIOL CHEM, V239, P2370; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATSUMI K, 1987, ARCH BIOCHEM BIOPHYS, V253, P413, DOI 10.1016/0003-9861(87)90194-9; TESTA B, 1995, METABOLISM DRUGS OTH, P415; TSUNEOKA Y, 1992, EUR J BIOCHEM, V208, P739, DOI 10.1111/j.1432-1033.1992.tb17242.x; Weller T, 1996, J MED CHEM, V39, P3139, DOI 10.1021/jm9509298; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; WOHLERS H, 1994, THESIS CHRISTIAN ALB; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZIEGLER DM, 1966, BIOCHEMISTRY-US, V5, P2932, DOI 10.1021/bi00873a024	38	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19615	19620		10.1074/jbc.272.31.19615	http://dx.doi.org/10.1074/jbc.272.31.19615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235969	hybrid			2022-12-27	WOS:A1997XP06300075
J	Dong, WJ; Wang, CK; Gordon, AM; Rosenfeld, SS; Cheung, HC				Dong, WJ; Wang, CK; Gordon, AM; Rosenfeld, SS; Cheung, HC			A kinetic model for the binding of Ca2+ to the regulatory site of troponin from cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; RESOLUTION; CALCIUM; COMPLEX	The kinetics of the binding of Ca2+ to the single regulatory site of cardiac muscle troponin was investigated by using troponin reconstituted from the three subunits, using a monocysteine mutant of troponin C (cTnC) labeled with the fluorescent probe 2-[(4'-(iodoacetamido)anilino]naphthalene-6-sulfonic acid (IAANS) at Cys-35, The kinetic tracings of binding experiments for troponin determined at free [Ca2+] > 1 mu M were resolved into two phases. The rate of the fast phase increased with increasing [Ca2+], reaching a maximum of about 35 s(-1) at 4 degrees C, and the rate of the slow phase was approximately 5 s(-1) and did not depend on [Ca2+], Dissociation of bound Ca2+ occurred in two phases, with rates of about 23 and 4 s(-1), The binding and dissociation results obtained with the binary complex formed between cardiac troponin I and the IAANS-labeled cTnC mutant were very similar to those obtained from reconstituted troponin, The kinetic data are consistent with a three-step sequential model similar to the previously reported mechanism for the binding of Ca2+ to a cTnC mutant labeled with the same probe at Cys-84 (Dong et al, (1996) J, Biol, Chem. 271, 688-694). In this model, the initial binding in the bimolecular step to form the Ca2+-troponin complex is assumed to be a rapid equilibrium, followed by two sequential first-order transitions, The apparent bimolecular rate constant is 5.1 x 10(7) M-1 s(-1) a factor of 3 smaller than that for cTnC, The rates of the first-order transitions are an order of magnitude smaller for troponin than for cTnC, These kinetic differences form a basis for the enhanced Ca2+ affinity of troponin relative to the Ca2+ affinity of isolated cTnC. Phosphorylation of the monocysteine mutant of troponin I by protein kinase A resulted in a 3-fold decrease in the bimolecular rate constant but a 2-fold increase in the two observed Ca2+ dissociation rates, These changes in the kinetic parameters are responsible for a 5-fold reduction in Ca2+ affinity of phosphorylated troponin for the specific site.	UNIV ALABAMA, DEPT NEUROL, BIRMINGHAM, AL 35294 USA; UNIV WASHINGTON, DEPT PHYSIOL & BIOPHYS, SEATTLE, WA 98195 USA	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle	Dong, WJ (corresponding author), UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA.		Dong, Wenji/A-8579-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052508] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52588, HL52508] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bevington P. R, 1969, DATA REDUCTION ERROR; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; IIO T, 1982, J BIOCHEM-TOKYO, V92, P1141, DOI 10.1093/oxfordjournals.jbchem.a134030; JONHSON, 1994, J BIOL CHEM, V269, P8919; LIAO RL, 1992, BIOPHYS J, V63, P986, DOI 10.1016/S0006-3495(92)81685-5; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; OVSAK M, 1991, PROTEINS, V11, P79; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SMITH SJ, 1990, BRIT J PHARMACOL, V100, P779, DOI 10.1111/j.1476-5381.1990.tb14092.x; SOLARO RJ, 1993, MODULATION CARDIAC C, P160; STRYNADK NCJ, 1989, ANNU REV BIOCHEM, V58, P591; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028	23	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19229	19235		10.1074/jbc.272.31.19229	http://dx.doi.org/10.1074/jbc.272.31.19229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235915	hybrid			2022-12-27	WOS:A1997XP06300021
J	Henle, ES; Linn, S				Henle, ES; Linn, S			Formation, prevention, and repair of DNA damage by iron hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESCHERICHIA-COLI; SINGLET OXYGEN; STRAND BREAKS; GLUTATHIONE-PEROXIDASE; OXIDATIVE DAMAGE; AQUEOUS-SOLUTION; SUPEROXIDE; PROTEIN; CELLS; PEROXYNITRITE		UNIV CALIF BERKELEY,DEPT BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								ALTMAN SA, 1995, FREE RADICAL BIO MED, V19, P897, DOI 10.1016/0891-5849(95)00095-F; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERTONCINI CR, 1995, NUCLEIC ACIDS RES, V15, P2995; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; CERUTTI P, 1994, ENVIRON HEALTH PERSP, V102, P123, DOI 10.2307/3432228; COTTON FA, 1988, ADV INORG CHEM RAD, P625; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DI MASCIO P, 1994, FEBS LETT, V355, P287, DOI 10.1016/0014-5793(94)01224-5; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Eaton JW, 1995, METABOLIC MOL BASES, P2371; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; ENRIGHT HU, 1992, NUCLEIC ACIDS RES, V20, P3341, DOI 10.1093/nar/20.13.3341; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; GUTTERIDGE JMC, 1986, BIOCHEM J, V234, P225, DOI 10.1042/bj2340225; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HEIMBERGER A, 1988, BIOCHEM BIOPH RES CO, V154, P392, DOI 10.1016/0006-291X(88)90698-5; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Henle ES, 1996, BIOCHEMISTRY-US, V35, P12212, DOI 10.1021/bi961235j; HENLE ES, 1995, RADIAT RES, V143, P144, DOI 10.2307/3579150; IDE H, 1994, BIOCHEMISTRY-US, V33, P7127, DOI 10.1021/bi00189a016; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JANICEK MF, 1985, NUCLEIC ACIDS RES, V13, P9011, DOI 10.1093/nar/13.24.9011; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KHAN AU, 1983, P NATL ACAD SCI-BIOL, V80, P5195, DOI 10.1073/pnas.80.17.5195; Koppenol W., 1994, FREE RADICAL DAMAGE, V28, P3; KORNBERG A, 1992, DNA REPLICATION, P142; KRINSKY NI, 1977, TRENDS BIOCHEM SCI, V2, P35, DOI 10.1016/0968-0004(77)90253-5; LAFLEUR MVM, 1993, MUTAT RES, V295, P1, DOI 10.1016/0921-8734(93)90006-O; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lloyd RS, 1993, NUCLEASES, P263; LUO Y, 1993, THESIS U CALIFORNIA; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MELLO AC, 1991, MUTAT RES, V251, P109, DOI 10.1016/0027-5107(91)90220-I; MELLO AC, 1984, BIOCHIM BIOPHYS ACTA, V781, P56, DOI 10.1016/0167-4781(84)90123-4; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MILLIGAN JR, 1993, RADIAT RES, V133, P158, DOI 10.2307/3578351; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MOURET JF, 1991, CHEM-BIOL INTERACT, V77, P187, DOI 10.1016/0009-2797(91)90073-G; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SIES H, 1993, MUTAT RES, V299, P183, DOI 10.1016/0165-1218(93)90095-U; SIES H, 1995, AM J CLIN NUTR, V62, P1315; SINGH AK, 1994, ARCH BIOCHEM BIOPHYS, V315, P331, DOI 10.1006/abbi.1994.1508; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; SUZUKI T, 1994, NUCLEIC ACIDS RES, V22, P4997, DOI 10.1093/nar/22.23.4997; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; VONSONNTAG C, 1987, CHEM BASIS RAD BIOL, P238; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; Wardman P, 1996, RADIAT RES, V145, P523, DOI 10.2307/3579270; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1994, P NATL ACAD SCI USA, V91, P6604, DOI 10.1073/pnas.91.14.6604; YAMAZAKI I, 1991, J AM CHEM SOC, V113, P7588, DOI 10.1021/ja00020a021	82	453	465	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19095	19098		10.1074/jbc.272.31.19095	http://dx.doi.org/10.1074/jbc.272.31.19095			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235895	hybrid			2022-12-27	WOS:A1997XP06300001
J	Nagira, M; Imai, T; Hieshima, K; Kusuda, J; Ridanpaa, M; Takagi, S; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O				Nagira, M; Imai, T; Hieshima, K; Kusuda, J; Ridanpaa, M; Takagi, S; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O			Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE PROTEIN-10; SEQUENCE; ANGIOGENESIS; INHIBITOR; CELLS; IDENTIFICATION; INTERLEUKIN-8; SIGNALS	By searching the Expressed Sequence Tag (EST) data base, we identified partial cDNA sequences potentially encoding a novel human CC chemokine. We determined the entire cDNA sequence which encodes a highly basic polypeptide of 134 amino acids total with a putative signal peptide of 23 amino acids. The predicted mature protein of 111 amino acids has the four canonical cysteine residues and shows 21-33% identity to other human CC chemokines, but has a unique carboxyl-terminal extension of about 30 amino acids which contains two extra cysteine residues. The mRNA was expressed strongly in tissues such as the lymph nodes, appendix, and spleen. The recombinant protein, which was produced by the baculovirus system and purified to homogeneity, was a highly efficient chemoattractant for certain human T cell lines and a highly potent one for freshly isolated peripheral blood lymphocytes and cultured normal T cells expanded by phytohemagglutinin and interleukin 2. Unlike most other CC chemokines, however, this novel chemokine was not chemotactic for monocytes or neutrophils, suggesting that it is specific for lymphocytes. From these results, we designated this novel CC chemokine as SLC from secondary lymphoid-tissue chemokine. SLC fused with the secreted form of alkaline phosphatase (SLC-SEAP) was used to characterize the SLC receptor. Binding of SLC-SEAP to freshly isolated lymphocytes was blocked by SLC (IC50, 0.12 nM) but not by any other CC chemokine so far tested, suggesting that resting lymphocytes express a class of receptors highly specific for SLC. By using somatic cell hybrids, radiation hybrids, and selected yeast and bacterial artificial chromosome clones, we mapped the SLC gene (SCYA21) at chromosome 9p13 and between chromosomal markers, D9S1978(WI-8765) and AFM326vd1, where the gene for another novel CC chemokine termed ELC from EBI1-ligand chemokine (SCYA19) also exists. Collectively, SLC is a novel CC chemokine specific for lymphocytes and, together with ELC, constitutes a new group of chemokines localized at chromosome 9p13.	SHIONOGI INST MED SCI,OSAKA 566,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED,KUMAMOTO 860,JAPAN; NIH,LAB GENET RESOURCES,SHINJUKU KU,TOKYO 16,JAPAN; UNIV HELSINKI,DEPT MED GENET,HAARTMAN INST,FIN-00280 HELSINKI,FINLAND	Shionogi & Company Limited; Kumamoto University; Kumamoto University; National Institute of Health Sciences - Japan; University of Helsinki			Nomiyama, Hisayuki/F-2840-2013; Hieshima, Kunio/AAF-7040-2019	Nomiyama, Hisayuki/0000-0002-2716-4043; Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BROXMEYER HE, 1990, BLOOD, V76, P1110; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COX DR, 1995, GENOME DIGEST, V4, P14; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3728; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; VanSnick J, 1996, J IMMUNOL, V157, P2570; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O	37	218	259	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19518	19524		10.1074/jbc.272.31.19518	http://dx.doi.org/10.1074/jbc.272.31.19518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235955	hybrid			2022-12-27	WOS:A1997XP06300061
J	Nakamura, J; Tajima, G				Nakamura, J; Tajima, G			Independence of two conformations of sarcoplasmic reticulum Ca2+-ATPase molecules in hydrolyzing acetyl phosphate - A two-pair model of the ATPase structural unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED CALCIUM-BINDING; ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; PUMP; TEMPERATURE; SUBSTRATE; MECHANISM; SITES; PH	The sarcoplasmic reticulum Ca2+-ATPase molecules have been shown to exist in two conformations (A and B) that result from intermolecular interaction of ATPase molecules (Nakamura, J., and Tajima, G. (1995) J. Biol. Chem, 270, 17350-17354). The A form binds two calcium ions noncooperatively, whereas the B form binds the calcium ions cooperatively, Here, we examined the in dependence of these two forms in the calcium-activated hydrolysis of acetyl phosphate (AcP) under asynchronous and synchronous conditions of their E-1-E-2 transitions at 0-5 and 25 degrees C. Irrespective of their synchronism and temperature, the two forms hydrolyzed AcP due to calcium that was bound to each of the forms, indicating the independence of the two forms in hydrolyzing AcP. Taking into account the monomer-dimer transition of the ATPase molecules on the sarcoplasmic reticulum membrane accompanying E-1-E-2 transition of the molecules (Dux, L., Taylor, K. A., Ting-Beall, H. P., and Martonosi, A, (1985) J. Biol, Chem. 260, 11730-11743), the two types of molecules seem to independently carry out such monomer-dimer transition of the same type of molecules, Two pairs, each consisting of the same type of molecules, are suggested to be the structural unit of the ATPase molecules.			Nakamura, J (corresponding author), TOHOKU UNIV, INST BIOL, GRAD SCH SCI, AOBA KU, SENDAI, MIYAGI 98077, JAPAN.							BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P340; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUX L, 1985, J BIOL CHEM, V260, P1730; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P809; IKEMOTO N, 1984, J BIOL CHEM, V259, P1790; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; LIPMANN F, 1945, J BIOL CHEM, V159, P21; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; PUCELL A, 1971, J BIOL CHEM, V246, P3389; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; TADA M, 1978, PHYSIOL REV, V58, P1	25	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19290	19294		10.1074/jbc.272.31.19290	http://dx.doi.org/10.1074/jbc.272.31.19290			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235924	hybrid			2022-12-27	WOS:A1997XP06300030
J	Page, K; Lange, Y				Page, K; Lange, Y			Cell adhesion to fibronectin regulates membrane lipid biosynthesis through 5'-AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; SIGNAL-TRANSDUCTION; HUMAN FIBROBLASTS; PLASMA-MEMBRANE; ATP DEPLETION; FATTY-ACID; PHOSPHORYLATION; CHOLESTEROL; REDUCTASE; INHIBITION	We have shown that attachment to a fibronectin substrate stimulates two pathways of lipid biosynthesis in cultured human fibroblasts. Detachment of these cells (mechanically, with trypsin, or by RGDS peptides) caused a significant decrease in their 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and in their incorporation of [H-3]acetate into fatty acids. This inhibition was substantially reversed by the reattachment of cells to fibronectin substrates, but not to poly-L-lysine substrates or to fibronectin in solution. Inhibiting phosphoprotein phosphatase activity with okadaic acid blocked the recovery of both biosynthetic activities. Both 3-hydroxy-3-methylglutaryl-coenzyme A reductase and fatty acid biosynthesis are known to be inhibited by the action of 5'-AMP-activated protein kinase, which is activated by an increase in the level of AMP relative to ATP, For example, in our system, sodium azide and 2-deoxy-D-glucose increased the ratio of cellular AMP to ATP and caused a decrease in lipid biosynthesis, We then verified the prediction that detachment of cells from substrates also caused an increase in the AMP/ATP ratio. We therefore conclude that the attach ment of cells to fibronectin promotes lipid biosynthesis, presumably in coordination with the cellular growth response evoked by attachment to the extracellular matrix.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University			Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; GIBSON DM, 1982, ADV ENZYME REGUL, V20, P263, DOI 10.1016/0065-2571(82)90020-6; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HENIN N, 1995, FASEB J, V9, P541, DOI 10.1096/fasebj.9.7.7737463; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANGE Y, 1984, J BIOL CHEM, V259, P4624; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; RAO KN, 1995, ANTICANCER RES, V15, P309; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; ROTHBLAT GH, 1976, LIPIDS, V11, P97, DOI 10.1007/BF02532658; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHOBERT B, 1995, ANAL BIOCHEM, V226, P288, DOI 10.1006/abio.1995.1227; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1991, BIOCHEM BIOPH RES CO, V181, P1486, DOI 10.1016/0006-291X(91)92107-U; WOODS A, 1992, J CELL SCI, V101, P277; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YEH LA, 1990, J BIOL CHEM, V255, P2308	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19339	19342		10.1074/jbc.272.31.19339	http://dx.doi.org/10.1074/jbc.272.31.19339			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235931	hybrid			2022-12-27	WOS:A1997XP06300037
J	WilliamsAbbott, L; Walter, BN; Cheung, TC; Goh, CR; Porter, AG; Ware, CF				WilliamsAbbott, L; Walter, BN; Cheung, TC; Goh, CR; Porter, AG; Ware, CF			The lymphotoxin-alpha (LT alpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LT alpha 1 beta 2 heterotrimeric ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL HYBRIDOMA; HETEROMERIC COMPLEX; 33-KDA GLYCOPROTEIN; SURFACE LYMPHOTOXIN; MOLECULAR-CLONING; VIRAL-PROTEINS; MICE DEFICIENT; FACTOR-BETA; FACTOR TNF	The lymphotoxins (LT) alpha and beta, members of the tumor necrosis factor (TNF) cytokine superfamily, are implicated as important regulators and developmental factors for the immune system. LT alpha is secreted as a homotrimer and signals through two TNF receptors of 55-60 kDa (TNFR60) or 75-80 kDa (TNFR80), LT alpha also assembles with LT beta into a membrane-anchored, heterotrimeric LT alpha 1 beta 2 complex that engages a distinct cognate receptor, the LT beta receptor (LT beta R), To investigate the role of the LT alpha subunit in the function of the membrane LT alpha 1 beta 2 complex, gene transfer via baculovirus was used to assemble LT alpha and -beta complexes in insect cells, LT alpha containing mutations at D50N or Y108F are secreted as homotrimers that fail to bind either TNF receptor and are functionally inactive in triggering cell death of the HT29 adenocarcinoma cell line, In contrast, these mutant LT alpha proteins retain the ability to co-assemble with LT beta into membrane-anchored LT alpha 1 beta 2 complexes that engage the LT beta R and trigger the death of HT29 cells, Membrane-anchored LT beta expressed on the cell surface in absence of the LT alpha subunit binds the LT beta R but is functionally inactive in the cell death assay, These results indicate that the TNF receptor-binding regions of the LT alpha subunit are not necessary for engagement of the LT beta R, but the LT alpha subunit is required for the assembly of LT beta into a functional heteromeric ligand.	LA JOLLA INST ALLERGY & IMMUNOL,DIV MOL IMMUNOL,SAN DIEGO,CA 92121; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92021; NATL UNIV SINGAPORE,INST MOL & CELL BIOL,SINGAPORE 119260,SINGAPORE	La Jolla Institute for Immunology; University of California System; University of California Riverside; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore					NCI NIH HHS [P01 CA69381] Funding Source: Medline; NIAID NIH HHS [AI33068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033068, R37AI033068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS JS, 1990, J IMMUNOL, V144, P2582; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; CHAI H, 1993, BIOTECHNOL APPL BIOC, V18, P259; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOH CR, 1991, PROTEIN ENG, V4, P785; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hochman PS, 1996, J INFLAMM, V46, P220; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; WARE CF, 1992, J IMMUNOL, V149, P3881; WARE CF, 1995, PATHWAYS CYTOLYSIS, P175	43	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19451	19456		10.1074/jbc.272.31.19451	http://dx.doi.org/10.1074/jbc.272.31.19451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235946	hybrid			2022-12-27	WOS:A1997XP06300052
J	Johnson, HJ; Rosenberg, L; Choi, HU; Garza, S; Hook, M; Neame, PJ				Johnson, HJ; Rosenberg, L; Choi, HU; Garza, S; Hook, M; Neame, PJ			Characterization of epiphycan, a small proteoglycan with a leucine-rich repeat core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; BOVINE ARTICULAR-CARTILAGE; GROWTH-FACTOR-BETA; OSTEOINDUCTIVE FACTOR; DECORIN; GLYCOSAMINOGLYCANS; FIBROMODULIN; BIGLYCAN; HOMOLOGY; BINDING	The epiphysis of developing bones is a cartilaginous structure that is eventually replaced by bone during skeletal maturation. We have separated a dermatan sulfate proteoglycan, epiphycan, from decorin and biglycan by using dissociative extraction of bovine fetal epiphyseal cartilage, followed by sequential ion-exchange, gel permeation, hydrophobic, and Zn2+ chelate chromatographic steps. Epiphycan is a member of the small leucine-rich proteoglycan family, contains seven leucine-rich repeats (LRRs), is related to osteoglycin (osteoinductive factor) (Bentz, H., Nathan, R. M., Rosen, D. M., Armstrong, R. M., Thompson, A. Y., Segarini, P. R., Mathews, M. C., Dasch, J., Piez, K. A., and Seyedin, S. M. (1989) J. Biol. Chem. 264, 20805-20810), and appears to be the bovine equivalent of the chick proteoglycan PG-Lb (Shinomura, T., and Kimata, K. (1992) J. Biol. Chem. 267, 1265-1270). The intact proteoglycan had a median size of similar to 133 kDa. The core protein was 46 kDa by electrophoretic analysis, had a calculated size of 34,271 Da, and had two approximately equimolar N termini (APTLES... and ETYDAT...) separated by 11 amino acids. There were at least three O-linked oligosaccharides in the N-terminal region of the protein, based on blank cycles in Edman degradation and corresponding serine or threonine residues in the translated cDNA sequence. The glycosaminoglycans ranged in size from 23 to 34 kDa were more heterogeneous than those in other dermatan sulfate small leucine-rich proteoglycans and were found in the acidic N-terminal region of the protein core, N-terminal to the LRRs. A four cysteine cluster was present at the N terminus of the LRRs, and a disulfide-bonded cysteine pair was present at the C terminus of the protein core. The seventh LRR and an N-linked oligosaccharide were between the two C-terminal cysteines. An additional potential N-glycosylation site near the C terminus did not appear to be substituted at a significant level.	SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; MONTEFIORE MED CTR,ORTHOPED RES LABS,BRONX,NY 10467; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030; TEXAS A&M UNIV,ALBERT B ALKEK INST BIOSCI & TECHNOL,CTR EXTRACELLULAR MATRIX BIOL,HOUSTON,TX 77030	State University System of Florida; University of South Florida; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University System					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR035322, R37AR021498] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35322, AR42919, AR21498] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kurita K, 1996, BIOCHEM J, V318, P909, DOI 10.1042/bj3180909; MARCUM JA, 1991, BIOCHEM BIOPH RES CO, V175, P706, DOI 10.1016/0006-291X(91)91623-K; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	26	53	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18709	18717		10.1074/jbc.272.30.18709	http://dx.doi.org/10.1074/jbc.272.30.18709			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228042	hybrid			2022-12-27	WOS:A1997XM34200033
J	Ray, WJ; Bain, G; Yao, M; Gottlieb, DI				Ray, WJ; Bain, G; Yao, M; Gottlieb, DI			CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; IN-VITRO; METABOLISM; EXPRESSION; RECEPTORS; GENES; BRAIN; ENZYMES; SYSTEM	A novel member of the cytochrome P450 superfamily, CYP26, which represents a new family of cytochrome P450 enzymes, has been cloned. CYP26 mRNA is upregulated during the retinoic acid (RA)-induced neural differentiation of mouse embryonic stem cells in vitro and is transiently expressed by embryonic stem cells undergoing predominantly non-neural differentiation. CYP26 transcript is detectable as early as embryonic day 8.5 in mouse embryos, suggesting a function for the gene in early development. CYP26 is expressed in mouse and human liver, as expected for a cytochrome P450, and is also expressed in regions of the brain and the placenta. Acute administration of 100 mg/kg all-trans-RA increases steady-state levels of transcript in the adult liver, but not in the brain, CYP26 is highly homologous to a Zebrafish gene, CYPRA1, which has been proposed to participate in the degradation of RA, but is minimally homologous to other mammalian cytochrome P450 proteins. Thus, we report the cloning of a member of a novel cytochrome P450 family that is expressed in mammalian embryos and in brain and is induced by RA in the liver.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Ray, William J/E-9834-2016	Ray, William/0000-0002-4491-167X				Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BURKE MD, 1979, PHARMACOL THERAPEUT, V7, P549, DOI 10.1016/0163-7258(79)90042-1; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GRAM TE, 1986, ANNU REV PHARMACOL, V26, P259; GUENGERICH FP, 1992, LIFE SCI, V50, P1471; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; LOPEZ SL, 1992, MECH DEVELOP, V36, P153, DOI 10.1016/0925-4773(92)90066-S; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NISITANI S, 1994, INT IMMUNOL, V6, P909, DOI 10.1093/intimm/6.6.909; NOJI S, 1992, J NUTR SCI VITAMINOL, V10, P481; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SNODGRASS HR, 1992, J CELL BIOCHEM, V49, P225, DOI 10.1002/jcb.240490304; SOPRANO DR, 1995, ANNU REV NUTR, V10, P169; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Tallman MS, 1996, LEUKEMIA, V10, pS12; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WARNER M, 1994, METH NEUROSCI, V22, P51; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WINKLER RG, 1995, PLANT CELL, V7, P1307, DOI 10.1105/tpc.7.8.1307	40	259	266	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18702	18708		10.1074/jbc.272.30.18702	http://dx.doi.org/10.1074/jbc.272.30.18702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228041	hybrid			2022-12-27	WOS:A1997XM34200032
J	Segnitz, B; Gehring, U				Segnitz, B; Gehring, U			The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TYROSINE KINASE INHIBITORS; GLUCOCORTICOID RECEPTOR; HERBIMYCIN-A; PROGESTERONE-RECEPTOR; WILD-TYPE; BINDING; EXPRESSION; CELLS; ASSOCIATION	The ansamycin antibiotic geldanamycin, which specifically interacts with the heat shock protein hsp90, was used to study the function of hsp90 in steroid hormone receptors, We observed inhibition of glucocorticoid-specific gene induction in several responsive cell systems, Hormone binding abilities of receptors for glucocorticoid, progestin, androgen, and estrogen were inhibited upon exposing intact cells to geldanamycin, Inhibition was only seen when geldanamycin was applied to cell cultures under growth conditions or was present during in vitro synthesis; presynthesized receptors in cell extracts were not affected, Upon withdrawal of geldanamycin, glucocorticoid binding ability was re gained; this was partially independent of de novo protein synthesis. Geldanamycin caused decreased levels of immunoreactive glucocorticoid receptors in wild-type cells with enhanced degradation occurring through the ubiquitin-proteasome pathway. Analysis of receptors from treated cells revealed a heteromeric structure of normal size in which the receptor polypeptide is complexed with normal amounts of hsp90 and the immunophilin p59, These data support the view that hsp90 actively participates in steroid-induced signal transduction, and they suggest that geldanamycin affects receptor action without disrupting hsp90-containing heterocomplexes per se. Nevertheless, complexes synthesized and assembled in vitro in the presence of geldanamycin differ from receptors of cellular origin.	UNIV HEIDELBERG,INST BIOL CHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; Chavany C, 1996, J BIOL CHEM, V271, P4974; Clark JW, 1996, INT J CANCER, V65, P186; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GEHRING U, 1987, MOL CELL ENDOCRINOL, V53, P33, DOI 10.1016/0303-7207(87)90189-4; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HARRISON RW, 1987, RECENT ADV STEROID H, P467; HARTIG E, 1993, J VIROL, V67, P813; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYASHI SI, 1967, J BIOL CHEM, V242, P3998; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KULKA RG, 1988, J BIOL CHEM, V263, P15726; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIGITA K, 1994, J IMMUNOL, V153, P3457; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Moore DD, 1995, GLOB MOB SURV; MURAKAMI Y, 1994, BIOCHEM J, V301, P57, DOI 10.1042/bj3010057; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; OKABE M, 1994, LEUKEMIA RES, V18, P867, DOI 10.1016/0145-2126(94)90169-4; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; REXIN M, 1991, J BIOL CHEM, V266, P24601; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SIMONS SS, 1994, VITAM HORM, V49, P49; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SPINDLERBARTH M, 1982, FEBS LETT, V138, P91, DOI 10.1016/0014-5793(82)80402-X; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705	50	145	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18694	18701		10.1074/jbc.272.30.18694	http://dx.doi.org/10.1074/jbc.272.30.18694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228040	hybrid			2022-12-27	WOS:A1997XM34200031
J	Spanjaard, RA; Ikeda, M; Lee, PJ; Charpentier, B; Chin, WW; Eberlein, TJ				Spanjaard, RA; Ikeda, M; Lee, PJ; Charpentier, B; Chin, WW; Eberlein, TJ			Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RAR gamma in induction of differentiation and apoptosis of S91 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; EMBRYONAL CARCINOMA-CELLS; HUMAN LUNG-CANCER; THYROID-HORMONE-RECEPTOR; BETA-GENE; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; TISSUE TRANSGLUTAMINASE; TARGETED DISRUPTION; NUCLEAR RECEPTORS	Retinoic acid (RA) and 9-cis-RA induce growth arrest and differentiation of S91 melanoma cells. RA activates retinoic acid receptors (RARs), whereas 9-cis-RA activates both RARs and retinoid X receptors (RXRs). Both classes of receptors function as ligand-dependent transcription factors. S91 melanoma cells contain mRNA for RXR alpha, RXR beta, RAR alpha, RAR gamma, and RAR beta in low levels. Among these, only RAR beta gene transcription is induced by retinoids. However, at present the individual role(s) for each RXR and RAR isoform in these processes is unclear. We assessed the function of all isoforms in the S91 melanoma model by using RXR and RAR isoform-specific retinoids to study their effects on cell growth, RAR beta expression, and differentiation. Activation of each of the endogenous RXR or RAR isoforms induces RAR beta gene expression, and blocks cellular proliferation. However, only the RAR gamma-ligands cause additional differentiation toward a melanocytic phenotype, which coincides with substantial apoptosis well before morphological changes are apparent. Apoptosis is completely dependent on de novo protein synthesis but cannot be induced by changes in activities of AP-1, protein kinase C, and protein kinase A, nor can it be blocked by the presence of the antioxidant glutathione. These results argue against a specific role for RAR beta, but suggest that RAR gamma has a critical role in a genetic switch between melanocytes and melanoma, and induction of ligand-dependent apoptosis.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GENET, BOSTON, MA 02115 USA; CTR INT RECH DERMATOL GALDERMA, F-06565 VALBONNE, FRANCE	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Galderma R&D SNC	Spanjaard, RA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG, DIV SURG ONCOL, LAB BIOL CANC THERAPY, BOSTON, MA 02115 USA.							AMOS B, 1990, METHOD ENZYMOL, V190, P217; ANZAI N, 1994, LEUKEMIA, V8, P446; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Beard RL, 1996, J MED CHEM, V39, P3556, DOI 10.1021/jm960386h; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Charpentier B, 1995, J MED CHEM, V38, P4993, DOI 10.1021/jm00026a006; CHARPENTIER B, 1993, Patent No. 658553; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DARMON M, 1988, Skin Pharmacology, V1, P161; DAWSON MI, 1995, CANCER RES, V55, P4446; DE LUCA LM, 1991, FASEB J, V5, P2924; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIVINCI A, 1994, INT J CANCER, V59, P422, DOI 10.1002/ijc.2910590322; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELIA D, 1993, CANCER RES, V53, P6036; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GANDRILLON O, 1994, ONCOGENE, V9, P749; GEBERT JF, 1991, ONCOGENE, V6, P1859; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; Li JJ, 1996, CANCER RES, V56, P483; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1978, J NATL CANCER I, V60, P1035, DOI 10.1093/jnci/60.5.1035; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARIOTTI A, 1994, J NATL CANCER I, V86, P1245, DOI 10.1093/jnci/86.16.1245; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MCBURNEY MW, 1993, CANCER INVEST, V11, P590, DOI 10.3109/07357909309011677; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGY L, 1995, MOL CELL BIOL, V15, P3540; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PONZONI M, 1995, CANCER RES, V55, P853; PRATT MAC, 1993, DIFFERENTIATION, V53, P105, DOI 10.1111/j.1432-0436.1993.tb00650.x; REDFERN CPF, 1990, FEBS LETT, V273, P19, DOI 10.1016/0014-5793(90)81041-L; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schadendorf D, 1995, Recent Results Cancer Res, V139, P183; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SIDELL N, 1995, INT J CANCER, V60, P507, DOI 10.1002/ijc.2910600414; SPANJAARD RA, 1994, MOL ENDOCRINOL, V8, P286, DOI 10.1210/me.8.3.286; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHANG XK, 1994, CANCER RES, V54, P5663; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	90	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18990	18999		10.1074/jbc.272.30.18990	http://dx.doi.org/10.1074/jbc.272.30.18990			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228081	hybrid			2022-12-27	WOS:A1997XM34200072
J	Bandell, M; Ansanay, V; Rachidi, N; Dequin, S; Lolkema, JS				Bandell, M; Ansanay, V; Rachidi, N; Dequin, S; Lolkema, JS			Membrane potential-generating malate (MleP) and citrate (CitP) transporters of lactic acid bacteria are homologous proteins - Substrate specificity of the 2-hydroxycarboxylate transporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; MALOLACTIC FERMENTATION; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; METABOLIC ENERGY; CLONING VECTORS; GENE; EXPRESSION	Membrane potential generation via malate/lactate exchange catalyzed by the malate carrier (MleP) of Lactococcus lactis, together with the generation of a pH gradient via decarboxylation of malate to lactate in the cytoplasm, is a typical example of a secondary proton motive force-generating system, The mleP gene was cloned, sequenced, and expressed in a malolactic fermentation-deficient L. lactis strain. Functional analysis revealed the same properties as observed in membrane vesicles of a malolactic fermentation-positive strain. MleP belongs to a family of secondary transporters in which the citrate carriers from Leuconostoc mesenteroides (CitP) and Klebsiella pneumoniae (CitS) ass; found also. CitP, but not CitS, is also involved in membrane potential generation via electrogenic citrate/lactate exchange, MleP, CitP, and CitS were analyzed for their substrate specificity, The 2-hydroxycarboxylate motif R1R2COHCOOH, common to the physiological substrates, was found to be essential for transport although same 2-oxocarboxylates could be transported to a lesser extent. Clear differences ill substrate specificity among the transporters were observed because of different tolerances toward the R substituents at the C2 atom, Both MleP and CitP transport a broad range of 2-hydroxycarboxylates with R substituents ranging in size from two hydrogen atoms (glycolate) to acetyl and methyl groups (citromalate) for MleP and two acetyl groups (citrate) for CitP. CitS was much less tolerant and transported only citrate and at a low rats citromalate. The substrate specificities are discussed in the context of the physiological function of the transporters.	UNIV GRONINGEN, DEPT MICROBIOL, CTR BIOL, GRONINGEN BIOTECHNOL & BIOMOL SCI INST, NL-9751 NN HAREN, NETHERLANDS; INRA, LAB MICROBIOL & TECHNOL FERMENTAT, INST PRODUITS VIGNE, F-34060 MONTPELLIER 1, FRANCE	University of Groningen; INRAE				Rachidi, Najma/0000-0002-1247-7768				Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; Abe K, 1996, J BIOL CHEM, V271, P3079, DOI 10.1074/jbc.271.6.3079; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; ANSANAY V, 1993, FEBS LETT, V332, P74, DOI 10.1016/0014-5793(93)80488-G; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DEFELIPE FL, 1995, MOL GEN GENET, V246, P590, DOI 10.1007/BF00298965; DEVOS WM, 1987, FEMS MICROBIOL LETT, V46, P281, DOI 10.1111/j.1574-6968.1987.tb02466.x; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; DRIESSEN AJM, 1991, METHOD CELL BIOL, V34, P147; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; ISHIGURO N, 1992, J BIOL CHEM, V267, P9559; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KONINGS WN, 1995, ARCH MICROBIOL, V164, P235, DOI 10.1007/s002030050260; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1996, HDB BIOL PHYS, V2, P229; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTYTEYSSET C, 1995, J BIOL CHEM, V270, P25370, DOI 10.1074/jbc.270.43.25370; MartyTeysset C, 1996, J BACTERIOL, V178, P6209, DOI 10.1128/jb.178.21.6209-6215.1996; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; Pos KM, 1996, BIOCHEMISTRY-US, V35, P1018, DOI 10.1021/bi951609t; RENAULT PP, 1987, APPL ENVIRON MICROB, V53, P320, DOI 10.1128/AEM.53.2.320-324.1987; SALEMA M, 1994, EUR J BIOCHEM, V225, P289, DOI 10.1111/j.1432-1033.1994.00289.x; SAMBROOK J, 1989, MOL CLONING LAG MANU; SIMON D, 1985, FEMS MICROBIOL LETT, V26, P239, DOI 10.1111/j.1574-6968.1985.tb01598.x; VANDERREST ME, 1992, J BACTERIOL, V174, P4893, DOI 10.1128/JB.174.15.4893-4898.1992; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; VAUGHAN EE, 1995, APPL ENVIRON MICROB, V61, P3172, DOI 10.1128/AEM.61.8.3172-3176.1995; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZEUTHEN T, 1995, INT REV CYTOL, V160, P99, DOI 10.1016/S0074-7696(08)61554-5	41	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18140	18146		10.1074/jbc.272.29.18140	http://dx.doi.org/10.1074/jbc.272.29.18140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218448	Green Published, hybrid			2022-12-27	WOS:A1997XL73500038
J	Li, HL; Forman, MS; Kurosaki, T; Pure, E				Li, HL; Forman, MS; Kurosaki, T; Pure, E			Syk is required for BCR-mediated activation of p90Rsk, but not p70S6k, via a mitogen-activated protein kinase-independent pathway in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASE; GAP-ASSOCIATED PROTEIN; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CROSS-LINKING; S6 KINASE; PHOSPHORYLATION; P72(SYK); RAPAMYCIN	The tyrosine kinases Syk and Lyn are activated in B lymphocytes following antibody induced cross-linking of the B cell receptor for antigen (BCR). It has been suggested that activation of Syk is dependent on Lyn. We tested this hypothesis by comparing the phosphorylation and activation of several downstream effector molecules in parental DT40, DT40Syk(-) and DT40Lyn-B cells. The phosphorylation and activation of p90Rsk was ablated in Syk-deficient B cells but unaffected in Lyn-deficient B cells while the phosphorylation/activation of Ras GTPase activating protein (Ras GAP) and mitogen activated protein (MAP) kinase required both Syk and Lyn. Thus, these data indicate that Syk can be activated in the absence of Lyn after BCR cross-linking and results ire the activation of p90Rsk via a MAP kinase-independent pathway in DT40Lyn(-) cells. We also demonstrated that BCR mediates the activation of p70S6k. However, activation of p70S6k in DT40Syk(-) and DT40Lyn(-) cells was comparable with that observed in parental cells. Thus, either Syk or Lyn may be sufficient for activation of p70S6k, or activation of p70S6k occurs independently of both Syk and Lyn. The kinase activity of Syk was required for the phosphorylation/activation of each of these downstream effector molecules but only the phosphorylation of Ras GAP was affected in cells expressing a mutant of Syn in which tyrosines 525 and 526 were substituted to phenlyalanines.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; KANSAI MED UNIV,INST HEPAT RES,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN	The Wistar Institute; Kansai Medical University			Kurosaki, Tomohiro/D-1306-2009; Li, Hsiu-Ling/C-3567-2011	Kurosaki, Tomohiro/0000-0002-6352-304X; 	NIAID NIH HHS [R01 AI25185] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025185] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAGAARDTILLERY KM, 1994, CELL IMMUNOL, V156, P493, DOI 10.1006/cimm.1994.1193; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; DARBY C, 1994, J IMMUNOL, V152, P5429; DUMONT FJ, 1994, J IMMUNOL, V152, P992; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; GOLD MR, 1993, J IMMUNOL, V150, P377; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kalab P, 1996, DEVELOPMENT, V122, P1957; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KINCH MS, 1994, J EXP MED, V180, P1729, DOI 10.1084/jem.180.5.1729; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1994, J IMMUNOL, V152, P2157; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW LC, 1996, MOL CELL BIOL, V16, P1305; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J CELL BIOL, V270, P16186; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; Patel HR, 1996, BIOCHEM BIOPH RES CO, V227, P507, DOI 10.1006/bbrc.1996.1537; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TRAHEY MT, 1988, SCIENCE, V335, P1697; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VIVER E, 1993, EUR J IMMUNOL, V23, P1872; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Xiao J, 1996, J BIOL CHEM, V271, P7659, DOI 10.1074/jbc.271.13.7659; YAGURA H, 1993, BLOOD, V81, P1535; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	67	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18200	18208		10.1074/jbc.272.29.18200	http://dx.doi.org/10.1074/jbc.272.29.18200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218456	hybrid			2022-12-27	WOS:A1997XL73500046
J	Sia, SK; Li, MX; Spyracopoulos, L; Gagne, SM; Liu, W; Putkey, JA; Sykes, BD				Sia, SK; Li, MX; Spyracopoulos, L; Gagne, SM; Liu, W; Putkey, JA; Sykes, BD			Structure of cardiac muscle troponin C unexpectedly reveals a closed regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CALCIUM; PROTEINS; BINDING; NMR; SENSITIVITY; ASSIGNMENTS; SPECTRA; COMPLEX; STATES	The regulation of cardiac muscle contraction must differ from that of skeletal muscles to effect different physiological and contractile properties. Cardiac troponin C (TnC), the key regulator of cardiac muscle contraction, possesses different functional and Ca2+-binding properties compared with skeletal TnC and features a Ca2+-binding site I, which is naturally inactive, The structure of cardiac TnC in the Ca2+-saturated state has been determined by nuclear magnetic resonance spectroscopy. The regulatory domain exists ill a ''closed'' conformation even in the Ca2+-bound (the ''on'') state, in contrast to all predicted models and differing significantly from the calcium-induced structure observed in skeletal TnC, This structure in the Ca2+-bound state, and its subsequent interaction with troponin I (TnI), are crucial in determining the specific regulatory mechanism for cardiac muscle contraction, Further; it will allow for an understanding of the action of calcium-sensitizing drugs, which bind to cardiac TnC and are known to enhance the ability of cardiac TnC to activate cardiac muscle contraction.	UNIV ALBERTA,MRC,GRP PROT STRUCT & FUNCT,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77225	University of Alberta; University of Texas System								ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; FUCHS F, 1989, J BIOL CHEM, V264, P20344; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1992, GRASP; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; RAO VG, 1995, BIOCHEMISTRY-US, V34, P562, DOI 10.1021/bi00002a022; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	38	191	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18216	18221		10.1074/jbc.272.29.18216	http://dx.doi.org/10.1074/jbc.272.29.18216			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218458	hybrid			2022-12-27	WOS:A1997XL73500048
J	Yu, B; Slepak, VZ; Simon, MI				Yu, B; Slepak, VZ; Simon, MI			Characterization of a Go alpha mutant that binds xanthine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; G-PROTEINS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ADP-RIBOSYLATION; PHOSPHOLIPASE-C; GTP HYDROLYSIS; RAS P21; SUBUNIT; RECEPTORS	Several GTP binding proteins, including EF-Tu, Ypt1, rab-5, and FtsY, and adenylosuccinate synthetase have been reported to bind xanthine nucleotides when the conserved aspartate residue in the NKXD motif was changed to asparagine, However, the corresponding single Go alpha mutant protein (D273N) did not bind either xanthine nucleotides or guanine nucleotides. Interestingly, the introduction of a second mutation to generate the Go alpha subunit D273N/Q205L switched nucleotide binding specificity to xanthine nucleotide. The double mutant protein Go alpha D273N/Q205L (Go alpha X) bound xanthine triphosphate, but not guanine triphosphate. Recombinant Go alpha X (Go alpha D273N/Q205L) formed heterotrimers with beta gamma complexes only in the presence of xanthine diphosphate (XDP),(1) and the binding to beta gamma was inhibited by xanthine triphosphate (XTP), Furthermore, as a result of binding to XTP, the Go alpha X protein underwent a conformational change similar to that of the activated wild-type Go alpha. In transfected COS-7 cells, we demonstrate that the interaction between Go alpha X and beta gamma occurred only when cell membranes were permeabilized to allow the uptake of xanthine diphosphate. This is the first example of a switch in nucleotide binding specificity from guanine to xanthine nucleotides in a heterotrimeric G protein alpha subunit.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology								AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURNE HR, 1991, NATURE, V366, P654; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P97; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KANG C, 1994, J BIOL CHEM, V269, P24046; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18015	18019		10.1074/jbc.272.29.18015	http://dx.doi.org/10.1074/jbc.272.29.18015			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218429	hybrid, Green Accepted			2022-12-27	WOS:A1997XL73500019
J	Akeson, M; Sainz, E; Mantey, SA; Jensen, RT; Battey, JF				Akeson, M; Sainz, E; Mantey, SA; Jensen, RT; Battey, JF			Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LUNG-CARCINOMA CELLS; BOMBESIN RECEPTOR; NEUROMEDIN-B; MOLECULAR-CLONING; EXPRESSION; RHODOPSIN; SUBTYPES; DISTINCT	The bombesin family of G-protein-coupled receptors includes the gastrin-releasing peptide receptor (GRP-R), the neuromedin B receptor (NMB-R), bombesin receptor subtype 3 (BRS-3), and bombesin receptor subtype 4 (bb4). All species homologues of GRP-R, NMB-R, and bb4 bind bombesin with dissociation constants in the nanomolar range; by comparison, human BRS-3 binds bombesin at much lower affinity (K-d > 1 mu m). We used this difference to help identify candidate residues that were potentially critical for forming the bombesin binding pocket. We reasoned that amino acids essential for bombesin binding would be conserved among all homologues of bb4, NMB-R, and GRP-R; conversely, at least one of these amino acids would not be conserved among homologues of BRS-3. Amino acid sequence alignment revealed nine residues that fit this model. We replaced each of these amino acids in mouse GRP-R with the homologous amino acid in human BRS-3. Four substitutions resulted in a significant decrease in bombesin affinity (R288H, Q121R, P199S, and A308S). The analo gous mutations in BRS-3 (R127Q, H294R, S205P, and S315A) together resulted in a receptor with a 100-fold increase in bombesin and GRP affinities relative to wildtype BRS-3. From this, we propose a preliminary map of some of the amino acids comprising the agonist binding pocket.	NATL INST DEAFNESS & OTHER COMMUN DISORDERS,MOL BIOL LAB,NIH,ROCKVILLE,MD 20850; NIDDK,DIGEST DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1994, BASIC METHODS MOL BI, P624; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HAN M, 1995, BIOCHEMISTRY-US, V34, P1425, DOI 10.1021/bi00004a037; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; KROOG GS, 1995, J BIOL CHEM, V270, P8217, DOI 10.1074/jbc.270.14.8217; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MINAMINO N, 1983, BIOCHEM BIOPH RES CO, V114, P541, DOI 10.1016/0006-291X(83)90814-8; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPINDEL ER, 1990, MOL ENDOCRINOL, V43, P1950; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	25	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17405	17409		10.1074/jbc.272.28.17405	http://dx.doi.org/10.1074/jbc.272.28.17405			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211882	hybrid			2022-12-27	WOS:A1997XK16500025
J	Annunen, P; Helaakoski, T; Myllyharju, J; Veijola, J; Pihlajaniemi, T; Kivirikko, KI				Annunen, P; Helaakoski, T; Myllyharju, J; Veijola, J; Pihlajaniemi, T; Kivirikko, KI			Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer - The alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta(2) tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EHLERS-DANLOS SYNDROME; LYSYL HYDROXYLASE GENE; SYNDROME TYPE-VI; BETA-SUBUNIT; BACULOVIRUS EXPRESSION; MOLECULAR-CLONING; 2 SIBLINGS; SEQUENCE; COLLAGEN	Prolyl 4-hydroxylase (proline hydroxylase, EC 1.14.11.2) catalyzes the formation of 4-hydroxyproline in collagens, The vertebrate enzyme is an alpha(2) beta(2) tetramer, the beta subunit of which is identical to protein disulfide-isomerase (PDI, EC 5.3.4.1), Pie report here on cloning of the recently discovered alpha(II) subunit from human sources, The mRNA for the alpha(II) subunit was found to be expressed in a variety of human tissues, and the presence of the corresponding polypeptide and the (alpha(II))(2) beta(2) tetramer was demonstrated in cultured human WI-38 and HT-1080 cells. The type II tetramer was found to represent about 30% of the total prolyl 4-hydroxylase in these cells and about 5-15% in various chick embryo tissues, The results of coexpression in insect cells argued strongly against the formation of a mixed alpha(I)alpha(II)beta(2) tetramer. PDI/beta polypeptide containing a histidine tag in its N terminus was found to form prolyl 4-hydroxylase tetramers as readily as the wild-type PDI/beta polypeptide, and histidine-tagged forms of prolyl 4-hydroxylase appear to offer an excellent source for a simple large scale purification of the recombinant enzyme. The properties of the purified human type II enzyme were very similar to Chose of the type I enzyme, beet the K-i of the former fbr poly(L-proline) was about 200-1000 times that of the latter. In agreement with this, a minor difference, about 3-6-fold, was found between the two enzymes in the K-m values for three peptide substrates. The existence of two forms of prolyl 4-hydroxylase in human cells raises the possibility that mutations in one enzyme form may not be lethal despite the central role of this enzyme in the synthesis of all collagens.	UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, FIN-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				ATREYA PL, 1991, J BIOL CHEM, V266, P2852; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUJIMOTO D, 1969, J BIOL CHEM, V244, P205; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HA VT, 1994, J CLIN INVEST, V93, P1716, DOI 10.1172/JCI117155; HAUTALA T, 1993, GENOMICS, V15, P399, DOI 10.1006/geno.1993.1074; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1969, J BIOL CHEM, V244, P4838; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467	32	102	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17342	17348		10.1074/jbc.272.28.17342	http://dx.doi.org/10.1074/jbc.272.28.17342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211872	hybrid			2022-12-27	WOS:A1997XK16500015
J	Gaits, F; Shiozaki, K; Russell, P				Gaits, F; Shiozaki, K; Russell, P			Protein phosphatase 2C acts independently of stress-activated kinase cascade to regulate the stress response in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; GENE PTC1; PATHWAYS; CELLS	Stress-activated signal transduction pathways, which are largely conserved among a broad spectrum of eukaryotic species, have a crucial role in the survival of many forms of stress. It is therefore important to discover how these pathways are both positively and negatively regulated. Recent genetic studies have implicated protein phosphatase 2C (PP2C) as a novel negative regulator of stress response pathways in both budding and fission yeasts, Moreover, it was hypothesized that PP2C dephosphorylates one or more components of protein kinase cascades that are at the core of stress-activated signal transduction pathways, Herein we present genetic and biochemical studies of the fission yeast Schizosaccharomyces pombe that disprove this hypothesis and indicate that PP2C instead negatively regulates a downstream element of the pathway. First, high expression of PPSC produces phenotypes that are inconsistent with negative regulation of the Wik1-Wis1-Spc1 stress-activated kinase cascade. Second, high expression of PPSC leads to sustained activating tyrosine phosphorylation of Spc1. Third, Spc1-dependent phosphorylation of Atf1, a transcription factor substrate of Spc1, is unaffected by high expression of PP2C, Fourth, high expression of PP2C suppresses Atf1-dependent transcription of a stress-response gene, These studies strongly suggest that PP2C acts down stream of Spc1 kinase in the stress-activated signal transduction pathway.	Scripps Res Inst, DEPT MOL BIOL MB3, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Shiozaki, Kazuhiro/K-3440-2019	Shiozaki, Kazuhiro/0000-0002-0395-5457; Gaits-Iacovoni, Frederique/0000-0002-9853-0442	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041281] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; ChinSang ID, 1996, GENE DEV, V10, P2314, DOI 10.1101/gad.10.18.2314; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Degols G, 1996, MOL CELL BIOL, V16, P2870; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUANG KN, 1995, GENETICS, V141, P1275; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIKAWA M, 1995, FEBS LETT, V375, P299, DOI 10.1016/0014-5793(95)01209-W; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RUSSELL PR, 1983, J BIOL CHEM, V258, P143; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	30	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17873	17879		10.1074/jbc.272.28.17873	http://dx.doi.org/10.1074/jbc.272.28.17873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211944	hybrid			2022-12-27	WOS:A1997XK16500087
J	Lee, YM; Park, TY; Schulz, RA; Kim, YS				Lee, YM; Park, TY; Schulz, RA; Kim, YS			Twist-mediated activation of the NK-4 homeobox gene in the visceral mesoderm of Drosophila requires two distinct clusters of E-box regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL GRADIENT MORPHOGEN; HOMEODOMAIN PROTEINS; FUNCTIONAL-ANALYSIS; AUTO-REGULATION; MULTIPLE-MODES; CELL FATE; EXPRESSION; EMBRYO; HEART; DNA	NK-4, also called msh2 and tinman, encodes a homeodomain transcription factor that is required for the development of the dorsal mesoderm and its derivatives in the Drosophila embryo. Genetic analyses indicate that NK-4 resides downstream of the mesodermal determinant twist, which encodes a basic helix-loop-helix-type transcription factor. However, the regulation of NK-4 by twist remains poorly understood, Using expression assays in cultured cells and transgenic flies, we show that two distinct clusters of E-box regulatory sequences, present upstream of the NK-4 gene, mediate NK-4 expression in the visceral mesoderm. These elements are conserved between the Drosophila melanogaster and Drosophila virilis NK-4 genes and serve as binding sites for Twist (E1 cluster) and NK-4 (E2 cluster) proteins. In cultured cells, Twist and NK-4 binding results in activation of NK-4 gene expression. In transgenic animals, the E1 and E2 clusters are functionally connected, and both elements are required for NK-4 activation in cells of the visceral mesoderm and also for NK-4 repression in cells of the somatic musculature. These results demonstrate that NK-4 is a direct transcriptional target for Twist and its own gene product in visceral mesodermal cells, supporting the idea that twist and NK-4 function in the subdivision of the mesoderm during Drosophila embryogenesis.	NHLBI, LMC, NIH, BETHESDA, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; UTMD Anderson Cancer Center								AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Chung KW, 1996, MOL CELLS, V6, P197; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Dessain S., 1993, ADV DEV BIOCH, V2, P1, DOI [10.1016/s1064-2722(08)60035-3, DOI 10.1016/S1064-2722(08)60035-3]; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EVANS SM, 1995, DEVELOPMENT, V121, P3889; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IRVINE KD, 1993, DEVELOPMENT, V117, P387; JAGLA K, 1994, NUCLEIC ACIDS RES, V22, P1202, DOI 10.1093/nar/22.7.1202; JAGLA K, 1993, GENE, V127, P165, DOI 10.1016/0378-1119(93)90715-F; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAGGERT K, 1995, DEVELOPMENT, V121, P2107; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; NIRENBERG M, 1995, ANN NY ACAD SCI, V758, P224, DOI 10.1111/j.1749-6632.1995.tb24830.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Park MY, 1996, DEV BIOL, V177, P104, DOI 10.1006/dbio.1996.0149; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; RAY RP, 1991, DEVELOPMENT, V113, P35; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SIMPSON P, 1983, GENETICS, V105, P615; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON D, 1992, CELL, V68, P201; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014	74	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17531	17541		10.1074/jbc.272.28.17531	http://dx.doi.org/10.1074/jbc.272.28.17531			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211899	hybrid			2022-12-27	WOS:A1997XK16500042
J	Kishore, R; Samuel, M; Khan, MY; Hand, J; Frenz, DA; Newman, SA				Kishore, R; Samuel, M; Khan, MY; Hand, J; Frenz, DA; Newman, SA			Interaction of the NH2-terminal domain of fibronectin with heparin - Role of the Omega-loops of the type I modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DRIVEN TRANSLOCATION; ULTRAVIOLET CIRCULAR-DICHROISM; NUCLEAR-MAGNETIC-RESONANCE; HUMAN-PLASMA FIBRONECTIN; AMINO-TERMINAL DOMAIN; FIBRIN-BINDING SITE; SECONDARY STRUCTURE; STAPHYLOCOCCUS-AUREUS; CELL-SURFACE; PROTEIN	Determinants of the interaction of the 29-kDa NH2-terminal domain of fibronectin with heparin were explored by analysis of normal and mutant recombinant NH2-terminal fibronectin fragments produced in an insect cell Baculovirus host vector system, A genomic/cDNA clone was constructed that specified a secretable human fibronectin NH2 fragment, With the use of site-directed mutagenesis a set of 29 kDa fragments was obtained that contained glycine or glutamic acid residues in place of basic residues at various candidate sites for heparin binding in the five type I modules that mako up the domain. The recombinant fragment containing the wild type sequence had a nearly normal circular dichroic spectra and a melting profile, as assayed by loss of ellipticity at 228 nm, that was indistinguishable from that of the native fragment obtained by trypsinization of plasma fibronectin, A substantial proportion of the wild type recombinant fragment bound to heparin-Sepharose, where it was eluted at the same NaCl concentration as the native fragment. The wild type fragment was capable of promoting matrix-driven translocation, a morphogenetic effect in artificial extracellular matrices that depends on the interaction of the fibronectin NH2 terminus with heparin-like molecules on the surfaces of particles. Mutant fragments in which arginines predicted to be most exposed in the folded fragment were converted to glycines retained the same affinity for heparin as the wild type fragment, In contrast, a mutant fragment in which the single basic residue (Arg(99)) in the minor loop (''Omega-loop'') Of the second type I module was converted to a glycine had an essentially normal melting profile but exhibited no binding to heparin and failed to promote matrix-driven translocation, A mutant fragment in which the single basic residue (Arg(52)) Of the first type I module was converted to a glycine also completely lacked heparin binding activity, but one in which the single basic residue (Arg(191)) the fourth type I module was converted to a glycine retained the ability to bind heparin. A mutant fragment in which the single basic residue (Lys(143)) in the Omega-loop of the third type I module was converted to a glutamic acid lacked heparin binding activity but had a CD spectrum similar to the heparin-liganded native protein and was capable of promoting matrix-driven translocation, The results indicate that multiple residues in the Omega-loops of the fibronectin NH2-terminal domain participate in its interactions with heparin, In addition, the conformation of one of the nonbinding mutants may mimic the heparin-induced structural alteration ill this fibronectin domain required for certain morphogenetic events.	NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595; DR RAM MANOHAR LOHAI UNIV,DEPT BIOCHEM,FAIZABAD 224001,UTTAR PRADESH,INDIA; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OTOBIOL,BRONX,NY 10461	New York Medical College; Yeshiva University; Albert Einstein College of Medicine	Kishore, R (corresponding author), NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595, USA.		Newman, Stuart/W-1617-2019		NICHD NIH HHS [HD22564] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022564] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALON R, 1994, J IMMUNOL, V152, P1304; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOISSONVIDAL C, 1991, J BIOMED MATER RES, V25, P67, DOI 10.1002/jbm.820250106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRUMFELD V, 1993, ARCH BIOCHEM BIOPHYS, V302, P134, DOI 10.1006/abbi.1993.1191; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Downie SA, 1995, DEV BIOL, V172, P519, DOI 10.1006/dbio.1995.8068; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRAKE SL, 1993, J BIOL CHEM, V268, P15859; FORGACS G, 1989, J THEOR BIOL, V140, P417, DOI 10.1016/S0022-5193(89)80096-7; Forgacs G, 1994, COLLOID SURFACE B, V3, P139, DOI 10.1016/0927-7765(94)80061-8; FRENZ DA, 1989, DEV BIOL, V136, P87, DOI 10.1016/0012-1606(89)90132-2; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HALL BK, 1992, ANAT EMBRYOL, V186, P107; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; HIDER RC, 1988, BIOPOLYMERS, V27, P113, DOI 10.1002/bip.360270109; HINES KL, 1994, P NATL ACAD SCI USA, V91, P5187, DOI 10.1073/pnas.91.11.5187; HOMANDBERG GA, 1987, THROMB RES, V48, P329, DOI 10.1016/0049-3848(87)90445-2; HUFF S, 1994, J BIOL CHEM, V269, P15563; Hynes RO, 1990, FIBRONECTINS; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; JAIKARIA NS, 1991, BIOCHEMISTRY-US, V30, P1538, DOI 10.1021/bi00220a014; JOZEFONVICZ J, 1990, Journal of Biomaterials Science Polymer Edition, V1, P147; Kahn P C, 1979, Methods Enzymol, V61, P339; KHAN MY, 1988, J BIOL CHEM, V263, P11314; KHAN MY, 1989, J BIOL CHEM, V264, P2139; KHAN MY, 1990, BIOCHEM J, V270, P33, DOI 10.1042/bj2700033; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; Mosher DF, 1989, FIBRONECTIN; Newman S, 1997, BIOPOLYMERS, V41, P337, DOI 10.1002/(SICI)1097-0282(199703)41:3<337::AID-BIP9>3.0.CO;2-T; NEWMAN SA, 1985, SCIENCE, V228, P885, DOI 10.1126/science.4001925; NEWMAN SA, 1987, P NATL ACAD SCI USA, V84, P4791, DOI 10.1073/pnas.84.14.4791; NEWMAN SA, 1996, STRUCTURE FUNCTION E, V2; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROSTAGNO A, 1994, J BIOL CHEM, V269, P31938; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL M, 1994, THROMB RES, V75, P259, DOI 10.1016/0049-3848(94)90237-2; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; STEVENS ES, 1987, J MOL BIOL, V197, P743, DOI 10.1016/0022-2836(87)90481-5; WELSH EJ, 1983, BIOPOLYMERS, V22, P821, DOI 10.1002/bip.360220305; WILLIAMS MJ, 1993, BIOCHEMISTRY-US, V32, P7388, DOI 10.1021/bi00080a008; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WOODY RW, 1972, BIOPOLYMERS, V11, P1149, DOI 10.1002/bip.1972.360110604; YANG JT, 1986, METHOD ENZYMOL, V130, P208	61	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17078	17085		10.1074/jbc.272.27.17078	http://dx.doi.org/10.1074/jbc.272.27.17078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202024	hybrid			2022-12-27	WOS:A1997XH44600056
J	Alkhatib, G; Ahuja, SS; Light, D; Mummidi, S; Berger, EA; Ahuja, SK				Alkhatib, G; Ahuja, SS; Light, D; Mummidi, S; Berger, EA; Ahuja, SK			CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants - Critical residues in the third extracellular loop support HIV-1 fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT VACCINIA VIRUS; ENVELOPE GLYCOPROTEIN; EXPRESSION; CELLS	There is a close correspondence between the ability of RANTES and macrophage inflammatory proteins 1 alpha and 1 beta to activate CC chemokine receptor 5 (CCR5) and the ability to inhibit CCR5-dependent membrane fusion mediated by the envelope glycoprotein of human immuno-deficiency virus (HIV), type 1, This finding suggests that some of the structural determinants for CC chemokine/CCR5 interactions and CCR5 HIV-1 fusion co-receptor activity may be shared, Recent studies rising human CCR5/CCR2B chimeras have suggested that the determinants of CCR5 co-receptor activity are complex and may involve multiple extracellular receptor domains and that viral co-receptor activity is dissociable from ligand-dependent signaling responses, However, conclusive evidence demonstrating an important role for the second and third extracellular regions of human CCR5 is lacking, Furthermore, to determine whether the determinants for CCR5 co-receptor activity overlap with those required for agonist activity, studies that compare the chemokine specificity for inhibition of envelope-mediated cell fusion and the agonist profile of chimeric receptors are necessary, In the present report, using a series of CCR5/CCR2B chimeras we ascribe an important role for the second and third extracellular loop of CCR5 in supporting the co-receptor activity of CCR5, We also provide evidence that the intracytoplasmic tail of CCR5 does not play an important role in supporting HIV-1 entry, The hypothesis that the structural determinants for CC chemokine/CCR5 interactions and CCR5 HIV-1 fusion co-receptor activity may be shared was confirmed by two novel observations: first, the fusion activity supported by two hybrid receptors could be inhibited by both RANTES and monocyte chemoattractant protein-1, chemokines specific to CCR5 and CCR2B, respectively; and second, the chemokine specificity for inhibition of envelope-mediated cell fusion matched the agonist profile of these hybrid receptors. These data shed new light on the structural determinants involved in these distinct activities of CCR5 and may have important implications for the development of CCR5-targeted anti-viral compounds.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892; S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EARL PL, 1991, CURRENT PROTOCOL S15, V2; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sabroe I, 1997, J IMMUNOL, V158, P1361; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	30	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19771	19776		10.1074/jbc.272.32.19771	http://dx.doi.org/10.1074/jbc.272.32.19771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242636	hybrid			2022-12-27	WOS:A1997XQ05900023
J	Waldeck, AR; Stowell, MHB; Lee, HK; Hung, SC; Matsson, M; Hederstedt, L; Ackrell, BAC; Chan, SI				Waldeck, AR; Stowell, MHB; Lee, HK; Hung, SC; Matsson, M; Hederstedt, L; Ackrell, BAC; Chan, SI			Electron paramagnetic resonance studies of succinate:ubiquinone oxidoreductase from Paracoccus denitrificans - Evidence for a magnetic interaction between the 3Fe-4S cluster and cytochrome b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; RESPIRATORY-CHAIN; FUMARATE REDUCTASE; ESCHERICHIA-COLI; COMPLEX-II; EPR CHARACTERISTICS; 3-IRON CLUSTER; C-OXIDASE; DEHYDROGENASE; UBISEMIQUINONE	Electron paramagnetic resonance (EPR) studies of succinate:ubiquinone oxidoreductase (SQR) from Paracoccus denitrificans have been undertaken in the purified and membrane-bound states, Spectroscopic ''signatures'' accounting for the three iron-sulfur clusters (2Fe-2S, 3Fe-4S, and 4Fe-4S), cytochrome b, flavin, and protein-bound ubisemiquinone radicals have been obtained in air-oxidized, succinate-reduced, and dithionite-reduced preparations at 4-10 K. Spectra obtained at 170 K in the presence of excess succinate showed a signal typical of that of a flavin radical, but superimposed with another signal. The superimposed signal originated from two bound ubisemiquinones, as shown by spectral simulations, Power saturation measurements performed on the air-oxidized enzyme provided evidence for a weak magnetic dipolar interaction operating between the oxidized 3Fe-4S cluster and the oxidized cytochrome b. Power saturation experiments performed on the succinate- and dithionite-reduced forms of the enzyme demonstrated that the 4Fe-4S cluster is coupled weakly to both the 2Fe-2S and the 3Fe-4S clusters, Quantitative interpretation of these power saturation experiments has been achieved through redox calculations. They revealed that a spin-spin interaction between the reduced 3Fe-4S cluster and the cytochrome b (oxidized) may also exist. These findings form the first direct EPR evidence for a close proximity (less than or equal to 2 nm) of the high potential 3Fe-4S cluster, situated in the succinate dehydrogenase part of the enzyme, and the low potential, low spin b-heme in the membrane anchor of the enzyme.	CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS 127 72,PASADENA,CA 91125; CALTECH,CARL & WINFRED BRAUN LABS CHEM,PASADENA,CA 91125; CALTECH,CARL & WINFRED BRAUN LABS MOL BIOL,PASADENA,CA 91125; LUND UNIV,DEPT MICROBIOL,S-23362 LUND,SWEDEN; UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DIV MOL BIOL,SAN FRANCISCO,CA 94121	California Institute of Technology; California Institute of Technology; California Institute of Technology; Lund University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Hederstedt, Lars/0000-0002-6650-6296; STOWELL, MICHAEL/0000-0001-7250-1419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022432, R37GM022432] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16251] Funding Source: Medline; NIGMS NIH HHS [GM 22432] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abragam A., 1986, ELECT PARAMAGNETIC R; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1984, J BIOL CHEM, V259, P4015; ALBRACHT SPJ, 1980, BIOCHIM BIOPHYS ACTA, V593, P173, DOI 10.1016/0005-2728(80)90055-9; ANEMULLER S, 1995, EUR J BIOCHEM, V232, P563; BEINERT H, 1975, EUR J BIOCHEM, V54, P185, DOI 10.1111/j.1432-1033.1975.tb04128.x; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BLUM H, 1980, BIOCHIM BIOPHYS ACTA, V621, P9, DOI 10.1016/0005-2795(80)90057-4; BONOMI F, 1983, EUR J BIOCHEM, V134, P439, DOI 10.1111/j.1432-1033.1983.tb07586.x; CAMMACK R, 1994, BIOCHEM SOC T, V22, P721, DOI 10.1042/bst0220721; CAMMACK R, 1987, CYTOCHROME SYSTEMS M, P485; CASTNER TG, 1959, PHYS REV, V115, P1506, DOI 10.1103/PhysRev.115.1506; CROWE BA, 1983, EUR J BIOCHEM, V137, P191, DOI 10.1111/j.1432-1033.1983.tb07814.x; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; EDMONDSON DE, 1981, ARCH BIOCHEM BIOPHYS, V208, P69, DOI 10.1016/0003-9861(81)90124-7; Eriksson L. E. G., 1973, BIOCHIM BIOPHYS ACTA, V293, P57; Galli C, 1996, J MAGN RESON SER B, V110, P284, DOI 10.1006/jmrb.1996.0044; HAGEN WR, 1985, BIOCHIM BIOPHYS ACTA, V828, P369, DOI 10.1016/0167-4838(85)90318-8; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HAGERHALL C, 1995, BBA-BIOENERGETICS, V1229, P356, DOI 10.1016/0005-2728(95)00023-C; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEDERSTEDT L, 1985, J BIOL CHEM, V260, P5554; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HURST JK, 1991, EUR J BIOCHEM, V202, P1275, DOI 10.1111/j.1432-1033.1991.tb16500.x; HYDE JS, 1970, BIOCHIM BIOPHYS ACTA, V222, P688, DOI 10.1016/0304-4165(70)90202-3; INGLEDEW WJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P176, DOI 10.1016/0003-9861(76)90427-6; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P756, DOI 10.1016/0006-291X(85)91303-8; MAGUIRE JJ, 1986, BIOCHEMISTRY-US, V25, P5202, DOI 10.1021/bi00366a033; MAGUIRE JJ, 1985, J BIOL CHEM, V260, P909; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MORNINGSTAR JE, 1985, J BIOL CHEM, V260, P3631; Moura I., 1989, ADV EPR APPLICATIONS, P813; OHNISHI T, 1976, J BIOL CHEM, V251, P2105; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; OHNISHI T, 1974, BIOCHEM BIOPH RES CO, V61, P1017, DOI 10.1016/0006-291X(74)90257-5; OHNISHI T, 1976, J BIOL CHEM, V251, P2094; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; ORMEJOHNSON NR, 1978, METHOD ENZYMOL, P252; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; PENNOYER JD, 1988, BIOCHIM BIOPHYS ACTA, V935, P195, DOI 10.1016/0005-2728(88)90216-2; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RICH PR, 1977, BIOCHIM BIOPHYS ACTA, V462, P501, DOI 10.1016/0005-2728(77)90097-4; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; STEFFENS GCM, 1990, J CHROMATOGR, V521, P291, DOI 10.1016/0021-9673(90)85053-X; STOWELL MHB, 1993, J PHYS CHEM-US, V97, P3054, DOI 10.1021/j100114a036; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; WILSON DF, 1964, J BIOL CHEM, V239, P2683; WOLFRAM S, 1994, MATHEMATICA; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; YU L, 1987, J BIOL CHEM, V262, P1137; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843	62	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19373	19382		10.1074/jbc.272.31.19373	http://dx.doi.org/10.1074/jbc.272.31.19373			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235936	hybrid, Green Accepted			2022-12-27	WOS:A1997XP06300042
J	Kiyokawa, N; Lee, EK; Karunagaran, D; Lin, SY; Hung, MC				Kiyokawa, N; Lee, EK; Karunagaran, D; Lin, SY; Hung, MC			Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; KINASE-C PHOSPHORYLATION; CELL-CYCLE; EGF-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; NEU GENE; IN-VIVO; ACTIVATION; INDUCTION	The function of epidermal growth factor receptor (EGFR) was found to be negatively regulated in M phase in which it showed less phosphotyrosine content and reduced intrinsic kinase activity accompanied by retarded electrophoretic mobility owing to total hyperphosphorylation, Ligand induced autophosphorylation and downstream signaling of EGFR were tightly suppressed in M phase due to a decrease in ligand binding affinity and the inability of epidermal growth factor (EGF) to induce receptor dimerization. There was no change in the number of surface-exposed EGF receptors between G(0)/G(1) and M phases of the cell cycle. Hyperphosphorylation (due to serine and/or threonine phosphorylation) correlates with the unresponsiveness of cells to EGF-mediated stimulation of tyrosine phosphorylation in cells that express the normal or basal level of EGFR. This M phase-specific negative regulation was overcome by overexpression of EGFR, which was responsive to ligand throughout the cell cycle and revealed ligand-induced signaling in the M phase. These findings indicate that EGFR does not respond to ligand stimulation in M phase and suggest that a negative regulation of ligand-receptor interactions in M phase may control the normal function of receptor tyrosine kinase and that receptor overexpression will disrupt this cell cycle-dependent regulation of receptor tyrosine kinases.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021; Karunagaran, Devarajan/A-8148-2010	Hung, Mien-Chie/0000-0003-4317-4740; Karunagaran, Devarajan/0000-0001-9331-8947	NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA060856] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, CA60856, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DERYNCK R, 1987, CANCER RES, V47, P707; DIFORE PP, 1987, CELL, V51, P1063; DIMARCO E, 1989, ONCOGENE, V4, P831; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GULLICK WJ, 1986, CANCER RES, V46, P285; HARPER JW, 1993, CELL, V75, P805; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MASSOGLIA S, 1990, MOL CELL BIOL, V10, P3048, DOI 10.1128/MCB.10.6.3048; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NEWBERRY EP, 1995, BIOCHEM BIOPH RES CO, V208, P253, DOI 10.1006/bbrc.1995.1331; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PILLAY I, 1995, CELL GROWTH DIFFER, V6, P39; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SAINSBURY JRC, 1985, LANCET, V1, P364; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; Sizeland A, 1991, GROWTH FACTORS, V4, P129, DOI 10.3109/08977199109000264; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	56	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18656	18665		10.1074/jbc.272.30.18656	http://dx.doi.org/10.1074/jbc.272.30.18656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228035	hybrid			2022-12-27	WOS:A1997XM34200026
J	Lee, SB; SolowCordero, DE; Kessler, E; Takahara, K; Greenspan, DS				Lee, SB; SolowCordero, DE; Kessler, E; Takahara, K; Greenspan, DS			Transforming growth factor-beta regulation of bone morphogenetic protein-1 procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; EPIDERMAL-KERATINOCYTES; TERMINAL PROTEINASE; MOUSE FIBROBLASTS; MESSENGER-RNA; N-PROTEINASE; PURIFICATION; EXPRESSION; CULTURE; TRANSCRIPTS	Transforming growth factor-beta 1 (TGF-beta 1) induces increased extracellular matrix deposition. Bone morphogenetic protein-1 (BMP-1) also plays key roles in regulating vertebrate matrix deposition; it is the procollagen C-proteinase (PCP) that processes procollagen types I-III, and it may also mediate biosynthetic processing of lysyl oxidase and laminin 5. Here we show that BMP-1 is itself up-regulated by TGF-beta 1 and that secreted BMP-1, induced by TGF-beta 1, is either processed to an active form or remains as unprocessed proenzyme, in a cell type-dependent manner. In MG-63 osteosacrcoma cells, TGF-beta 1 elevated levels of BMP-1 mRNA similar to 7-fold and elevated levels of mRNA for mammalian tolloid (mTld), an alternatively spliced product of the BMP1 gene, to a lesser extent, Induction of RNA was dose- and time-dependent and cycloheximide-inhibitable. Secreted BMP-1 and mTld, induced by TGF-beta 1 in MG-63 and other fibrogenic cell cultures, were predominantly in forms in which proregions had been removed to yield activated enzyme. TGF-beta 1 treatment also induced procollagen N-proteinase activity in fibrogenic cultures, while expression of the procollagen C-proteinase enhancer (PCPE), a glycoprotein that stimulates PCP activity, was unaffected. In contrast to fibrogenic cells, keratinocytes lacked detectable PCPE under any culture conditions and were induced by TGF-beta 1 to secrete BMP-1 and mTld predominantly as unprocessed proenzymes.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; FIBROGEN INC,S SAN FRANCISCO,CA 94080; TEL AVIV UNIV,FAC MED,CHAIM SHEBA MED CTR,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL	University of Wisconsin System; University of Wisconsin Madison; FibroGen; Chaim Sheba Medical Center; Tel Aviv University			Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446; Solow-Cordero, David/0000-0002-9886-5058	NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano S., 1996, Molecular Biology of the Cell, V7, p58A; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CHU ML, 1985, J BIOL CHEM, V260, P2315; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; GEESIN JC, 1988, J INVEST DERMATOL, V90, P420, DOI 10.1111/1523-1747.ep12460849; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; Harlow E., 1988, ANTIBODIES LAB MANUA; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOWE JG, 1981, J BIOL CHEM, V256, P2836; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KONIG A, 1991, J INVEST DERMATOL, V96, P803, DOI 10.1111/1523-1747.ep12474424; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYYNANEN J, 1991, BIOCHEM BIOPH RES CO, V180, P673, DOI 10.1016/S0006-291X(05)81118-0; Sambrook J., 2002, MOL CLONING LAB MANU; STACEY A, 1987, J VIROL, V61, P2549, DOI 10.1128/JVI.61.8.2549-2554.1987; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	46	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19059	19066		10.1074/jbc.272.30.19059	http://dx.doi.org/10.1074/jbc.272.30.19059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228090	hybrid			2022-12-27	WOS:A1997XM34200081
J	Liang, P; Amons, R; Clegg, JS; MacRae, TH				Liang, P; Amons, R; Clegg, JS; MacRae, TH			Molecular characterization of a small heat shock alpha-crystallin protein in encysted Artemia embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CRYSTALLIN; CAENORHABDITIS-ELEGANS; FRANCISCANA EMBRYOS; CHAPERONE ACTIVITY; A-CRYSTALLIN; BRINE SHRIMP; GENE; EXPRESSION; STRESS; HSP27	Molecular chaperones protect cells during stress by limiting the denaturation/aggregation of proteins and facilitating their renaturation. In this context, brine shrimp embryos can endure a wide variety of stressful conditions, including temperature extremes, prolonged anoxia, and desiccation, thus encountering shortages of both energy (ATP) and water. How the embryos survive these stresses is the subject of continuing study, a situation true for other organisms facing similar physiological challenges. To approach this question we cloned and sequenced a cDNA for p26, a molecular chaperone specific to oviparous Artemia embryos. p26 is the first representative of the small heat shock/alpha-crystallin family from crustaceans to be sequenced, and it possesses the conserved alpha-crystallin domain characteristic of these proteins. The secondary structure of this domain was predicted to consist predominantly of beta-pleated sheet, and it appeared to lack regions of alpha-helix. Unique properties of the nonconserved amino terminus, which showed weak similarity to nucleolins and fibrillarins, are enrichments in both glycine and arginine. The carboxyl-terminal tail is the longest yet reported for a small heat shock/alpha-crystallin protein, and it is hydrophilic, a common attribute of this region. Site-specific differences between amino acids from p26 and other small heat shock/alpha-crystallin proteins bring into question the functions proposed for some of these residues. Probing of Southern blots disclosed a multi-gene family for p26, whereas two size classes of p26 mRNA at 0.7 add 1.9 kilobase pairs were seen on Northern blots; the larger probably representing nonprocessed transcripts, Examination of immunofluorescently stained samples with the confocal microscope revealed that a limited portion of intracellular p26 is found in the nuclei of encysted embryos and that it resides within discrete compartments of this organelle. The results in this paper demonstrate clearly that p26 is a novel member of the small heat shock/alpha-crystallin family of proteins. These data, in concert with its restriction to embryos undergoing oviparous development, suggest that p26 functions as a molecular chaperone during exposure to stress, perhaps able; to limit protein degradation and thus ensure a ready supply of functional proteins when growth is reinitiated.	DALHOUSIE UNIV,DEPT BIOL,HALIFAX,NS B3H 4J1,CANADA; LEIDEN UNIV,DEPT MED BIOCHEM,NL-2300 RA LEIDEN,NETHERLANDS; UNIV CALIF DAVIS,BODEGA MARINE LAB,BODEGA BAY,CA 94923	Dalhousie University; Leiden University; Leiden University - Excl LUMC; University of California System; University of California Davis			Liang, Ping/D-2709-2009; Liang, Ping/S-3790-2018	Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636				ANDERSON E, 1970, J ULTRA MOL STRUCT R, V32, P497, DOI 10.1016/S0022-5320(70)80025-9; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHEN Q, 1994, J BIOL CHEM, V269, P13216; CLEGG JS, 1995, EXP CELL RES, V219, P1, DOI 10.1006/excr.1995.1197; CLEGG JS, 1994, EXP CELL RES, V212, P77, DOI 10.1006/excr.1994.1120; CLEGG JS, 1993, J COMP PHYSIOL B, V163, P48, DOI 10.1007/BF00309664; CLEGG JS, 1994, J EXP ZOOL, V270, P332, DOI 10.1002/jez.1402700312; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P11; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; CRABBE MJC, 1994, BIOCHEM J, V297, P653, DOI 10.1042/bj2970653; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DECHAFFOY D, 1978, DIFFERENTIATION, V12, P99; DECHAFFOY D, 1976, BIOCHEM J, V158, P639, DOI 10.1042/bj1580639; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Drinkwater L.E., 1991, P93; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; HAND SC, 1988, SCIENCE, V239, P1425, DOI 10.1126/science.239.4846.1425; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Head MW, 1996, J CELL SCI, V109, P1029; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HONTORIA F, 1993, J EXP BIOL, V178, P149; JACK RS, 1992, EUR J BIOCHEM, V209, P503, DOI 10.1111/j.1432-1033.1992.tb17314.x; Jackson SA, 1996, DEV GROWTH DIFFER, V38, P153; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JONES D, 1986, J BIOL CHEM, V261, P2006; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGDON CM, 1990, EUR J CELL BIOL, V52, P17; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Liang P, 1997, EUR J BIOCHEM, V243, P225, DOI 10.1111/j.1432-1033.1997.0225a.x; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Marin R, 1996, EXP CELL RES, V223, P1, DOI 10.1006/excr.1996.0052; MARTIN J, 1994, BIOESSAYS, V16, P689, DOI 10.1002/bies.950160916; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; NAKANISHI Yu.H., 1962, ANNOT ZOOL JAPON, V35, P223; Neufer PD, 1996, J BIOL CHEM, V271, P24089, DOI 10.1074/jbc.271.39.24089; OSBORNE MA, 1993, ANNU REV BIOCHEM, V62, P219; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; ROBERTS MP, 1972, BIOCHIM BIOPHYS ACTA, V697, P148; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Sambrook J., 2002, MOL CLONING LAB MANU; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SQUIRES SL, 1989, CELLULAR MOL BIOL AR, P221; Strouboulis J, 1996, J CELL SCI, V109, P1991; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601	77	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19051	19058		10.1074/jbc.272.30.19051	http://dx.doi.org/10.1074/jbc.272.30.19051			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228089	hybrid			2022-12-27	WOS:A1997XM34200080
J	Sampson, MJ; Lovell, RS; Craigen, WJ				Sampson, MJ; Lovell, RS; Craigen, WJ			The murine voltage-dependent anion channel gene family - Conserved structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; BENZODIAZEPINE RECEPTOR; BIDIRECTIONAL PROMOTER; CREATINE-KINASE; PORIN; VDAC; SEQUENCE; YEAST; TRANSLATION; PROTEIN	Voltage-dependent anion channels (VDACs) are pore-forming proteins found in the outer mitochondrial membrane of all eucaryotes. VDACs are the binding sites for several cytosolic enzymes, including the isoforms of hexokinase and glycerol kinase, VDACs have recently been shown to conduct ATP when in the open state, allowing bound kinases preferential access to mitochondrial ATP and providing a possible mechanism for the regulation of adenine nucleotide flux, Two human VDAC cDNAs have been described previously, and we recently reported the isolation of mouse VDAC1 and VDAC2 cDNAs, as well as a third novel VDAC cDNA, designated VDAC3, In this report we describe the structural organization of each mouse VDAC gene and demonstrate that, based on conserved exon/intron boundaries, the three VDAC isoforms belong to a single gene family, The 5'-flanking region of each VDAC gene was shown to have transcription promoter activity by transient expression in cultured cells. The promoter region of each VDAC isoform lacks a canonical TATA box, but all are G+C-rich, a characteristic of housekeeping gene promoters. To examine the conservation of VDAC function, each mouse VDAC was expressed in yeast lacking the endogenous VDAC gene, Both VDAC1 and VDAC2 are able to complement the phenotypic defect associated with the mutant yeast strain, VDAC3, however, is only able to partially complement the mutant phenotype, suggesting an alternative physiologic function for the VDAC3 protein.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823] Funding Source: NIH RePORTER; NICHD NIH HHS [1P30-HD27823] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1990, EXPERIENTIA, V46, P161, DOI 10.1007/BF02027312; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGAN AM, 1987, GENE, V59, P1; COHEN N, 1988, ONCOGENE, V3, P137; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUO XJ, 1986, YEAST, V2, pS138; HA HJ, 1993, J BIOL CHEM, V268, P12143; Huizing M, 1996, PEDIATR RES, V39, P760, DOI 10.1203/00006450-199605000-00003; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P807; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE AC, 1994, J BIOL CHEM, V269, P30974; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; Melton D W, 1987, Oxf Surv Eukaryot Genes, V4, P34; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PFALLER R, 1985, J BIOL CHEM, V260, P8188; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Sambrook J., 2002, MOL CLONING LAB MANU; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; SAMPSON MJ, 1996, GENOMICS, V38, P192; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SITZLER S, 1991, GENE, V100, P155, DOI 10.1016/0378-1119(91)90361-E; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; WEICHSELBRAUN I, 1990, FEBS LETT, V275, P49, DOI 10.1016/0014-5793(90)81436-R; ZIZI M, 1994, J BIOL CHEM, V269, P1614	48	175	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18966	18973		10.1074/jbc.272.30.18966	http://dx.doi.org/10.1074/jbc.272.30.18966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228078	hybrid			2022-12-27	WOS:A1997XM34200069
J	Slack, JP; Grupp, IL; Ferguson, DG; Rosenthal, N; Kranias, EG				Slack, JP; Grupp, IL; Ferguson, DG; Rosenthal, N; Kranias, EG			Ectopic expression of phospholamban in fast-twitch skeletal muscle alters sarcoplasmic reticulum Ca2+ transport and muscle relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; DEPENDENT PROTEIN-KINASE; CALCIUM-RELEASE CHANNEL; GENE-EXPRESSION; FUNCTIONAL RECONSTITUTION; PHOSPHOLIPID-VESICLES; CA-2+ ATPASE; PHOSPHORYLATION; CA-2+-ATPASE; SLOW	There are three isoforms of the sarcoplasmic reticulum Ca2+-ATPase; they are known as SERCA1, SERCA2, and SERCA3. Phospholamban is present in tissues that express the SERCA2 isoform and is an inhibitor of the affinity of SERCA2 for calcium, In vitro reconstitution and cell culture expression studies have shown that phospholamban can also regulate SERCA1, the fast-twitch skeletal muscle isoform, To determine whether regulation of SERCA1 by phospholamban can be of physiological relevance, we generated transgenic mice that ectopically express phospholamban in fast-twitch skeletal muscle, a tissue normally devoid of phospholamban, Ectopic expression of phospholamban was associated with a decrease in the affinity of SERCA1 for calcium, Assessment of isometric twitch contractions of intact fast-twitch skeletal muscles revealed depressed rates of relaxation in transgenic mice compared with wild-type cohorts, Furthermore, the prolongation of muscle relaxation appeared to correlate with the levels of phospholamban expressed in two transgenic mouse lines, These findings indicate that ectopic expression of phospholamban in fast-twitch skeletal muscle is associated with inhibition of SERCA1 activity and decreased relaxation rates of this muscle.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; CASE WESTERN RESERVE UNIV, DEPT ANAT, CLEVELAND, OH 44106 USA; MASSACHUSETTS GEN HOSP E, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA	University System of Ohio; University of Cincinnati; Case Western Reserve University				Rosenthal, Nadia/0000-0002-7599-7365	NHLBI NIH HHS [HL52318, HL26057, HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318, R01HL026057, R37HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BOWMAN WC, 1980, HDB EXPT PHARMACOLOG, V54, P47; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; DRAGO GA, 1995, BIOCHEM SOC T, V2345, pS15; FEHER JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P171, DOI 10.1016/0003-9861(88)90382-7; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HARRER JM, 1995, MOL CELL BIOCHEM, V146, P13, DOI 10.1007/BF00926876; HAWKINS C, 1995, MOL CELL BIOCHEM, V142, P131, DOI 10.1007/BF00928934; HOFFMAN B B, 1990, P187; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KIM HW, 1990, J BIOL CHEM, V265, P1702; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; KRANIAS EG, 1983, BIOCHIM BIOPHYS ACTA, V749, P62, DOI 10.1016/0167-4838(83)90151-6; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; LEWISCARL SA, 1995, MUSCLE NERVE, V18, P1232; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MIYAKODA G, 1987, J BIOCHEM-TOKYO, V102, P211, DOI 10.1093/oxfordjournals.jbchem.a122034; PAGANI ED, 1984, AM J PHYSIOL, V247, pH909, DOI 10.1152/ajpheart.1984.247.6.H909; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SLACK JP, 1997, IN PRESS AM J PHYSL; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SZYMANSKA G, 1992, MOL CELL BIOCHEM, V114, P65; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; XIAO RP, 1994, J BIOL CHEM, V269, P19151	42	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18862	18868		10.1074/jbc.272.30.18862	http://dx.doi.org/10.1074/jbc.272.30.18862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228063	hybrid			2022-12-27	WOS:A1997XM34200054
J	Keidel, S; Lamour, FPY; Apfel, CM				Keidel, S; Lamour, FPY; Apfel, CM			Mutational analysis reveals that all-trans-retinoic acid, 9-cis-retinoic acid, and antagonist interact with distinct binding determinants of RAR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RECEPTOR-ALPHA; X-RECEPTOR; NUCLEAR RECEPTORS; RXR-ALPHA; BETA; LIGAND; PROTEIN; GAMMA; DOMAIN	Retinoids exert their pleiotropic effects on cell differentiation and proliferation through specific nuclear receptors, the retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Two biologically highly active natural retinoids have been identified, all-trans-retinoic acid (t-RA) and 9-cis-retinoic acid (9-cis-RA). The RXRs exclusively bind 9-cis-RA, whereas the RARs bind both isomers of RA with comparable affinity. Recently published results suggest that RARs have the same binding site for t-RA and 9-cis-RA but with different determinants (1-3). Antagonist binding on RAR alpha has been suggested to induce distinct conformational changes in comparison with agonist binding, To elucidate the region minimally required for efficient binding of agonist (t-RA and 9-cis-RA) and antagonist Ro 41-5253 to the RAR alpha, we generated N- and C-terminally truncated mutants of the receptor. Characterization of these deletion mutant proteins using protease mapping and ligand binding experiments revealed that different parts of the ligand-binding domain are necessary for t-RA, 9-cis-RA, and antagonist binding. Three distinct regions of the ligand-binding domain of the human retinoic acid receptor-alpha are required for binding of t-RA (RAR alpha 187-402), 9-cis-RA (RAR alpha 188-409), and the antagonist Ro 41-5253 (RAR alpha 226-414).	F HOFFMANN LA ROCHE & CO LTD,PRPI,DEPT INFECT DIS,PRECLIN RES,CH-4070 BASEL,SWITZERLAND	Roche Holding								ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHYTIL F, 1984, PHARMACOL REV, V36, P93; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Lamour FPY, 1996, MOL CELL BIOL, V16, P5386; LAUDET V, 1992, Current Biology, V2, P293; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Roberts A.B., 1984, RETINOIDS, V2, P210; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18267	18272		10.1074/jbc.272.29.18267	http://dx.doi.org/10.1074/jbc.272.29.18267			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218465	hybrid			2022-12-27	WOS:A1997XL73500055
J	Hu, SM; Vincenz, C; Ni, J; Gentz, R; Dixit, VM				Hu, SM; Vincenz, C; Ni, J; Gentz, R; Dixit, VM			I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME	The pivotal discovery that the death proteases caspase 8 (FLICE) and caspase 10 (Mch4/FLICE2) are recruited to the CD-95 and tumor necrosis factor receptor-1 signaling complexes suggested a mechanism used by these cytotoxic receptors to initiate apoptosis, In this report, we describe the cloning and characterization of I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis, The overall architecture of I-FLICE is strikingly similar to that of FLICE and Mch4/FLICE2, However, I-FLICE lacks both a catalytic active site and residues that form the substrate binding pocket, in keeping with its dominant negative inhibitory function, I-FLICE is the first example of a catalytically inert caspase that can inhibit apoptosis.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012; Hu, Shimin/H-3427-2019	dixit, vishva m/0000-0001-6983-0326; Hu, Shimin/0000-0001-7110-3814	NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [AG13671] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	23	357	375	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17255	17257		10.1074/jbc.272.28.17255	http://dx.doi.org/10.1074/jbc.272.28.17255			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211860	hybrid			2022-12-27	WOS:A1997XK16500003
J	Wu, GY; Krupnick, JG; Benovic, JL; Lanier, SM				Wu, GY; Krupnick, JG; Benovic, JL; Lanier, SM			Interaction of arrestins with intracellular domains of muscarinic and alpha(2)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; RHODOPSIN INTERACTION; WILD-TYPE; BINDING; INACTIVATION; EXPRESSION; FAMILY	The intracellular domains of G-protein-coupled receptors provide sites for interaction with key proteins involved in signal inititaion and termination. As an initial approach to identify proteins interacting with these receptors and the receptor motifs required for such interactions, we used intracellular subdomains of G-protein-coupled receptors as probes to screen brain cytosol proteins. Peptides from the third intracellular loop (i3) of the M-2-muscarinic receptor (MR) (His(208)-Arg(387)), M-3-MR (Gly(308)-Leu(497)), or alpha(2A/D)-adrenergic receptor (AR) (Lys(224)-Phe(374)) were generated in bacteria as glutathione S-transferase (GST) fusion proteins, bound to glutathione-Sepharose and used as affinity matrices to detect interacting proteins in fractionated bovine brain cytosol. Bound proteins were identified by immunoblotting following SDS-polyacrylamide gel electrophoresis. Brain arrestins bound to the GST-M-3 fusion protein, but from the alpha(2A/D)-AR and M-2-MR. However, each of the receptor subdomains bound purified beta-arrestin and arrestin-3. The interaction of the M-3-MR and M-2-Mr i3 peptides with arrestins was further investigated. the tin and [H-3]arrestin-3, but did not interact with in vitro translated or purified visual arrestin. The properties and specificity of the interaction of in vitro translated [H-3]beta-arrestin, [H-3]visual arrestin, and [H-3]beta-arrestin/ visual arrestin chimeras with the M-2-MR, i3 peptide were similar to those observed with the intact purified M-2-MR that was phosphorylated and/or activated by agonist, Subsequent binding site localization studies indicated that the interaction of p-arrestin with the M-3-MR peptide required both the amino (Gly(308)-Leu(368)) and carbonyl portions (Lys(425)-Leu(497)) of the receptor subdomain, in contrast, the carboxyl region of the M-3-MR i3 peptide was sufficient for its interaction with arrestin-3.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Medical University of South Carolina; Jefferson University				Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47419] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PLANGGER A, 1994, J BIOL CHEM, V269, P26969; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH WC, 1994, J BIOL CHEM, V269, P15407; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; ZUAHG J, 1996, J BIOL CHEM, V271, P18302	26	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17836	17842		10.1074/jbc.272.28.17836	http://dx.doi.org/10.1074/jbc.272.28.17836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211939	hybrid			2022-12-27	WOS:A1997XK16500082
J	Chen, HI; Einbond, A; Kwak, SJ; Linn, H; Koepf, E; Peterson, S; Kelly, JW; Sudol, M				Chen, HI; Einbond, A; Kwak, SJ; Linn, H; Koepf, E; Peterson, S; Kelly, JW; Sudol, M			Characterization of the WW domain of human yes-associated protein and its polyproline-containing ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; ROUS-SARCOMA VIRUS; SH3 DOMAINS; INSITU HYBRIDIZATION; CHANNEL ACTIVITY; SOLID SUPPORTS; BINDING; GENE; HOMOLOGY; MUTATION	We had previously identified the WW domain as a novel globular domain that is composed of 38-40 semi-conserved amino acids and is involved in mediating protein-protein interaction, The WW domain is shared by proteins of diverse functions including structural, regulatory, and signaling proteins in yeast, nematode, and mammals, Functionally it is similar to the Src homology 3 domain in that it binds polyproline ligands. By screening a 16-day mouse embryo expression library, we identified two putative ligands of the WW domain of Yes kinase-associated protein which we named WW domain-binding proteins 1 and 2, These proteins interacted with the WW domain via a short proline-rich motif with She consensus sequence of four consecutive prolines followed by a tyrosine, Herein, we report the cDNA cloning and characterization of the human orthologs of WW domain-binding proteins I and 2, The products encoded by these cDNA clones represent novel proteins with no known function, Furthermore, these proteins show no homology to each other except for a proline-rich motif, By fluorescence in situ hybridization oil human metaphase chromosomes, we mapped the human genes for WW domain-binding proteins 1 and 2 to chromosomes 2p12 and 17q25, respectively. In addition, using site-directed mutagenesis, we determined which residues in the WW domain of Yes kinase-associated protein are critical for binding. Finally, by synthesizing peptides in which the various positions of the four consecutive proline-tyrosine motif and the five surrounding residues were replaced by all possible amino acid residues, we further elucidated the binding requirements of this motif.	CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Texas A&M University System; Texas A&M University College Station					NCI NIH HHS [CAO1605, CA45757] Funding Source: Medline; NIGMS NIH HHS [TT32GM07739-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BASTARD C, 1992, BLOOD, V79, P2527; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN HI, 1996, TECH PROTEIN CHEM, V7, P3; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; HANG HHQ, 1994, MOL BIOL IN SITU HYB, P35; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HILDEBRANDT F, 1993, AM J HUM GENET, V53, P1256; HURET JL, 1986, HUM GENET, V74, P447, DOI 10.1007/BF00280504; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SCIOT R, 1993, HISTOPATHOLOGY, V23, P439, DOI 10.1111/j.1365-2559.1993.tb00492.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	162	175	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17070	17077		10.1074/jbc.272.27.17070	http://dx.doi.org/10.1074/jbc.272.27.17070			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202023	hybrid			2022-12-27	WOS:A1997XH44600055
J	Gellibolian, R; Bacolla, A; Wells, RD				Gellibolian, R; Bacolla, A; Wells, RD			Triplet repeat instability and DNA topology: An expansion model based on statistical mechanics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-CLOSURE PROBABILITIES; MONTE-CARLO; TORSIONAL RIGIDITY; WORMLIKE CHAINS; CIRCULAR DNA; FLEXIBILITY; TRANSCRIPTION; REPLICATION; ENERGETICS; DEPENDENCE	The variance of writhe, the contribution of writhe to supercoiling, and the free energies of supercoiling were calculated for (CTG.CAG)(n) and (CGG.CCG)(n) triplet repeat sequences (TRS) by statistical mechanics from the bending and torsional moduli previously determined, Expansions of these sequences are inherited by non-mendelian transmission and are linked with several hereditary neuromuscular diseases, The variance of writhe was greater for the TRS than for random B-DNA, For random B-DNA, (CGG)(n), and (CTG)(n), the contribution of writhe to supercoiling was 70, 78, and 79%, whereas the free energy of supercoiling at a length of 10 kilobase pairs was 1040.RT, 760.RT, and 685.RT, respectively, These data indicate that the TRS are preferential sites for the partitioning of supercoiling, Calculations of the differences in free energy of supercoiling between the TRS and random B-DNA revealed a local minimum at similar to 520 base pairs, Human medical genetic studies have shown that individuals carrying up to 180-200 copies of TRS (540-600 base pairs, premutations) in the fragile X or myotonic dystrophy gene loci are usually asymptomatic, whereas large expansions (>200 repeats, full mutations), which lead to disease, are observed in their offspring, Therefore, the length corresponding to the local minimum in free energy of supercoiling correlates with the genetic breakpoint between premutation and full mutation, We propose that (a) TRS instability is mediated by DNA mispairing caused by the accumulation of supercoiling within the repeats, and (b) the expansions that take place at the premutation to full mutation threshold are associated with increased mispairing caused by the optimal partitioning of writhe within the TRS at this length.	TEXAS A&M UNIV,TEXAS MED CTR,CTR GENOME RES,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; TEXAS A&M UNIV,TEXAS MED CTR,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System			Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIGMS NIH HHS [GM 52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BEDNAR J, 1995, J MOL BIOL, V254, P579, DOI 10.1006/jmbi.1995.0640; BURD JF, 1970, J MOL BIOL, V53, P435, DOI 10.1016/0022-2836(70)90076-8; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1985, BIOPOLYMERS, V24, P1881, DOI 10.1002/bip.360241004; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LEBRET M, 1980, BIOPOLYMERS, V19, P619, DOI 10.1002/bip.1980.360190312; LEVENE SD, 1986, J MOL BIOL, V189, P73, DOI 10.1016/0022-2836(86)90382-7; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; SHIMADA J, 1984, MACROMOLECULES, V17, P689, DOI 10.1021/ma00134a028; SHIMADA J, 1985, J MOL BIOL, V184, P319, DOI 10.1016/0022-2836(85)90383-3; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16793	16797		10.1074/jbc.272.27.16793	http://dx.doi.org/10.1074/jbc.272.27.16793			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201984	hybrid			2022-12-27	WOS:A1997XH44600016
J	Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM				Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM			Mutants of rat intestinal fatty acid-binding protein illustrate the critical role played by enthalpy-entropy compensation in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT-PROBE ADIFAB; TRANSPORT PROTEINS; RETINOL-BINDING; REFINEMENT; RESOLUTION; PALMITATE; ADIPOCYTE; FAMILY	Site-specific variants of rat intestinal fatty acid-binding protein were constructed to identify the molecular interactions that are important for binding to fatty acids (FAs). Several variants displayed affinities that appeared incompatible with the crystal structure of the protein-FA complex. Thermodynamic measurements provided an explanation for these apparent inconsistencies and revealed that binding affinities often inaccurately reported changes in protein-FA interactions because changes in the binding entropy and enthalpy were usually compensatory. These results demonstrate that understanding the effects of amino acid replacements on ligand binding requires measurements of enthalpy and entropy, in addition to affinity.	MED BIOL INST,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COOK HW, 1991, BIOCH LIPIDS LIPOPRO, V20, P141; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701; EADS J, 1993, J BIOL CHEM, V268, P26375; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANDBERG WS, 1993, P NATL ACAD SCI USA, V90, P8367, DOI 10.1073/pnas.90.18.8367; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	23	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16737	16740		10.1074/jbc.272.27.16737	http://dx.doi.org/10.1074/jbc.272.27.16737			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201976	hybrid			2022-12-27	WOS:A1997XH44600008
J	Alarco, AM; Balan, I; Talibi, D; Mainville, N; Raymond, M				Alarco, AM; Balan, I; Talibi, D; Mainville, N; Raymond, M			AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; MULTIPLE-DRUG-RESISTANCE; AZOLE ANTIFUNGAL AGENTS; CANDIDA-ALBICANS GENE; FLUCONAZOLE RESISTANCE; MOLECULAR-CLONING; PLEIOTROPIC DRUG; OXIDATIVE STRESS; YEAST; PROTEIN	We have isolated a Candida albicans gene that confers resistance to the azole derivative fluconazole (FCZ) when overexpressed in Saccharomyces cerevisiae. This gene encodes a protein highly homologous to S. cerevisiae yAP-1, a bZip transcription factor known to mediate cellular resistance to toxicants such as cycloheximide (CYH), 4-nitroquinoline N-oxide (4-NQO), cadmium, and hydrogen peroxide. The gene was named CAP1, for C. albicans AP-1. Cap1 and yAP-1 are functional homologues, since CAP1 expression in a yap1 mutant strain partially restores the ability of the cells to grow on toxic concentrations of cadmium or hydrogen peroxide. We have found that the expression of YBR008c, an open reading frame identified in the yeast genome sequencing project and predicted to code for a multidrug trans porter of the major facilitator superfamily, is dramatically induced in S. cervisiae cells overexpressing CAP1. Overexpression of either CAP1 or YAP1 in a wild type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance. YBR008c has been renamed FLR1, for fluconazole resistance 1. The expression of an FLR1-lacZ reporter construct is strongly induced by the overexpression of either CAP1 or YAP1, indicating that the FLR1 gene is transcriptionally regulated by the Cap1 and yAP-1 proteins. Taken collectively, our results demonstrate that FLR1 represents a new YAP1-controlled multidrug resistance molecular determinant in S. cerevisiae, A similar detoxification pathway is also likely to operate in C. albicans.	CLIN RES INST MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								Albertson GD, 1996, ANTIMICROB AGENTS CH, V40, P2835, DOI 10.1128/AAC.40.12.2835; Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BENYAACOV R, 1994, ANTIMICROB AGENTS CH, V38, P648, DOI 10.1128/AAC.38.4.648; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Clark FS, 1996, ANTIMICROB AGENTS CH, V40, P419, DOI 10.1128/AAC.40.2.419; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER D, 1994, GENETICS, V136, P505; Dixon DM, 1996, PUBLIC HEALTH REP, V111, P226; Dupont BF, 1996, J MYCOL MED, V6, P12; EHRENHOFERMURRAY AE, 1994, MOL GEN GENET, V244, P287, DOI 10.1007/BF00285456; FLING ME, 1991, MOL GEN GENET, V227, P318, DOI 10.1007/BF00259685; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GOLDWAY M, 1995, ANTIMICROB AGENTS CH, V39, P422, DOI 10.1128/AAC.39.2.422; GOMPELKLEIN P, 1990, CURR GENET, V18, P93, DOI 10.1007/BF00321122; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HITCHCOCK CA, 1993, BIOCHEM SOC T, V21, P1039, DOI 10.1042/bst0211039; HITCHCOCK CA, 1993, ANTIMICROB AGENTS CH, V37, P1962, DOI 10.1128/AAC.37.9.1962; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KATZMANN DJ, 1996, MOL CELL BIOL, V20, P109; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEPPERT G, 1990, GENETICS, V125, P13; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Maenza JR, 1997, CLIN INFECT DIS, V24, P28, DOI 10.1093/clinids/24.1.28; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; Miller J. H, 1972, EXPT MOL GENETICS; Miyahara K, 1996, CURR GENET, V29, P103, DOI 10.1007/s002940050023; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; Ouellette Marc, 1994, Trends in Microbiology, V2, P407, DOI 10.1016/0966-842X(94)90620-3; PARKINSON T, 1995, ANTIMICROB AGENTS CH, V39, P1696, DOI 10.1128/AAC.39.8.1696; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCZCYPKA MS, 1984, J BIOL CHEM, V269, P22853; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SRIKANTHA T, 1993, GENE, V131, P53, DOI 10.1016/0378-1119(93)90668-S; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WHITEWAY M, 1992, P NATL ACAD SCI USA, V89, P9410, DOI 10.1073/pnas.89.20.9410; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	74	166	181	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19304	19313		10.1074/jbc.272.31.19304	http://dx.doi.org/10.1074/jbc.272.31.19304			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235926	hybrid			2022-12-27	WOS:A1997XP06300032
J	Zhang, YL; Li, Y; Wu, Y; Yan, HG				Zhang, YL; Li, Y; Wu, Y; Yan, HG			Structural and functional roles of tyrosine 78 of yeast guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROBING PROTEIN-STRUCTURE; DYNAMIC NUCLEAR-POLARIZATION; ADENYLATE KINASE; SOLVENT PERTURBATION; MAGNETIC-RESONANCE; ANTIVIRAL ACTIVITY; ALPHA-LACTALBUMIN; REFINED STRUCTURE; NMR-SPECTROSCOPY; ESCHERICHIA-COLI	The hydroxyl group of Tyr-78 of yeast guanylate kinase (GK) is hydrogen-bonded to the phosphate of the bound GRIP as revealed by x-ray crystallography. The structural and functional roles of Tyr-78 were evaluated by site-directed mutagenesis, kinetics, guanidine hydrochloride-induced denaturation, and nuclear magnetic resonance spectroscopy (NMR). Substitution of Tyr-78 with a phenylalanine resulted in a decrease in k(cat) by a factor of 131, an increase in K-m(GMP) by a factor of 20 and an increase in K-i(GMP) by a factor of 18. K-m(MgATP) and K-i(MgATP) were very similar to those of the wild-type (WT) GK. The conformational stability of the mutant was lower than that of the WT by 1.0 kcal/mol as measured by guanidine hydrochloride-induced denaturation. Detailed comparison of the TOCSY and NOESY spectra of the WT GK and the mutant indicated that the conformation of Y78F is little perturbed relative to that of the WT GK at the free state and the conformation of Y78F.GMP complex is also very similar to that of the WT.GMP complex. The results taken together showed that the hydrogen bond between Tyr-78 and GMP stabilizes the GK.GMP complex by 1.7 kcal/mol, the ternary complex by 1.8 kcal/mol, and the transition state by 4.6 kcal/mol. Tyr-78 is not essential for proper folding of the enzyme but it may contribute to the conformational stability. Solvent-accessible aromatic residues were identified by using the paramagnetic probe 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. Comparison of the free and GMP-bound forms of the WT GK by NMR indicated that there are changes in conformation and dynamics upon binding of GMP.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University					NIGMS NIH HHS [GM51901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Agarwal K C, 1978, Methods Enzymol, V51, P483; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; Brady WA, 1996, J BIOL CHEM, V271, P16734, DOI 10.1074/jbc.271.28.16734; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CLELAND WW, 1986, INVESTIGATIONS RATES; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; Fitzgibbon J, 1996, FEBS LETT, V385, P185, DOI 10.1016/0014-5793(96)00365-1; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; IMPROTA S, 1995, EUR J BIOCHEM, V227, P78, DOI 10.1111/j.1432-1033.1995.tb20361.x; IMPROTA S, 1995, EUR J BIOCHEM, V227, P87, DOI 10.1111/j.1432-1033.1995.tb20362.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KARKAS JD, 1987, BIOCHIM BIOPHYS ACTA, V911, P127, DOI 10.1016/0167-4838(87)90001-X; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MILLER WH, 1992, J BIOL CHEM, V267, P21220; MILLER WH, 1980, J BIOL CHEM, V255, P7204; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; Pace C N, 1986, Methods Enzymol, V131, P266; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHANG Y, 1997, STRUCTURAL FUNCTIONA	38	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19343	19350		10.1074/jbc.272.31.19343	http://dx.doi.org/10.1074/jbc.272.31.19343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235932	hybrid			2022-12-27	WOS:A1997XP06300038
J	Ju, H; Zou, R; Venema, VJ; Venema, RC				Ju, H; Zou, R; Venema, VJ; Venema, RC			Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; MEMBRANE DOMAINS; SEQUENCE; PROTEIN; COMPONENT; MECHANISMS; VESICLES; DISEASE; REVEALS; VIP21	Endothelial nitric-oxide synthase (eNOS) and caveolin-1 are associated within endothelial plasmalemmal caveolae. It is not known, however, whether eNOS and caveolin-1 interact directly or indirectly or whether the interaction affects eNOS activity. To answer these questions, we have cloned the bovine caveolin-1 cDNA and have investigated the eNOS-caveolin-1 interaction in an in vitro binding assay system using glutathione S-transferase (GST)-caveolin-1 fusion proteins and baculovirus-expressed bovine eNOS. We have also mapped the domains involved in the interaction using an in vivo yeast two-hybrid system. Results obtained using both in vitro and in vivo protein interaction assays show that both Nand C-terminal cytosolic domains of caveolin-1 interact directly with the eNOS oxygenase domain. Interaction of eNOS with GST-caveolin-1 fusion proteins significantly inhibits enzyme catalytic activity. A synthetic peptide corresponding to caveolin-1 residues 82-101 also potently and reversibly inhibits eNOS activity by interfering with the interaction of the enzyme with Ca2+/calmodulin (CaM). Regulation of eNOS in endothelial cells, therefore, may involve not only positive allosteric regulation by Ca2+/CaM, but also negative allosteric regulation by caveolin-1.	MED COLL GEORGIA, VASC BIOL CTR, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VENEMA RC, 1996, J BIOL CHEM, V226, P703	27	507	528	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18522	18525		10.1074/jbc.272.30.18522	http://dx.doi.org/10.1074/jbc.272.30.18522			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228013	hybrid			2022-12-27	WOS:A1997XM34200004
J	Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J				Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J			Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors - Insights into mechanisms of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HIGH-AFFINITY BINDING; MONOCLONAL-ANTIBODIES; CROSS-LINKING; ALPHA-SUBUNIT; SIDE-CHAIN; SITE; DOMAIN; REGION; MUTAGENESIS	Insulin and insulin-like growth factor 1 (IGF-1) are peptides that share nearly 50% sequence homology. However, although their cognate receptors also exhibit significant overall sequence homology, the affinity of each peptide for the non-cognate receptor is 2-3 orders of magnitude lower than for the cognate receptor. The molecular basis for this discrimination is unclear, as are the molecular mechanisms underlying ligand binding. We have recently identified a major ligand binding site of the insulin receptor by alanine scanning mutagenesis. These studies revealed that a number of amino acids critical for insulin binding are conserved in the IGF-1 receptor, suggesting that they may play a role in ligand binding. We therefore performed alanine mutagenesis of these amino acids to determine whether this is the case. cDNAs encoding alanine-substituted secreted recombinant IGF-1 receptors were expressed in 293 EBNA cells, and the ligand binding properties of the expressed proteins were evaluated. Mutation of Phe(701) resulted in a receptor with undetectable IGF-1 binding; alanine substitution of the corresponding amino acid of the insulin receptor, Phe(714), produces a 140-fold reduction in affinity for insulin, Mutation of Asp(8), Asn(11), Phe(58), Phe(692), Glu(693), His(697), and Asn(698) produces a 3.5-6-fold reduction in affinity for IGF-1. In contrast, alanine mutation of the corresponding amino acids of the insulin receptor with the exception of Asp(12) produces reductions in affinity that are 50-fold or greater. The affinity of insulin for these mutants relative to wild type receptor was similar to that of their relative affinity for IGF-1 with two exceptions; the IC50 values for insulin binding to the mutants of Arg(10), which has normal affinity for IGF-1, and His(697), which has a 6-fold reduction in affinity for IGF-1, were both at least 2 orders of magnitude greater than for wild type receptor. The K-d values for insulin of the corresponding alanine mutants of the insulin receptor, Arg(14) and His(710), are 2-3 orders of magnitude greater than for wild type receptor. However, in contrast, the relative affinity of des(25-30)[Phe(B25) alpha-carboxamide]insulin for these IGF-1 receptor mutants is reduced only 4- and 50-fold, respectively.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; NOVO NORDISK AS, INSULIN RES, DK-2880 BAGSVAERD, DENMARK	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Novo Nordisk	Mynarcik, DC (corresponding author), SUNY STONY BROOK, HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,HSC T15, RM 060, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DREYER, 1991, DIABETES, V40, P1488; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; Harlow E., 1988, ANTIBODIES LAB MANUA; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Leroith Derek, 1992, Biological Signals, V1, P173; McPherson M. J., 1991, PCR PRACTICAL APPROA; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; MYRNARCIK DC, 1997, J BIOL CHEM, V272, P2077; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	39	72	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18650	18655		10.1074/jbc.272.30.18650	http://dx.doi.org/10.1074/jbc.272.30.18650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228034	hybrid			2022-12-27	WOS:A1997XM34200025
J	Sheikh, S; Ni, L; Hurley, TD; Weiner, H				Sheikh, S; Ni, L; Hurley, TD; Weiner, H			The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; ESTERASE-ACTIVITY; CYSTEINE RESIDUE; EXPRESSION; RAT; PURIFICATION; INVOLVEMENT; SERINE-74	The sequence alignment of all known aldehyde dehydrogenases showed that only 23 residues were completely conserved (Hempel, J., Nicholas, R., and Lindahl, R. (1993) Protein Sci, 2, 1890-1900). Of these 14 were glycines and prolines, Site-directed mutagenesis showed that Cys(302) was the essential nucleophile and that Glu(268) was the general base necessary to activate Cys(302) for both the dehydrogenase and esterase reaction, Here we report the mutational analysis of other conserved residues possessing reactive side chains Arg(84), Lys(192), Thr(384), Glu(399), and Ser(471), along with partially conserved Glu(398) and Lys(489), to determine their involvement in the catalytic process and correlate these finding with the known structure of mitochondrial ALDH (Steinnetz, C. G., Xie, P.-G., Weiner, H., and Hurley, T. D. (1997) Structure 5, 701-711), No residue was found to be absolutely essential, but all the mutations caused a decrease in the specific activity of the enzyme, None of the mutations affected the K-m for aldehyde significantly, although k(3), the rate constant calculated for aldehyde binding was decreased, The K-m and dissociation constant (R-ia) for NAD(+) increased significantly for R192Q and S471A compared with the native enzyme, Mutations of only Lys(192) and Glu(399), both NAD(+)-ribose binding residues, led to a change in the rate-limiting step such that hydride transfer became rate-limiting, not deacylation. Esterase activity of all mutants decreased even though mutations affected different catalytic steps in the dehydrogenase reaction.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABELES RH, 1992, BIOCHEMISTRY-US, P126; ABROILA DP, 1987, BIOCHEMISTRY-US, V26, P5679; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FELDMAN RI, 1972, J BIOL CHEM, V247, P260; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HEMPEL JD, 1981, J BIOL CHEM, V256, P889; KITSON TM, 1985, ENZYMOLOGY CARBONYL, V2, P43; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LOOMES KM, 1990, BIOCHEMISTRY-US, V29, P2070, DOI 10.1021/bi00460a015; LOOMES KM, 1986, BIOCHEM J, V238, P617, DOI 10.1042/bj2380617; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; NUKHERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23; ROUT UK, 1994, BIOCHEMISTRY-US, V33, P8955, DOI 10.1021/bi00196a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDHU RS, 1975, J BIOL CHEM, V250, P7894; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TU GC, 1988, J BIOL CHEM, V263, P1212; VASILIOU V, 1995, EUR J DRUG METAB PH, V20, P53; VEDADI M, 1997, ENZYMOLOGY CARBONYL, V6, P269; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; WEINER H, 1976, J BIOL CHEM, V251, P3853; WEINER H, 1985, ENZYMOLOGY CARBONYL, V2, P57; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	30	68	69	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18817	18822		10.1074/jbc.272.30.18817	http://dx.doi.org/10.1074/jbc.272.30.18817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228056	hybrid			2022-12-27	WOS:A1997XM34200047
J	Banan, M; Rojas, IC; Lee, WH; King, HL; Harriss, JV; Kobayashi, R; Webb, CF; Gottlieb, PD				Banan, M; Rojas, IC; Lee, WH; King, HL; Harriss, JV; Kobayashi, R; Webb, CF; Gottlieb, PD			Interaction of the nuclear matrix-associated region (MAR)-binding proteins, SATB1 and CDP/Cux, with a MAR element (L2a) in an upstream regulatory region of the mouse CD8a gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; MUTUALLY EXCLUSIVE INTERACTION; HEAVY-CHAIN ENHANCER; DNA-BINDING PROTEIN; GAMMA-GLOBIN GENE; TOPOISOMERASE-II; CELL-TYPE; DROSOPHILA-MELANOGASTER; HOMEODOMAIN PROTEIN; NEGATIVE REGULATION	Matrix-associated regions (MARs), AT-rich DNA segments that have an affinity for the nuclear matrix, have been shown to play a role in transcriptional regulation of eukaryotic genes. The present study demonstrates that a DNA element, called L2a, which has been implicated in the transcriptional regulation of the mouse CD8a gene encoding an important T cell coreceptor, is a MAR. Moreover, thee identities of two nuclear proteins, L2a-P1 and L2a-P2, previously shown to bind to the L2a element, have been determined. The L2a-P1 protein found to be present in all CD8-positive T cell lines tested is SATB1, a known MAR-binding protein. The widely expressed L2a-P2 protein is CDP/Cux, a MAR-binding protein that has been associated with repression of gene transcription, interaction of both proteins with the L2a element was studied using the missing nucleoside approach. DNase i footprinting, and electrophoretic mobility shift assays with wild type and mutant L2a elements. The data suggest that CDP/Cux bound to the L2a element is displaced by binding of SATB1 and the accompanying conformational change in the DNA lying between the primary binding sites of SATB1 and CDP/Cux. We suggest that displacement of CDP/Cux by SATB1 favors transcription of the CD8a gene, possibly by enhancing or altering its association with the nuclear matrix.	UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, INST MOL & CELLULAR BIOL, AUSTIN, TX 78712 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; OKLAHOMA MED RES FDN, DEPT IMMUNOL, OKLAHOMA CITY, OK 73104 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Cold Spring Harbor Laboratory; Oklahoma Medical Research Foundation			Banan, Mehdi/L-9762-2017		NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM046462, R29GM046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONE AM, 1988, J IMMUNOL, V141, P1369; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURDA PJ, 1976, J EXP MED, V144, P476, DOI 10.1084/jem.144.2.476; DURDA PJ, 1978, J IMMUNOL, V121, P983; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GU JJ, 1992, IMMUNOGENETICS, V36, P283; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HWANG I, 1993, IMMUNOGENETICS, V37, P129; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LANDRY DB, 1993, J EXP MED, V178, P941, DOI 10.1084/jem.178.3.941; LEE WH, 1994, INT IMMUNOL, V6, P1307, DOI 10.1093/intimm/6.9.1307; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANIATIS T, 1983, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RALPH P, 1973, J IMMUNOL, V110, P1470; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WHITE J, 1989, J IMMUNOL, V143, P1822; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; ZONG RT, 1995, J BIOL CHEM, V270, P24010, DOI 10.1074/jbc.270.41.24010	60	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18440	18452		10.1074/jbc.272.29.18440	http://dx.doi.org/10.1074/jbc.272.29.18440			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218488	hybrid			2022-12-27	WOS:A1997XL73500078
J	Horie, N; Takeishi, K				Horie, N; Takeishi, K			Identification of functional elements in the promoter region of the human gene for thymidylate synthase and nuclear factors that regulate the expression of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FM3A CELLS; TRANSCRIPTION FACTOR; NEGATIVE MUTANTS; CACCC ELEMENT; SEQUENCES; BETA; COOPERATION; CHROMOSOME; INDUCTION; UPSTREAM	To identify the essential motifs of the promoter of the human gene for thymidylate synthase (TS), we constructed a set of deletion mutants from the 5'-terminal region of the human TS gene, From the results of assays of the expression of chloramphenicol acetyltransferase (CAT), we identified two functional elements with positive effects on the promoter activity: a CACCC box (CCACACCC) and an Spl-binding motif (GAGGCGGA) that was homologous to the Spl binding site in the mouse TS gene, In addition, negative regulatory sequences were identified between the two positive elements and in the region upstream of the CACCC box, The results of gel mobility shift analyses suggested that Spl binds to the Spl-binding motif of the human TS gene promoter and that multiple nuclear factors that are related to Spl bind to the CACCC box, Furthermore, the binding of Spl to mutated Spl-binding motifs in the promoter region of the human TS gene was correlated with the promoter activity, as measured by the CAT assay, Therefore, the Spl motif seems to be a major contributor to the basic promoter activity of the human TS gene, although multiple positive and negative regulatory elements are involved in the regulated expression of this gene.	UNIV SHIZUOKA, SCH FOOD & NUTR SCI, SHIZUOKA 422, JAPAN	University of Shizuoka								ASH J, 1995, NUCLEIC ACIDS RES, V23, P4649, DOI 10.1093/nar/23.22.4649; AYUSAWA D, 1986, MOL CELL BIOL, V6, P3463, DOI 10.1128/MCB.6.10.3463; AYUSAWA D, 1986, J MOL BIOL, V190, P559, DOI 10.1016/0022-2836(86)90241-X; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CIESLA J, 1995, BBA-GENE STRUCT EXPR, V1261, P233, DOI 10.1016/0167-4781(95)00008-5; DENG T, 1986, J BIOL CHEM, V261, P6000; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; HARTMANN KU, 1961, J BIOL CHEM, V236, P3006; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HAURANI FI, 1978, J CELL PHYSIOL, V95, P49, DOI 10.1002/jcp.1040950107; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORI T, 1985, JPN J CANCER RES, V76, P977; HORI T, 1984, SISTER CHROMATID EXC, P149; HORI TA, 1984, CANCER RES, V44, P703; HORIE N, 1993, BIOCHIM BIOPHYS ACTA, V1216, P409, DOI 10.1016/0167-4781(93)90008-2; HORIE N, 1995, CELL STRUCT FUNCT, V20, P191, DOI 10.1247/csf.20.191; HORIE N, 1992, BIOCHEM BIOPH RES CO, V185, P127, DOI 10.1016/S0006-291X(05)80965-9; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KANEDA S, 1992, SOMAT CELL MOLEC GEN, V18, P409, DOI 10.1007/BF01233080; KANEDA S, 1990, J BIOL CHEM, V265, P20277; KOYAMA H, 1982, CANCER RES, V42, P4210; LIAO WC, 1994, GENE AMST, P183; LOCHSHIN A, 1979, P NATL ACAD SCI USA, V76, P750; MALEY F, 1960, J BIOL CHEM, V235, P2968; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEVINS JR, 1992, SCIENCE, V258, P424; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENO T, 1985, GENETIC CONSEQUENCES, P241; TAKAYANAGI A, 1992, NUCLEIC ACIDS RES, V20, P4021, DOI 10.1093/nar/20.15.4021; TAKEISHI K, 1989, J BIOCHEM-TOKYO, V106, P575, DOI 10.1093/oxfordjournals.jbchem.a122898; TAKEISHI K, 1984, J BIOCHEM, V95, P1477, DOI 10.1093/oxfordjournals.jbchem.a134755; WAKABAYASHI M, 1996, NUCL ACIDS S SER, V35, P227	36	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18375	18381		10.1074/jbc.272.29.18375	http://dx.doi.org/10.1074/jbc.272.29.18375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218479	hybrid			2022-12-27	WOS:A1997XL73500069
J	Vilalta, A; Trivedi, A; Wang, ZX; Roeder, RC; Johnson, DL				Vilalta, A; Trivedi, A; Wang, ZX; Roeder, RC; Johnson, DL			An RNA polymerase III-defective mutation in TATA-binding protein disrupts its interaction with a transcription factor IIIB subunit in Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL SEQUENCE ELEMENT; MAMMALIAN U6 GENES; FACTOR-TFIIIB; CONTAINING COMPLEX; 2 COMPONENTS; IN-VITRO; TBP; SPECIFICITY; EXPRESSION; LESS	A subunit of the Drosophila RNA polymerase III transcription factor IIIB (TFIIIB) complex has been identified using antibodies directed against the analogous human protein, hIIIB90. This protein has an apparent molecular mass of 105 kDa and has been designated dTAF(III)105. Drosophila S-2 cell extracts that were immunodepleted of dTAF(III)105 were substantially reduced in their capacity to support tRNA gene transcription, A protein (far Western) blot analysis revealed chat dTAF(III)105, present in a TFIIIB fraction, directly interacts with TATA-binding protein (TBP). Coimmunoprecipitation assays demonstrated that this protein associates with TBP in S-2 cell extracts, Our previous studies have identified a mutation at position 332 within Drosophila TBP that changes a highly conserved arginine residue to a histidine residue, which renders it specifically defective in its ability to support RNA polymerase III transcription in S-2 cells (Trivedi, A., Vilalta, A., Gopalan, S., and Johnson, D. L. (1996) Mot. Cell, Biol. 16, 6909-6916), We further demonstrate that extracts prepared from a stable cell line expressing epitope tagged wild-type TBP exhibit an increase in tRNA gene transcription, whereas extracts derived from cells expressing the mutant TBP protein do not. Coimmunoprecipitation assays and far Western blot analysis demonstrate that this mutation in TBP abolishes its ability to stably interact with dTAF(III)105. Thus, we have identified both a Drosophila protein that is directly associated with TBP in the TFIIIB complex, dTAF(III)105, and an amino acid residue within the highly conserved carboxyl-terminal region of TBP that is critical for dTAF(III)105-TBP interactions.	UNIV SO CALIF, SCH PHARM, DEPT MOL PHARMACOL & BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT MOL PHARMACOL & BIOCHEM, LOS ANGELES, CA 90033 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	University of Southern California; University of Southern California; Rockefeller University								BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3432, DOI 10.1093/nar/22.16.3432; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JOHNSON DL, 1991, J BIOL CHEM, V266, P16037; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM K, 1994, J BIOL CHEM, V269, P4891; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; McBryant SJ, 1996, MOL CELL BIOL, V16, P4639; MEISSNER W, 1995, MOL CELL BIOL, V15, P5888; Mital R, 1996, MOL CELL BIOL, V16, P7031; MUT V, 1997, SCIENCE, V275, P1136; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; Trivedi A, 1996, MOL CELL BIOL, V16, P6909; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG HD, 1995, MOL CELL BIOL, V15, P6720; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; Yoon JB, 1996, MOL CELL BIOL, V16, P1; YOON JB, 1995, MOL CELL BIOL, V15, P2019; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	54	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18087	18092		10.1074/jbc.272.29.18087	http://dx.doi.org/10.1074/jbc.272.29.18087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218440	hybrid			2022-12-27	WOS:A1997XL73500030
J	Yan, C; Whitsett, JA				Yan, C; Whitsett, JA			Protein kinase A activation of the surfactant protein B gene is mediated by phosphorylation of thyroid transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIUM; CATALYTIC SUBUNIT; MESSENGER-RNA; CYCLIC-AMP; FACTOR-I; SP-A; LUNG; EXPRESSION; CAMP; MECHANISMS	Thyroid transcription factor 1 (TTF-1) is a homeodomain-containing nuclear transcription factor expressed in epithelial cells of the lung and thyroid. TTF-1 binds to and activates the transcription of genes expressed selectively in the respiratory epithelium including pulmonary surfactant A, B, C and Clara cell secretory protein. Transfection with a plasmid encoding the cyclic AMP-dependent protein kinase (protein kinase A; PKA) catalytic subunit, Cat-beta, stimulated the phosphorylation of a TTF-l-flag fusion protein 6-7-fold in H441 pulmonary adenocarcinoma cells. Recombinant TTF-1 was phosphorylated by purified PKA catalytic subunit in the presence of [gamma-P-32]ATP. PKA catalytic subunit family members, Cat-alpha and Cat-beta markedly enhanced the transcriptional activation of surfactant B gene promoters by TTF-1 in vitro. Peptide mapping was used to identify a PKA phosphorylation site at the NH2 terminus of TTF-1. A 17-amino acid synthetic peptide comprising this site completely inhibited the PKA-dependent phosphorylation of TTF-1 in vitro. A substitution mutation of TTF-1 (Thr(9) --> Ala) abolished phosphorylation by PKA and reduced transactivation of the surfactant B gene promoter. Transfection with a plasmid encoding the cAMP regulatory element binding factor inhibited transcriptional activity of the surfactant protein B gene promoter. Phosphorylation of TTF-1 mediates PKA-dependent activation of surfactant protein B gene transcription.	CHILDRENS HOSP,MED CTR,DIV NEONATOL,TCHRF,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, P01HL051832, R37HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL51832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FARRELL PM, 1990, BIOCHIM BIOPHYS ACTA, V1044, P84, DOI 10.1016/0005-2760(90)90222-J; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Holzinger A, 1996, HYBRIDOMA, V15, P49, DOI 10.1089/hyb.1996.15.49; HOWARD P, 1991, J BIOL CHEM, V266, P10189; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WHITE G, 1995, RECEPTOR CHANNEL, V3, P1; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WHITSETT JA, 1996, LUNG SCI FDN, P2167; WHITSETT JA, 1991, PULMONARY SURFACTANT, P77; WHITSETT JA, 1991, BASIC MECH PEDIAT RE, P303; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; YAN C, 1992, P NATL ACAD SCI USA, V89, P8859, DOI 10.1073/pnas.89.19.8859; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	35	66	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17327	17332		10.1074/jbc.272.28.17327	http://dx.doi.org/10.1074/jbc.272.28.17327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211870	hybrid			2022-12-27	WOS:A1997XK16500013
J	Pedram, A; Razandi, M; Hu, RM; Levin, ER				Pedram, A; Razandi, M; Hu, RM; Levin, ER			Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NATRIURETIC-PEPTIDE; GENE-EXPRESSION; C-RECEPTOR; IN-VIVO; HYPOXIA; ATRIAL; ANGIOGENESIS; INDUCTION; SECRETION	The proliferation of vascular endothelial cells (EC) is an important event in angiogenesis, The synthesis of the EC growth factor, vascular endothelial cell growth factor (VEGF), is stimulated by a variety of activators; but the effects of important vasoactive peptides are not well understood, and there are no known natural inhibitors of VEGF production, We found that the vasoactive peptides endothelin (ET)-1 and ET-3 stimulated the synthesis of VEGF protein 3-4-fold in cultured human vascular smooth muscle cells, comparable in magnitude to hypoxia. ET-1 and ET-3 acted through the ETA and ETB receptors, respectively, and signaling through protein kinase C was important. Atrial natriuretic peptide (ANP), C-type natriuretic peptide, and C-ANP-(4-23), a ligand for the natriuretic peptide clearance receptor, equipotently inhibited production of VEGF by as much as 88% and inhibited ET- or hypoxia-stimulated VEGF transcription, EC proliferation and invasion of matrix were stimulated by VEGF secreted into the medium by ET-incubated vascular smooth muscle cells, This was inhibited by ANP. Our results identify the natriuretic peptides as the first peptide inhibitors of VEGF synthesis and indicate a novel mechanism by which vasoactive peptides could modulate angiogenesis.	UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT PHARMACOL, IRVINE, CA 92717 USA; DEPT VET AFFAIRS MED CTR, LONG BEACH, CA 90822 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System			Levin, Ellis/J-5402-2013		NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; Doi K, 1996, HYPERTENSION, V27, P811, DOI 10.1161/01.HYP.27.3.811; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FRANK HJL, 1993, ENDOCRINOLOGY, V133, P1092, DOI 10.1210/en.133.3.1092; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; HU RM, 1992, J BIOL CHEM, V267, P17384; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; Joukov V, 1996, EMBO J, V15, P290; KAGAMU H, 1994, BIOCHEM BIOPH RES CO, V202, P1612, DOI 10.1006/bbrc.1994.2117; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MCCARRON RM, 1993, NEUROSCI LETT, V156, P31, DOI 10.1016/0304-3940(93)90432-K; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORBIDELLI L, 1995, AM J PHYSIOL-HEART C, V269, pH686, DOI 10.1152/ajpheart.1995.269.2.H686; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NAZARIO B, 1995, J CLIN INVEST, V95, P1151, DOI 10.1172/JCI117763; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PORTER JG, 1992, AM J PHYSIOL, V263, pC1001, DOI 10.1152/ajpcell.1992.263.5.C1001; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; REZANDI M, 1996, AM J PHYSIOL, V270, pH1342; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SCHREY MP, 1992, CANCER RES, V52, P1786; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SVETLOV S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P75, DOI 10.1016/0167-4889(93)90160-Q; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG YZ, 1994, AM J PHYSIOL-CELL PH, V267, pC1130, DOI 10.1152/ajpcell.1994.267.4.C1130; YOSHIMOTO S, 1991, STROKE, V22, P378, DOI 10.1161/01.STR.22.3.378	62	175	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17097	17103		10.1074/jbc.272.27.17097	http://dx.doi.org/10.1074/jbc.272.27.17097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202027	hybrid			2022-12-27	WOS:A1997XH44600059
J	Takagi, J; Kamata, T; Meredith, J; PuzonMcLaughlin, W; Takada, Y				Takagi, J; Kamata, T; Meredith, J; PuzonMcLaughlin, W; Takada, Y			Changing ligand specificities of alpha v beta 1 and alpha v beta 3 integrins by swapping a short diverse sequence of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ATTACHMENT; POINT MUTATION; GPIIB-IIIA; BINDING; ADHESION; ALPHA; FIBRONECTIN; EXPRESSION; DOMAIN; SITE	Integrins mediate signal transduction through interaction with multiple cellular or extracellular matrix ligands. Integrin alpha v beta 3 recognizes fibrinogen, von Willebrand factor, and vitronectin, while alpha v beta 1 does not. We studied the mechanisms for defining ligand specificity of these integrins by swapping the highly diverse sequences in the I domain-like structure of the beta 1 and beta 3 subunits. When the sequence CTSEQNC (residues 187-193) of beta 1 is replaced with the corresponding CYD-MKTTC sequence of beta 3, the ligand specificity of alpha v beta 1 is altered. The mutant (alpha v beta 1-3-1), like alpha v beta 3, recognizes fibrinogen, von Willebrand factor, and vitronectin (a gain-of-function effect). The alpha v beta 1-3-1 mutant is recruited to focal contacts on fibrinogen and vitronectin, suggesting that the mutant transduces intracellular signals on adhesion. The reciprocal beta 3-1-3 mutation blocks binding of alpha v beta 3 to these multiple ligands and to LM609, a function-blocking anti-alpha v beta 3 antibody. These results suggest that the highly divergent sequence is a key determinant of integrin ligand specificity. Also, the data support a recent hypothetical model of the I domain of beta, in which the sequence is located in the ligand binding site.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1994, J BIOL CHEM, V269, P20913; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; COCK J, 1992, BIOCH BIOPHYS A, V1119, P312; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Ferrer M, 1996, THROMB HAEMOSTASIS, V76, P292; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5542; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIERSCHBACHER MD, 1982, J BIOL CHEM, V257, P9593; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEINER B, 1993, J BIOL CHEM, V268, P6870; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P282; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	48	110	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19794	19800		10.1074/jbc.272.32.19794	http://dx.doi.org/10.1074/jbc.272.32.19794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242639	hybrid			2022-12-27	WOS:A1997XQ05900026
J	Cai, DY; Williams, NK; Klinman, JP				Cai, DY; Williams, NK; Klinman, JP			Effect of metal on 2,4,5-trihydroxyphenylalanine (Topa) quinone biogenesis in the Hansenula polymorpha copper amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL MONOAMINE-OXIDASE; ACTIVE-SITE; YEAST; GENERATION; COFACTOR; MECHANISM; CLONING; STATE	Previous studies of wild-type and mutant forms of a recombinant copper amine oxidase from Hansenula polymorpha, expressed in Saccharomyces cerevisiae, have indicated a self-processing mechanism for 2,4,5-trihydroxyphenylalanine (topa) quinone biogenesis involving the active site copper (Cai, D., and Klinman, J. P. (1994) J. Biol. Chem. 269, 32039-32042), In contrast to prokaryotic copper amine oxidases, however, it has not been possible to initiate topa quinone formation by the addition of exogenous copper to precursor H. polymorpha amine oxidase lacking copper, Metal analysis of copper-depleted wild-type enzyme reveals 0.2-0.3 mol copper, together with 0.6 mol zinc, Despite changes in the zinc and copper levels in growth media, the level of zinc in purified enzyme remains fairly constant, Further, we have been unable to displace protein-bound zinc by exogenously added copper, The H. polymorpha amine oxidase gene was subsequently expressed in Escherichia coli and found to be almost completely free of copper and zinc. In vitro reconstitution of this apoprotein confirms that zinc binds to H. polymorpha amine oxidase and prevents reconstitution with copper, By contrast, addition of copper first to apoprotein leads to formation of topa quinone and stable activity in the presence of added zinc, These findings indicate efficient binding of either zinc or copper to a site that undergoes little or no exchange, The data confirm that topa quinone biogenesis in the H. polymorpha system is catalyzed by copper and occurs in the absence of added factors, We conclude that the mechanisms of cofactor biogenesis in pro- and eukaryotic systems are likely to be similar or identical, The results described herein imply different pathways for the in vivo assembly of heterologously expressed amine oxidases in S. cerevisiae and E. coli.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI D, 1994, BIOCHEMISTRY-US, V33, P7674; CAI DY, 1994, J BIOL CHEM, V269, P32039; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; DEHOOP MJ, 1992, YEAST, V8, P243, DOI 10.1002/yea.320080402; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; FONTECAVE M, 1995, STRUCTURE, V15, P1127; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Large P. J., 1986, YEAST, V2, P1; LOWERY MD, 1992, INORG CHIM ACTA, V233, P198; LU Y, 1992, J AM CHEM SOC, V114, P3560, DOI 10.1021/ja00035a064; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; MCCRACKEN J, 1992, J AM CHEM SOC, V114, P3715, DOI 10.1021/ja00036a021; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; Ruggiero CE, 1997, BIOCHEMISTRY-US, V36, P1953, DOI 10.1021/bi9628836; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	23	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19277	19281		10.1074/jbc.272.31.19277	http://dx.doi.org/10.1074/jbc.272.31.19277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235922	hybrid			2022-12-27	WOS:A1997XP06300028
J	DellaRocca, GJ; vanBiesen, T; Daaka, Y; Luttrell, DK; Luttrell, LM; Lefkowitz, RJ				DellaRocca, GJ; vanBiesen, T; Daaka, Y; Luttrell, DK; Luttrell, LM; Lefkowitz, RJ			Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors - Convergence of G(i)- and G(q)-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BETA-GAMMA-SUBUNITS; MAP KINASE; TYROSINE-KINASE; LYSOPHOSPHATIDIC ACID; EXPRESSION; PHOSPHORYLATION; FIBROBLASTS; PP60C-SRC; P21(RAS)	Many receptors that couple to heterotrimeric guanine-nucleotide binding proteins (G proteins) have been shown to mediate rapid activation of the mitogen-activated protein kinases Erk1 and Erk2, In different cell types, the signaling pathways employed appear to be a function of the available repertoire of receptors, G proteins, and effecters, In HEK-293 cells, stimulation of either alpha 1B- or alpha 2A-adrenergic receptors (ARs) leads to rapid 5-10-fold increases in Erk1/2 phosphorylation, Phosphorylation of Erk1/2 in response to stimulation of the alpha 2A-AR is effectively attenuated by pretreatment with pertussis toxin or by coexpression of a G beta gamma subunit complex sequestrant peptide (beta ARK1ct) and dominant-negative mutants of Ras (N17-Ras), mSOS1 (SOS-Pro), and Raf (Delta N-Raf), Erk1/2 phosphorylation in response to alpha 1B-AR stimulation is also attenuated by coexpression of N17-Ras, SOS-Pro, or Delta N-Raf, but not by coexpression of beta ARK1ct or by pretreatment with pertussis toxin. The alpha 1B- and alpha 2A-AR signals are both blocked by phospholipase C inhibition, intracellular Ca2+ chelation, and inhibitors of protein-tyrosine kinases, Overexpression of a dominant-negative mutant of c-Src or of the negative regulator of c-Src function, Csk, results in attenuation of the alpha 1B-AR- and alpha 2A-AR-mediated Erk1/2 signals. Chemical inhibitors of calmodulin, but not of PKC, and overexpression of a dominant-negative mutant of the protein-tyrosine kinase Pyk2 also attenuate mitogen-activated protein kinase phosphorylation after both alpha 1B- and alpha 2A-AR stimulation, Erk1/2 activation, then, proceeds via a common Ras-, calcium-, and tyrosine kinase-dependent pathway for both G(i)- and G(q/11)-coupled receptors, These results indicate that in HEK-293 cells, the G beta gamma subunit-mediated alpha 2A-AR- and the Ga-q/11-mediated alpha 1B-AR-coupled Erk1/2 activation pathways converge at the level of phospholipase C. These data suggest that calcium-calmodulin plays a central role in the calcium-dependent regulation of tyrosine phosphorylation by G protein-coupled receptors in some systems.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; GLAXO WELLCOME RES & DEV LTD, DEPT MOL BIOCHEM, RES TRIANGLE PK, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; GlaxoSmithKline			Della Rocca, Gregory/AAM-5281-2021; Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984	47	382	385	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19125	19132		10.1074/jbc.272.31.19125	http://dx.doi.org/10.1074/jbc.272.31.19125			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235901	hybrid			2022-12-27	WOS:A1997XP06300007
J	Chen, LC; Fitzpatrick, VD; Vandlen, RL; Tashjian, AH				Chen, LC; Fitzpatrick, VD; Vandlen, RL; Tashjian, AH			Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; AMP-INDEPENDENT ACTIONS; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; BRAIN; RAT; HORMONE; KIDNEY	To elucidate the signaling events mediated by specific somatostatin receptor (SSTR) subtypes, we expressed SSTR1 and SSTR2 individually in rat pituitary GH(1)2C(1) and F4C1 cells, which lack endogenous somatostatin receptors. In transfected GH(1)2C(1) cells, both SSTR1 and SSTR2 coupled to inhibition of Ca2+ influx and hyperpolarization of membrane potential via a pertussis toxin (PTx)-sensitive mechanism. These effects reflected modulation of ion channel activities which are important for regulation of hormone secretion. Somatostatin analogs MK678 and CH275 acted as subtype selective agonists as expected. In transfected F4C1 cells, both SSTR1 and SSTR2 mediated somatostatin-induced inhibition of adenylyl cyclase via a PTx-sensitive pathway. In addition, activation of SSTR2 in F4C1 cells, but not SSTR1, stimulated phospholipase C (PLC) activity and an increase in [Ca2+](i) due to release of Ca2+ from intracellular stores. Unlike adenylyl cyclase inhibition, the PLC-mediated response was only partially sensitive to PTx. To determine the structural determinants in SSTR2 necessary for activation of PLC, we constructed chimeric receptors in which domains of SSTR2 were introduced into SSTR1. Chimeric receptors containing only the third intracellular loop, or all three intracellular loops from SSTR2, mediated inhibition of adenylyl cyclase, but failed to stimulate PLC activity as did wild-type SSTR2. Furthermore, the C terminal tail of SSTR2 was not required for coupling to PLC. Thus, by expressing individual somatostatin receptor subtypes in pituitary cells, we have identified both overlapping and distinct signaling pathways for SSTR1 and SSTR2, and have shown that sequences other than simply the intracellular domains are required for SSTR2 to couple to the PLC signaling pathway.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Roche Holding; Genentech					NIDDK NIH HHS [DK11011] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHEN L, 1994, 76 ANN M END SOC, P589; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FUJII Y, 1994, FEBS LETT, V355, P117, DOI 10.1016/0014-5793(94)01159-1; GARCIA PD, 1994, MOL PHARMACOL, V45, P402; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LI XJ, 1992, J BIOL CHEM, V267, P21307; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; LIU YF, 1994, J BIOL CHEM, V269, P13880; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18666	18672		10.1074/jbc.272.30.18666	http://dx.doi.org/10.1074/jbc.272.30.18666			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228036	hybrid			2022-12-27	WOS:A1997XM34200027
J	Gangarosa, LM; Sizemore, N; GravesDeal, R; Oldham, SM; Der, CJ; Coffey, RJ				Gangarosa, LM; Sizemore, N; GravesDeal, R; Oldham, SM; Der, CJ; Coffey, RJ			A Raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA TGF-ALPHA; ACTIVATION; PROTEIN; KINASE; RNA; HYBRIDIZATION; EXPRESSION	We recently have shown that activated Ras, but not Raf, causes transformation of intestinal (RIE-1, IEC-6) epithelial cells, whereas both activated Ras and Raf transform NIH 3T3 fibroblasts (Oldham, S. M., Clark, G. J., Gangarosa, L. M., Coffey, R. J., and Her, C. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6924-6928). The observations that conditioned medium from Ras-, but not Raf-, transfected RIE-1 cells, as well as exogenous transforming growth factor alpha (TGF alpha), promoted morphological transformation of parental RIE-1 cells prompted us to identify epidermal growth factor (EGF) receptor (EGFR) ligands produced by Ras-transformed RIE-1 cells responsible for this autocrine effect. Since studies in fibroblasts have shown that v-Src is transforming, we also determined if v-Src could transform RIE-1 cells. H- or K-Ras-transformed cells secreted significant amounts of TGF alpha protein, and mRNA transcripts for TGF alpha, amphiregulin (AR), and heparin-binding EGF-like growth factor (HB-EGF) were induced. Like Ras, v-Src caused morphological and growth transformation of parental RIE-1 cells. However, TGF alpha protein was not secreted by RIE-1 cells stably expressing v-Src or activated Raf, and only minor increases in EGFR ligand mRNA expression were detected in these cells. A selective EGFR tyrosine kinase inhibitor PD153035 attenuated the Ras-, but not Src-, transformed phenotype. Taken together, these observations provide a mechanistic and biochemical basis for the ability of activated Ras, but not activated Raf, to cause transformation of RIE-1 cells. Finally, we suggest that an EGFR dependent mechanism is necessary for Ras, but not Src, transformation of these intestinal epithelial cells.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA46413, CA55008, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413, R01CA042978, R01CA055008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085; BOS JL, 1989, CANCER RES, V49, P4682; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COFFEY RJ, 1988, CANCER RES, V48, P1596; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; FILMUS J, 1993, ONCOGENE, V8, P1017; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	29	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18926	18931		10.1074/jbc.272.30.18926	http://dx.doi.org/10.1074/jbc.272.30.18926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228072	hybrid			2022-12-27	WOS:A1997XM34200063
J	Teneberg, S; MillerPodraza, H; Lampert, HC; Evans, DJ; Evans, DG; Danielsson, D; Karlsson, KA				Teneberg, S; MillerPodraza, H; Lampert, HC; Evans, DJ; Evans, DG; Danielsson, D; Karlsson, KA			Carbohydrate binding specificity of the neutrophil-activating protein of Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; MAGNETIC-RESONANCE ANALYSIS; PEPTIC-ULCER DISEASE; GASTRIC LYMPHOMA; POLYMORPHONUCLEAR LEUKOCYTES; GLYCOLIPID RECEPTORS; CHEMOTACTIC FACTOR; ANOMERIC STRUCTURE; GLYCOSPHINGOLIPIDS; INFECTION	The Possible interaction of the neutrophil-activating protein of Helicobacter pylori with target cell glycoconjugates was investigated by the binding of I-125-labeled recombinant protein to glycosphingolipids from human neutrophils in solid phase assays, Thereby, a distinct binding of the neutrophil-activating protein to four bands in the acid glycosphingolipid fraction from human neutrophils was detected, whereas no binding to the non-acid glycosphingolipids or polyglycosyl ceramides from these cells was obtained, When using glycosphingolipids not present in the cell membrane of human neutrophils, it was found that the neutrophil-activating protein also bound to sulfated glycosphingolipids as sulfatide and sulfated gangliotetraosyl ceramide, Comparison of the binding preferences df the protein to reference glycosphingolipids from other sources suggested that in human granulocytes, the neutrophil-activating protein of H. pylori preferentially recognizes glycoconjugates with a terminally unsubstituted NeuAc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4GlcNAc beta sequence.	VET AFFAIRS MED CTR,BACTERIAL ENTEROPATHOGENS LAB,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; OREBRO MED CTR HOSP,DEPT CLIN MICROBIOL & IMMUNOL,S-70185 OREBRO,SWEDEN	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Teneberg, S (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,MEDICINAREGATAN 9A,S-41390 GOTHENBURG,SWEDEN.				NIAID NIH HHS [AI28837] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028837] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; CRAIG PM, 1992, GUT, V33, P1020, DOI 10.1136/gut.33.8.1020; DIXON MF, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409105353; DUNN BE, 1990, J BIOL CHEM, V265, P9464; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P177, DOI 10.1016/0003-9861(79)90083-3; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P164, DOI 10.1016/0003-9861(79)90082-1; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P191, DOI 10.1016/0003-9861(79)90084-5; FREDLUND H, 1988, APMIS, V96, P941, DOI 10.1111/j.1699-0463.1988.tb00966.x; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HANDA S, 1963, JPN J EXP MED, V33, P347; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HIGASHI H, 1985, CANCER RES, V45, P3796; IGLESIAS JL, 1982, EUR J BIOCHEM, V123, P247, DOI 10.1111/j.1432-1033.1982.tb19760.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; KOZOL R, 1993, DIGEST DIS SCI, V38, P137, DOI 10.1007/BF01296786; KUNDU SK, 1981, FED PROC, V40, P1545; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MILLERPODRAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1168, P330, DOI 10.1016/0005-2760(93)90190-K; NIELSEN H, 1992, GUT, V33, P738, DOI 10.1136/gut.33.6.738; OCONNOR HJ, 1994, SCAND J GASTROENTERO, V29, P11, DOI 10.3109/00365529409105354; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RAUTELIN H, 1993, GUT, V34, P599, DOI 10.1136/gut.34.5.599; RAUWS EAJ, 1989, CAMPYLOBACTER PYLORI, P49; REYMUNDE A, 1993, DIGEST DIS SCI, V38, P1697, DOI 10.1007/BF01303180; RUDIGER H, 1993, LECTINS GLYCOBIOLOGY, P31; SAMUELSSON BE, 1990, METHOD ENZYMOL, V193, P623, DOI 10.1016/0076-6879(90)93442-N; SIPPONEN P, 1994, SCAND J GASTROENTERO, V29, P24, DOI 10.3109/00365529409105356; SOLNICK JV, 1993, INFECT AG DIS, V1, P294; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takemura T, 1996, GASTROENTEROLOGY, V110, P21, DOI 10.1053/gast.1996.v110.pm8536858; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YANG ZT, 1994, J BIOL CHEM, V269, P14620; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6	50	102	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19067	19071		10.1074/jbc.272.30.19067	http://dx.doi.org/10.1074/jbc.272.30.19067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228091	hybrid			2022-12-27	WOS:A1997XM34200082
J	Tobias, PS; Soldau, K; Iovine, NM; Elsbach, P; Weiss, J				Tobias, PS; Soldau, K; Iovine, NM; Elsbach, P; Weiss, J			Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; GRAM-NEGATIVE BACTERIA; AMINO-TERMINAL FRAGMENT; BINDING-PROTEIN; SOLUBLE CD14; LIPID-A; ENDOTOXIN; RECEPTOR; SERUM	Lipopolysaccharide (LPS)-binding protein (LBP) and bactericidal/permeability-increasing protein (BPI) are closely related LPS binding proteins whose binding to LPS has markedly different functional consequences, To gain better insight into the possible basis of these functional differences, the physical properties of LBP-LPS and BPI-LPS complexes have been compared in this study by sedimentation, light scattering, and fluorescence analyses, These studies reveal dramatic differences in the physical properties of LPS complexed to LBP versus BPI, They suggest that of the two proteins, only LBP can disperse LPS aggegates, However, BPI can enhance both the sedimentation velocity and apparent size of LPS aggregates while inhibiting LPS-LBP binding even at very low (1:40 to 1:20) BPI:LPS molar ratios.	NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA	New York University; New York University	Tobias, PS (corresponding author), Scripps Res Inst, DEPT IMMUNOL, IMM 12, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32021] Funding Source: Medline; NIDDK NIH HHS [R37 DK05472] Funding Source: Medline; NIGMS NIH HHS [5T32GM07308] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Capodici C, 1996, J IMMUNOL, V156, P4789; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; ELSBACH P, 1995, INFECT AGENT DIS, V4, P102; Elsbach Peter, 1994, Trends in Microbiology, V2, P324, DOI 10.1016/0966-842X(94)90449-9; GALANOS C, 1986, EUR J BIOCHEM, V160, P55, DOI 10.1111/j.1432-1033.1986.tb09939.x; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HOFER M, 1991, CHEM PHYS LIPIDS, V59, P167, DOI 10.1016/0009-3084(91)90005-V; Katz SS, 1996, INFECT IMMUN, V64, P3592, DOI 10.1128/IAI.64.9.3592-3600.1996; Levy O, 1996, EUR J HAEMATOL, V56, P263; MANNION BA, 1989, J IMMUNOL, V142, P2807; MESZAROS K, 1993, J LEUKOCYTE BIOL, V54, P558, DOI 10.1002/jlb.54.6.558; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WEINRAUCH Y, 1995, J CLIN INVEST, V95, P1916, DOI 10.1172/JCI117873; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; ZAREMBER K, 1997, J CLIN INVEST, V89, P672	26	95	104	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18682	18685		10.1074/jbc.272.30.18682	http://dx.doi.org/10.1074/jbc.272.30.18682			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228038	hybrid			2022-12-27	WOS:A1997XM34200029
J	Belaguli, NS; Schildmeyer, LA; Schwartz, RJ				Belaguli, NS; Schildmeyer, LA; Schwartz, RJ			Organization and myogenic restricted expression of the murine serum response factor gene - A role for autoregulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; BOX TRANSCRIPTION FACTORS; TERNARY COMPLEX-FORMATION; C-FOS; ACTIN GENE; PROMOTER ELEMENTS; BINDING ACTIVITY; XENOPUS EMBRYOS; FACTOR SRF; PROTEIN	Serum response factor (SRF), a member of an ancient family of DNA-binding proteins, is generally assumed to be a ubiquitous transcription factor involved in regulating growth factor-responsive genes, However, avian SRF was recently shown (Croissant, J. D., Kim, J.-H., Eichele, G., Goering, L., Lough, J., Prywes, R., and Schwartz, R. J. (1996) Dev. Biol. 177, 250-264) to be preferentially expressed in myogenic lineages and is required for regulating post-replicative muscle gene expression. Given the central importance of SRF for the muscle tissue-restricted expression of the striated alpha-actin gene family, we wanted to determine how SRP might contribute to this muscle-restricted expression, sere we have characterized the murine SRF genomic locus, which has seven exons interrupted by six introns, with the entire locus spanning 11 kilobases, Murine SRF transcripts were processed to two 3'-untranslated region polyadenylation signals, yielding 4.5- and 2.5-kilobase mRNA species. Murine SRF mRNA levels were the highest in adult skeletal and cardiac muscle, but barely detected in Liver, lung, and spleen tissues, During early mouse development, in situ hybridization analysis revealed enrichment of SRF transcripts in the myotomal portion of somites, the myocardium of the heart, and the smooth muscle media of vessels of mouse embryos, Likewise, murine SRF promoter activity was tissue-restricted, being 80-fold greater in primary skeletal myoblasts than ill Liver-derived HepG2 cells, In addition, SRF promoter activity increased 6-fold when myoblasts withdrew from the cell cycle and fused into differentiated myotubes. A 310-base pair promoter fragment depended upon multiple intact serum response elements in combination with Sp1 sites for maximal myogenic restricted activity. Furthermore, cotransfected SRF expression vector stimulated SRF promoter transcription, whereas dominant-negative SRF mutants blocked SRF promoter activity, demonstrating a positive role for an SRF-dependent autoregulatory loop.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine					NHLBI NIH HHS [R01 HL50422, P01 HL49953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFFOLTER M, 1994, DEVELOPMENT, V120, P743; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Groisman R, 1996, J BIOL CHEM, V271, P5258; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Guillemin K, 1996, DEVELOPMENT, V122, P1353; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG H, 1995, PLANT MOL BIOL, V28, P549, DOI 10.1007/BF00020401; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1994, ONCOGENE, V9, P1047; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PIERCE JW, 1995, J IMMUNOL, V155, P1972; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; STONE EM, 1990, INTERVENING SEQUENCE, P61; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, P881; TREISMAN R, 1990, CANCER BIOL, V1, P47; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	56	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18222	18231		10.1074/jbc.272.29.18222	http://dx.doi.org/10.1074/jbc.272.29.18222			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218459	hybrid			2022-12-27	WOS:A1997XL73500049
J	Hayashi, Y; Kiyono, T; Fujita, M; Ishibashi, M				Hayashi, Y; Kiyono, T; Fujita, M; Ishibashi, M			cca1 is required for formation of growth-arrested confluent monolayer of rat 3Y1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DISPLAY; MESSENGER-RNAS; VIRUS; RETROVIRUS; PROTEIN	A novel cDNA fragment, named cca1 (confluent 3Y1 cell-associated 1), was previously isolated on the basis of preferential accumulation of the corresponding mRNA in growth-arrested confluent but not in growing subconfluent rat 3Y1 cells, The cca1 cDNA was found to consist of 5022 nucleotides with an open reading frame of 1905 nucleotides, encoding a protein of 635 amino acids. Unlike the 3Y1 cell case, cca1 mRNA was not detected in confluent 3Y1 BU, 3Y1 BU/pTK, 3Y1-16E6, or F2408 cells, whose growth patterns monitored by phalloidin staining and bromodeoxyuridine incorporation were different from those of the confluent 3Y1. cells. A restoration of the confluent 3Y1-type growth pattern was observed in the cca1 cDNA-introduced 3Y1 BU and 3Y1 BU/pTK cells after reaching confluence but not in the cDNA-introduced 3Y1-16E6 or F2408 cells, The results allow us to conclude that cca1 is required but not sufficient for formation of growth-arrested confluent monolayer of 3Y1 cells.	AICHI CANC CTR,RES INST,LAB VIRAL ONCOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center			Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; FUJITA M, 1994, BLOOD, V84, P2591, DOI 10.1182/blood.V84.8.2591.bloodjournal8482591; Hayashi Y, 1997, BBA-GENE STRUCT EXPR, V1352, P145, DOI 10.1016/S0167-4781(97)00051-1; HEDBERG KM, 1995, EXP CELL RES, V219, P266, DOI 10.1006/excr.1995.1227; HIRAIWA A, 1993, VIROLOGY, V192, P102, DOI 10.1006/viro.1993.1012; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7	16	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18082	18086		10.1074/jbc.272.29.18082	http://dx.doi.org/10.1074/jbc.272.29.18082			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218439	hybrid			2022-12-27	WOS:A1997XL73500029
J	Hall, JA; Thorgeirsson, TE; Liu, J; Shin, YK; Nikaido, H				Hall, JA; Thorgeirsson, TE; Liu, J; Shin, YK; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Electron paramagnetic resonance study of ligand-induced global conformational changes by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-TRANSPORT; MEMBRANE; OVERPRODUCTION; SPECTROSCOPY; CHEMOTAXIS; RECEPTOR; MUTANTS; SYSTEM	Binding of ligands to the maltose-binding protein (MBP) of Escherichia coli often causes a global conformational change involving the closure of its two lobes. We have introduced a cysteine residue onto each of these lobes by site-directed mutagenesis and modified these residues with spin labels. Using EPR spectroscopy, we examined the changes, caused by the Ligand binding, in distance between the two spin labels, hence between the two lobes. The binding of both maltose and maltotetraose induced a considerable closure of the N- and C-terminal lobes of MBP, Little closure occurred upon the binding of maltotetraitol or beta-cyclodextrin. Previous study by fluorescence and UV differential absorbance spectroscopy (Ball, J. A., Gehring, K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17605-17609) showed that maltose and a large portion of maltotetraose bound to MBP via one mode (R mode or ''end-on'' mode), which is physiologically active and leads to the subsequent transport of the ligands across the cytoplasmic membrane, in contrast, maltotetraitol and beta-cyclodextrin bound to MBP via a different mode (B mode or ''middle'' mode), which is physiologically inactive. The present work suggests that the B mode is nonproductive because ligands binding in this manner prevent the closure of the two domains of MBP, and, as a result, the resulting ligand-MBP complex is incapable of interacting properly with the inner membrane-associated transporter complex.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Thorgeirsson, Thorgeir/0000-0002-5149-7040	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009644, R01AI009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM051290] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline; NIGMS NIH HHS [GM-51290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BETH AH, 1984, J BIOL CHEM, V259, P9717; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DUPLAY P, 1984, J BIOL CHEM, V259, P606; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; MILLHAUSER GL, 1995, METHOD ENZYMOL, V246, P589; MILLHAUSER GL, 1992, TRENDS BIOCHEM SCI, V17, P448, DOI 10.1016/0968-0004(92)90486-S; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARFF AJ, 1995, J MOL BIOL, V246, P8, DOI 10.1006/jmbi.1994.0059; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; ZUKIN RS, 1979, BIOCHEMISTRY-US, V18, P2139, DOI 10.1021/bi00578a001	24	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17610	17614		10.1074/jbc.272.28.17610	http://dx.doi.org/10.1074/jbc.272.28.17610			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211909	hybrid			2022-12-27	WOS:A1997XK16500052
J	Requena, JR; Ahmed, MU; Fountain, CW; Degenhardt, TP; Reddy, S; Perez, C; Lyons, TJ; Jenkins, AJ; Baynes, JW; Thorpe, SR				Requena, JR; Ahmed, MU; Fountain, CW; Degenhardt, TP; Reddy, S; Perez, C; Lyons, TJ; Jenkins, AJ; Baynes, JW; Thorpe, SR			Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ADVANCED GLYCOSYLATION; LIPID-PEROXIDATION; COMPLICATIONS; INVIVO; PHOSPHATIDYLSERINE; ERYTHROCYTES; PROTEINS; STRESS	N-epsilon-(Carboxymethyl)lysine (CML) is a stable chemical modification of proteins formed from both carbohydrates and lipids during autoxidation reactions, We hypothesized that carboxymethyl lipids such as (carboxymethyl)phosphatidylethanolamine (carboxymethyl-PE) would also be formed in these reactions, and we therefore developed a gas chromatography-mass spectrometry assay for quantification of carboxymethylethanolamine (CME) following hydrolysis of phospholipids. In vitro, CME was formed during glycation of dioleoyl-PE under air and from linoleoylpalmitoyl-PE, but not from dioleoyl-PE, in the absence of glucose, In vivo, CME was detected in lipid extracts of red blood cell membranes, similar to 0.14 mmol of CME/mol of ethanolamine, from control and diabetic subjects, (n = 22, p > 0.5), Levels of CML in erythrocyte membrane proteins were similar to 0.2 mmol/mol of lysine for both control and diabetic subjects (p > 0.5), For this group of diabetic subjects there was no indication of increased oxidative modification of either lipid or protein components of red cell membranes, CME was also detected in fasting urine at 2-3 nmol/mg of creatinine in control and diabetic subjects (p = 0.085), CME inhibited detection of advanced glycation end product (AGE)-modified protein in a competitive enzyme-linked immunosorbent assay using an anti-AGE antibody previously shown to recognize CML, suggesting that carboxymethyl-PE may be a component of AGE lipids detected in AGE low density lipoprotein, Measurement of levels of CME in blood, tissues, and urine should be useful for assessing oxidative damage to membrane lipids during aging and in disease.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29245	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina				Lyons, Timothy/0000-0003-2106-1622; Jenkins, Alicia/0000-0003-0583-3717	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011472] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL55782] Funding Source: Medline; NIA NIH HHS [AG11472] Funding Source: Medline; NIDDK NIH HHS [DK19971] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P2212; Beutler E., 1995, WILLIAMS HEMATOLOGY, P364; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8; JAIN SK, 1985, J CLIN INVEST, V76, P281, DOI 10.1172/JCI111958; JAIN SK, 1989, DIABETES, V38, P1539, DOI 10.2337/diabetes.38.12.1539; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; KUME S, 1995, AM J PATHOL, V147, P654; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; LYONS TJ, 1995, DIABETES CLIN SCI PR, P288; LYONS TJ, 1997, IN PRESS DIABETES RE; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; MONNIER VM, 1989, MAILLARD REACTION AG, P1; PAMPLONA R, 1995, LIFE SCI, V57, P873, DOI 10.1016/0024-3205(95)02020-J; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027	32	80	83	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17473	17479		10.1074/jbc.272.28.17473	http://dx.doi.org/10.1074/jbc.272.28.17473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211892	Green Published, hybrid			2022-12-27	WOS:A1997XK16500035
J	Flores, MVC; Atkins, D; Wade, D; OSullivan, WJ; Stewart, TS				Flores, MVC; Atkins, D; Wade, D; OSullivan, WJ; Stewart, TS			Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYMES; MESSENGER-RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES; CATALYTIC ACTIVITY; MALARIA PARASITES; CELLULAR UPTAKE; GENE-TRANSFER; IN-VITRO; SEQUENCE; STABILITY	Catalytic RNA (ribozymes) suppressed the growth of the human malarial parasite Plasmodium falciparum in vitro. The phosphorothioated hammerhead ribozymes targeted unique regions of the P. falciparum carbamoylphosphate synthetase II gene. The P. falciparum carbamoyl-phosphate synthetase II gene encodes the first and limiting enzyme in the pathway, and its mRNA transcript contains two large insert regions absent in other carbamoyl-phosphate synthetases, including that from humans, These inserts are ideal targets for nucleic acid therapy, Exogenous delivery of ribozymes to cultures reduced malarial viability up to 55% at 0.5 mu M ribozyme concentrations, which is significantly greater than control levels (5-15% reduction), suggesting a sequence-specific inhibition, This inhibition was shown to be stage-specific, with optimal inhibitions being detected after 24 h, coincident with maximal production of the carbamoyl-phosphate synthetase enzyme in the course of the life cycle of the parasite, A decrease in total carbamoyl-phosphate synthetase activity was observed only in cultures treated with the ribozymes. The task of developing alternative therapeutic agents against malaria is urgent due to the evolution of drug-resistant strains of P. falciparum, the most virulent of all human malarial parasites, Another critical issue to be addressed is the possibility of eliminating or reducing any systemic toxicity to the host, which can potentially be provided by nucleic acid therapy, This work is the first reported assessment of the ability of ribozymes as antimalarials. Ribozyme inhibition assays can also aid in identifying important antimalarial loci for chemotherapy The malarial parasite can, in turn, be a useful in vivo host to study the catalysis and function of new ribozyme designs.	JOHNSON & JOHNSON RES PROPRIETARY LTD,ST LEONARDS,NSW 2065,AUSTRALIA	Johnson & Johnson	Flores, MVC (corresponding author), UNIV NEW S WALES,SCH BIOCHEM & MOL GENET,SYDNEY,NSW 2052,AUSTRALIA.							Barker RH, 1996, P NATL ACAD SCI USA, V93, P514, DOI 10.1073/pnas.93.1.514; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; CLARK DL, 1994, MOL BIOCHEM PARASIT, V63, P129, DOI 10.1016/0166-6851(94)90015-9; COLLINS FH, 1995, ANNU REV ENTOMOL, V40, P195, DOI 10.1146/annurev.en.40.010195.001211; DAWSON PA, 1993, MOL BIOCHEM PARASIT, V60, P153, DOI 10.1016/0166-6851(93)90039-Z; Desjardins JP, 1996, J PHARMACOL EXP THER, V278, P1419; FLORES MV, 1991, INT J PARASITOL, V21, P605, DOI 10.1016/0020-7519(91)90067-H; FLORES MVC, 1994, MOL BIOCHEM PARASIT, V68, P315, DOI 10.1016/0166-6851(94)90176-7; FLORES MVC, 1997, IN PRESS PARASITOL R; Flory CM, 1996, P NATL ACAD SCI USA, V93, P754, DOI 10.1073/pnas.93.2.754; GERO AM, 1990, BLOOD CELLS, V16, P467; GERO AM, 1984, J PARASITOL, V70, P536, DOI 10.2307/3281402; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; HENDRIKS EF, 1996, THESIS U NEW S WALES; HENDRY P, 1995, NUCLEIC ACIDS RES, V23, P3928, DOI 10.1093/nar/23.19.3928; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; KIEHNTOPF M, 1995, J MOL MED, V73, P65, DOI 10.1007/BF00270579; KOZARSKY PE, 1994, CURR OPIN INFECT DIS, V7, P701, DOI 10.1097/00001432-199412000-00014; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEVIS JT, 1995, ANTISENSE RES DEV, V5, P251, DOI 10.1089/ard.1995.5.251; LI WB, 1991, MOL BIOCHEM PARASIT, V46, P229, DOI 10.1016/0166-6851(91)90047-A; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAHIEU M, 1994, BLOOD, V84, P3758, DOI 10.1182/blood.V84.11.3758.bloodjournal84113758; MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205; MILLER N, 1994, PARASITOL TODAY, V10, P92, DOI 10.1016/0169-4758(94)90006-X; Perriman R, 1993, Antisense Res Dev, V3, P253; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RAPAPORT E, 1992, P NATL ACAD SCI USA, V89, P8577, DOI 10.1073/pnas.89.18.8577; SARTORIUS C, 1991, PARASITOL TODAY, V7, P90, DOI 10.1016/0169-4758(91)90204-2; SARTORIUS C, 1991, NUCLEIC ACIDS RES, V19, P1613, DOI 10.1093/nar/19.7.1613; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Stein CA, 1996, TRENDS BIOTECHNOL, V14, P147, DOI 10.1016/0167-7799(96)20006-X; SULLIVAN SM, 1994, J INVEST DERMATOL, V103, pS85, DOI 10.1038/jid.1994.15; TAO LF, 1995, ANTISENSE RES DEV, V5, P123, DOI 10.1089/ard.1995.5.123; TEMSAMANI J, 1994, ANTISENSE RES DEV, V4, P35, DOI 10.1089/ard.1994.4.35; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	40	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16940	16945		10.1074/jbc.272.27.16940	http://dx.doi.org/10.1074/jbc.272.27.16940			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202005	hybrid			2022-12-27	WOS:A1997XH44600037
J	Hazen, SL; Gaut, JP; Hsu, FF; Crowley, JR; dAvignon, A; Heinecke, JW				Hazen, SL; Gaut, JP; Hsu, FF; Crowley, JR; dAvignon, A; Heinecke, JW			p-hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; HYPOCHLOROUS ACID; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; 6-AMINOQUINOLYL-N-HYDROXYSUCCINIMIDYL CARBAMATE; ATHEROSCLEROTIC LESIONS; APOLIPOPROTEIN-B; MACROPHAGES; DERIVATIZATION	Activated human phagocytes employ the myeloperoxidase-H2O2-Cl- system to convert L-tyrosine to p-hydroxyphenylacetaldehyde (pHA). We have explored the possibility that pHA covalently reacts with proteins to form Schiff base adducts, which may play a role in modifying targets at sites of inflammation, Because Schiff bases are labile to acid hydrolysis, prior to analysis the adducts were rendered stable by reduction with NaC-NBH3. Purified pHA reacted with N-alpha-acetyllysine, an analog of protein lysine residues. The reduced reaction product was identified as N-alpha-acetyl-N-epsilon-(2-(p-hydroxyphenyl)ethyl)lysine by H-1 NMR spectroscopy and mass spectrometry. The compound N-epsilon-(2-(p-hydroxyphenyl)ethyl)lysine (pHA-lysine) was likewise identified in acid hydrolysates of bovine serum albumin (BSA) that were first exposed to myeloperoxidase, H2O2, L-tyrosine, and Cl- and then reduced with NaCNBH3. Other halides (F-, Br-, I-) and the pseudohalide SCN- could not replace Cl- as a substrate in the myeloperoxidase-H2O2-L-tyrosine system. In the absence of the enzymatic system, pHA-lysine was detected in reduced reaction mixtures of BSA, L-tyrosine, and reagent HOCl. In contrast, pHA-lysine was undetectable when BSA was incubated with L-tyrosine and HOBr-, peroxynitrite, hydroxyl radical, or a variety of other peroxidases, indicating that the aldehyde-protein adduct was selectively produced by HOCl. Human neutrophils activated in the presence of tyrosine also modified BSA lysine residues, pHA-lysine formation required L-tyrosine and cell activation; it tvas inhibited by peroxidase inhibitors and catalase, implicating myeloperoxidase and H2O2 in the reaction pathway, pHA-lysine was detected in inflamed human tissues that were reduced, hydrolyzed, and then analyzed by mass spectrometry, indicating that the reaction of pHA with proteins may be of physiological importance. These observations raise the possibility that the identification of pHA-lysine in tissues will pinpoint targets where phagocytes inflict oxidative damage in vivo.	WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT CHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Gaut, Joseph/ABD-4600-2021; Gaut, Joseph/ABB-3387-2020; Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NCRR NIH HHS [RR-05018, RR-00954] Funding Source: Medline; NIA NIH HHS [R01 AG12298] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agner K., 1972, STRUCTURE FUNCTION O, P329; AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWNLEE M, 1991, ANNU REV MED, V42, P159, DOI 10.1146/annurev.me.42.020191.001111; Bucala R, 1992, Adv Pharmacol, V23, P1; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HORI H, 1994, J BIOL CHEM, V269, P8388; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LIEBER CS, 1994, ANN MED, V26, P325, DOI 10.3109/07853899409148346; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; LIU HJ, 1994, J CHROMATOGR A, V670, P59; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RHODES J, 1995, NATURE, V377, P71, DOI 10.1038/377071a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SELL DR, 1989, J BIOL CHEM, V264, P21597; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; WEIL I, 1949, J AM CHEM SOC, V71, P1664, DOI 10.1021/ja01173a033; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	57	72	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16990	16998		10.1074/jbc.272.27.16990	http://dx.doi.org/10.1074/jbc.272.27.16990			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202012	hybrid			2022-12-27	WOS:A1997XH44600044
J	Collins, RN; Brennwald, P; Garrett, M; Lauring, A; Novick, P				Collins, RN; Brennwald, P; Garrett, M; Lauring, A; Novick, P			Interactions of nucleotide release factor Dss4p with Sec4p in the post-Golgi secretory pathway of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; SITE-SPECIFIC MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; GDP/GTP EXCHANGE; ENDOPLASMIC-RETICULUM; PHENOTYPIC SELECTION; VESICULAR TRANSPORT; ACTIVATING PROTEIN; ESCHERICHIA-COLI	SEC4 is an essential gene encoding a small GTPase that is involved in Golgi to cell surface transport in Saccharomyces cerevisiae and is a paradigm for studies on the mode of action of Rab proteins. We describe]here the features of interaction of Sec4p with the accessory protein Dss4p, Dss4p is found both on membranes and in the cytosol; however, it is the membrane fraction that is complexed to Sec4p. Dss4p, like its mammalian counterpart, Mss4, binds zinc, and disruption of the zinc-binding site disrupts the ability of the protein to interact with Sec4p, DSS4 overexpression can rescue the lethal phenotype of two alleles of SEC4, corresponding to dominant mutations of Ras, We demonstrate that this suppression is due to the ability of Dss4p to form a tight complex with the mutant forms of Sec4p and hence sequester the mutant protein from its inhibitory effect. These results imply an in vivo role for Dss4p as a guanine nucleotide dissociation stimulator. In vitro the protein has the ability to stimulate the dissociation rate of both GDP and GTP from Sec4p. We examined the relationship of GDI1 and DSS4 with SEC4 both genetically and biochemically. These results exclude a role for DSS4 in the recruitment of Sec4p/GDI onto membranes.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University					NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM35370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035370, R37GM035370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BoyMarcotte E, 1996, MOL BIOL CELL, V7, P529, DOI 10.1091/mbc.7.4.529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NOVICK P, 1992, METHOD ENZYMOL, V219, P352; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROBERTS DM, 1995, METHOD ENZYMOL, V257, P84; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, J SAMBROOK MOL CLONI; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1047, DOI 10.1093/hmg/3.7.1047; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	55	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18281	18289		10.1074/jbc.272.29.18281	http://dx.doi.org/10.1074/jbc.272.29.18281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218467	hybrid			2022-12-27	WOS:A1997XL73500057
J	Elwess, NL; Filoteo, AG; Enyedi, A; Penniston, JT				Elwess, NL; Filoteo, AG; Enyedi, A; Penniston, JT			Plasma membrane Ca2+ pump isoforms 2a and 2b are unusually responsive to calmodulin and Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; BINDING DOMAINS; CALCIUM-ATPASE; CA-2+ PUMP; CA2+-ATPASE; EXPRESSION; PRODUCTS; MUSCLE; ENZYME	The full-length a and b variants of the rat plasma membrane calcium pump, isoform 2 (rPMCA2a and rPMCA2b), were constructed and expressed in COS-7 cells, To characterize these isoforms, calcium transport was determined in a microsomal fraction, Both rPMCA2a and rPMCA2b had a much higher affinity for calmodulin than the corresponding forms of hPMCA4, and rPMCA2b had the highest affinity among the isoforms that have been tested so far, When analyzed at a relatively high calmodulin concentration, rPMCA2b and, to a lesser extent, rPRMCA2a showed higher apparent calcium affinity; i.e. they were more active at lower Ca2+ concentrations than hPMCA4b. This indicates that these two variants of rat isoform 2 will tend to maintain a lower free cytosolic Ca2+ level in cells where they are expressed, Both variants also showed a higher level of basal activity (in the complete absence of calmodulin) than hPMCA4b, a property which would reinforce their ability to maintain a low free cytosolic Ca2+ concentration, Experiments designed to determine the source of the higher apparent Ca2+ affinity of rPMCA2b showed that it came from the properties of the carboxyl terminus, rather than from any difference in the catalytic core.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KHAN I, 1991, BIOCHEM J, V277, P345, DOI 10.1042/bj2770345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PENNISTON JT, 1994, CELL PHYSIOL BIOCHEM, V4, P148, DOI 10.1159/000154718; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687	22	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17981	17986		10.1074/jbc.272.29.17981	http://dx.doi.org/10.1074/jbc.272.29.17981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218424	hybrid			2022-12-27	WOS:A1997XL73500014
J	Iwahashi, J; Yamazaki, S; Komiya, T; Nomura, N; Nishikawa, S; Endo, T; Mihara, K				Iwahashi, J; Yamazaki, S; Komiya, T; Nomura, N; Nishikawa, S; Endo, T; Mihara, K			Analysis of the functional domain of the rat liver mitochondrial import receptor Tom20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; PRECURSOR PROTEINS; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; PURIFICATION; MOM19; MEMBRANE; MAS20P	Tom20 is an outer mitochondrial membrane protein and functions as a component of the import receptor complex for the cytoplasmically synthesized mitochondrial precursor proteins. It consists of the M-terminal membrane-anchor segment, the tetratricopeptide repeat (TPR) motif, a charged amino acids-rich linker segment between the membrane anchor and the TPR motif, and the C-terminal acidic amino acid cluster. To assess the functional significance of these segments in mammalian Tom20, we cloned rat Tom20 and expressed mutant rat Tom20 proteins in Delta tom20 yeast cells and examined their ability to complement the defects of respiration-driven growth and mitochondrial protein import. Tom20N69, a mutant consisting of the membrane anchor and the linker segments, was targeted to mitochondria and complemented the growth and import defects as efficiently as wild type Tom20, whereas a mutant lacking the linker segment did not. In vitro protein import into mitochondria isolated from the complemented yeast cells revealed that the precursor targeted to yeast Tom70 was efficiently imported into the mitochondria via rat Tom20N69. Thus the linker segment is essential for the function of rat Tom20, whereas the TPR motif and the C-terminal acidic amino acids are not.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 812,JAPAN; KAZUSA DNA RES INST,CHIBA 292,JAPAN; NAGOYA UNIV,FAC SCI,DEPT CHEM,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Kyushu University; Kazusa DNA Research Institute; Nagoya University				Yamazaki, Soh/0000-0001-5038-1567				Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bomer U, 1996, J MOL BIOL, V262, P389, DOI 10.1006/jmbi.1996.0522; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EMI Y, 1990, P NATL ACAD SCI USA, V87, P9746, DOI 10.1073/pnas.87.24.9746; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOPING IS, 1995, FEBS LETT, V373, P45; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; IWAHASHI J, 1992, J BIOCHEM-TOKYO, V111, P451, DOI 10.1093/oxfordjournals.jbchem.a123778; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MATSUMOTO T, 1986, J BIOCHEM-TOKYO, V100, P1359, DOI 10.1093/oxfordjournals.jbchem.a121842; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; ONO H, 1990, J BIOCHEM-TOKYO, V107, P840, DOI 10.1093/oxfordjournals.jbchem.a123135; ONO H, 1991, BIOCHEM BIOPH RES CO, V180, P450, DOI 10.1016/S0006-291X(05)81314-2; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; STOTZ E, 1955, METHOD ENZYMOL, V2, P740, DOI 10.1016/S0076-6879(55)02295-7; Yamazaki S, 1997, J BIOCHEM, V121, P8	32	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18467	18472		10.1074/jbc.272.29.18467	http://dx.doi.org/10.1074/jbc.272.29.18467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218491	hybrid			2022-12-27	WOS:A1997XL73500081
J	Nilsson, A; Stys, D; Drakenberg, T; Spangfort, MD; Forsen, S; Allen, JF				Nilsson, A; Stys, D; Drakenberg, T; Spangfort, MD; Forsen, S; Allen, JF			Phosphorylation controls the three-dimensional structure of plant light harvesting complex II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE IR SPECTROPHOTOMETRY; PROTEIN SECONDARY STRUCTURE; WATER H2O SOLUTIONS; RHODOBACTER-SPHAEROIDES R-26; CHLOROPHYLL A/B COMPLEX; BINDING-PROTEIN; SYNTHETIC PEPTIDES; INFRARED-SPECTROSCOPY; CIRCULAR-DICHROISM; EXCITATION-ENERGY	The most abundant chlorophyll-binding complex in plants is the intrinsic membrane protein light-harvesting complex II (LHC II), LHC II acts as a light-harvesting antenna and has an important role in the distribution of absorbed energy between the two photosystems of photosynthesis. We used spectroscopic techniques to study a synthetic peptide with identical sequence to the LHC IIb N terminus found in pea, with and without the phosphorylated Thr at the 5th amino acid residue, and to study both forms of the native full-length protein, Our results show that the N terminus of LHC II changes structure upon phosphorylation and that the structural change resembles that of rabbit glycogen phosphorylase, one of the few phosphoproteins where both phosphorylated and non-phosphorylated structures have been solved. Our results indicate that phosphorylation of membrane proteins may regulate their function through structural protein-protein interactions in surface-exposed domains.	LUND UNIV,S-22007 LUND,SWEDEN; LUND UNIV,S-22100 LUND,SWEDEN	Lund University; Lund University			Štys, Dalibor/G-5213-2015; Allen, John/K-6309-2019	Allen, John/0000-0002-0950-0429				ALLEN JF, 1992, TRENDS BIOCHEM SCI, V17, P12, DOI 10.1016/0968-0004(92)90418-9; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; BARBER J, 1982, ANNU REV PLANT PHYS, V33, P261, DOI 10.1146/annurev.pp.33.060182.001401; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; BURKE JJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P252, DOI 10.1016/0003-9861(78)90031-0; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CASHMORE AR, 1984, P NATL ACAD SCI USA, V81, P1960; CHENG LL, 1995, PHYSIOL PLANTARUM, V93, P173, DOI 10.1034/j.1399-3054.1995.930124.x; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DURRING M, 1991, J MOL BIOL, V217, P577; FABIAN H, 1994, J BIOMOL STRUCT DYN, V12, P573, DOI 10.1080/07391102.1994.10508760; GAL A, 1992, FEBS LETT, V298, P33, DOI 10.1016/0014-5793(92)80016-A; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; HOBE S, 1995, BIOCHEMISTRY-US, V34, P10224, DOI 10.1021/bi00032a016; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KOHORN BD, 1990, J BIOL CHEM, V265, P2118; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KUHLBRANDT W, 1983, J CELL BIOL, V96, P1414, DOI 10.1083/jcb.96.5.1414; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUMAR A, 1984, J MAGN RESON, V60, P143, DOI 10.1016/0022-2364(84)90040-4; LARSSON UK, 1983, EUR J BIOCHEM, V136, P25, DOI 10.1111/j.1432-1033.1983.tb07700.x; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LUDIAM CF, 1995, BIOCHEMISTRY-US, V34, P2; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; OTVOS L, 1988, J PROTEIN CHEM, V7, P365, DOI 10.1007/BF01024886; OTVOS L, 1991, INT J PEPT PROT RES, V38, P476; PAULSEN H, 1993, PHOTOCHEM PHOTOBIOL, V57, P139, DOI 10.1111/j.1751-1097.1993.tb02269.x; PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Stys D, 1995, PHYSIOL PLANTARUM, V95, P651, DOI 10.1111/j.1399-3054.1995.tb05535.x; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; TORII H, 1992, J CHEM PHYS, V96, P3379, DOI 10.1063/1.461939; TREMOLIERES A, 1994, EUR J BIOCHEM, V221, P721, DOI 10.1111/j.1432-1033.1994.tb18785.x; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WOLLMAN FA, 1980, ARCH BIOCHEM BIOPHYS, V201, P646, DOI 10.1016/0003-9861(80)90555-X; WU WG, 1981, LIPIDS, V6, P820; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	66	69	72	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18350	18357		10.1074/jbc.272.29.18350	http://dx.doi.org/10.1074/jbc.272.29.18350			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218476	Green Published, hybrid			2022-12-27	WOS:A1997XL73500066
J	Pohl, M; Silvente-Poirot, S; Pisegna, JR; Tarasova, NI; Wank, SA				Pohl, M; Silvente-Poirot, S; Pisegna, JR; Tarasova, NI; Wank, SA			Ligand-induced internalization of cholecystokinin receptors - Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED INTERNALIZATION; SWISS 3T3 CELLS; G-PROTEIN; SIGNAL-TRANSDUCTION; INDUCED DESENSITIZATION; PHEROMONE RECEPTOR; SEQUESTRATION; ENDOCYTOSIS	Internalization of a variety of different heptahelical G protein-coupled receptors has been shown to be influenced by a number of different structural determinants of the receptors, including the carboxyl terminus. To investigate the role of the carboxyl terminus of cholecystokinin (CCK) receptors in receptor internalization, the rat wild type (WT) CCK-A receptor (WT CCKAR) and the rat WT CCK-B receptor (WT CCKBR) were truncated after amino acid residue 399 (CCKAR Tr399) and 408 (CCKBR Tr408), thereby deleting the carboxyl-terminal 45 and 44 residues, respectively. All WT and mutant CCK receptors were stably expressed in NIH/3T3 cells. Internalization of the CCKAR Tr399 was not significantly different from the WT CCKAR. In contrast, internalization of the CCKBR Tr408 was decreased to 26% compared with the WT CCKBR internalization of 92%. The mutation of all 10 serine and threonine residues (as potential phosphorylation sites) in the carboxyl terminus of the CCKBR to alanines (mutant CCKBR Delta SP/T) could account for the majority of this effect (39% internalization). All mutant receptors displayed similar ligand binding characteristics, G protein coupling, and signal transduction as their respective WT receptors, indicating that the carboxyl termini are not necessary for these processes. Thus, internalization of the CCKBR, unlike that of the CCKAR, depends on the carboxyl terminus of the receptor. These results suggest that, despite the high degree of homology between CCKAR and CCKBR, the structural determinants that mediate the interaction with the endocytic pathway reside in different regions of the receptors.	NIDDK, DIGEST DIS BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOL ASPECTS DRUG DESIGN SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Poirot, Sandrine/D-5448-2017	Tarasova, Nadya/0000-0002-4949-0069; Silvente-Poirot, Sandrine/0000-0003-2245-9069	NIDDK NIH HHS [P30 DK041301] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; VA [5I01RX000194-03] Funding Source: Federal RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA; RRD VA; VA(US Department of Veterans Affairs)		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BODEN PR, 1988, NEUROPEPTIDES, V12, P95, DOI 10.1016/0143-4179(88)90037-6; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHERNER JA, 1989, AM J PHYSIOL, V256, pG837, DOI 10.1152/ajpgi.1989.256.5.G837; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CIVAN MM, 1993, AM J PHYSIOL, V265, pC1658, DOI 10.1152/ajpcell.1993.265.6.C1658; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hermans E, 1996, MOL PHARMACOL, V49, P365; HERTEL C, 1990, J BIOL CHEM, V265, P17988; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MARC S, 1988, BIOCHEM J, V255, P705; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tarasova NI, 1997, CELL TISSUE RES, V287, P325, DOI 10.1007/s004410050757; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	44	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18179	18184		10.1074/jbc.272.29.18179	http://dx.doi.org/10.1074/jbc.272.29.18179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218453	Green Accepted, hybrid			2022-12-27	WOS:A1997XL73500043
J	Scholten, JD; Zimmerman, KK; Oxender, MG; Leonard, D; SeboltLeopold, J; Gowan, R; Hupe, DJ				Scholten, JD; Zimmerman, KK; Oxender, MG; Leonard, D; SeboltLeopold, J; Gowan, R; Hupe, DJ			Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl:protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; FARNESYLTRANSFERASE; MECHANISM; BINDING; BRAIN	Investigation of the comparative activities of various inhibitors of farnesyl:protein transferase (FPTase) has led to the observation that the presence of phosphate or pyrophosphate ions in the assay buffer increases the potency of farnesyl diphosphate (FPP) competitive inhibitors, In addition to exploring the phenomenon of phosphate synergy, we report here the effects of various other ions including sulfate, bicarbonate, and chloride on the inhibitory ability of three FPP competitive compounds: Cbz-His-Tyr-Ser(OBn)TrpNH(2) (2), Cbz-His-Tyr(OPO42-)-Ser(OBn)TrpNH(2) (3), and alpha-hydroxyfarnesyl phosphonic acid (4), Detailed kinetic analysis of FPTase inhibition revealed a high degree of synergy for compound 2 and each of these ions, Phosphorylation of 2 to give 3 completely eliminated any ionic synergistic effect, Moreover, these ions have an antagonistic effect on the inhibitory potency of compound 4, The anions in the absence of inhibitor exhibit non-competitive: inhibition with respect to FPP, These results suggest that phosphate, pyrophosphate, bicarbonate, sulfate, and chloride ions may be binding at the active site of both free enzyme and product-bound enzyme with normal substrates, These bound complexes increase the potency of FPP competitive inhibitors and mimic an enzyme:product form of the enzyme, None of the anions studied here proved to be synergistic with respect to inhibition of geranylgeranyl transferase I, These findings provide insight into the mechanism of action of FPP competitive inhibitors for FPTase and point to enzymatic differences between FPTase and geranylgeranyl transferase I that may facilitate the design of more potent and specific inhibitors for these therapeutically relevant target enzymes.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT CHEM,ANN ARBOR,MI 48105	Pfizer	Scholten, JD (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT BIOCHEM,ANN ARBOR,MI 48105, USA.							AMATRUDA TT, 1960, J CLIN ENDOCR METAB, V20, P339, DOI 10.1210/jcem-20-3-339; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BODANSKY M, 1984, PRACTICE PEPTIDE SYN; BUCHLI R, 1994, PEDIATR RES, V35, P431, DOI 10.1203/00006450-199404000-00009; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; JAMES WJ, 1992, BIOCHEMISTRY-US, V31, P6421; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LEFTHERIS K, 1994, BIOORG MED CHEM LETT, V4, P887, DOI 10.1016/S0960-894X(01)80257-2; LEONARD D, 1994, 107 ACS NAT M SAN DI; Leonard DM, 1997, J MED CHEM, V40, P192, DOI 10.1021/jm960602m; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; Scholten JD, 1996, BIOORGAN MED CHEM, V4, P1537, DOI 10.1016/0968-0896(96)00146-0; SEBOLTLEOPOLD J, 1994, 85 ANN M AACR TOR CA; SEGAL IH, 1975, ENZYME KINETICS BEHA, P493; SEIDEL HM, 1994, BIOCHEMISTRY-US, V33, P5641, DOI 10.1021/bi00184a037; SIESS EA, 1984, EUR J BIOCHEM, V141, P543, DOI 10.1111/j.1432-1033.1984.tb08227.x; SINGH SB, 1993, TETRAHEDRON, V49, P5917, DOI 10.1016/S0040-4020(01)87178-7; Stewart JM, 1984, SOLID PHASE PEPTIDE; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Wai J S, 1994, Bioorg Med Chem, V2, P939, DOI 10.1016/S0968-0896(00)82043-X	30	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18077	18081		10.1074/jbc.272.29.18077	http://dx.doi.org/10.1074/jbc.272.29.18077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218438	hybrid			2022-12-27	WOS:A1997XL73500028
J	Yao, RJ; Yoshihara, M; Osada, H				Yao, RJ; Yoshihara, M; Osada, H			Specific activation of a c-Jun NH2-terminal kinase isoform and induction of neurite outgrowth in PC-12 cells by staurosporine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; PC12 CELLS; MAP KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; HA-RAS; DIFFERENTIATION; RAF-1; RECEPTOR	Staurosporine, a protein kinase inhibitor, is known to mimic the effect of nerve growth factor (NGF) in promoting neurite outgrowth, To elucidate the mechanism by which staurosporine induces neurite outgrowth in PC-12 cells, we performed an in-gel kinase assay using myelin basic protein as a substrate, and found that staurosporine induced the activation of a kinase with an apparent molecular mass of 57 kDa, The dose of staurosporine required to activate this kinase was consistent with that required to induce neurite outgrowth, Interestingly, the staurosporine-activated kinase was immunoprecipitated by anti-c-Jun NH2-terminal kinase (JNK) isoforms antibody, but not by anti-JNK1-specific antibody or anti-ERK1 antibody, raising the possibility that this kinase is a novel JNK isoform, The substrate specificity of the kinase was distinct from those of osmotic shock-activated JNKs and NGF-activated ERK1, The kinase phosphorylates transcription factors including c-Jun, Elk-l, and ATF2, as well as myelin basic protein, suggesting that it plays a role in gene induction. Furthermore, staurosporine induced immediate-early genes including Nur77 and fos, but not jun. The activation of the staurosporine-activated kinase, as well as the induction of neurite outgrowth, did not require Res function, while Pas was required for the activation of ERKs and neurite outgrowth induced by NGF. Taken together, these results indicate staurosporine specifically activates a JNK isoform, which may contribute to biological activities including neurite outgrowth.	INST PHYS & CHEM RES,ANTIBIOT LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN			Osada, Hiroyuki/AAY-6254-2020					AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; FUKUDA M, 1995, ONCOGENE, V11, P239; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HASHIMOTO S, 1989, EXP CELL RES, V184, P351, DOI 10.1016/0014-4827(89)90334-0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIO M, 1993, GENE DEV, V7, P2135; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sambrook J., 2002, MOL CLONING LAB MANU; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18261	18266		10.1074/jbc.272.29.18261	http://dx.doi.org/10.1074/jbc.272.29.18261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218464	hybrid			2022-12-27	WOS:A1997XL73500054
J	Feschenko, MS; Sweadner, KJ				Feschenko, MS; Sweadner, KJ			Phosphorylation of Na,K-ATPase by protein kinase C at Ser(18) occurs in intact cells but does not result in direct inhibition of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE CELLS; NA+-K+-ATPASE; NA+,K+-ATPASE ACTIVITY; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; STIMULATION; INSULIN; KIDNEY; SITE; IDENTIFICATION	Na,K-ATPase activity has been demonstrated to be regulated by a variety of hormones in different tissues. It is known to be directly phosphorylated on its alpha-subunit, but the functional effects of protein kinases remain controversial, We have developed a sensitive, antibody-based assay for detection of the level of phosphorylation of the alpha 1-isoform of rat Na,K-ATPase at the serine residue that is most readily phosphorylated by protein kinase C (PKC) in vitro, Ser(18), By stimulation of endogenous PKC and inhibition of phosphatase activity, it was possible to consistently obtain a very high stoichiometry of phosphorylation (close to 0.9) in several types of intact cells, This demonstrates the accessibility and competency of the site for endogenous phosphorylation. The cells used were derived from rat (NRK 52E, C6, L6, and primary cultures of cerebellar granule cells, representing epithelial cells, glia, muscle cells, and neurons). In the presence of the phosphatase inhibitor calyculin A, full phosphorylation was preserved during subsequent assays of enzyme activity in vitro. Assay of the hydrolysis of ATP in NRK and C6 cells, however, indicated that there was no significant effect of phosphorylation on the V-max of the Na,K-ATPase or on the apparent affinity for Na+, Any regulatory effect of PHC on sodium pump activity thus must be lost upon disruption or permeabilization of the cells and is not a direct consequence of enzyme alteration by covalent phosphorylation of Ser(18).	MASSACHUSETTS GEN HOSP, CTR NEUROSCI, LAB MEMBRANE BIOL, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27653] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1996, AM J PHYSIOL-CELL PH, V270, pC131, DOI 10.1152/ajpcell.1996.270.1.C131; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BERTORELLO AM, 1992, J CELL SCI, V101, P343; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FERAILLE E, 1994, AM J PHYSIOL, V267, pF55, DOI 10.1152/ajprenal.1994.267.1.F55; FERAILLE E, 1995, AM J PHYSIOL-CELL PH, V268, pC1277, DOI 10.1152/ajpcell.1995.268.5.C1277; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; Jorgensen P L, 1974, Methods Enzymol, V32, P277; LAVER W G, 1990, Methods (Orlando), V1, P70, DOI 10.1016/S1046-2023(05)80148-3; LI DL, 1995, AM J PHYSIOL-RENAL, V269, pF673, DOI 10.1152/ajprenal.1995.269.5.F673; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; Lopina O. D., 1995, Biophysical Journal, V68, pA308; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; Marcaida G, 1996, J NEUROCHEM, V66, P99; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MCKEE M, 1994, P NATL ACAD SCI USA, V91, P12056, DOI 10.1073/pnas.91.25.12056; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENG LA, 1991, DEV BRAIN RES, V63, P1, DOI 10.1016/0165-3806(91)90061-M; SATOH T, 1993, AM J PHYSIOL, V265, pF399, DOI 10.1152/ajprenal.1993.265.3.F399; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3	41	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17726	17733		10.1074/jbc.272.28.17726	http://dx.doi.org/10.1074/jbc.272.28.17726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211924	hybrid			2022-12-27	WOS:A1997XK16500067
J	Glickman, JF; Pavlovich, JG; Reich, NO				Glickman, JF; Pavlovich, JG; Reich, NO			Peptide mapping of the murine DNA methyltransferase reveals a major phosphorylation site and the start of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA-CELLS; GENE PROMOTER; EXPRESSION; BINDING; PROTEIN; METHYLATION; SPECIFICITY; ACTIVATION; CDNA; (CYTOSINE-5-)-METHYLTRANSFERASE	The murine DNA methyltransferase catalyzes the transfer of methyl groups from S-adenosylmethionine to cytosines within d(CpG) dinucleotides. The enzyme is necessary for normal embryonic development and is implicated in a number of important processes, including the control of gene expression and cancer, Metabolic labeling and high pressure liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) were performed on DNA methyltransferase purified from murine erythroleukemia cells, Serine 514 was identified as a major phosphorylation site that lies in a domain required for targeting of the enzyme to the replication foci, These results present a potential mechanism for the regulation of DNA methylation. HPLC-ESI-MS peptide mapping data demonstrated that the purified murine DNA methyltransferase protein contains the N-terminal regions predicted by the recently revised 5' gene sequences (Yoder, J. A., Yen, R.-W. C., Vertino, P. M., Bestor, T. H., and Baylin, S. B. (1996) J. Biol, Chem, 271, 31092-31097), The evidence suggests a start of translation at the first predicted methionine, with no alternate translational start sites, Our peptide mapping results provide a more detailed structural characterization of the DNA methyltransferase that will facilitate future structure/function studies.	UNIV CALIF SANTA BARBARA, PROGRAM BIOCHEM & MOL BIOL, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Glickman, Joseph/H-3021-2013	Glickman, Joseph/0000-0002-6706-4039				Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; BENOIT G, 1994, BIOL REPROD, V50, P1312, DOI 10.1095/biolreprod50.6.1312; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; CAIAFA P, 1991, BIOCHIM BIOPHYS ACTA, V1090, P38, DOI 10.1016/0167-4781(91)90034-J; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; GLICKMAN JF, 1994, BIOCHEM BIOPH RES CO, V204, P1003, DOI 10.1006/bbrc.1994.2562; GREEN GR, 1993, J BIOL CHEM, V268, P11247; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Kimura H, 1996, J BIOCHEM, V120, P1182; KREBS EG, 1975, BIOCH CARBOHYDRATES, P337; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI CCH, 1994, J BIOL CHEM, V269, P30089; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Nan XS, 1996, MOL CELL BIOL, V16, P414; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SUZUKI M, 1990, J BIOCHEM-TOKYO, V108, P356, DOI 10.1093/oxfordjournals.jbchem.a123206; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; TEUBNER B, 1995, J CELL PHYSIOL, V165, P284, DOI 10.1002/jcp.1041650209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRASLER JM, 1992, NUCLEIC ACIDS RES, V20, P2541, DOI 10.1093/nar/20.10.2541; WILLIAMS KR, 1993, PRACTICAL GUIDE PROT, P45; XU GR, 1995, BIOCHEM BIOPH RES CO, V207, P544, DOI 10.1006/bbrc.1995.1222; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zhang XY, 1996, FEBS LETT, V392, P179, DOI 10.1016/0014-5793(96)00810-1; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZUCKER KE, 1985, J CELL BIOCHEM, V29, P337, DOI 10.1002/jcb.240290407	41	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17851	17857		10.1074/jbc.272.28.17851	http://dx.doi.org/10.1074/jbc.272.28.17851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211941	hybrid			2022-12-27	WOS:A1997XK16500084
J	Pepitoni, S; Wood, IC; Buckley, NJ				Pepitoni, S; Wood, IC; Buckley, NJ			Structure of the m1 muscarinic acetylcholine receptor gene and its promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; CHO-K1 CELLS; RAT; EXPRESSION; SUBTYPES; REGION; TRANSCRIPTION; SEQUENCE; CLONING; NEURONS	The mi receptor is one of five muscarinic receptors that mediate the metabotropic actions of acetylcholine in the nervous system where it is expressed predominantly in the telencephalon and autonomic ganglia, RNase protection, primer extension, and 5'-rapid amplification of cDNA ends analysis of a rat cosmid clone containing the entire mi gene demonstrated that the rat mi. gene consists of a single 657-base pairs (bp) noncoding exon separated by a 13.5-kilobase (kb) intron from a 2.54-kb coding exon that contains the entire open reading frame. The splice acceptor for the coding exon starting at -71 bp relative to the adenine of the initiating methionine. This genomic structure is similar to that of the m4 gene (Wood, I. C., Roopra, A., Harrington, C. A., and Buckley, N. J. (1995) J. Biol, Chem. 270, 30933-30940 and Wood, I, C., Roopra, A., and Buckley, N. J. (1996) J. Biol. Chem. 271, 14221-14225). Like the m4 gene, the mi promoter lacks TATA and CAAT consensus motifs, and the first exon and 5'-flanking region are not gc-rich, The 5'-flanking region also contains the consensus regulatory elements Sp-1, NZF-1, AP-I, AP-2, E-box, NF kappa B, and Oct-1, Unike the m4 promoter, there is no evidence of a RE1/NRSE silencer element in the mi promoter. Deletional analysis and transient transfection assays demonstrates that reporter constructs containing 0.9 kb of 5'-flanking sequence and the first exon are sufficient to drive cell-specific expression of reporter gene in IMR32 neuroblastoma cells while remaining silent in 3T3 fibrobasts.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,WELLCOME LAB MOL PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Wood, Ian/AAK-9423-2021; Buckley, Noel J/B-9675-2012	Wood, Ian/0000-0003-1886-2533; Buckley, Noel J/0000-0003-1152-0653	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOEM LJ, 1993, MOL BRAIN RES, V17, P194, DOI 10.1016/0169-328X(93)90002-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANN MR, 1987, MOL PHARMACOL, V32, P450; Brown D. A., 1995, MOL B INT U, P165; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOYLE GW, 1994, J NEUROSCI, V14, P2455; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MARRION NV, 1989, BRIT J PHARMACOL, V98, P557, DOI 10.1111/j.1476-5381.1989.tb12630.x; Mieda M, 1996, J BIOL CHEM, V271, P5177; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; MURASAWA S, 1995, J BIOL CHEM, V270, P20042, DOI 10.1074/jbc.270.34.20042; Parks CL, 1996, J BIOL CHEM, V271, P4417; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; ROSOFF ML, 1997, P NATL ACAD SCI USA, V93, P14889; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZHU QS, 1995, J NEUROSCI, V15, P4885	47	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17112	17117		10.1074/jbc.272.27.17112	http://dx.doi.org/10.1074/jbc.272.27.17112			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202029	hybrid			2022-12-27	WOS:A1997XH44600061
J	Suzuki, A; Shibata, N; Suzuki, M; Saitoh, F; Oyamada, H; Kobayashi, H; Suzuki, S; Okawa, Y				Suzuki, A; Shibata, N; Suzuki, M; Saitoh, F; Oyamada, H; Kobayashi, H; Suzuki, S; Okawa, Y			Characterization of beta-1,2-mannosyltransferase in Candida guilliermondii and its utilization in the synthesis of novel oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL MANNAN; YEAST GLYCOPROTEIN-BIOSYNTHESIS; ALBICANS NIH A-207; SACCHAROMYCES-CEREVISIAE; PATHOGENIC YEAST; OUTER CHAIN; SEROTYPE-A; OLIGOMANNOSYL RESIDUES; LINKED OLIGOSACCHARIDES; B-792 STRAIN	A particulate insoluble enzyme fraction containing mannosyltransferases from Candida guilliermondii IFO 10279 strain cells was obtained as the residue after extracting a 105,000 x g pellet of cell homogenate with 1% Triton X-100. Incubation of this fraction with a mannopentaose, Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, in the presence of GDP-mannose and Mn2+ ion at pH 6.0 save a third type of beta-1,2 linkage-containing mannohexaose, Man beta 1-->2Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, the structure of which was identified by means of a sequential NMR assignment. The results of a substrate specificity study indicated that the beta-1,2-mannosyltransferase requires a mannobiosyl unit, Man alpha 1-->3Man alpha 1-->, at the nonreducing terminal site. We synthesized novel oligosaccharides using substrates possessing a nonreducing terminal alpha-1,3-linked mannose unit prepared from various yeast mannans. Further incubation of the enzymatically synthesized oligosaccaride with the enzyme fraction gave the following structure, Man beta 1-->2Man beta 1-->2Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, which has been found to correspond to antigenic factor 9. Incubation of Candida albicans serotype B mannan with the enzyme fraction gave significantly transformed mannan, which contains the third type of beta-1,2-linked mannose units.			Suzuki, A (corresponding author), TOHOKU COLL PHARMACEUT SCI, DEPT HYG CHEM 2, AOBA KU, 4-4-1 KOMATSUSHIMA, SENDAI, MIYAGI 981, JAPAN.							BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; FAILLE C, 1990, INFECT IMMUN, V58, P3537, DOI 10.1128/IAI.58.11.3537-3544.1990; GAIKWAD SM, 1995, BBA-PROTEIN STRUCT M, V1250, P144, DOI 10.1016/0167-4838(95)00082-6; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HEARN VM, 1993, STRUCTURE ANTIGENS, P211; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HILL K, 1992, GENETICS, V130, P273; KARSON EM, 1978, J BIOL CHEM, V253, P6484; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; Kobayashi H, 1996, FEBS LETT, V395, P109, DOI 10.1016/0014-5793(96)01013-7; KOBAYASHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P662, DOI 10.1016/0003-9861(92)90739-J; KOBAYASHI H, 1994, INFECT IMMUN, V62, P615, DOI 10.1128/IAI.62.2.615-622.1994; KOBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V272, P364, DOI 10.1016/0003-9861(89)90230-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; LEHLE L, 1974, BIOCHIM BIOPHYS ACTA, V350, P225, DOI 10.1016/0005-2744(74)90220-4; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; LI RK, 1993, J BIOL CHEM, V268, P18293; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NISHIKAWA A, 1990, MICROBIOL IMMUNOL, V34, P825, DOI 10.1111/j.1348-0421.1990.tb01061.x; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; SAITO K, 1993, EUR J BIOCHEM, V217, P677, DOI 10.1111/j.1432-1033.1993.tb18293.x; SANBLAS G, 1994, J MED VET MYCOL, V32, P321; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; Shibata N, 1996, ARCH BIOCHEM BIOPHYS, V336, P49, DOI 10.1006/abbi.1996.0531; SHIBATA N, 1993, ARCH BIOCHEM BIOPHYS, V302, P113, DOI 10.1006/abbi.1993.1188; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; Shibata N, 1996, J BIOL CHEM, V271, P9259, DOI 10.1074/jbc.271.16.9259; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; SHIBATA N, 1997, IN PRESS EUR J BIOCH; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI A, 1995, FEBS LETT, V373, P275, DOI 10.1016/0014-5793(95)01061-I; Suzuki A, 1996, EUR J BIOCHEM, V240, P37, DOI 10.1111/j.1432-1033.1996.0023h.x; SUZUKI S, 1991, FUNGAL CELL WALL IMM, P111; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZHANG W, 1981, J BIOL CHEM, V256, P73	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16822	16828		10.1074/jbc.272.27.16822	http://dx.doi.org/10.1074/jbc.272.27.16822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201988	hybrid			2022-12-27	WOS:A1997XH44600020
J	Wang, K; Peterson, PA; Karlsson, L				Wang, K; Peterson, PA; Karlsson, L			Decreased endosomal delivery of major histocompatibility complex class II-invariant chain complexes in dynamin-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; B-LYMPHOBLASTOID-CELLS; ENDOCYTIC PATHWAY; HLA-DR; ANTIGEN PRESENTATION; SURFACE EXPRESSION; PRESENTING CELLS; PLASMA-MEMBRANE; MOLECULES; COMPARTMENT	Major histocompatibility complex class II molecules are heterodimeric cell surface molecules which acquire antigenic peptides in the endosomal/lysosomal system. Invariant chain (Ii), a third chain which is associated with class II molecules intracellularly mediates the endosomal targeting, but it is debated whether class II molecules reach the endosomal system mainly from the trans-Golgi network or via the cell surface. Dynamin is a cytosolic GTPase which is necessary for the formation of clathrin-coated vesicles from the plasma membrane, but which is not required for vesicle formation from the trans-Golgi network. Here we have used HeLa cells expressing a dominant negative form of dynamin to show that inhibition of clathrin-mediated uptake from the plasma membrane leads to accumulation of transfected Ii-class II complexes at the cell surface, while delivery of such complexes to endosomes/lysosomes is decreased. Our data therefore suggest that in this experimental system the majority of Ii-class II complexes traverse the cell surface before they reach the endosomal system.	RW JOHNSON PHARMACEUT RES INST,SAN DIEGO,CA 92121	Johnson & Johnson; Johnson & Johnson USA								AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; Takaesu NT, 1997, J IMMUNOL, V158, P187; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	43	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17055	17060		10.1074/jbc.272.27.17055	http://dx.doi.org/10.1074/jbc.272.27.17055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202021	hybrid			2022-12-27	WOS:A1997XH44600053
J	Johannes, L; Tenza, D; Antony, C; Goud, B				Johannes, L; Tenza, D; Antony, C; Goud, B			Retrograde transport of KDEL-bearing B-fragment of Shiga toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SHIGELLA-DYSENTERIAE; BINDING PROTEIN; GOLGI-COMPLEX; GLYCOLIPID-BINDING; BREFELDIN-A; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; CRYSTAL-STRUCTURE; MEDIAL GOLGI	To investigate retrograde transport along the biosynthetic/secretory pathway, we have constructed a recombinant Shiga toxin B-fragment carrying an N-glycosylation site and a KDEL retrieval motif at its carboxyl terminus (B-Glyc-KDEL), After incubation with HeLa cells, B-Glyc-KDEL was progressively glycosylated in the endoplasmic reticulum (ER) and remained stably associated with this compartment. B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus. Morphological studies showed that B-Glyc-KDEL was delivered from the plasma membrane, via endosomes and the cisternae of the Golgi apparatus, to the ER. Moreover, the addition of a sulfation site allowed us to show that B-Glyc-KDEL on transit to the ER entered the Golgi apparatus through the trans-Golgi network. Transport of B-Glyc-KDEL to the ER was slowed down by nocodazole, indicating that microtubules are important for the retrograde pathway. Our results document the existence of a continuous pathway from the plasma membrane to the endoplasmic reticulum via the Golgi apparatus and show that a fully folded exogenous protein arriving in the endoplasmic reticulum via this pathway can undergo N-glycosylation.	INST CURIE,CNRS,UMR 144,LAB MECAN MOL TRANSPORT INTRACELLULAIRE,F-75248 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Goud, Bruno/GWC-4807-2022; antony, claude/K-5342-2013; Johannes, Ludger/W-8593-2019; Johannes, Ludger/M-9778-2017	Johannes, Ludger/0000-0002-2168-0004; Johannes, Ludger/0000-0002-2168-0004				ANTONY C, 1992, J CELL SCI, V103, P785; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; EIKLID K, 1980, J RECEPTOR RES, V1, P199, DOI 10.3109/10799898009044098; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; GARRED O, 1995, EXP CELL RES, V218, P39, DOI 10.1006/excr.1995.1128; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JOHNSTON PA, 1994, J CELL SCI, V107, P529; KHINE AA, 1994, J CELL PHYSIOL, V161, P319, DOI 10.1002/jcp.1041610217; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1995, BIOCHEM SOC T, V23, P544, DOI 10.1042/bst0230544; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V92, P223; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	52	175	185	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19554	19561		10.1074/jbc.272.31.19554	http://dx.doi.org/10.1074/jbc.272.31.19554			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235960	hybrid			2022-12-27	WOS:A1997XP06300066
J	Kitmitto, A; Holzenburg, A; Ford, RC				Kitmitto, A; Holzenburg, A; Ford, RC			Two-dimensional crystals of photosystem I in higher plant grana margins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; ELECTRON-MICROSCOPY; SPINACH-CHLOROPLASTS; PROTEIN COMPLEXES; P700 CHLOROPHYLL; HETEROGENEITY; IDENTIFICATION; RECONSTITUTION; ORGANIZATION; BINDING	In this report, we present new structural data on the size, shape, and oligomeric form of higher plant photosystem I (PSI) formed within the thylakoid grana margins. We show that PSI complexes can be assembled into ordered molecular monolayers (two-dimensional crystals) using thylakoid membranes from a variety of higher plant sources. Digital image analysis of negatively stained two-dimensional crystals (a = 26.9 nm, b = 28.0 nm, gamma = 90 degrees, p22(1)2(1) plane group) resulted in a projection map consisting of 4 monomers/unit cell. Higher plant PSI is slightly larger than its cyanobacterial equivalent but shows many similar features. Structural changes after urea and salt washing of the crystals supported the biochemical characterization and were mainly assigned to the stromal side of the complex where the psaC, psaD, and psaE gene products are known to be bound, Labeling with ferredoxin colloidal gold complexes provided direct evidence for a segregated PSI population, with 5 nm diameter ferredoxin-gold particles enriched in the thylakoid grana margins and the two-dimensional crystals. This lateral segregation of photosynthetic complexes is important for the understanding of the kinetics of electron transfer between photosystem II and PSI in higher plants.	UMIST, DEPT BIOCHEM & APPL MOL BIOL, MANCHESTER M60 1QD, LANCS, ENGLAND; UNIV LEEDS, DEPT BIOCHEM & MOL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Manchester; University of Leeds				Ford, Robert/0000-0002-0958-1505				ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; ALMOG O, 1991, P NATL ACAD SCI USA, V88, P5312, DOI 10.1073/pnas.88.12.5312; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1978, THESIS U LUND SWEDEN; ANDREASSON E, 1988, BIOCHIM BIOPHYS ACTA, V936, P339, DOI 10.1016/0005-2728(88)90010-2; ANDREASSON E, 1993, BIOCHIM BIOPHYS ACTA, V1141, P175, DOI 10.1016/0005-2728(93)90040-M; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARBER J, 1980, FEBS LETT, V118, P1, DOI 10.1016/0014-5793(80)81207-5; BASSI R, 1989, EUR J CELL BIOL, V50, P84; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P49, DOI 10.1016/0005-2728(90)90177-6; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DUNAHAY TG, 1985, PLANT PHYSIOL, V78, P606, DOI 10.1104/pp.78.3.606; FISH LE, 1986, J BIOL CHEM, V261, P8134; FISH LE, 1985, J BIOL CHEM, V260, P1413; FORD RC, 1983, FEBS LETT, V160, P159, DOI 10.1016/0014-5793(83)80957-0; FORD RC, 1988, EMBO J, V7, P2287, DOI 10.1002/j.1460-2075.1988.tb03071.x; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HARRIS JR, 1993, J STRUCT BIOL, V111, P22, DOI 10.1006/jsbi.1993.1032; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HEFTI A, 1992, FEBS LETT, V296, P29, DOI 10.1016/0014-5793(92)80396-X; HOLZENBURG A, 1994, MICRON, V25, P447, DOI 10.1016/0968-4328(94)00034-4; HORISBERGER M, 1977, J HISTOCHEM CYTOCHEM, V25, P295, DOI 10.1177/25.4.323352; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; IKEUCHI M, 1991, FEBS LETT, V280, P332, DOI 10.1016/0014-5793(91)80324-V; Jekow P, 1996, Z NATURFORSCH C, V51, P195; Karrasch S, 1996, J MOL BIOL, V262, P336, DOI 10.1006/jmbi.1996.0517; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1993, J BIOL CHEM, V268, P23353; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Nicholson WV, 1996, BIOCHEM J, V315, P543, DOI 10.1042/bj3150543; PETER GF, 1991, J BIOL CHEM, V266, P16745; SEIBERT M, 1987, FEBS LETT, V219, P207; STAEHELIN LA, 1986, PHOTOSYNTHESIS, V3, P1; STEFANSSON H, 1995, BBA-BIOENERGETICS, V1231, P323, DOI 10.1016/0005-2728(95)00103-P; VALLON O, 1986, PHOTOBIOCH PHOTOBIOP, V12, P203; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; WYNN RM, 1988, FEBS LETT, V229, P293, DOI 10.1016/0014-5793(88)81143-8; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	42	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19497	19501		10.1074/jbc.272.31.19497	http://dx.doi.org/10.1074/jbc.272.31.19497			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235952	hybrid			2022-12-27	WOS:A1997XP06300058
J	Wang, D; Hu, YM; Zheng, F; Zhou, K; Kohlhaw, GB				Wang, D; Hu, YM; Zheng, F; Zhou, K; Kohlhaw, GB			Evidence that intramolecular interactions are involved in masking the activation domain of transcriptional activator Leu3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY GENE LEU3; SACCHAROMYCES-CEREVISIAE; DNA RECOGNITION; SHUTTLE VECTORS; YEAST; COMPLEX; GAL4; MANIPULATION; MUTAGENESIS; PROTEINS	The Leu3 protein of Saccharomyces cerevisiae regulates the expression of genes involved in branched chain amino acid biosynthesis and in ammonia assimilation. It is modulated by alpha-isopropylmalate, an intermediate in leucine biosynthesis. In the presence of alpha-isopropylmalate, Leu3p is a transcriptional activator, In the absence of the signal molecule, the activation domain is masked, and Leu3p acts as a repressor, The recent discovery that Leu3p retains its regulatory properties when expressed in mammalian cells (Guo, H., and Kohlhaw, G. B. (1996) FEES Lett. 390, 191-195) suggests that masking and unmasking of the activation domain occur without the participation of auxiliary proteins. Here we present experimental support for this notion and address the mechanism of masking, We show that modulation of Leu3p is exceedingly sensitive to mutations in the activation domain. An activation domain double mutant (D872N/D874N; designated Leu3-dd) was constructed that has the characteristics of a permanently masked activator, Using separately expressed segments containing either the DNA binding domain-middle region or the activation domain of wild type Leu3p (or Leu3-dd) in a modified yeast two-hybrid system, we provide direct evidence for alpha-isopropylmalate-dependent interaction between these segments, Finally, we use the phenotype of Leu3-dd-containing cells (slow growth in the absence of added leucine) to select for suppressor mutations that map to the middle region of Leu3-dd. The properties of nine such suppressors further support the idea that masking is an intramolecular process and suggest a means for mapping the surface involved in masking.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CADWELL RC, 1994, PCR METH APPL, V3, pS136; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DUNN B, 1993, CURRENT PROTOCOLS MO, V2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fink GR., 1970, METHODS ENZYMOL VOL, V17, P59, DOI DOI 10.1016/0076-6879(71)17167-4; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; Guo H, 1996, FEBS LETT, V390, P191, DOI 10.1016/0014-5793(96)00653-9; HAMPSEY DM, 1983, P NATL ACAD SCI-BIOL, V80, P1270, DOI 10.1073/pnas.80.5.1270; HU Y, 1996, THESIS PURDUE U; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Miller J. H, 1972, EXPT MOL GENETICS; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; SCHULZ WA, 1993, BIOL CHEM H-S, V374, P313, DOI 10.1515/bchm3.1993.374.1-6.313; SIKORSKI RS, 1989, GENETICS, V122, P19; SZE JY, 1993, J BIOL CHEM, V268, P2505; SZE JY, 1993, MOL CELL BIOL, V13, P5702, DOI 10.1128/MCB.13.9.5702; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; Wade PA, 1996, MOL CELL BIOL, V16, P1641; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU K, 1991, THESIS PURDUE U; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	34	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19383	19392		10.1074/jbc.272.31.19383	http://dx.doi.org/10.1074/jbc.272.31.19383			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235937	hybrid			2022-12-27	WOS:A1997XP06300043
J	Wang, SL; Du, EZ; Martin, TD; Davis, RA				Wang, SL; Du, EZ; Martin, TD; Davis, RA			Coordinate regulation of lipogenesis, the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; CULTURED LIVER-CELLS; FATTY-ACIDS; HEPG2 CELLS; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; CHOLESTERYL ESTER; APO-B; TRANSLOCATION	Stable plasmid-driven expression of the liver-specific gene product cholesterol 7 alpha-hydroxylase (7 alpha-hydroxylase) was used to alter the cellular content of transcriptionally active sterol response element binding protein 1 (SREBP1), As a result of stable expression of 7 alpha-hydroxylase, individual single cell clones expressed varying amounts of mature SREBP1 protein, These single cell clones provided an opportunity to identify SREBP1-regulated genes that may influence the assembly and secretion of apoB-containing lipoproteins, Our results show that in McArdle rat hepatoma cells, which normally do not express 7 alpha-hydroxylase, plasmid-driven expression of 7 alpha-hydroxylase results in the following: 1) a linear relationship between (i) the cellular content of mature SREBP1 and 7 alpha-hydroxylase protein, (ii) the relative expression of 7 alpha-hydroxylase mRNA and the mRNA's encoding the enzymes regulating fatty acid, i.e. acetyl-CoA carboxylase and sterol synthesis, i.e. HMG-CoA reductase, (iii) the relative expression of 7 alpha-hydroxylase mRNA and microsomal triglyceride transfer protein mRNA, a gene product that is essential for the assembly and secretion of apoB-containing lipoproteins; 2) increased synthesis of all lipoprotein lipids (cholesterol, cholesterol esters, triglycerides, and phospholipids); and 3) increased secretion of apoB100 without any change in apoB mRNA, Cells expressing 7 alpha-hydroxylase contained significantly less cholesterol (both free and esterified), The increased cellular content of mature SREBP1 and increased secretion of apoB100 were concomitantly reversed by 25-hydroxycholesterol, suggesting that the content of mature SREBP1, known to be decreased by 25-hydroxycholesterol, mediates the changes in the lipoprotein assembly and secretion pathway that are caused by 7 alpha-hydroxylase. These data suggest that several steps in the assembly and secretion of apoB-containing lipoproteins by McArdle hepatoma cells may be coordinately linked through the cellular content of mature SREBP1.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOL BIOL LAB,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOL BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51643, HL52005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELIN B, 1978, J LIPID RES, V19, P1004; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BOREN J, 1994, J BIOL CHEM, V269, P25879; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHAN L, 1977, ENDOCRINOLOGY, V100, P1636, DOI 10.1210/endo-100-6-1636; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; COLEMAN RA, 1988, J LIPID RES, V29, P33; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; DAVIS RA, 1996, N COMP BIOC, V31, P473; DAVIS RA, 1991, BIOCH LIPIDS MEMBRAN, V20, P403; DAVIS RA, 1997, J NUTR, V127, P7955; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOLPHIN PJ, 1971, BIOCHEM J, V124, P751, DOI 10.1042/bj1240751; DU EZ, 1994, J BIOL CHEM, V269, P24169; DUELAND S, 1992, J BIOL CHEM, V267, P22695; EDWARDS PA, 1996, N COMP BIOC, V31, P341; EINARSSON K, 1991, EUR J CLIN PHARMACOL, V40, pS53, DOI 10.1007/BF01409410; ERICKSON SK, 1986, J LIPID RES, V27, P875; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAGEDORN HH, 1973, DEV BIOL, V31, P285, DOI 10.1016/0012-1606(73)90265-0; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KHAN B, 1989, BIOCHEM J, V258, P807, DOI 10.1042/bj2580807; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LIN MCM, 1994, J BIOL CHEM, V269, P29138; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Trawick JD, 1996, J LIPID RES, V37, P588; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1994, J BIOL CHEM, V269, P18514; WANG S, 1996, J BIOL CHEM, V271, P12124; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1989, J BIOL CHEM, V264, P11373	60	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19351	19358		10.1074/jbc.272.31.19351	http://dx.doi.org/10.1074/jbc.272.31.19351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235933	hybrid			2022-12-27	WOS:A1997XP06300039
J	Briggs, SD; Sharkey, M; Stevenson, M; Smithgall, TE				Briggs, SD; Sharkey, M; Stevenson, M; Smithgall, TE			SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC ACTIVITY; FC-GAMMA-RI; SH3 DOMAIN; FUNCTIONAL ASSOCIATION; HIGH-AFFINITY; GENE HCK; RECEPTOR; BINDING; CELLS; MACROPHAGES	Tyrosine kinases of the Src family are regulated via their Src homology 2 (SH2) and SH3 domains. The Nef protein of human immunodeficiency virus-1 (HIV-1) has previously been shown to bind with high affinity and specificity in vitro to the SH3 domain of Hck, a Src family member expressed primarily in myeloid cells. However, the effect of Nef on Hck activity in living cells is unknown. Here we show that Rat-2 fibroblasts coexpressing Hck and Nef rapidly developed transformed foci, whereas control cells expressing either protein alone did not. Nef formed a stable complex with Hck and stimulated its tyrosine kinase activity in vivo. Mutagenesis of the Nef proline-rich motif essential for SH3 binding completely blocked complex formation, kinase activation, and transformation, indicating that the Nef SH3-binding function is required for its effects on Hck, These results provide direct evidence that SH3 engagement is sufficient to activate a Src family kinase in vivo and suggest that Hck may be activated by Nef in HIV-infected macrophages.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA	University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [CA58667] Funding Source: Medline; NIAID NIH HHS [AI 32890, AI 39812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BOULET I, 1992, ONCOGENE, V7, P703; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Myers G, 1994, HUMAN RETROVIRUSES A; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1993, J BIOL CHEM, V268, P18070; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	43	177	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17899	17902		10.1074/jbc.272.29.17899	http://dx.doi.org/10.1074/jbc.272.29.17899			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218412	hybrid			2022-12-27	WOS:A1997XL73500002
J	Jordan, SW; Cronan, JE				Jordan, SW; Cronan, JE			A new metabolic link - The acyl carrier protein of lipid synthesis donates lipoic acid to the pyruvate dehydrogenase complex in Escherichia coli and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; BIOSYNTHESIS; PURIFICATION; DOMAIN; PHOSPHORYLATION; EXPRESSION; LIGASE; GENES; LPLA	Lipoic acid is an essential enzyme cofactor that requires covalent attachment to its cognate proteins to confer biological activity. The major lipoylated proteins are highly conserved enzymes of central metabolism the pyruvate and alpha-ketoglutarate dehydrogenase complexes. The classical lipoate ligase uses ATP to activate the lipoate carboxyl group followed by attachment of the cofactor to a specific subunit of each dehydrogenase complex, and it was assumed that all lipoate attachment proceeded by this mechanism. However, our previous work indicated that Escherichia coli could form lipoylated proteins in the absence of detectable ATP-dependent ligase activity raising the possibility of a Glass of enzyme that attaches lipoate to the dehydrogenase complexes by a different mechanism. We now report that E. coli and mitochondria contain lipoate transferases that use lipoyl-acyl carrier protein as the lipoate donor. This finding demonstrates a direct link between fatty acid synthesis and lipoate attachment and also provides the first direct demonstration of a role for the enigmatic acyl carrier proteins of mitochondria.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Jordan, SW (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,CHEM & LIFE SCI LAB B103,601 S GOODWIN AVE,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; PARRY RJ, 1977, J AM CHEM SOC, V99, P6464, DOI 10.1021/ja00461a061; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RANDALL DD, 1977, BIOCHIM BIOPHYS ACTA, V485, P336, DOI 10.1016/0005-2744(77)90169-3; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; REED LJ, 1958, J BIOL CHEM, V232, P123; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SHINTANI DK, 1994, PLANT PHYSIOL, V104, P1221, DOI 10.1104/pp.104.4.1221; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; WADA H, 1998, P NATL ACAD SCI USA, V94, P1591; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WIELAND OH, 1972, FEBS LETT, V27, P240, DOI 10.1016/0014-5793(72)80630-6; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	35	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17903	17906		10.1074/jbc.272.29.17903	http://dx.doi.org/10.1074/jbc.272.29.17903			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218413	hybrid			2022-12-27	WOS:A1997XL73500003
J	Boylan, MO; Jepeal, LI; Jarboe, LA; Wolfe, MM				Boylan, MO; Jepeal, LI; Jarboe, LA; Wolfe, MM			Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a mouse neuroendocrine tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; DIABETES-MELLITUS; PEPTIDE GIP; TRANSCRIPTION FACTORS; ACID-SECRETION; RELEASE; RAT; CHOLECYSTOKININ; HORMONES; PREPROGLUCAGON	Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid gastrointestinal regulatory peptide that, in the presence of glucose, stimulates insulin secretion. GIP is expressed in K cells of the small intestine and in cells of the submandibular salivary gland. Using a rat GIP cDNA as a specific probe, we screened a number of established cell lines for the expression of GIP mRNA. STC-1 cells, a cell line derived from a mouse neuroendocrine tumor, were found to express high levels of GIP mRNA. GIP-specific transcripts were not detected in other cell lines tested, which included cells of intestinal, salivary, and endocrine origin. Analysis of GIP-luciferase fusions identified two promoters, a distal and a proximal promoter, upstream of the translation initiation codon for GIP. The distal promoter, located upstream of position +1, corresponds to the principal promoter of the GIP gene and can promote cell-specific transcription. Sequential deletion and site-directed mutational analysis of the distal promoter demonstrated that the sequence between -193 and -182 determines cell-specific expression of GIP. Contained in this region is a consensus GATA motif, suggesting that a member of the GATA family of DNA-binding proteins is involved in the cell-specific regulation of the GIP gene.	BOSTON MED CTR, GASTROENTEROL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, GASTROENTEROL SECT, BOSTON, MA 02118 USA	Boston Medical Center; Boston University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048042] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK48042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGERBERTH B, 1993, EUR J BIOCHEM, V216, P623, DOI 10.1111/j.1432-1033.1993.tb18182.x; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BROWN JC, 1978, DIABETES, V27, P782, DOI 10.2337/diab.27.7.782; BROWN JC, 1970, SCAND J GASTROENTERO, V5, P537; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P867, DOI 10.1139/o71-122; BUCHAN AMJ, 1978, HISTOCHEMISTRY, V56, P37, DOI 10.1007/BF00492251; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEATOR IGM, 1975, AM J SURG, V130, P128, DOI 10.1016/0002-9610(75)90360-8; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826, DOI 10.1210/jcem-37-5-826; EBERT R, 1979, GASTROENTEROLOGY, V76, P515; ELAHI D, 1984, DIABETES, V33, P950, DOI 10.2337/diabetes.33.10.950; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HIGASHIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V193, P182, DOI 10.1006/bbrc.1993.1607; HIGASHIMOTO Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P72, DOI 10.1016/0167-4781(92)90054-4; HIGASHIMOTO Y, 1995, COMP BIOCHEM PHYS C, V110, P207, DOI 10.1016/0742-8413(94)00087-Q; INAGAKI N, 1989, MOL ENDOCRINOL, V3, P1014, DOI 10.1210/mend-3-6-1014; JONES IR, 1989, DIABETOLOGIA, V32, P668; KIEFFER TJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE316, DOI 10.1152/ajpendo.1995.269.2.E316; KIEFFER TJ, 1994, AM J PHYSIOL-ENDOC M, V267, pE489, DOI 10.1152/ajpendo.1994.267.4.E489; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; LEE ME, 1990, J BIOL CHEM, V265, P10446; MADSEN OD, 1986, J CELL BIOL, V103, P2025, DOI 10.1083/jcb.103.5.2025; MANGEL AW, 1993, AM J PHYSIOL, V264, pG1031, DOI 10.1152/ajpgi.1993.264.6.G1031; MAXWELL V, 1980, DIGEST DIS SCI, V25, P113, DOI 10.1007/BF01308308; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1976, ENDOCRINOLOGY, V99, P780, DOI 10.1210/endo-99-3-780; RINDI G, 1990, AM J PATHOL, V136, P1349; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOMEYA Y, 1993, FEBS LETT, V317, P67, DOI 10.1016/0014-5793(93)81493-J; TAKEDA J, 1987, P NATL ACAD SCI USA, V84, P7005, DOI 10.1073/pnas.84.20.7005; THOMAS FB, 1977, GASTROENTEROLOGY, V72, P49; TISCHLER AS, 1983, SCAND J GASTROENTERO, V18, P33; TSENG CC, 1994, AM J PHYSIOL, V266, pG887, DOI 10.1152/ajpgi.1994.266.5.G887; TSENG CC, 1995, MOL CELL ENDOCRINOL, V115, P13, DOI 10.1016/0303-7207(95)03665-T; TSENG CC, 1993, P NATL ACAD SCI USA, V90, P1992, DOI 10.1073/pnas.90.5.1992; VILLAR HV, 1976, ANN SURG, V184, P97, DOI 10.1097/00000658-197607000-00016; WOLFE MM, 1983, GASTROENTEROLOGY, V84, P941; YAMAGISHI T, 1980, GASTROENTEROLOGY, V78, P931	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17438	17443		10.1074/jbc.272.28.17438	http://dx.doi.org/10.1074/jbc.272.28.17438			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211887				2022-12-27	WOS:A1997XK16500030
J	Orii, Y; Miki, T				Orii, Y; Miki, T			Oxidation process of bovine heart ubiquinol cytochrome c reductase as studied by stopped-flow rapid-scan spectrophotometry and simulations based on the mechanistic Q cycle model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; PROTONMOTIVE Q-CYCLE; YEAST COMPLEX-III; ELECTRON-TRANSFER; BEEF-HEART; SUCCINATE-UBIQUINONE; BC(1) COMPLEX; BC1 COMPLEX; OXIDOREDUCTASE; UBISEMIQUINONE	Stopped-flow rapid-scan spectrophotometry was employed to study complicated oxidation processes of ubiquinol-cytochrome c reductase (QCR) that was purified from bovine heart mitochondria and maximally contained 0.36 mol of ubiquinone-10/mol of heme c(1). When fully reduced QCR was allowed to react with dioxygen in the presence of cytochrome c plus cytochrome c oxidase, the oxidation of b-type hemes accompanied an initial lag, apparently low potential heme b(L) was oxidized first, followed by high potential heme b(H). Antimycin A inhibited the oxidation of both b-type hemes, The oxidation of heme c(1) was triphasic and became biphasic in the presence of antimycin A, On the other hand, starting from partially reduced QCR that was poised at a higher redox potential with succinate and succinate-cytochrome c reductase, the b-type hemes were oxidized immediately without a lag, When the ubiquinone content in QCR was as low as 0.1 mol/mol heme c(1) the oxidation of the b-type hemes was almost suppressed. As the Q-deficient QCR was supplemented with ubiquinol-2, the rapid oxidation of b-type hemes was restored to some extent, These results indicate that a limited amount of ubiquinone-10 found in purified preparations of QCR is obligatory for electron transfer from the b-type hemes to iron-sulfur protein (ISP) and heme c(1), The characteristic oxidation profiles of heme b(L), heme b(H), and heme c(1) were simulated successfully based on a mechanistic Q cycle model, According to She simulations the two-electron oxidation of ubiquinol-10 via the ISP and heme c(1) pathway, which is more favorable thermodynamically than the bifurcation of electron flow into both ISP and heme b(L), does really occur as long as heme b(L) is in the reduced state and provides ubiquinone-10 at center i. Mechanistically this process takes time, thus explaining the initial lag in the oxidation of the b-type hemes. With the partially reduced QCR, inherent ubisemiquinone at center i immediately oxidizes reduced heme b(H) thus eliminating the lag. The mechanistic Q cycle model consists of 56 reaction species, which are interconnected by the reaction paths specified with microscopic rate constants, The simulations further indicate that the rate constants for electron transfer between the redox centers can be from 10(5) to 10(3) s(-1) and are rarely rate-limiting. On the other hand, a shuttle of ubiquinone or ubiquinol between center o and center i and the oxidation of heme c(1) can be rate-limiting, The interplay of the microscopic rate constants determines the actual reaction pathway that is shown schematically by the ''reaction map,'' Most significantly, the simulations support the consecutive oxidation of ubiquinol in center o as long as both heme b(L) and heme b(H) are in the reduced state, Only when heme b(L) is oxidized and ISP is reduced can SQ(o) donate an electron to heme b(L). Thus, we propose that a kinetic control mechanism, or ''a kinetic switch,'' is significant for the bifurcation of electron flow.			Orii, Y (corresponding author), KYOTO UNIV, GRAD SCH MED, DEPT PUBL HLTH, SAKYO KU, KYOTO 606, JAPAN.							Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BRAUDT U, 1996, BIOCHIM BIOPHYS ACTA, V1275, P41; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DEVRIES S, 1988, BIOCHIM BIOPHYS ACTA, V935, P208, DOI 10.1016/0005-2728(88)90217-4; DEVRIES S, 1980, FEBS LETT, V122, P143; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HATEFI Y, 1982, BIOCHEMISTRY-US, V21, P6614, DOI 10.1021/bi00268a045; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; KAWAMOTO M, 1994, J MOL BIOL, V244, P238, DOI 10.1006/jmbi.1994.1722; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KUNZ WS, 1984, FEBS LETT, V172, P261, DOI 10.1016/0014-5793(84)81137-0; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MIKI T, 1994, J BIOL CHEM, V269, P1827; MIKI T, 1991, BIOCHEMISTRY-US, V30, P230, DOI 10.1021/bi00215a033; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P10561, DOI 10.1021/bi00201a001; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; ORII Y, 1990, FEBS LETT, V267, P117, DOI 10.1016/0014-5793(90)80303-Z; ORII Y, 1991, J BIOL CHEM, V266, P14310; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RICH PR, 1983, BIOCHIM BIOPHYS ACTA, V722, P271, DOI 10.1016/0005-2728(83)90073-7; RICH PR, 1986, FEBS LETT, V194, P176, DOI 10.1016/0014-5793(86)80072-2; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; Saribas AS, 1995, BIOCHEMISTRY-US, V34, P16004, DOI 10.1021/bi00049a014; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TSAI AL, 1987, J BIOL CHEM, V262, P8677; TSAI AL, 1983, J BIOL CHEM, V258, P2122; VANHOEK AN, 1987, BIOCHIM BIOPHYS ACTA, V892, P152, DOI 10.1016/0005-2728(87)90257-X; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WIKSTROM M, 1986, J BIOENERG BIOMEMBR, V18, P181, DOI 10.1007/BF00743463; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1974, J BIOL CHEM, V249, P4905; YU CA, 1972, J BIOL CHEM, V247, P1012; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1982, J BIOL CHEM, V257, P2016	50	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17594	17604		10.1074/jbc.272.28.17594	http://dx.doi.org/10.1074/jbc.272.28.17594			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211907	hybrid			2022-12-27	WOS:A1997XK16500050
J	Wohrl, BM; Krebs, R; Thrall, SH; LeGrice, SFJ; Scheidig, AJ; Goody, RS				Wohrl, BM; Krebs, R; Thrall, SH; LeGrice, SFJ; Scheidig, AJ; Goody, RS			Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66 - Implications for DNA synthesis and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; SUBUNIT; P51; RESISTANCE; MECHANISM; TEMPLATE	The highly conserved primer grip region in the p66 subunit of HIV-1 reverse transcriptase (RT) is formed by the beta 12-beta 13 hairpin (residues 227-235), It has been proposed to play a role in aligning the 3'-OH end of the primer in a position for nucleophilic attack on an incoming dNTP, To analyze the importance of the primer grip for RT function, mutant RTs were used that contain single alanine substitutions of residues Trp(229), Met(230), Gly(231), and Tyr(232) in the p66 subunit of the heterodimeric p66/51 enzyme, Steady-state and pre-steady-state kinetic analyses of the enzymes were performed, All mutant enzymes revealed reduced polymerase activity, Mutation of Y232A showed the smallest effect on polymerase function, Equilibrium fluorescence titrations demonstrated that the affinity of the mutants for tRNA was only slightly affected. However, the affinity for primer-template DNA was reduced 27-fold for mutant p66(W229A)/51 and 23-fold for mutant p66(G231A)/51, and the maximal pre-steady-state rate of nucleotide incorporation, k(pol), was reduced 27-fold for p66(W229A)/51 and 70-fold for p66(G231A)/51, respectively, Mutant p66(M230A)/51 revealed no reduced affinity for primer-template but showed a 71-fold reduced affinity for dTTP. Additionally, the mutations Trp(229) and Gly(231) affected the stability of the RT heterodimer.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University	Wohrl, BM (corresponding author), MAX PLANCK INST MOL PHYSIOL, PHYS BIOCHEM ABT, RHEINLANDDAMM 201, D-44139 DORTMUND, GERMANY.		Goody, Roger S/J-8845-2014; Scheidig, Axel/C-9141-2011	Goody, Roger S/0000-0002-0772-0444; 	NIGMS NIH HHS [GM52263] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PL, 1994, ANTIMICROB AGENTS CH, V38, P1909, DOI 10.1128/AAC.38.9.1909; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255; KATI WM, 1992, J BIOL CHEM, V267, P25988; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	26	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17581	17587		10.1074/jbc.272.28.17581	http://dx.doi.org/10.1074/jbc.272.28.17581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211905	hybrid			2022-12-27	WOS:A1997XK16500048
J	Jayadev, S; Hayter, HL; Andrieu, N; Gamard, CJ; Liu, B; Balu, R; Hayakawa, M; Ito, F; Hannun, YA				Jayadev, S; Hayter, HL; Andrieu, N; Gamard, CJ; Liu, B; Balu, R; Hayakawa, M; Ito, F; Hannun, YA			Phospholipase A(2) is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; SPHINGOMYELIN TURNOVER; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; CYTOTOXIC ACTION; APOPTOSIS; DIFFERENTIATION; ACTIVATION; RECEPTOR; MEDIATOR	The role of cytosolic phospholipase A(2) (cPLA(2)) in the regulation of ceramide formation was examined in a cell line (L929) responsive to the cytotoxic action of tumor necrosis factor alpha (TNF alpha). In L929 cells, the addition of TNF alpha resulted in the release of arachidonate, which was followed by a prolonged accumulation of ceramide occurring over 5-12 h and reaching 250% over base line. The formation of ceramide was accompanied by the hydrolysis of sphingomyelin and the activation of three distinct sphingomyelinases (neutral Mg2+-dependent, neutral Mg2+-independent, and acidic enzymes). The variant cell line C12, which lacks cPLA(2), is resistant to the cytotoxic action of TNF alpha. TNF alpha was able to activate nuclear factor kappa B in both the wild-type L929 cells and the C12 cells. However, TNF alpha was unable to cause the release of arachidonate or the accumulation of ceramide in C12 cells. C-6-ceramide overcame the resistance to TNF alpha and caused cell death in C12 cells to a level similar to that in L929 cells, The introduction of the cPLA(2) gene into C12 cells resulted in partial restoration of TNF alpha-induced arachidonate release, ceramide accumulation, and cytotoxicity. This study suggests that cPLA(2) is a necessary component in the pathways leading to ceramide accumulation and cell death.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; INST LOUIS BUGNARD,LAB BIOCHIM MALAD METAB,F-31054 TOULOUSE,FRANCE; SETSUNAN UNIV,DEPT BIOCHEM,HIRAKATA,OSAKA 57301,JAPAN	Duke University; Duke University; Setsunan University			Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ito, Fumiaki/0000-0002-4129-4899	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMYTH MJ, 1992, J CELL BIOCHEM, V50, P210, DOI 10.1002/jcb.240500211; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	27	143	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17196	17203		10.1074/jbc.272.27.17196	http://dx.doi.org/10.1074/jbc.272.27.17196			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202042	hybrid			2022-12-27	WOS:A1997XH44600074
J	Larson, EM; OBrien, CM; Zhu, GH; Spreitzer, RJ; Portis, AR				Larson, EM; OBrien, CM; Zhu, GH; Spreitzer, RJ; Portis, AR			Specificity for activase is changed by a Pro-89 to Arg substitution in the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLAMYDOMONAS CHLOROPLAST GENE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; XYLULOSE 1,5-BISPHOSPHATE; DIRECTED MUTAGENESIS; CO2/O-2 SPECIFICITY; OXYGENASE ACTIVASE; CRYSTAL-STRUCTURE; REINHARDTII	Tobacco activase does not markedly facilitate the activation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39) from non-Solanaceae species, including the green alga Chlamydomonas reinhardtii, To examine the basis of this specificity, we focused on two exposed residues in the large subunit of Rubisco that are unique to the Solanaceae proteins, By employing in vitro mutagenesis and chloroplast transformation, P89R and K356Q substitutions were separately made in the Chlamydomonas enzyme to change these residues to those present in tobacco. Both mutants were indistinguishable from the wild type when grown with minimal medium in the light and contained wild-type levels of holoenzyme. Purified Rubisco was assessed for facilitated activation by spinach and tobacco activase, Both wild-type and K356Q Rubisco were similar in that spinach activase was much more effective than tobacco activase, In contrast, P89R Rubisco was not activated by spinach activase but was well activated by tobacco activase, Thus, the relative specificities of the spinach and tobacco activases for Chlamydomonas Rubisco were switched by changing a single residue at position 89, This result provides evidence for a site on the Rubisco holoenzyme that interacts directly with Rubisco activase.	AGR RES SERV,PHOTOSYNTH RES UNIT,USDA,URBANA,IL 61801; UNIV ILLINOIS,DEPT CROP SCI,URBANA,IL 61801; UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Nebraska System; University of Nebraska Lincoln								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS A, 1988, PLANT PHYSIOL, V87, P244, DOI 10.1104/pp.87.1.244; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; DWLWICHE CF, 1996, MOL BIOL EVOL, V13, P873; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1991, PLANT PHYSIOL, V95, P604, DOI 10.1104/pp.95.2.604; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; Mate CJ, 1996, PLANTA, V198, P604, DOI 10.1007/BF00262648; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; PORTIS AR, 1992, ANNU REV PLANT PHYS, V43, P415, DOI 10.1146/annurev.pp.43.060192.002215; PORTIS AR, 1995, PLANT PHYSIOL, V109, P1441, DOI 10.1104/pp.109.4.1441; ROBINSON SP, 1989, PLANT PHYSIOL, V90, P968, DOI 10.1104/pp.90.3.968; ROESLER KR, 1990, PLANT PHYSIOL, V94, P1837, DOI 10.1104/pp.94.4.1837; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; SOMERVILLE CR, 1982, PLANT PHYSIOL, V70, P381, DOI 10.1104/pp.70.2.381; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6293, DOI 10.1073/pnas.80.20.6293; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	41	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17033	17037		10.1074/jbc.272.27.17033	http://dx.doi.org/10.1074/jbc.272.27.17033			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202018	hybrid			2022-12-27	WOS:A1997XH44600050
J	Park, J; Kim, I; Oh, YJ; Lee, KW; Han, PL; Choi, EJ				Park, J; Kim, I; Oh, YJ; Lee, KW; Han, PL; Choi, EJ			Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-KINASE; OXYGEN	Bcl-2 is an intracellular membrane-associated protein that prevents cell death induced by a variety of apoptotic stimuli. A mechanism by which Bcl-2 exerts an anti-cell death effect is, however, not fully understood, In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Concomitantly, Bcl-2 disrupted a signaling cascade to the c-Jun N-terminal kinase activation induced by the apoptotic stresses. Bcl-2 also prevented the etoposide-induced stimulation of MEKK1. Furthermore, overexpression of c-Jun N-terminal kinase antagonized the death-protective function of Bcl-2. These data suggest that suppression of the c-Jun N-terminal kinase signaling pathway may be critical for Bcl-2 action.	HANHYO INST TECHNOL,CELL BIOL LAB,YUSEONG KU,TAEJON 305390,SOUTH KOREA; HANHYO INST TECHNOL,GENET MOL LAB,YUSEONG KU,TAEJON 305390,SOUTH KOREA; KOREA UNIV,GRAD SCH BIOTECHNOL,SEOUL 136701,SOUTH KOREA; YONSEI UNIV,COLL SCI,DEPT BIOL,SEOUL 120749,SOUTH KOREA	Korea University; Yonsei University				Han, Pyung-Lim/0000-0002-1735-6746				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAMPLIN R, 1987, BLOOD, V69, P1551; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMESAKI S, 1993, CANCER RES, V53, P4251; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park JR, 1996, J CELL BIOCHEM, V60, P12, DOI 10.1002/(SICI)1097-4644(19960101)60:1<12::AID-JCB3>3.0.CO;2-6; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	26	118	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16725	16728		10.1074/jbc.272.27.16725	http://dx.doi.org/10.1074/jbc.272.27.16725			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201973	hybrid			2022-12-27	WOS:A1997XH44600005
J	Plancon, L; Chami, M; Letellier, L				Plancon, L; Chami, M; Letellier, L			Reconstitution of FhuA, an Escherichia coli outer membrane protein, into liposomes - Binding of phage T5 to FhuA triggers the transfer of DNA into the proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR LIPOSOMES; REVERSE-PHASE EVAPORATION; ION CHANNELS; TRITON X-100; RECEPTOR; K-12; TRANSPORT; INVOLVEMENT; INSERTION; INJECTION	The Escherichia coli outer membrane protein FhuA catalyzes the transport of ferrichrome and is the receptor of bacteriophage T5. Purified FhuA was reconstituted into liposomes. The size of the proteoliposomes and the distribution of the proteins in the vesicles were determined by freeze fracture electron microscopy. Unilamellar vesicles with a diameter larger than 200 nm were observed frequently. FhuA was symetrically oriented in the proteoliposomes. Reconstituted FhuA was functional as binding of phage T5 induced the release of phage DNA and its transfer inside the vesicles.	UNIV PARIS 11, LAB BIOMEMBRANES, URA CNRS 1116, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Universite Paris Saclay								AGGERBECK LP, 1986, METHOD ENZYMOL, V128, P457; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CARMEL G, 1991, J BACTERIOL, V173, P4394, DOI 10.1128/JB.173.14.4394-4403.1991; CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HOFFMANN H, 1986, J BACTERIOL, V166, P404, DOI 10.1128/jb.166.2.404-411.1986; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; KILLMANN H, 1992, J BACTERIOL, V174, P3479, DOI 10.1128/JB.174.11.3479-3486.1992; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; LABEDAN B, 1974, J VIROL, V13, P1093, DOI 10.1128/JVI.13.5.1093-1100.1974; LETELLIER L, 1989, BIOCHIMIE, V71, P167, DOI 10.1016/0300-9084(89)90147-8; Letellier L, 1997, J BIOL CHEM, V272, P8836; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; PLANCON L, 1996, THESIS U PARIS SUD O; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; ROESSNER CA, 1983, J BIOL CHEM, V258, P643; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; ZWEIG M, 1973, VIROLOGY, V51, P443, DOI 10.1016/0042-6822(73)90443-1	27	48	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16868	16872		10.1074/jbc.272.27.16868	http://dx.doi.org/10.1074/jbc.272.27.16868			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201994	hybrid			2022-12-27	WOS:A1997XH44600026
J	Wang, Z; Yang, ZQ; Chacko, S				Wang, Z; Yang, ZQ; Chacko, S			Functional and structural relationship between the calmodulin-binding, actin-binding, and actomyosin-ATPase inhibitory domains on the C terminus of smooth muscle caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; CHICKEN GIZZARD; F-ACTIN; KINASE PHOSPHORYLATION; MYOSIN SUBFRAGMENTS; REGULATORY PROTEIN; TROPOMYOSIN; PURIFICATION; EXPRESSION; SITES	Multiple functional domains responsible for calmodulin (CaM) binding and actin-binding/actomyosin ATPase inhibition are present in the region between residues 598-756 of the chicken gizzard smooth muscle caldesmon (CaD) molecule, To precisely localize these functional domains and to further elucidate the structural basis of these domains, we analyzed a series of purified mutants of chicken gizzard smooth muscle CaD generated by internal deletions of amino acid sequences and expression in a baculovirus expression system. Our results demonstrate that, in addition to a strong actin-binding site sequence between residues 718-723 (Wang, Z., and Chacko, S, (1996) J, Biol. Chem, 271, 25707-25714), two weak actin-binding motifs are present in the regions between residues 690-699 and 650-666. These weak actin-binding regions function independently and are associated with weak actomyosin inhibitory activity, Analysis of the CaM-binding sites A (residues 658-666) slid B (residues 690-695), the major CaM-binding sites in the C-terminal region of CaD, provided direct evidence for the involvement of both CaM-binding sites in the CaM-mediated reversal of the inhibition of actomyosin ATPase activity by CaD and for the functional independence of the two CaM-binding sites, Furthermore, the sequences between residues 598-649, upstream of CaM-binding site ih, and 700-717, downstream of CaM-binding site B, appear to have no effect on either actin-binding or CaM-binding. The data also suggest that both CaM-binding sites A and B structurally overlap or Pie in close proximity to the adjacent weak actin-binding sites and weak actomyosin ATPase inhibitory determinants.	UNIV PENN, SCH VET MED, DEPT PATHOBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIV UROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039740, R01DK047514] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47514, DK 39740] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; Borovikov YS, 1996, BIOCHEMISTRY-US, V35, P13849, DOI 10.1021/bi960996j; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DOBROWOLSKI Z, 1988, BIOCHIM BIOPHYS ACTA, V956, P140, DOI 10.1016/0167-4838(88)90260-9; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; HEASLIP RJ, 1985, BIOCHEMISTRY-US, V24, P2731, DOI 10.1021/bi00332a020; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; LASH JA, 1986, J BIOL CHEM, V261, P6155; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 1996, J BIOL CHEM, V271, P25707, DOI 10.1074/jbc.271.41.25707; Wang Z, 1996, J BIOL CHEM, V271, P2234, DOI 10.1074/jbc.271.4.2234; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	48	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16896	16903		10.1074/jbc.272.27.16896	http://dx.doi.org/10.1074/jbc.272.27.16896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201998	hybrid			2022-12-27	WOS:A1997XH44600030
J	Klein, U; Ramirez, MT; Kobilka, BK; vonZastrow, M				Klein, U; Ramirez, MT; Kobilka, BK; vonZastrow, M			A novel interaction between adrenergic receptors and the alpha-subunit of eukaryotic initiation factor 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; NUCLEOTIDE-EXCHANGE FACTOR; GLUTATHIONE-S-TRANSFERASE; SIGNAL-TRANSDUCTION; FUSION PROTEINS; DOWN-REGULATION; PURIFICATION; MUTATIONS; BINDING	The alpha-subunit of eukaryotic initiation factor 2B (eIF-2B), a guanine nucleotide exchange protein that functions in regulation of translation, was observed to associate with the carboxyl-terminal cytoplasmic domains of the alpha(2A)- and alpha(2B)-adrenergic receptors in a yeast two-hybrid screen of a cDNA library prepared from 293 cells, This protein association was confirmed in vitro by affinity chromatography and was shown to be specific for a subset of G protein-coupled receptors, including the alpha(2A)-, alpha(2B)-, alpha(2C)-, and beta(2)-adrenergic receptors, but not the vasopressin (V-2) receptor. Association of these proteins in vivo was confirmed by specific co-immunoprecipitation of eIF-2B alpha with full-length beta(2)-adrenerse receptors expressed in transfected 293 cells and by fluorescence microscopy showing co-localization of these proteins in intact cells. Remarkably, eIF-2B alpha co-localized with receptors exclusively in regions of the plasma membrane that are in contact with the extracellular medium, but failed to associate with membranes making cell-cell contacts, Overexpression of eIF-2B alpha in 293 cells caused a small (similar to 15%) but significant enhancement of beta(2)-adrenergic receptor-mediated activation of adenylyl cyclase, without affecting forskolin or V-2 receptor-mediated activation, These observations suggest a new role for a previously identified guanine nucleotide exchange protein in membrane biology and cell signaling.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,NINA IRELAND LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NHLBI NIH HHS [HL07740-05] Funding Source: Medline; NIDA NIH HHS [DA00218] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007740] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLOWERS KM, 1995, P NATL ACAD SCI USA, V92, P4274, DOI 10.1073/pnas.92.10.4274; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Kimball SR, 1996, PROG NUCLEIC ACID RE, V54, P165, DOI 10.1016/S0079-6603(08)60363-3; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LINK R, 1992, MOL PHARMACOL, V42, P16; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; PAN Y, 1994, J BIOL CHEM, V269, P31933; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Soehlemann Peter, 1995, European Journal of Biochemistry, V232, P464; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410	36	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19099	19102		10.1074/jbc.272.31.19099	http://dx.doi.org/10.1074/jbc.272.31.19099			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235896	hybrid			2022-12-27	WOS:A1997XP06300002
J	Fridovich, I				Fridovich, I			Superoxide anion radical (O-2 radical anion), superoxide dismutases, and related matters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; ESCHERICHIA-COLI; OXIDATIVE STRESS; CAULOBACTER-CRESCENTUS; COPPER; GENE; ACONITASE; SENSITIVITY; MUTANT; CELLS				Fridovich, I (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.							ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; Andersen PM, 1996, BRAIN, V119, P1153, DOI 10.1093/brain/119.4.1153; BALIN AK, 1976, J CELL PHYSIOL, V89, P235, DOI 10.1002/jcp.1040890207; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; BEAMAN L, 1990, INFECT IMMUN, V58, P3122, DOI 10.1128/IAI.58.9.3122-3128.1990; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; CHARY P, 1994, GENETICS, V137, P723; CURNUTTE JT, 1976, J CLIN INVEST, V57, P1059, DOI 10.1172/JCI108348; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DelaTorre R, 1996, EXPERIENTIA, V52, P871; Demple B, 1996, GENE, V179, P53, DOI 10.1016/S0378-1119(96)00329-0; DENQ KX, 1993, SCIENCE, V261, P1047; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FLINT DH, 1993, J BIOL CHEM, V268, P23369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GARDNER PR, 1997, IN PRESS BIOSCI REP; GREENLEE L, 1962, BIOCHEMISTRY-US, V1, P779, DOI 10.1021/bi00911a008; HODGSON EK, 1973, PHOTOCHEM PHOTOBIOL, V18, P451, DOI 10.1111/j.1751-1097.1973.tb06449.x; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; Imlay KRC, 1996, J BACTERIOL, V178, P2564, DOI 10.1128/jb.178.9.2564-2571.1996; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; KASHKET ER, 1962, J BACTERIOL, V83, P1094, DOI 10.1128/JB.83.5.1094-1100.1962; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kim EJ, 1996, EUR J BIOCHEM, V241, P178, DOI 10.1111/j.1432-1033.1996.0178t.x; KUBICEK CP, 1985, APPL ENVIRON MICROB, V50, P1336, DOI 10.1128/AEM.50.5.1336-1338.1985; KUO CF, 1987, J BIOL CHEM, V262, P4724; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LESCHOT NJ, 1981, HUM GENET, V57, P220, DOI 10.1007/BF00282029; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; LIOCHEV S, 1986, ARCH BIOCHEM BIOPHYS, V250, P139, DOI 10.1016/0003-9861(86)90710-1; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Liochev SI, 1997, P NATL ACAD SCI USA, V94, P2891, DOI 10.1073/pnas.94.7.2891; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V318, P408, DOI 10.1006/abbi.1995.1247; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; Miller A.-F., 1997, COMMENTS MOL CELL BI, V9, P1; MILLER DP, 1986, OSIRIS, V2, P107, DOI 10.1086/368654; MOAN J, 1979, NATURE, V279, P450, DOI 10.1038/279450a0; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; PURDY D, 1994, MICROBIOL-UK, V140, P1203, DOI 10.1099/13500872-140-5-1203; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; Rosenblum JS, 1996, P NATL ACAD SCI USA, V93, P4471, DOI 10.1073/pnas.93.9.4471; SADOSKY B, 1994, J BACTERIOL, V176, P3790, DOI 10.1128/JB.176.12.3790-3799.1994; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SIDDIQUE T, 1996, NEUROLOGY S2, V47, P27; STEINMAN HM, 1990, J BACTERIOL, V172, P2901, DOI 10.1128/jb.172.6.2901-2910.1990; STEINMAN HM, 1993, J BACTERIOL, V175, P1198, DOI 10.1128/JB.175.4.1198-1202.1993; StJohn G, 1996, J BACTERIOL, V178, P1578, DOI 10.1128/jb.178.6.1578-1584.1996; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SWENSON PA, 1974, J BACTERIOL, V117, P551, DOI 10.1128/JB.117.2.551-559.1974; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Valentine JS, 1995, NATO ADV SCI INST SE, V459, P77; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; YAROM R, 1988, J NEUROL SCI, V88, P41, DOI 10.1016/0022-510X(88)90204-3; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	76	972	1020	12	126	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18515	18517		10.1074/jbc.272.30.18515	http://dx.doi.org/10.1074/jbc.272.30.18515			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228011	hybrid			2022-12-27	WOS:A1997XM34200002
J	Liu, MY; Yu, B; Nabanishi, O; Wieland, T; Simon, M				Liu, MY; Yu, B; Nabanishi, O; Wieland, T; Simon, M			The Ca2+-dependent binding of calmodulin to an N-terminal motif of the heterotrimeric G protein beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-DERIVED CELLS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; POTASSIUM CHANNEL; PEPTIDE COMPLEX; ALPHA-SUBUNITS; KINASE-II; ACTIVATION; BRAIN	Ca2+ ion concentration changes are critical events in signal transduction, The Ca2+-dependent interactions of calmodulin (CaM) with its target proteins play an essential role in a variety of cellular functions, In this study, we investigated the interactions of G protein beta gamma sub units with CaM, We found that CaM binds to known beta gamma subunits and these interactions are Ca2+-dependent, The CaM-binding domain in G beta gamma subunits is identified as G beta residues 40-63. Peptides derived hom the G beta protein not only produce a Ca2+-dependent gel mobility shifting of CaM but also inhibit the CaM-mediated activation of CaM kinase II, Specific amino acid residues critical for the binding of G beta gamma to CaM were also identified, We then investigated the potential function of these interactions and showed that binding of CaM to G beta gamma inhibits the pertussis toxin-catalyzed ADP-ribosylation of G alpha o subunits, presumably by inhibiting heterotrimer formation, Furthermore, we demonstrated that interaction with CaM has Little effect on the activation of phospholipase C-beta 2 by G beta gamma subunits, supporting the notion that different domains of G beta gamma are responsible for the interactions of different effecters, These findings shed light on the molecular basis for the interactions of G beta gamma with Ca2+-CaM and point to the potential physiological significance of these interactions in cellular functions.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				ASANO T, 1986, FEBS LETT, V205, P135; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM D, ANN REV NEUROSCI, V17, P441; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEGRADO WF, 1987, PROTEINS, V2, P20, DOI 10.1002/prot.340020104; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MA JY, 1994, P NATL ACAD SCI USA, V91, P12351, DOI 10.1073/pnas.91.25.12351; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	54	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18801	18807		10.1074/jbc.272.30.18801	http://dx.doi.org/10.1074/jbc.272.30.18801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228054	hybrid			2022-12-27	WOS:A1997XM34200045
J	Park, JS; Choi, E; Lee, SH; Lee, C; Seo, YS				Park, JS; Choi, E; Lee, SH; Lee, C; Seo, YS			A DNA helicase from Schizosaccharomyces pombe stimulated by single-stranded DNA-binding protein at low ATP concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; REPLICATION PROTEIN; SACCHAROMYCES-CEREVISIAE; DEPENDENT ATPASE; CALF THYMUS; CELLS; YEAST; REPAIR; PURIFICATION; PRIMASE	A DNA helicase named DNA helicase I was isolated from cell-free extracts of the fission yeast Schizosaccharomyces pombe. Both DNA helicase and single-stranded DNA-dependent ATPase activities copurified with a polypeptide of 95 kDa on an SDS-polyacrylamide gel. The helicase possessed a sedimentation coefficient of 6.0 S and a Stokes radius of 44.8 Angstrom determined by glycerol gradient centrifugation and gel filtration analysis, respectively. From these data the native molecular mass was calculated to be 110 kDa, indicating that the active enzyme is a monomer. The DNA-unwinding and ATP hydrolysis activities associated with DNA helicase I have been examined. One notable property of the enzyme was its relatively high rate of ATP turnover (35-50 molecules of ATP hydrolyzed/s/enzyme molecule) that may contribute to its inefficient unwinding activity at low concentrations of ATP (<0.2 mM). Addition of an ATP-regenerating system to the reaction mixture re stored the DNA-unwinding activity of the enzyme. S. pombe single-stranded DNA-binding protein (SpSSB, also called SpRPA) stimulated the DNA helicase activity significantly at low levels of ATP (0.025-0.2 mM) even in the absence of an ATP-regenerating system. In contrast, SpRPA had no effect on ATP hydrolysis at any ATP concentration examined. These observations suggest that the stimulation of DNA unwinding by SpRPA is not simply a result of suppression of nonproductive ATP hydrolysis. Rather, the role of SpRPA is to lower the K-m for ATP in the unwinding reaction, allowing the helicase to function efficiently at low ATP concentrations.	SAMSUNG BIOMED RES INST, BASIC RES CTR, SEOUL 135230, SOUTH KOREA	Sungkyunkwan University (SKKU); Samsung Medical Center			Seo, Yeonsoo/C-1605-2011					ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUZDER SN, 1994, NATURE, V369, P568; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LI XY, 1992, CHROMOSOMA, V102, pS93, DOI 10.1007/BF02451791; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; PARK MS, 1996, J BIOL CHEM, V271, P1896; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SHIMIZU K, 1993, J BIOL CHEM, V268, P9578; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; Tuteja N, 1996, NAT GENET, V13, P11, DOI 10.1038/ng0596-11; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	56	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18910	18919		10.1074/jbc.272.30.18910	http://dx.doi.org/10.1074/jbc.272.30.18910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228070	hybrid			2022-12-27	WOS:A1997XM34200061
J	Saunders, C; Limbird, LE				Saunders, C; Limbird, LE			Disruption of microtubules reveals two independent apical targeting mechanisms for G-protein-coupled receptors in polarized renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; BREFELDIN-A; GOLGI-COMPLEX; SELECTIVE-INHIBITION; MONENSIN; SURFACE; TRANSCYTOSIS; DELIVERY	G-protein-coupled receptors demonstrate differing trafficking itineraries in polarized Madin-Darby canine kidney (MDCK II) cells. The alpha(2A) adrenergic receptor (alpha(2A)AR) is directly delivered to the basolateral subdomain; the A(1) adenosine receptor (A(1)AdoR) is apically enriched in its targeting; and the alpha(2B)AR subtype is randomly delivered to both domains but selectively retained basolaterally (Keefer, J. R., and Limbird, L. E. (1993) J. Biol. Chem. 268, 11340-11347; Saunders, C., Keefer, J. R., Kennedy, A. P., Wells, J. N., and Limbird, L. E. (1996) J. Biol. Chem. 271, 995-1002; Wozniak, M., and Limbird, L. E. (1996) J. Biol. Chem. 271, 5017-5024). The present studies explore the role of the polarized cytoskeleton in localization of G-protein-coupled receptors in MDCK II cells, Nocodazole or colchicine, which disrupt microtubules, did not perturb lateral localization of alpha(2)AR subtypes but led to a relocalization the A(1)AdoR to the basolateral surface, revealed by immunocytochemical and metabolic labeling strategies. Conversely, the apical component of the random delivery of alpha(2B)AR was not affected by these agents, suggesting microtubule-dependent and -independent apical targeting mechanisms for G-protein-coupled receptors in polarized cells, Apparent rerouting of the apically targeted A(1)AdoR was selective for microtubule-disrupting agents, since cytochalasin D, which disrupts actin polymerization, did not alter A(1)AdoR or alpha(2B)AR localization or targeting, These data suggest that multiple apical targeting mechanisms exist for G-protein-coupled receptors and that microtubule-disrupting agents serve as tools to probe their different trafficking mechanisms.	VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHELER C, 1989, J CELL BIOL, V109, P179; ALONSO FV, 1981, J CELL BIOL, V89, P700, DOI 10.1083/jcb.89.3.700; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; AUNT DA, 1997, MOL PHARMACOL, V51, P711; BAAS PW, 1992, J CELL BIOL, V116, P1231, DOI 10.1083/jcb.116.5.1231; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018; DANIELSEN EM, 1983, BIOCHEM J, V216, P37, DOI 10.1042/bj2160037; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FISH EM, 1994, NEW ENGL J MED, V330, P1580; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HASTINGS RH, 1994, AM J PHYSIOL, V266, pL544, DOI 10.1152/ajplung.1994.266.5.L544; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; HYAMS JS, 1994, MICROTUBULES, P33; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; LAFONT F, 1994, NATURE, V372, P801; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nelson W J, 1991, Semin Cell Biol, V2, P375; Nelson W J, 1990, Semin Cell Biol, V1, P359; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Oksche A, 1996, MOL PHARMACOL, V50, P820; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; ROSA P, 1992, J BIOL CHEM, V267, P12227; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEIN BS, 1984, J BIOL CHEM, V259, P4762; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VAN MEER G, 1993, J CELL SCI, V104, P833; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WAN JS, 1992, J BIOL CHEM, V267, P13446; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wozniak M, 1996, J BIOL CHEM, V271, P5017	51	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19035	19045		10.1074/jbc.272.30.19035	http://dx.doi.org/10.1074/jbc.272.30.19035			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228087	hybrid			2022-12-27	WOS:A1997XM34200078
J	Whistler, JL; Rine, J				Whistler, JL; Rine, J			Ras2 and Ras1 protein phosphorylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-ANALYSIS; LUNG CARCINOMAS; TYROSINE KINASE; YEAST; CYCLASE; CELLS; DNA; TRANSFORMATION; ACTIVATION; MUTATIONS	This work describes the phosphorylation of Saccharomyces cerevisiae Ras proteins and explores the physiological role of the phosphorylation of Ras2 protein, Proteins expressed from activated alleles of RAS were less stable and less phosphorylated than proteins from cells expressing wild-type alleles of RAS. This difference in phosphorylation level did not result from increased signaling through the Ras-cAMP pathway or reflect the primarily GTP-bound nature of activated forms of Ras protein per se. In addition, phosphorylation of Ras protein was not dependent on proper localization of the Ras2 protein to the plasma membrane nor on the interaction of Ras2p with its exchange factor, Cdc25p. The preferred phosphorylation site on Ras2 protein was identified as serine 214, This site, when mutated to alanine, led to promiscuous phosphorylation of Ras2 protein on nearby serine residues, A decrease in phosphorylation may lead 60 a decrease in signaling through the Ras-cAMP pathway.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035827, T32GM007232] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ESO 1896] Funding Source: Medline; NIGMS NIH HHS [GM35827, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1994, GENETICS, V136, P87; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASBBY MN, 1995, METHOD ENZYMOL, V250, P235; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; COBITZ AR, 1989, P NATL ACAD SCI USA, V86, P858, DOI 10.1073/pnas.86.3.858; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; Freeman NL, 1996, MOL CELL BIOL, V16, P548; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HAYASHI K, 1983, JPN J CANCER RES, V74, P798; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCCORMICK F, 1991, COLD SH Q B, V56, P237; MINTZER KA, 1994, CELL SIGNAL, V6, P681, DOI 10.1016/0898-6568(94)90050-7; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NAKANO H, 1984, P NATL ACAD SCI-BIOL, V81, P71, DOI 10.1073/pnas.81.1.71; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260	39	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18790	18800		10.1074/jbc.272.30.18790	http://dx.doi.org/10.1074/jbc.272.30.18790			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228053	hybrid			2022-12-27	WOS:A1997XM34200044
J	Maiti, T; Maitra, U				Maiti, T; Maitra, U			Characterization of translation initiation factor 5 (eIF5) from Saccharomyces cerevisiae - Functional homology with mammalian eIF5 and the effect of depletion of eIF5 on protein synthesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTES; IMMUNOCHEMICAL CHARACTERIZATION; PURIFICATION; COMPLEX; YEAST; EXPRESSION; RELEASE; MECHANISM; BINDING; CLONING	Eukaryotic translation initiation factor 5 (eIF5) interacts in vitro with the 40 S initiation complex (40 S.AUG.Met-tRNA(f).eIF2.GTP) to mediate the hydrolysis of ribosome-bound GTP, In Saccharomyces cerevisiae, eIF5 is encoded by a single copy essential gene, TIF5, that encodes a protein of 45,346 daltons, To understand the function of eIF5 in vivo, we constructed a conditional mutant yeast strain in which a functional but a rapidly degradable form of eIF5 fusion protein was synthesized from the repressible GAL promoter, Depletion of eIF5 from this mutant yeast strain resulted in inhibition of both cell growth and the rate of in, vivo protein synthesis, Analysis of the polysome profiles of eIF5-depleted cells showed greatly diminished polysomes with simultaneous increase in free ribosomes. Furthermore, lysates of cells depleted of eIF5 were dependent on exogenously added yeast eIF5 for efficient translation of mRNAs in vitro, This is the first demonstration that the TIF5 gene encodes a protein involved in initiation of translation in eukaryotic cells, Additionally, we show that rat eIF5 can functionally substitute yeast eIF5 in translation of mRNAs in vitro as well as in complementing in vivo a genetic disruption in the chromosomal copy of TIF5.			Maiti, T (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,JACK & PEARL RESNICK CAMPUS,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENNE R, 1978, J BIOL CHEM, V253, P3078; BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRICK WC, 1995, TRANSLATIONAL CONTRO, P31; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL PJ, 1991, NUCLEIC ACIDS RES, V19, P4949, DOI 10.1093/nar/19.18.4949; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; Si KS, 1996, J BIOL CHEM, V271, P16934, DOI 10.1074/jbc.271.28.16934; SIROSKI RS, 1989, GENETICS, V122, P19; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; [No title captured]	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18333	18340		10.1074/jbc.272.29.18333	http://dx.doi.org/10.1074/jbc.272.29.18333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218474	hybrid			2022-12-27	WOS:A1997XL73500064
J	Sem, DS; Casimiro, DR; Kliewer, SA; Provencal, J; Evans, RM; Wright, PE				Sem, DS; Casimiro, DR; Kliewer, SA; Provencal, J; Evans, RM; Wright, PE			NMR spectroscopic studies of the DNA-binding domain of the monomer-binding nuclear orphan receptor, human estrogen related receptor-2 - The carboxyl-terminal extension to the zinc-finger region is unstructured in the free form of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; SECONDARY STRUCTURE ELEMENTS; MULTIPLE QUANTUM NMR; GLUCOCORTICOID RECEPTOR; RETINOIC ACID; SEQUENTIAL ASSIGNMENTS; RESPONSE ELEMENTS; HETERONUCLEAR NMR; CRYSTAL-STRUCTURE; HYDROPHOBIC CORE	Unlike steroid and retinoid receptors, which associate with DNA as dimers, human estrogen related receptor-2 (hERR2) belongs to a growing subclass of nuclear hormone receptors that bind DNA with high affinity as monomers. A carboxyl-terminal extension (CTE) to the zinc-finger domain has bean implicated to be responsible for determining the stoichiometry of binding by a nuclear receptor to its response element. To better understand the mechanism by which DNA specificity is achieved, the solution structure of the DNA-binding domain of hERR2 (residues 96-194) consisting of the two putative zinc fingers and the requisite 26-amino acid CTE was analyzed by multidimensional heteronuclear magnetic resonance spectroscopy. The highly conserved zinc-finger region (residues 103-168) has a fold similar to those reported for steroid and retinoid receptors, with two helices that originate from the carboxyl-terminal ends of the two zinc fingers and that pack together orthogonally, forming a hydrophobic core. The CTE element of hERR2 is unstructured and highly flexible, exhibiting nearly random coil chemical shifts, extreme sensitivity of the backbone amide protons to solvent presaturation, and reduced heteronuclear {H-1-N-15} nuclear Overhauser effect values. This is in contrast to the dimer-binding retinoid X and thyroid hormone receptors, where, in each case, a helix has been observed within the CTE. The implications of this property of the hERR2 CTE are discussed.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Sem, Daniel/0000-0002-2108-6646; Wright, Peter/0000-0002-1368-0223				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAX A, 1987, J AM CHEM SOC, V109, P6511, DOI 10.1021/ja00255a047; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; Blake P R, 1994, Adv Inorg Biochem, V10, P201; BRAUNSCHWEILER L, 1983, MOL PHYS, V48, P535, DOI 10.1080/00268978300100381; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DAVIS DG, 1989, J MAGN RESON, V81, P603, DOI 10.1016/0022-2364(89)90100-5; DELSUC MA, 1986, J MAGN RESON, V69, P504, DOI 10.1016/0022-2364(86)90164-2; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JASANOFF A, 1993, BIOCHEMISTRY-US, V32, P1423, DOI 10.1021/bi00057a005; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PARKER KL, 1993, TRENDS ENDOCRIN MET, V4, P46, DOI 10.1016/S1043-2760(05)80014-1; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RANCE M, 1986, CHEM PHYS LETT, V124, P572, DOI 10.1016/0009-2614(86)85078-3; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	58	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18038	18043		10.1074/jbc.272.29.18038	http://dx.doi.org/10.1074/jbc.272.29.18038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218433	hybrid			2022-12-27	WOS:A1997XL73500023
J	Grujic, D; Susulic, VS; Harper, ME; HimmsHagen, J; Cunningham, BA; Corkey, BE; Lowell, BB				Grujic, D; Susulic, VS; Harper, ME; HimmsHagen, J; Cunningham, BA; Corkey, BE; Lowell, BB			beta 3-adrenergic receptors on white and brown adipocytes mediate beta 3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake - A study using transgenic and gene knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; MESSENGER-RNA; OBESE GENE; MOLECULAR CHARACTERIZATION; ADRENERGIC-RECEPTOR; EXPRESSION; ADIPOSE; CLONING; TISSUES; RATS	beta 3-Adrenergic receptors (beta,7-ARs) are expressed predominantly on white and brown adipocytes, and acute treatment of mice with CL 316,243, a potent and highly selective beta 3-AR agonist, produces a a-fold increase in energy expenditure, a 50-100-fold increase in insulin levels, and a 40-50% reduction in food intake, Recently, we generated gene knockout mice lacking functional beta 3-ARs and demonstrated that each of these responses were mediated exclusively by beta 3-ARs. However, the tissue site responsible for producing these actions is unknown. In the present study, genetically engineered mice were created in which beta 3-ARs are expressed exclusively ill white and brown adipocytes (WAT+BAT-mice), or in brown adipocytes only (BAT-mice). This was accomplished by injecting tissue-specific beta 3-AR transgenic constructs into mouse zygotes homozygous for the beta 3-AR knockout allele. Control, knockout, WAT+BAT, and BAT-mice were then treated acutely with CL, and the effects on various parameters were assessed, As previously observed, all effects of CL were completely absent in gene knockout mice lacking beta 3-ARs. The effects on O-2 consumption, insulin secretion, and food intake were completely rescued with transgenic re-expression of beta 3-ARs in white and brown adipocytes (WAT+BAT-mice), demonstrating that each of these responses is mediated exclusively by beta 3-Ars in white and/or brown adipocytes, and that beta 3-ARs in other tissue sites were not required. Importantly, transgenic re-expression of beta 3-Ars in brown adipocytes only (BAT-mice) failed to rescue, in any way, CL-mediated effects on insulin levels and food intake and only minimally restored effects on oxygen consumption, indicating that any effect on insulin secretion and food intake, and a full stimulation of oxygen consumption required the presence of beta 3-ARs in white adipocytes. The mechanisms by which beta 3-AR. agonist stimulation of white adipocytes produces these responses are unknown but may involve novel mediators not previously known to effect: these processes.	BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; BOSTON UNIV, MED CTR,DEPT BIOCHEM,EVANS DEPT MED, DIABET & METAB UNIT, BOSTON, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Ottawa; Boston University			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Harper, Mary-Ellen/0000-0003-3864-5886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, P30DK046200, K08DK002119] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49569, DK46200, DK02119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BERKOWITZ DE, 1995, EUR J PHARM-MOLEC PH, V289, P223, DOI 10.1016/0922-4106(95)90098-5; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BROBECK JR, 1960, RECENT PROG HORM RES, V16, P439; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; Deng CJ, 1996, BRIT J PHARMACOL, V118, P929, DOI 10.1111/j.1476-5381.1996.tb15488.x; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1995, CELL SIGNAL, V7, P9, DOI 10.1016/0898-6568(94)00066-K; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; Hogan B, 1994, MANIPULATING MOUSE E; HOLLOWAY BR, 1992, AM J CLIN NUTR, V55, P262; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; RODRIGUEZ M, 1995, MOL BRAIN RES, V29, P369, DOI 10.1016/0169-328X(94)00274-I; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; STROMINGER JL, 1953, YALE J BIOL MED, V25, P383; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS RF, 1993, MOL PHARMACOL, V43, P343; TSUJII S, 1992, BRAIN RES, V587, P226, DOI 10.1016/0006-8993(92)91001-U; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; WOODS SC, 1990, INT J OBESITY, V14, P69; WOODS SC, 1989, ANN NY ACAD SCI, V575, P236; YOSHIDA T, 1992, AM J CLIN NUTR, V55, P237; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	195	195	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17686	17693		10.1074/jbc.272.28.17686	http://dx.doi.org/10.1074/jbc.272.28.17686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211919	hybrid			2022-12-27	WOS:A1997XK16500062
J	Liao, J; Ku, NO; Omary, MB				Liao, J; Ku, NO; Omary, MB			Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SKIN DISEASES; INTERMEDIATE FILAMENTS; EPITHELIAL-CELLS; TRANSGENIC MICE; MITOTIC ARREST; PROTEIN-KINASE; SEQUENCE; EXPRESSION; CDNA; CYTOKERATIN-8	Simple epithelia express keratins 8 (K8) and 18 (K18) as their major intermediate filament proteins, We previously showed that several types of cell stress such as heat and virus infection result in a distinct hyperphosphorylated form of K8 (termed HK8). To better characterize K8/18 phosphorylation, we generated monoclonal antibodies by immunizing mice with hyperphosphorylated keratins that were purified from colonic cultured human HT29 cells pretreated with okadaic acid. One antibody specifically recognized HK8, and the epitope was identified as (71)LLpSPL which corresponds to K8 phosphorylation at Ser-73, Generation of HK8 occurs in mitotic HT29 cells, basal crypt mitotic cells in normal mouse intestine, and in regenerating mouse hepatocytes after partial hepatectomy, Prominent levels of HK8 were also generated in HT29 cells that were induced to undergo apoptosis using anisomycin or etoposide. In addition, mouse hepatotoxicity that is induced by chronic feeding with griseofulvin resulted in HK8 formation in the liver. Our results demonstrate that a ''reverse immunological'' approach, coupled with enhancing in vivo phosphorylation using phosphatase inhibitors, can result in the identification of physiologic phosphorylation states, As such, K8 Ser-73 phosphorylation generates a distinct HK8 species under a variety of in vivo conditions including mitosis, apoptosis, and cell stress. The low steady state levels of HK8 during mitosis, in contrast to stress and apoptosis, suggest that accumulation of HK8 may represent a physiologic stress marker for simple epithelia.	VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,CTR DIGEST DIS,STANFORD,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University				Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK47918, DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Ando S, 1996, BIOCHEM BIOPH RES CO, V221, P67, DOI 10.1006/bbrc.1996.0546; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1994, J CELL SCI, V107, P1833; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; COLLIN C, 1992, DIFFERENTIATION, V51, P137, DOI 10.1111/j.1432-0436.1992.tb00690.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HUTTER H, 1993, LAB INVEST, V69, P576; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KNAPP B, 1986, NUCLEIC ACIDS RES, V14, P751, DOI 10.1093/nar/14.2.751; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; Liao J, 1996, ELECTROPHORESIS, V17, P1671, DOI 10.1002/elps.1150171104; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; LOCK RB, 1994, CANCER RES, V54, P4933; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORITA T, 1988, GENE, V68, P109; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YAMAMOTO R, 1990, MOL ENDOCRINOL, V4, P370, DOI 10.1210/mend-4-3-370; Yang JM, 1996, J INVEST DERMATOL, V107, P439, DOI 10.1111/1523-1747.ep12365483	50	110	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17565	17573		10.1074/jbc.272.28.17565	http://dx.doi.org/10.1074/jbc.272.28.17565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211903	hybrid			2022-12-27	WOS:A1997XK16500046
J	Sundaramoorthy, M; Kishi, K; Gold, MH; Poulos, TL				Sundaramoorthy, M; Kishi, K; Gold, MH; Poulos, TL			Crystal structures of substrate binding site mutants of manganese peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; LIGNIN-DEGRADING BASIDIOMYCETE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; NONPHENOLIC LIGNIN; OXIDIZED STATES; MODEL COMPOUNDS; DEGRADATION; OXIDATION; MECHANISM	Manganese peroxidase (MnP), an extracellular heme enzyme from the lignin-degrading basidiomycetous fungus, Phanerochaete chrysosporium, catalyzes the oxidation of Mn-II to Mn-III. The latter, acting as a diffusible redox mediator, is capable of oxidizing a variety of lignin model compounds. The proposed Mn-II binding site of MnP consists of a heme propionate, three acidic Ligands (Glu-35, Glu-39, and Asp-179), and two water molecules. Using crystallographic methods, this binding site was probed by altering the amount of Mn-II bound to the protein. Crystals grown in the absence of Mn-II, or in the presence of EDTA, exhibited diminished electron density at this site, Crystals prawn in excess Mn-II exhibited increased electron density at the proposed binding site but nowhere else in the protein. This suggests that there is only one major Mn-II binding site in MnP. Crystal structures of a single mutant (D179N) and a double mutant (E35Q,D179N) at this site were determined, The mutant structures lack a cation at the Mn-II binding site. The structure of the Mn-II binding site is altered significantly in both mutants, resulting in increased access to the solvent and substrate.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOL BIOL,PORTLAND,OR 97291	University of California System; University of California Irvine; University of California System; University of California Irvine								Alic M, 1997, BBA-PROTEIN STRUCT M, V1338, P1, DOI 10.1016/S0167-4838(96)00235-X; ALIC M, 1990, CURR GENET, V17, P305, DOI 10.1007/BF00314877; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BAO WL, 1994, FEBS LETT, V354, P297, DOI 10.1016/0014-5793(94)01146-X; BRUNGER AT, 1992, XPLOP MANUAL; BUMPUS JA, 1987, BIOESSAYS, V6, P166, DOI 10.1002/bies.950060405; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; EDWARDS SL, 1987, BIOCHEMISTRY-US, V26, P1503, DOI 10.1021/bi00380a002; ENGH R, 1991, ACTA CRYSTALLOGR A, V47, P110; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GODFREY BJ, 1990, GENE, V93, P119, DOI 10.1016/0378-1119(90)90144-G; GOLD MH, 1989, ACS SYM SER, V389, P127; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1989, ENZYME MICROB TECH, V11, P776, DOI 10.1016/0141-0229(89)90129-4; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P824; JOHNSON F, 1993, PLANT PEROXIDASES BI, P31; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOSHI DK, 1993, APPL ENVIRON MICROB, V59, P1779, DOI 10.1128/AEM.59.6.1779-1785.1993; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; MAYFIELD MB, 1994, GENE, V142, P231, DOI 10.1016/0378-1119(94)90266-6; MINO Y, 1988, J BIOL CHEM, V263, P7029; ORTH AB, 1994, GENE, V148, P161, DOI 10.1016/0378-1119(94)90251-8; ORTH AB, 1993, APPL ENVIRON MICROB, V59, P4017, DOI 10.1128/AEM.59.12.4017-4023.1993; PEASE EA, 1989, J BIOL CHEM, V264, P13531; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; SUNDARAMOORTHY M, 1994, J MOL BIOL, V238, P845, DOI 10.1006/jmbi.1994.1338; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; VALLI K, 1992, APPL ENVIRON MICROB, V58, P221, DOI 10.1128/AEM.58.1.221-228.1992; VALLI K, 1992, J BACTERIOL, V174, P2131, DOI 10.1128/JB.174.7.2131-2137.1992; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1992, J BIOL CHEM, V267, P23688	53	78	81	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17574	17580		10.1074/jbc.272.28.17574	http://dx.doi.org/10.1074/jbc.272.28.17574			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211904	hybrid			2022-12-27	WOS:A1997XK16500047
J	Bacolla, A; Gellibolian, R; Shimizu, M; Amirhaeri, S; Kang, S; Ohshima, K; Larson, JE; Harvey, SC; Stollar, BD; Wells, RD				Bacolla, A; Gellibolian, R; Shimizu, M; Amirhaeri, S; Kang, S; Ohshima, K; Larson, JE; Harvey, SC; Stollar, BD; Wells, RD			Flexible DNA: Genetically unstable CTG center dot CAG and CGG center dot CCG from human hereditary neuromuscular disease genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; HELICAL REPEAT; ESCHERICHIA-COLI; DYNAMIC CONTRIBUTIONS; PERSISTENCE LENGTH; TORSIONAL RIGIDITY; TRIPLET REPEATS; RING-CLOSURE; FLEXIBILITY; DEPENDENCE	The properties of duplex CTG.CAG and CGG.CCG, which are involved in the etiology of several hereditary neurodegenerative diseases, were investigated by a variety of methods, including circularization kinetics, apparent helical repeat determination, and polyacrylamide gel electrophoresis, The bending moduli were 1.13 x 10(-19) erg.cm for CTG and 1.27 x 10(-19) erg cm for CGG, similar to 40% less than for random B-DNA. Also, the persistence lengths of the triplet repeat sequences were similar to 60% the value for random B-DNA. However, the torsional moduli and the helical repeats were 2.3 x 10(-19) erg.cm and 10.4 base pairs (bp)/turn for CTG and 2.4 x 10(-19) erg.cm and 10.3 bp/turn for CGG, respectively, all within the range for random B-DNA, Determination of the apparent helical repeat by the band shift assay indicated that the writhe of the repeats was different from that of random B-DNA, In addition, molecules of 224-245 bp in length (64-71 triplet repeats) were able to form topological isomers upon cyclization. The low bending moduli are consistent with predictions from crystallographic variations in slide, roll, and tilt. No unpaired bases or non-B-DNA structures could be detected by chemical and enzymatic probe analyses, two-dimensional agarose gel electrophoresis, and immunological studies. Hence, CTG and CGG are more flexible and highly writhed than random B-DNA and thus would be expected to act as sinks for the accumulation of superhelical density.	TEXAS A&M UNIV, CTR GENOME RES, INST BIOSCI & TECHNOL, TEXAS MED CTR, HOUSTON, TX 77030 USA; TEXAS A&M UNIV, CTR GENOME RES, DEPT BIOCHEM & BIOPHYS, TEXAS MED CTR, HOUSTON, TX 77030 USA; UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham; Tufts University			Shimizu, Miho/O-9903-2019; Shimizu, Miho/Q-8522-2017; Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Shimizu, Miho/0000-0003-4070-8209; Shimizu, Miho/0000-0003-4070-8209; Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032375, P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32375, GM 52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BEDNAR J, 1995, J MOL BIOL, V254, P579, DOI 10.1006/jmbi.1995.0640; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DAVIES KE, 1993, GENOME ANAL GENOME R, V7; Deissler H, 1996, J BIOL CHEM, V271, P4327; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HARRINGTON RE, 1994, PROG NUCLEIC ACID RE, V47, P195, DOI 10.1016/S0079-6603(08)60253-6; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KRAHE R, 1995, HYPERVARIABLE GENETI, P29; LEVENE SD, 1986, J MOL BIOL, V189, P73, DOI 10.1016/0022-2836(86)90382-7; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; NELSON DL, 1993, GENOME ANAL, V7, P1; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PANZER S, 1995, STEM CELLS, V13, P146, DOI 10.1002/stem.5530130206; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SHIMADA J, 1984, MACROMOLECULES, V17, P689, DOI 10.1021/ma00134a028; SHIMADA J, 1985, J MOL BIOL, V184, P319, DOI 10.1016/0022-2836(85)90383-3; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Sinden R. R., 1995, DNA STRUCTURE FUNCTI; STOLLAR BD, 1992, PROG NUCLEIC ACID RE, V42, P39, DOI 10.1016/S0079-6603(08)60573-5; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1966, J MOL BIOL, V19, P469, DOI 10.1016/S0022-2836(66)80017-7; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3	60	91	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16783	16792		10.1074/jbc.272.27.16783	http://dx.doi.org/10.1074/jbc.272.27.16783			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201983	hybrid			2022-12-27	WOS:A1997XH44600015
J	Collins, BE; Kiso, M; Hasegawa, A; Tropak, MB; Roder, JC; Crocker, PR; Schnaar, RL				Collins, BE; Kiso, M; Hasegawa, A; Tropak, MB; Roder, JC; Crocker, PR; Schnaar, RL			Binding specificities of the sialoadhesin family of I-type lectins - Sialic acid linkage and substructure requirements for binding of myelin-associated glycoprotein, Schwann cell myelin protein, and sialoadhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE CD22-BETA; NEURON-SPECIFIC GANGLIOSIDE; LINKED CARBOHYDRATE UNITS; IMMUNOGLOBULIN SUPERFAMILY; FUNCTIONAL TOPOGRAPHY; ERYTHROCYTE RECEPTOR; TISSUE MACROPHAGES; NATURAL LIGANDS; L-SELECTIN; CD22	The carbohydrate binding specificities of three sialoadhesins, a subgroup of I-type lectins (immunoglobulin superfamily lectins), were compared by measuring lectin-transfected COS cell adhesion to natural and synthetic gangliosides. The neural sialoadhesins, myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP), had similar and stringent binding specificities, Each required an alpha 2,3-linked sialic acid on the terminal galactose of a neutral saccharide core, and they shared the following rank-order potency of binding: G(Q1b alpha) much greater than G(D1a) = G(T1b) much greater than G(M3) = G(M4) much greater than G(M1), G(D1b), G(D3), G(Q1b) (nonbinders). In contrast, sialoadhesin had less exacting specificity, binding to gangliosides that bear either terminal alpha 2,3- or alpha 2,8-linked sialic acids with the following rank-order potency of binding: G(Q1b alpha) > G(D1a) = G(D1b) = G(T1b) = G(M3) = G(M4) > G(D3) = G(Q1b) much greater than G(M1) (nonbinder), CD22 did not bind to any ganglioside tested. Binding of MAG, SMP, and sialoadhesin was abrogated by chemical modification of either the sialic acid carboxylic acid group or glycerol side chain on a target ganglioside. Synthetic ganglioside G(M3) derivatives further distinguished lectin binding specificities, Deoxy and/or methoxy derivatives of the 4-, 7-, 8-, or g-position of sialic acid attenuated or eliminated binding of MAG, as did replacement of the sialic acid acetamido group with a hydroxyl. In contrast, the 4- and 7-deoxysialic acid derivatives supported sialoadhesin binding at near control levels (the other derivatives did not support binding). These data are consistent with sialoadhesin binding to one face of the sialic acid moiety, whereas MAG (and SMP) may have more complex binding sites or may bind sialic acids only in the context of more restricted oligosaccharide conformations.	JOHNS HOPKINS UNIV,DEPT PHARMACOL,SCH MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT NEUROSCI,SCH MED,BALTIMORE,MD 21205; GIFU UNIV,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Johns Hopkins University; Johns Hopkins University; Gifu University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cancer Research UK; University of Oxford			Roder, John/G-6468-2013; Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Crocker, Paul/0000-0001-6230-0293	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07626] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTIA J, 1993, J NEUROCHEM, V61, P718; BLACKBURN CC, 1986, J BIOL CHEM, V61, P2873; BLACKBURN CC, 1983, J BIOL CHEM, V258, P11800; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; DELL A, 1994, METHOD ENZYMOL, V230, P108; DERRINGTON EA, 1989, J NEUROCHEM, V53, P1686, DOI 10.1111/j.1471-4159.1989.tb09231.x; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FAHRIG T, 1993, EUR J NEUROSCI, V5, P1118, DOI 10.1111/j.1460-9568.1993.tb00966.x; FERRETTI P, 1986, J NEUROCHEM, V46, P1888; FINNE J, 1975, BIOCHIM BIOPHYS ACTA, V412, P317, DOI 10.1016/0005-2795(75)90046-X; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HOTTA K, 1995, J CARBOHYD CHEM, V14, P491, DOI 10.1080/07328309508005353; HOTTA K, 1994, J CARBOHYD CHEM, V13, P665, DOI 10.1080/07328309408011673; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KISO M, 1994, METHOD ENZYMOL, V242, P173; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; LEDEEN RW, 1979, COMPLEX CARBOHYDRATE, P1; MEYERFRANKE A, 1995, J NEUROSCI RES, V41, P311, DOI 10.1002/jnr.490410304; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RAO BNN, 1994, J BIOL CHEM, V269, P19663; SADOUL R, 1990, J NEUROSCI RES, V25, P1, DOI 10.1002/jnr.490250102; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SGROI D, 1993, J BIOL CHEM, V268, P7011; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR6; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yang LJS, 1996, ANAL BIOCHEM, V236, P161, DOI 10.1006/abio.1996.0145	53	121	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16889	16895		10.1074/jbc.272.27.16889	http://dx.doi.org/10.1074/jbc.272.27.16889			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201997	hybrid			2022-12-27	WOS:A1997XH44600029
J	Hubner, S; Xiao, CY; Jans, DA				Hubner, S; Xiao, CY; Jans, DA			The protein kinase CK2 site (Ser(111/112)) enhances recognition of the Simian virus 40 large T-antigen nuclear localization sequence by importin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; TRANSPORT; IDENTIFICATION; SIGNAL; PHOSPHORYLATION; SUBSTRATE; CELLS; NUCLEOPORINS; LOCATION; BINDING	The mechanism by which phosphorylation regulates nuclear localization sequence (NLS)-dependent nuclear protein import is largely unclear. Whereas nuclear accumulation of SV40 large tumor antigen (T-ag) fusion proteins is completely dependent on the T-ag NLS (amino acids 126-132), the rate of nuclear import is increased 50-fold by amino acid residues 111-125 and in particular a site for the protein kinase CK2 (CK2) at serine 111/112. Because the first step of nuclear protein import involves the binding of the NLS by an NLS-receptor complex such as the importin 58/97 heterodimer, we established a novel enzyme-linked immunosorbent assay to test whether NLS recognition is influenced by amino acids amino-terminal to the NLS and the CK2 site. We found that recognition of the T-ag NLS by importin 58/97 was enhanced 10-fold in the presence of amino acid residues 111-125 and strongly dependent on importin 97. A T-ag fusion protein in which the spacer between the CK2 site and the NLS was decreased showed 30% reduced binding by importin 58/97. Maximal nuclear accumulation of this protein was reduced by more than 50%, indicating the physiological importance of the correctly positioned CK2 site. Phosphorylation by CR2 increased the T-ag NLS binding affinity for importin 58/97 by a further 40%. We conclude that flanking sequences and in particular phosphorylation at the CK2 site are mechanistically important in NLS recognition and represent the basis of their enhancement of T-ag nuclear import. This study thus represents the first elucidation of the mechanistic basis of the regulation of nuclear protein import through phosphorylation within a phosphorylation-regulated NLS.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNAL LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	38	217	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17191	17195		10.1074/jbc.272.27.17191	http://dx.doi.org/10.1074/jbc.272.27.17191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202041	hybrid			2022-12-27	WOS:A1997XH44600073
J	Kahsai, TZ; Enders, GC; Gunwar, S; Brunmark, C; Wieslander, J; Kalluri, R; Zhou, J; Noelken, ME; Hudson, BG				Kahsai, TZ; Enders, GC; Gunwar, S; Brunmark, C; Wieslander, J; Kalluri, R; Zhou, J; Noelken, ME; Hudson, BG			Seminiferous tubule basement membrane - Composition and organization of type IV collagen chains, and the linkage of alpha 3(IV) and alpha 5(IV) chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOLLAGENOUS DOMAIN HEXAMER; RECESSIVE ALPORT SYNDROME; AMINO-ACID-SEQUENCE; GOODPASTURE ANTIGEN; POLYACRYLAMIDE GELS; ALPHA-4(IV) CHAIN; CDNA ISOLATION; COL4A3 GENE; IDENTIFICATION; LOCALIZATION	Seminiferous tubule basement membrane (STEM) plays an important role in spermatogenesis, In the present study, the composition and structural organization of type IV collagen of bovine STEM was investigated, STEM was found to be composed of all six a-chains of type IV collagen based upon immunocytochemical and biochemical analysis, The content of alpha 3(IV) chain (40%) and the alpha 4(IV) chain (18%) was substantially higher than in any other basement membrane collagen, The supramolecular structure of the six alpha(IV) chains was investigated using pseudolysin (EC 3.4.24.26) digestion to excise triple-helical molecules, subsequent collagenase digestion to produce NC1 hexamers and antibody affinity chromatography to resolve populations of NC1 hex amers, The hexamers, which reflect specific arrangements of alpha(IV) chains, were characterized for their alpha(IV) chain composition using high performance liquid chromatography, two-dimensional electrophoresis, and immunoblotting with alpha(IV) chain-specific antibodies, Three major hexamer populations were found that represent the classical network of the alpha 1(IV) and alpha 2(IV) chains and two novel networks, one composed of the alpha 1(IV)-alpha 6(IV) chains and the other composed of the alpha 3(IV)-alpha 6(IV) chains, The results establish a structural linkage between the alpha 3(IV) and alpha 5(IV) chains, suggesting a molecular basis for the conundrum in which mutations in the gene encoding the alpha 5(IV) chain cause defective assembly of the alpha 3(IV) chain in the glomerular basement membrane of patients with Alport syndrome.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT ANAT & CELL BIOL,KANSAS CITY,KS 66160; UNIV LUND HOSP,DEPT NEPHROL,S-22185 LUND,SWEDEN; UNIV PENN,SCH MED,PENN CTR MOL STUDIES KIDNEY DIS RENAL ELECTROLYTE,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Lund University; Skane University Hospital; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard Medical School			; Kalluri, Raghu/E-2677-2015	Hudson, Billy/0000-0002-5420-4100; Kalluri, Raghu/0000-0002-2190-547X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NCRR NIH HHS [BRSG S07 RR05373] Funding Source: Medline; NIDDK NIH HHS [DK 18381] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; DAVIDOFF MS, 1990, CELL TISSUE RES, V262, P253, DOI 10.1007/BF00309880; DEKRETSER DM, 1975, BIOL REPROD, V12, P317, DOI 10.1095/biolreprod12.3.317; ENDERS GC, 1986, J CELL BIOL, V103, P1109, DOI 10.1083/jcb.103.3.1109; ENDERS GC, 1995, BIOL REPROD, V53, P1489, DOI 10.1095/biolreprod53.6.1489; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KALLURI R, 1995, KIDNEY INT, V47, P1199, DOI 10.1038/ki.1995.170; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; LIAN G, 1992, BIOL REPROD, V47, P316, DOI 10.1095/biolreprod47.3.316; LONG CG, 1995, BIOPOLYMERS, V35, P621, DOI 10.1002/bip.360350608; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PARANKO J, 1992, CELL TISSUE RES, V268, P521, DOI 10.1007/BF00319159; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SALOMON F, 1982, LAB INVEST, V47, P543; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHLATT S, 1993, J ANDROL, V14, P340; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TUNG K, 1988, HOSP PRACT, V23, P191; TUNG K, 1988, HOSP PRACT OFF ED, V23, P205; TUNG K, 1988, HOSP PRACT OFF ED, V23, P201; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VERGOUWEN RPFA, 1991, J REPROD FERTIL, V93, P233, DOI 10.1530/jrf.0.0930233; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WISDOM BJ, 1992, CONNECT TISSUE RES, V27, P225, DOI 10.3109/03008209209006998; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1992, J BIOL CHEM, V267, P12475; [No title captured]	66	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17023	17032		10.1074/jbc.272.27.17023	http://dx.doi.org/10.1074/jbc.272.27.17023			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202017	hybrid			2022-12-27	WOS:A1997XH44600049
J	Matsumoto, A; Mitchell, A; Kurata, H; Pyle, L; Kondo, K; Itakura, H; Fidge, N				Matsumoto, A; Mitchell, A; Kurata, H; Pyle, L; Kondo, K; Itakura, H; Fidge, N			Cloning and characterization of HB2, a candidate high density lipoprotein receptor - Sequence homology with members of the immunoglobulin superfamily of membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; RAT; PURIFICATION; LIVER; EXPRESSION; CELLS; ACID	The protection against coronary artery disease attributed to high density lipoprotein (HDL) may be associated with several functions, including its central role in reverse cholesterol transport, possible antioxidant and antithrombotic properties and others not yet identified which may depend on specific interactions between HDL and cell receptors. Several HDL-binding proteins have been identified including two candidate liver HDL receptors, HB1 and HB2 recently purified in this laboratory, We now report the cloning, sequencing and some properties of HB2, the most abundant of the pair, it shows significant homology with the adhesion molecules ALCAM and BEN of the immunoglobulin superfamily and the cDNA, when transfected into HepG2 or eos cells, caused specific HDL3 binding to increase by 80-100%. Further, ligand blotting of glycoproteins isolated from phorbol 12-myristate 13-acetate-treated THP-1 cells or from transfected HepG2 and Chinese hamster ovary cells also provided evidence of increased binding of HDL3 to HB2, Differentiation of THP-1 cells into macrophages resulted in a striking increase in HB2 mRNA which was attenuated if cells were cholesterol-loaded by incubation with attenuated law density lipoprotein. If the interaction between HDL and NE, reduces the adhesion-induced inflammatory cellular events that characterize arterial wall injury, thereby achieving the protect-ion associated with higher plasma levels of HDL, these findings may provide a clue to one mitigating effect of HDL in heart disease.	BAKER MED RES INST,MELBOURNE,VIC 3181,AUSTRALIA; NATL INST HLTH & NUTR,TOKYO 162,JAPAN	Baker Heart and Diabetes Institute; National Institute of Health & Nutrition - Japan								Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AILHAUD G, 1992, CURR OPIN LIPIDOL, V3, P222; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOND HM, 1991, BIOCHEM J, V279, P633, DOI 10.1042/bj2790633; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; DECROM RPG, 1994, ARTERIOSCLER THROMB, V14, P305, DOI 10.1161/01.ATV.14.2.305; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; KAGAMI A, 1985, J LIPID RES, V26, P705; LUTTON C, 1994, CR ACAD SCI III-VIE, V317, P731; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MATHAI D, 1990, ARTERIOSCLEROSIS, V10, P1045, DOI 10.1161/01.ATV.10.6.1045; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; Tribble DL, 1995, J LIPID RES, V36, P2580; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; ZEIHER AM, 1994, CIRCULATION, V89, P2525, DOI 10.1161/01.CIR.89.6.2525	24	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16778	16782		10.1074/jbc.272.27.16778	http://dx.doi.org/10.1074/jbc.272.27.16778			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201982	hybrid			2022-12-27	WOS:A1997XH44600014
J	Schwarz, O; Schurmann, P; Strotmann, H				Schwarz, O; Schurmann, P; Strotmann, H			Kinetics and thioredoxin specificity of thiol modulation of the chloroplast H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ENERGY-DEPENDENT CHANGES; GAMMA-SUBUNIT; SPINACH-CHLOROPLASTS; CDNA SEQUENCE; SYNTHASE; ACTIVATION; PHOTOPHOSPHORYLATION; CONFORMATION; HYDROLYSIS	The kinetics of thiol modulation of the chloroplast H+-ATPase (CF0CF1) in membrana were analyzed by employing thioredoxins that were kept reduced by 0.1 mM dithiothreitol. The kinetics of thiol modulation depend on the extent of the proton gradient. The process is an exponential function of the thioredoxin concentration and reaction time and can be described by an irreversible second order reaction. The results indicate that the formation of the complex between thioredoxin and CF0CF1 is slow compared with the subsequent reduction step. Furthermore we have compared the efficiencies of the Escherichia coli thioredoxin Trx and the two chloroplast thioredoxins Tr-m and Tr-f. The second order rate constants are 0.057 (Tr-f), 0.024 (Trx), and 0.010 s(-1) mu M-1 (Tr-m) suggesting that Tr-f rather than Tr-m is the physiological reductant for the chloroplast ATPase. The often employed artificial reductant dithiothreitol exhibits a second order rate constant in thiol modulation of 1.02.10(-6) s(-1) mu M-1.	UNIV DUSSELDORF,INST BIOCHEM PFLANZEN,D-40225 DUSSELDORF,GERMANY; UNIV NEUCHATEL,LAB BIOCHIM VEGETALE,CH-2007 NEUCHATEL,SWITZERLAND	Heinrich Heine University Dusseldorf; University of Neuchatel								AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BAKKERGRUNWALD T, 1974, BIOCHIM BIOPHYS ACTA, V347, P290, DOI 10.1016/0005-2728(74)90052-8; BARZVI D, 1980, FEBS LETT, V119, P68, DOI 10.1016/0014-5793(80)80999-9; BUCHANAN BB, 1979, TRENDS BIOCHEM SCI, V4, P93, DOI 10.1016/0968-0004(79)90191-9; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DANN MS, 1992, PLANT PHYSIOL, V99, P153, DOI 10.1104/pp.99.1.153; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GALMICHE JM, 1990, BIOCHIMIE, V72, P25, DOI 10.1016/0300-9084(90)90169-H; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GROTH G, 1995, FEBS LETT, V358, P142, DOI 10.1016/0014-5793(94)01414-V; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; KOTHEN G, 1995, BBA-BIOENERGETICS, V1229, P208, DOI 10.1016/0005-2728(95)00005-4; LOHSE D, 1989, BIOCHIM BIOPHYS ACTA, V976, P94, DOI 10.1016/S0005-2728(89)80193-8; LOHSE D, 1989, BIOCHIM BIOPHYS ACTA, V976, P85, DOI 10.1016/S0005-2728(89)80192-6; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MCKINNEY DW, 1977, PHYTOCHEMISTRY, V17, P794; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1984, J BIOL CHEM, V269, P7281; PANCIC PG, 1993, FEBS LETT, V320, P61, DOI 10.1016/0014-5793(93)81658-M; PETRACK B, 1965, J BIOL CHEM, V240, P906; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SCHUMANN J, 1981, PHOTOSYNTHESIS, V2, P881; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; SHOSHAN V, 1979, J BIOL CHEM, V254, P8801; STRELOW F, 1993, FEBS LETT, V323, P19, DOI 10.1016/0014-5793(93)81439-7; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; STROTMANN H, 1987, FEBS LETT, V221, P265, DOI 10.1016/0014-5793(87)80938-9; STROTMANN H, 1984, ANNU REV PLANT PHYS, V35, P97; STROTMANN H, 1973, BIOCHIM BIOPHYS ACTA, V314, P202, DOI 10.1016/0005-2728(73)90135-7; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; VanWalraven HS, 1996, FEBS LETT, V379, P309, DOI 10.1016/0014-5793(95)01536-1; WEISS MA, 1977, J BIOL CHEM, V252, P8007; WERNER S, 1990, FEBS LETT, V261, P204, DOI 10.1016/0014-5793(90)80671-5; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1977, NATURE, V266, P565, DOI 10.1038/266565a0; YU LM, 1988, J BIOL CHEM, V263, P19342	44	82	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16924	16927		10.1074/jbc.272.27.16924	http://dx.doi.org/10.1074/jbc.272.27.16924			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202002	Green Submitted, hybrid			2022-12-27	WOS:A1997XH44600034
J	Zhang, N; Zhong, R; Wang, ZY; Deuel, TF				Zhang, N; Zhong, R; Wang, ZY; Deuel, TF			Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFIN REGULATORY PEPTIDE; HEPARIN-BINDING-PROTEIN; DEVELOPING BRAIN; CELLS; EXPRESSION; CLONING; ACID; PURIFICATION; MOUSE; TUMOR	Pleiotrophin (PTN) is a recently described 18- kDa heparin binding growth/differentiation factor. It also is a proto-oncogene; cells transformed by the Ptn gene form highly angiogenic tumors when implanted into the nude mouse. PTN may be an important regulator of transformation in other tumors, because constitutively high levels of expression of the pleiotrophin (Ptn) gene are found in human breast cancer and other malignant cell lines, and its levels of expression are high in many human tumor specimens. To determine whether PTN is an important regulator of the malignant phenotype of human breast cancer cells, we constructed a mutant cDNA to encode a truncated PTN designed to heterodimerize with the product of the endogenous Ptn gene during processing, The mutant gene product blocked transformation of NIH 3T3 cells by the wild type (wt) Ptn gene product, The mutant Ptn cDNA was then introduced into human breast cancer MDA-MB-231 cells, and clonal lines that stably express the mutant Ptn cDNA were selected. The truncated PTN was shown to form heterodimers with the endogenous Ptn gene product in these cells. Furthermore, the MDA-MB-231 cells that express the mutant Ptn gene were no longer transformed; they failed to form plaques or colonies in soft agar and were unable to form tumors in the athymic nude mouse, The results establish an important role of PTN in the dysregulated growth of human breast cancer cells and suggest that constitutive expression of PTN may be essential to the malignant phenotype of human breast cancers in vivo.	HARVARD UNIV, SCH MED,DIV GROWTH REGULAT, BETH ISRAEL DEACONESS MED CTR,DEPT MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NCI NIH HHS [CA66029, CA49712-06] Funding Source: Medline; NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712, R01CA066029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 1996, MOL CARCINOGEN, V17, P112, DOI 10.1002/(SICI)1098-2744(199611)17:3<112::AID-MC2>3.0.CO;2-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; FABRI L, 1992, BIOCHEM INT, V28, P1; FANG WJ, 1992, J BIOL CHEM, V267, P25889; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TSUTSUI J, 1993, CANCER RES, V53, P1281; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YEH HJ, 1993, 23 ANN M SOC NEUR; ZHOU HY, 1992, BIOCHEM BIOPH RES CO, V186, P1288, DOI 10.1016/S0006-291X(05)81545-1	26	75	81	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16733	16736		10.1074/jbc.272.27.16733	http://dx.doi.org/10.1074/jbc.272.27.16733			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201975	hybrid			2022-12-27	WOS:A1997XH44600007
J	Barrie, AP; Clohessy, AM; Buensuceso, CS; Rogers, MV; Allen, JM				Barrie, AP; Clohessy, AM; Buensuceso, CS; Rogers, MV; Allen, JM			Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a ras-independent, mitogen-activated protein kinase ERK kinase 1 or 2-dependent manner in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; 38-AMINO ACID FORM; MAP KINASE; SUSTAINED ACTIVATION; NEURITE OUTGROWTH; B-RAF; DIFFERENTIATION; POLYPEPTIDE; EXPRESSION; INHIBITION	Sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) is critical for initiating differentiation of the PC12 cell to a sympathetic-like neurone. The neuropeptide, pituitary adenylyl cyclase-activating peptide (PACAP), has been demonstrated to cause cell to adopt a neuronal phenotype, although the mechanism of this activity is unclear. PACAP through its type I receptor stimulates a biphasic activation of ERK1/2; a > 10-fold increase within 5 min, followed by a > 5-fold increase that is sustained for greater than or equal to 60 min. An equivalent stimulation is seen in PC12 cells expressing a dominant negative Ras mutant. However, the mitogen-activated kinase/ERK kinase 1/2 (MEK1/2) inhibitor PD98059 blocked both PACAP-induced stimulation of ERK1/2 activity and neurite outgrowth. Thus, activation signal from the PACAP type I receptor on the ERK1/2 cascade pathway is received downstream of Ras, either at Raf or MEK. Down-regulation of protein kinase C or its inhibition by calphostin C blocked the ability of PACAP to stimulate ERK1/2. We conclude that activation of PACAP type I receptor activates protein kinase C, which then activates the ERK1/2 cascade in a Ras-independent manner at either Raf or MEK1/2.	UNIV GLASGOW,DEPT MED & THERAPEUT,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; GLAXO WELLCOME RES & DEV LTD,CELLULAR BIOASSAY DESIGN GRP,LEAD DISCOVERY UNIT,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND	University of Glasgow; University of Glasgow; GlaxoSmithKline					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P3; BRAAS KM, 1994, ENDOCRINOLOGY, V134, P186, DOI 10.1210/en.134.1.186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENSUCESO BS, 1995, THESIS U LONDON; COLBERT RA, 1994, J NEUROSCI, V14, P7141; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUKUDA M, 1995, ONCOGENE, V11, P239; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STORM SM, 1990, ONCOGENE, V5, P345; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSAO H, 1990, J BIOL CHEM, V265, P15471; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wolf N, 1995, NEUROSCI LETT, V200, P207, DOI 10.1016/0304-3940(95)12116-L; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	34	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19666	19671		10.1074/jbc.272.32.19666	http://dx.doi.org/10.1074/jbc.272.32.19666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242621	hybrid			2022-12-27	WOS:A1997XQ05900008
J	Dang, QD; Sabetta, M; DiCera, E				Dang, QD; Sabetta, M; DiCera, E			Selective loss of fibrinogen clotting in a loop-less thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOMODULIN; ANTICOAGULANT	The autolysis loop of thrombin comprises nine residues, from Glu(146) to Lys(149e), five of which (Ala(149a)-Lys(149e)) are inserted relative to trypsin and chymotrypsin. Deletion of the insertion Ala(149a)-Lys(149e) causes no significant change in the properties of the enzyme, except for a slight enhancement of protein C activation. Deletion of the entire Glu(146)-Lys(149e) loop, however, reduces fibrinogen clotting 240-fold, but decreases protein C activation only 2-fold. This loop-less mutant is de facto an exclusive activator of protein C, having lost the primary procoagulant function of thrombin. Because the autolysis loop affects fibrinogen binding, but not protein C activation, it provides a target for new drugs designed to suppress exclusively the procoagulant activity of thrombin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; BODE W, 1992, PROTEIN SCI, V1, P426; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	18	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19649	19651		10.1074/jbc.272.32.19649	http://dx.doi.org/10.1074/jbc.272.32.19649			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242618	hybrid			2022-12-27	WOS:A1997XQ05900005
J	Langlands, K; Yin, XY; Anand, G; Prochownik, EV				Langlands, K; Yin, XY; Anand, G; Prochownik, EV			Differential interactions of Id proteins with basic-helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; DNA-BINDING MOTIF; IMMUNOGLOBULIN ENHANCER; HETERO-OLIGOMERIZATION; CRYSTAL-STRUCTURE; INSULIN GENE; MUSCLE; RECOGNITION; ACTIVATION; DOMAIN	Dimerization of three Id proteins (Idl, Id2, and Id3) with the four class A E proteins (E12, E47, E2-2, and HEB) and two groups of class B proteins, the myogenic regulatory factors (MRFs: MyoD, myogenin, Myf-5 and MRF4/Myf-6), and the hematopoietic factors (Scl/Tal-1, Tal-2, and Lyl-1) were tested in a quantitative yeast 2-hybrid assay, All three Ids bound with high affinity to E proteins, but a much broader range of interactions was observed between Ids and the class B factors, Idl and Id2 interacted strongly with MyoD;and Myf-5 and weakly with myogenin and MRF4/Myf-6, whereas Id3 interacted weakly with all four MRFs. Similar specificities were observed in co-immunoprecipitation and mammalian a-hybrid analyses, No interactions were found between the Ids and any of the hematopoietic factors, Each Id was able to disrupt the ability of E protein-MyoD complexes to transactivate from a muscle creatine kinase reporter construct in vivo, Finally, mutagenesis experiments showed that the differences between Idl and Id3 binding map to three amino acids in the first helix and to a small cluster of upstream residues, The Id proteins thus display a signature range of interactions with all of their potential dimerization partners and may play a role in myogenesis which is distinct from that in hematopoiesis.	CHILDRENS HOSP, MED CTR, HEMATOL ONCOL SECT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, INST CANC, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Langlands, Kenneth/0000-0001-7629-9967	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEED RW, 1993, ONCOGENE, V8, P599; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1992, TRANSCRIPTIONAL REGU, P1037; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SOOSAAR A, 1994, MOL BRAIN RES, V25, P176, DOI 10.1016/0169-328X(94)90297-6; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	71	189	193	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19785	19793		10.1074/jbc.272.32.19785	http://dx.doi.org/10.1074/jbc.272.32.19785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242638	hybrid			2022-12-27	WOS:A1997XQ05900025
J	Rothermel, BA; Thornton, JL; Butow, RA				Rothermel, BA; Thornton, JL; Butow, RA			Rtg3p, a basic helix-loop-helix/leucine zipper protein that functions in mitochondrial-induced changes in gene expression, contains independent activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ENCODING PEROXISOMAL PROTEINS; SACCHAROMYCES-CEREVISIAE; DIOXIN RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ORGANELLE COMMUNICATION; CRYSTAL-STRUCTURE; RECOGNITION; YEAST	Rtg3p and Rtg1p are basic helix-loop helix/leucine zipper protein transcription factors in yeast that interact and bind to sites in an upstream activation sequence element in the 5'-flanking region of CIT2, a gene encoding a peroxisomal isoform of citrate synthase, These factors are required both for basal expression of CIT2 and its elevated expression in cells with dysfunctional mitochondria, such as in respiratory-deficient petite cells lacking mitochondrial DNA (rho degrees), This elevated expression of CIT2 is called the retrograde response, Here we show that fusion constructs between the Gal4p DNA binding domain and Rtg3p transactivate the expression of a LacZ reporter gene under the control of a GAL1 promoter element, We have identified two activation domains in Rtg3p: a strong carboxyl-terminal domain from amino acids 375-486, and a weaker amino-terminal domain from amino acids 1-175; neither of these activation domains contain the bHLH/Zip motif. We have also identified a serine/threonine-rich domain of Rtg3p within amino acids 176-282 that is inhibitory to transactivation, In addition, the transcriptional activity of the Gal4-Rtg3p fusion proteins does not require either Rtg1p or Rtg2p; the latter is a protein containing an hsp70-like ATP binding domain that is also necessary for CIT2 expression, In contrast, transcriptional activation by Gal4-Rtg1p fusion proteins requires the Rtg1p basic helix-loop-helix/leucine zipper protein domain, as well as Rtg3p and Rtg2p, These data suggest that transcriptional activation by the Rtg1p-Rtg3p complex is largely the function of Rtg3p, Experiments are also presented suggesting that Rtg3p is limiting for gene expression in respiratory-competent (rho(+)) cells.	UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; PROBST MR, 1993, MOL PHARMACOL, V44, P511; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; ROTHERMEL BA, 1995, J BIOL CHEM, V49, P29476; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VERMA IM, 1995, GENE DEV, V9, P2728; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	48	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19801	19807		10.1074/jbc.272.32.19801	http://dx.doi.org/10.1074/jbc.272.32.19801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242640	hybrid			2022-12-27	WOS:A1997XQ05900027
J	Fiorentini, C; Fabbri, A; Flatau, G; Donelli, G; Matarrese, P; Lemichez, E; Falzano, L; Boquet, P				Fiorentini, C; Fabbri, A; Flatau, G; Donelli, G; Matarrese, P; Lemichez, E; Falzano, L; Boquet, P			Escherichia coli cytotoxic necrotizing factor 1 (CNF1), a toxin that activates the Rho GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEINS-RHO; GROWTH-FACTOR; LETHAL TOXIN; CELLS; RAC; PURIFICATION; BORDETELLA; 3-KINASE; MYOSIN	Cytotoxic necrotizing factor 1 (CNF1), a 110-kDa protein toxin from pathogenic Escherichia coli induces actin reorganization into stress fibers and retraction fibers in human epithelial cultured cells allowing them to spread. CNF1 is acting in the cytosol since microinjection of the toxin into HEp-2 cells mimics the effects of the externally applied CNF1. Incubation in vitro of CNF1 with recombinant small GTPases induces a modification of Rho (but not of Pac, Cdc42, Pas, or Rab6) as demonstrated by a discrete increase in the apparent molecular weight of the molecule. Preincubation of cells with CNF1 impairs the cytotoxic effects of Clostridium difficile toxin B, which inactivates Rho but not those of Clostridium sordellii LT toxin, which inhibits Ras and Rac. As shown for Rho-GTP, CNF1 activates, in a time- and dose-dependent manner, a cytoskeleton-associated phosphatidylinositol 4-phosphate 5-kinase. However, neither the phosphatidylinositol 4,5-bisphosphate (PIP2) nor the phosphatidylinositol 3,4-bisphosphate (PI 3,4-P-2) or 3,4,5-trisphosphate (PIP3) cellular content were found increased in CNF1 treated HEp-2 cells. Cellular effects of CNF1 were not blocked by LY294002, a stable inhibitor of the phosphoinositide 3-kinase. Incubation of HEp-2 cells with CNF1 induces relocalization of myosin 2 in stress fibers but not in retraction fibers. Altogether, our data indicate that CNF1 is a toxin that selectively activates the Rho GTP-binding protein, thus inducing contractility and cell spreading.	FAC MED,INSERM,U452,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Fiorentini, C (corresponding author), IST SUPER SANITA,DEPT ULTRASTRUCT,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Fiorentini, Carla/Q-2088-2015; Lemichez, Emmanuel/G-3559-2013; Matarrese, Paola/A-4369-2014; FIORENTINI, CARLA/AAG-8005-2019; Fabbri, Alessia/AAA-4594-2019	Fiorentini, Carla/0000-0003-1707-6282; Lemichez, Emmanuel/0000-0001-9080-7761; FIORENTINI, CARLA/0000-0003-1707-6282; Fabbri, Alessia/0000-0002-3075-3367; matarrese, paola/0000-0001-5477-3752; falzano, loredana/0000-0003-4074-180X				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1994, ZBL BAKT S, V24, P404; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KLOTZ C, 1986, J CELL BIOL, V103, P613, DOI 10.1083/jcb.103.2.613; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OSTERMAN A, 1993, J MUSCLE RES CELL M, V14, P186, DOI 10.1007/BF00115453; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SEKINE A, 1989, J BIOL CHEM, V264, P8602; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; ZALCMAN G, 1995, ONCOGENE, V10, P1935	38	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19532	19537		10.1074/jbc.272.31.19532	http://dx.doi.org/10.1074/jbc.272.31.19532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235957	hybrid			2022-12-27	WOS:A1997XP06300063
J	Stulnig, TM; Berger, M; Sigmund, T; Stockinger, H; Horejsi, V; Waldhausl, W				Stulnig, TM; Berger, M; Sigmund, T; Stockinger, H; Horejsi, V; Waldhausl, W			Signal transduction via glycosyl phosphatidylinositol-anchored proteins in T cells is inhibited by lowering cellular cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES P56(LCK); DECAY-ACCELERATING FACTOR; ALKALINE-PHOSPHATASE; IL-2 PRODUCTION; LYMPHOCYTES-T; DETERGENT INSOLUBILITY; SURFACE EXPRESSION; COUNTER-RECEPTOR; HUMAN MONOCYTES; CO-EXPRESSION	Glycosylphosphatidylinositol (GPI)-anchored proteins can deliver costimulatory signals to lymphocytes, but the exact pathway of signal transduction involved is not yet characterized. GPI anchored proteins are fixed to the cell surface solely by a phospholipid moiety and are clustered in distinct membrane domains that are formed by an unique lipid composition requiring cholesterol. To elucidate the role of membrane lipids for signal transduction via GPI-anchored proteins, we studied the influence of reduced cellular cholesterol content on calcium signaling via GPI-anchored CD59 and CD48 in Jurkat T cells. Lowering cholesterol by different inhibitors of cellular cholesterol synthesis suppressed calcium response via GPI anchored proteins by about 50%, whereas stimulation via CD3 was only minimally affected (<10%). The decrease in overall calcium response via GPI-anchored proteins was reflected by inhibition of calcium release from intracellular stores. Cell surface expression of GPI-anchored proteins was not changed quantitatively by lowering cellular cholesterol, and neither was the pattern of immunofluorescence in microscopic examination. In addition, the distribution of GPI-anchored proteins in detergent-insoluble complexes remained unaltered. These results suggest that cellular cholesterol is an important prerequisite for signal transduction via GPI-anchored proteins beyond formation of membrane domains.	UNIV VIENNA,INST IMMUNOL,VIENNA INT RES COOPERAT CTR,A-1235 VIENNA,AUSTRIA; ACAD SCI CZECH REPUBL,INST MOL GENET,CR-14220 PRAGUE 4,CZECH REPUBLIC	University of Vienna; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Stulnig, TM (corresponding author), UNIV VIENNA,DEPT INTERNAL MED 3,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Horejsi, Vaclav/G-3113-2014; Stockinger, Hannes/E-5173-2011	Horejsi, Vaclav/0000-0003-4925-0142; Stockinger, Hannes/0000-0001-6404-4430; Stulnig, Thomas/0000-0003-3300-6161				BARBONI E, 1995, J CELL SCI, V108, P487; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; CINEK T, 1992, J IMMUNOL, V149, P2262; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CODIAS EK, 1992, J IMMUNOL, V149, P1825; COOK RG, 1992, CELL IMMUNOL, V144, P367, DOI 10.1016/0008-8749(92)90252-K; DAVIS LS, 1988, J IMMUNOL, V141, P2246; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DECKERT M, 1995, EUR J IMMUNOL, V25, P1815, DOI 10.1002/eji.1830250704; DIANZANI U, 1993, J IMMUNOL, V151, P3961; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ESFAHANI M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P217, DOI 10.1016/0005-2736(93)90204-D; FLEMING TJ, 1994, J IMMUNOL, V153, P1955; FRA AM, 1994, J BIOL CHEM, V269, P30745; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HAHN AB, 1989, J IMMUNOL, V143, P407; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; HAVRAN WL, 1988, J IMMUNOL, V140, P1034; IVANOV V, 1994, J IMMUNOL, V153, P2394; KATO K, 1993, EUR J IMMUNOL, V23, P1412, DOI 10.1002/eji.1830230638; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KLICKSTEIN LB, 1995, LEUKOCYTE TYPING, V5, P1476; KNIEP B, 1994, BIOCHEM BIOPH RES CO, V203, P1069, DOI 10.1006/bbrc.1994.2291; KORTY PE, 1991, J IMMUNOL, V146, P4092; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; KROCZEK RA, 1986, J IMMUNOL, V136, P4379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCKI DW, 1995, J IMMUNOL, V154, P4363; LEE SK, 1994, EMBO J, V13, P2167, DOI 10.1002/j.1460-2075.1994.tb06493.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; MASAIA M, 1990, J IMMUNOL, V145, P1664; MASCHEK BJ, 1993, J IMMUNOL, V150, P3198; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; MULLER CP, 1983, J IMMUNOL, V131, P1356; REISER H, 1990, J IMMUNOL, V145, P2077; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROWAN WC, 1909, INT IMMUNOL, V7, P69; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SOLOMON R, 1996, P NATL ACAD SCI USA, V93, P6053; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STULNIG TM, 1995, J GERONTOL A-BIOL, V50, pB383, DOI 10.1093/gerona/50A.6.B383; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; THELIN A, 1994, BIOCHIM BIOPHYS ACTA, V1215, P145; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; XIE MS, 1995, BIOCHEM J, V305, P529, DOI 10.1042/bj3050529	64	103	104	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19242	19247		10.1074/jbc.272.31.19242	http://dx.doi.org/10.1074/jbc.272.31.19242			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235917	hybrid			2022-12-27	WOS:A1997XP06300023
J	Ladner, RD; Caradonna, SJ				Ladner, RD; Caradonna, SJ			The human dUTPase gene encodes both nuclear and mitochondrial isoforms - Differential expression of the isoforms and characterization of a cDNA encoding the mitochondrial species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHASE GENE; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CYTO-TOXICITY; MESSENGER-RNA; DNA-SYNTHESIS; CELLS; INHIBITION; ENZYME	We have previously identified distinct nuclear and mitochondrial isoforms of dUTPase in human cells, reporting the cDNA sequence of the nuclear isoform (DUT-N), We now report a cDNA corresponding to the mitochondrial isoform (DUT-M), The DUT-M cDNA contains an 252-amino acid open reading frame, encoding a protein with a predicted M-r of 26,704, The amino-terminal region of the protein contains an arginine-rich, 69-residue mitochondrial targeting presequence that is absent in the mature protein. In vitro transcription and translation of the DUT-M cDNA results in the production of a precursor protein with an apparent molecular mass of 31 kDa as judged by SDS-polyacrylamide gel electrophoresis. The DUT-M precursor is enzymatically active and immunoreacts with a dUTPase specific monoclonal antibody, Mitochondrial import and processing studies demonstrate that the DUT-M precursor is processed into a 23-kDa protein and imported into mitochondria in vitro, Isoelectric focusing experiments demonstrate that the DUT-N has a pI of 6.0, while the processed form of DUT-M has a more basic pI of 8.1, measurements that are in agreement with predicted values, Studies aimed at understanding the expression of these isoforms were performed utilizing quiescent and replicating 34Lu human lung fibroblasts as a model cell culture system, Northern blot analysis, employing an isoform specific probe, demonstrates that DUT-N and DUT-M are encoded by two distinct mRNA species of 1.1 and 1.4 kilobases, respectively, Western and Northern blot analysis reveal that DUT-M protein and mRNA are expressed in a constitutive fashion, independent of cell cycle phase or proliferation status, In contrast, DUT-N protein and mRNA levels are tightly regulated to coincide with nuclear DNA replication status, Because DUT-N and DUT-M have identical amino acid and cDNA sequences in their overlapping regions, we set out to determine if they were encoded by the same gene, The 5' region of the gene encoding dUTPase was isolated and characterized by a combination of Southern hybridization and DNA sequencing, These analyses demonstrate that the dUTPase isoforms are encoded by the same gene with isoform-specific transcripts arising through the use of alternative 5' exons, This finding represents the first example in humans of alternative 5' exon usage to generate differentially expressed nuclear and mitochondrial specific protein isoforms.			Ladner, RD (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT MOL BIOL,2 MED CTR DR,STRATFORD,NJ 08084, USA.		Caradonna, Salvatore/AFU-8514-2022	Caradonna, Salvatore/0000-0002-2104-581X	NATIONAL CANCER INSTITUTE [R01CA042605] Funding Source: NIH RePORTER; NCI NIH HHS [CA42605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Beck W R, 1986, Adv Exp Med Biol, V195 Pt B, P97; CANMAN CE, 1994, CANCER RES, V54, P2296; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Cohen D, 1997, GENOMICS, V40, P213, DOI 10.1006/geno.1996.4540; CURTIN NJ, 1991, CANCER RES, V51, P2346; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Duyao M P, 1992, Curr Top Microbiol Immunol, V182, P421; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; JENH CH, 1985, MOL CELL BIOL, V5, P2527, DOI 10.1128/MCB.5.10.2527; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MAJELLO B, 1995, ONCOGENE, V10, P1841; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; NEVINS JR, 1992, SCIENCE, V258, P424; PARDO EG, 1990, EXP CELL RES, V186, P90, DOI 10.1016/0014-4827(90)90214-U; PETROVABENEDICT R, 1987, AM J HUM GENET, V40, P257; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; SEDWICK WD, 1981, P NATL ACAD SCI-BIOL, V78, P917, DOI 10.1073/pnas.78.2.917; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; TUBOI S, 1990, ADV ENZYME REGUL, V30, P289	41	82	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19072	19080		10.1074/jbc.272.30.19072	http://dx.doi.org/10.1074/jbc.272.30.19072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228092	hybrid			2022-12-27	WOS:A1997XM34200083
J	Thiriet, C; Hayes, JJ				Thiriet, C; Hayes, JJ			Antisera directed against anti-histone H4 antibodies recognize linker histones - Novel immunological probes to detect histone interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CHROMATIN SUBUNITS; NUCLEOSOMAL DNA; ACETYLATION; ORGANIZATION; RESOLUTION; PROTEINS; OCTAMER; SURFACE; TAILS	We introduce a novel immunological approach to detect structural interactions between chromosomal proteins, Antigenically pure core histone H4 was prepared from chicken erythrocytes and used to produce antihistone H4 antisera, IgG fractions were isolated from purified anti-H4 antibodies and used as antigens to produce ''second generation'' antisera. Epitopes cross-reacting with the second generation antisera were then identified within chromosomal proteins, These epitopes were presumed to mimic the complementary molecular surface of the original anti-H4 antibodies, and thus proteins containing these epitopes were putatively identified as specific ligands of H4 in chromatin, Surprisingly, we found this immunoreactivity was predominantly directed against H1 compared with H5 from chicken erythrocytes. Further, the immunoreactive epitopes were located within the C-terminal tail domain of the linker histones, These results suggest similar complementary interactions occur between H4 and the C-terminal tail domain of H1s in native chromatin, This could occur either within a single nucleosome as suggested by a previous report (Baneres, J.-L., Essalouh, L., Jariel-Encontre, I., Mesnier, D., Garrod, S., and Parello, J. (1994) J. Mol. Biol., 243, 48-59) or between neighboring nucleosomes within the condensed chromatin fiber, The implications of these results with regard to the structure of the chromatin fiber and the future utility of this technique are discussed.	UNIV ROCHESTER, MED CTR, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester					NIGMS NIH HHS [R01GM52426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BANERES JL, 1994, J MOL BIOL, V243, P48, DOI 10.1006/jmbi.1994.1629; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Bustin M, 1979, Curr Top Microbiol Immunol, V88, P105; DOUSSON S, 1989, EUR J IMMUNOL, V19, P1123, DOI 10.1002/eji.1830190624; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; HACQUES MF, 1990, BIOCHEM BIOPH RES CO, V168, P637, DOI 10.1016/0006-291X(90)92368-A; HARLOW E, 1988, ANTIBODIES; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; Karantza V, 1996, BIOCHEMISTRY-US, V35, P2037, DOI 10.1021/bi9518858; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIDL P, 1987, J BIOL CHEM, V262, P10195; MENDELSON E, 1984, BIOCHEMISTRY-US, V23, P3459, DOI 10.1021/bi00310a012; MULLER S, 1982, EMBO J, V1, P421, DOI 10.1002/j.1460-2075.1982.tb01185.x; MULLER S, 1985, FEBS LETT, V182, P459, DOI 10.1016/0014-5793(85)80354-9; MULLER S, 1982, EMBO J, V1, P939, DOI 10.1002/j.1460-2075.1982.tb01275.x; MULLER S, 1991, MOL IMMUNOL, V28, P763, DOI 10.1016/0161-5890(91)90119-5; MULLER S, 1989, METHOD ENZYMOL, V170, P431; NOTHACKER KD, 1986, EUR J CELL BIOL, V39, P278; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; STOLLAR BD, 1970, J BIOL CHEM, V245, P1261; STROSBERG AD, 1983, SPRINGER SEMIN IMMUN, V6, P67, DOI 10.1007/BF01857367; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THIRIET C, 1995, ELECTROPHORESIS, V16, P357, DOI 10.1002/elps.1150160161; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TURNER BM, 1981, EUR J CELL BIOL, V24, P266; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde KE., 1989, SPRINGER SERIES MOL; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wolffe A., 1995, CHROMATIN STRUCTURE	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18740	18745		10.1074/jbc.272.30.18740	http://dx.doi.org/10.1074/jbc.272.30.18740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228046	hybrid			2022-12-27	WOS:A1997XM34200037
J	Balla, T; Downing, GJ; Jaffe, H; Kim, S; Zolyomi, A; Catt, KJ				Balla, T; Downing, GJ; Jaffe, H; Kim, S; Zolyomi, A; Catt, KJ			Isolation and molecular cloning of wortmannin-sensitive bovine type III phosphatidylinositol 4-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; BINDING PROTEIN; PURIFICATION; GENE; CELLS; PHOSPHORYLATION; TRANSFORMATION	Agonist-sensitive phosphoinositide pools are maintained by recently-identified wortmannin (WT)-sensitive phosphatidylinositol (PI) 4-kinase(s) (Nakanishi, S., Catt, K. J., and Balla, T. (1995) Proc, Natl. Acad. Sci, U.S.A. 92, 5317-5321). Two loosely membrane-associated WT-sensitive type III: PI 4-kinases were isolated from bovine adrenal cortex as [H-3]WT-labeled 110- and 210-kDa proteins, Based on peptide sequences from the smaller enzyme, a 3.9-kilobase pair (kb) cDNA with an open reading frame encoding a 90-kDa protein was isolated from a bovine brain cDNA library, Expression of this cDNA in COS-7 cells yielded a 110-kDa protein with WT-sensitive PI 4-kinase activity. Northern blot analysis of a human mRNA panel showed a single similar to 3.8-kb transcript. Peptide sequences obtained from the 210-kDa enzyme corresponded to those of a recently described rat 230-kDa PI 4-kinase, A 6.5-kb cDNA containing an open reading frame of 6129 nucleotides that encoded a 230-kDa protein, was isolated from brain cDNA, Northern blot analysis of human mRNA revealed a major 7.5-kb transcript, The molecular cloning of these novel WT-sensitive type III PI 4-kinases will allow detailed analysis of their signaling and other regulatory functions in mammalian cells.	NINCDS,LNC,PROT PEPTIDE SEQUENCING FACIL,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Balla, T (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,NIH,BLDG 49,RM 6A36,49 CONVENT DR,BETHESDA,MD 20892, USA.			Balla, Tamas/0000-0002-9077-3335				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen CD, 1996, J BIOL CHEM, V271, P28607, DOI 10.1074/jbc.271.45.28607; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1985, FEBS LETT, V11, P259; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HARWOOD JL, 1969, BIOCHIM BIOPHYS ACTA, V171, P75, DOI 10.1016/0005-2744(69)90107-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIU JP, 1994, J BIOL CHEM, V269, P21043; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MICHELL RH, 1967, BIOCHIM BIOPHYS ACTA, V144, P649, DOI 10.1016/0005-2760(67)90053-7; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PORTER FD, 1988, J BIOL CHEM, V263, P8989; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	52	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18358	18366		10.1074/jbc.272.29.18358	http://dx.doi.org/10.1074/jbc.272.29.18358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218477	hybrid			2022-12-27	WOS:A1997XL73500067
J	Bujacz, G; Alexandratos, J; Wlodawer, A				Bujacz, G; Alexandratos, J; Wlodawer, A			Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; RESOLUTION; PROTEIN; REGION	Retroviral integrases (INs) contain two known metal binding domains, The N-terminal domain includes a zinc finger motif and has been shown to bind Zn2+, whereas the central catalytic core domain includes a triad of acidic amino acids that bind Mn2+ or Mg2+, the metal cofactors required for enzymatic activity, The integration reaction occurs in two distinct steps; the first is a specific endonucleolytic cleavage step called ''processing,'' and the second is a polynucleotide transfer or ''joining'' step, Our previous results showed that the metal preference for in vitro activity of avian sarcoma virus IN is Mn2+ > Mg2+ and that a single cation of either metal is coordinated by two of the three critical active site residues (Asp-64 and Asp-121) in crystals of the isolated catalytic domain, Here, we report that Ca2+, Zn2+, and Cd2+ can also bind in the active site of the catalytic domain, Furthermore, two zinc and cadmium cations are bound at the active site, with all three residues of the active site triad (Asp-64, Asp-121, and Glu-157) contributing to their coordination, These results are consistent with a two-metal mechanism for catalysis by retroviral integrases, We also show that Zn2+ can serve as a cofactor for the endonucleolytic reactions catalyzed by either the full-length protein, a derivative lacking the N-terminal domain, or the isolated catalytic domain of avian sarcoma virus IN, However, polynucleotidyl transferase activities are severely impaired or undetectable in the presence of Zn2+. Thus, although the processing and joining steps of integrase employ a similar mechanism and the same active site triad, they can be clearly distinguished by their metal preferences.	NCI,FREDERICK CANC RES & DEV CTR,MACROMOL STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; TECH UNIV LODZ,FAC FOOD CHEM & BIOTECHNOL,PL-90924 LODZ,POLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Lodz University of Technology			Bujacz, Grzegorz/M-4446-2018	Bujacz, Grzegorz/0000-0002-3787-7522	NCI NIH HHS [CA-06927, CA-47486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BOCK CW, 1995, J AM CHEM SOC, V117, P3754, DOI 10.1021/ja00118a012; Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; OTWINOWSKI Z, 1992, OSCILLATION DATA PRO; RICE P, 1996, CURR OPIN STRUC BIOL, V6, P78; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHENG R, 1996, P NATL ACAD SCI USA, V93, P13639	28	126	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18161	18168		10.1074/jbc.272.29.18161	http://dx.doi.org/10.1074/jbc.272.29.18161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218451	hybrid			2022-12-27	WOS:A1997XL73500041
J	Kataoka, M; Yoshiyama, K; Matsuura, K; Hijiya, N; Higuchi, Y; Yamamoto, S				Kataoka, M; Yoshiyama, K; Matsuura, K; Hijiya, N; Higuchi, Y; Yamamoto, S			Structure of the murine CD156 gene, characterization of its promoter, and chromosomal location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; TRANSCRIPTION FACTOR; METALLOPROTEASE DOMAIN; INSITU HYBRIDIZATION; MEMBRANE-PROTEINS; INTERFERON-GAMMA; REGULATED GENE; DNA-BINDING; FACTOR-I; EXPRESSION	The murine cell surface antigen mCD156 is a glycoprotein that is expressed in monocytic cell limes and consists of a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, and an epidermal growth factor-like domain in the extracellular region, The mCD156 gene is composed of 24 exons and 23 introns and spans approximately 14 kilobases, The first exon encodes most of the signal peptide sequence, and the transmembrane region is encoded by a single exon (19), In contrast, the other regions are composed of multiple exons, Of these, exons 7-12 and 12-15 encode a metalloprotease domain and a disintegrin domain, respectively, Sequence analysis of the 5'-flanking DNA revealed many potential regulatory motifs, Chloramphenicol acetyltransferase analysis demonstrated that nucleotides at positions -183, -334, and -623 contained cis-acting enhancing elements in a mouse monocytic cell line, aHINS-B3, Nucleotides at positions -183 and -390 contained elements responsible for lipopolysaccharide (LPS) inducibility, although several other 5'-flanking regions were also involved in LPS responsiveness, Regions -202, -507, and -659 play a role in interferon-gamma inducibility. Some of the potential regulatory motifs and other unknown cis elements may be involved in the constitutive expression, and LPS and interferon-gamma inducibilities, The mCD156 gene was mapped to chromosome 7, region F3-F4.	OITA MED UNIV,DEPT PATHOL,OITA 87955,JAPAN	Oita University								ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERG AJ, 1978, CELL, V12, P721; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENATHNACH R, 1981, ANN REV BIOCH, V50, P349; Cho CH, 1996, GENOMICS, V34, P413, DOI 10.1006/geno.1996.0305; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CUNIFF NFA, 1991, MOL CELL BIOL, V11, P4; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FENG GS, 1994, ONCOGENE, V9, P1745; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; HEINLEIN UAO, 1994, DEV GROWTH DIFFER, V36, P49; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, FISH DETECTION DAPI; HIGUCHI Y, 1997, TISSUE ANTIGENS, V48, P423; HOWARD DL, 1996, BIOCHEM J, V317, P45; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; KATAGIRI T, 1995, CYTOGENET CELL GENET, V68, P39, DOI 10.1159/000133884; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Maniatis T., 1982, MOL CLONING; MATSUURA K, 1992, J BIOL CHEM, V267, P2787; MAYERS RM, 1986, SCIENCE, V232, P613; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAKOV AN, 1990, J EXP MED, V171, P35; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SHIN HS, 1994, MOL CELL BIOL, V14, P2914, DOI 10.1128/MCB.14.5.2914; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TANAKA T, 1995, CELL, V78, P931; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; Yoshiyama K, 1997, GENOMICS, V41, P56, DOI 10.1006/geno.1997.4607; ZAHNG DE, 1994, MOL CELL BIOL, V14, P373	64	37	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18209	18215		10.1074/jbc.272.29.18209	http://dx.doi.org/10.1074/jbc.272.29.18209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218457	hybrid			2022-12-27	WOS:A1997XL73500047
J	Assaraf, YG; Goldman, ID				Assaraf, YG; Goldman, ID			Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L1210 LEUKEMIA-CELLS; DIHYDROFOLATE-REDUCTASE; BINDING-PROTEINS; TRANSPORT; METHOTREXATE; EFFLUX; PYRIMETHAMINE; MITOCHONDRIA; TRIMETREXATE; EXPRESSION	We previously described a 1,000-fold pyrimethamine-resistant Chinese hamster ovary cell line (Pyr(R100)) which retains parental dihydrofolate reductase activity and methotrexate (MTX) sensitivity, This study characterizes the basis for the 14-fold decrease in folic acid and leucovorin concentrations required for clonogenic growth of pyr(R100) cells relative to parental AA8 cells. Under conditions in which folic acid reduction was blocked by trimetrexate, Pyr(R100) cells displayed relative to parental AAS cells a: 1) 17- and 5-fold increase in the net transport of folic acid and MTX, respectively; 2) 23- and 5-fold decrease in the efflux rate constant for folic acid and MTX, respectively; and 3) a-fold increase in folic acid influx with no significant change in MTX influx. The markedly increased net folic acid transport in Pyr(R100) cells could not be explained by cellular folic acid binding, mitochondrial sequestration, polyglutamylation, nor by a decreased membrane potential. The effect of energy deprivation all folic acid and MTX transport in both cell. lines was quite different. Glucose and pyruvate deprivation nearly abolished the increase in net folic acid transport in Pyr(R100) cells. In contrast, energy deprivation increased net MTX transport in AAS cells, whereas no change was seen with Pyr(R100) cells, Furthermore, while folic acid influx in Pyr(R100) and AA8 cells was markedly reduced with energy deprivation, MTX influx was slot affected, Provision of glucose and pyruvate to energy-deprived cells resulted in a rapid onset of MTX efflux hom parental AAS cells but not from Pyr(R100) cells, Taken together these results indicate that the markedly enhanced net transport of folic acid and MTX in Pyr(R100) cells is largely due to the complete loss of exit pump activity, Furthermore, the energy source that sustains the augmented levels of folic acid appears linked to the influx process and is distinct from the energy source that sustains MTX gradients under these conditions, We conclude that the loss of folic acid efflux is an efficient means of augmenting cellular uptake of folate cofactors and subsequent survival on picomolar folate concentrations, This constitutes the first demonstration of the loss of folic acid exporter activity in mammalian cells as a response to lipophilic antifolate selective pressure.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL; YESHIVA UNIV ALBERT EINSTEIN COLL MED, CTR CANC, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, CTR CANC, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Technion Israel Institute of Technology; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Assaraf, Yehuda G./0000-0001-6692-8221	NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; BLAKELY RD, 1985, FOLATES PTERINS CHEM, V2; BLAKELY RL, 1986, FOLATES PTERINS NUTR, V3; BOBZIEN WF, 1972, J CLIN INVEST, V51, P1688, DOI 10.1172/JCI106970; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; LICHTSTEIN D, 1979, P NATL ACAD SCI USA, V76, P2580, DOI 10.1073/pnas.76.6.2580; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P1143; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; Saxena M, 1996, BIOCHEM J, V320, P273, DOI 10.1042/bj3200273; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SPRECHER H, 1995, J BIOL CHEM, V270, P20668, DOI 10.1074/jbc.270.35.20668; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898	33	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17460	17466		10.1074/jbc.272.28.17460	http://dx.doi.org/10.1074/jbc.272.28.17460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211890	hybrid			2022-12-27	WOS:A1997XK16500033
J	Sato, N; Sadar, MD; Bruchovsky, N; Saatcioglu, F; Rennie, PS; Sato, S; Lange, PH; Gleave, ME				Sato, N; Sadar, MD; Bruchovsky, N; Saatcioglu, F; Rennie, PS; Sato, S; Lange, PH; Gleave, ME			Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-jun in the human prostate cancer cell line LNCaP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; OSTEOCALCIN GENE; RETINOIC ACID; AP-1 SITE; FOS-JUN; C-JUN	In exploring the possible mechanisms of androgen independence of prostate-specific antigen (PSA) gene expression, we investigated the effect of elevating AP-1 by both 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment and transfection of the c-Jun expression vector in LNCaP cells, Transcription of PSA is initiated when ligand-activated androgen receptor (AR) binds to a region in the PSA promoter that contains an androgen-responsive element (ARE), It was found that TPA inhibited androgen-induced PSA gene expression by a mechanism that did not alter nuclear levels of AR protein, Overexpression of AP-1 (jun and fos proteins) also inhibited androgen-induced PSA promoter activity, These observations were apparently related to the disruption of AR ARE complexes as demonstrated by the results of electrophoretic mobility shift assays, Specifically, c-Jun inhibited the formation of AR ARE complexes and conversely that AR-glutathione S-transferase proteins inhibited the formation of c-Jun TPA-responsive element (TRE) complexes, Consistent with the inhibitory effect of both proteins, anti-c-Jun antibody blocked the inhibition of AR.ARE complex formation by c-Jun, A similar, but less marked, effect was obtained when anti-AR antibody was used to prevent AR inhibition of c-Jun TRE complex formation, These findings together with results obtained from co-immunoprecipitation experiments strongly suggest that mutual repression of DNA binding activity is due to direct interaction between the two proteins and that the degree of repression may be determined by the ratio of AR to c-Jun, The mechanism of repression studied in mutant analysis experiments yielded evidence of an interaction between the DNA- and ligand-binding domains of AR and the leucine zipper region of c-Jun, Thus, the AR is similar to other nuclear receptors in its ability to interact with AP-1, This association provides a link between AP-1 and AR signal transduction pathways and may play a role in the regulation of the androgen-responsive PSA gene.	BRITISH COLUMBIA CANC AGCY,DEPT CANC ENDOCRINOL,VANCOUVER,BC V5Z 4E6,CANADA; UNIV CALIF SAN DIEGO,SCH MED,CTR MOL GENET,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195	British Columbia Cancer Agency; University of California System; University of California San Diego; University of Washington; University of Washington Seattle			Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NIDDK NIH HHS [P50 DK47656] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAIGHN ME, 1979, INVEST UROL, V17, P16; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN KH, 1991, BIOTECHNIQUES, V11, P752; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sato N, 1996, J STEROID BIOCHEM, V58, P139, DOI 10.1016/0960-0760(96)00018-0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VERMA IM, 1989, CURR OPIN CELL BIOL, V1, P536; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, CANCER BIOL, V1, P27; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOUNG CYF, 1994, ONCOL RES, V6, P203; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	54	184	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17485	17494		10.1074/jbc.272.28.17485	http://dx.doi.org/10.1074/jbc.272.28.17485			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211894	hybrid			2022-12-27	WOS:A1997XK16500037
J	Yao, J; Mackman, N; Edgington, TS; Fan, ST				Yao, J; Mackman, N; Edgington, TS; Fan, ST			Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells - Regulation by Egr-1, c-Jun, and NF-kappa B transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR GENE; ACTIVATOR PROTEIN-1; MESSENGER-RNA; E-SELECTIN; REGION; MACROPHAGES; ELEMENT; VIRUS	Biosynthesis of tumor necrosis factor-alpha (TNF-alpha) is predominantly by cells of the monocytic lineage. This study examined the role of various cis-acting regulatory elements in the lipopolysaccharide (LPS) induction of the human TNF-alpha promoter in cells of monocytic lineage, Functional analysis of monocytic THP-1 cells transfected with plasmids containing various lengths of TNF-alpha promoter localized enhancer elements in a region (-182 to -37 base pairs (bp)) that were required for optimal transcription of the TNF-alpha gene in response to LPS, Two regions were identified: region I (-182 to -162 bp) contained an overlapping Sp1/Egr-1 site, and region II (-119 to -88) contained CRE and NF-kappa B (designated kappa B3) sites, In unstimulated THP-1, CRE-binding protein and, to a lesser extent, c-Jun complexes were found to bind to the CRE site, LPS stimulation increased the binding of c-Jun-containing complexes, In addition, LPS stimulation induced the binding of cognate nuclear factors to the Egr-1 and kappa B3 sites, which were identified as Egr-1 and p50/p65, respectively, The CRE and kappa B3 sites in region II together conferred strong LPS responsiveness to a heterologous promoter, whereas individually they failed to provide transcriptional activation, Furthermore, increasing the spacing between the CRE and the kappa B3 sites completely abolished LPS induction, suggesting a cooperative interaction between c-Jun complexes and p50/p65, These studies indicate that maximal LPS induction of the TNF-alpha promoter is mediated by concerted participation of at least two separate cis-acting regulatory elements.	SCRIPPS RES INST, DEPT IMMUNOL, IMM 17, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16411, HL-48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLEMAN DL, 1992, J IMMUNOL, V149, P3045; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DOKTER WHA, 1993, BLOOD, V81, P337; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; FAN ST, 1995, J IMMUNOL, V154, P3266; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; KARIN M, 1995, J BIOL CHEM, V270, P16488; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RHOADES KL, 1995, CELL IMMUNOL, V161, P125, DOI 10.1006/cimm.1995.1016; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P459; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	31	410	422	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17795	17801		10.1074/jbc.272.28.17795	http://dx.doi.org/10.1074/jbc.272.28.17795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211933	hybrid			2022-12-27	WOS:A1997XK16500076
J	Sacher, M; Stone, S; FerroNovick, S				Sacher, M; Stone, S; FerroNovick, S			The synaptobrevin-related domains of Bos1p and Sec22p bind to the syntaxin-like region of Sed5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION COMPLEX; YEAST; VESICLES; ER; IDENTIFICATION; ENCODES; YPT1	SNAREs (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors) ape cytoplasmically oriented membrane proteins that reside on vesicular carriers (V-SNARE) and target organelles (t-SNARE). The pairing of a stage-specific v-SNARE with its cognate t-SNARE may mediate the specificity of membrane traffic. In the yeast Saccharomyces cerevisiae transport between the endoplasmic reticulum and Golgi complex employs two v-SNAREs, Bos1p and Sec22p, each containing a domain that is related to the neuronal v-SNARE synaptobrevin, Sed5p, which is homologous to syntaxin, is the t-SNARE that functions at this stage of the secretory pathway. Here we report that, regions of Bos1p and Sec22p, which are homologous to synaptobrevin, bind to the syntaxin-like domain of Sed5p, Furthermore, we demonstrate that efficient v-SNARE/t-SNARE interactions require the participation of both v-SNAREs, indicating that, unlike post-Golgi membrane traffic, the active form of the endoplasmic reticulum to Golgi V-SNARE is a heteromeric complex.	HOWARD HUGHES MED INST,BOYER CTR MOL MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University								DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P182; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jiang Y, 1995, COLD SPRING HARB SYM, V60, P119, DOI 10.1101/SQB.1995.060.01.015; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STONE S, 1997, IN PRESS MOL BIOL CE	18	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17134	17138		10.1074/jbc.272.27.17134	http://dx.doi.org/10.1074/jbc.272.27.17134			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202032	hybrid			2022-12-27	WOS:A1997XH44600064
J	Blangy, A; Arnaud, L; Nigg, EA				Blangy, A; Arnaud, L; Nigg, EA			Phosphorylation by p34(cdc2) protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150(Glued)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; VESICLE MOTILITY; FISSION YEAST; KINECTIN; COMPLEX; ACTIN; LOCALIZATION	The kinesin-related motor HsEg5 is essential for centrosome separation, and its association with centrosomes appears to be regulated by phosphorylation of tail residue threonine 927 by the p34(cdc2) protein kinase. To identify proteins able to interact with the tail of HsEg5, we performed a yeast two-hybrid screen with a HsEg5 stalk-tail construct as bait. We isolated a cDNA coding for the central, alpha-helical region of human p150(Glued), a prominent component of the dynactin complex. The interaction between HsEg5 and p150(Glued) was enhanced upon activation of p34(CDC28), the budding yeast homolog of p34(cdc2), provided that HsEg5 had a phosphorylatable residue at position 927. Phosphorylation also enhanced the specific binding of p150(Glued) to the tail domain of HsEg5 in vitro, indicating that the two proteins are able to interact directly. Immunofluorescence microscopy revealed co-localization of HsEg5 and p150(Glued) during mitosis but not during interphase, consistent with a cell cycle-dependent association between the two proteins. Taken together, these results suggest that HsEg5 and p150(Glued) may interact in mammalian cells in vivo and that p34(cdc2) may regulate this interaction. Furthermore, they imply that the dynactin complex may functionally interact not only with dynein but also with kinesin-related motors.	UNIV GENEVA, DEPT MOL BIOL, CH-1211 GENEVA 4, SWITZERLAND; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Geneva; Swiss Institute Experimental Cancer Research				BLANGY, Anne/0000-0001-7043-0784; nigg, erich/0000-0003-4835-5719				Bai C, 1996, METHOD ENZYMOL, V273, P331; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Bruno KS, 1996, P NATL ACAD SCI USA, V93, P4775, DOI 10.1073/pnas.93.10.4775; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HARPER JW, 1993, CELL, V75, P805; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karsenti E, 1996, SEMIN CELL DEV BIOL, V7, P367, DOI 10.1006/scdb.1996.0046; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MILLER GH, 1992, NATURE, V355, P244, DOI 10.1038/355244a0; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Thaler C D, 1996, Int Rev Cytol, V164, P269; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171	62	122	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19418	19424		10.1074/jbc.272.31.19418	http://dx.doi.org/10.1074/jbc.272.31.19418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235942	Green Published, hybrid			2022-12-27	WOS:A1997XP06300048
J	Gulati, S; Chen, ZQ; Brody, LC; Rosenblatt, DS; Banerjee, R				Gulati, S; Chen, ZQ; Brody, LC; Rosenblatt, DS; Banerjee, R			Defects in auxiliary redox proteins lead to functional methionine synthase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN; HETEROGENEITY; CBLG; BIOSYNTHESIS; SYNTHETASE; BINDING; CULTURE; SYSTEM; LIVER; CELLS	Methionine synthase catalyzes a methyl transfer reaction from methyltetrahydrofolate to homocysteine to form methionine and tetrahydrofolate and is dependent on methylcobalamin, a derivative of vitamin B-12, for activity, Due to the lability of the intermediate, cob(I) alamin, the activity of methionine synthase is additionally dependent on a redox activation system. In bacteria, two flavoproteins, NADPH-flavodoxin reductase and flavodoxin, shuttle electrons from NADPH to methionine synthase, Their mammalian counterparts are unknown, and a putative intrinsic thiol oxidase activity of the mammalian methionine synthase has been proposed to be involved, We demonstrate that the mammalian methionine synthase can be activated in an NADPH-dependent reaction and requires a minimum of two redox proteins, This model is consistent with our results from biochemical complementation studies between cblG and cblE cell lines and mutation detection analysis in cblG cell lines, These demonstrate that the cblG; cell line has defects affecting methionine synthase directly, whereas the cblE cell line has defects in the redox proteins, We have also identified a P1173L mutation in the activation domain of methionine synthase in the cblG cell line WG1505.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MRC,GENET GRP,MONTREAL,PQ H3A 1A1,CANADA; NIH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892	University of Nebraska System; University of Nebraska Lincoln; McGill University; McGill University; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)					NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHE H, 1974, BIOCHEM BIOPH RES CO, V57, P417, DOI 10.1016/0006-291X(74)90947-4; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; FENTON WA, 1995, METABOLIC MOL BASES, P3111; FISKERSTRAND T, 1994, CANCER RES, V54, P4899; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; GREEN R, 1995, FOLATE HLTH DIS, P75; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HALL CA, 1989, CLIN INVEST MED, V12, P262; HOFFMAN RM, 1976, P NATL ACAD SCI USA, V73, P1523, DOI 10.1073/pnas.73.5.1523; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; MALINOW MR, 1995, CLIN CHEM, V41, P173; MATTHEWS R G, 1986, P697; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; ROSENBLATT DS, 1984, J CLIN INVEST, V74, P2149, DOI 10.1172/JCI111641; ROSENBLATT DS, 1995, METABOLIC MOL BASES, P3129; SHEVELL MI, 1992, CAN J NEUROL SCI, V19, P472, DOI 10.1017/S0317167100041676; SILLAOTS SL, 1992, BIOCHEM MED METAB B, V47, P242, DOI 10.1016/0885-4505(92)90032-T; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WATKINS D, 1988, J CLIN INVEST, V81, P1690, DOI 10.1172/JCI113507; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	29	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19171	19175		10.1074/jbc.272.31.19171	http://dx.doi.org/10.1074/jbc.272.31.19171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235907	hybrid			2022-12-27	WOS:A1997XP06300013
J	Molden, J; Chang, Y; You, Y; Moore, PS; Goldsmith, MA				Molden, J; Chang, Y; You, Y; Moore, PS; Goldsmith, MA			A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCES; CASTLEMANS DISEASE; MOLECULAR-CLONING; TYROSINE KINASE; INTERLEUKIN-6; IL-6; BINDING; EXPRESSION; PROTEINS; TRANSDUCER	The present studies analyzed the biologic activity of a gene product (vIL-6) encoded by the recently discovered Kaposi's sarcoma-associated herpesvirus (KSHV) bearing 24.8% amino acid identity with human interleukin-6 (huIL-6). Based on this similarity, we hypothesized that this viral homolog might trigger the JAK/STAT pathway, which typically is engaged by IL-6 and other cytokines, Activation of receptor-associated Janus tyrosine kinases (JAKs) results in the subsequent phosphorylation of signal transducers and activators of transcription (STATs) leading to nuclear entry and transcriptional regulation of target genes, Treatment of HepG2 cells with culture medium containing recombinant KSHV-encoded vIL-6 led to rapid induction of JAK1 phosphorylation and a nuclear DNA-binding activity found to contain STAT1 and STAT3. An antibody to the IL-6 receptor (IL-6R) alpha subunit effectively neutralized the response to huIL-6 but failed to block STAT activation by vIL-6. In contrast, an antibody reactive with the gp130 subunit of IL-6R abrogated signaling of both responses. Moreover, a transfected cell line expressing human gp130 without IL-6R alpha exhibited a robust response to vIL-6 but not to huIL-6. These results demonstrate that KSHV encodes a cytokine that activates specific JAK/STAT signaling via interactions with the gp130 signal transducing subunit independently of the IL-6R alpha chain. This activity may have an impact on gp130-mediated signaling in response to native cytokines and thereby influence disease pathogenesis upon KSHV infection.	GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94110; COLUMBIA UNIV,SCH PUBL HLTH,DEPT PATHOL,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; Columbia University; University of California System; University of California San Francisco			Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; 	NCI NIH HHS [R01 CA67391] Funding Source: Medline; NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG EHY, 1997, IN PRESS P NATL ACAD; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Komanduri KV, 1996, J ACQ IMMUN DEF SYND, V13, P215, DOI 10.1097/00042560-199611010-00003; LAMB P, 1994, BLOOD, V83, P2063; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SONNE O, 1990, EUR J CLIN INVEST, V20, P366, DOI 10.1111/j.1365-2362.1990.tb01872.x; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	231	244	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19625	19631		10.1074/jbc.272.31.19625	http://dx.doi.org/10.1074/jbc.272.31.19625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235971	hybrid			2022-12-27	WOS:A1997XP06300077
J	Topping, TB; Randall, LL				Topping, TB; Randall, LL			Chaperone SecB from Escherichia coli mediates kinetic partitioning via a dynamic equilibrium with its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; LEADER PEPTIDE; EXPORT; CHEMOTAXIS; TRANSPORT; SEQUENCES; RECEPTOR; FRAME	We have shown that the complexes between SecB, a chaperone from Escherichia coli, and two physiological ligands, galactose-binding protein and maltose-binding protein, are in rapid, dynamic equilibrium between the bound and free states, Binding to SecB is readily reversible, and each time the ligand is released it undergoes a kinetic partitioning between folding to its native state and re-binding to SecB. Binding requires that the polypeptide be devoid of tertiary structure; once the protein has folded, it is no longer a ligand. Conditions were established in which folding of the polypeptides was sufficiently slow so that at each cycle of dissociation rebinding was favored over folding and a kinetically stable complex between SecB and each polypeptide ligand was observed, Evidence that the ligand is continually released to the bulk solution and rebound was obtained by altering the conditions to increase the rate of folding of each ligand so that folding of the ligand was faster than reassociation with SecB thereby allowing the system to partition to free SecB and folded polypeptide ligand. We conclude that complexes between the chaperone SecB and ligands are in dynamic, rapid equilibrium with the free states. This mode of binding is simpler than that documented for chaperones that function to facilitate folding such as the Hsp70s and Hsp60s, where hydrolysis of ATP is coupled to the binding and release of ligands, This difference may reflect the fact that SecB does not mediate folding but is specialized to facilitate protein export. Without a requirement for exogenous energy it efficiently performs its sole duty: to keep proteins in a nonnative conformation and thus competent for export.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; DUPLAY P, 1984, J BIOL CHEM, V259, P606; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MAHONEY WC, 1981, J BIOL CHEM, V256, P4350; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SCRIPTURE JB, 1983, J BIOL CHEM, V258, P853; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TOPPING TB, 1994, PROTEIN SCI, V3, P730; VYTAS NK, 1987, NATURE, V327, P635	22	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19314	19318		10.1074/jbc.272.31.19314	http://dx.doi.org/10.1074/jbc.272.31.19314			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235927	hybrid			2022-12-27	WOS:A1997XP06300033
J	Ko, YH; Bianchet, M; Amzel, LM; Pedersen, PL				Ko, YH; Bianchet, M; Amzel, LM; Pedersen, PL			Novel insights into the chemical mechanism of ATP synthase - Evidence that in the transition state the gamma-phosphate of ATP is near the conserved alanine within the P-loop of the beta-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; RAT-LIVER; ESCHERICHIA-COLI; ADENYLATE KINASE; F1 MOIETY; BINDING; MYOSIN; VANADATE; PHOTOCLEAVAGE; MITOCHONDRIA	The chemical mechanism by which the F-1 moiety of ATP synthase hydrolyzes and synthesizes ATP remains unknown, For this reason, we have carried out studies with orthovanadate (V-i), a phosphate analog which has the potential of ''locking'' all ATPase, in its transition state by forming a MgADP.V-i complex, and also the potential, in a photochemical reaction resulting in peptide bond cleavage, of identifying an amino, acid very near the gamma-phosphate of ATP. Upon incubating purified rat liver F-1 with MgADP and V-i for 2 h to promote formation of a MgADP.V-i-F-1 complex, the ATPase activity of the enzyme was markedly inhibited in a reversible manner, When the resultant complex was formed in the presence of ultraviolet light inhibition could not be reversed, and SDS-polyacrylamide gel electrophoresis revealed, in addition to the five known subunit bands characteristic of F-1 (i.e. alpha, beta, gamma, delta, and epsilon), two new electrophoretic species of 17 and 34 kDa, Western blot and N-terminal sequencing analyses identified both bands as arising from the beta subunit with the site of peptide bond cleavage occurring at alanine 158, a conserved residue within F-1-ATPases and the third residue within the nucleotide binding consensus GX(4)GK(T/S) (P-loop). Quantification of the amount of ADP bound within the MgADP.V-i-F-1 complex revealed about 1.0 mol/mol F-1, while quantification of the peptide cleavage products revealed that no more than one beta subunit had been cleaved, Consistent with the cleavage reaction involving oxidation of the methyl group of alanine was the finding that [H-3] from NaB[H-3](4) incorporates into MgADP.V-i-F-1 complex following treatment with ultraviolet light, These novel findings provide information about the transition state involved in the hydrolysis of ATP by a single beta subunit within F-1-ATPases and implicate alanine 158 as residing very near the gamma-phosphate of ATP during catalysis, When considered with earlier studies on myosin and adenylate kinase, these studies also implicate a special role for the third residue within the GX(4)GK(T/S) sequence of many other nucleotide-binding proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University			Bianchet, Mario a/K-2131-2015	Bianchet, Mario a/0000-0001-9032-7549; Amzel, L. Mario/0000-0002-0129-9572	NCI NIH HHS [CA10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Coulston GW, 1997, SCIENCE, V275, P191, DOI 10.1126/science.275.5297.191; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CROSS RL, 1982, J BIOL CHEM, V257, P2101; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TAGAYA M, 1989, J BIOL CHEM, V264, P990; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202	28	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18875	18881		10.1074/jbc.272.30.18875	http://dx.doi.org/10.1074/jbc.272.30.18875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228065	hybrid			2022-12-27	WOS:A1997XM34200056
J	Lochhead, A; Nekrasova, E; Arshavsky, VY; Pyne, NJ				Lochhead, A; Nekrasova, E; Arshavsky, VY; Pyne, NJ			The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CATESBIANA ROD PHOTORECEPTORS; INHIBITORY SUBUNIT; NUCLEOTIDE PHOSPHODIESTERASE; VISUAL TRANSDUCTION; CATALYTIC SUBUNITS; PHOSPHORYLATION; LUNG; SITES; KINASE	The cGMP phosphodiesterase from retinal rods (PDE-6) is an alpha beta gamma(2) heterotetramer, The alpha and beta subunits contain catalytic sites for cGMP hydrolysis, whereas the gamma subunits serve as a protein inhibitor of the enzyme, Visual excitation of photoreceptors enables the activated GTP-bound form of the G-protein transducin to remove the inhibitory action of the gamma subunit, thereby triggering PDE-B activation, The type 5 phosphodiesterase (PDE-B) isoform shares a number of similar characteristics with PDE-6, including binding of cGMP to non catalytic sites, the cyclic nucleotide specificity, and inhibitor sensitivities, Although the functional role of PDE 5 remains unclear, it has been shown to be activated by protein kinase A (PKA) (Burns, F., Rodger, I. W. & Pyne, N. J. (1992) Biochem, J. 283, 487-491), Here we report that both the recombinant gamma subunit and a peptide corresponding to amino acids 24-46 in this protein inhibited the activation of PDE-5 by PKA, Furthermore, immunoblotting airway smooth muscle membranes with a specific antibody against amino acids 24-46 of the PDE-6 gamma subunit identified two major immunoreactive small molecular mass proteins of 14 and 18 kDa (p14 and p18), These appear to form a complex with PDE-5, because PDE activity was immunoprecipitated using antibody against the PDE-6 gamma subunit, p14 and p18 were also substrates for phosphorylation by a unidentified kinase that was stimulated by a pertussis toxin-sensitive G-protein, Phosphorylation of p14/p18 in membranes treated with guanine nucleotides correlated with a concurrent reduction in the activation of PDE-B by PKA, We suggest that p14 and p18 share an epitope common to PDE-B gamma and that this region may interact with PDE-6 to prevent its activation by PKA.	UNIV STRATHCLYDE,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND; HARVARD UNIV,SCH MED,HOWE LAB OPHTHALMOL,BOSTON,MA 02114	University of Strathclyde; Harvard University; Harvard Medical School				Pyne, Nigel/0000-0002-5657-4578	NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10336] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BURNS F, 1992, BIOCHEM BIOPH RES CO, V189, P1389, DOI 10.1016/0006-291X(92)90228-D; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; FRANCIS SH, 1988, METHOD ENZYMOL, V159, P722; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GRADY M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P313, DOI 10.1016/0167-4889(93)90060-3; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; MUMBY MC, 1982, J BIOL CHEM, V257, P13283; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; PYNE NJ, 1986, BIOCHEM J, V234, P325, DOI 10.1042/bj2340325; PYNE S, 1993, BIOCHEM PHARMACOL, V45, P593, DOI 10.1016/0006-2952(93)90132-G; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WU Z, 1992, BIOL CYCLIC NUCLEOTI, P29; WYATT TM, 1994, FASEB J, V8, P372; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18397	18403		10.1074/jbc.272.29.18397	http://dx.doi.org/10.1074/jbc.272.29.18397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218482	hybrid			2022-12-27	WOS:A1997XL73500072
J	Murao, K; Terpstra, V; Green, SR; Kondratenko, N; Steinberg, D; Quehenberger, O				Murao, K; Terpstra, V; Green, SR; Kondratenko, N; Steinberg, D; Quehenberger, O			Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE CHOLESTEROL TRANSPORT; GENE FAMILY; MEDIATED ENDOCYTOSIS; SIGNAL TRANSDUCTION; SELECTIVE UPTAKE; SR-BI; A-I; CD36; MACROPHAGES; ESTERS	Recently, a murine scavenger receptor type B class I (SR-BI) was identified that binds high density lipoprotein (HDL) and mediates the selective uptake of cholesterol esters, The human (C) under bar D36 and (L) under bar IMPII (a) under bar nalogous-1 (CLA-1) receptor shows high sequence homology with SR-BI, but their functional relationship has not been determined, Transfected cells expressing CLA-1 bound HDL with a K-d of about 35 mu g/ml, similar to the K-d for HDL binding to rodent SR-BI. This binding resulted in an intracellular accumulation of HDL-derived [H-3]cholesterol esters without internalization or degradation of I-125-apolipoprotein. CLA-1 was strongly expressed in the adrenal gland and was also abundant in liver and testis, suggesting that CLA-I, like SR-BI, could play a role in the metabolism of HDL, However, CLA-1 was also expressed in monocytes and, like SR-BI, recognized modified forms of low density lipoproteins as well as native LDL and anionic phospholipids. These findings suggest that CLA-1 might have additional physiological functions, We found that CLA-1 recognizes apoptotic thymocytes. Our results demonstrate that CLA-1, a close structural homologue of SR-BI, is also functionally related to SR-BI and may play an important role as a ''docking receptor'' for HDL in connection with selective uptake of cholesterol esters, An additional role in recognition of damaged cells is suggested by these studies.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BADIMON JJ, 1992, CIRCULATION, V86, P86; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FADOK VA, 1992, J IMMUNOL, V148, P2207; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALT DE, 1992, BLOOD, V80, P1105; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEIDER JG, 1978, J LIPID RES, V19, P514; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huh HY, 1996, BLOOD, V87, P2020; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MIZOBUCHI M, 1994, J NEUROCHEM, V62, P322; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001	46	288	299	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17551	17557		10.1074/jbc.272.28.17551	http://dx.doi.org/10.1074/jbc.272.28.17551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211901	hybrid			2022-12-27	WOS:A1997XK16500044
J	Pettitt, TR; Martin, A; Horton, T; Liossis, C; Lord, JM; Wakelam, MJO				Pettitt, TR; Martin, A; Horton, T; Liossis, C; Lord, JM; Wakelam, MJO			Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions - Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; THYROTROPIN-RELEASING-HORMONE; MOLECULAR-SPECIES ANALYSIS; CANINE KIDNEY-CELLS; ALPHA-THROMBIN; CULTURED FIBROBLASTS; SN-1,2-DIACYLGLYCEROL; 1,2-DIGLYCERIDES; HYDROLYSIS	Stimulation of cells with certain agonists often activates both phospholipases C and D. These generate diacylglycerol and phosphatidate, respectively, although the two lipids are also apparently interconvertable through the actions of phosphatidate phosphohydrolase and diacylglycerol kinase. Diacylglycerol activates protein kinase C while one role for phosphatidate is the activation of actin stress fiber formation, Therefore, if the two lipids are interconvertable, it is theoretically possible that an uncontrolled signaling loop could arise. To address this issue structural analysis of diacylglycerol, phosphatidate, and phosphatidylbutanol (formed in the presence of butan-1-ol) from both Swiss 3T3 and porcine aortic endothelial cells was performed. This demonstrated that phospholipase C activation generates primarily polyunsaturated species while phospholipase D activation generates saturated/monounsaturated species. in the endothelial cells, where phospholipase D was activated by lysophosphatidic acid independently of phospholipase C, there was no activation of protein kinase C. Thus we propose that only poly-unsaturated diacylglycerols and saturated/monounsaturated phosphatidates function as intracellular messengers and that their interconversion products are inactive.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham				Wakelam, Michael/0000-0003-4059-9276; Lord, Janet/0000-0003-1030-6786	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALBOA MA, 1995, J BIOL CHEM, V270, P29843; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1992, REV PHYSL BIOCH PHAR, V119, P14; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HA KS, 1993, J BIOL CHEM, V268, P10534; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE C, 1991, J BIOL CHEM, V266, P22837; MONACO ME, 1991, BIOCHEM J, V279, P337, DOI 10.1042/bj2790337; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Olivier AR, 1996, BIOCHEM J, V318, P519, DOI 10.1042/bj3180519; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; RODRIGUEZ R, 1987, MOL ENDOCRINOL, V1, P802, DOI 10.1210/mend-1-11-802; Sawai H, 1997, J BIOL CHEM, V272, P2452; WAKELAM MJO, 1988, CURRENT TOPICS MEMBR, V32, P87; WAKELAM MJO, 1995, RECEPTOR TRANSDUCTIO, P271; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	28	171	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17354	17359		10.1074/jbc.272.28.17354	http://dx.doi.org/10.1074/jbc.272.28.17354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211874	hybrid			2022-12-27	WOS:A1997XK16500017
J	Barbier, CS; Short, SA; Senear, DF				Barbier, CS; Short, SA; Senear, DF			Allosteric mechanism of induction of CytR-regulated gene expression - CytR repressor-cytidine interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; PURINE REPRESSOR; INDUCER BINDING; RNA-POLYMERASE; DNA-BINDING; PROMOTER; COREPRESSOR; IDENTIFICATION; CONSTRUCTION	Transcription from cistrons of the Escherichia coli CytR regulon is activated by E. coli cAMP receptor protein (CRP) and repressed by a multiprotein complex composed elf CRP and CytR. De-repression results when CytR binds cytidine. CytR is a homodimer and a LacI family member, A central question for all LacI family proteins concerns the allosteric mechanism that couples ligand binding to the protein-DNA and protein-protein interactions that regulate transcription. To explore this mechanism for CytR, we analyzed nucleoside binding in vitro and its coupling to cooperative CytR binding to operator DNA, Analysis of the thermodynamic linkage between sequential cytidine binding to dimeric CytR and cooperative binding of CytR to deoP2 indicates that de-repression results from just one of the two cytidine binding steps. go test this conclusion in vivo, CytR mutants that have wild-type repressor function but are cytidine induction-deficient (CID) were identified, Each has a substitution for Asp(281) or neighboring residue. CID CytR281N was found to bind cytidine with three orders of magnitude lower affinity than wild-type CytR. Other CytR mutants that do not exhibit the CID phenotype were: found to bind cytidine with affinity similar to wild-type CytR. The rate of transcription regulated by heterodimeric CytR composed of one CytR281N and one wild-type subunit was compared with that regulated by wild-type CytR under inducing conditions. The data support the conclusion that the first cytidine binding step alone is sufficient to induce.	GLAXO WELLCOME INC, MOL SCI, RES TRIANGLE PK, NC 27709 USA; UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92697 USA	GlaxoSmithKline; University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1989, CURRENT PROTOCOLS S7, V2; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; COZZARELLI NR, 1968, P NATL ACAD SCI USA, V60, P992, DOI 10.1073/pnas.60.3.992; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GERLACH P, 1990, MOL MICROBIOL, V4, P479, DOI 10.1111/j.1365-2958.1990.tb00614.x; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HAMMERJE, 1971, EUR J BIOCHEM, V19, P533; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HSIEH M, 1994, J BIOL CHEM, V269, P13825; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; Kristensen HH, 1996, J MOL BIOL, V260, P113, DOI 10.1006/jmbi.1996.0385; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maniatis T, 1989, MOL CLONING; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; PERINI L, 1995, BIOPHYS J, V68, pA295; Perini LT, 1996, J BIOL CHEM, V271, P33242, DOI 10.1074/jbc.271.52.33242; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x; RAZZELL WE, 1964, J BIOL CHEM, V239, P1789; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAUNDERS PP, 1969, J BIOL CHEM, V244, P3691; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; SHORT SA, 1984, GENE, V31, P205, DOI 10.1016/0378-1119(84)90211-7; SINGER JT, 1985, J BACTERIOL, V163, P1095, DOI 10.1128/JB.163.3.1095-1100.1985; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAXMAN E, 1993, ANAL BIOCHEM, V210, P425, DOI 10.1006/abio.1993.1220; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	48	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16962	16971		10.1074/jbc.272.27.16962	http://dx.doi.org/10.1074/jbc.272.27.16962			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202008	hybrid			2022-12-27	WOS:A1997XH44600040
J	Deissler, H; Wilm, M; Genc, B; Schmitz, B; Ternes, T; Naumann, F; Mann, M; Doerfler, W				Deissler, H; Wilm, M; Genc, B; Schmitz, B; Ternes, T; Naumann, F; Mann, M; Doerfler, W			Rapid protein sequencing by tandem mass spectrometry and cDNA cloning of p20-CGGBP - A novel protein that binds to the unstable triplet repeat 5'-d(CGG)(n)-3' in the human FMR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; IN-VITRO; TRINUCLEOTIDE REPEATS; METHYLATION ANALYSIS; CGG REPEAT; DNA; IDENTIFICATION; INSTABILITY; RESOLUTION; EXPANSION	The autonomous expansion of the unstable 5'-d(CGG)(n)-3' repeat in the 5'-untranslated region of the human FMR1 gene leads to the fragile X syndrome, one of the most frequent causes of mental retardation in human males, We have recently described the isolation of a protein p20-CGGBP that binds sequence-specifically to the double stranded trinucleotide repeat 5'-d(CGG)-3' (Deissler, H., Behn-Krappa, A., and Doerfler, W. (1996) J. Biol. Chem. 271, 4327-4334), We demonstrate now that the p20-CGGBP can also bind to an interrupted repeat sequence, Peptide sequence tags of p20-CGGBP obtained by nanoelectrospray mass spectrometry were screened against an expressed sequence tag data base, retrieving a clone that contained the full-length coding sequence for p20-CGGBP. A bacterially expressed fusion protein p20-CGGBP-6xHis exhibits a binding pattern to the double-stranded 5'-d(CGG),-3' repeat similar to that of the authentic p20-CGGBP, This novel protein lacks any overall homology to other known proteins but carries a putative nuclear localization signal, The p20-CGGBP gene is conserved among mammals but shows no homology to non-vertebrate species, The gene encoding the sequence for the new protein has been mapped to human chromosome 3.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY	University of Cologne; European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Deissler, Heidrun/0000-0003-0086-7811; Wilm, Matthias/0000-0002-5461-6834				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; Deissler H, 1996, J BIOL CHEM, V271, P4327; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; ILM M, 1996, ANAL CHEM, V66, P1; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; MCMURRAY CT, 1995, CHROMOSOMA, V104, P2; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PEREVOZCHIKOV AP, 1994, DOKL AKAD NAUK+, V338, P411; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; THOMSON BA, 1995, ANAL CHEM, V67, P1696, DOI 10.1021/ac00106a008; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706	47	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16761	16768		10.1074/jbc.272.27.16761	http://dx.doi.org/10.1074/jbc.272.27.16761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201980	hybrid			2022-12-27	WOS:A1997XH44600012
J	Franklin, CC; Kraft, AS				Franklin, CC; Kraft, AS			Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; C-JUN; TYROSINE-PHOSPHATASE; IN-VIVO; PHOSPHORYLATION; GROWTH; DOMAIN; 3CH134	Phorbol ester tumor promoters, such as phorbol 12-myristate 13-acetate (PMA), are potent activators of extracellular signal-regulated kinase 2 (ERK2), stress-activated protein kinase (SAPK), and p38 mitogen-activated protein kinase (MAPK) in U937 human leukemic cells, These kinases are regulated by the reversible dual phosphorylation of conserved threonine and tyrosine residues, The dual specificity protein phosphatase MAPK phosphatase-l (MKP-1) has been shown to dephosphorylate and inactivate ERK2, SAPK, and p38 MAPK in transient transfection studies. Here we demonstrate that PMA treatment induces MKP-1 protein expression in U937 cells, which is detectable within 30 min with maximal levels attained after 4 h, This time course coincides with the rapid inactivation of PMA-induced SAPK activity, but not ERK2 phosphorylation, which remains elevated for up to 6 h, To examine directly the role of MKP-1 in the regulation of these protein kinases in vivo, we established a U937 cell line that conditionally expresses MKP-1 from the human metallothionein IIa promoter, Conditional expression of MKP-1 inhibited PMA-induced ERK2, SAPK, and p38 MAPK activity, By titrating the levels of MKP-1 expression from the human metallothionein IIa promoter, however, it was found that p38 MAPK and SAPK were much more sensitive to inhibition by MKP-1 than ERK2, This differential substrate specificity of MKP-1 can be functionally extended to nuclear transcriptional events in that PMA-induced c-Jun transcriptional activity was more sensitive to inhibition by MKP-1 than either Elk-l or c-Myc. Conditional expression of MKP-1 also abolished the induction of endogenous MKP-1 protein expression in response to PMA treatment, This negative feedback regulatory mechanism is likely due to MKP-1-mediated inhibition of ERK2, as studies utilizing the MEK1/2 inhibitor PD98059 suggest that ERK2 activation is required for PMA-induced MKP-1 expression, These findings suggest that ERK2-mediated induction of MKP-1 may play an important role in preferentially attenuating signaling through the p38 MAPK and SAPK signal transduction pathways.			Franklin, CC (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV MED ONCOL,DENVER,CO 80262, USA.				NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dorfman K, 1996, ONCOGENE, V13, P925; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; Franklin CC, 1995, ONCOGENE, V11, P2365; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SETH A, 1992, J BIOL CHEM, V267, P24796; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	48	387	392	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16917	16923		10.1074/jbc.272.27.16917	http://dx.doi.org/10.1074/jbc.272.27.16917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202001	hybrid			2022-12-27	WOS:A1997XH44600033
J	Astier, A; Manie, SN; Avraham, H; Hirai, H; Law, SF; Zhang, YH; Golemis, EA; Fu, YG; Druker, BJ; Haghayeghi, N; Freedman, AS; Avraham, S				Astier, A; Manie, SN; Avraham, H; Hirai, H; Law, SF; Zhang, YH; Golemis, EA; Fu, YG; Druker, BJ; Haghayeghi, N; Freedman, AS; Avraham, S			The related adhesion focal tyrosine kinase differentially phosphorylates p130(Cas) and the Cas-like protein, p105(HEF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC; DOMAIN; CRK; MEGAKARYOCYTES; IDENTIFICATION; FIBRONECTIN; CELLS; C3G	The related adhesion focal tyrosine kinase (RAFTK) is tyrosine-phosphorylated following beta 1 integrin or B cell antigen receptor stimulation in human B cells. Two substrates that are tyrosine-phosphorylated following integrin ligation in B cells are p130(Cas) and the Cas family member human enhancer of filamentation 1 (HEF1), both of which can associate with RAFTK. In this report we observed that RAFTK was involved in the phosphorylation of these two proteins. While a catalytically active RAFTK was required for both p130(Cas) and HEF1, phosphorylation of p130(Cas), but not of HEF1, was dependent on an intact autophosphorylation site (Tyr(402)) on RAFTK. To determine if RAFTK phosphorylated p130(Cas) and HEF1 directly or through an intermediate, we assayed the ability of RAFTK and of a Tyr(402) mutant to phosphorylate purified HEF1 and p130(Cas) domains. RAFTK was able to phosphorylate the substrate domains of both p130(Cas) and HEF1, but only the C-terminal domain of p130(Cas). Furthermore, Tyr(402), which mediates the binding of RAFTK to c-Src kinase, was required for the phosphorylation of the C-terminal domain of p130(Cas). These data suggest that RAFTK itself is sufficient for HEF1 phosphorylation, whereas a cooperation between RAFTK and Src kinases is required for the complete phosphorylation of p130(Cas).	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL DEACONESS MED CTR, DIV EXPT MED & HEMATOL ONCOL RES, BOSTON, MA 02115 USA; UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo; Fox Chase Cancer Center; Oregon Health & Science University			Astier, Anne L/A-1641-2008; Zhang, Yuzhu/A-7109-2009; Manie, Serge/ABC-8331-2021; Zhang, Yuzhu/C-3606-2014	Astier, Anne L/0000-0002-0144-3431; Zhang, Yuzhu/0000-0001-7882-5692; Zhang, Yuzhu/0000-0001-7882-5692; Druker, Brian/0000-0001-8331-8206; manie, serge/0000-0002-9168-1977; Golemis, Erica/0000-0003-3618-3673; Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA055207, P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA55207, CA66996] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Ishino M, 1995, ONCOGENE, V11, P2331; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Law SF, 1996, MOL CELL BIOL, V16, P3327; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORTARINI R, 1992, CANCER RES, V52, P4499; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vuori K, 1996, MOL CELL BIOL, V16, P2606	32	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19719	19724		10.1074/jbc.272.32.19719	http://dx.doi.org/10.1074/jbc.272.32.19719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242628	hybrid			2022-12-27	WOS:A1997XQ05900015
J	Brunori, M; Giuffre, A; DItri, E; Sarti, P				Brunori, M; Giuffre, A; DItri, E; Sarti, P			Internal electron transfer in Cu-heme oxidases - Thermodynamic or kinetic control?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; MOLECULAR-OXYGEN; INTERMEDIATE; SITE; TEMPERATURE; REDUCTION; BINDING; PROTONS; STEPS; PH	We present novel experimental evidence that, starting with the oxidized enzyme, the internal electron transfer in cytochrome c oxidase is kinetically controlled, The anaerobic reduction of the oxidized enzyme by ruthenium hexamine has been followed in the absence and presence of CO or NO, used as trapping ligands for reduced cytochrome alpha(3). In the presence of NO, the rate of formation of the cytochrome alpha(3)(2+)-NO adduct is independent of the concentration of ruthenium hexamine and of NO, indicating that in the oxidized enzyme cytochrome a and as are not its very rapid redox equilibrium; on the other hand, CO proved to be a poor ''trapping'' ligand, We conclude that the intrinsic sate constant for alpha --> alpha(3) electron transfer in the oxidized enzyme is 25 s(-1). These data are discussed with reference to a model (Verkhovsky, M.I., Morgan, J.E., and Wikstrom, M. (1995) Biochemistry 34, 7483-7491) in which H+ diffusion and/or binding at the binuclear site is the rate-limiting step in the reduction of cytochrome alpha(3) in the oxidized enzyme.	UNIV ROMA LA SAPIENZA, CNR, CTR MOL BIOL, I-00185 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Brunori, M (corresponding author), UNIV ROMA LA SAPIENZA, DIPARTIMENTO SCI BIOCHIM, PIAZZALE ALDO MORO 5, I-00185 ROME, ITALY.		Giuffrè, Alessandro/K-4341-2015; Sarti, Paolo/D-2946-2009	Giuffrè, Alessandro/0000-0001-5301-0681; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BAKER GM, 1987, J BIOL CHEM, V262, P595; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BLAIR DF, 1986, J BIOL CHEM, V261, P1524; BRUNORI M, 1994, FEBS LETT, V350, P164, DOI 10.1016/0014-5793(94)00779-9; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; EINARSDOTTIR O, 1995, BBA-BIOENERGETICS, V1229, P129, DOI 10.1016/0005-2728(94)00196-C; GIBSON QH, 1965, J BIOL CHEM, V240, P888; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; OLIVEBERG M, 1989, BIOCHIM BIOPHYS ACTA, V977, P322, DOI 10.1016/S0005-2728(89)80087-8; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; SARTI P, 1988, ANN NY ACAD SCI, V550, P161, DOI 10.1111/j.1749-6632.1988.tb35332.x; SCOTT RA, 1980, J AM CHEM SOC, V102, P3219, DOI 10.1021/ja00529a054; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859	33	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19870	19874		10.1074/jbc.272.32.19870	http://dx.doi.org/10.1074/jbc.272.32.19870			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242650	hybrid			2022-12-27	WOS:A1997XQ05900037
J	Tarroni, P; Rossi, D; Conti, A; Sorrentino, V				Tarroni, P; Rossi, D; Conti, A; Sorrentino, V			Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOOT PROTEIN ISOFORMS; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CARDIAC-MUSCLE; DIHYDROPYRIDINE RECEPTOR; POSTNATAL-DEVELOPMENT; GENE-EXPRESSION; GROWTH-FACTORS; MICE LACKING; CONTRACTION	In vertebrate skeletal muscles, the type 1 isoform of ryanodine receptor (RyR1) is essential in triggering contraction by releasing Ca2+ from the sarcoplasmic reticulum in response to plasma membrane depolarisation. Recently, the presence of another RyR isoform, RyR3, has been detected in mammalian skeletal muscle cells, raising the question of the eventual relevance of RyR3 for muscle cell physiology. The expression of RyR3 was investigated during differentiation of skeletal muscle cells, Using antibodies able to distinguish the different RyR isoforms and Western blot analysis, the RyR3 protein was detected in the microsomal fractions of differentiated skeletal muscle cells but not of undifferentiated cells, Accordingly, blocking muscle differentiation by the addition of either transforming growth factor-beta or basic fibroblast growth factor prevented the expression of the RyR3 protein. In differentiated skeletal muscle cells, RyR3 was expressed independent of cell fusion and myotube formation. The expression of RyR3 was also investigated during development of the diaphragm muscle, The RyR3 content in the diaphragm muscle increased between the late stage of fetal development and the first postnatal days. However, at variance with RyR1, which reached maximum levels of expression 2-3 weeks after birth, the expression of RyR3 was found to be higher in the neonatal phase of the diaphragm muscle development (2-15 days after birth) than in the same muscle from adult mice. The differential content of RyR3 in adult skeletal muscles was found not to be mediated by neurotrophic factors or electrical activity, These findings indicate that RyR3 is preferentially expressed in differentiated skeletal muscle cells. In addition, during skeletal muscle development, its expression is regulated differently from that of RyR1.	SAN RAFFAELE SCI INST,DIBIT,I-21032 MILAN,ITALY; UNIV SIENA,SCH MED,INST HISTOL,I-53100 SIENA,ITALY	University of Siena			Conti, Antonio/AAN-7161-2020; Sorrentino, Vincenzo/A-4793-2014; Rossi, Daniela/G-7764-2012	Conti, Antonio/0000-0001-9150-5271; Sorrentino, Vincenzo/0000-0002-8573-8631; Rossi, Daniela/0000-0003-0463-7327; Tarroni, Paola/0000-0001-7398-0722	Telethon [653] Funding Source: Medline	Telethon(Fondazione Telethon)		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; AIREY JA, 1990, J BIOL CHEM, V265, P14187; AMBLER SK, 1988, J BIOL CHEM, V263, P1952; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CIRC RES, V75, P503, DOI 10.1161/01.RES.75.3.503; BULTEAU L, 1994, ARCH INT PHYSL BIOCH, V102; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; COGNARD C, 1992, PFLUG ARCH EUR J PHY, V422, P207, DOI 10.1007/BF00370424; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DANGAIN J, 1991, CAN J PHYSIOL PHARM, V69, P1294, DOI 10.1139/y91-190; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; EMERSON CP, 1975, J MOL BIOL, V93, P431, DOI 10.1016/0022-2836(75)90238-7; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; FLUCHER BE, 1994, MOL BIOL CELL, V5, P1105, DOI 10.1091/mbc.5.10.1105; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HU JS, 1990, J BIOL CHEM, V265, P7914; IVANENKO A, 1995, J BIOL CHEM, V270, P4220, DOI 10.1074/jbc.270.9.4220; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; KELVIN DJ, 1989, J CELL BIOL, V108, P159, DOI 10.1083/jcb.108.1.159; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; Louboutin JP, 1996, MUSCLE NERVE, V19, P994, DOI 10.1002/(SICI)1097-4598(199608)19:8<994::AID-MUS7>3.0.CO;2-3; LOUBOUTIN JP, 1995, MUSCLE NERVE, V18, P1292, DOI 10.1002/mus.880181112; LU XY, 1994, J BIOL CHEM, V269, P6511; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PEREON Y, 1993, J COMP PHYSIOL B, V163, P203; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAY A, 1995, J BIOL CHEM, V270, P25837, DOI 10.1074/jbc.270.43.25837; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; Sierralta J, 1996, J BIOL CHEM, V271, P17028, DOI 10.1074/jbc.271.29.17028; SORRENTINO V, 1995, RYANDINE RECEPTORS; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	59	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19808	19813		10.1074/jbc.272.32.19808	http://dx.doi.org/10.1074/jbc.272.32.19808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242641	hybrid			2022-12-27	WOS:A1997XQ05900028
J	Yao, KM; Sha, M; Lu, ZJ; Wong, GG				Yao, KM; Sha, M; Lu, ZJ; Wong, GG			Molecular analysis of a novel winged helix protein, WIN - Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORK HEAD PROTEIN; TRANSCRIPTION FACTOR; ENDOCRINE-CELLS; GENE FAMILY; MOUSE; CLONING; RAT; SPECIFICITY; HNF-3-BETA; ACTIVATION	We have cloned a novel winged helix factor, WIN, from the rat insulinoma cell line, INS-1. Northern blot analysis demonstrated that WIN is highly expressed in a variety of insulinoma cell lines and rat embryonic pancreas and liver, In adults, WIN expression was detected in thymus, testis, lung, and several intestinal regions, We determined the DNA sequences bound in vitro by baculovirus-expressed WIN protein ire a polymerase chain reaction-based selection procedure, WIN was found to bind with high affinity to the selected sequence 5'-AGATTGAGTA-3', which is similar to the recently identified HNF-6 binding sequence 5'-DHWATTGAYTWWD-3' (where W = A or T, Y = T or C, H is not G, and D is not C), We have isolated human WIN cDNAs by library screening and 5'-rapid amplification of cDNA ends, Sequence analysis indicates that the carboxyl terminus of human WIN has been previously isolated as a putative phosphorylation substrate, MPM2-reactive phosphoprotein 2 (MPP2); WIN may be regulated by phosphorylation, Alignment of the rat and human WIN cDNAs and their comparison with mouse genomic sequence revealed that the WIN DNA binding domain is encoded by four exons, two of which (exons 4 and 6) are alternatively spliced to generate at least three classes of mRNA transcripts, These transcripts were shown by RNase protection assay to be differentially expressed in different tissues, Alternative splicing within the winged helix DNA binding domain might result in modulation of DNA binding specificity.	GENET INST INC,CAMBRIDGE,MA 02140				/C-4457-2009	/0000-0002-5923-0869				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; GUS Y, 1995, DEVELOPMENT, V121, P11; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HACKER U, 1995, EMBO J, V14, P5306, DOI 10.1002/j.1460-2075.1995.tb00215.x; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Offield MF, 1996, DEVELOPMENT, V122, P983; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	44	108	113	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19827	19836		10.1074/jbc.272.32.19827	http://dx.doi.org/10.1074/jbc.272.32.19827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242644	hybrid			2022-12-27	WOS:A1997XQ05900031
J	Kawasaki, H; Morooka, T; Shimohama, S; Kimura, J; Hirano, T; Gotoh, Y; Nishida, E				Kawasaki, H; Morooka, T; Shimohama, S; Kimura, J; Hirano, T; Gotoh, Y; Nishida, E			Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; NITRIC-OXIDE; MAMMALIAN-CELLS; NEURONAL DEATH; MESSENGER-RNA; NEUROTOXICITY; PHOSPHORYLATION	In the mammalian central nervous system glutamate is the major excitatory neurotransmitter and plays a crucial role in plasticity and toxicity of certain neural cells. We found that glutamate stimulated activation of p38 and stress-activated protein kinase (SAPK, also known as c-Jun N-terminal kinase (JNK)), two subgroup members of the mitogen-activated protein kinase superfamily in matured cerebellar granule cells. The p38 activation was largely mediated by N-methyl-D-aspartate receptors. Furthermore, we have revealed a novel signaling pathway, that is, Ca2+-mediated activation of p38 in glutamate-treated granule cells. The glutamate concentration effective for inducing apoptosis correlated with that for inducing p38 activation, SB203580, a specific inhibitor for p38, inhibited glutamate-induced apoptosis. Thus p38 might be involved in glutamate-induced apoptosis in cerebellar granule cells.	KYOTO UNIV,FAC MED,DEPT GENET & MOL BIOL,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT BIOPHYS,GRAD SCH SCI,BUNKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT NEUROL,BUNKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,BUNKYO KU,KYOTO 60601,JAPAN	Kyoto University; Kyoto University; Kyoto University; Kyoto University			KAWASAKI, Hiroshi/L-3736-2015; Kawasaki, Hiroshi/C-4404-2015	Kawasaki, Hiroshi/0000-0002-2514-1497				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BESSHO Y, 1993, J NEUROCHEM, V60, P253, DOI 10.1111/j.1471-4159.1993.tb05845.x; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COX JA, 1990, NEURON, V4, P941, DOI 10.1016/0896-6273(90)90147-8; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FINKBEINER S, 1988, P NATL ACAD SCI USA, V85, P4071, DOI 10.1073/pnas.85.11.4071; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDENREICH A, 1996, J BIOL CHEM, V271, P9891; HEISENBERG CP, 1992, NEUROREPORT, V3, P685, DOI 10.1097/00001756-199208000-00008; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MANEV H, 1989, MOL PHARMACOL, V36, P106; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RESINK A, 1994, BRAIN RES, V655, P222, DOI 10.1016/0006-8993(94)91617-9; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	363	372	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18518	18521		10.1074/jbc.272.30.18518	http://dx.doi.org/10.1074/jbc.272.30.18518			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228012	hybrid			2022-12-27	WOS:A1997XM34200003
J	Peterson, BZ; Johnson, BD; Hockerman, GH; Acheson, M; Scheuer, T; Catterall, WA				Peterson, BZ; Johnson, BD; Hockerman, GH; Acheson, M; Scheuer, T; Catterall, WA			Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; FUNCTIONAL EXPRESSION; ALLOSTERIC TRANSITION; CA2+ CHANNELS; BINDING DOMAINS; MOLECULAR-BASIS; SMOOTH-MUSCLE; H-3 AZIDOPINE; BETA-SUBUNIT	The dihydropyridine Ca2+ antagonist drugs used in the therapy of cardiovacular disorders inhibit L-type Ca2+ channels by binding to a single high affinity site, Photoaffinity labeling and analysis of mutant Ca2+ channels implicate the IIIS6 and IVS6 segments in high affinity binding, The amino acid residues that are required for high affinity binding of dihydropyridine Ca2+ channel antagonists were probed by alanine scanning mutagenesis of the alpha(1C) subunit, transient expression in mammalian cells, and analysis by measurements of ligand binding and block of Ba2+ currents through expressed Ca2+ channels, Eleven amino acid residues in transmembrane segments IIIS6 and IVS6 were identified whose mutation reduced the affinity for the Ca2+ antagonist PN200-110 by 2-25-fold. Both amino acid residues conserved among Ca2+ channels and those specific to L-type Ca2+ channels were found to be required for high affinity dihydropyridine binding, In addition, mutation F1462A increased the affinity for the dihydropyridine Ca2+ antagonist PN200-110 by 416-fold with no effect on the affinity for the Ca2+ agonist Bay K8644. The residues in transmembrane segments IIIS6 and IVS6 that are required for high affinity binding are primarily aligned on single faces of these two alpha helices, supporting a ''domain interface model'' of dihydropyridine binding and action in which the IIIS6 and IVS6 interact to form a high affinity dihydropyridine receptor site on L-type Ca2+ channels.			Peterson, BZ (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312, P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07312, P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE R, 1994, MOL PHARMACOL, V46, P660; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BECHEM M, 1987, J MOL CELL CARDIOL, V19, P63, DOI 10.1016/S0022-2828(87)80005-6; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; DIOCHOT S, 1995, PFLUG ARCH EUR J PHY, V431, P10, DOI 10.1007/BF00374372; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FERRY DR, 1984, FEBS LETT, V169, P112, DOI 10.1016/0014-5793(84)80299-9; GALIZZI JP, 1986, J BIOL CHEM, V261, P1393; GLOSSMANN H, 1984, J CARDIOVASC PHARM S, V6, P508; GOULD RJ, 1983, COLD SPRING HARB SYM, V48, P355, DOI 10.1101/SQB.1983.048.01.039; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KASS RS, 1989, J GEN PHYSIOL, V93, P1109, DOI 10.1085/jgp.93.6.1109; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1995, BIOCHEMISTRY-US, V34, P9350, DOI 10.1021/bi00029a010; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SEDYL K, 1993, PFLUGERS ARCH, V424, P552; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	59	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18752	18758		10.1074/jbc.272.30.18752	http://dx.doi.org/10.1074/jbc.272.30.18752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228048	hybrid			2022-12-27	WOS:A1997XM34200039
J	Yabe, D; Nakamura, T; Kanazawa, N; Tashiro, K; Honjo, T				Yabe, D; Nakamura, T; Kanazawa, N; Tashiro, K; Honjo, T			Calumenin, a Ca2+-binding protein retained in the endoplasmic reticulum with a novel carboxyl-terminal sequence, HDEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; GLUCOSE-REGULATED PROTEIN; LUMINAL ER PROTEINS; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; RECEPTOR; CALRETICULIN; RETENTION; MEMBRANE; SIGNAL	We have identified and characterized a cDNA encoding a novel Ca2+-binding protein named calumenin from mouse heart by the signal sequence trap method, The deduced amino acid sequence (315 residues) of calumenin contains an amino-terminal signal sequence and sis Ca2+-binding (EF-hand) motifs and shows homology with reticulocalbin, Erc-55, and Cab45. These proteins seem to form a new subset of the EF-hand protein family expressed in the lumen of the endoplasmic reticulum (ER) and Golgi apparatus. Purified calumenin had Ca2+-binding ability. The carboxyl-terminal tetrapeptide His-Asp-Glu-Phe was shown to be responsible far retention of calumenin in ER by the retention assay, immunostaining with a confocal laser microscope, and the deglycosylation assay, This is the first report indicating that the Phe residue is included in the ER retention signal, Calumenin is expressed most strongly in heart of adult and 18.5-day embryos. The calumenin gene (Calu) was mapped at the proximal portion of mouse chromosome 7.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Yabe, Daisuke/J-6682-2014; Honjo, Tasuku/N-4470-2016; Nakamura, Tomoyuki/AAX-9340-2020; Kanazawa, Nobuo/AAM-7353-2021	Yabe, Daisuke/0000-0002-5334-7687; Kanazawa, Nobuo/0000-0003-3000-9711				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRILLIANT MH, 1994, MAMM GENOME, V5, pS104; BRINK PA, 1995, CIRCULATION, V91, P1633, DOI 10.1161/01.CIR.91.6.1633; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHIESI M, 1981, J CELL BIOL, V91, P728, DOI 10.1083/jcb.91.3.728; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DANG CV, 1985, J BIOL CHEM, V260, P9713; DODDS D, 1995, J NEUROCHEM, V64, P2339; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; JACOBS K, 1996, Patent No. 5536637; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P47; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OBRIG TG, 1971, J BIOL CHEM, V246, P174; OHTA T, 1995, J BIOL CHEM, V270, P15571, DOI 10.1074/jbc.270.26.15571; OZAWA M, 1993, J BIOL CHEM, V268, P699; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SEMENZA JC, 1992, J MOL BIOL, V224, P1, DOI 10.1016/0022-2836(92)90571-Z; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WEIS K, 1994, J BIOL CHEM, V269, P19142; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, J BIOL CHEM, V266, P4500	54	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18232	18239		10.1074/jbc.272.29.18232	http://dx.doi.org/10.1074/jbc.272.29.18232			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218460	hybrid			2022-12-27	WOS:A1997XL73500050
J	Chen, Q; EngelbergKulka, H; AmsterChoder, O				Chen, Q; EngelbergKulka, H; AmsterChoder, O			The localization of the phosphorylation site of BglG, the response regulator of the Escherichia coli bgl sensory system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; PHOSPHOTRANSFERASE SYSTEM; BACILLUS-SUBTILIS; TRANSCRIPTIONAL ANTITERMINATOR; PROTEIN-PHOSPHORYLATION; OPERON; FAMILY; GENES; PHOSPHOENOLPYRUVATE; EXPRESSION	BglG, the response regulator of the bgl sensory system, was recently shown to be phosphorylated on a histidine residue, We report here the localization of the phosphorylation site to histidine 208, Localization of the phosphorylated histidine was carried out in two steps, We first engineered BglG derivatives with a specific protease (factor Xa) cleavage site that allowed asymmetric splitting of each prephosphorylated protein to well defined peptides, of which only one was labeled by radioactive phosphate, This allowed the localization of the phosphorylation site to the last 111 residues, Subsequently, we identified the phosphorylated histidine by mutating each of the three histidines located in this region to an arginine and following the ability of the resulting mutants to be in vivo regulated and in vitro phosphorylated by BglF, the bgl system sensor, Histidine 208 was the only histidine which failed both tests, The use of simple techniques to map the phosphorylation site should make this protocol applicable for the localization of phosphorylation sites in other proteins, The bgl system represents a new family of sensory systems, Thus, the mapping reported here is an important step toward the definition of the functional domains involved in the transduction of a signal by the components that constitute systems of this novel family.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL BIOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1993, J CELL BIOCHEM, V51, P83, DOI 10.1002/jcb.240510115; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BENHAR I, 1991, GENE, V103, P79, DOI 10.1016/0378-1119(91)90394-Q; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRUGER S, 1995, J BACTERIOL, V177, P5590; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; Miller J.H., 1972, EXPT MOL GENETICS; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PRASAD I, 1974, J BACTERIOL, V120, P638, DOI 10.1128/JB.120.2.638-650.1974; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SAIER MH, 1975, J BIOL CHEM, V250, P7078; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFLER S, 1967, J BACTERIOL, V93, P254, DOI 10.1128/JB.93.1.254-263.1967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	32	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17263	17268		10.1074/jbc.272.28.17263	http://dx.doi.org/10.1074/jbc.272.28.17263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211862	hybrid			2022-12-27	WOS:A1997XK16500005
J	Deprez, J; Vertommen, D; Alessi, DR; Hue, L; Rider, MH				Deprez, J; Vertommen, D; Alessi, DR; Hue, L; Rider, MH			Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BOVINE HEART; S6 KINASE; FRUCTOSE 2,6-BISPHOSPHATE; RAT-LIVER; FRUCTOSE-2,6-BISPHOSPHATASE; IDENTIFICATION; PURIFICATION; MUTAGENESIS; GLYCOLYSIS	To understand the insulin induced activation of 6-phosphofructo-2-kinase (PFK-S) of the bifunctional enzyme PFK-2/fructose-2,6-bisphosphatase in heart, the effect of phosphorylation by protein kinases of the insulin signaling pathways on PFK-2 activity was studied. Purified PFK-2/fructose-2,6-bisphosphatase from bovine heart is a mixture of two isoforms (M-r 58,000 and 54,000 on SDS-polyacrylamide gels). The M-r 54,000 protein is an alternatively spliced form, lacking phosphorylation sites for protein kinases, Recombinant enzymes corresponding to the M-r 58,000 (Bill) and M-r 54,000 (BH3) forms were expressed and used as substrates for phosphorylation. The recombinant BH1 isoform was phosphorylated by p70 ribosomal S6 kinase (p70(s6k)), mitogen activated protein kinase activated protein kinase-l, and protein kinase B (PKB), whereas the recombinant BH3 isoform was a poor substrate for these protein kinases. Treatment with all protein kinases activated PFK-P in the recombinant Bill preparation. Phosphorylation of the recombinant BH1 isoform correlated with PFK-S activation and was reversed by treatment with protein phosphatase 2A. All the protein kinases phosphorylated Ser-466 and Ser-483 in the BH1 isoform, but to different extents: p70(s6k) preferentially phosphorylated Ser-466, whereas mitogen-activated protein kinase-activated protein kinase-l and PKB phosphorylated Ser 466 and Ser-483 to a similar extent, We propose that PKB is part of the insulin signaling cascade for PFK-S activation in heart.	INT INST CELLULAR & MOL PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Dundee				Vertommen, Didier/0000-0001-7648-8282; Alessi, Dario/0000-0002-2140-9185				ABE Y, 1995, BIOCHEMISTRY-US, V34, P2553, DOI 10.1021/bi00008a020; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALLEN G, 1989, SEQUENCING PROTEINS, P140; BELACOSSA A, 1991, SCIENCE, V254, P244; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIKRI M, 1995, BIOCHEMISTRY-US, V34, P8876, DOI 10.1021/bi00027a040; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CREPIN KM, 1993, J BIOL CHEM, V268, P15277; CROSS DAE, 1995, NATURE, V378, P229; DARVILLE MI, 1991, FEBS LETT, V288, P91, DOI 10.1016/0014-5793(91)81009-W; DEPRE C, 1993, J BIOL CHEM, V268, P13274; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Gevaert K, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P15; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1990, FRUCTOSE 2 6 BISPHOS, P173; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KITAMURA K, 1988, J BIOL CHEM, V263, P1696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, FEBS LETT, V310, P139, DOI 10.1016/0014-5793(92)81315-D; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKATA J, 1991, BIOCHEM BIOPH RES CO, V180, P470, DOI 10.1016/S0006-291X(05)81088-5; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Vertommen D, 1996, J BIOL CHEM, V271, P17875, DOI 10.1074/jbc.271.30.17875; VIDAL H, 1993, FEBS LETT, V330, P329, DOI 10.1016/0014-5793(93)80898-5	41	333	350	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17269	17275		10.1074/jbc.272.28.17269	http://dx.doi.org/10.1074/jbc.272.28.17269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211863	hybrid			2022-12-27	WOS:A1997XK16500006
J	Hargrove, MS; Whitaker, T; Olson, JS; Vali, RJ; Mathews, AJ				Hargrove, MS; Whitaker, T; Olson, JS; Vali, RJ; Mathews, AJ			Quaternary structure regulates hemin dissociation from human hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION; ASSOCIATION; STABILITY; MYOGLOBIN; BINDING; GLOBIN	Rate constants for hemin dissociation from the alpha and beta subunits of native and recombinant human hemoglobins were measured as a function of protein concentration at pH 7.0, 37 degrees C, using H64Y/V68F apomyoglobin as a hemin acceptor reagent, Hemin dissociation rates were also measured for native isolated alpha and beta chains and for recombinant hemoglobin tetramers stabilized by alpha subunit fusion, The rate constant for hemin dissociation from beta subunits in native hemoglobin increases from 1.5 h(-1) in tetramers at high protein concentration to 15 h(-1) in dimers at low concentrations, The rate of hemin dissociation from alpha subunits in native hemoglobin is significantly smaller (0.3-0.6 h(-1)) and shows little dependence on protein concentration, Recombinant hemoglobins containing a fused di-alpha subunit remain tetrameric under all concentrations and show rates of hemin loss similar to those observed for wild-type and native hemoglobin at high protein concentration, Rates of hemin dissociation from monomeric alpha and beta chains are much greater, 12 and 40 h(-1), respectively, at pH 7, 37 degrees C, Aggregation of monomers to form alpha(1) beta(1) dimers greatly stabilizes bound hemin in cu chains, decreasing its rate of hemin loss similar to 20-fold. In contrast, dimer formation has little stabilizing effect on hemin binding to beta subunits, A significant reduction in the rate of hemin loss from beta subunits does occur after formation of the alpha(1) beta(2) interface in tetrameric hemoglobin, These results suggest that native human hemoglobin may have evolved to lose heme rapidly after red cell lysis, allowing the prosthetic group to be removed by serum albumin and apohemopexin.	RICE UNIV,WM KECK CTR COMPUTAT BIOL,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; SOMATOGEN INC,BOULDER,CO 80301	Rice University				Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-08280, GM-35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN ME, 1971, J BIOL CHEM, V246, P2796; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; Bucci E, 1981, Methods Enzymol, V76, P97; BUNN HF, 1968, J BIOL CHEM, V243, P465; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; GIBSON QH, 1948, BIOCHEM J, V42, P113; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; HENSLEY P, 1975, J BIOL CHEM, V250, P952; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LOOKER D, 1994, METHOD ENZYMOL, V231, P364; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; NAGEL RL, 1971, J BIOL CHEM, V246, P69; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; WIEDERMANN BL, 1975, J BIOL CHEM, V250, P5273; ZHANG L, 1991, J BIOL CHEM, V266, P24698	24	122	125	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17385	17389		10.1074/jbc.272.28.17385	http://dx.doi.org/10.1074/jbc.272.28.17385			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211878	hybrid			2022-12-27	WOS:A1997XK16500021
J	Kollar, R; Reinhold, BB; Petrakova, E; Yeh, HJC; Ashwell, G; Drgonova, J; Kapteyn, JC; Klis, FM; Cabib, E				Kollar, R; Reinhold, BB; Petrakova, E; Yeh, HJC; Ashwell, G; Drgonova, J; Kapteyn, JC; Klis, FM; Cabib, E			Architecture of the yeast cell wall - beta(1->6)-glucan interconnects mannoprotein, beta(1-3)-glucan, and chitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; NUCLEAR MAGNETIC-RESONANCE; SACCHAROMYCES-CEREVISIAE; SIDE-CHAIN; ENDOPLASMIC-RETICULUM; PATHOGENIC YEAST; CANDIDA-ALBICANS; BETA-GLUCAN; MANNAN; PROTEINS	In a previous study (Kollar, R., Petrakova, E., Ashwell, G,, Robbins, P, W,, and Cabib, E, (1995) J, Biol, Chem. 270, 1170-1178), the linkage region between chitin and beta(1-->3)-glucan was solubilized and isolated in the form of oligosaccharides, after digestion of yeast cell walls with beta(1-->3)-glucanase, reduction with borotritide, and subsequent incubation with chitinase. In addition to the oligosaccharides, the solubilized fraction contained tritium-labeled high molecular weight material, We have now investigated the nature of this material and found that it represents areas in which all four structural components of the cell wall, beta(1-->)-glucan, beta(1-->6)-glucan, chitin, and mannoprotein are linked together, Mannoprotein, with a protein moiety about 100 kDa in apparent size, is attached to beta(1-->6)-glucan through a remnant of a glycosylphosphatidylinositol anchor containing five iv-linked mannosyl residues, The beta(1-->6)-glucan has some beta(1-->)-linked branches, and it is to these branches that the reducing terminus of chitin chains appears to be attached in a beta(1-->4) or beta(1-->2) linkage, Finally, the reducing end of beta(1-->6)-glucan is connected to the nonreducing terminal glucose of beta(1-->3)-glucan through a linkage that remains to be established, A fraction of the isolated material has three of the main components but lacks mannoprotein, From these results and previous findings on the linkage between mannoproteins and beta(1-->6)-glucan, it is concluded that the latter polysaccharide has a central role in the organization of the yeast cell wall, The possible mechanism of synthesis and physiological significance of the cross-links is discussed.	NIDDK,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892; NIDDK,LAB CELL BIOCHEM & BIOL,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,BOSTON,MA 02118; US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV AMSTERDAM,INST MOL CELL BIOL,NL-1098 SM AMSTERDAM,NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Boston University; US Food & Drug Administration (FDA); University of Amsterdam			Klis, Frans M/B-9085-2008; Drgonova, Jana/B-2903-2008	Klis, Frans M/0000-0003-0079-9492; Drgonova, Jana/0000-0002-4623-8466				ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; ANGEL AS, 1980, MEHTODS ENZYMOL, V193, P587; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BASSIEUX D, 1977, CARBOHYD RES, V56, P19, DOI 10.1016/S0008-6215(00)84233-0; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BOCK K, 1973, TETRAHEDRON LETT, V13, P1037; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1988, MICROBIOL SCI, V5, P370; CABIB E, 1996, MYCOTA, V3, P243; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLSON P, 1974, J AM CHEM SOC, V96, P8081, DOI 10.1021/ja00833a038; DEBRUYN A, 1975, B SOC CHIM BELG, V84, P721; DENOBEL JG, 1990, YEAST, V6, P491, DOI 10.1002/yea.320060606; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FLEET GH, 1974, J BACTERIOL, V119, P207, DOI 10.1128/JB.119.1.207-219.1974; Frankhauser C., 1993, J BIOL CHEM, V268, P26365; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; JIMENEZBARBERO J, 1993, CARBOHYD RES, V250, P289, DOI 10.1016/0008-6215(93)84007-S; KEPTEYN JC, 1996, GLYCOBIOLOGY, V6, P337; KITAMURA K, 1974, J GEN APPL MICROBIOL, V20, P323, DOI 10.2323/jgam.20.323; KOBAYASHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P662, DOI 10.1016/0003-9861(92)90739-J; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE J, 1993, J AM SOC MASS SPECTR, V4, P197, DOI 10.1016/1044-0305(93)85081-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MANNERS DJ, 1973, BIOCHEM J, V135, P31, DOI 10.1042/bj1350031; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MILLER MW, 1994, J BIOL CHEM, V269, P9289; MOLANO J, 1980, J CELL BIOL, V85, P199, DOI 10.1083/jcb.85.2.199; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; NOVICK P, 1983, J CELL BIOL, V96, P541, DOI 10.1083/jcb.96.2.541; OGAWA T, 1982, CARBOHYD RES, V104, P271, DOI 10.1016/S0008-6215(00)82588-4; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBERTS RL, 1982, ANAL BIOCHEM, V127, P402, DOI 10.1016/0003-2697(82)90194-4; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; Ruiz-Herrera J., 1991, FUNGAL CELL WALL STR; SAITO H, 1987, CARBOHYD RES, V58, P293; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Shibata N, 1996, J BIOL CHEM, V271, P9259, DOI 10.1074/jbc.271.16.9259; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; TRAYER IP, 1971, J BIOL CHEM, V246, P6666; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; YOSHIOKA Y, 1985, CARBOHYD RES, V140, P93, DOI 10.1016/0008-6215(85)85052-7; ZLOTNIK H, 1984, J BACTERIOL, V159, P1018, DOI 10.1128/JB.159.3.1018-1026.1984	59	466	478	0	81	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17762	17775		10.1074/jbc.272.28.17762	http://dx.doi.org/10.1074/jbc.272.28.17762			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211929	hybrid, Green Submitted			2022-12-27	WOS:A1997XK16500072
J	Shulman, T; Sauer, FG; Jackman, RM; Chang, CN; Landolfi, NF				Shulman, T; Sauer, FG; Jackman, RM; Chang, CN; Landolfi, NF			An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; HUMANIZED ANTIBODIES; SIGNAL-TRANSDUCTION; LIGAND-BINDING; FACTOR PDGF; ACTIVATION	A panel of murine monoclonal antibodies was generated against the extracellular domain of the human platelet-derived growth factor (PDGF) beta receptor (PDGFR beta). These antibodies were assayed for both the ability to inhibit binding of PDGF BB 60 PDGFR beta(+) cells as well as the capacity to inhibit PDGF BB-mediated mitogenesis, As expected, all antibodies that could pre vent PDGF BB binding also inhibited mitogenesis. However one antibody (M4TS.11), with no detectable ability to inhibit PDGF BE binding, was a potent inhibitor of proliferation induced by PDGF EB. Further characterization indicated that M4TS.11 impaired PDGFR beta dimerization, revealing the mechanism by which it prevented PDGF EB-mediated mitogenesis, Using domain deletion mutants of the extracellular portion of PDGFR beta, the determinant recognized by this antibody was localized to the fourth extracellular domain of PDGFR beta, indicating that this domain, which is not involved in ligand binding, actively participates in receptor dimerization and signal transduction. The M4TS.11 antibody could also inhibit PDGF BB-mediated proliferation of responsive cells from both the baboon and the rabbit, indicating the determinant recognized by the antibody is not limited to humans and making it possible to use this antibody to evaluate the therapeutic benefit of interfering with PDGF in animal models of human disease.	PROT DESIGN LABS INC,MT VIEW,CA 94043									BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLAESSONWELSH L, 1993, CYTOKINES, V5, P31; Co MS, 1996, CANCER RES, V56, P1118; CO MS, 1992, J IMMUNOL, V148, P1149; CO MS, 1991, NATURE, V351, P501, DOI 10.1038/351501a0; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KNORR M, 1992, INVEST OPHTH VIS SCI, V33, P2207; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KOYOMA N, 1994, CIRC RES, V75, P682; LOWENTHAL JW, 1996, CURRENT PROTOCOLS IM; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WESTERMARK B, 1993, BIOL PLATELET DERIVE, V5, P146	25	19	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17400	17404		10.1074/jbc.272.28.17400	http://dx.doi.org/10.1074/jbc.272.28.17400			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211881	hybrid			2022-12-27	WOS:A1997XK16500024
J	Tenson, T; Xiong, LQ; Kloss, P; Mankin, AS				Tenson, T; Xiong, LQ; Kloss, P; Mankin, AS			Erythromycin resistance peptides selected from random peptide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT PEPTIDE; TRANSLATIONAL ATTENUATION; BACTERIAL-RIBOSOMES; LEADER PEPTIDE; MESSENGER-RNAS; AMINO-ACID; CHLORAMPHENICOL; DETERMINANT; SEQUENCE; CODON	Translation of a B-codon mini-gene encoded in Escherichia coli 23 S rRNA was previously shown to render cells resistant to erythromycin (Tenson, T., DeBlasio, A., and Mankin, A. S. (1996) Proc, Natl, Acad, Sci, U. S. A. 93, 5641-5646), Erythromycin resistance was mediated by a specific interaction of the 23 S rRNA-encoded pentapeptide with the ribosome. In the present study, peptides conferring erythromycin resistance were selected from in vivo expressed random peptide libraries to study structural features important for peptide activity, Screening of a al-codon mini-gene library (the general structure ATG (NNN)(20) TAA) demonstrated that only short peptides (3-6 amino acids long) conferred erythromycin resistance. Sequence comparison of erythromycin resistance peptides isolated from the 5-codon library (ATG (NNN)(4) TAA) revealed a strong preference for leucine or isoleucine as a third amino acid and a hydrophobic amino acid at the C terminus of the peptide, When tested against other antibiotics, erythromycin resistance peptides rendered cells resistant to other macrolides, oleandomycin and spiramycin, but not to chloramphenicol or clindamycin. Defining the consensus amino acid sequence of erythromycin resistance peptides provided insights into a possible mode of peptide action and the nature of the peptide binding site on the ribosome.	UNIV ILLINOIS, CTR PHARMACEUT BIOTECHNOL MC 870, CHICAGO, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Tenson, Tanel/I-6431-2015	Tenson, Tanel/0000-0002-0260-3601	NIGMS NIH HHS [GM53762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG FN, 1969, BIOCHIM BIOPHYS ACTA, V186, P396, DOI 10.1016/0005-2787(69)90020-3; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; Cundliffe E., 1981, MOL BASIS ANTIBIOTIC, V2nd, P402; Dam M, 1996, J MOL BIOL, V259, P1, DOI 10.1006/jmbi.1996.0296; DATTA N, 1974, J GEN MICROBIOL, V83, P191, DOI 10.1099/00221287-83-1-191; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GU ZP, 1993, J BACTERIOL, V175, P5309, DOI 10.1128/JB.175.17.5309-5313.1993; HOUGHTEN RA, 1993, TRENDS GENET, V9, P235, DOI 10.1016/0168-9525(93)90087-X; LOVETT PS, 1994, J BACTERIOL, V176, P6415, DOI 10.1128/JB.176.21.6415-6417.1994; LOVETT PS, 1990, J BACTERIOL, V172, P1, DOI 10.1128/JB.172.1.1-6.1990; MAO JCH, 1972, BIOCHEMISTRY-US, V11, P4864, DOI 10.1021/bi00775a035; MAYFORD M, 1989, J MOL BIOL, V206, P69, DOI 10.1016/0022-2836(89)90524-X; MCELWAIN KB, 1993, MOL GEN GENET, V241, P564, DOI 10.1007/BF00279898; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOFFAT JG, 1994, J BACTERIOL, V176, P7115, DOI 10.1128/JB.176.22.7115-7117.1994; MOTTAGUITABAR S, 1994, EMBO J, V13, P249, DOI 10.1002/j.1460-2075.1994.tb06255.x; OTAKA T, 1975, P NATL ACAD SCI USA, V72, P2649, DOI 10.1073/pnas.72.7.2649; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; TAI PC, 1974, BIOCHEMISTRY-US, V13, P4653, DOI 10.1021/bi00719a029; Tenson T, 1995, BIOCHEM CELL BIOL, V73, P1061, DOI 10.1139/o95-114; Tenson T, 1996, P NATL ACAD SCI USA, V93, P5641, DOI 10.1073/pnas.93.11.5641; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P169; WADE HE, 1966, BIOCHEM J, V101, P467, DOI 10.1042/bj1010467; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P797, DOI 10.1128/AAC.39.4.797; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	28	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17425	17430		10.1074/jbc.272.28.17425	http://dx.doi.org/10.1074/jbc.272.28.17425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211885	hybrid			2022-12-27	WOS:A1997XK16500028
J	Yamaoka, T; Kondo, M; Honda, S; Iwahana, H; Moritani, M; Ii, S; Yoshimoto, K; Itakura, M				Yamaoka, T; Kondo, M; Honda, S; Iwahana, H; Moritani, M; Ii, S; Yoshimoto, K; Itakura, M			Amidophosphoribosyltransferase limits the rate of cell growth-linked de novo purine biosynthesis in the presence of constant capacity of salvage purine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE SYNTHESIS; HUMAN-FIBROBLASTS; SYNTHESIS DENOVO; PHOSPHORIBOSYLPYROPHOSPHATE; HYPOXANTHINE; METABOLISM; HEPATOCYTES; LYMPHOCYTES; EXPRESSION; REPRESSOR	Factors controlling relative flux rates of the de novo and salvage pathways of purine nucleotide biosynthesis during animal cell growth are not fully understood, To examine the relative role of each pathway for cell. growth, three cell lines including CHO K1 (a wild-type Chinese hamster ovary fibroblast cell line), CHO ade (-)A (an auxotrophic cell line deficient of amidophosphoribosyltransferase (ATase), a presumed rate-limiting enzyme of the de novo pathway), and CHO ade (-)A transfected with human ATase cDNA ((-)A+hATase) resulting in 30-350% of the ATase activity of CHO K1, were cultured in purine-rich or purine-free media, Based on the enzyme activities of ATase and hypoxanthine phosphoribosyltransferase, the metabolic rate of the de novo and salvage pathways, the rate of cell growth (growth rate) in three cell lines under various culture conditions, and the effect of hypoxanthine infusion on the metabolic rate of the de novo pathway in rat liver, we concluded the following, 1) In (-)A+hATase transfectants, ATase activity limits the rate of the de novo pathway, which is closely linked with the growth rate, 2) Purine nucleotides are synthesized preferentially by the salvage path way as long as hypoxanthine, the most essential source of purine salvage, can be utilized, which was confirmed in rat liver in vivo by hypoxanthine infusion, The preferential usage of the salvage pathway results in sparing the energy expenditure required for de novo synthesis, 3) The regulatory capacity of the de novo pathway (about 200%) was larger than that of the salvage pathway (about 20%) with constant hypoxanthine phosphoribosyltransferase activity.	UNIV TOKUSHIMA, SCH MED, OTSUKA DEPT CLIN & MOL NUTR, TOKUSHIMA 770, JAPAN	Tokushima University								AHMED N, 1994, LEUKEMIA RES, V18, P441, DOI 10.1016/0145-2126(94)90080-9; ALEXIOU M, 1992, DEVELOPMENT, V114, P185; ALLISON AC, 1975, LANCET, V2, P1179; BARDOT V, 1994, BRIT J CANCER, V70, P212, DOI 10.1038/bjc.1994.282; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BOSS GR, 1982, J BIOL CHEM, V257, P4242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSH S, 1976, J CLIN INVEST, V58, P289, DOI 10.1172/JCI108471; DESROSIERS C, 1980, CAN J BIOCHEM CELL B, V58, P599; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; HERSHFIELD MS, 1977, SCIENCE, V197, P1284, DOI 10.1126/science.197600; ITAKURA M, 1987, AM J PHYSIOL, V253, pE684, DOI 10.1152/ajpendo.1987.253.6.E684; ITAKURA M, 1979, J BIOL CHEM, V333, P999; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1994, BIOCHIM BIOPHYS ACTA, V1261, P369; IWAMAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KING ME, 1983, J CLIN INVEST, V72, P965, DOI 10.1172/JCI111068; LILIEMARK J, 1992, LEUKEMIA RES, V16, P275, DOI 10.1016/0145-2126(92)90065-F; NATSUMEDA Y, 1985, CANCER RES, V45, P2556; NATSUMEDA Y, 1984, CANCER RES, V44, P2475; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROWE PB, 1983, P NATL ACAD SCI-BIOL, V80, P7333, DOI 10.1073/pnas.80.23.7333; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; STEEN AM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P77, DOI 10.1016/0167-4781(91)90155-F; THOMPSON LF, 1985, J IMMUNOL, V134, P3794; TSUCHIYA M, 1990, AM J PHYSIOL, V258, pC841, DOI 10.1152/ajpcell.1990.258.5.C841; UEMURA N, 1992, BLOOD, V80, P3198; WEBER G, 1987, ADV ENZYME REGUL, V26, P335, DOI 10.1016/0065-2571(87)90022-7; WEBER G, 1983, ADV ENZYME REGUL, V21, P53, DOI 10.1016/0065-2571(83)90008-0; ZOREFSHANI E, 1980, ENZYME, V25, P413, DOI 10.1159/000459290	35	52	54	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17719	17725		10.1074/jbc.272.28.17719	http://dx.doi.org/10.1074/jbc.272.28.17719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211923	hybrid			2022-12-27	WOS:A1997XK16500066
J	Zhang, XL; Loijens, JC; Boronenkov, IV; Parker, GJ; Norris, FA; Chen, J; Thum, O; Prestwich, GD; Majerus, PW; Anderson, RA				Zhang, XL; Loijens, JC; Boronenkov, IV; Parker, GJ; Norris, FA; Chen, J; Thum, O; Prestwich, GD; Majerus, PW; Anderson, RA			Phosphatidylinositol-4-phosphate 5-kinase isozymes catalyze the synthesis of 3-phosphate-containing phosphatidylinositol signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHOLIPIDS; 4-PHOSPHATE 5-KINASE; HUMAN PLATELETS; PATHWAY; 3,4-BISPHOSPHATE; CELLS; PHOSPHORYLATION; HYDROLYSIS; SEQUENCE; KINASES	Phosphatidylinositol-4-phosphate 5-kinases (PIP5Ks) utilize phosphatidylinositols containing D-3-position phosphates as substrates to form phosphatidylinositol 3,4-bisphosphate, In addition, type I PIP5Ks phosphorylate phosphatidylinositol a,4-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate, while type IT kinases have less activity toward this substrate. Remarkably, these kinases can convert phosphatidylinositol 3-phosphate to phosphatidylinositol 3,4,5-trisphosphate in a concerted reaction, Kinase activities toward the 3-position phosphoinositides are comparable with those seen with phosphatidylinositol 4-phosphate as the substrate. Therefore, the PIP5Ks can synthesize phosphatidyl-inositol 4,5-bisphosphate and two 3-phosphate-containing polyphosphoinositides. These unexpected activities position the PIP5Ks as potential participants in the generation of all polyphosphoinositide signaling molecules.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63100; WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM & MOL BIOPHYS,DIV HEMATOL ONCOL,ST LOUIS,MO 63100; UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM MOL & CELLULAR BIOL,MADISON,WI 53706; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah			Thum, Oliver/F-2201-2010	Thum, Oliver/0000-0002-2568-1450; Anderson, Richard/0000-0001-6265-8359	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672, HL 16634] Funding Source: Medline; NIGMS NIH HHS [GM 51968] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BREARLEY CA, 1993, BIOCHEM J, V290, P145, DOI 10.1042/bj2900145; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LING LE, 1989, J BIOL CHEM, V264, P5080; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	33	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17756	17761		10.1074/jbc.272.28.17756	http://dx.doi.org/10.1074/jbc.272.28.17756			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211928	hybrid			2022-12-27	WOS:A1997XK16500071
J	Azad, AK; Sirakova, TD; Fernandes, ND; Kolattukudy, PE				Azad, AK; Sirakova, TD; Fernandes, ND; Kolattukudy, PE			Gene knockout reveals a novel gene cluster for the synthesis of a class of cell wall lipids unique to pathogenic mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; MYCOCEROSIC ACID SYNTHASE; PHTHIOCEROL DIESTER; TUBERCULOSIS; LEPRAE; BIOSYNTHESIS; SUPPRESSION; GLYCOLIPIDS; LEPROSY; ENZYME	Surface-exposed unusual lipids containing phthiocerol and phenolphthiocerol are found only in the cell wall of slow-growing pathogenic mycobacteria and are thought to play important roles in host-pathogen interaction, The enzymology and molecular genetics of biosynthesis of phthiocerol and phenolphthiocerol are unknown, We postulate the domain organization of a set of multifunctional enzymes and a cluster of genes (pps) that would encode these enzymes for the biosynthesis of phthiocerol and phenolphthiocerol, A cosmid containing the postulated pps gene cluster was identified by screening a genomic library of Mycobacterium bovis BCG with the postulated homologous domains from mycocerosic acid synthase and fatty acid synthase genes as probes, Homologous cosmids were also identified in the genomic libraries of Mycobacterium tuberculosis and Mycobacterium leprae, M. bovis BCG was transformed with a pps disruption construct, made from the BCG cosmid by introducing the hygromycin resistance gene as the positive-selectable marker and the sacB gene as the counter-selectable marker, Gene disruption by homologous recombination with double crossover was confirmed by polymerase chain reaction and Southern hybridization, Chromatographic analysis showed that the phenolphthiocerol derivative, mycoside B, and phthiocerol dimycocerosates were not produced by the gene knockout mutants, This result confirms the identity of the pps genes, With the identification of the pps gene clusters in both M. tuberculosis and M. leprae, it should be possible to test the postulated roles of these unique lipids in tuberculosis and leprosy.	OHIO STATE UNIV, NEUROBIOTECHNOL CTR, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM MED, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			kolattukudy, pappachan e/A-1350-2012		NCI NIH HHS [CA66029] Funding Source: Medline; NIAID NIH HHS [R01 AI35272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1996, WORLD HLTH REP; Asselineau C, 1984, MYCOBACTERIA SOURC A, P345; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Balasubramanian V, 1996, J BACTERIOL, V178, P273, DOI 10.1128/jb.178.1.273-279.1996; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DAFFE M, 1989, BIOCHIM BIOPHYS ACTA, V1002, P333, DOI 10.1016/0005-2760(89)90347-0; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; GASTAMBIDEODIER M, 1967, B SOC CHIM BIOL, V49, P849; GASTAMBIDEODIER M, 1966, CR ACAD SCI C CHIM, V262, P1401; GASTAMBIDEODIER M, 1963, CHEM IND-LONDON, P1285; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; LAUNOIS P, 1989, RES IMMUNOL, V140, P847, DOI 10.1016/0923-2494(89)90044-8; LYDIATE DJ, 1989, J GEN MICROBIOL, V135, P941; MATHUR M, 1992, J BIOL CHEM, V267, P19388; McFadden J, 1996, MOL MICROBIOL, V21, P205, DOI 10.1046/j.1365-2958.1996.6271345.x; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Pelicic V, 1996, J BACTERIOL, V178, P1197, DOI 10.1128/jb.178.4.1197-1199.1996; PUZO G, 1990, CRIT REV MICROBIOL, V17, P305, DOI 10.3109/10408419009105730; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; REYRAT JM, 1995, P NATL ACAD SCI USA, V92, P8768, DOI 10.1073/pnas.92.19.8768; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; TAKAYAMA K, 1984, MYCOBACTERIA SOURC A, P315; Thurman P, 1989, Acta Leprol, V7 Suppl 1, P74; VACHULA M, 1989, J IMMUNOL, V142, P1696; YOUNG DB, 1993, J BACTERIOL, V175, P1, DOI 10.1128/JB.175.1.1-6.1993; Young Douglas B., 1994, P559	34	116	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16741	16745		10.1074/jbc.272.27.16741	http://dx.doi.org/10.1074/jbc.272.27.16741			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201977	hybrid			2022-12-27	WOS:A1997XH44600009
J	Baumann, C; Xirasagar, S; Gollnick, P				Baumann, C; Xirasagar, S; Gollnick, P			The trp RNA-binding attenuation protein (TRAP) from Bacillus subtilis binds to unstacked trp leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED POLYNUCLEOTIDES; DNA; COMPLEXES; BACTERIOPHAGE-T4; CONFORMATION; TRANSCRIPTS; STABILITY; DICHROISM; SEQUENCE; REPEATS	TRAP (trp RNA-binding attenuation protein) is a tryptophan-activated RNA-binding protein that regulates expression of the trp biosynthetic genes by binding to a series of GAG and UAG trinucleotide repeats generally separated by two or three spacer nucleotides, previously, we showed that TRAP contains II identical subunits arranged in a symmetrical ring, Based on this structure, we proposed a model for the TRAP.RNA interaction where the RNA wraps around the protein with each repeat of the RNA contacting one or a combination of two adjacent subunits of the TRAP oligomer, Here, we have shown that RNAs selected in vitro based on their ability to bind tryptophan-activated TRAP contain multiple G/UAG repeats and show a strong bias for pyrimidines as the spacer nucleotides between these repeats, The affinity of the TRAP RNA interaction displays a nonlinear temperature dependence, increasing between 5 degrees C and 47 degrees C and then decreasing from 47 degrees C to 67 degrees C, Differential scanning calorimetry and circular dichroism spectroscopy demonstrate that TRAP is highly thermostable with few detectable changes in the structure between 25 degrees C and 70 degrees C, suggesting that the temperature dependence of this interaction reflects changes in the RNA, Results from circular dichroism and UV absorbance spectroscopy support this hypothesis, demonstrating that trp leader RNA becomes unstacked upon binding TRAP, We propose that the bias toward pyrimidines in the spacer nucleotides of the in vitro selected RNAs represents the inability of Us and Cs to form stable base stacking interactions, which allows the flexibility needed for the RNA to wrap around the TRAP oligomer.	SUNY BUFFALO, DEPT SCI BIOL, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BRAHMS J, 1966, J MOL BIOL, V15, P467, DOI 10.1016/S0022-2836(66)80122-5; BROYDE S, 1978, NUCLEIC ACIDS RES, V5, P2729, DOI 10.1093/nar/5.8.2729; COLEMAN JE, 1979, CRC CR REV BIOCH MOL, V7, P247, DOI 10.3109/10409238009105463; DOORNBOS J, 1983, EUR J BIOCHEM, V131, P571, DOI 10.1111/j.1432-1033.1983.tb07301.x; FERRARI ME, 1994, BIOCHEMISTRY-US, V33, P12896, DOI 10.1021/bi00209a022; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Hall KB, 1995, METHOD ENZYMOL, V259, P261; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KANE JF, 1972, J BIOL CHEM, V247, P1587; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LENG M, 1966, J MOL BIOL, V15, P455, DOI 10.1016/S0022-2836(66)80121-3; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEERHAGEN MA, 1986, BIOPOLYMERS, V25, P1419, DOI 10.1002/bip.360250805; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Tuerk Craig, 1994, P475; VANAMERONGEN H, 1989, J MOL BIOL, V209, P433, DOI 10.1016/0022-2836(89)90008-9; VANAMERONGEN H, 1987, BIOCHEMISTRY-US, V26, P4646, DOI 10.1021/bi00389a009; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	38	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19863	19869		10.1074/jbc.272.32.19863	http://dx.doi.org/10.1074/jbc.272.32.19863			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242649	hybrid			2022-12-27	WOS:A1997XQ05900036
J	Kondoh, S; Ishii, K; Nakamura, Y; Taira, N				Kondoh, S; Ishii, K; Nakamura, Y; Taira, N			A mammalian transient type K+ channel, rat Kv1.4, has two potential domains that could produce rapid inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; PEPTIDE; MECHANISMS; SUBUNIT; BLOCKS	The ''ball and chain'' model has been shown to be suitable for explaining the rapid inactivation of voltage-dependent K+ channels, For the Drosophila Shaker K+ channel (ShB), the first 20 residues of the amino terminus have been identified as the inactivation ball that binds to the open channel pore and blocks ion flow (Hoshi, T., Zagotta, W. N., and Aldrich, R. W. (1990) Science 250, 533-538; Zagotta, W. N., Hoshi, T., and Aldrich, R. W. (1990) Science 250, 568-571), We studied the structural elements responsible for rapid inactivation of a mammalian transient type K+ channel (rat Kv1.4) by constructing various mutants in the amino terminus and expressing them in Xenopus oocytes, Although it has been reported that the initial 37 residues might form the inactivation ball for rat Kv1.4 (Tseng-Crank, J., Yao, J.-A., Berman M. F., and Tseng, G.-N. (1993) J. Gen. Physiol, 102, 1057-1083), we found that not only the initial 37 residues, but also the following region, residues 40-68, could function independently as an inactivation gate, Like the Shaker inactivation ball, both potential inactivation domains have a hydrophobic amino-terminal region and a hydrophilic carboxyl-terminal region having net positive charge, which is essential for the domains to function as an inactivation gate.	TOHOKU UNIV,SCH MED,DEPT PHARMACOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University								Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; COMER MB, 1994, AM J PHYSIOL-HEART C, V267, pH1383, DOI 10.1152/ajpheart.1994.267.4.H1383; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; OKADA H, 1992, BIOCHEM BIOPH RES CO, V18, P430; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sambrook J., 2002, MOL CLONING LAB MANU; SOLARO CR, 1992, SCIENCE, V257, P1694, DOI 10.1126/science.1529355; TORO L, 1994, BIOCHEMISTRY-US, V33, P7220, DOI 10.1021/bi00189a026; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; TSENG GN, 1992, CIRC RES, V71, P657, DOI 10.1161/01.RES.71.3.657; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	20	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19333	19338		10.1074/jbc.272.31.19333	http://dx.doi.org/10.1074/jbc.272.31.19333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235930	hybrid			2022-12-27	WOS:A1997XP06300036
J	Ammit, AJ; ONeill, C				Ammit, AJ; ONeill, C			Studies of the nature of the binding by albumin of platelet-activating factor released from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN-SERUM ALBUMIN; FACTOR PAF; LIMITED PROTEOLYSIS; CULTURE; RADIOIMMUNOASSAY; PROSTACYCLIN; THIOREDOXIN; SYNTHESIZE; MODULATION	This report confirms that human umbilical vein endothelial cells activated by A23187 produce platelet-activating factor (PAF) (22.4 +/- 9.9 ng/10(6) cells/h; mean +/- S.E.). A proportion of the PAF produced (56%) was released by cells into the medium, The PAF released, however, was not detected without prior organic extraction, and the method of organic extraction was critical for detection, Extraction with 80% ethanol was not successful, but a modified methanol/chloroform extraction method was, These observations may explain some of the conflicting reports in the literature on release of PAF by activated endothelial cells, The requirements for organic extraction may reflect the nature of cell-released PAF's binding by albumin; it was observed that PAF added to identical media could be detected in a bioassay without the requirement for extraction, Such PAF was also readily degraded by PAF-acetylhydrolase added to media, while PAF released from cells was resistant to such degradation, suggesting that it was released in a ''protected'' configuration, Stimulation of cells was performed in media with albumin as the only extracellular macromolecule. Limited proteolytic digestion of the albumin with trypsin and pepsin showed that PAF released by cells was located exclusively between amino acids 240 and 386 (domain II), while no synthetic PAF added to media was located on this region, These results are identical to those described for the release of PAF by the early embryo, Albumin exposed to embryos had a higher thiol concentration (0.77 +/- 0.04 mu mol of thiol/mu mol of albumin; mean +/- S.E.) than control media to which an equivalent amount of synthetic PAF was added (0.59 +/- 0.02 mu mol of thiol/mu mol of albumin) (measured with Ellman's reagent), Furthermore, albumin from conditioned media was more susceptible to reduction by 10 mM dithiothreitol than control albumin, as assessed by its mobility on PAGE. The protected configuration of released PAF was caused by cell-dependent conformational changes to albumin involving cysteine-cysteine disulfide bonds, Partial reduction with dithiothreitol of albumin exposed to cells resulted in released PAF being able to be detected directly in a bioassay without the requirement for prior organic extraction.	UNIV SYDNEY,ROYAL N SHORE HOSP,HUMAN REPROD UNIT,DEPT PHYSIOL,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV SYDNEY,ROYAL N SHORE HOSP,HUMAN REPROD UNIT,DEPT OBSTET & GYNAECOL,ST LEONARDS,NSW 2065,AUSTRALIA	Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney				O'Neill, Christopher/0000-0003-4003-8727; Ammit, Alaina/0000-0003-0555-2544				Ammit AJ, 1997, J REPROD FERTIL, V109, P309, DOI 10.1530/jrf.0.1090309; AMMIT AJ, 1991, J PHARMACOL METHOD, V29, P7; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bratton D, 1989, PLATELET ACTIVATING, P23; BRODERSEN R, 1990, EUROPEAN J BIOCH, V189, P339; BROWN JR, 1976, FED PROC, V35, P2141; BROWN JR, 1974, FED PROC, V33, P1389; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P25; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; BUSSOLINO F, 1987, BIOCHIM BIOPHYS ACTA, V927, P43, DOI 10.1016/0167-4889(87)90064-4; CABRE F, 1993, AGENTS ACTIONS, V38, P212, DOI 10.1007/BF01976213; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CARAMELO C, 1987, EUR J CLIN INVEST, V17, P7, DOI 10.1111/j.1365-2362.1987.tb01218.x; CARAMELO C, 1984, BIOCHEM BIOPH RES CO, V120, P789, DOI 10.1016/S0006-291X(84)80176-X; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; COLLIER M, 1990, HUM REPROD, V5, P323, DOI 10.1093/oxfordjournals.humrep.a137098; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; DEAN MF, 1994, BIOCHEM J, V304, P861, DOI 10.1042/bj3040861; DEMPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENT G, 1990, PLATELET ACTIVATING, P23; FELDHOFF RC, 1975, BIOCHEMISTRY-US, V14, P4508, DOI 10.1021/bi00691a027; FOUNTOULAKIS M, 1992, J BIOL CHEM, V267, P7095; GHIGGERI GM, 1983, CLIN CHIM ACTA, V130, P257, DOI 10.1016/0009-8981(83)90124-9; HIRAFUJI M, 1987, BIOCHIM BIOPHYS ACTA, V930, P359, DOI 10.1016/0167-4889(87)90009-7; HOLTZMAN MJ, 1991, BIOCHEM BIOPH RES CO, V177, P357, DOI 10.1016/0006-291X(91)91991-K; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; KING TP, 1961, J BIOL CHEM, V236, pPC5; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MONTRUCCHIO G, 1993, CIRCULATION, V88, P1479; ONEILL C, 1985, J REPROD FERTIL, V75, P375; PETERS T, 1975, BIOCHEMISTRY-US, V14, P3384, DOI 10.1021/bi00686a015; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; QUINN P, 1985, FERTIL STERIL, V44, P493; REED RG, 1989, J BIOL CHEM, V264, P9867; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SALARI H, 1986, J CHROMATOGR, V382, P89, DOI 10.1016/S0378-4347(00)83507-0; SMAL MA, 1990, J IMMUNOL METHODS, V128, P183, DOI 10.1016/0022-1759(90)90209-E; SMAL MA, 1990, J MOL RECOGNITION, V3, P168; STEWART AG, 1989, BRIT J PHARMACOL, V96, P503, DOI 10.1111/j.1476-5381.1989.tb11845.x; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; SUGATANI J, 1990, LIFE SCI, V46, P1443, DOI 10.1016/0024-3205(90)90460-9; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1987, AM REV RESPIR DIS, V136, P204, DOI 10.1164/ajrccm/136.1.204	55	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18772	18778		10.1074/jbc.272.30.18772	http://dx.doi.org/10.1074/jbc.272.30.18772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228051	hybrid			2022-12-27	WOS:A1997XM34200042
J	Lutsenko, S; Petrukhin, K; Cooper, MJ; Gilliam, CT; Kaplan, JH				Lutsenko, S; Petrukhin, K; Cooper, MJ; Gilliam, CT; Kaplan, JH			N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilson's and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CADMIUM-RESISTANCE; ESCHERICHIA-COLI; CANDIDATE GENE; ATPASE; ORGANIZATION; SITE; CDNA	N-terminal domains of the Wilson's and Menkes disease proteins (N-WND and N-MNK) were overexpressed in a soluble form in Escherichia coli as fusions;vith maltose-binding protein, purified, and their metal-binding properties were characterized, Both N-MNK and N-WND bind copper specifically as indicated by the results of metal-chelate chromatography, direct copper-binding measurements, and chemical modification of Cys residues hi the presence of different heavy metals. When E. coli cells are grown in the presence of copper, N-MNK and N-WND bind copper in vivo with stoichiometry of 5-6 nmol of copper/nmol of protein. Copper released from the copper-N-MNK and copper-N-WND complexes reacts with the Cu(I)-selective chelator bicinchoninic acid in the absence of reducing agents. This suggests that in proteins, it is bound in reduced Cu(I) form, in agreement with the spectroscopic properties of the copper-bound domains. Copper bound to the domains in vivo or in vitro specifically protects the N-MNK and N-WND against labeling with the cysteine-directed probe; this indicates that Cys residues in the repetitive motifs GMTCXPCXXXIE are involved in coordination of copper. Direct involvement of the N-terminal domains in the binding of copper suggests their important role in copper-dependent functions of human copper-transporting adenosine triphosphatases (Wilson's and Menkes disease proteins).	MERCK RES LABS, DEPT HUMAN GENET, W POINT, PA 19486 USA; COLUMBIA UNIV, DEPT GENET, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA	Merck & Company; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute	Lutsenko, S (corresponding author), OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA.			Petrukhin, Konstantin/0000-0002-5545-6924; Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL 30315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Danks DM, 1989, METABOLIC BASIS INHE, P1411; HARRIS TJR, 1986, MOL BIOL MED, V3, P279; KALER SG, 1994, NAT GENET, V8, P195, DOI 10.1038/ng1094-195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; LUTSENKO S, 1997, IN PRESS ANN REV ACA; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOMAS GR, 1995, NAT GENET, V9, P210; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WALSH CT, 1988, FASEB J, V2, P124, DOI 10.1096/fasebj.2.2.3277886; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	22	205	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18939	18944		10.1074/jbc.272.30.18939	http://dx.doi.org/10.1074/jbc.272.30.18939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228074	hybrid			2022-12-27	WOS:A1997XM34200065
J	Pietila, M; Alhonen, L; Halmekyto, M; Kanter, P; Janne, J; Porter, CW				Pietila, M; Alhonen, L; Halmekyto, M; Kanter, P; Janne, J; Porter, CW			Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in transgenic mice overexpressing spermidine/spermine N-1-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; SPERMINE N1-ACETYLTRANSFERASE; CELL-TRANSFORMATION; C-MYC; EXPRESSION; METABOLISM; ONCOGENE; MUTATION; ANALOGS; ODC	We have generated a transgenic mouse line that overexpresses the rate controlling enzyme of polyamine catabolism, spermidine/spermine N-1-acetyltransferase. Tissues of these mice showed markedly distorted polyamine pools, which in most cases were characterized by the appearance of N-1-acetylspermidine, not normally found in mouse tissues, a massive accumulation of putrescine, and decreases in spermidine and/or spermine pools. The most striking phenotypic change was permanent hair loss at the age of 3 to 4 weeks which was typified histologically by the appearance of extensive follicular cysts in the dermis, The effect seemed attributable to putrescine interference with hair development, possibly with differentiation/proliferation of epidermal cells located in hair follicles, Female members of the transgenic line were found to be infertile apparently due to ovarian hypofunction and hypoplastic uteri, The findings demonstrate the utility of spermidine/spermine N-1-acetyltransferase overexpression as an effective means for genetically modulating total tissue polyamine pools in transgenic animals and examining the developmental and oncogenic consequences.	ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263; UNIV KUOPIO,AI VIRTANEN INST,FIN-70211 KUOPIO,FINLAND	Roswell Park Cancer Institute; University of Eastern Finland					NATIONAL CANCER INSTITUTE [R01CA022153, R01CA065942] Funding Source: NIH RePORTER; NCI NIH HHS [CA-65942, CA-22153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALHONEN L, 1995, INT J CANCER, V63, P402, DOI 10.1002/ijc.2910630317; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; HALMEKYTO M, 1993, BIOCHEM J, V291, P505, DOI 10.1042/bj2910505; HALMEKYTO M, 1991, J BIOL CHEM, V266, P19746; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Hogan B, 1986, MANIPULATING MOUSE E, P1; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; JONES JM, 1993, MAMM GENOME, V4, P639, DOI 10.1007/BF00360900; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Lutz W, 1996, ONCOGENE, V13, P803; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEGOSH L, 1995, CANCER RES, V55, P4205; MOSHIER JA, 1993, CANCER RES, V53, P2618; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PENA A, 1993, J BIOL CHEM, V268, P27277; PERALTASOLER A, 1996, J INVEST DERMATOL, V106, P1108; PILZ RB, 1990, J BIOL CHEM, V265, P8880; POLVINEN K, 1988, BIOCHEM BIOPH RES CO, V155, P373, DOI 10.1016/S0006-291X(88)81095-7; Porter C. W., 1992, V62, P301; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; VARGIU C, 1994, FEBS LETT, V355, P163, DOI 10.1016/0014-5793(94)01183-4; VOGELPETROVIC M, 1996, BIOCHEMISTRY-US, V35, P14436; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879	39	107	109	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18746	18751		10.1074/jbc.272.30.18746	http://dx.doi.org/10.1074/jbc.272.30.18746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228047	hybrid			2022-12-27	WOS:A1997XM34200038
J	Antoine, B; LefranoisMartinez, AM; LeGuillou, G; Leturque, A; Vandewalle, A; Kahn, A				Antoine, B; LefranoisMartinez, AM; LeGuillou, G; Leturque, A; Vandewalle, A; Kahn, A			Role of the GLUT 2 glucose transporter in the response of the L-type pyruvate kinase gene to glucose in liver-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; TRANSGENIC MICE; MESSENGER-RNA; BETA-CELLS; ISLET CELLS; EXPRESSION; GLUCOKINASE; PROMOTER; LINES; CARCINOGENESIS	Twenty-six different hepatoma cell lines established from cancer-prone transgenic mice exhibited a close correlation between expression of the GLUT 2 glucose transporter and activation of the L-type pyruvate kinase (L-PK) gene by glucose, as judged by Northern blot analyses and transient transfection assays. The L-PK gene and a transfected L-PK construct were silent in GLUT 2(+) cells and active in GLUT 2(-) cells cultured in glucose-free medium, Transfection of GLUT 2(-) cells with a GLUT 2 expression vector restored the inducibility of the L-PK promoter by glucose, mainly by suppressing the glucose-independent activity of this promoter, Culture of GLUT 2(-) cells, in which the L-PK gene is constitutively expressed, in a culture medium using fructose as fuel selected GLUT 2(+) clones in which the L-PK gene responded to glucose. The expression of the L-PKgene in GLUT 2(-) cells cultured in the absence of glucose was correlated with a high intracellular glucose B-phosphate (Glu-6-P) concentration while under similar culture conditions Glu-6-P concentration was very low in GLUT 2(+) cells, Consequently, a role of GLUT 2 in the glucose responsiveness of glucose-sensitive genes in cultured hepatoma cells could be to allow for Glu-6-P depletion under gluconeogenic culture conditions. In the absence of GLUT 2, glucose endogeneously produced might be unable to be exported from the cells and would be phosphorylated again to Glu-6-P by constitutively expressed hexokinase isoforms, continuously generating the glycolytic intermediates active on the L-PK gene transcription.	CNRS,CTR RECH ENDOCRINOL MOL & DEV,F-92190 MEUDON,FRANCE; UNIV PARIS 07,INST FEDERAT RECH,INSERM U246,F-75018 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Antoine, B (corresponding author), UNIV PARIS 05,INST COCHIN GENET MOL,INSERM U129,F-75014 PARIS,FRANCE.		Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; ANTOINE B, 1997, IN PRESS EXP CELL RE; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CARTIER N, 1992, ONCOGENE, V7, P1413; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FERRER J, 1995, DIABETES, V44, P1369, DOI 10.2337/diabetes.44.12.1369; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; LACHAAL M, 1993, AM J PHYSIOL, V265, pE914, DOI 10.1152/ajpendo.1993.265.6.E914; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; MARIE S, 1993, J BIOL CHEM, V268, P23881; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; NEWGARD CB, 1994, DIABETES, V43, P341, DOI 10.2337/diabetes.43.3.341; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SHAPIRA F, 1961, ENZYMOL BIOL CLIN, V7, P170; SLEIN MW, 1963, METHOD ENZYMAT AN, P1238; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VALERA A, 1994, J BIOL CHEM, V269, P28543; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	37	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17937	17943		10.1074/jbc.272.29.17937	http://dx.doi.org/10.1074/jbc.272.29.17937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218418	hybrid			2022-12-27	WOS:A1997XL73500008
J	Devos, R; Guisez, Y; VanderHeyden, J; White, DW; Kalai, M; Fountoulakis, M; Plaetinck, G				Devos, R; Guisez, Y; VanderHeyden, J; White, DW; Kalai, M; Fountoulakis, M; Plaetinck, G			Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE-PRODUCT; PROTEIN; LINKING	The leptin receptor is a class I transmembrane protein with either a short or a long cytoplasmic domain. Using chemical cross-linking we have analyzed the binding of leptin to its receptor. Cross-linking of radiolabeled leptin to different isoforms of the leptin receptor expressed on COS-l cells reveals leptin receptor monomer, homodimer, and oligomer complexes. Cotransfection of the long and short form of She leptin receptor did not provide any evidence for the formation of heterodimer complexes, Soluble forms consisting of either the entire extracellular domain or the two cytokine receptor homologous domains of the leptin receptor were purified to homogeneity from recombinant baculovirus-infected insect cells by leptin affinity chromatography, Gel filtration chromatography showed that these proteins exist in a dimeric form. Analysis of the complex formed between soluble leptin receptor and leptin by native polyacrylamide gel electrophoresis, and data obtained from the amino acid composition of the complex provide direct evidence that the extracellular domain of the leptin receptor binds leptin in a I:I ratio.	F HOFFMANN LA ROCHE & CO LTD, GENE TECHNOL, CH-4002 BASEL, SWITZERLAND; MILLENIUM PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Roche Holding; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Devos, R (corresponding author), F HOFFMANN LA ROCHE & CO LTD, ROCHE RES GENT, J PLATEAUSTR 22, B-9000 GHENT, BELGIUM.							Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GHILARDI N, 1996, P NATL ACAD SCI USA, V93, P9231; Glaum SR, 1996, MOL PHARMACOL, V50, P230; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lynn RB, 1996, BIOCHEM BIOPH RES CO, V219, P884, DOI 10.1006/bbrc.1996.0328; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; Malik KF, 1996, ENDOCRINOLOGY, V137, P1497, DOI 10.1210/en.137.4.1497; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	139	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18304	18310		10.1074/jbc.272.29.18304	http://dx.doi.org/10.1074/jbc.272.29.18304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218470	hybrid			2022-12-27	WOS:A1997XL73500060
J	Pilcher, BK; GaitherGanim, J; Parks, WC; Welgus, HG				Pilcher, BK; GaitherGanim, J; Parks, WC; Welgus, HG			Cell type-specific inhibition of keratinocyte collagenase-1 expression by basic fibroblast growth factor and keratinocyte growth factor - A common receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; PROTEIN-KINASE-C; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; 92-KDA GELATINASE; IMMUNOGLOBULIN DOMAIN; LIGAND SPECIFICITY; EPITHELIAL-CELLS; GENE-EXPRESSION	Collagenase-1 is invariantly expressed by migrating basal keratinocytes in all forms of human skin wounds, and its expression is induced by contact with native type I collagen, However, net differences in enzyme production between acute and chronic wounds may be modulated by soluble factors present within the tissue environment, Basic fibroblast growth factor (bFGF, FGF-2;) and keratinocyte growth factor (KGF, FGF-9), which are produced during wound healing, inhibited collagenase-1 expression by keratinocytes in a dose dependent manner, However, KGF was >100-fold more effective than bFGF at inhibiting collagenase-1 expression, suggesting that this differential signaling is transduced via an FGF receptor that binds these ligands with different affinities, Reverse transcriptase-polymerase chain reaction analysis of human keratinocyte mRNA for fibroblast growth factor receptors (FGFRs) revealed expression of only FGFR-2 IIIb, the KGF-specific receptor, which also binds bFGF with low affinity, and FGFR-3 IIIb, which does not bind bFGF or KGF, FGFRs that bind bFGF with high affinity were not detected, Our results suggest that bFGF and KGF inhibit collagenase-1 expression through the KGF cell-surface receptor (FG;FR-P IIIb), Because bFGF induces collagenase-1 in most cell types, cell-specific expression of FGFR family members may dictate the regulation of matrix metalloproteinases in a tissue-specific manner.	WASHINGTON UNIV, SCH MED,DIV DERMATOL,DEPT MED,BARNES JEWISH HOSP, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805, F32AR008339] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08339, AR35805] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUA CC, 1991, CONNECT TISSUE RES, V26, P271, DOI 10.3109/03008209109152444; Chubinskaya S, 1996, LAB INVEST, V74, P232; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FIRESTEIN G S, 1992, Current Opinion in Rheumatology, V4, P348, DOI 10.1097/00002281-199206000-00012; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GARLICK JA, 1993, IN PRESS J INVEST DE; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HURLEY MM, 1995, BIOCHEM BIOPH RES CO, V214, P331, DOI 10.1006/bbrc.1995.2292; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KENNEDY SH, 1995, AM J PATHOL, V146, P764; KURITA Y, 1992, ARCH DERMATOL RES, V284, P193, DOI 10.1007/BF00375792; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LAMBERT CA, 1993, BIOCHEM J, V290, P135, DOI 10.1042/bj2900135; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P767, DOI 10.1111/1523-1747.ep12560956; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PEKONEN F, 1993, MOL CELL ENDOCRINOL, V95, P43, DOI 10.1016/0303-7207(93)90027-H; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; Sasaki Tetsuo, 1992, Journal of Dermatology (Tokyo), V19, P664; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	76	32	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18147	18154		10.1074/jbc.272.29.18147	http://dx.doi.org/10.1074/jbc.272.29.18147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218449	hybrid			2022-12-27	WOS:A1997XL73500039
J	Pronin, AN; Satpaev, DK; Slepak, VZ; Benovic, JL				Pronin, AN; Satpaev, DK; Slepak, VZ; Benovic, JL			Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; DEPENDENT PHOSPHORYLATION; MEMBRANE PHOSPHOLIPIDS; C SUBSTRATE; PURIFICATION; FAMILY; GRK5; EXPRESSION; MECHANISM; ISOFORMS	G protein-coupled receptor kinases (GBKs) specifically phosphorylate and regulate the activated form of multiple G protein coupled receptors, Recent studies have revealed that GRKs are also subject to regulation, In this regard, GRK2 and GRK5 can be phosphorylated and either activated or inhibited, respectively, by protein kinase C, Here we demonstrate that calmodulin, another mediator of calcium signaling, is a potent inhibitor of GRK activity with a selectivity for GRK5 (IC50 similar to 50 nM) > GRK6 much greater than GRK2 (IC50 similar to 2 mu M) much greater than GRK1 Calmodulin inhibition of GRK5 is mediated via a reduced ability of the kinase to bind to both receptor and phospholipid. Interestingly, calmodulin also activates autophospho rylation of GRK5 at sites distinct from the two major autophosphorylation sites on GRK5, Moreover, calmodulin-stimulated autophosphorylation directly inhibits GRKS interaction with receptor even in the absence of calmodulin, Using glutathione S-transferase-GRK5 fusion proteins either to inhibit calmodulin-stimulated autophosphorylation or to bind directly to calmodulin, we determined that an amino-terminal domain of GRK5 (amino acids 20-39) is sufficient for calmodulin binding, This domain is abundant in basic and hydrophobic residues, characteristics typical of calmodulin binding sites, and is highly conserved in GRK4, GRK5, and GRK6, These studies suggest that calmodulin may serve a general role in mediating calcium-dependent regulation of GRK activity.	THOMAS JEFFERSON UNIV,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107; UNIV MIAMI,SCH MED,DEPT MOL & CELLULAR PHARMACOL,MIAMI,FL 33136; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	Jefferson University; University of Miami; Jefferson University					NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Diviani D, 1996, J BIOL CHEM, V271, P5049; GNEGY ME, 1993, ANN REV PHARM TOXICO, V32, P45; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KATADA T, 1987, J BIOL CHEM, V262, P11897; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PENN RB, 1994, J BIOL CHEM, V269, P14924; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1992, SCIENCE, V257, P264; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	38	137	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18273	18280		10.1074/jbc.272.29.18273	http://dx.doi.org/10.1074/jbc.272.29.18273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218466	hybrid			2022-12-27	WOS:A1997XL73500056
J	Oda, H; Nakabeppu, Y; Furuichi, M; Sekiguchi, M				Oda, H; Nakabeppu, Y; Furuichi, M; Sekiguchi, M			Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase - Alternative splicing of transcription products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; G.C->T.A TRANSVERSIONS; DNA GLYCOSYLASE; MUTT PROTEIN; 8-HYDROXYGUANINE; 8-OXOGUANINE; MUTAGENESIS; NUCLEOTIDE; OXIDATION; SUBSTRATE	The enzyme 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase (8-oxo-dGTPase) hydrolyzes 8-oxo-dGTP to 8-oxo-dGMP, thereby preventing misincorporation of 8-oxo-dGTP into DNA. We investigated expression of MTH1 gene encoding 8-oxo-dGTPase. Large amounts of MTH1 mRNA were present in thymus and testis, embryonic tissues, and certain cell lines. In peripheral blood lymphocytes, the level of MTH1 mRNA was significantly increased after concomitant treatment with phytohemagglutinin and interleukin-a. Analyses of the 5' regions of the MTH1 transcripts revealed that 7 types of MTH1 mRNAs, which may be produced by transcription initiation at different sites and/or alternative splicing. The MTH1 gene consists of 5 major exons, some of which are composed of differentially processed segments. All types of MTH1 mRNAs carry the entire coding region, and may be functional. Three ATG initiation codons in-frame were found in the 5' regions of some of the MTH1 mRNAs, There is a polymorphic alteration at the 5' splicing site (GT to GC) located in exon 2, an event which affects splicing patterns of the MTH1 transcript. Allele frequency of this polymorphism is about 20% among healthy volunteers.	FUKUOKA DENT COLL,DEPT BIOL,SAWARA KU,FUKUOKA 81401,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Fukuoka Dental College (FDC); Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAPTISTE J, 1993, PCR PROTOCOLS CURREN, P365; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; FARRELL RE, 1993, RNA METHODOLOGIES LA, P158; FINANCSEK I, 1982, GENE, V18, P115; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Igarashi H, 1997, J BIOL CHEM, V272, P3766, DOI 10.1074/jbc.272.6.3766; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KANG D, 1995, J BIOL CHEM, V270, P25942; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; NGHEIM Y, 1988, P NATL ACAD SCI USA, V85, P2709; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; SAKUMI K, 1993, J BIOL CHEM, V268, P14659; Sambrook J., 2002, MOL CLONING LAB MANU; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	43	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17843	17850		10.1074/jbc.272.28.17843	http://dx.doi.org/10.1074/jbc.272.28.17843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211940	hybrid			2022-12-27	WOS:A1997XK16500083
J	Ruby, SW				Ruby, SW			Dynamics of the U1 small nuclear ribonucleoprotein during yeast spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; U2 SNRNP ADDITION; SPLICING FACTOR; PREMESSENGER RNA; SITE SELECTION; 5' END; PROTEIN; COMPLEXES; PATHWAY; PRP9	U1 small nuclear ribonucleoprotein (snRNP) may function during several steps of spliceosome assembly. Most spliceosome assembly assays, however, fail to detect the U1 snRNP. Here, I used a new native gel electrophoretic assay to find the yeast U1 snRNP in three pre-splicing complexes (delta, beta(1), alpha(2)) formed in vitro. The order of complex formation is deduced to be delta --> beta(1) --> alpha(2) --> alpha(1) --> beta(2), the active spliceosome, The delta complex is formed when U1 snRNP binds to pre-mRNA in the absence of ATP. There are two forms of delta: a major one, delta(un), unstable to competitor RNA; and a minor one, delta(commit), committed to the splicing pathway. The other complexes are formed in the presence of ATP and contain the following snRNPs: beta(1), the pre-spliceosome, has both U1 and U2; alpha(2) has all five, however, U1 is reduced compared with the others; and alpha(1) and beta(2) have U2, U5, and U6. Prior work by others suggests that U1 is ''handing off'' the 5' splice site region to the U5 and U6 snRNPs before splicing begins. The reduced levels of U1 snRNP in the alpha(2) complex suggests that the handoff occurs during formation of this complex.			Ruby, SW (corresponding author), UNIV NEW MEXICO,CTR HLTH SCI,CANC RES & TREATMENT CTR,DEPT CELL BIOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.							ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Ast G, 1997, RNA, V3, P371; Ast G, 1996, SCIENCE, V272, P881, DOI 10.1126/science.272.5263.881; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1993, P NATL ACAD SCI USA, V90, P8229, DOI 10.1073/pnas.90.17.8229; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHAMPIONARNAUD P, 1995, MOL CELL BIOL, V15, P5750; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V20, P3625, DOI 10.1093/nar/20.14.3625; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURMAN E, 1995, J BIOL CHEM, V270, P15515, DOI 10.1074/jbc.270.26.15515; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRETZNER L, 1987, CELL, V50, P593, DOI 10.1016/0092-8674(87)90032-8; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; NEWMAN AJ, 1994, CURR OPIN GENET DEV, V4, P298, DOI 10.1016/S0959-437X(05)80057-7; PIKIELNY CW, 1986, CELL, V45, P869, DOI 10.1016/0092-8674(86)90561-1; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; Sambrook J., 2002, MOL CLONING LAB MANU; Schwer B, 1996, RNA, V2, P574; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; Wiest DK, 1996, J BIOL CHEM, V271, P33268, DOI 10.1074/jbc.271.52.33268; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yean SL, 1996, GENE EXPRESSION, V5, P301; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	59	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17333	17341		10.1074/jbc.272.28.17333	http://dx.doi.org/10.1074/jbc.272.28.17333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211871	hybrid			2022-12-27	WOS:A1997XK16500014
J	Kruip, J; Chitnis, PR; Lagoutte, B; Rogner, M; Boekema, EJ				Kruip, J; Chitnis, PR; Lagoutte, B; Rogner, M; Boekema, EJ			Structural organization of the major subunits in cyanobacterial photosystem 1 - Localization of subunits PsaC, -D, -E, -F, and -J	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REACTION-CENTER; SYNECHOCYSTIS SP PCC-6803; CHEMICAL CROSS-LINKING; SYNECHOCOCCUS-SP PCC-6301; SP PCC 6803; PERFUSION CHROMATOGRAPHY; TARGETED INACTIVATION; CORE COMPLEXES; PSI-E; POLYPEPTIDES	Based on an improved isolation procedure using perfusion chromatography, trimeric Photosystem 1 (PS1) complexes have been isolated from various deletion mutants of the mesophilic cyanobacterium Synechocystis PCC 6803. These mutants are only deficient in the deleted subunits, which was carefully checked by high resolution gel electrophoresis in combination with immunoblotting. These highly purified and well characterized PS1 particles were then examined by electron microscopy, followed by computer-aided image processing with single particle averaging techniques as described earlier (Kruip, J., Boekema, E. J., Bald, D., Boonstra, A. F., and Rogner, M. (1993) J. Biol. Chem. 268, 23353-23360). This precise methodological approach allowed a confident localization of the PS1 subunits PsaC, -D, -E, -F, and -J; it also shows shape and size of these subunits once integrated in the PS1 complex. Subunits PsaC, -D, and -E form a ridge on the stromal site, with PsaE toward the edge of each monomer within the trimer and PsaD extending toward the trimeric center, leaving PsaC in between. PsaF (near PsaE) and PsaJ are close together on the outer edge of each monomer; their proximity is also supported by chemical cross-linking, using the zero-length cross-linker EDC. This localization of PsaF contradicts the position suggested by the published low resolution x-ray analysis and shows for the first time the existence of at least one transmembrane cu-helix for PsaF. A topographic three-dimensional map has been drawn from this set of results showing the location of the major PS1 subunits (besides PsaA and PsaB). These data also led to the assignment of electron density in the recent medium resolution x-ray structure for PS1 (Krauss, N., Schubert, W.-D., Klukas, O., Fromme, P., Witt, H. T., Saenger, W. (1996) Nat. Struct. Biol. 3, 965-973).	UNIV MUNSTER, INST BOT, D-48149 MUNSTER, GERMANY; UNIV GRONINGEN, DEPT BIOPHYS CHEM, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9747 AG GRONINGEN, NETHERLANDS; CEA, DEPT BIOL CELLULAIRE & MOL, SERV BIOENERGET, F-91191 GIF SUR YVETTE, FRANCE; IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	University of Munster; University of Groningen; CEA; UDICE-French Research Universities; Universite Paris Saclay; Iowa State University								ALMOG O, 1991, P NATL ACAD SCI USA, V88, P5312, DOI 10.1073/pnas.88.12.5312; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; FORD RC, 1987, EMBO J, V6, P1581, DOI 10.1002/j.1460-2075.1987.tb02403.x; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARAUZ G, 1991, IMAGE ANAL BIOL, P196; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1993, J BIOL CHEM, V268, P23353; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; REGNIER FE, 1991, NATURE, V350, P634, DOI 10.1038/350634a0; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; TJUS SE, 1995, PHOTOSYNTH RES, V45, P41, DOI 10.1007/BF00032234; TJUS SE, 1991, PHOTOSYNTH RES, V27, P209, DOI 10.1007/BF00035842; VALLON O, 1993, EUR J BIOCHEM, V214, P907, DOI 10.1111/j.1432-1033.1993.tb17994.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WITT I, 1987, FEBS LETT, V221, P260, DOI 10.1016/0014-5793(87)80937-7; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; XU QA, 1994, J BIOL CHEM, V269, P3205; XU QA, 1994, PLANT PHYSIOL, V106, P617, DOI 10.1104/pp.106.2.617; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	57	75	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17061	17069		10.1074/jbc.272.27.17061	http://dx.doi.org/10.1074/jbc.272.27.17061			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202022	hybrid, Green Published			2022-12-27	WOS:A1997XH44600054
J	Yoshida, A; Suzuki, M; Ikenaga, H; Takeuchi, M				Yoshida, A; Suzuki, M; Ikenaga, H; Takeuchi, M			Discovery of the shortest sequence motif for high level mucin-type O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; BOVINE UDP-GALNAC; STRUCTURAL CHARACTERIZATION; SUBMAXILLARY MUCIN; D-GALACTOSAMINE; KAPPA-CASEIN; PURIFICATION; TRANSFERASE; CLONING; ERYTHROPOIETIN	The consensus primary amino acid sequence for mucin-type O-glycosylation sites Has not beers identified, To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT). We chose the sequence PDAASAAP from human erythropoietin (hEPO) for further systematic substitutions because it accepted GalNAc and was a fairly simple sequence consisting only of four kinds of amino acids, Several substitutions showed that threonine is similar to 40-fold better than serine as the glycosylated amino acid and a proline at position +3 on the C-terminal side is very important, go define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in;a parent peptide AAATAAA. The results clearly indicated that pralines at positions +1 and +3 had a positive effect. The O-GalNAc transfer level of AAATPAP was increased approximately 90-fold from AAATAAA. The deletion of amino acids from the N-terminal side of the glycosylation site suggested that five amino acids from position -1 to +3 were especially important for glycosylation. Moreover, the influence of all 20 amino acids at positions -1, +2, and +4 was analyzed. Uncharged amino acids were preferred at position -1, and small or positively charged amino acids were preferred at position +2. No preference was observed at position +4. We propose a mucin-type O-glycosylation motif, XTPXP, which may be suitable as a signal for protein O-glycosylation. The features observed in this study also appear to he very useful for prediction of mucin-type O-glycosylation sites in glycoproteins.	KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, GLYCOTECHNOL GRP, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Kirin Brewery Company Limited								Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HILL HD, 1977, J BIOL CHEM, V252, P3799; HOMA FL, 1993, J BIOL CHEM, V268, P12609; KUBOTA N, 1990, J BIOCHEM, V107, P486, DOI 10.1093/oxfordjournals.jbchem.a123072; LAI PH, 1986, J BIOL CHEM, V261, P3116; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TAKEUCHI M, 1985, AGR BIOL CHEM TOKYO, V49, P1059, DOI 10.1080/00021369.1985.10866844; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOSHIDA A, 1995, GLYCOCONJUGATE J, V12, P824, DOI 10.1007/BF00731244; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	31	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16884	16888		10.1074/jbc.272.27.16884	http://dx.doi.org/10.1074/jbc.272.27.16884			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201996	hybrid			2022-12-27	WOS:A1997XH44600028
J	Weigel, PH; Hascall, VC; Tammi, M				Weigel, PH; Hascall, VC; Tammi, M			Hyaluronan synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROUP-A STREPTOCOCCI; MOLECULAR CHARACTERIZATION; OLIGODENDROGLIOMA CELLS; ACID SYNTHESIS; GENE; SOLUBILIZATION; LOCALIZATION; BIOSYNTHESIS; SYNTHETASE; ACTIVATION		CLEVELAND CLIN FDN, DEPT BIOMED ENGN, CLEVELAND, OH 44195 USA; UNIV KUOPIO, DEPT ANAT, KUOPIO 70211, FINLAND	Cleveland Clinic Foundation; University of Eastern Finland	Weigel, PH (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZS EA, 1993, J RHEUMATOL, V20, P3; BAME KJ, 1992, P NATL ACAD SCI USA, V89, P2267; CRATER DL, 1995, J BIOL CHEM, V270, P28676, DOI 10.1074/jbc.270.48.28676; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; Heldermon C, 1996, MOL BIOL CELL, V7, P320; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lidholt K, 1997, J BIOL CHEM, V272, P2682, DOI 10.1074/jbc.272.5.2682; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; Mitchell BS, 1996, CLIN EXP METASTAS, V14, P107, DOI 10.1007/BF00121207; MORALES TI, 1988, J BIOL CHEM, V263, P3632; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NG KF, 1989, J BIOL CHEM, V264, P11776; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; RITTIG M, 1993, GRAEF ARCH CLIN EXP, V231, P313, DOI 10.1007/BF00919026; RITTIG M, 1992, EXP EYE RES, V54, P455, DOI 10.1016/0014-4835(92)90057-Y; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; SPICER AP, 1997, IN PRESS GENO ICS; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	48	569	603	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					13997	14000		10.1074/jbc.272.22.13997	http://dx.doi.org/10.1074/jbc.272.22.13997			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9206724	hybrid			2022-12-27	WOS:A1997XB49200001
J	Wishingrad, MA; Koshlukova, S; Halvorsen, SW				Wishingrad, MA; Koshlukova, S; Halvorsen, SW			Ciliary neurotrophic factor stimulates the phosphorylation of two forms of STAT3 in chick ciliary ganglion neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; EPIDERMAL GROWTH-FACTOR; SYMPATHETIC NEURONS; CHOLINE-ACETYLTRANSFERASE; TYROSINE PHOSPHORYLATION; NEURONOTROPHIC FACTOR; SIGNAL TRANSDUCERS; TROPHIC FACTOR; RECEPTOR; TRANSCRIPTION	Ciliary neurotrophic factor (CNTF) is a neuropoietic cytokine that was identified, purified, and cloned based on its neurotrophic activity on cultured chick ciliary ganglion neurons, The molecular mechanisms by which CNTF elicits its effects on these neurons are unknown. We have previously identified functional receptors for CNTF on ciliary ganglion neurons and demonstrated the CNTF-specific tyrosine phosphorylation of ale approximately 90-kDa protein. Here we show that CNTF included the rapid tyrosine phosphorylation and nuclear accumulation of this protein and identify it as an avian form of the transcription factor, STAT3. identification was confirmed by its recognition with two distinct anti-STAT3 antibodies and the lack of binding to antibodies against STAT1, -2, -4, -5, or -6, The phosphorylation was stable for up to 2 h but required the continued presence of CNTF. CNTF also induced the tyrosine phosphorylation of a similar protein in cultured chick dorsal root ganglion and retinal neurons, In addition, we identify a second, 100-kda form of STAT3 that appears in response to CNTF. Unlike previous reports, utilizing mammalian cell lines that detected a slower migrating form of STAT3 resulting from H7-sensitive protein phosphorylation, H7 did not prevent the appearance of the 100-kDa form in ciliary neurons, Thus, the 100-kDa avian protein mag represent a novel form of CNTF-inducible STAT3.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NINDS NIH HHS [NS 30232] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS030232, R01NS030232] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HALVORSEN SW, 1989, J NEUROSCI, V9, P3673; HELLER S, 1995, DEVELOPMENT, V121, P2681; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOFMANN HD, 1988, J NEUROCHEM, V51, P109, DOI 10.1111/j.1471-4159.1988.tb04842.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Koshlukova S, 1996, NEUROSCIENCE, V72, P821, DOI 10.1016/0306-4522(95)00560-9; LACHMUND A, 1994, NEUROSCIENCE, V62, P361, DOI 10.1016/0306-4522(94)90371-9; LANDMESSER L, 1974, J PHYSIOL-LONDON, V241, P737, DOI 10.1113/jphysiol.1974.sp010681; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Malek RL, 1997, J NEUROBIOL, V32, P81, DOI 10.1002/(SICI)1097-4695(199701)32:1<81::AID-NEU8>3.0.CO;2-A; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MARGIOTTA JF, 1994, DEV BIOL, V163, P188, DOI 10.1006/dbio.1994.1135; NISHI R, 1981, J NEUROSCI, V1, P505; NISHI R, 1994, J NEUROBIOL, V25, P612, DOI 10.1002/neu.480250604; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SCHOTZINGER R, 1994, J NEUROBIOL, V25, P620, DOI 10.1002/neu.480250605; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Simon R, 1995, NEUROREPORT, V7, P153, DOI 10.1097/00001756-199512000-00037; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	41	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19752	19757		10.1074/jbc.272.32.19752	http://dx.doi.org/10.1074/jbc.272.32.19752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242633	hybrid			2022-12-27	WOS:A1997XQ05900020
J	Asahi, M; Fujii, J; Takao, T; Kuzuya, T; Hori, M; Shimonishi, Y; Taniguchi, N				Asahi, M; Fujii, J; Takao, T; Kuzuya, T; Hori, M; Shimonishi, Y; Taniguchi, N			The oxidation of selenocysteine is involved in the inactivation of glutathione peroxidase by nitric oxide donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSYLATION; SERUM-ALBUMIN; PEROXYNITRITE; SUPEROXIDE; ACID; NITROTYROSINE; PROTEINS; KINETICS; INJURY; THIOLS	Glutathione peroxidase (GPx) was inactivated by S-nitroso-N-acetyl-D,L-penicillamine (SNAP), a nitric oxide donor (Asahi, M., Fujii, J., Suzuki, K., See, H. G., Kuzuya, T., Hori, M., Tada, M., Fujii, S., and Taniguchi, N. (1995) J. Biol. Chem. 270, 21035-21039). The structural basis of the inactivation was studied. We also show that 3-morpholinosydnonimine N-ethylcarbamide, a peroxynitrite precursor, as well as synthetic peroxynitrite also inactivated bovine GPx. The degree of incorporation of a sulfhydryl reagent, n-octyldithionitrobenzoic acid, into GPx decreased after pretreatment with SNAP as evidenced by mass spectrometry. To identify the modification site of this enzyme by SNAP, both SNAP-pretreated and untreated GPxs were reacted with n-octyldithionitrobenzoic acid and digested with lysylendopeptidase, and the resulting peptides were subjected to mass spectrometry. This technique identified a bridge between two peptides, one of which contains Sec(45) at the catalytic center and Cys(74), and the other contains Cys(91). Although there are two possible combinations, selenocysteine 45 (Sec(45)) and Cys(91) or Cys(74) and Cys(91), the tertiary structure of GPx indicates that a cross-link between Sec(45) and Cys(91) is more feasible. This is consistent with the experimental evidence that SNAP specifically inactivates GPx, in which Sec(45) forms the catalytic center. Thus, we conclude that SNAP mainly oxidized Sec(45) to form a selenenyl sulfide (Se-S) with a free thiol, leading to the inactivation of the enzyme. These data suggest that nitric oxide and its derivatives directly inactivate GPx in a specific manner via the production of a selenenyl sulfide, resulting in an increase in intracellular peroxides that are responsible for cellular damage.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Matsuda Y, 1991, Protein Expr Purif, V2, P170, DOI 10.1016/1046-5928(91)90067-S; MOLINA VL, 1992, J BIOL CHEM, V267, P24929; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURATA H, 1994, RAPID COMMUN MASS SP, V8, P205, DOI 10.1002/rcm.1290080216; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Stadtman ER, 1994, OXIDATIVE PROCESSES, P117; STADTMAN TC, 1980, ANNU REV BIOCHEM, V49, P93, DOI 10.1146/annurev.bi.49.070180.000521; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takao T, 1996, RAPID COMMUN MASS SP, V10, P637, DOI 10.1002/(SICI)1097-0231(199604)10:6<637::AID-RCM544>3.3.CO;2-0; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011	48	101	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19152	19157		10.1074/jbc.272.31.19152	http://dx.doi.org/10.1074/jbc.272.31.19152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235904	hybrid			2022-12-27	WOS:A1997XP06300010
J	Cole, JL; Carroll, SS; Blue, ES; Viscount, T; Kuo, LC				Cole, JL; Carroll, SS; Blue, ES; Viscount, T; Kuo, LC			Activation of RNase L by 2',5'-oligoadenylates - Biophysical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; DNA-INDUCED DIMERIZATION; COLI REP HELICASE; PROTEIN-SYNTHESIS; INHIBITOR; ENZYME	Ribonuclease L (RNase L) is an endoribonuclease that is activated upon binding of adenosine oligomers linked 2' to 5' to cleave viral and cellular RNAs. We recently proposed a model for activation in which activator A binds to monomer, E, to form EA, which subsequently dimerizes to the active form, E(2)A(2) (Cole, J. L., Carroll, S. S., and Kuo, L. C. (1996) J. Biol. Chem. 271, 3978-3981). Here, we have employed this model to define the equilibrium constants for activator binding (K-a) and dimerization of EA to E(2)A(2) (K-d) by equilibrium analytical ultracentrifugation and fluorescence measurements. Multi-wavelength sedimentation data were globally fit to the model above, yielding values of K-a = 1.69 mu M and K-d = 17.8 nM for 2',5'-linked adenosine trimer. Fluorescent conjugates of 2',5'-linked adenosine trimer with 7-hydroxycoumarin have been prepared. The coumarin emission anisotropy shows a large increases upon binding to RNase L, Analysis of anisotropy titrations yields values of K-a and K-d close to those obtained by sedimentation. The sedimentation parameters for unmodified 2',5'-linked adenosine trimer also agree with those obtained by enzyme kinetic methods (Carroll, S. S., Cole, J. L., Viscount, T., Geib, J., Gehman, J., and Kuo, L. C. (1997) J. Biol. Chem. 272, 19193-19198). Thus, the data presented here clearly define the energetics of RNase L activation and support the minimal activation model.			Cole, JL (corresponding author), MERCK RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Cole, James/G-2586-2011					Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Carroll SS, 1996, J BIOL CHEM, V271, P4988; Carroll SS, 1997, J BIOL CHEM, V272, P19193, DOI 10.1074/jbc.272.31.19193; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cole JL, 1996, J BIOL CHEM, V271, P3979; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1980, VIROLOGY, V101, P81, DOI 10.1016/0042-6822(80)90485-7; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P88; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; Wong I, 1995, METHOD ENZYMOL, V259, P95; WONG I, 1992, J BIOL CHEM, V267, P7596; Wyman J., 1990, BINDING LINKAGE FUNC, P203	16	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19187	19192		10.1074/jbc.272.31.19187	http://dx.doi.org/10.1074/jbc.272.31.19187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235909	hybrid			2022-12-27	WOS:A1997XP06300015
J	Hong, M; Lee, VMY				Hong, M; Lee, VMY			Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; DISEASE-LIKE PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; ALZHEIMER-LIKE STATE; ADULT HUMAN-BRAIN; P70 S6 KINASE; MAP KINASE; FACTOR-II; MICROTUBULE-BINDING	Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary lesions associated with Alzheimer's disease. Hyperphosphorylation reduces the affinity of tau for microtubules and is thought to be a critical event in the pathogenesis of this disease. Recently, glycogen-synthase kinase-3 has been shown to phosphorylate tau in vitro and in non-neuronal cells transfected with tau. The activity of glycogen-synthase kinase-3 can be down-regulated in response to insulin or insulin-like growth factor-1 through the activation of the phosphatidylinositol 3-kinase pathway. We therefore hypothesize that insulin or insulin-like growth factor-1 may affect tau phosphorylation through the inhibition of glycogen-synthase kinase-3 in neurons. Using cultured human neuronal NT2N cells, we demonstrate that glycogen-synthase kinase-3 phosphorylates tau and reduces its affinity for microtubules and that insulin and insulin-like growth factor-1 stimulation reduces tau phosphorylation and promotes tau binding to microtubules. We further demonstrate that these effects of insulin and insulin-like growth factor-1 are mediated through the inhibition of glycogen-synthase kinase-3 via the phosphatidylinositol 3-kinase/protein kinase B signaling pathway.	UNIV PENN,SCH MED,CTR NEURODEGENERAT DIS RES,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania								ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DICKSON DW, 1991, NEUROBIOL AGING, V13, P179; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FUJISAWA Y, 1991, BIOL PSYCHIAT, V30, P1219, DOI 10.1016/0006-3223(91)90158-I; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goedert M., 1997, MOL GENETIC BASIS NE, P613; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HASELBACHER GK, 1985, P NATL ACAD SCI USA, V82, P2153, DOI 10.1073/pnas.82.7.2153; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1458, DOI 10.1210/endo-125-3-1458; Hoyer S, 1994, J Neural Transm Suppl, V44, P259; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LATIMER DA, 1995, FEBS LETT, V365, P42, DOI 10.1016/0014-5793(95)00434-B; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1986, J NEUROSCI, V6, P514; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POWIS G, 1994, CANCER RES, V54, P2419; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SARA VR, 1982, NEUROSCI LETT, V34, P39; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagner U, 1996, J CELL SCI, V109, P1537; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	63	424	454	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19547	19553		10.1074/jbc.272.31.19547	http://dx.doi.org/10.1074/jbc.272.31.19547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235959	hybrid			2022-12-27	WOS:A1997XP06300065
J	Bakker, H; VanTetering, A; Agterberg, M; Smit, AB; VandenEijnden, DH; VanDie, I				Bakker, H; VanTetering, A; Agterberg, M; Smit, AB; VandenEijnden, DH; VanDie, I			Deletion of two exons from the Lymnaea stagnalis beta 1->4-N-acetylglucosaminyltransferase gene elevates the kinetic efficiency of the encoded enzyme for both UDP-sugar donor and acceptor substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1-4 N-ACETYLGALACTOSAMINYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; SCHISTOSOMA-MANSONI; GENOMIC STRUCTURE; ALBUMIN GLAND; BINDING-SITES; IDENTIFICATION; EXPRESSION; SEQUENCE	Lymnaea stagnalis UDP-GlcNAc:GlcNAc beta-R beta 1-->4-N-acetylglucosaminyltransferase (beta 4-GlcNAcT) is an enzyme with structural similarity to mammalian UDP-Gal: GlcNAc beta-R beta 1-->4-galactosyltransferase (beta 4-GalT). Here, we report that also the exon organization of the genes encoding these enzymes is very similar. The beta 4-GlcNAcT gene (12.5 kilobase pairs, spanning 10 exons) contains four exons, encompassing sequences that are absent in the beta 4-GalT gene. Two of these exons (exons 7 and 8) show a high sequence similarity to part of the preceding exon (exon 6), suggesting that they have originated by exon duplication. The exon in the beta 4-GalT gene, corresponding to beta 4-GlcNAcT exon 6, encodes a region that has been proposed to be involved in the binding of UDP-Gal. The question therefore arose, whether the repeating sequences encoded by exon 7 and 8 of the beta 4-GlcNAcT gene would determine the specificity of the enzyme for UDP-GlcNAc, or for the less preferred UDP-GalNAc. It was found that deletion of only the sequence encoded by exon 8 resulted in a completely inactive enzyme. By contrast, deletion of the amino acid residues encoded by exons 7 and 8 resulted in an enzyme with an elevated kinetic efficiency for both UDP-sugar donors, as well as for its acceptor substrates. These results suggest that at least part of the donor and acceptor binding domains of the beta 4-GlcNAcT are structurally linked and that the region encompassing the insertion contributes to acceptor recognition as well as to UDP-sugar binding and specificity.	VRIJE UNIV AMSTERDAM,DEPT MED CHEM,NL-1081 BT AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,DEPT EXPT ZOOL,NL-1081 BT AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam			Bakker, Hans/A-1787-2017; Smit, August B/E-8410-2011; Bakker, Hans/AAA-1623-2020	Bakker, Hans/0000-0002-1364-9154; Bakker, Hans/0000-0002-1364-9154				AGTERBERG M, 1993, EUR J BIOCHEM, V217, P241, DOI 10.1111/j.1432-1033.1993.tb18239.x; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BOEGGEMAN EE, 1995, GLYCOCONJUGATE J, V12, P865, DOI 10.1007/BF00731249; BOGERD J, 1993, CELL MOL NEUROBIOL, V13, P123, DOI 10.1007/BF00735369; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; LI WH, 1983, FUNDAMENTALS MOL EVO, P14; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MULDER H, 1995, EUR J BIOCHEM, V227, P175, DOI 10.1111/j.1432-1033.1995.tb20374.x; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Neeleman AP, 1996, P NATL ACAD SCI USA, V93, P10111, DOI 10.1073/pnas.93.19.10111; NYAME K, 1989, J BIOL CHEM, V264, P3235; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PATTHY L, 1994, CURR OPIN STRUC BIOL, V4, P383, DOI 10.1016/S0959-440X(94)90108-2; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VANDENEIJNDEN DH, 1995, ADV EXP MED BIOL, V376, P47; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; WATKINS WM, 1988, BIOCHIMIE, V70, P1597, DOI 10.1016/0300-9084(88)90295-7; YADAV S, 1990, J BIOL CHEM, V265, P14163; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; ZU HY, 1995, BIOCHEM BIOPH RES CO, V206, P362, DOI 10.1006/bbrc.1995.1050	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18580	18585		10.1074/jbc.272.30.18580	http://dx.doi.org/10.1074/jbc.272.30.18580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228024	Green Published, hybrid			2022-12-27	WOS:A1997XM34200015
J	Ponnampalam, SN; Bauer, CE				Ponnampalam, SN; Bauer, CE			DNA binding characteristics of CrtJ - A redox-responding repressor of bacteriochlorophyll, carotenoid, and light harvesting-II gene expression in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN REPRESSOR; ESCHERICHIA-COLI; CORYNEBACTERIUM-DIPHTHERIAE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; BIOSYNTHESIS GENE; RNA-POLYMERASE; CLONED GENES; PROTEIN; SPHAEROIDES	Previous genetic analysis indicated that the photosynthesis gene cluster from Rhodobacter capsulatus coded for the transcription factor, CrtJ, that is responsible for aerobic repression of bacteriochlorophyll, carotenoid, and light harvesting-II gene expression. In this study, we have heterologously overexpressed and purified CrtJ to homogeneity and shown by gel mobility shift assays that CrtJ is biologically active. DNase I footprint analysis confirms molecular genetic studies by showing that CrtJ binds to conserved palindromic sequences that overlap the -10 and -35 promoter regions of the bchC operon. Graphs of the percentage of DNA bound versus protein concentration show sigmoidal curves, which is highly indicative of cooperative binding of CrtJ to the two palindromic sites. A binding constant for interaction of CrtJ with the palindrome that spans the -10 region was calculated to be 4.8 x 10(-9) M, whereas affinity for the palindrome that spans the -35 region was found to be 2.9 x 10(-9) hi. Binding of CrtJ to the bchC promoter region was also found to be redox-sensitive, with CrtJ exhibiting a 4.5-fold higher binding affinity under oxidizing versus reducing conditions.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT CHEM,BIOCHEM PROGRAM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM040941, GM 539040, R37 GM040941, GM 00618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, K04GM000618, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1986, J MOL BIOL, V192, P513, DOI 10.1016/0022-2836(86)90273-1; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; Gomelsky M, 1997, J BACTERIOL, V179, P128, DOI 10.1128/jb.179.1.128-134.1997; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Johnson A D, 1980, Methods Enzymol, V65, P839; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; PENFOLD RJ, 1991, CURR MICROBIOL, V23, P259, DOI 10.1007/BF02092027; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; PTASHNE M, 1986, GENETIC SWITCH GENE, P87; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER R, 1979, THESIS HARVARD U; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; SCHMITT MP, 1992, P NATL ACAD SCI USA, V89, P7576, DOI 10.1073/pnas.89.16.7576; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG ZO, 1994, INFECT IMMUN, V62, P1600, DOI 10.1128/IAI.62.5.1600-1608.1994; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	46	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18391	18396		10.1074/jbc.272.29.18391	http://dx.doi.org/10.1074/jbc.272.29.18391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218481	hybrid			2022-12-27	WOS:A1997XL73500071
J	Sato, A; Perlas, E; BenMenahem, D; Kudo, M; Pixley, MR; Furuhashi, M; Hsueh, AJW; Boime, I				Sato, A; Perlas, E; BenMenahem, D; Kudo, M; Pixley, MR; Furuhashi, M; Hsueh, AJW; Boime, I			Cystine knot of the gonadotropin alpha subunit is critical for intracellular behavior but not for in vitro biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; HAMSTER OVARY CELLS; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; CYSTEINE RESIDUES; DISULFIDE BONDS; FUNCTIONAL EXPRESSION	The common alpha subunit of glycoprotein hormones contains five disulfide bonds. Based on the published crystal structure, the assignments are 7-31, 59-87, 10-60, 25-82, and 32-84; the last three comprise the cystine knot, a structure also seen in a variety of growth factors, Previously, we demonstrated that the efficiency of secretion and the ability to form heterodimers by alpha subunits hearing single cysteine residue mutants in the cystine knot were significantly reduced. These results suggested that the cystine knot is critical for the intracellular integrity of the subunit, To assess if the presence of the free thiol. affected the secretion kinetics, we constructed paired cysteine mutants of each disulfide bond of the alpha subunit. The secretion rate for these monomers was comparable with mild type except for the alpha-10-60 mutant, which was 40% lower. The recovery of the alpha 7-31 and alpha 59-87 mutants was greater than 95%, whereas for the cystine knot mutants, it was 20-40%. Co-expression of the wild-type chorionic gonadotropin beta subunit with double cysteine mutants did not enhance the recovery of alpha mutants in the media, Moreover, compared with wild-type, the efficiency of heterodimer formation of the alpha 10-60 or alpha 32-84 mutants was less than 5%. Because subunit assembly is required for biological activity, steadies oil the role of these disulfide bonds in signal transduction mere not possible. To bypass the assembly step, we exploited the single chain model, where the alpha and beta subunits are genetically fused. The recovery of secreted tethered gonadotropins bearing mutations in the cystine knot was increased significantly. Although dimer-specific monoclonal antibodies discriminated the conformation of single chain alpha 10-60 and alpha 32-84 mutants from the native heterodimer, these mutants were nevertheless biologically active. Thus, individual bonds of cystine knot are important for secretion and heteradimer formation but not for in vitro bioactivity. Moreover, the data suggest that the native heterodimer configuration is not a prerequisite for receptor binding or signal transduction.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; STANFORD UNIV, MED CTR, DIV REPROD BIOL, DEPT OBSTET GYNECOL, STANFORD, CA 94305 USA	Washington University (WUSTL); Stanford University				Ben-Menahem, David/0000-0002-8985-0591	NICHD NIH HHS [N01-HD67922] Funding Source: Medline; NIDDK NIH HHS [5 P60 DK20579] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BENKIRANE MM, 1987, ENDOCRINOLOGY, V121, P1171, DOI 10.1210/endo-121-3-1171; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, J BIOL CHEM, V266, P6904; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; Garnier J., 1978, STRUCTURE FUNCTION G, P381; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; KIM P, 1997, IN PRESS ENDOCR REV; KRICHEVSKY A, 1988, ENDOCRINOLOGY, V123, P584, DOI 10.1210/endo-123-1-584; KRICHEVSKY A, 1994, ENDOCRINE, V2, P511; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; ZENG HW, 1995, ENDOCRINOLOGY, V136, P2948, DOI 10.1210/en.136.7.2948	43	38	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18098	18103		10.1074/jbc.272.29.18098	http://dx.doi.org/10.1074/jbc.272.29.18098			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218442	hybrid			2022-12-27	WOS:A1997XL73500032
J	Hall, JA; Gehring, K; Nikaido, H				Hall, JA; Gehring, K; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Correlation with the structure of ligands and the structure of binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-TRANSPORT; MALTODEXTRIN TRANSPORT; CHEMOTAXIS; SPECTROSCOPY; MUTANTS	Ligands that are transported by the maltose transport system of Escherichia coli must first bind to the periplasmic maltose-binding protein (MBP). However, binding of a ligand does not always lead to its transport. As reported earlier, reduced or oxidized maltodextrins bind tightly to MBP but are not transported; some mutant MBPs, such as MalE254, bind maltodextrins tightly but cannot produce their transport, In this study, UV differential spectroscopy and fluorescence emission spectroscopy were used to study the modes by which various ligands bind to MBP, Maltose binding produced a red shift in the fluorescence emission spectrum of wild type MBP and a sharp hypochromatic trend below 265 nm in its UV spectrum (R mode (for red)), On the other hand, binding of reduced, oxidized, or cyclic maltodextrins produced a pronounced blue shift in the fluorescence emission spectrum of wild type MBP and a peak at about 250 nm in its UV difference spectrum (B mode (for blue), Binding of reducing maltodextrins to wild type MBP produced spectral changes that seemed to be a mixture of predominantly R mode binding and some B mode binding, whereas their binding to mutant MBP MalE254 produced changes indicative of pure B mode binding, Thus, the ligands that are bound exclusively via the B mode to either the wild type or MalE254 MBP are not transported.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	University of California System; University of California Berkeley; McGill University			Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184	NIAID NIH HHS [AI-09644] Funding Source: Medline; NIGMS NIH HHS [GM-07232] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FERENCI T, 1978, FEBS LETT, V94, P212; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; MILLER DM, 1983, J BIOL CHEM, V258, P3665; PARK JT, 1949, J BIOL CHEM, V181, P149; SCHAFFER R, 1963, METHODS CARBOHYDR CH, V2, P11; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; Wolfrom M. L., 1963, METHODS CARBOHYDR CH, V2, P65	20	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17605	17609		10.1074/jbc.272.28.17605	http://dx.doi.org/10.1074/jbc.272.28.17605			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211908	hybrid			2022-12-27	WOS:A1997XK16500051
J	Ram, PA; Waxman, DJ				Ram, PA; Waxman, DJ			Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CYTOCHROME-P450; GENE-TRANSCRIPTION; IN-VIVO; PHOSPHORYLATION; RECEPTOR; PROTEIN; TRANSLOCATION; RECRUITMENT; EXPRESSION; TARGET	Growth hormone (GH) rapidly stimulates tyrosine phosphorylation followed by serine/threonine phosphorylation of multiple cytoplasmic STAT transcription factors, including one, STAT5b, that is uniquely responsive to the temporal pattern of plasma GH stimulation in rat liver and is proposed to play a central role in the activation of male-expressed liver genes by GH pulses in vivo (Waxman, D, J,, Bam, P. A., Park, S. H., and Choi, H. K. (1995) J. Biol. Chem. 270, 13262-13270). We now show that JAK2, the GH receptor-associated tyrosine kinase, is present both in the cytosol and in the nucleus in cultured liver cells and in rat liver in vivo and that GH-activated STAT3 but not STAT5b becomes associated with nuclear JAK2. GH is also shown to activate by 3-4-fold SHP-1, a phosphotyrosine phosphatase that contains two src homology 2 (SH2) domains. GI-I also induces nuclear translocation and binding of SHP-1 to tyrosine-phosphorylated STAT5b, suggesting that this GH-activated phosphatase may play a role in dephosphorylation leading to deactivation of nuclear STAT5b following the termination of a plasma GH pulse in male rat Liver in vivo, No such association of SHP-1 with GH-activated STATE was detected, a finding that could help explain the marked desensitization of STAT3, but not STAT5b, to subsequent GH pulses following an initial GH activation event.	BOSTON UNIV,DEPT BIOL,DIV CELL & MOL BIOL,BOSTON,MA 02215	Boston University				Waxman, David/0000-0001-7982-9206				Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goffin V, 1996, CLIN ENDOCRINOL, V45, P247, DOI 10.1046/j.1365-2265.1996.00799.x; GOUILLEUX F, 1994, EMBO J, V13, P1361; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1982, ACTA PHYSIOL SCAND, V114, P261, DOI 10.1111/j.1748-1716.1982.tb06980.x; KEMPE KC, 1995, BIOCHEM PHARMACOL, V49, P1091, DOI 10.1016/0006-2952(95)98506-5; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425	43	159	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17694	17702		10.1074/jbc.272.28.17694	http://dx.doi.org/10.1074/jbc.272.28.17694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211920	hybrid			2022-12-27	WOS:A1997XK16500063
J	ElBenna, J; Dang, PMC; Gaudry, M; Fay, M; Morel, F; Hakim, J; GougerotPocidalo, MA				ElBenna, J; Dang, PMC; Gaudry, M; Fay, M; Morel, F; Hakim, J; GougerotPocidalo, MA			Phosphorylation of the respiratory burst oxidase subunit p67(phox) during human neutrophil activation - Regulation by protein kinase C-dependent and independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHORBOL-MYRISTATE ACETATE; NADPH OXIDASE; FORMYL PEPTIDES; COMPONENTS; TRANSLOCATION; P47(PHOX); MEMBRANE; REDISTRIBUTION; STIMULATION	The respiratory burst oxidase of phagocytes and B lymphocytes catalyzes the reduction of oxygen to superoxide anion (O-2(radical anion) at the expense of NADPH. This multicomponent enzyme is dormant in resting cells but is activated on exposure to an appropriate stimulus, The phosphorylation-dependent mechanisms regulating the activation of the respiratory burst oxidase are unclear, particularly the phosphorylation status of the cytosolic component p67(phox). In this study, we found that activation of human neutrophils with formyl-methionyl-leucyl-phenylalanine (fMLP), a chemotactic peptide, or phorbol myristate acetate (PMA), a stimulator of protein kinase C (PKC), resulted in the phosphorylation of p67(phox). Using an anti-p67(phox) antibody or all anti-p47(phox) antibody, we showed that phosphorylated p67(phox) and p47(phox) form a complex, Phosphoamino acid analysis of the phosphorylated p67(phox) revealed only P-32-labeled serine residues, Two-dimensional tryptic peptide mapping analysis showed that p67(phox) is phosphorylated at the same peptide whether fMLP or PMA is used as a stimulus, In addition, PHC induced the phosphorylation of recombinant GST-p67(phox) in vitro, at the same peptide as that phosphorylated in intact cells, PMA-induced phosphorylation of p67(phox) was strongly inhibited by the PKC inhibitor GF109203X. In contrast, fMLP-induced phosphorylation was minimally affected by this PKC inhibitor. Taken together, these results show that p67(phox) is phosphorylated in human neutrophils by different pathways, one of which involves protein kinase C.	CHU GRENOBLE, ENZYMOL LAB, F-38043 GRENOBLE, FRANCE	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	ElBenna, J (corresponding author), CHU XAVIER BICHAT, INSERM U294, SERV HEMATOL & IMMUNOL BIOL, 46 RUE HENRI HUCHARD, F-75018 PARIS, FRANCE.			Gaudry, Murielle/0000-0002-9281-2334				BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COMBADIERE C, 1993, BLOOD, V82, P2890; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; Heyworth PG, 1996, BLOOD, V87, P4404, DOI 10.1182/blood.V87.10.4404.bloodjournal87104404; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; TANUGICHOLLEY LC, 1995, BLOOD, V85, P242, DOI 10.1182/blood.V85.1.242.bloodjournal851242; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; WOLFSON M, 1985, J IMMUNOL, V135, P2057	32	132	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17204	17208		10.1074/jbc.272.27.17204	http://dx.doi.org/10.1074/jbc.272.27.17204			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202043	hybrid			2022-12-27	WOS:A1997XH44600075
J	Machado, AK; Morgan, BA; Merrill, GF				Machado, AK; Morgan, BA; Merrill, GF			Thioredoxin reductase-dependent inhibition of MCB cell cycle box activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HO GENE; DISULFIDE BOND FORMATION; DNA-BINDING ACTIVITY; BUDDING YEAST; S-CEREVISIAE; TRANSCRIPTION; PROTEIN; IDENTIFICATION; ELEMENTS; START	Mlu1 cell cycle box (MCB) elements are found near the start site of yeast genes expressed at G(1)/S. Basal promoters dependent on the elements for upstream activating sequence activity are inactive in Delta swi6 yeast, Yeast were screened for mutations that activated MCB reporter genes in the absence of Swi6, The mutations identified a single complementation group, Functional cloning revealed the mutations were alleles of the TRR1 gene encoding thioredoxin reductase, Although deletion of TRR1 activated RICE reporter genes, high copy expression did not suppress reporter gene activity;. The trr1 mutations strongly (20 fold) stimulated MCB- and SCB (Swi4/Swi6 cell cycle box)-containing reporter genes, but also weakly (3-fold) stimulated reporter genes that lacked these elements, The trr1 mutations did not affect the level or periodicity of three endogenous MCB gene mRNAs (TMP1, RNR1, and SW14). Deletion of thioredoxin genes TRX1 and TRX2 recapitulated the stimulatory effect of trr1 mutations on MCB reporter gene activity, Conditions expected to oxidize thioredoxin (exposure to H2O2) induced MCB gene expression, whereas conditions expected to conserve thioredoxin (exposure to hydroxyurea) inhibited MCB gene expression, The results suggest that thioredoxin oxidation contributes to MCB element activation and suggest a link between thioredoxin-oxidizing processes such as ribonucleotide reduction and cell cycle-specific gene transcription.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,CORVALLIS,OR 97331; NATL INST MED RES,LAB YEAST GENET,LONDON NW7 1AA,ENGLAND	Oregon State University; Oregon State University; MRC National Institute for Medical Research								ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3328; BENEZRA R, 1994, CELL, V79, P1257; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1994, GENETICS, V138, P1015; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; PIZZAGALLI A, 1992, CURR GENET, V21, P183, DOI 10.1007/BF00336839; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; Rose MD., 1990, METHODS YEAST GENETI; SCHMIDT EE, 1989, J BIOL CHEM, V264, P21247; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1067; SIDOROVA J, 1994, YEAST GEN MOL BIOL M, P8; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVA CM, 1989, J BIOL CHEM, V264, P6638; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; VEMU S, 1995, J BIOL CHEM, V270, P20724, DOI 10.1074/jbc.270.35.20724; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	41	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17045	17054		10.1074/jbc.272.27.17045	http://dx.doi.org/10.1074/jbc.272.27.17045			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202020	hybrid			2022-12-27	WOS:A1997XH44600052
J	Sumiyoshi, H; Inoguchi, K; Khaleduzzaman, M; Ninomiya, Y; Yoshioka, H				Sumiyoshi, H; Inoguchi, K; Khaleduzzaman, M; Ninomiya, Y; Yoshioka, H			Ubiquitous expression of the alpha 1(XIX) collagen gene (Col19a1) during mouse embryogenesis becomes restricted to a few tissues in the adult organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PRO-ALPHA-2(XI) COLLAGEN; DIFFERENTIAL EXPRESSION; 5' END; CHAIN; PROTEINS; REGION; PROPEPTIDE; SEQUENCE; VARIANTS	Type XIX collagen is a poorly characterized member of the fibril-associated collagens with an interrupted triple helices (FACIT) class of collagen molecules, As a first step toward elucidating its function, we have isolated full size cDNA clones from the mouse alpha 1(XIX) collagen gene (Col19 alpha 1) and established its pattern of expression in the developing embryo and adult organism, Col19 alpha 1 transcripts can be detected as early as II days of gestation and in all embryonic tissues, except the liver, of an Is-day postcoitum mouse, in contrast, only a few adult tissues, brain, eye, and testis, seem to accumulate Col19 alpha 1 mRNA, Col19 alpha 1 transcripts are at least 10 times more abundant in adult than fetal brain and significantly less in adult than fetal muscle and skin, Consistent with the RNA data, polyclonal antibodies for alpha 1(XIX) collagen reacted with a 150-kDa protein in the neutral salt extraction of adult mouse brain tissues. We therefore propose that type XIX collagen plays a distinct role from the other FACIT molecules, particularly in the assembly of embryonic matrices and in the maintenance of specific adult tissues.	OKAYAMA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,OKAYAMA 700,JAPAN	Okayama University			Khaledian, Hossein/S-7707-2016	Khaledian, Hossein/0000-0002-4082-2987				Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; DUBLET B, 1989, J BIOL CHEM, V264, P13150; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; INOGUCHI K, 1995, J BIOCHEM-TOKYO, V117, P137, DOI 10.1093/oxfordjournals.jbchem.a124700; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; MYERS JC, 1994, J BIOL CHEM, V269, P18549; OH SP, 1992, GENOMICS, V14, P225, DOI 10.1016/S0888-7543(05)80210-1; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; STROKES DG, 1991, J BIOL CHEM, V266, P8626; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; YOSHIOKA H, 1995, GENOMICS, V28, P337, DOI 10.1006/geno.1995.1151; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	24	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17104	17111		10.1074/jbc.272.27.17104	http://dx.doi.org/10.1074/jbc.272.27.17104			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202028	hybrid, Green Submitted			2022-12-27	WOS:A1997XH44600060
